



(86) **Date de dépôt PCT/PCT Filing Date:** 2003/02/21
(87) **Date publication PCT/PCT Publication Date:** 2003/09/04
(45) **Date de délivrance/Issue Date:** 2014/12/30
(85) **Entrée phase nationale/National Entry:** 2004/08/23
(86) **N° demande PCT/PCT Application No.:** US 2003/005271
(87) **N° publication PCT/PCT Publication No.:** 2003/072719
(30) **Priorité/Priority:** 2002/02/21 (US60/358,934)

(51) **Cl.Int./Int.Cl.** **C12N 15/45** (2006.01),
A61K 35/76 (2006.01), **A61K 39/155** (2006.01),
A61P 31/14 (2006.01), **C07K 14/11** (2006.01),
C07K 14/115 (2006.01), **C07K 14/135** (2006.01),
C07K 16/10 (2006.01), **C12N 15/86** (2006.01),
C12N 7/00 (2006.01), **C12N 7/01** (2006.01),
C12Q 1/00 (2006.01), ...
(72) **Inventeurs/Inventors:**
HALLER, AURELIA, US;
TANG, RODERICK, US;
FOUCHIER, RONALDUS ADRIANUS MARIA, NL;
VAN DEN HOOGEN, BERNADETTA GERARDA, NL; ...

(54) **Titre : SOUCHES DE METAPNEUMOVIRUS ET LEUR UTILISATION DANS DES PREPARATIONS VACCINALES ET COMME VECTEURS D'EXPRESSION DE SEQUENCES ANTIGENIQUES**
(54) **Title: METAPNEUMOVIRUS STRAINS AND THEIR USE IN VACCINE FORMULATIONS AND AS VECTORS FOR EXPRESSION OF ANTIGENIC SEQUENCES**

M							
	00-1	hRSV	bRSV	PMV	APV-A	APV-C	APV-B
00-1	1,00	0,37	0,37	0,37	0,77	0,87	0,75
hRSV	---	1,00	0,91	0,41	0,37	0,37	0,37
bRSV	---	---	1,00	0,42	0,35	0,36	0,35
PMV	---	---	---	1,00	0,37	0,38	0,38
APV-A	---	---	---	---	1,00	0,78	0,89
APV-C	---	---	---	---	---	1,00	0,77
APV-B	---	---	---	---	---	---	1,00
N							
	00-1	hRSV	bRSV	PVM	APV-A	APV-C	APV-B
00-1	1,00	0,20	0,22	0,21	0,40	0,52	0,40
hRSV	---	1,00	0,59	0,30	0,18	0,21	0,18
bRSV	---	---	1,00	0,31	0,21	0,23	0,21
PVM	---	---	---	1,00	0,21	0,23	0,21
APVA	---	---	---	---	1,00	0,42	1,00
AEVC	---	---	---	---	---	1,00	0,42
APVB	---	---	---	---	---	---	1,00
F							
	00-1	hRSV	bRSV	PVM	APV-A	APV-C	APV-B
00-1	1,00	0,32	0,33	0,37	0,67	0,80	0,66
hRSV	---	1,00	0,82	0,40	0,35	0,35	0,35
bRSV	---	---	1,00	0,41	0,34	0,36	0,34
PVM	---	---	---	1,00	0,38	0,38	0,39
APV-A	---	---	---	---	1,00	0,72	0,84
APV-C	---	---	---	---	---	1,00	0,72
APV-B	---	---	---	---	---	---	1,00
P							
	00-1	hRSV	bRSV	PMV	APV-A	APV-C	
00-1	1,00	0,25	0,26	0,27	0,55	0,67	
hRSV	---	1,00	0,81	0,30	0,28	0,26	
bRSV	---	---	1,00	0,29	0,28	0,26	
PMV	---	---	---	1,00	0,23	0,27	
APV-A	---	---	---	---	1,00	0,52	
APV-C	---	---	---	---	---	1,00	
L8							
	00-1	hRSV	bRSV	APV-A			
00-1	1,00	0,36	0,35	0,56			
hRSV	---	1,00	0,79	0,36			
bRSV	---	---	1,00	0,35			
APV-A	---	---	---	1,00			
L9/10							
	00-1	hRSV	bRSV	APV-A			
00-1	1,00	0,30	0,30	0,53			
hRSV	---	1,00	0,83	0,34			
bRSV	---	---	1,00	0,32			
APV-A	---	---	---	1,00			

(57) **Abrégé/Abstract:**
The present invention provides an isolated mammalian negative strand RNA virus, metapneumovirus (MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae. The invention also provides isolated mammalian negative strand RNA viruses

(51) **Cl.Int./Int.Cl. (suite/continued)** *C12Q 1/02* (2006.01), *C12Q 1/68* (2006.01), *C12Q 1/70* (2006.01), *G01N 33/50* (2006.01), *G01N 33/569* (2006.01)

(72) **Inventeurs(suite)/Inventors(continued):** OSTERHAUS, ALBERTUS DOMINICUS MARCELLINUS ERASMUS, NL

(73) **Propriétaires(suite)/Owners(continued):** VIRONOVATIVE BV, NL; MEDIMMUNE, LLC, US

(74) **Agent:** OSLER, HOSKIN & HARCOURT LLP

(57) **Abrégé(suite)/Abstract(continued):**

identifiable as phylogenetically corresponding or relating to the genus Metapneumovirus and components thereof. In particular the invention provides a mammalian MPV, subgroups and variants thereof. The invention relates to genomic nucleotide sequences of different isolates of mammalian metapneumoviruses, in particular human metapneumoviruses. The invention relates to the use of the sequence information of different isolates of mammalian metapneumoviruses for diagnostic and therapeutic methods. The present invention relates to nucleotide sequences encoding the genome of a metapneumovirus or a portion thereof, including both mammalian and avian metapneumovirus. The invention further encompasses chimeric or recombinant viruses encoded by said nucleotide sequences. The invention also relates to chimeric and recombinant mammalian MPV that comprise one or more non-native or heterologous sequences. The invention further relates to vaccine formulations comprising mammalian or avian metapneumovirus, including recombinant and chimeric forms of said viruses. The vaccine preparation of the invention encompass multivalent vaccines, including bivalent and trivalent vaccine preparations.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 September 2003 (04.09.2003)

PCT

(10) International Publication Number
WO 03/072719 A2

(51) International Patent Classification⁷: C12N
(21) International Application Number: PCT/US03/05271
(22) International Filing Date: 21 February 2003 (21.02.2003)
(25) Filing Language: English
(26) Publication Language: English
(30) Priority Data:
60/358,934 21 February 2002 (21.02.2002) US
(71) Applicants (for all designated States except US): MED-
IMMUNE VACCINES, INC. [US/US]; 35 W. Watkins
Mill Road, Gaithersburg, MD 20878 (US). VIRONOVA-
TIVE BV [NL/NL]; P.O. Box 1738, NL-3000 DR Rotter-
dam (NL).

(72) Inventors; and
(75) Inventors/Applicants (for US only): HALLER, Aurelia
[AT/US]; 313 Hillview Avenue, Redwood City, CA 94062
(US). TANG, Roderick [MY/US]; 730 Chestnut Street,
#3, San Carlos, CA 94070 (US). FOUCHIER, Ronal-
dus, Adrianus, Maria [NL/NL]; Essenburgsingel 44a,
NL-3021 AR Rotterdam (NL). VAN DEN HOOGEN,
Bernadetta, Gerarda [NL/NL]; Essenburgsingel 44a,
NL-3021 AR Rotterdam (NL). OSTERHAUS, Alber-
tus, Dominicus, Marcellinus, Erasmus [NL/NL]; Dr.
Breveestraat 16, NL-3981 CH Bunnik (NL).
(74) Agents: CORUZZI, Laura, A. et al.; Pennie & Edmonds
LLP, 1155 Avenue of the Americas, New York, NY 10036
(US).
(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

[Continued on next page]

(54) Title: METAPNEUMOVIRUS STRAINS AND THEIR USE IN VACCINE FORMULATIONS AND AS VECTOR FOR EX-
PRESSION OF ANTIGENIC SEQUENCES

M							
	00-1	hRSV	bRSV	PMV	APV-A	APV-C	APV-B
00-1	1,00	0,37	0,37	0,37	0,77	0,87	0,75
hRSV	---	1,00	0,91	0,41	0,37	0,37	0,37
bRSV	---	---	1,00	0,42	0,35	0,36	0,35
PMV	---	---	---	1,00	0,37	0,38	0,38
APV-A	---	---	---	---	1,00	0,78	0,89
APV-C	---	---	---	---	---	1,00	0,77
APV-B	---	---	---	---	---	---	1,00
N							
	00-1	hRSV	bRSV	PVM	APV-A	APV-C	APV-B
00-1	1,00	0,20	0,22	0,21	0,40	0,52	0,40
hRSV	---	1,00	0,59	0,30	0,18	0,21	0,18
bRSV	---	---	1,00	0,31	0,21	0,23	0,21
PVM	---	---	---	1,00	0,21	0,23	0,21
APVA	---	---	---	---	1,00	0,42	1,00
APVC	---	---	---	---	---	1,00	0,42
APVB	---	---	---	---	---	---	1,00
F							
	00-1	hRSV	bRSV	PVM	APV-A	APV-C	APV-B
00-1	1,00	0,32	0,33	0,37	0,67	0,80	0,66
hRSV	---	1,00	0,82	0,40	0,35	0,35	0,35
bRSV	---	---	1,00	0,41	0,34	0,36	0,34
PVM	---	---	---	1,00	0,38	0,38	0,39
APV-A	---	---	---	---	1,00	0,72	0,84
APV-C	---	---	---	---	---	1,00	0,72
APV-B	---	---	---	---	---	---	1,00
P							
	00-1	hRSV	bRSV	PMV	APV-A	APV-C	
00-1	1,00	0,25	0,26	0,27	0,55	0,67	
hRSV	---	1,00	0,81	0,30	0,28	0,26	
bRSV	---	---	1,00	0,29	0,28	0,26	
PMV	---	---	---	1,00	0,23	0,27	
APV-A	---	---	---	---	1,00	0,52	
APV-C	---	---	---	---	---	1,00	
LB							
	00-1	hRSV	bRSV	APV-A			
00-1	1,00	0,36	0,35	0,56			
hRSV	---	1,00	0,79	0,36			
bRSV	---	---	1,00	0,35			
APV-A	---	---	---	1,00			
L9/10							
	00-1	hRSV	bRSV	APV-A			
00-1	1,00	0,30	0,30	0,53			
hRSV	---	1,00	0,83	0,34			
bRSV	---	---	1,00	0,32			
APV-A	---	---	---	1,00			

(57) Abstract: The present invention provides an isolated mammalian negative strand RNA virus, metapneumovirus (MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae. The invention also provides isolated mammalian negative strand RNA viruses identifiable as phylogenetically corresponding or relating to the genus Metapneumovirus and components thereof. In particular the invention provides a mammalian MPV, subgroups and variants thereof. The invention relates to genomic nucleotide sequences of different isolates of mammalian metapneumoviruses, in particular human metapneumoviruses. The invention relates to the use of the sequence information of different isolates of mammalian metapneumoviruses for diagnostic and therapeutic methods. The present invention relates to nucleotide sequences encoding the genome of a metapneumovirus or a portion thereof, including both mammalian and avian metapneumovirus. The invention further encompasses chimeric or recombinant viruses encoded by said nucleotide sequences. The invention also relates to chimeric and recombinant mammalian MPV that comprise one or more non-native or heterologous sequences. The invention further relates to vaccine formulations comprising mammalian or avian metapneumovirus, including recombinant and chimeric forms of said viruses. The vaccine preparation of the invention encompass multivalent vaccines, including bivalent and trivalent vaccine preparations.

WO 03/072719 A2

WO 03/072719 A2

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI,

SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

DEMANDES OU BREVETS VOLUMINEUX

**LA PRÉSENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.**

CECI EST LE TOME __1__ DE __2__

NOTE: Pour les tomes additionels, veuillez contacter le Bureau Canadien des Brevets.

JUMBO APPLICATIONS / PATENTS

**THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.**

THIS IS VOLUME __1__ OF __2__

NOTE: For additional volumes please contact the Canadian Patent Office.

METAPNEUMOVIRUS STRAINS AND THEIR USE IN VACCINE FORMULATIONS AND AS VECTORS FOR EXPRESSION OF ANTIGENIC SEQUENCES

1. INTRODUCTION

The invention relates to an isolated mammalian negative strand RNA virus, metapneumovirus (MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae. The present invention also relates to isolated mammalian negative strand RNA viruses identifiable as phylogenetically corresponding or relating to the genus Metapneumovirus and components thereof. The invention relates to genomic nucleotide sequences of different isolates of mammalian metapneumoviruses, in particular human metapneumoviruses. The invention relates to the use of the sequence information of different isolates of mammalian metapneumoviruses for diagnostic and therapeutic methods. The present invention relates to nucleotide sequences encoding the genome of a metapneumovirus or a portion thereof, including both mammalian and avian metapneumovirus. The invention further encompasses chimeric or recombinant viruses encoded by said nucleotide sequences. The invention also relates to chimeric and recombinant mammalian MPV that comprise one or more non-native or heterologous sequences. The invention further relates to vaccine formulations comprising mammalian or avian metapneumovirus, including recombinant and chimeric forms of said viruses. The vaccine preparations of the invention encompass multivalent vaccines, including bivalent and trivalent vaccine preparations.

2. BACKGROUND OF THE INVENTION

Classically, as devastating agents of disease, paramyxoviruses account for many animal and human deaths worldwide each year. The Paramyxoviridae form a family within the order of Mononegavirales (negative-sense single stranded RNA viruses), consisting of the sub-families Paramyxovirinae and Pneumovirinae. The latter sub-family is at present taxonomically divided in the genera Pneumovirus and Metapneumovirus (Pringle, 1999, Arch. Virol. 144/2, 2065-2070). Human respiratory syncytial virus (hRSV), a species of the Pneumovirus genus, is the single most important cause of lower respiratory tract infections during infancy and early childhood worldwide (Domachowske, & Rosenberg, 1999, Clin. Microbio. Rev. 12(2): 298-309). Other members of the Pneumovirus genus include the bovine and ovine respiratory syncytial viruses and pneumonia virus of mice (PVM).

In the past decades several etiological agents of mammalian disease, in particular of respiratory tract illnesses (RTI), in particular of humans, have been identified (Evans, In: Viral Infections of Humans, Epidemiology and Control. 3th edn. (ed. Evans, A.S) 22-28 (Plenum Publishing Corporation, New York, 1989)). Classical etiological agents of RTI with mammals are respiratory syncytial viruses belonging to the genus Pneumovirus found with humans (hRSV) and ruminants such as cattle or sheep (bRSV and/or oRSV). In human RSV differences in reciprocal cross neutralization assays, reactivity of the G proteins in immunological assays and nucleotide sequences of the G gene are used to define two hRSV antigenic subgroups. Within the subgroups the amino acid sequences show 94 % (subgroup A) or 98% (subgroup B) identity, while only 53% amino acid sequence identity is found between the subgroups. Additional variability is observed within subgroups based on monoclonal antibodies, RT-PCR assays and RNase protection assays. Viruses from both subgroups have a worldwide distribution and may occur during a single season. Infection may occur in the presence of pre-existing immunity and the antigenic variation is not strictly required to allow re-infection. *See*, for example Sullender, 2000, Clinical Microbiology Reviews 13(1): 1-15; Collins et al. Fields Virology, ed. B.N. Knipe, Howley, P.M. 1996, Philadelphia: Lippencott-Raven. 1313-1351; Johnson et al., 1987, (Proc Natl Acad Sci USA, 84(16): 5625-9; Collins, in The Paramyxoviruses, D.W. Kingsbury, Editor. 1991, Plenum Press: New York. p. 103-153.

Another classical Pneumovirus is the pneumonia virus of mice (PVM), in general only found with laboratory mice. However, a proportion of the illnesses observed among mammals can still not be attributed to known pathogens.

2.1 AVIAN METAPNEUMOVIRUS

Respiratory disease caused by an avian pneumovirus (APV) was first described in South Africa in the late 1970s (Buys et al., 1980, Turkey 28:36-46) where it had a devastating effect on the turkey industry. The disease in turkeys was characterized by sinusitis and rhinitis and was called turkey rhinotracheitis (TRT). The European isolates of APV have also been strongly implicated as factors in swollen head syndrome (SHS) in chickens (O'Brien, 1985, Vet. Rec. 117:619-620). Originally, the disease appeared in broiler chicken flocks infected with Newcastle disease virus (NDV) and was assumed to be a secondary problem associated with Newcastle disease (ND). Antibody against European APV was detected in affected chickens after the onset of SHS (Cook et al., 1988, Avian Pathol. 17:403-410), thus implicating APV as the cause.

Avian pneumovirus (APV) also known as turkey rhinotracheitis virus (TRTV), the aetiological agent of avian rhinotracheitis, an upper respiratory tract infection of turkeys (Giraud et al., 1986, Vet. Res. 119:606-607), is the sole member of the recently assigned Metapneumovirus genus, which, as said was until now not associated with infections, or what is more, with disease of mammals. Serological subgroups of APV can be differentiated on the basis of nucleotide or amino acid sequences of the G glycoprotein and neutralization tests using monoclonal antibodies that also recognize the G glycoprotein. However, other differences in the nucleotide and amino acid sequences can be used to distinguish serological subgroups of APV. Within subgroups A, B and D, the G protein shows 98.5 to 99.7% aa sequence identity within subgroups while between the subgroups only 31.2- 38% aa identity is observed. See for example Collins et al., 1993, Avian Pathology, 22: p. 469-479; Cook et al., 1993, Avian Pathology, 22: 257-273; Bayon-Auboyer et al., J Gen Virol, 81(Pt 11): 2723-33; Seal, 1998, Virus Res, 58(1-2): 45-52; Bayon-Auboyer et al., 1999, Arch Virol, 144(6): 91-109; Juhasz, et al., 1994, J Gen Virol, 75(Pt 11): 2873-80.

A further serotype of APV is provided in WO00/20600,

1, which describes the Colorado isolate of APV and compared it to known APV or TRT

strains with in vitro serum neutralization tests. First, the Colorado isolate was tested against monospecific polyclonal antisera to recognized TRT isolates. The Colorado isolate was not neutralized by monospecific antisera to any of the TRT strains. It was, however, neutralized by a hyperimmune antiserum raised against a subgroup A strain. This antiserum neutralized the homologous virus to a titre of 1:400 and the Colorado isolate to a titer of 1: 80. Using the above method, the Colorado isolate was then tested against TRT monoclonal antibodies. In each case, the reciprocal neutralization titer was <10. Monospecific antiserum raised to the Colorado isolate was also tested against TRT strains of both subgroups. None of the TRT strains tested were neutralized by the antiserum to the Colorado isolate.

The Colorado strain of APV does not protect SPF chicks against challenge with either a subgroup A or a subgroup B strain of TRT virus. These results suggest that the Colorado isolate may be the first example of a further serotype of avian pneumovirus (*See, Bayon-Auboyer et al., 2000, J. Gen. Vir. 81:2723-2733*).

The avian pneumovirus is a single stranded, non-segmented RNA virus that belongs to the sub-family Pneumovirinae of the family Paramyxoviridae, genus metapneumovirus (Cavanagh and Barrett, 1988, *Virus Res. 11:241-256*; Ling et al., 1992, *J. Gen. Virol. 73:1709-1715*; Yu et al., 1992, *J. Gen. Virol. 73:1355-1363*). The Paramyxoviridae family is divided into two sub-families: the Paramyxovirinae and Pneumovirinae. The subfamily Paramyxovirinae includes, but is not limited to, the genera: Paramyxovirus, Rubulavirus, and Morbillivirus. Recently, the sub-family Pneumovirinae was divided into two genera based on gene order, and sequence homology, *i.e.* pneumovirus and metapneumovirus (Naylor et al., 1998, *J. Gen. Virol. 79:1393-1398*; Pringle, 1998, *Arch. Virol. 143:1449-1159*). The pneumovirus genus includes, but is not limited to, human respiratory syncytial virus (hRSV), bovine respiratory syncytial virus (bRSV), ovine respiratory syncytial virus, and mouse pneumovirus. The metapneumovirus genus includes, but is not limited to, European avian pneumovirus (subgroups A and B), which is distinguished from hRSV, the type species for the genus pneumovirus (Naylor et al., 1998, *J. Gen. Virol. 79:1393-1398*; Pringle, 1998, *Arch. Virol. 143:1449-1159*). The US isolate of APV represents a third subgroup (subgroup C) within metapneumovirus genus because it has been found to be antigenically and genetically different from European isolates (Seal, 1998, *Virus Res. 58:45-52*; Senne et al., 1998, In: *Proc. 47th WPDC, California, pp. 67-68*).

Electron microscopic examination of negatively stained APV reveals pleomorphic, sometimes spherical, virions ranging from 80 to 200 nm in diameter with long filaments ranging from 1000 to 2000 nm in length (Collins and Gough, 1988, *J. Gen. Virol.* 69:909-916). The envelope is made of a membrane studded with spikes 13 to 15 nm in length. The nucleocapsid is helical, 14 nm in diameter and has 7 nm pitch. The nucleocapsid diameter is smaller than that of the genera Paramyxovirus and Morbillivirus, which usually have diameters of about 18 nm.

Avian pneumovirus infection is an emerging disease in the USA despite its presence elsewhere in the world in poultry for many years. In May 1996, a highly contagious respiratory disease of turkeys appeared in Colorado, and an APV was subsequently isolated at the National Veterinary Services Laboratory (NVSL) in Ames, Iowa (Senne et al., 1997, *Proc. 134th Ann. Mtg., AVMA*, pp. 190). Prior to this time, the United States and Canada were considered free of avian pneumovirus (Pearson et al., 1993, In: *Newly Emerging and Re-emerging Avian Diseases: Applied Research and Practical Applications for Diagnosis and Control*, pp. 78-83; Hecker and Myers, 1993, *Vet. Rec.* 132:172). Early in 1997, the presence of APV was detected serologically in turkeys in Minnesota. By the time the first confirmed diagnosis was made, APV infections had already spread to many farms. The disease is associated with clinical signs in the upper respiratory tract: foamy eyes, nasal discharge and swelling of the sinuses. It is exacerbated by secondary infections. Morbidity in infected birds can be as high as 100%. The mortality can range from 1 to 90% and is highest in six to twelve week old poults.

Avian pneumovirus is transmitted by contact. Nasal discharge, movement of affected birds, contaminated water, contaminated equipment; contaminated feed trucks and load-out activities can contribute to the transmission of the virus. Recovered turkeys are thought to be carriers. Because the virus is shown to infect the epithelium of the oviduct of laying turkeys and because APV has been detected in young poults, egg transmission is considered a possibility.

2.2 PIV INFECTIONS

Parainfluenza viral infection results in serious respiratory tract disease in infants and children. (Tao et al., 1999, *Vaccine* 17: 1100-08). Infectious parainfluenza viral infections

account for approximately 20% of all hospitalizations of pediatric patients suffering from respiratory tract infections worldwide. *Id.*

PIV is a member of the genus respirovirus (PIV1, PIV3) or rubulavirus (PIV2, PIV4) of the paramyxoviridae family. PIV is made up of two structural modules: (1) an internal ribonucleoprotein core, or nucleocapsid, containing the viral genome, and (2) an outer, roughly spherical lipoprotein envelope. Its genome is a single strand of negative sense RNA, approximately 15,456 nucleotides in length, encoding at least eight polypeptides. These proteins include, but are not limited to, the nucleocapsid structural protein (NP, NC, or N depending on the genera), the phosphoprotein (P), the matrix protein (M), the fusion glycoprotein (F), the hemagglutinin-neuraminidase glycoprotein (HN), the large polymerase protein (L), and the C and D proteins of unknown function. *Id.*

The parainfluenza nucleocapsid protein (NP, NC, or N) consists of two domains within each protein unit including an amino-terminal domain, comprising about two-thirds of the molecule, which interacts directly with the RNA, and a carboxyl-terminal domain, which lies on the surface of the assembled nucleocapsid. A hinge is thought to exist at the junction of these two domains thereby imparting some flexibility to this protein (*see* Fields et al. (ed.), 1991, Fundamental Virology, Second Edition, Raven Press, New York).

The matrix protein (M), is apparently involved with viral assembly and interacts with both the viral membrane as well as the nucleocapsid proteins. The phosphoprotein (P), which is subject to phosphorylation, is thought to play a regulatory role in transcription, and may also be involved in methylation, phosphorylation and polyadenylation. The fusion glycoprotein (F) interacts with the viral membrane and is first produced as an inactive precursor, then cleaved post-translationally to produce two disulfide linked polypeptides. The active F protein is also involved in penetration of the parainfluenza virion into host cells by facilitating fusion of the viral envelope with the host cell plasma membrane. *Id.* The glycoprotein, hemagglutinin-neuraminidase (HN), protrudes from the envelope allowing the virus to contain both hemagglutinin and neuraminidase activities. HN is strongly hydrophobic at its amino terminal which functions to anchor the HN protein into the lipid bilayer. *Id.* Finally, the large polymerase protein (L) plays an important role in both transcription and replication. *Id.*

2.3 RSV INFECTIONS

Respiratory syncytial virus (RSV) is the leading cause of serious lower respiratory tract disease in infants and children (Feigen et al., eds., 1987, In: Textbook of Pediatric Infectious Diseases, WB Saunders, Philadelphia at pages 1653-1675; New Vaccine Development, Establishing Priorities, Vol. 1, 1985, National Academy Press, Washington DC at pages 397-409; and Ruuskanen et al., 1993, Curr. Probl. Pediatr. 23:50-79). The yearly epidemic nature of RSV infection is evident worldwide, but the incidence and severity of RSV disease in a given season vary by region (Hall, 1993, Contemp. Pediatr. 10:92-110). In temperate regions of the northern hemisphere, it usually begins in late fall and ends in late spring. Primary RSV infection occurs most often in children from 6 weeks to 2 years of age and uncommonly in the first 4 weeks of life during nosocomial epidemics (Hall et al., 1979, New Engl. J. Med. 300:393-396). Children at increased risk for RSV infection include, but are not limited to, preterm infants (Hall et al., 1979, New Engl. J. Med. 300:393-396) and children with bronchopulmonary dysplasia (Groothuis et al., 1988, Pediatrics 82:199-203), congenital heart disease (MacDonald et al., New Engl. J. Med. 307:397-400), congenital or acquired immunodeficiency (Ogra et al., 1988, Pediatr. Infect. Dis. J. 7:246-249; and Pohl et al., 1992, J. Infect. Dis. 165:166-169), and cystic fibrosis (Abman et al., 1988, J. Pediatr. 113:826-830). The fatality rate in infants with heart or lung disease who are hospitalized with RSV infection is 3%-4% (Navas et al., 1992, J. Pediatr. 121:348-354).

RSV infects adults as well as infants and children. In healthy adults, RSV causes predominantly upper respiratory tract disease. It has recently become evident that some adults, especially the elderly, have symptomatic RSV infections more frequently than had been previously reported (Evans, A.S., eds., 1989, Viral Infections of Humans. Epidemiology and Control, 3rd ed., Plenum Medical Book, New York at pages 525-544). Several epidemics also have been reported among nursing home patients and institutionalized young adults (Falsey, A.R., 1991, Infect. Control Hosp. Epidemiol. 12:602-608; and Garvie et al., 1980, Br. Med. J. 281:1253-1254). Finally, RSV may cause serious disease in immunosuppressed persons, particularly bone marrow transplant patients (Hertz et al., 1989, Medicine 68:269-281).

Treatment options for established RSV disease are limited. Severe RSV disease of the lower respiratory tract often requires considerable supportive care, including

administration of humidified oxygen and respiratory assistance (Fields et al., eds, 1990, Fields Virology, 2nd ed., Vol. 1, Raven Press, New York at pages 1045-1072).

While a vaccine might prevent RSV infection, and/or RSV-related disease, no vaccine is yet licensed for this indication. A major obstacle to vaccine development is safety. A formalin-inactivated vaccine, though immunogenic, unexpectedly caused a higher and more severe incidence of lower respiratory tract disease due to RSV in immunized infants than in infants immunized with a similarly prepared trivalent parainfluenza vaccine (Kim et al., 1969, Am. J. Epidemiol. 89:422-434; and Kapikian et al., 1969, Am. J. Epidemiol. 89:405-421). Several candidate RSV vaccines have been abandoned and others are under development (Murphy et al., 1994, Virus Res. 32:13-36), but even if safety issues are resolved, vaccine efficacy must also be improved. A number of problems remain to be solved. Immunization would be required in the immediate neonatal period since the peak incidence of lower respiratory tract disease occurs at 2-5 months of age. The immaturity of the neonatal immune response together with high titers of maternally acquired RSV antibody may be expected to reduce vaccine immunogenicity in the neonatal period (Murphy et al., 1988, J. Virol. 62:3907-3910; and Murphy et al., 1991, Vaccine 9:185-189). Finally, primary RSV infection and disease do not protect well against subsequent RSV disease (Henderson et al., 1979, New Engl. J. Med. 300:530-534).

Currently, the only approved approach to prophylaxis of RSV disease is passive immunization. Initial evidence suggesting a protective role for IgG was obtained from observations involving maternal antibody in ferrets (Prince, G.A., Ph.D. diss., University of California, Los Angeles, 1975) and humans (Lambrecht et al, 1976, J. Infect. Dis. 134:211-217; and Glezen et al., 1981, J. Pediatr. 98:708-715). Hemming et al. (Morell et al., eds., 1986, Clinical Use of Intravenous Immunoglobulins, Academic Press, London at pages 285-294) recognized the possible utility of RSV antibody in treatment or prevention of RSV infection during studies involving the pharmacokinetics of an intravenous immune globulin (IVIG) in newborns suspected of having neonatal sepsis. In this study, it was noted that one infant, whose respiratory secretions yielded RSV, recovered rapidly after IVIG infusion. Subsequent analysis of the IVIG lot revealed an unusually high titer of RSV neutralizing antibody. This same group of investigators then examined the ability of hyperimmune serum or immune globulin, enriched for RSV neutralizing antibody, to protect cotton rats and

primates against RSV infection (Prince et al., 1985, *Virus Res.* 3:193-206; Prince et al., 1990, *J. Virol.* 64:3091-3092; Hemming et al., 1985, *J. Infect. Dis.* 152:1083-1087; Prince et al., 1983, *Infect. Immun.* 42:81-87; and Prince et al., 1985, *J. Virol.* 55:517-520). Results of these studies indicate that IVIG may be used to prevent RSV infection, in addition to treating or preventing RSV-related disorders.

Recent clinical studies have demonstrated the ability of this passively administered RSV hyperimmune globulin (RSV IVIG) to protect at-risk children from severe lower respiratory infection by RSV (Groothuis et al., 1993, *New Engl. J. Med.* 329:1524-1530; and The PREVENT Study Group, 1997, *Pediatrics* 99:93-99). While this is a major advance in preventing RSV infection, this treatment poses certain limitations in its widespread use. First, RSV IVIG must be infused intravenously over several hours to achieve an effective dose. Second, the concentrations of active material in hyperimmune globulins are insufficient to treat adults at risk or most children with compromised cardiopulmonary function. Third, intravenous infusion necessitates monthly hospital visits during the RSV season. Finally, it may prove difficult to select sufficient donors to produce a hyperimmune globulin for RSV to meet the demand for this product. Currently, only approximately 8% of normal donors have RSV neutralizing antibody titers high enough to qualify for the production of hyperimmune globulin.

One way to improve the specific activity of the immunoglobulin would be to develop one or more highly potent RSV neutralizing monoclonal antibodies (MAbs). Such MAbs should be human or humanized in order to retain favorable pharmacokinetics and to avoid generating a human anti-mouse antibody response, as repeat dosing would be required throughout the RSV season. Two glycoproteins, F and G, on the surface of RSV have been shown to be targets of neutralizing antibodies (Fields et al., 1990, *supra*; and Murphy et al., 1994, *supra*).

A humanized antibody directed to an epitope in the A antigenic site of the F protein of RSV, SYNAGIS®, is approved for intramuscular administration to pediatric patients for prevention of serious lower respiratory tract disease caused by RSV at recommended monthly doses of 15 mg/kg of body weight throughout the RSV season (November through April in the northern hemisphere). SYNAGIS® is a composite of human (95%) and murine (5%) antibody sequences. *See*, Johnson et al., 1997, *J. Infect. Diseases* 176:1215-1224 and U.S.

Patent No. 5,824,307 . The human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the VH genes of Cor (Press et al., 1970, Biochem. J. 117:641-660) and Cess (Takashi et al., 1984, Proc. Natl. Acad. Sci. USA 81:194-198). The human light chain sequence was derived from the constant domain of C_κ and the variable framework regions of the VL gene K104 with J_κ-4 (Bentley et al., 1980, Nature 288:5194-5198). The murine sequences derived from a murine monoclonal antibody, Mab 1129 (Beeler et al., 1989, J. Virology 63:2941-2950), in a process which involved the grafting of the murine complementarity determining regions into the human antibody frameworks.

A significant portion of human respiratory disease is caused by members of the viral sub-families Paramyxovirinae and Pneumovirinae. The identification of another mammalian Pneumovirinae that infects humans, hMPV, is described for the first time herein. There still remains a need for an effective vaccine to confer protection against a variety of viruses that result in respiratory tract infection.

Citation or discussion of a reference herein shall not be construed as an admission that such is prior art to the present invention.

3. SUMMARY OF THE INVENTION

The invention relates to an isolated mammalian negative strand RNA virus, metapneumovirus (MPV), within the sub-family Pneumovirinae, of the family Paramyxoviridae. The present invention also relates to isolated mammalian negative strand RNA viruses identifiable as phylogenitically corresponding or relating to the genus Metapneumovirus and components thereof. In particular, the invention relates to a mammalian MPV that is phylogenitically more closely related to a virus isolate deposited as I-2614 with CNCM, Paris than it is related to APV type C. In more specific embodiments, the mammalian MPV can be a variant A1, A2, B1 or B2 mammalian MPV. However, the mammalian MPVs of the present invention may encompass additional variants yet to be identified, and are not limited to variants A1, A2, B1 or B2.

The invention relates to genomic nucleotide sequences of different isolates of mammalian metapneumoviruses, in particular human metapneumoviruses. The invention

relates to the use of the sequence information of different isolates of mammalian metapneumoviruses for diagnostic and therapeutic methods. The present invention relates to the differences of the genomic nucleotide sequences among the different metapneumovirus-isolates, and their use in the diagnostic and therapeutic methods of the invention. In specific embodiments, the nucleotide sequence of a mammalian MPV that encodes for the N, M, F, L, P, M2-1, M2-2, SH or G ORFs may be used to identify a virus of the invention. In other specific embodiments, the nucleotide sequence of mammalian MPV that encodes for the N, M, F, L, P, M2-1, M2-2, SH or G ORFs used to classify a mammalian MPV into variant A1, A2, B1 or B2. In a specific embodiment, the invention relates to the use of the single nucleotide polymorphisms (SNPs) among different metapneumovirus isolates for diagnostic purposes.

The invention relates to recombinant and chimeric viruses that are derived from a mammalian MPV or avian pneumovirus (APV). In accordance with the present invention, a recombinant virus is one derived from a mammalian MPV or an APV that is encoded by endogenous or native genomic sequences or non-native genomic sequences. In accordance with the invention, a non-native sequence is one that is different from the native or endogenous genomic sequence due to one or more mutations, including, but not limited to, point mutations, rearrangements, insertions, deletions etc., to the genomic sequence that may or may not result in a phenotypic change. In accordance with the invention, a chimeric virus of the invention is a recombinant MPV or APV which further comprises a heterologous nucleotide sequence. In accordance with the invention, a chimeric virus may be encoded by a nucleotide sequence in which heterologous nucleotide sequences have been added to the genome or in which endogenous or native nucleotide sequences have been replaced with heterologous nucleotide sequences. In certain embodiments, a chimeric virus of the invention is derived from a MPV or APV in which one or more of the ORFs or a portion thereof is replaced by a homologous ORF or a portion thereof from another strain of metapneumovirus. In an exemplary embodiment, the ORF of the F gene of a mammalian MPV is replaced by the ORF of the F gene of an APV. In certain other embodiments, a chimeric virus of the invention is derived from an APV in which one or more of the ORFs is replaced by a homologous ORF of a mammalian MPV.

The present invention relates to nucleotide sequences encoding the genome of a metapneumovirus (including mammalian and avian strains) or a portion thereof. The present invention relates to nucleotide sequences encoding gene products of a metapneumovirus. In particular, the invention relates to, but is not limited to, nucleotide sequences encoding an F protein, a G protein, an M protein, an SH protein, an N protein, a P protein, an M2 protein, or an L protein of a MPV. In particular the invention relates to nucleotide sequences encoding an F protein, a G protein, an M protein, an SH protein, an N protein, a P protein, an M2 protein, or an L protein of a variant of mammalian MPV, such as but not limited to variant A1, A2, B1 or B2 of a MPV. The present invention further relates to a cDNA or RNA that encodes the genome or a portion thereof of a metapneumovirus, including both mammalian and avian, in addition to a nucleotide sequence which is heterologous or non-native to the viral genome. The invention further encompasses chimeric or recombinant viruses encoded by said cDNAs or RNAs.

The invention further relates to polypeptides and amino acid sequences of an F protein, a G protein, an M protein, an SH protein, an N protein, a P protein, an M2 protein, or an L protein of a mammalian MPV and different variants of mammalian MPV. The invention further relates to antibodies against an F protein, a G protein, an M protein, an SH protein, an N protein, a P protein, an M2 protein, or an L protein of a mammalian MPV and different variants of mammalian MPV. The antibodies can be used for diagnostic and therapeutic methods. In certain more specific embodiments, the antibodies are specific to mammalian MPV. In certain embodiments, the antibodies are specific to a variant of mammalian MPV. The invention further relates to vaccine formulations and immunogenic compositions comprising one or more of the following: an F protein, a G protein, an M protein, an SH protein, an N protein, a P protein, an M2 protein, and/or an L protein of a mammalian MPV.

The invention further relates to vaccine formulations and immunogenic compositions comprising mammalian or avian metapneumovirus, including recombinant and chimeric forms of said viruses. In particular, the present invention encompasses vaccine preparations comprising recombinant or chimeric forms of MPV and/or APV. The invention further relates to vaccines comprising chimeric MPV wherein the chimeric MPV encodes one or more APV proteins and wherein the chimeric MPV optionally additionally expresses one or

more heterologous or non-native sequences. The invention also relates to vaccines comprising chimeric APV wherein the chimeric APV encodes one or more hMPV proteins and wherein the chimeric APV optionally additionally expresses one or more heterologous or non-native sequences. The present invention also relates to multivalent vaccines, including bivalent and trivalent vaccines. In particular, multivalent vaccines of the invention encompass two or more antigenic polypeptides expressed by the same or different pneumoviral vectors. The antigenic polypeptides of the multivalent vaccines include but are not limited to, antigenic polypeptides of MPV, APV, PIV, RSV, influenza or another negative strand RNA virus, or another virus, such as morbillivirus.

The invention further relates to methods for treating a respiratory tract infection in a subject. In certain embodiments, the invention relates to treating a respiratory tract infection in a subject by administering to the subject a vaccine formulation comprising a mammalian MPV. In specific embodiments, the methods for treating a respiratory tract infection in a subject comprise administering to the subject a vaccine formulation or an immunogenic composition comprising a recombinant or a chimeric mammalian MPV or APV. In more specific embodiments, the recombinant or chimeric mammalian MPV is attenuated. In a specific embodiment, the invention relates to treating a respiratory tract infection in a human patient comprising administering to the human patient a vaccine formulation comprising a recombinant or chimeric APV, or a nucleotide sequence encoding an F protein, a G protein, an M protein, an SH protein, an N protein, a P protein, an M2 protein, or an L protein of APV.

The invention provides an isolated negative-sense single stranded RNA virus MPV belonging to the sub-family *Pneumovirinae* of the family *Paramyxoviridae* and identifiable as phylogenetically corresponding to the genus *Metapneumovirus*, wherein the virus is phylogenetically more closely related to a virus isolate comprising the nucleotide sequence of SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, or SEQ ID NO:21 than it is related to turkey rhinotracheitis virus, the etiological agent of avian rhinotracheitis. In certain embodiments, the invention provides an isolated negative-sense single stranded RNA metapneumovirus, wherein the genome of the virus comprises a nucleotide sequence of SEQ ID NO:18. In certain embodiments, the invention provides a n isolated negative-sense single stranded RNA metapneumovirus, wherein the genome of the virus comprises a nucleotide

sequence of SEQ ID NO:19. In certain embodiments, the invention provides an isolated negative-sense single stranded RNA metapneumovirus, wherein the genome of the virus comprises a nucleotide sequence of SEQ ID NO:20. In certain embodiments, the invention provides an isolated negative-sense single stranded RNA metapneumovirus, wherein the genome of the virus comprises a nucleotide sequence of SEQ ID NO:21. In certain embodiments, the invention provides an isolated nucleic acid, wherein the nucleic acid has a nucleotide sequence that is at least 70% identical to SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20 or SEQ ID NO:21, wherein sequence identity is determined over the entire length of SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21 or SEQ ID NO:22. In certain embodiments, the invention provides an isolated nucleic acid, wherein the nucleic acid encodes a protein comprising (i) an amino acid sequence that is at least 66% identical to the G protein of a mammalian MPV variant B1 (SEQ ID NO:324); (ii) an amino acid sequence that is at least 98.5% identical to the N protein of a mammalian MPV variant B1 (SEQ ID NO:368); (iii) an amino acid sequence that is at least 96% identical to the P protein of a mammalian MPV variant B1 (SEQ ID NO:376); (iv) an amino acid sequence that is identical to the M protein of a mammalian MPV variant B1 (SEQ ID NO:360); (v) an amino acid sequence that is at least 99% identical to the F protein of a mammalian MPV variant B1 (SEQ ID NO:316); (vi) an amino acid sequence that is at least 98% identical to the M2-1 protein of a mammalian MPV variant B1 (SEQ ID NO:340); (vii) an amino acid sequence that is at least 99% identical to the M2-2 protein of a mammalian MPV variant B1 (SEQ ID NO:348); (viii) an amino acid sequence that is at least 83% identical to the SH protein of a mammalian MPV variant B1 (SEQ ID NO:384); or (ix) an amino acid sequence that is at least 99% identical to the L protein of a mammalian MPV variant B1 (SEQ ID NO:332). In certain embodiments, the invention provides an isolated nucleic acid, wherein the nucleic acid encodes a protein comprising (i) an amino acid sequence that is at least 66% identical to the G protein of a mammalian MPV variant A1 (SEQ ID NO:322); (ii) an amino acid sequence that is at least 99.5% identical to the N protein of a mammalian MPV variant A1 (SEQ ID NO:366); (iii) an amino acid sequence that is at least 96% identical to the P protein of a mammalian MPV variant A1 (SEQ ID NO:374); (iv) an amino acid sequence that is at least 99% identical to the M protein of a mammalian MPV variant A1 (SEQ ID NO:358); (v) an amino acid sequence that is at least 98% identical to the F protein of a mammalian MPV variant A1 (SEQ ID NO:314); (vi)

an amino acid sequence that is at least 99% identical to the M2-1 protein of a mammalian MPV variant A1 (SEQ ID NO:338) (vii) an amino acid sequence that is at least 96% identical to the M2-2 protein of a mammalian MPV variant A1 (SEQ ID NO:346) (viii) an amino acid sequence that is at least 84% identical to the SH protein of a mammalian MPV variant A1 (SEQ ID NO:382); or (ix) an amino acid sequence that is at least 99% identical to the L protein of a virus of a mammalian MPV variant A1 (SEQ ID NO:330). In certain embodiments, the invention provides an isolated nucleic acid, wherein the nucleic acid encodes a protein comprising (i) an amino acid sequence that is at least 66% identical to the G protein of a mammalian MPV variant A2 (SEQ ID NO:332); (ii) an amino acid sequence that is at least 99.5% identical to the N protein of a mammalian MPV variant A2 (SEQ ID NO:367); (iii) an amino acid sequence that is at least 96% identical to the P protein of a mammalian MPV variant A2 (SEQ ID NO:375); (iv) an amino acid sequence that is at least 99% identical to the M protein of a mammalian MPV variant A2 (SEQ ID NO:359); (v) an amino acid sequence that is at least 98% identical to the F protein of a mammalian MPV variant A2 (SEQ ID NO:315); (vi) an amino acid sequence that is at least 99% identical to the M2-1 protein of a mammalian MPV variant A2 (SEQ ID NO: 339); (vii) an amino acid sequence that is at least 96% identical to the M2-2 protein of a mammalian MPV variant A2 (SEQ ID NO:347); (viii) an amino acid sequence that is at least 84% identical to the SH protein of a mammalian MPV variant A2 (SEQ ID NO:383); or (ix) an amino acid sequence that is at least 99% identical to the L protein of a mammalian MPV variant A2 (SEQ ID NO:331). In certain embodiments, the invention provides an isolated nucleic acid, wherein the nucleic acid encodes a protein comprising (i) an amino acid sequence that is at least 66% identical to the G protein of a mammalian MPV variant B2 (SEQ ID NO:325); (ii) an amino acid sequence that is at least 97% identical to the N protein of a mammalian MPV variant B2 (SEQ ID NO:369); (iii) an amino acid sequence that is at least 96% identical to the P protein of a mammalian MPV variant B2 (SEQ ID NO:377); (iv) an amino acid sequence that is identical to the M protein of a mammalian MPV variant B2 (SEQ ID NO:361) (v) an amino acid sequence that is at least 99% identical to the F protein of a mammalian MPV variant B2 (SEQ ID NO:317); (vi) an amino acid sequence that is at least 98% identical to the M2-1 protein of a mammalian MPV variant B2 (SEQ ID NO:341); (vii) an amino acid sequence that is at least 99% identical to the M2-2 protein of a mammalian MPV variant B2 (SEQ ID

NO:349); (viii) an amino acid sequence that is at least 84% identical to the SH protein of a mammalian MPV variant B2 (SEQ ID NO:385); or (ix) an amino acid sequence that is at least 99% identical to the L protein of a mammalian MPV variant B2 (SEQ ID NO:333). In certain embodiments, the invention provides an isolated nucleic acid, wherein the nucleic acid hybridizes specifically under high stringency, medium stringency, or low stringency conditions to a nucleic acid of a mammalian MPV.

In certain embodiments, the invention provides a virus comprising the nucleotide sequence of SEQ ID NO:18-21 or a fragment thereof.

In certain embodiments, the invention provides an isolated protein, wherein the protein comprises (i) an amino acid sequence that is at least 66% identical to the G protein of a mammalian MPV variant B1 (SEQ ID NO:324); (ii) an amino acid sequence that is at least 98.5% identical to the N protein of a mammalian MPV variant B1 (SEQ ID NO:368); (iii) an amino acid sequence that is at least 96% identical to the P protein of a mammalian MPV variant B1 (SEQ ID NO:376); (iv) an amino acid sequence that is identical to the M protein of a mammalian MPV variant B1 (SEQ ID NO:360); (v) an amino acid sequence that is at least 99% identical to the F protein of a mammalian MPV variant B1 (SEQ ID NO:316); (vi) an amino acid sequence that is at least 98% identical to the M2-1 protein of a mammalian MPV variant B1 (SEQ ID NO:340); (vii) an amino acid sequence that is at least 99% identical to the M2-2 protein of a mammalian MPV variant B1 (SEQ ID NO:348); (viii) an amino acid sequence that is at least 83% identical to the SH protein of a mammalian MPV variant B1 (SEQ ID NO:384); or (ix) an amino acid sequence that is at least 99% identical to the L protein of a mammalian MPV variant B1 (SEQ ID NO:332). In certain embodiments, the invention provides an isolated protein, wherein the protein comprises: (i) an amino acid sequence that is at least 66% identical to the G protein of a mammalian MPV variant A1 (SEQ ID NO:322); (ii) an amino acid sequence that is at least 99.5% identical to the N protein of a mammalian MPV variant A1 (SEQ ID NO:366); (iii) an amino acid sequence that is at least 96% identical to the P protein of a mammalian MPV variant A1 (SEQ ID NO:374); (iv) an amino acid sequence that is at least 99% identical to the M protein of a mammalian MPV variant A1 (SEQ ID NO:358); (v) an amino acid sequence that is at least 98% identical to the F protein of a mammalian MPV variant A1 (SEQ ID NO:314); (vi) an amino acid sequence that is at least 99% identical to the M2-1 protein of a mammalian MPV variant A1 (SEQ ID NO:338)

(vii) an amino acid sequence that is at least 96% identical to the M2-2 protein of a mammalian MPV variant A1 (SEQ ID NO:346) (viii) an amino acid sequence that is at least 84% identical to the SH protein of a mammalian MPV variant A1 (SEQ ID NO:382); or (ix) an amino acid sequence that is at least 99% identical to the L protein of a virus of a mammalian MPV variant A1 (SEQ ID NO:330) In certain embodiments, the invention provides isolated protein, wherein the protein comprises (i) an amino acid sequence that is at least 66% identical to the G protein of a mammalian MPV variant A2 (SEQ ID NO:332); (ii) an amino acid sequence that is at least 99.5% identical to the N protein of a mammalian MPV variant A2 (SEQ ID NO:367); (iii) an amino acid sequence that is at least 96% identical to the P protein of a mammalian MPV variant A2 (SEQ ID NO:375) (iv) an amino acid sequence that is at least 99% identical to the M protein of a mammalian MPV variant A2 (SEQ ID NO:359); (v) an amino acid sequence that is at least 98% identical to the F protein of a mammalian MPV variant A2 (SEQ ID NO:315) (vi) an amino acid sequence that is at least 99% identical to the M2-1 protein of a mammalian MPV variant A2 (SEQ ID NO: 339); (vii) an amino acid sequence that is at least 96% identical to the M2-2 protein of a mammalian MPV variant A2 (SEQ ID NO:347) (viii) an amino acid sequence that is at least 84% identical to the SH protein of a mammalian MPV variant A2 (SEQ ID NO:383); or (ix) an amino acid sequence that is at least 99% identical to the L protein of a mammalian MPV variant A2 (SEQ ID NO:331). In certain embodiments, the invention provides an isolated protein, wherein the protein comprises: (i) an amino acid sequence that is at least 66% identical to the G protein of a mammalian MPV variant B2 (SEQ ID NO:325); (ii) an amino acid sequence that is at least 97% identical to the N protein of a mammalian MPV variant B2 (SEQ ID NO:369) (iii) an amino acid sequence that is at least 96% identical to the P protein of a mammalian MPV variant B2 (SEQ ID NO:377) (iv) an amino acid sequence that is identical to the M protein of a mammalian MPV variant B2 (SEQ ID NO:361); (v) an amino acid sequence that is at least 99% identical to the F protein of a mammalian MPV variant B2 (SEQ ID NO:317); (vi) an amino acid sequence that is at least 98% identical to the M2-1 protein of a mammalian MPV variant B2 (SEQ ID NO:341); (vii) an amino acid sequence that is at least 99% identical to the M2-2 protein of a mammalian MPV variant B2 (SEQ ID NO:349); (viii) an amino acid sequence that is at least 84% identical to the SH protein of a mammalian MPV variant B2 (SEQ ID NO:385); or (ix) an amino acid sequence

that is at least 99% identical to the L protein of a mammalian MPV variant B2 (SEQ ID NO:333). In certain embodiments, the invention provides an antibody, wherein the antibody binds specifically to a protein consisting of (i) an amino acid sequence that is at least 66% identical to the G protein of a mammalian MPV variant B1 (SEQ ID NO:324); (ii) an amino acid sequence that is at least 98.5% identical to the N protein of a mammalian MPV variant B1 (SEQ ID NO:368); (iii) an amino acid sequence that is at least 96% identical the P protein of a mammalian MPV variant B1 (SEQ ID NO:376) (iv an amino acid sequence that is identical the M protein of a mammalian MPV variant B1 (SEQ ID NO:360); (v) an amino acid sequence that is at least 99% identical the F protein of a mammalian MPV variant B1 (SEQ ID NO:316); (vi) an amino acid sequence that is at least 98% identical the M2-1 protein of a mammalian MPV variant B1 (SEQ ID NO:340) (vii) an amino acid sequence that is at least 99% identical the M2-2 protein of a mammalian MPV variant B1 (SEQ ID NO:348); (viii) an amino acid sequence that is at least 83% identical the SH protein of a mammalian MPV variant B1 (SEQ ID NO:384); (ix) an amino acid sequence that is at least 99% identical the L protein a mammalian MPV variant B1 (SEQ ID NO:332). In certain embodiments, the invention provides an antibody, wherein the antibody binds specifically to a protein consisting of: (i) an amino acid sequence that is at least 66% identical to the G protein of a mammalian MPV variant A1 (SEQ ID NO:322); (ii) an amino acid sequence that is at least 99.5% identical to the N protein of a mammalian MPV variant A1 (SEQ ID NO:366); (iii an amino acid sequence that is at least 96% identical to the P protein of a mammalian MPV variant A1 (SEQ ID NO:374); (iv) an amino acid sequence that is at least 99% identical to the M protein of a mammalian MPV variant A1 (SEQ ID NO:358); (v) an amino acid sequence that is at least 98% identical to the F protein of a mammalian MPV variant A1 (SEQ ID NO:314); (vi) an amino acid sequence that is at least 99% identical to the M2-1 protein of a mammalian MPV variant A1 (SEQ ID NO:338); (vii) an amino acid sequence that is at least 96% identical to the M2-2 protein of a mammalian MPV variant A1 (SEQ ID NO:346); (viii) an amino acid sequence that is at least 84% identical to the SH protein of a mammalian MPV variant A1 (SEQ ID NO:382); (ix) an amino acid sequence that is at least 99% identical to the L protein of a virus of a mammalian MPV variant A1 (SEQ ID NO:330). In certain embodiments, the invention provides a n antibody, wherein the antibody binds specifically to a protein consisting of: (i) an amino acid sequence that is at

least 66% identical to the G protein of a mammalian MPV variant A2 (SEQ ID NO:332); (ii) an amino acid sequence that is at least 96% identical to the N protein of a mammalian MPV variant A2 (SEQ ID NO:367) (iii) an amino acid sequence that is at least 96% identical to the P protein of a mammalian MPV variant A2 (SEQ ID NO:375); (iv) an amino acid sequence that is at least 99% identical to the M protein of a mammalian MPV variant A2 (SEQ ID NO:359); (v) an amino acid sequence that is at least 98% identical to the F protein of a mammalian MPV variant A2 (SEQ ID NO:315) (vi) an amino acid sequence that is at least 99% identical to the M2-1 protein of a mammalian MPV variant A2 (SEQ ID NO: 339); (vii) an amino acid sequence that is at least 96% identical to the M2-2 protein of a mammalian MPV variant A2 (SEQ ID NO:347); (viii) an amino acid sequence that is at least 84% identical to the SH protein of a mammalian MPV variant A2 (SEQ ID NO:383); (ix) an amino acid sequence that is at least 99% identical to the L protein of a mammalian MPV variant A2 (SEQ ID NO:331) In certain embodiments, the invention provides an antibody, wherein the antibody binds specifically to a protein consisting of: (i) an amino acid sequence that is at least 66% identical to the G protein of a mammalian MPV variant B2 (SEQ ID NO:325); (ii) an amino acid sequence that is at least 97% identical to the N protein of a mammalian MPV variant B2 (SEQ ID NO:369); (iii) an amino acid sequence that is at least 96% identical to the P protein of a mammalian MPV variant B2 (SEQ ID NO:377) (iv) an amino acid sequence that is identical to the M protein of a mammalian MPV variant B2 (SEQ ID NO:361); (v) an amino acid sequence that is at least 99% identical to the F protein of a mammalian MPV variant B2 (SEQ ID NO:317); (vi) an amino acid sequence that is at least 98% identical to the M2-1 protein of a mammalian MPV variant B2 (SEQ ID NO:341); (vii) an amino acid sequence that is at least 99% identical to the M2-2 protein of a mammalian MPV variant B2 (SEQ ID NO:349) (viii) an amino acid sequence that is at least 84% identical to the SH protein of a mammalian MPV variant B2 (SEQ ID NO:385); or (ix) an amino acid sequence that is at least 99% identical to the L protein of a mammalian MPV variant B2 (SEQ ID NO:333). In certain embodiments, the invention provides a method for detecting a variant B1 mammalian MPV in a sample, wherein said method comprises contacting the sample with the antibody of specific to a variant B1. In certain embodiments, the invention provides method for detecting a variant A1 mammalian MPV in a sample, wherein said method comprises contacting the sample with the antibody specific to variant

A1. In certain embodiments, the invention provides a method for detecting a variant A2 mammalian MPV in a sample, wherein said method comprises contacting the sample with the antibody specific to variant A2. In certain embodiments, the invention provides a method for detecting a variant B2 mammalian MPV in a sample, wherein said method comprises contacting the sample with the antibody specific to B2.

In certain embodiments, the invention provides a method for identifying a viral isolate as a mammalian MPV, wherein said method comprises contacting said isolate or a component thereof with the antibody specific to a mammalian MPV. In certain embodiments, the invention provides method for virologically diagnosing a MPV infection of a mammal comprising determining in a sample of said mammal the presence of a viral isolate or component thereof by contacting the sample with the antibody specific to a MPV. In certain embodiments, the invention provides method for virologically diagnosing a mammalian MPV infection of a subject, wherein said method comprises obtaining a sample from the subject and contacting the sample with an antibody specific to MPV wherein if the antibody binds to the sample the subject is infected with mammalian MPV.

In certain embodiments, the invention provides an infectious recombinant virus, wherein the recombinant virus comprises the genome of a mammalian MPV and further comprises a non-native MPV sequence. In certain embodiments, the invention provides a recombinant nucleic acid, wherein the recombinant nucleic acid comprises (i) a nucleic acid encoding a G polypeptide of an MPV A1 variant; and (ii) a nucleic acid encoding a non-native MPV polypeptide. In certain embodiments, the invention provides recombinant nucleic acid, wherein the recombinant nucleic acid comprises (i) a nucleic acid encoding a G polypeptide of an MPV A2 variant; and (ii) a nucleic acid encoding a non-native MPV polypeptide. In certain embodiments, the invention provides s recombinant nucleic acid, wherein the recombinant nucleic acid comprises (i) a nucleic acid encoding a G polypeptide of an MPV B1 variant; and (ii) a nucleic acid encoding a non-native MPV polypeptide. In certain embodiments, the invention provides a recombinant nucleic acid, wherein the recombinant nucleic acid comprises (i) a nucleic acid encoding a G polypeptide of an MPV B2 variant; and (ii) a nucleic acid encoding a non-native MPV polypeptide.

In certain embodiments, the invention provides an infectious chimeric virus, wherein the chimeric virus comprises the genome of a mammalian MPV of a first variant, wherein

one or more of the open reading frames in the genome of the mammalian MPV of the first variant have been replaced by the analogous open reading frame from a mammalian MPV of a second variant. In certain embodiments, the invention provides an infectious chimeric virus, wherein the chimeric virus comprises the genome of a mammalian MPV of a first variant, wherein one or more of open reading frames of a mammalian MPV of a second variant are inserted into the genome of the mammalian MPV of the first variant.

In certain embodiments, the invention provides an infectious chimeric virus, wherein the chimeric virus comprises the genome of a mammalian MPV, wherein one or more of the open reading frames in the genome of the mammalian MPV have been replaced by an ORF which encodes one or more of an avian MPV F protein; an avian MPV G protein (iii) an avian MPV SH protein; (iv) an avian MPV N protein (v) an avian MPV P protein; (vi) an avian MPV M2 protein; (vii) an avian MPV M2-1 protein; (viii) an avian MPV M2-2 protein; or (ix) an avian MPV L protein. In certain embodiments, the invention provides an infectious chimeric virus, wherein the chimeric virus comprises the genome of an avian MPV, wherein one or more of the open reading frames in the genome of the avian MPV have been replaced by an ORF which encodes one or more of (i) a mammalian MPV F protein (ii) a mammalian MPV G protein; (iii) a mammalian MPV SH protein; (iv) a mammalian MPV N protein; (v) a mammalian MPV P protein; (vi) a mammalian MPV M2 protein; (vii) a mammalian MPV M2-1 protein; (viii) a mammalian MPV M2-2 protein; or (ix) a mammalian MPV L protein.

In certain embodiments, the invention provides an immunogenic composition, wherein the immunogenic composition comprises the infectious recombinant virus of the invention.

In certain embodiments, the invention provides a method for detecting a mammalian MPV in a sample, wherein the method comprises contacting the sample with a nucleic acid sequence of the invention. In certain embodiments, the invention provides a pharmaceutical composition, wherein the pharmaceutical composition comprises the infectious recombinant virus of the invention.

In certain embodiments, the invention provides a method for treating or preventing a respiratory tract infection in a mammal, said method comprising administering a vaccine comprising a mammalian metapneumovirus.

In certain embodiments, the invention provides an method for treating or preventing a respiratory tract infection in a mammal, said method comprising administering a vaccine comprising the recombinant mammalian metapneumovirus of the invention.

In certain embodiments, the invention provides an method for treating or preventing a respiratory tract infection in a mammal, said method comprising administering a vaccine comprising avian metapneumovirus. In certain embodiments, the invention provides a method for treating or preventing a respiratory tract infection in a human, said method comprising administering a vaccine comprising avian metapneumovirus. In certain embodiments, the invention provides a method for treating or preventing a respiratory tract infection in a subject, said method comprising administering to the subject the composition of the invention.

In certain embodiments, the invention provides a method for identifying a compound useful for the treatment of infections with mammalian MPV, wherein the method comprises: (a) infecting an animal with a mammalian MPV; (b) Administering to the animal a test compound; and (c) determining the effect of the test compound on the infection of the animal, wherein a test compound that reduces the extent of the infection or that ameliorates the symptoms associated with the infection is identified as a compound useful for the treatment of infections with mammalian MPV. In certain embodiments, the invention provides a method for identifying a compound useful for the treatment of infections with mammalian MPV, wherein the method comprises (a) infecting a cell culture with a mammalian MPV (b) incubating the cell culture with a test compound; and (c) determining the effect of the test compound on the infection of the cell culture, wherein a test compound that reduces the extent of the infection is identified as a compound useful for the treatment of infections with mammalian MPV. In certain embodiments, the invention provides a method for diagnosing a mammalian MPV infection of an animal, wherein the method comprises determining in a sample of said animal the presence of a viral isolate or component thereof by reacting said sample with a nucleic acid or an antibody reactive with a component of an avian pneumovirus, said nucleic acid or antibody being cross-reactive with a component of MPV.

In certain embodiments, the invention provides a method for serologically diagnosing a mammalian MPV infection of an animal, wherein the method comprises contacting a sample from the animal with the protein of the invention. In certain embodiments, the

invention provides a method for serologically diagnosing a mammalian MPV infection of an animal, wherein the method comprises contacting a sample from the animal with a protein of an APV. In certain embodiments, the invention provides a method for diagnosing an APV infection of a bird comprising contacting a sample from the animal with the protein of the invention.

In certain embodiments, the invention provides an isolated negative-sense single stranded RNA virus MPV belonging to the sub-family *Pneumovirinae* of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus, wherein the virus is phylogenetically more closely related to a virus isolate deposited as I-2614 with CNCM, Paris than to turkey rhinotracheitis virus, the etiological agent of avian rhinotracheitis.

3.1 CONVENTIONS AND ABBREVIATIONS

cDNA	complementary DNA
L	large protein
M	matrix protein (lines inside of envelope)
F	fusion glycoprotein
HN	hemagglutinin-neuraminidase glycoprotein
N, NP or NC	nucleoprotein (associated with RNA and required for polymerase activity)
P	phosphoprotein
MOI	multiplicity of infection
NA	neuraminidase (envelope glycoprotein)
PIV	parainfluenza virus
hPIV	human parainfluenza virus
hPIV3	human parainfluenza virus type 3
APV/hMPV	recombinant APV with hMPV sequences
hMPV/APV	recombinant hMPV with APV sequences
Mammalian MPV	mammalian metapneumovirus
nt	nucleotide

RNP	ribonucleoprotein
rRNP	recombinant RNP
vRNA	genomic virus RNA
cRNA	antigenomic virus RNA
hMPV	human metapneumovirus
APV	avian pneumovirus
MVA	modified vaccinia virus Ankara
FACS	Fluorescence Activated Cell Sorter
CPE	cytopathic effects
Position 1	Position of the first gene of the viral genome to be transcribed
Position 2	Position between the first and the second open reading frame of the native viral genome, or alternatively, the position of the second gene of the viral genome to be transcribed
Position 3	Position between the second and the third open reading frame of the native viral genome, or alternatively, the position of the third gene of the viral genome to be transcribed.
Position 4	Position between the third and the fourth open reading frame of the native viral genome, or alternatively, the position of the fourth gene of the viral genome to be transcribed.
Position 5	Position between the fourth and the fifth open reading frame of the native viral genome, or alternatively, the position of the fifth gene of the viral genome to be transcribed.
Position 6	Position between the fifth and the sixth open reading frame of the native viral genome, or alternatively, the position of the sixth gene of the viral genome to be transcribed.

4. DESCRIPTION OF THE FIGURES

Figure 1: Percentage homology found between the amino acid sequence of isolate 00-1 and other members of the Pneumovirinae. Percentages (x100) are given for the amino acid sequences of N, P, M, F and two RAP-PCR fragments in L (8 and 9/10).

Figure 2: Seroprevalence of MPV in humans categorized by age group, using immunofluorescence and virus neutralisation assays.

Figure 3: Schematic representation of the genome of APV with the location and size of the fragments obtained with RAP-PCR and RT-PCR on virus isolate 00-1 (A1).

Fragments 1 to 10 were obtained using RAP-PCR. Fragment A was obtained with a primer in RAP-PCR fragment 1 and 2 and a primer that was designed based on alignment of leader and trailer sequences of APV and RSV (Randhawa et al., 1997, J.Virol. 71:9849-9854).

Fragment B was obtained using primers designed in RAP-PCR fragment 1 and 2 and RAP-PCR fragment 3. Fragment C was obtained with primers designed in RAP-PCR fragment 3 and RAP-PCR fragments 4, 5, 6, and 7.

Figure 4: Comparison of the N, P, M and F ORFs of members of the subfamily *Pneumovirinae* and virus isolate 00-1 (A1). The alignment shows the amino acid sequence of the complete N, F, M and P proteins and partial L proteins of virus isolate 00-1 (A1). Amino acids that differ between isolate 00-1 (A1) and the other viruses are shown, identical amino acids are represented by periods. Gaps are represented as dashes. Numbers correspond to amino acid positions in the proteins. Abbreviations are as follows: APV-A, B or C: Avian Pneumovirus type A, B or C; hRSV: bovine or human respiratory syncytial virus; PVM: pneumonia virus of mice. L8: fragment 8 obtained with RAP-PCR located in L, L 9/10: consensus of fragment 9 and 10 obtained with RAP-PCR, located in L. For the L alignment only bRSV, hRSV and APV-A sequences were available.

Figure 5: Alignment of the predicted amino acid sequence of the nucleoprotein of MPV with those of other pneumoviruses. The conserved regions are represented by boxes and labeled A, B, and C. The conserved region among pneumoviruses is shown in gray and

shaded. Gaps are represented by dashes, periods indicate the positions of identical amino acid residues compared to MPV.

Figure 6: Amino acid sequence comparison of the phosphoprotein of MPV with those of other pneumoviruses. The region of high similarity is boxed, and the glutamate rich region is in grey and shaded. Gaps are represented by dashes. Periods indicate the position of identical amino acid residues compared to MPV.

Figure 7: Comparison of the deduced amino acid sequence of the matrix protein of MPV with those of other pneumoviruses. The conserved hexapeptide sequence is in grey and shaded. Gaps are represented by dashes. Periods indicate the position of identical amino acid residues relative to MPV.

Figure 8: Genomic map of MPV isolate 00-1 (A1). The nucleotide positions of the start and stop codons are indicated under each ORF. The double lines which cross the L ORF indicate the shortened representation of the L gene. The three reading frames below the map indicate the primary G ORF (nt 6262-6972) and overlapping potential secondary ORFs.

Figure 9: Alignment of the predicted amino acid sequence of the fusion protein of MPV with those of other pneumoviruses. The conserved cysteine residues are boxed. *N*-linked glycosylation sites are underlined. The cleavage site of F0 is double underlined; the fusion peptide, signal peptide, and membrane anchor domain are shown in grey and shaded. Gaps are represented by dashes, and periods indicate the position of identical amino acids relative to MPV.

Figure 10: Comparison of amino acid sequences of the M2 ORFs of MPV with those of other pneumoviruses. The alignment of M2-1 ORFs is shown in panel A, with the conserved amino terminus shown in grey and shaded. The three conserved cysteine residues are printed bold face and indicated by #. The alignment of the M2-2 ORFs is shown in panel B. Gaps are represented by dashes and periods indicate the position of identical amino acids relative to MPV.

Figure 11: Amino acid sequence analyses of the SH ORF of MPV. (A) Amino acid sequence of the SH ORF of MPV, with the serine and threonine residues in grey and shaded, cysteine residues in bold face, and the hydrophobic region doubly underlined. Potential *N*-linked glycosylation sites are single underlined. Arrows indicate the positions of the basic amino acids flanking the hydrophobic domain. (B) Alignment of the hydrophobicity plots of the SH proteins of MPV, APV-A and hRSV-B. A window of 17 amino acids was used. Arrows indicate a strong hydrophobic domain. Positions within the ORF are given on the X-axis.

Figure 12: Amino acid sequence analyses of the G ORF of MPV. (A) Amino acid sequence of the G ORF of MPV, with serine, threonine, and proline residues in grey and shaded. The cysteine residue is in bold face, and the hydrophobic region is doubly underlined. The potential *N*-linked glycosylation sites are singly underlined. (B) Alignment of the hydrophobicity plots of the G proteins of MPV, APV-A and hRSV-B. A window of 17 amino acids was used. Arrows indicate the hydrophobic region, and positions within the ORF are given at the X-axis.

Figure 13: Comparison of the amino acid sequences of a conserved domain of the polymerase gene of MPV and other paramyxoviruses. Domain III is shown with the four conserved polymerase motifs (A, B, C, D) in domain III (Poch et al., 1989 EMBO J 8:3867-74; Poch et al., 1990, J. Gen. Virol 71:1153-62) boxed. Gaps are represented by dashes and periods indicate the position of identical amino acid residues relative to MPV. Abbreviations used are as follows: hPIV-3: human parainfluenza virus type 3; SV: sendai virus; hPIV-2: human parainfluenza virus type 2; NDV: New castle disease virus; MV: measles virus; nipah: Nipah virus.

Figure 14: Phylogenetic analyses of the N, F, M, and F ORF s of members of the genus Pneumovirinae and virus isolate 00-1 (A1). Phylogenetic analysis was performed on viral sequences from the following genes: F (panel A), N (panel B), M (panel C), and P (panel D). The phylogenetic trees are based on maximum likelihood analyses using 100

bootstraps and 3 jumbles. The scale representing the number of nucleotide changes is shown for each tree.

Figure 15: Phylogenetic analyses of the M2-1 and L ORFs of MPV and selected paramyxoviruses. The M2-1 ORF was aligned with the M2-1 ORFs of other members of the genus *Pneumovirinae* (A) and the L ORF was aligned with L ORFs members of the genus *pneumovirinae* and selected other paramyxoviruses as described in the legend of Figure 13. Phylogenetic trees were generated by maximum likelihood analyses using 100 bootstraps and 3 jumbles. The scale representing the number of nucleotide changes is shown for each tree. Numbers in the trees represent bootstrap values based on the consensus trees.

Figure 16: Phylogenetic relationship for parts of the F (panel A), N (panel B), M (panel C) 20 and L (panel D) ORFs of nine of the primary MPV isolates with APV-C, its closest relative genetically. The phylogenetic trees are based on maximum likelihood analyses. The scale representing the number of nucleotide changes is shown for each tree. Accession numbers for APV-C: panel A: D00850; panel B: U39295; panel C: X58639; and panel D: U65312.

Figure 17: Alignment of the F genes of different isolates of hMPV of all four variants, variant A1, A2, B1, or B2.

Figure 18: Alignment of the F proteins of different isolates of hMPV of all four variants, variant A1, A2, B1, or B2.

Figure 19: Alignment of the G genes of different isolates of hMPV of all four variants, variant A1, A2, B1, or B2.

Figure 20: Alignment of the G proteins of different isolates of hMPV of all four variants, variant A1, A2, B1, or B2.

Figure 21: Phylogenetic tree based on the F gene sequences showing the phylogenetic relationship of the different hMPV isolates with the respective variants of hMPV.

Figure 22: Phylogenetic tree based on the G gene sequences showing the phylogenetic relationship of the different hMPV isolates with the respective variants of hMPV is shown in Figure 13.

Figure 23: Growth curve of hMPV isolate 00-1 (A1) in Vero cells. The Vero cells were infected at a MOI of 0.1.

Figure 24: Sequence of CAT-hMPV minireplicon construct. The function encoded by a segment of sequence is indicated underneath the sequence.

Figure 25: Expression of CAT from the CAT-hMPV minireplicon. The different constructs used for transfection are indicated on the x-axis; the amount of CAT expression is indicated on the y-axis. The Figure shows CAT expression 24 hours after transfection and CAT expression 48 hours after transfection. Standards were dilutions of CAT protein.

Figure 26: Leader and Trailer Sequence Comparison: Alignments of the leader and trailer sequences of different viruses as indicated are shown.

Figure 27: hMPV genome analysis: PCR fragments of hMPV genomic sequence relative to the hMPV genomic organization are shown. The position of mutations are shown underneath the vertical bars indicating the PCR fragments.

Figure 28: Restriction maps of hMPV isolate 00-1 (A1) and hMPV isolate 99-1 (B1). Restriction sites in the respective isolates are indicated underneath the diagram showing the genomic organization of hMPV. The scale on top of the diagram indicates the position in the hMPV genome in kb.

Figure 29A and 29B: hMPV cDNA assembly. The diagram on top shows the genomic organization of hMPV, the bars underneath indicate the PCR fragments (*see* Figure 27) that are assembled to result in a full length cDNA encoding the virus. The numbers on top of the bars representing the PCR fragments indicate the position in the viral genome in basepairs.

Figure 30: Nucleotide and amino acid sequence information from the 3'end of the genome of MPV isolate 00-1 (A1). ORFs are given. N: ORF for nucleoprotein; P: ORF for phosphoprotein; M: ORF for matrix protein; F: ORF for fusion protein; GE: gene end; GS: gene start.

Figure 31 A and B: Nucleotide and amino acid sequence information from obtained fragments in the polymerase gene (L) of MPV isolates 00-1 (A1). Positioning of the fragments in L is based on protein homologies with APV-A (accession number U65312). The translated fragment 8 (Figure 31 A) is located at amino acid number 8 to 243, and the consensus of fragments 9 and 10 (Figure 31 B) is located at amino acid number 1358 to 1464 of the APV-A L ORF.

Figure 32: Results of RT-PCR assays on throat and nose swabs of 12 guinea pigs 15 inoculated with ned/00/01 (A1) and/or ned/99/01 (B1).

Figure 33A: IgG response against ned/00/01 (A1) and ned/99/01 (B1) for guinea pigs infected with ned/00/01 (A1) and re-infected with ned/00/01 (A1) (GP 4, 5 and 6) or ned/99/01 (B1) (GP 1 and 3).

Figure 33B: IgG response against ned/00/01 (A1) and ned/99/01 (B1) for guinea pigs infected with ned/99/01 and re-infected with either ned/00/01 (A1) (GP's 8 and 9) or with ned/99/01 (B1) (GP's 10, 11, 12).

Figure 34: Specificity of the ned/00/01 (A1) and ned/99/01 (B1) ELISA on sera taken from guinea pigs infected with either ned/00/01 (A1) or ned/99/01 (B1).

Figure 35: Mean IgG response against ned/00/01 (A1) and ned/99/01 (B1) ELISA of 3 homologous (00-1/00-1), 2 homologous (99-1/99-1), 2 heterologous (99-1/00-1) and 2 heterologous (00-1/99-1) infected guinea pigs.

Figure 36: Mean percentage of APV inhibition of hMPV infected guinea pigs.

Figure 37: Virus neutralization titers of ned/00/01 (A1) and ned/99/01 (B1) infected guinea pigs against ned/00/01 (A1), ned/99/01 (B1) and APV-C.

Figure 38: Results of RT-PCR assays on throat swabs of cynomolgous macaques inoculated (twice) with ned/00/01 (A1).

Figure 39 A (top two panels): IgA, IgM and IgG response against ned/00/01 (A1) of 2 cynomolgous macaques (re)infected with ned/00/01 (A1).

Figure 39 B (bottom panels): IgG response against APV of 2 Cynomolgous macaques infected with ned/00/01 (A1).

Figure 40: Comparison of the use of the hMPV ELISA and the APV inhibition ELISA for the detection of IgG antibodies in human sera.

Figure 41: Comparison of two prototypic hMPV isolates with APV-A and APV-C; DNA similarity matrices for nucleic acids encoding the various viral proteins.

Figure 42: Comparison of two prototypic hMPV isolates with APV-A and APV-C; protein similarity matrices for the various viral proteins.

Figure 42b: Comparison of the coding sequences of four prototypes of mammalian MPV. The left column shows nucleic acid sequence comparisons and the right column shows amino acid sequence comparisons. NL/1/00 is the prototype of variant A1 (SEQ ID NO:19).

NL/17/00 is the prototype of variant A2 (SEQ ID NO:20). NL/1/99 the prototype of variant B1 (SEQ ID NO:18). NL/1/94 is the prototype of variant B2 (SEQ ID NO:21).

Figure 43: Amino acid alignment of the nucleoprotein of two prototype hMPV isolates.

Figure 44: Amino acid alignment of the phosphoprotein of two prototype hMPV isolates.

Figure 45: Amino acid alignment of the matrix protein of two prototype hMPV isolates.

Figure 46: Amino acid alignment of the fusion protein of two prototype hMPV isolates.

Figure 47: Amino acid alignment of the M2-1 protein of two prototype hMPV isolates.

Figure 48: Amino acid alignment of the M2-2 protein of two prototype hMPV isolates.

Figure 49: Amino acid alignment of the short hydrophobic protein of two prototype hMPV isolates.

Figure 50: Amino acid alignment of the attachment glycoprotein of two prototype hMPV isolates.

Figure 51: Amino acid alignment of the N-terminus of the polymerase protein of two prototype hMPV isolates.

Figure 52: Noncoding sequences of hMPV isolate 00-1 (A1). (A) The noncoding sequences between the ORFs and at the genomic termini are shown in the positive sense. From left to right, stop codons of indicated ORFs are shown, followed by the noncoding sequences, the gene start signals and start codons of the indicated subsequent ORFs. Numbers indicate the first position of start and stop codons in the hMPV map. Sequences that display similarity to published gene end signals are underlined and sequences that display similarity to UAAAAAU/A/C are represented with a line above the sequence. (B) Nucleotide sequences of the genomic termini of hMPV. The genomic termini of hMPV are aligned with each other and with those of APV. Underlined regions represent the primer sequences used in RT-PCR assays which are based on the 3' and 5' end sequences of APV and RSV. Bold italicized nucleotides are part of the gene start signal of the N gene. Le: leader, Tr: trailer.

Figure 53: Sequence comparison of the genomic sequence of hMPV isolate 00-1 (A1) with hMPV isolate 99-1 (B1).

Figure 54: Leader sequences of human metapneumovirus (hMPV) NL/1/00 (A1) genomic RNA was determined using a combination of polyadenylation and 3' RACE methods.

Figure 55: Sequencing analyses on PCR products directly and on PCR clones both indicated that the leader region of hMPV consisted of 5' ACG CGA AAA AAA CGC GTA TA (expressed as positive sense cDNA orientation) at the 3' most proximal 20 nucleotides in the leader sequence. The two newly identified nucleotides are underlined.

5. DETAILED DESCRIPTION OF THE INVENTION

The invention relates to an isolated mammalian negative strand RNA virus, metapneumovirus (MPV) and variants thereof, within the sub-family *Pneumovirinae*, of the family *Paramyxoviridae*. The present invention also relates to isolated mammalian negative strand RNA viruses identifiable as phylogenetically corresponding or relating to the genus metapneumovirus and components thereof. The mammalian MPVs of the invention can be a variant A1, A2, B1 or B2 mammalian MPV. However, the mammalian MPVs of the present

invention may encompass additional variants of MPV yet to be identified, and are not limited to variants A1, A2, B1 or B2.

The invention relates to genomic nucleotide sequences of different variants of isolates of mammalian metapneumoviruses (MPV), in particular human metapneumoviruses including isolates of variants A1, A2, B1 and B2. The invention relates to the use of the sequence information of different isolates of mammalian metapneumoviruses for diagnostic and therapeutic methods. The present invention relates to the differences of the genomic nucleotide sequences among the different metapneumovirus-isolates, and their use in the diagnostic and therapeutic methods of the invention. In particular, the invention relates to the use of the single nucleotide polymorphisms (SNPs) among different metapneumovirus isolates for diagnostic and therapeutic methods. The present invention also relates to the use serological characterization of the different isolates of mammalian metapneumoviruses, alone or in combination with the sequence information of the different isolates, for diagnostic and therapeutic methods.

The present invention relates to nucleotide sequences encoding the genome of a metapneumovirus or a portion thereof, including both mammalian and avian metapneumovirus (APV). The present invention relates to nucleotide sequences encoding gene products of a metapneumovirus, including both mammalian and avian metapneumoviruses. The present invention further relates to nucleic acids, including DNA and RNA, that encodes the genome or a portion thereof of a metapneumovirus, including both mammalian and avian, in addition to a nucleotide sequence which is heterologous or non-native to the viral genome. The invention further encompasses recombinant or chimeric viruses encoded by said nucleotide sequences.

In accordance with the present invention, a recombinant virus is one derived from a mammalian MPV or an APV that is encoded by endogenous or native genomic sequences or non-native genomic sequences. In accordance with the invention, a non-native sequence is one that is different from the native or endogenous genomic sequence due to one or more mutations, including, but not limited to, point mutations, rearrangements, insertions, deletions etc., the genomic sequence that may or may not result in a phenotypic change. In accordance with the invention, a chimeric virus is a recombinant MPV or APV which further comprises a heterologous nucleotide sequence. In accordance with the invention, a chimeric virus may be

encoded by a nucleotide sequence in which heterologous nucleotide sequences have been added to the genome or in which endogenous or native nucleotide sequences have been replaced with heterologous nucleotide sequences.

The invention further relates to vaccine formulations comprising mammalian or avian metapneumovirus, including recombinant forms of said viruses. In particular, the present invention encompasses vaccine preparations comprising recombinant or chimeric forms of MPV or APV that express antigenic glycoproteins, including glycoproteins of MPV, or APV and/or non-native MPV or APV glycoproteins. The invention also encompasses vaccine preparations comprising recombinant forms of MPV or APV that encode antigenic sequences of another negative strand RNA virus, including PIV or RSV, or a heterologous glycoprotein of another species or strain of metapneumovirus. The invention further relates to vaccines comprising chimeric hMPV wherein the chimeric hMPV encodes one or more APV proteins and wherein the chimeric hMPV optionally additionally expresses one or more heterologous or non-native sequences. The invention also relates to vaccines comprising chimeric APV wherein the chimeric APV encodes one or more hMPV proteins and wherein the chimeric APV optionally additionally expresses one or more heterologous or non-native sequences. The present invention also relates to multivalent vaccines, including bivalent and trivalent vaccines. In particular, the bivalent and trivalent vaccines of the invention encompass two or more antigenic polypeptides expressed by the same or different pneumoviral vectors encoding antigenic proteins of MPV, APV, PIV, RSV, influenza or another negative strand RNA virus, or morbillivirus.

5.1 MAMMALIAN METAPNEUMOVIRUS

STRUCTURAL CHARACTERISTICS OF A MAMMALIAN METAPNEUMOVIRUS

The invention provides a mammalian MPV. The mammalian MPV is a negative-sense single stranded RNA virus belonging to the sub-family *Pneumovirinae* of the family Paramyxoviridae. Moreover, the mammalian MPV is identifiable as phylogenetically corresponding to the genus Metapneumovirus, wherein the mammalian MPV is phylogenetically more closely related to a virus isolate deposited as I-2614 with CNCM, Paris (SEQ ID NO:19) than to turkey rhinotracheitis virus, the etiological agent of avian rhinotracheitis. A virus is identifiable as phylogenetically corresponding to the genus

Metapneumovirus by, *e.g.*, obtaining nucleic acid sequence information of the virus and testing it in phylogenetic analyses. Any technique known to the skilled artisan can be used to determine phylogenetic relationships between strains of viruses. For exemplary methods *see* section 5.9. Other techniques are disclosed in International Patent Application PCT/NL02/00040, published as WO 02/057302.

In particular, PCT/NL02/00040 discloses nucleic acid sequences that are suitable for phylogenetic analysis at page 12, line 27 to page 19, line 29.

A virus can further be identified as a mammalian MPV on the basis of sequence similarity as described in more detail below.

In addition to phylogenetic relatedness and sequence similarity of a virus to a mammalian MPV as disclosed herein, the similarity of the genomic organization of a virus to the genomic organization of a mammalian MPV disclosed herein can also be used to identify the virus as a mammalian MPV. For a representative genomic organization of a mammalian MPV *see* Figure 27. In certain embodiments, the genomic organization of a mammalian MPV is different from the genomic organization of pneumoviruses within the sub-family *Pneumovirinae* of the family *Paramyxoviridae*. The classification of the two genera, metapneumovirus and pneumovirus, is based primarily on their gene constellation; metapneumoviruses generally lack non-structural proteins such as NS1 or NS2 (*see also* Randhawa *et al.*, 1997, J. Virol. 71:9849-9854) and the gene order is different from that of pneumoviruses (RSV: '3-NS1-NS2-N-P-M-SH-G-F-M2-L-5', APV: '3-N-P-M-F-M2-SH-G-L-5') (Lung, *et al.*, 1992, J. Gen. Virol. 73:1709-1715; Yu, *et al.*, 1992, *Virology* 186:426-434; Randhawa, *et al.*, 1997, J. Virol. 71:9849-9854).

Further, a mammalian MPV of the invention can be identified by its immunological properties. In certain embodiments, specific anti-sera can be raised against mammalian MPV that can neutralize mammalian MPV. Monoclonal and polyclonal antibodies can be raised against MPV that can also neutralize mammalian MPV. (*See*, PCT WO 02/057302).

The mammalian MPV of the invention is further characterized by its ability to infect a mammalian host, *i.e.*, a mammalian cultured cell or a mammal. Unlike APV, mammalian MPV does not replicate or replicates only at low levels in chickens and turkeys. Mammalian MPV replicates, however, in mammalian hosts, such as cynomolgous macaques. In certain,

more specific, embodiments, a mammalian MPV is further characterized by its ability to replicate in a mammalian host. In certain, more specific embodiments, a mammalian MPV is further characterized by its ability to cause the mammalian host to express proteins encoded by the genome of the mammalian MPV. In even more specific embodiments, the viral proteins expressed by the mammalian MPV are inserted into the cytoplasmic membranes of the mammalian host. In certain embodiments, the mammalian MPV of the invention can infect a mammalian host and cause the mammalian host to produce new infectious viral particles of the mammalian MPV. For a more detailed description of the functional characteristics of the mammalian MPV of the invention, see section 5.1.2.

In certain embodiments, the appearance of a virus in an electron microscope or its sensitivity to chloroform can be used to identify the virus as a mammalian MPV. The mammalian MPV of the invention appears in an electron microscope as paramyxovirus-like particle. Consistently, a mammalian MPV is sensitive to treatment with chloroform; a mammalian MPV is cultured optimally on tMK cells or cells functionally equivalent thereto and it is essentially trypsin dependent in most cell cultures. Furthermore, a mammalian MPV has a typical cytopathic effects (CPE) and lacks haemagglutinating activity against species of red blood cells. The CPE induced by MPV isolates are similar to the CPE induced by hRSV, with characteristic syncytia formation followed by rapid internal disruption of the cells and subsequent detachment from the culture plates. Although most paramyxoviruses have haemagglutinating activity, most of the pneumoviruses do not (Pringle, C.R. In: *The Paramyxoviruses*; (ed. D.W. Kingsbury) 1-39 (Plenum Press, New York, 1991)). A mammalian MPV contains a second overlapping ORF (M2-2) in the nucleic acid fragment encoding the M2 protein. The occurrence of this second overlapping ORF occurs in other pneumoviruses as shown in Ahmadian *et al.*, 1999, *J. Gen. Vir.* 80:2011-2016.

In certain embodiments, the invention provides methods to identify a viral isolate as a mammalian MPV. A test sample can, *e.g.*, be obtained from an animal or human. The sample is then tested for the presence of a virus of the sub-family *Pneumovirinae*. If a virus of the sub-family *Pneumovirinae* is present, the virus can be tested for any of the characteristics of a mammalian MPV as discussed herein, such as, but not limited to, phylogenetic relatedness to a mammalian MPV, nucleotide sequence identity to a nucleotide sequence of a mammalian MPV, amino acid sequence identity/homology to a amino acid

sequence of a mammalian MPV, and genomic organization. Furthermore, the virus can be identified as a mammalian MPV by cross-hybridization experiments using nucleic acid sequences from a MPV isolate, RT-PCR using primers specific to mammalian MPV, or in classical cross-serology experiments using antibodies directed against a mammalian MPV isolate. In certain other embodiments, a mammalian MPV can be identified on the basis of its immunological distinctiveness, as determined by quantitative neutralization with animal antisera. The antisera can be obtained from, *e.g.*, ferrets, pigs or macaques that are infected with a mammalian MPV (*see, e.g.*, Example 8).

In certain embodiments, the serotype does not cross-react with viruses other than mammalian MPV. In other embodiments, the serotype shows a homologous-to-heterologous titer ratio >16 in both directions. If neutralization shows a certain degree of cross-reaction between two viruses in either or both directions (homologous-to-heterologous titer ratio of eight or sixteen), distinctiveness of serotype is assumed if substantial biophysical/biochemical differences of DNA sequences exist. If neutralization shows a distinct degree of cross-reaction between two viruses in either or both directions (homologous-to-heterologous titer ratio of smaller than eight), identity of serotype of the isolates under study is assumed. Isolate I-2614, herein also known as MPV isolate 00-1, can be used as prototype.

In certain embodiments, a virus can be identified as a mammalian MPV by means of sequence homology/identity of the viral proteins or nucleic acids in comparison with the amino acid sequence and nucleotide sequences of the viral isolates disclosed herein by sequence or deposit. In particular, a virus is identified as a mammalian MPV when the genome of the virus contains a nucleic acid sequence that has a percentage nucleic acid identity to a virus isolate deposited as I-2614 with CNCM, Paris which is higher than the percentages identified herein for the nucleic acids encoding the L protein, the M protein, the N protein, the P protein, or the F protein as identified herein below in comparison with APV-C (*see* Table 1). (*See*, PCT WO 02/05302, at pp. 12 to 19.

Without being bound by theory, it is generally known that viral species, especially RNA virus species, often constitute a quasi species wherein the members of a cluster of the viruses display sequence heterogeneity. Thus, it is expected that each individual isolate may have a somewhat different percentage of sequence identity when compared to APV-C.

The highest amino sequence identity between the proteins of MPV and any of the known other viruses of the same family to date is the identity between APV-C and human MPV. Between human MPV and APV-C, the amino acid sequence identity for the matrix protein is 87%, 88% for the nucleoprotein, 68% for the phosphoprotein, 81% for the fusion protein and 56-64% for parts of the polymerase protein, as can be deduced when comparing the sequences given in Figure 30, see also Table 1. Viral isolates that contain ORFs that encode proteins with higher homology compared to these maximum values are considered mammalian MPVs. It should be noted that, similar to other viruses, a certain degree of variation is found between different isolated of mammalian MPVs.

Table 1: Amino acid sequence identity between the ORFs of MPV and those of other paramyxoviruses .

	N	P	M	F	M2-1	M2-2	L
APV A	69	55	78	67	72	26	64
APV B	69	51	76	67	71	27	⁻²
APV C	88	68	87	81	84	56	⁻²
hRSVA	42	24	38	34	36	18	42
hRSV B	41	23	37	33	35	19	44
bRSV	42	22	38	34	35	13	44
PVM	45	26	37	39	33	12	⁻²
others ³	7-11	4-9	7-10	10-18	⁻⁴	⁻⁴	13-14

Footnotes:

1.No sequence homologies were found with known G and SH proteins and were thus excluded

2. Sequences not available.

3. others: human parainfluenza virus type 2 and 3, Sendai virus, measles virus, nipah virus, phocine distemper virus, and New Castle Disease virus.

4. ORF absent in viral genome.

In certain embodiments, the invention provides a mammalian MPV, wherein the amino acid sequence of the SH protein of the mammalian MPV is at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at

least 99%, or at least 99.5% identical to the amino acid sequence of SEQ ID NO:382 (SH protein of isolate NL/1/00; see Table 14). The isolated negative-sense single stranded RNA metapneumovirus that comprises the SH protein that is at least 30% identical to SEQ ID NO:382 (SH protein of isolate NL/1/00; see Table 14) is capable of infecting a mammalian host. In certain embodiments, the isolated negative-sense single stranded RNA metapneumovirus that comprises the SH protein that is at least 30% identical to SEQ ID NO:382 (SH protein of isolate NL/1/00; see Table 14) is capable of replicating in a mammalian host. In certain embodiments, a mammalian MPV contains a nucleotide sequence that encodes a SH protein that is at least 30% identical to SEQ ID NO:382 (SH protein of isolate NL/1/00; see Table 14).

In certain embodiments, the invention provides a mammalian MPV, wherein the amino acid sequence of the G protein of the mammalian MPV is at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of SEQ ID NO:322 (G protein of isolate NL/1/00; see Table 14). The isolated negative-sense single stranded RNA metapneumovirus that comprises the G protein that is at least 20% identical to SEQ ID NO:322 (G protein of isolate NL/1/00; see Table 14) is capable of infecting a mammalian host. In certain embodiments, the isolated negative-sense single stranded RNA metapneumovirus that comprises the G protein that is at least 20% identical to SEQ ID NO:322 (G protein of isolate NL/1/00; see Table 14) is capable of replicating in a mammalian host. In certain embodiments, a mammalian MPV contains a nucleotide sequence that encodes a G protein that is at least 20% identical to SEQ ID NO:322 (G protein of isolate NL/1/00; see Table 14).

In certain embodiments, the invention provides a mammalian MPV, wherein the amino acid sequence of the L protein of the mammalian MPV is at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of SEQ ID NO:330 (L protein of isolate NL/1/00; see Table 14). The isolated negative-sense single stranded RNA metapneumovirus that comprises the L protein that is at least 85% identical to SEQ ID NO:330 (L protein of isolate NL/1/00; see Table 14) is capable of infecting a mammalian host. In certain embodiments, the isolated negative-sense single

stranded RNA metapneumovirus that comprises the L protein that is at least 85% identical to SEQ ID NO:330 (L protein of isolate NL/1/00; see Table 14) is capable of replicating in a mammalian host. In certain embodiments, a mammalian MPV contains a nucleotide sequence that encodes a L protein that is at least 20% identical to SEQ ID NO:330 (L protein of isolate NL/1/00; see Table 14).

In certain embodiments, the invention provides a mammalian MPV, wherein the amino acid sequence of the N protein of the mammalian MPV is at least 90%, at least 95%, or at least 98% identical to the amino acid sequence of SEQ ID NO:366. The isolated negative-sense single stranded RNA metapneumovirus that comprises the N protein that is at least 90% identical in amino acid sequence to SEQ ID NO:366 is capable of infecting mammalian host. In certain embodiments, the isolated negative-sense single stranded RNA metapneumovirus that comprises the N protein that is 90% identical in amino acid sequence to SEQ ID NO:366 is capable of replicating in a mammalian host. The amino acid identity is calculated over the entire length of the N protein. In certain embodiments, a mammalian MPV contains a nucleotide sequence that encodes a N protein that is at least 90%, at least 95%, or at least 98% identical to the amino acid sequence of SEQ ID NO:366.

The invention further provides mammalian MPV, wherein the amino acid sequence of the P protein of the mammalian MPV is at least 70%, at least 80%, at least 90%, at least 95% or at least 98% identical to the amino acid sequence of SEQ ID NO:374. The mammalian MPV that comprises the P protein that is at least 70% identical in amino acid sequence to SEQ ID NO:374 is capable of infecting a mammalian host. In certain embodiments, the mammalian MPV that comprises the P protein that is at least 70% identical in amino acid sequence to SEQ ID NO:374 is capable of replicating in a mammalian host. The amino acid identity is calculated over the entire length of the P protein. In certain embodiments, a mammalian MPV contains a nucleotide sequence that encodes a P protein that is at least 70%, at least 80%, at least 90%, at least 95% or at least 98% identical to the amino acid sequence of SEQ ID NO:374.

The invention further provides, mammalian MPV, wherein the amino acid sequence of the M protein of the mammalian MPV is at least 90%, at least 95% or at least 98% identical to the amino acid sequence of SEQ ID NO:358. The mammalian MPV that comprises the M protein that is at least 90% identical in amino acid sequence to SEQ ID

NO:358 is capable of infecting mammalian host. In certain embodiments, the isolated negative-sense single stranded RNA metapneumovirus that comprises the M protein that is 90% identical in amino acid sequence to SEQ ID NO:358 is capable of replicating in a mammalian host. The amino acid identity is calculated over the entire length of the M protein. In certain embodiments, a mammalian MPV contains a nucleotide sequence that encodes a M protein that is at least 90%, at least 95% or at least 98% identical to the amino acid sequence of SEQ ID NO:358.

The invention further provides mammalian MPV, wherein the amino acid sequence of the F protein of the mammalian MPV is at least 85%, at least 90%, at least 95% or at least 98% identical to the amino acid sequence of SEQ ID NO:314. The mammalian MPV that comprises the F protein that is at least 85% identical in amino acid sequence to SEQ ID NO:314 is capable of infecting a mammalian host. In certain embodiments, the isolated negative-sense single stranded RNA metapneumovirus that comprises the F protein that is 85% identical in amino acid sequence to SEQ ID NO:314 is capable of replicating in mammalian host. The amino acid identity is calculated over the entire length of the F protein. In certain embodiments, a mammalian MPV contains a nucleotide sequence that encodes a F protein that is at least 85%, at least 90%, at least 95% or at least 98% identical to the amino acid sequence of SEQ ID NO:314.

The invention further provides mammalian MPV, wherein the amino acid sequence of the M2-1 protein of the mammalian MPV is at least 85%, at least 90%, at least 95% or at least 98% identical to the amino acid sequence of SEQ ID NO:338. The mammalian MPV that comprises the M2-1 protein that is at least 85% identical in amino acid sequence to SEQ ID NO:338 is capable of infecting a mammalian host. In certain embodiments, the isolated negative-sense single stranded RNA metapneumovirus that comprises the M2-1 protein that is 85% identical in amino acid sequence to SEQ ID NO:338 is capable of replicating in a mammalian host. The amino acid identity is calculated over the entire length of the M2-1 protein. In certain embodiments, a mammalian MPV contains a nucleotide sequence that encodes a M2-1 protein that is at least 85%, at least 90%, at least 95% or at least 98% identical to the amino acid sequence of SEQ ID NO:338.

The invention further provides mammalian MPV, wherein the amino acid sequence of the M2-2 protein of the mammalian MPV is at least 60%, at least 70%, at least 80%, at least

90%, at least 95% or at least 98% identical to the amino acid sequence of SEQ ID NO:346. The isolated mammalian MPV that comprises the M2-2 protein that is at least 60% identical in amino acid sequence to SEQ ID NO:346 is capable of infecting mammalian host. In certain embodiments, the isolated negative-sense single stranded RNA metapneumovirus that comprises the M2-2 protein that is 60% identical in amino acid sequence to SEQ ID NO:346 is capable of replicating in a mammalian host. The amino acid identity is calculated over the entire length of the M2-2 protein. In certain embodiments, a mammalian MPV contains a nucleotide sequence that encodes a M2-1 protein that is at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or at least 98% identical to the amino acid sequence of SEQ ID NO:346.

In certain embodiments, the invention provides mammalian MPV, wherein the negative-sense single stranded RNA metapneumovirus encodes at least two proteins, at least three proteins, at least four proteins, at least five proteins, or six proteins selected from the group consisting of (i) a N protein with at least 90% amino acid sequence identity to SEQ ID NO:366; (ii) a P protein with at least 70% amino acid sequence identity to SEQ ID NO:374 (iii) a M protein with at least 90% amino acid sequence identity to SEQ ID NO:358 (iv) a F protein with at least 85% amino acid sequence identity to SEQ ID NO:314 (v) a M2-1 protein with at least 85% amino acid sequence identity to SEQ ID NO:338; and (vi) a M2-2 protein with at least 60% amino acid sequence identity to SEQ ID NO:346.

The invention provides two subgroups of mammalian MPV, subgroup A and subgroup B. The invention also provides four variants A1, A2, B1 and B2. A mammalian MPV can be identified as a member of subgroup A if it is phylogenetically closer related to the isolate 00-1 (SEQ ID NO:19) than to the isolate 99-1 (SEQ ID NO:18). A mammalian MPV can be identified as a member of subgroup B if it is phylogenetically closer related to the isolate 99-1 (SEQ ID NO:18) than to the isolate 00-1 (SEQ ID NO:19). In other embodiments, nucleotide or amino acid sequence homologies of individual ORFs can be used to classify a mammalian MPV as belonging to subgroup A or B.

The different isolates of mammalian MPV can be divided into four different variants, variant A1, variant A2, variant B1 and variant B2 (*see* Figures 21 and 22). The isolate 00-1 (SEQ ID NO:19) is an example of the variant A1 of mammalian MPV. The isolate 99-1 (SEQ ID NO:18) is an example of the variant B1 of mammalian MPV. A mammalian MPV

can be grouped into one of the four variants using a phylogenetic analysis. Thus, a mammalian MPV belongs to a specific variant if it is phylogenetically closer related to a known member of that variant than it is phylogenetically related to a member of another variant of mammalian MPV. The sequence of any ORF and the encoded polypeptide may be used to type a MPV isolate as belonging to a particular subgroup or variant, including N, P, L, M, SH, G, M2 or F polypeptides. In a specific embodiment, the classification of a mammalian MPV into a variant is based on the sequence of the G protein. Without being bound by theory, the G protein sequence is well suited for phylogenetic analysis because of the high degree of variation among G proteins of the different variants of mammalian MPV.

In certain embodiments of the invention, sequence homology may be determined by the ability of two sequences to hybridize under certain conditions, as set forth below. A nucleic acid which is hybridizable to a nucleic acid of a mammalian MPV, or to its reverse complement, or to its complement can be used in the methods of the invention to determine their sequence homology and identities to each other. In certain embodiments, the nucleic acids are hybridized under conditions of high stringency.

It is well-known to the skilled artisan that hybridization conditions, such as, but not limited to, temperature, salt concentration, pH, formamide concentration (*see, e.g.,* Sambrook et al., 1989, Chapters 9 to 11, *Molecular Cloning, A Laboratory Manual*, 2d Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York).

In certain embodiments, hybridization is performed in aqueous solution and the ionic strength of the solution is kept constant while the hybridization temperature is varied dependent on the degree of sequence homology between the sequences that are to be hybridized. For DNA sequences that 100% identical to each other and are longer than 200 basepairs, hybridization is carried out at approximately 15-25°C below the melting temperature (T_m) of the perfect hybrid. The melting temperature (T_m) can be calculated using the following equation (Bolton and McCarthy, 1962, *Proc. Natl. Acad. Sci. USA* 84:1390):

$$T_m = 81.5^{\circ}\text{C} - 16.6(\log_{10}[\text{Na}^{+}]) + (\%G+C) - 0.63(\%\text{formamide}) - (600/l)$$

Wherein (T_m) is the melting temperature, $[Na^+]$ is the sodium concentration, $G+C$ is the Guanine and Cytosine content, and l is the length of the hybrid in basepairs. The effect of mismatches between the sequences can be calculated using the formula by Bonner et al. (Bonner et al., 1973, J. Mol. Biol. 81:123-135): for every 1% of mismatching of bases in the hybrid, the melting temperature is reduced by 1-1.5°C.

Thus, by determining the temperature at which two sequences hybridize, one of skill in the art can estimate how similar a sequence is to a known sequence. This can be done, e.g., by comparison of the empirically determined hybridization temperature with the hybridization temperature calculated for the known sequence to hybridize with its perfect match. Through the use of the formula by Bonner et al., the relationship between hybridization temperature and per cent mismatch can be exploited to provide information about sequence similarity.

By way of example and not limitation, procedures using such conditions of high stringency are as follows. Prehybridization of filters containing DNA is carried out for 8 h to overnight at 65°C in buffer composed of 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% FicollTM, 0.02% BSA, and 500 µg/ml denatured salmon sperm DNA. Filters are hybridized for 48 h at 65°C in prehybridization mixture containing 100 µg/ml denatured salmon sperm DNA and 5-20 X 10⁶ cpm of ³²P-labeled probe. Washing of filters is done at 37°C for 1 h in a solution containing 2X SSC, 0.01% PVP, 0.01% Ficoll, and 0.01% BSA. This is followed by a wash in 0.1X SSC at 50°C for 45 min before autoradiography. Other conditions of high stringency which may be used are well known in the art. In other embodiments of the invention, hybridization is performed under moderate or low stringency conditions, such conditions are well-known to the skilled artisan (*see e.g.*, Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York; *see also*, Ausubel et al., eds., in the Current Protocols in Molecular Biology series of laboratory technique manuals, 1987-1997 Current Protocols, © 1994-1997 John Wiley and Sons, Inc.).

An illustrative low stringency condition is provided by the following system of buffers: hybridization in a buffer comprising 35% formamide, 5X SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 µg/ml denatured salmon sperm DNA, and 10% (wt/vol) dextran sulfate for 18-20 hours at 40°C, washing in a buffer consisting of 2X SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and

0.1% SDS for 1.5 hours at 55°C, and washing in a buffer consisting of 2X SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS for 1.5 hours at 60°C.

In certain embodiments, a mammalian MPV can be classified into one of the variant using probes that are specific for a specific variant of mammalian MPV. Such probes include primers for RT-PCR and antibodies. Illustrative methods for identifying a mammalian MPV as a member of a specific variant are described in section 5.9 below.

In certain embodiments of the invention, the different variants of mammalian MPV can be distinguished from each other by way of the amino acid sequences of the different viral proteins (see, e.g., Figure 42b). In other embodiments, the different variants of mammalian MPV can be distinguished from each other by way of the nucleotide sequences of the different ORFs encoded by the viral genome (see, e.g., Figure 42b). A variant of mammalian MPV can be, but is not limited to, A1, A2, B1 or B2. The invention, however, also contemplates isolates of mammalian MPV that are members of another variant yet to be identified. The invention also contemplates that a virus may have one or more ORF that are closer related to one variant and one or more ORFs that are closer phylogenetically related to another variant. Such a virus would be classified into the variant to which the majority of its ORFs are closer phylogenetically related. Non-coding sequences may also be used to determine phylogenetic relatedness.

An isolate of mammalian MPV is classified as a variant B1 if it is phylogenetically closer related to the viral isolate NL/1/99 (SEQ ID NO:18) than it is related to any of the following other viral isolates: NL/1/00 (SEQ ID NO:19), NL/17/00 (SEQ ID NO:20) and NL/1/94 (SEQ ID NO:21). One or more of the ORFs of a mammalian MPV can be used to classify the mammalian MPV into a variant. A mammalian MPV can be classified as an MPV variant B1, if the amino acid sequence of its G protein is at least 66%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% or at least 99.5% identical to the G protein of a mammalian MPV variant B1 as represented by the prototype NL/1/99 (SEQ ID NO:324); if the amino acid sequence of its N protein is at least 98.5% or at least 99% or at least 99.5% identical to the N protein of a mammalian MPV variant B1 as represented by the prototype NL/1/99 (SEQ ID NO:368); if the amino acid sequence of its P protein is at least 96%, at least 98%, or at least 99% or at least 99.5% identical to the P protein of a mammalian MPV variant B1 as represented by the prototype

NL/1/99 (SEQ ID NO:376); if the amino acid sequence of its M protein is identical to the M protein of a mammalian MPV variant B1 as represented by the prototype NL/1/99 (SEQ ID NO:360); if the amino acid sequence of its F protein is at least 99% identical to the F protein of a mammalian MPV variant B1 as represented by the prototype NL/1/99 (SEQ ID NO:316); if the amino acid sequence of its M2-1 protein is at least 98% or at least 99% or at least 99.5% identical to the M2-1 protein of a mammalian MPV variant B1 as represented by the prototype NL/1/99 (SEQ ID NO:340); if the amino acid sequence of its M2-2 protein is at least 99% or at least 99.5% identical to the M2-2 protein of a mammalian MPV variant B1 as represented by the prototype NL/1/99 (SEQ ID NO:348); if the amino acid sequence of its SH protein is at least 83%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% or at least 99.5% identical to the SH protein of a mammalian MPV variant B1 as represented by the prototype NL/1/99 (SEQ ID NO:384); and/or if the amino acid sequence of its L protein is at least 99% or at least 99.5% identical to the L protein of a mammalian MPV variant B1 as represented by the prototype NL/1/99 (SEQ ID NO:332).

An isolate of mammalian MPV is classified as a variant A1 if it is phylogenetically closer related to the viral isolate NL/1/00 (SEQ ID NO:19) than it is related to any of the following other viral isolates: NL/1/99 (SEQ ID NO:18), NL/17/00 (SEQ ID NO:20) and NL/1/94 (SEQ ID NO:21). One or more of the ORFs of a mammalian MPV can be used to classify the mammalian MPV into a variant. A mammalian MPV can be classified as an MPV variant A1, if the amino acid sequence of its G protein is at least 66%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% or at least 99.5% identical to the G protein of a mammalian MPV variant A1 as represented by the prototype NL/1/00 (SEQ ID NO:322); if the amino acid sequence of its N protein is at least 99.5% identical to the N protein of a mammalian MPV variant A1 as represented by the prototype NL/1/00 (SEQ ID NO:366); if the amino acid sequence of its P protein is at least 96%, at least 98%, or at least 99% or at least 99.5% identical to the P protein of a mammalian MPV variant A1 as represented by the prototype NL/1/00 (SEQ ID NO:374); if the amino acid sequence of its M protein is at least 99% or at least 99.5% identical to the M protein of a mammalian MPV variant A1 as represented by the prototype NL/1/00 (SEQ ID NO:358); if the amino acid sequence of its F protein is at least 98% or at least 99% or at least 99.5% identical to the F protein of a mammalian MPV variant A1 as represented by the prototype

NL/1/00 (SEQ ID NO:314); if the amino acid sequence of its M2-1 protein is at least 99% or at least 99.5% identical to the M2-1 protein of a mammalian MPV variant A1 as represented by the prototype NL/1/00 (SEQ ID NO:338); if the amino acid sequence of its M2-2 protein is at least 96% or at least 99% or at least 99.5% identical to the M2-2 protein of a mammalian MPV variant A1 as represented by the prototype NL/1/00 (SEQ ID NO:346); if the amino acid sequence of its SH protein is at least 84%, at least 90%, at least 95%, at least 98%, or at least 99% or at least 99.5% identical to the SH protein of a mammalian MPV variant A1 as represented by the prototype NL/1/00 (SEQ ID NO:382); and/or if the amino acid sequence of its L protein is at least 99% or at least 99.5% identical to the L protein of a virus of a mammalian MPV variant A1 as represented by the prototype NL/1/00 (SEQ ID NO:330).

An isolate of mammalian MPV is classified as a variant A2 if it is phylogenetically closer related to the viral isolate NL/17/00 (SEQ ID NO:20) than it is related to any of the following other viral isolates: NL/1/99 (SEQ ID NO:18), NL/1/00 (SEQ ID NO:19) and NL/1/94 (SEQ ID NO:21). One or more of the ORFs of a mammalian MPV can be used to classify the mammalian MPV into a variant. A mammalian MPV can be classified as an MPV variant A2, if the amino acid sequence of its G protein is at least 66%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or at least 99.5% identical to the G protein of a mammalian MPV variant A2 as represented by the prototype NL/17/00 (SEQ ID NO:332); if the amino acid sequence of its N protein is at least 99.5% identical to the N protein of a mammalian MPV variant A2 as represented by the prototype NL/17/00 (SEQ ID NO:367); if the amino acid sequence of its P protein is at least 96%, at least 98%, at least 99% or at least 99.5% identical to the P protein of a mammalian MPV variant A2 as represented by the prototype NL/17/00 (SEQ ID NO:375); if the amino acid sequence of its M protein is at least 99%, or at least 99.5% identical to the M protein of a mammalian MPV variant A2 as represented by the prototype NL/17/00 (SEQ ID NO:359); if the amino acid sequence of its F protein is at least 98%, at least 99% or at least 99.5% identical to the F protein of a mammalian MPV variant A2 as represented by the prototype NL/17/00 (SEQ ID NO:315); if the amino acid sequence of its M2-1 protein is at least 99%, or at least 99.5% identical to the M2-1 protein of a mammalian MPV variant A2 as represented by the prototype NL/17/00 (SEQ ID NO: 339); if the amino acid sequence of its M2-2 protein is at least 96%, at least 98%, at least 99% or at least 99.5% identical to the M2-

2 protein of a mammalian MPV variant A2 as represented by the prototype NL/17/00 (SEQ ID NO:347); if the amino acid sequence of its SH protein is at least 84%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or at least 99.5% identical to the SH protein of a mammalian MPV variant A2 as represented by the prototype NL/17/00 (SEQ ID NO:383); if the amino acid sequence of its L protein is at least 99% or at least 99.5% identical to the L protein of a mammalian MPV variant A2 as represented by the prototype NL/17/00 (SEQ ID NO:331).

An isolate of mammalian MPV is classified as a variant B2 if it is phylogenetically closer related to the viral isolate NL/1/94 (SEQ ID NO:21) than it is related to any of the following other viral isolates: NL/1/99 (SEQ ID NO:18), NL/1/00 (SEQ ID NO:19) and NL/17/00 (SEQ ID NO:20). One or more of the ORFs of a mammalian MPV can be used to classify the mammalian MPV into a variant. A mammalian MPV can be classified as an MPV variant B2, if the amino acid sequence of its G protein is at least 66%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% or at least 99.5% identical to the G protein of a mammalian MPV variant B2 as represented by the prototype NL/1/94 (SEQ ID NO:325); if the amino acid sequence of its N protein is at least 99% or at least 99.5% identical to the N protein of a mammalian MPV variant B2 as represented by the prototype NL/1/94 (SEQ ID NO:369); if the amino acid sequence of its P protein is at least 96%, at least 98%, or at least 99% or at least 99.5% identical to the P protein of a mammalian MPV variant B2 as represented by the prototype NL/1/94 (SEQ ID NO:377); if the amino acid sequence of its M protein is identical to the M protein of a mammalian MPV variant B2 as represented by the prototype NL/1/94 (SEQ ID NO:361); if the amino acid sequence of its F protein is at least 99% or at least 99.5% identical to the F protein of a mammalian MPV variant B2 as represented by the prototype NL/1/94 (SEQ ID NO:317); if the amino acid sequence of the M2-1 protein is at least 98% or at least 99% or at least 99.5% identical to the M2-1 protein of a mammalian MPV variant B2 as represented by the prototype NL/1/94 (SEQ ID NO:341); if the amino acid sequence that is at least 99% or at least 99.5% identical to the M2-2 protein of a mammalian MPV variant B2 as represented by the prototype NL/1/94 (SEQ ID NO:349); if the amino acid sequence of its SH protein is at least 84%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% or at least 99.5% identical to the SH protein of a mammalian MPV variant B2 as represented by the

prototype NL/1/94 (SEQ ID NO:385); and/or if the amino acid sequence of its L protein is at least 99% or at least 99.5% identical to the L protein of a mammalian MPV variant B2 as represented by the prototype NL/1/94 (SEQ ID NO:333).

In certain embodiments, the percentage of sequence identity is based on an alignment of the full length proteins. In other embodiments, the percentage of sequence identity is based on an alignment of contiguous amino acid sequences of the proteins, wherein the amino acid sequences can be 25 amino acids, 50 amino acids, 75 amino acids, 100 amino acids, 125 amino acids, 150 amino acids, 175 amino acids, 200 amino acids, 225 amino acids, 250 amino acids, 275 amino acids, 300 amino acids, 325 amino acids, 350 amino acids, 375 amino acids, 400 amino acids, 425 amino acids, 450 amino acids, 475 amino acids, 500 amino acids, 750 amino acids, 1000 amino acids, 1250 amino acids, 1500 amino acids, 1750 amino acids, 2000 amino acids or 2250 amino acids in length.

5.2 FUNCTIONAL CHARACTERISTICS OF A MAMMALIAN MPV

In addition to the structural definitions of the mammalian MPV, a mammalian MPV can also be defined by its functional characteristics. In certain embodiments, the mammalian MPV of the invention is capable of infecting a mammalian host. The mammalian host can be a mammalian cell, tissue, organ or a mammal. In a specific embodiment, the mammalian host is a human or a human cell, tissue or organ. Any method known to the skilled artisan can be used to test whether the mammalian host has been infected with the mammalian MPV. In certain embodiments, the virus is tested for its ability to attach to a mammalian cell. In certain other embodiments, the virus is tested for its ability to transfer its genome into the mammalian cell. In an illustrative embodiment, the genome of the virus is detectably labeled, e.g., radioactively labeled. The virus is then incubated with a mammalian cell for at least 1 minute, at least 5 minutes at least 15 minutes, at least 30 minutes, at least 1 hour, at least 2 hours, at least 5 hours, at least 12 hours, or at least 1 day. The cells are subsequently washed to remove any viral particles from the cells and the cells are then tested for the presence of the viral genome by virtue of the detectable label. In another embodiment, the presence of the viral genome in the cells is detected using RT-PCR using mammalian MPV specific primers. (See , PCT WO 02/057302 at pp. 37 to 44).

In certain embodiments, the mammalian virus is capable to infect a mammalian host and to cause proteins of the mammalian MPV to be inserted into the cytoplasmic membrane of the mammalian host. The mammalian host can be a cultured mammalian cell, organ, tissue or mammal. In an illustrative embodiment, a mammalian cell is incubated with the mammalian virus. The cells are subsequently washed under conditions that remove the virus from the surface of the cell. Any technique known to the skilled artisan can be used to detect the newly expressed viral protein inserted in the cytoplasmic membrane of the mammalian cell. For example, after infection of the cell with the virus, the cells are maintained in medium comprising a detectably labeled amino acid. The cells are subsequently harvested, lysed, and the cytoplasmic fraction is separated from the membrane fraction. The proteins of the membrane fraction are then solubilized and then subjected to an immunoprecipitation using antibodies specific to a protein of the mammalian MPV, such as, but not limited to, the F protein or the G protein. The immunoprecipitated proteins are then subjected to SDS PAGE. The presence of viral protein can then be detected by autoradiography. In another embodiment, the presence of viral proteins in the cytoplasmic membrane of the host cell can be detected by immunocytochemistry using one or more antibodies specific to proteins of the mammalian MPV.

In even other embodiments, the mammalian MPV of the invention is capable of infecting a mammalian host and of replicating in the mammalian host. The mammalian host can be a cultured mammalian cell, organ, tissue or mammal. Any technique known to the skilled artisan can be used to determine whether a virus is capable of infecting a mammalian cell and of replicating within the mammalian host. In a specific embodiment, mammalian cells are infected with the virus. The cells are subsequently maintained for at least 30 minutes, at least 1 hour, at least 2 hours, at least 5 hours, at least 12 hours, at least 1 day, or at least 2 days. The level of viral genomic RNA in the cells can be monitored using Northern blot analysis, RT-PCR or *in situ* hybridization using probes that are specific to the viral genome. An increase in viral genomic RNA demonstrates that the virus can infect a mammalian cell and can replicate within a mammalian cell.

In even other embodiments, the mammalian MPV of the invention is capable of infecting a mammalian host, wherein the infection causes the mammalian host to produce new infectious mammalian MPV. The mammalian host can be a cultured mammalian cell or

a mammal. Any technique known to the skilled artisan can be used to determine whether a virus is capable of infecting a mammalian host and cause the mammalian host to produce new infectious viral particles. In an illustrative example, mammalian cells are infected with a mammalian virus. The cells are subsequently washed and incubated for at least 30 minutes, at least 1 hour, at least 2 hours, at least 5 hours, at least 12 hours, at least 1 day, at least 2 days, at least one week, or at least twelve days. The titer of virus can be monitored by any method known to the skilled artisan. For exemplary methods see section 5.8.

In certain, specific embodiments, the mammalian MPV is a human MPV. The tests described in this section can also be performed with a human MPV. In certain embodiments, the human MPV is capable of infecting a mammalian host, such as a mammal or a mammalian cultured cell.

In certain embodiments, the human MPV is capable to infect a mammalian host and to cause proteins of the human MPV to be inserted into the cytoplasmic membrane of the mammalian host.

In even other embodiments, the human MPV of the invention is capable of infecting a mammalian host and of replicating in the mammalian host.

In even other embodiments, the human MPV of the invention is capable of infecting a mammalian host and of replicating in the mammalian host, wherein the infection and replication causes the mammalian host to produce and package new infectious human MPV.

In certain embodiments, the mammalian MPV, even though it is capable of infecting a mammalian host, is also capable of infecting an avian host, such as a bird or an avian cultured cell. In certain embodiments, the mammalian MPV is capable to infect an avian host and to cause proteins of the mammalian MPV to be inserted into the cytoplasmic membrane of the avian host. In even other embodiments, the mammalian MPV of the invention is capable of infecting an avian host and of replicating in the avian host. In even other embodiments, the mammalian MPV of the invention is capable of infecting an avian host and of replicating in the avian host, wherein the infection and replication causes the avian host to produce and package new infectious mammalian MPV.

5.3 RECOMBINANT AND CHIMERIC METAPNEUMOVIRUS

The present invention encompasses recombinant or chimeric viruses encoded by viral vectors derived from the genomes of metapneumovirus, including both mammalian and avian variants. In accordance with the present invention a recombinant virus is one derived from a mammalian MPV or an APV that is encoded by endogenous or native genomic sequences or non-native genomic sequences. In accordance with the invention, a non-native sequence is one that is different from the native or endogenous genomic sequence due to one or more mutations, including, but not limited to, point mutations, rearrangements, insertions, deletions etc., to the genomic sequence that may or may not result in a phenotypic change. The recombinant viruses of the invention encompass those viruses encoded by viral vectors derived from the genomes of metapneumovirus, including both mammalian and avian variants, and may or may not, include nucleic acids that are non-native to the viral genome. In accordance with the present invention, a viral vector which is derived from the genome of a metapneumovirus is one that contains a nucleic acid sequence that encodes at least a part of one ORF of a mammalian metapneumovirus, wherein the polypeptides encoded by the ORF have amino acid sequence identity as set forth in Section 5.1. *supra*, and Table 1.

In accordance with the present invention, the recombinant viruses of the invention encompass those viruses encoded by viral vectors derived from the genome of a mammalian metapneumovirus (MPV), in particular a human metapneumovirus. In particular embodiments of the invention, the viral vector is derived from the genome of a metapneumovirus A1, A2, B1 or B2 variant. In accordance with the present invention, these viral vectors may or may not include nucleic acids that are non-native to the viral genome

In accordance with the present invention, the recombinant viruses of the invention encompass those viruses encoded by viral vectors derived from the genome of an avian pneumovirus (APV), also known as turkey rhinotracheitis virus (TRTV). In particular embodiments of the invention, the viral vector is derived from the genome of an APV subgroup A, B, C or D. In a preferred embodiment, a viral vector derived from the genome of an APV subgroup C. In accordance with the present invention these viral vectors may or may not include nucleic acids that are non-native to the viral genome.

In another preferred embodiment of the invention, the recombinant viruses of the invention encompass those viruses encoded by a viral vector derived from the genome of an APV that contains a nucleic acid sequence that encodes a F-ORF of APV subgroup C. In

certain embodiments, a viral vector derived from the genome of an APV is one that contains a nucleic acid sequence that encodes at least a N-ORF, a P-ORF, a M-ORF, a F-ORF, a M2-1-ORF, a M2-2-ORF or a L-ORF of APV.

In accordance with the invention, a chimeric virus is a recombinant MPV or APV which further comprises a heterologous nucleotide sequence. In accordance with the invention, a chimeric virus may be encoded by a nucleotide sequence in which heterologous nucleotide sequences have been added to the genome or in which endogenous or native nucleotide sequences have been replaced with heterologous nucleotide sequences.

In accordance with the invention, the chimeric viruses are encoded by the viral vectors of the invention which further comprise a heterologous nucleotide sequence. In accordance with the present invention a chimeric virus is encoded by a viral vector that may or may not include nucleic acids that are non-native to the viral genome. In accordance with the invention a chimeric virus is encoded by a viral vector to which heterologous nucleotide sequences have been added, inserted or substituted for native or non-native sequences. In accordance with the present invention, the chimeric virus may be encoded by nucleotide sequences derived from different strains of mammalian MPV. In particular, the chimeric virus is encoded by nucleotide sequences that encode antigenic polypeptides derived from different strains of MPV.

In accordance with the present invention, the chimeric virus may be encoded by a viral vector derived from the genome of an APV, in particular subgroup C, that additionally encodes a heterologous sequence that encodes antigenic polypeptides derived from one or more strains of MPV.

A chimeric virus may be of particular use for the generation of recombinant vaccines protecting against two or more viruses (Tao et al., J. Virol. 72, 2955-2961; Durbin et al., 2000, J. Virol. 74, 6821-6831; Skiadopoulos et al., 1998, J. Virol. 72, 1762-1768; Teng et al., 2000, J. Virol. 74, 9317-9321). For example, it can be envisaged that a MPV or APV virus vector expressing one or more proteins of another negative strand RNA virus, *e.g.*, RSV or a RSV vector expressing one or more proteins of MPV will protect individuals vaccinated with such vector against both virus infections. A similar approach can be envisaged for PIV or other paramyxoviruses. Attenuated and replication-defective viruses may be of use for

vaccination purposes with live vaccines as has been suggested for other viruses. (*See*, PCT WO 02/057302, at pp. 6 and 23).

In accordance with the present invention the heterologous sequence to be incorporated into the viral vectors encoding the recombinant or chimeric viruses of the invention include sequences obtained or derived from different strains of metapneumovirus, strains of avian pneumovirus, and other negative strand RNA viruses, including, but not limited to, RSV, PIV and influenza virus, and other viruses, including morbillivirus.

In certain embodiments of the invention, the chimeric or recombinant viruses of the invention are encoded by viral vectors derived from viral genomes wherein one or more sequences, intergenic regions, termini sequences, or portions or entire ORF have been substituted with a heterologous or non-native sequence. In certain embodiments of the invention, the chimeric viruses of the invention are encoded by viral vectors derived from viral genomes wherein one or more heterologous sequences have been added to the vector.

In certain embodiments, the virus of the invention contains heterologous nucleic acids. In a preferred embodiment, the heterologous nucleotide sequence is inserted or added at Position 1 of the viral genome. In another preferred embodiment, the heterologous nucleotide sequence is inserted or added at Position 2 of the viral genome. In even another preferred embodiment, the heterologous nucleotide sequence is inserted or added at Position 3 of the viral genome. Insertion or addition of nucleic acid sequences at the lower-numbered positions of the viral genome results in stronger or higher levels of expression of the heterologous nucleotide sequence compared to insertion at higher-numbered positions due to a transcriptional gradient across the genome of the virus. Thus, inserting or adding heterologous nucleotide sequences at lower-numbered positions is the preferred embodiment of the invention if high levels of expression of the heterologous nucleotide sequence is desired.

Without being bound by theory, the position of insertion or addition of the heterologous sequence affects the replication rate of the recombinant or chimeric virus. The higher rates of replication can be achieved if the heterologous sequence is inserted or added at Position 2 or Position 1 of the viral genome. The rate of replication is reduced if the heterologous sequence is inserted or added at Position 3, Position 4, Position 5, or Position 6.

Without being bound by theory, the size of the intergenic region between the viral gene and the heterologous sequence further determines rate of replication of the virus and expression levels of the heterologous sequence.

In certain embodiments, the viral vector of the invention contains two or more different heterologous nucleotide sequences. In a preferred embodiment, one heterologous nucleotide sequence is at Position 1 and a second heterologous nucleotide sequence is at Position 2 of the viral genome. In another preferred embodiment, one heterologous nucleotide sequence is at Position 1 and a second heterologous nucleotide sequence is at Position 3 of the viral genome. In even another preferred embodiment, one heterologous nucleotide sequence is at Position 2 and a second heterologous nucleotide sequence is at Position 3 of the viral genome. In certain other embodiments, a heterologous nucleotide sequence is inserted at other, higher-numbered positions of the viral genome. In accordance with the present invention, the position of the heterologous sequence refers to the order in which the sequences are transcribed from the viral genome, *e.g.*, a heterologous sequence at Position 1 is the first gene sequence to be transcribed from the genome.

The selection of the viral vector may depend on the species of the subject that is to be treated or protected from a viral infection. If the subject is human, then an attenuated mammalian metapneumovirus or an avian pneumovirus can be used to provide the antigenic sequences.

In accordance with the present invention, the viral vectors can be engineered to provide antigenic sequences which confer protection against infection by a metapneumovirus, including sequences derived from mammalian metapneumovirus, human metapneumovirus, MPV variants A1, A2, B1 or B2, sequences derived from avian pneumovirus, including APV subgroups A, B, C or D, although C is preferred. The viral vectors can be engineered to provide antigenic sequences which confer protection against infection or disease by another virus, including negative strand RNA virus, including influenza, RSV or PIV, including PIV3. The viral vectors may be engineered to provide one, two, three or more antigenic sequences. In accordance with the present invention the antigenic sequences may be derived from the same virus, from different strains or variants of the same type of virus, or from different viruses, including morbillivirus.

In certain embodiments of the invention, the heterologous nucleotide sequence to be inserted into the genome of the virus of the invention is derived from a metapneumovirus. In certain specific embodiments of the invention, the heterologous nucleotide sequence is derived from a human metapneumovirus. In another specific embodiment, the heterologous nucleotide sequence is derived from an avian pneumovirus. More specifically, the heterologous nucleotide sequence of the invention encodes a F gene of a human metapneumovirus. More specifically, the heterologous nucleotide sequence of the invention encodes an G gene of a human metapneumovirus. More specifically, the heterologous nucleotide sequence of the invention encodes a F gene of an avian pneumovirus. More specifically, the heterologous nucleotide sequence of the invention encodes a G gene of an avian pneumovirus. In specific embodiments, a heterologous nucleotide sequences can be any one of SEQ ID NO:1 through SEQ ID NO:5, SEQ ID NO:14, and SEQ ID NO:15. In certain specific embodiments, the nucleotide sequence encodes a protein of any one of SEQ ID NO:6 through SEQ ID NO:13, SEQ ID NO:16, and SEQ ID NO:17.

In a specific embodiment of the invention, the heterologous nucleotide sequence encodes a chimeric F protein. In an illustrative embodiment, the ectodomain of the chimeric F-protein is the ectodomain of a human MPV and the transmembrane domain and the luminal domain are derived from the F-protein of an avian metapneumovirus. Without being bound by theory, a chimeric human MPV that encodes the chimeric F-protein consisting of the human ectodomain and the avian luminol/transmembrane domain is attenuated because of the avian part of the F-protein, yet highly immunogenic against hMPV because of the human ectodomain.

In certain embodiments, two different heterologous nucleotide sequences are inserted or added to the viral vectors of the invention, derived from metapneumoviral genomes, including mammalian and avian. For example, the heterologous nucleotide sequence is derived from a human metapneumovirus, an avian pneumovirus, RSV, PIV, or influenza. In a preferred embodiment, the heterologous sequence encodes the F-protein of human metapneumovirus, avian pneumovirus, RSV or PIV respectively. In another embodiment, the heterologous sequence encodes the HA protein of influenza.

In certain embodiments, the viral vector of the invention contains two different heterologous nucleotide sequences wherein a first heterologous nucleotide sequence is

derived from a metapneumovirus, such as a human metapneumovirus or an avian pneumovirus, and a second nucleotide sequence is derived from a respiratory syncytial virus (*see* Table 2). In specific embodiments, the heterologous nucleotide sequence derived from respiratory syncytial virus is a F gene of a respiratory syncytial virus. In other specific embodiments, the heterologous nucleotide sequence derived from respiratory syncytial virus is a G gene of a respiratory syncytial virus. In a specific embodiment, the heterologous nucleotide sequence derived from a metapneumovirus is inserted at a lower-numbered position than the heterologous nucleotide sequence derived from a respiratory syncytial virus. In another specific embodiment, the heterologous nucleotide sequence derived from a metapneumovirus is inserted at a higher-numbered position than the heterologous nucleotide sequence derived from a respiratory syncytial virus.

In certain embodiments, the virus of the invention contains two different heterologous nucleotide sequences wherein a first heterologous nucleotide sequence is derived from a metapneumovirus, such as a human metapneumovirus or an avian pneumovirus, and a second nucleotide sequence is derived from a parainfluenza virus, such as, but not limited to PIV3 (*see* Table 2). In specific embodiments, the heterologous nucleotide sequence derived from PIV is a F gene of PIV. In other specific embodiments, the heterologous nucleotide sequence derived from PIV is a G gene of a PIV. In a specific embodiment, the heterologous nucleotide sequence derived from a metapneumovirus is inserted at a lower-numbered position than the heterologous nucleotide sequence derived from a PIV. In another specific embodiment, the heterologous nucleotide sequence derived from a metapneumovirus is inserted at a higher-numbered position than the heterologous nucleotide sequence derived from a PIV.

The expression products and/or recombinant or chimeric virions obtained in accordance with the invention may advantageously be utilized in vaccine formulations. The expression products and chimeric virions of the present invention may be engineered to create vaccines against a broad range of pathogens, including viral and bacterial antigens, tumor antigens, allergen antigens, and auto antigens involved in autoimmune disorders. In particular, the chimeric virions of the present invention may be engineered to create vaccines for the protection of a subject from infections with PIV, RSV, and/or metapneumovirus.

In another embodiment, the chimeric virions of the present invention may be engineered to create anti-HIV vaccines, wherein an immunogenic polypeptide from gp160, and/or from internal proteins of HIV is engineered into the glycoprotein HN protein to construct a vaccine that is able to elicit both vertebrate humoral and cell-mediated immune responses. In yet another embodiment, the invention relates to recombinant metapneumoviral vectors and viruses which are engineered to encode mutant antigens. A mutant antigen has at least one amino acid substitution, deletion or addition relative to the wild-type viral protein from which it is derived.

In certain embodiments, the invention relates to trivalent vaccines comprising a recombinant or chimeric virus of the invention. In specific embodiments, the virus used as backbone for a trivalent vaccine is a chimeric avian-human metapneumovirus or a chimeric human-avian metapneumovirus containing a first heterologous nucleotide sequence derived from a RSV and a second heterologous nucleotide sequence derived from PIV. In an exemplary embodiment, such a trivalent vaccine will be specific to (a) the gene products of the F gene and/or the G gene of the human metapneumovirus or avian pneumovirus, respectively, dependent on whether chimeric avian-human or chimeric human-avian metapneumovirus is used; (b) the protein encoded by the heterologous nucleotide sequence derived from a RSV; and (c) the protein encoded by the heterologous nucleotide sequence derived from PIV. In a specific embodiment, the first heterologous nucleotide sequence is the F gene of the respiratory syncytial virus and is inserted in Position 1, and the second heterologous nucleotide sequence is the F gene of the PIV and is inserted in Position 3. Many more combinations are encompassed by the present invention and some are shown by way of example in Table 2. Further, nucleotide sequences encoding chimeric F proteins could be used (*see supra*). In some less preferred embodiments, the heterologous nucleotide sequence can be inserted at higher-numbered positions of the viral genome.

Table 2. Exemplary arrangements of heterologous nucleotide sequences in the viruses used for trivalent vaccines.

<u>Combination</u>	<u>Position 1</u>	<u>Position 2</u>	<u>Position 3</u>
1	F-gene of PIV	F-gene of RSV	-
2	F-gene of RSV	F-gene of PIV	-
3	-	F-gene of PIV	F-gene of RSV
4	-	F-gene of RSV	F-gene of PIV
5	F-gene of PIV	-	F-gene of RSV
6	F-gene of RSV	-	F-gene of PIV
7	HN-gene of PIV	G-gene of RSV	-
8	G-gene of RSV	HN-gene of PIV	-
9	-	HN-gene of PIV	G-gene of RSV
10	-	G-gene of RSV	HN-gene of PIV
11	HN-gene of PIV	-	G-gene of RSV
12	G-gene of RSV	-	HN-gene of PIV
13	F-gene of PIV	G-gene of RSV	-
14	G-gene of RSV	F-gene of PIV	-
15	-	F-gene of PIV	G-gene of RSV
16	-	G-gene of RSV	F-gene of PIV
17	F-gene of PIV	-	G-gene of RSV
18	G-gene of RSV	-	F-gene of PIV
19	HN-gene of PIV	F-gene of RSV	-
20	F-gene of RSV	HN-gene of PIV	-
21	-	HN-gene of PIV	F-gene of RSV
22	-	F-gene of RSV	HN-gene of PIV
23	HN-gene of PIV	-	F-gene of RSV
24	F-gene of RSV	-	HN-gene of PIV

In certain embodiments, the expression products and recombinant or chimeric virions of the present invention may be engineered to create vaccines against a broad range of pathogens, including viral antigens, tumor antigens and auto antigens involved in autoimmune disorders. One way to achieve this goal involves modifying existing metapneumoviral genes to contain foreign sequences in their respective external domains. Where the heterologous sequences are epitopes or antigens of pathogens, these chimeric viruses may be used to induce a protective immune response against the disease agent from which these determinants are derived.

Thus, the present invention relates to the use of viral vectors and recombinant or chimeric viruses to formulate vaccines against a broad range of viruses and/or antigens. The viral vectors and chimeric viruses of the present invention may be used to modulate a subject's immune system by stimulating a humoral immune response, a cellular immune

response or by stimulating tolerance to an antigen. As used herein, a subject means: humans, primates, horses, cows, sheep, pigs, goats, dogs, cats, avian species and rodents.

The invention may be divided into the following stages solely for the purpose of description and not by way of limitation: (a) construction of recombinant cDNA and RNA templates; (b) expression of heterologous gene products using recombinant cDNA and RNA templates; (c) rescue of the heterologous gene in recombinant virus particles; and (d) generation and use of vaccines comprising the recombinant virus particles of the invention.

5.4 CONSTRUCTION OF THE RECOMBINANT cDNA AND RNA

In certain embodiments, the viral vectors are derived from the genomes of human or mammalian metapneumovirus of the invention. In other embodiments, the viral vectors are derived from the genome of avian pneumovirus. In certain embodiments, viral vectors contain sequences derived from mammalian MPV and APV, such that a chimeric human MPV/APV virus is encoded by the viral vector. In an exemplary embodiment, the F-gene and/or the G-gene of human metapneumovirus have been replaced with the F-gene and/or the G-gene of avian pneumovirus to construct chimeric hMPV/APV virus. In other embodiments, viral vectors contain sequences derived from APV and mammalian MPV, such that a chimeric APV/hMPV virus is encoded by the viral vector. In more exemplary embodiments, the F-gene and/or the G-gene of avian pneumovirus have been replaced with the F-gene and/or the G-gene of human metapneumovirus to construct the chimeric APV/hMPV virus.

The present invention also encompasses recombinant viruses comprising a viral vector derived from a mammalian MPV or APV genome containing sequences endogenous or native to the viral genome, and may or may not contain sequences non-native to the viral genome. Non-native sequences include those that are different from native or endogenous sequences which may or may not result in a phenotypic change. The recombinant viruses of the invention may contain sequences which result in a virus having a phenotype more suitable for use in vaccine formulations, e.g., attenuated phenotype or enhanced antigenicity. The mutations and modifications can be in coding regions, in intergenic regions and in the leader and trailer sequences of the virus.

In certain embodiments the viral vectors of the invention comprise nucleotide sequences derived from hMPV, APV, hMPV/APV or APV/hMPV, in which native nucleotide sequences have been substituted with heterologous sequences or in which heterologous sequences have been added to the native metapneumoviral sequences.

In a more specific embodiment, a chimeric virus comprises a viral vector derived from MPV, APV, APV/hMPV, or hMPV/APV in which heterologous sequences derived from PIV have been added. In a more specific embodiment, a recombinant virus comprises a viral vector derived from MPV, APV, APV/hMPV, or hMPV/APV in which sequences have been replaced by heterologous sequences derived from PIV. In other specific embodiments, a chimeric virus comprises a viral vector derived from MPV, APV, APV/hMPV, or hMPV/APV in which heterologous sequences derived from RSV have been added. In a more specific embodiment, a chimeric virus comprises a viral vector derived from MPV, APV, APV/hMPV, or hMPV/APV in which sequences have been replaced by heterologous sequences derived from RSV.

Heterologous gene coding sequences flanked by the complement of the viral polymerase binding site/promoter, *e.g.*, the complement of 3'-hMPV virus terminus of the present invention, or the complements of both the 3'- and 5'-hMPV virus termini may be constructed using techniques known in the art. In more specific embodiments, a recombinant virus of the invention contains the leader and trailer sequence of hMPV or APV. In certain embodiments, the intergenic regions are obtained from hMPV or APV. The resulting RNA templates may be of the negative-polarity and contain appropriate terminal sequences which enable the viral RNA-synthesizing apparatus to recognize the template. Alternatively, positive-polarity RNA templates which contain appropriate terminal sequences which enable the viral RNA-synthesizing apparatus to recognize the template, may also be used. Recombinant DNA molecules containing these hybrid sequences can be cloned and transcribed by a DNA-directed RNA polymerase, such as bacteriophage T7, T3, the SP6 polymerase or eukaryotic polymerase such as polymerase I and the like, to produce *in vitro* or *in vivo* the recombinant RNA templates which possess the appropriate viral sequences that allow for viral polymerase recognition and activity. In a more specific embodiment, the RNA polymerase is fowlpox virus T7 RNA polymerase or a MVA T7 RNA polymerase.

An illustrative approach for constructing these hybrid molecules is to insert the heterologous nucleotide sequence into a DNA complement of a hMPV, APV, APV/hMPV or hMPV/APV genome, so that the heterologous sequence is flanked by the viral sequences required for viral polymerase activity; *i.e.*, the viral polymerase binding site/promoter, hereinafter referred to as the viral polymerase binding site, and a polyadenylation site. In a preferred embodiment, the heterologous coding sequence is flanked by the viral sequences that comprise the replication promoters of the 5' and 3' termini, the gene start and gene end sequences, and the packaging signals that are found in the 5' and/or the 3' termini. In an alternative approach, oligonucleotides encoding the viral polymerase binding site, *e.g.*, the complement of the 3'-terminus or both termini of the virus genomic segment can be ligated to the heterologous coding sequence to construct the hybrid molecule. The placement of a foreign gene or segment of a foreign gene within a target sequence was formerly dictated by the presence of appropriate restriction enzyme sites within the target sequence. However, recent advances in molecular biology have lessened this problem greatly. Restriction enzyme sites can readily be placed anywhere within a target sequence through the use of site-directed mutagenesis (*e.g.*, see, for example, the techniques described by Kunkel, 1985, Proc. Natl. Acad. Sci. U.S.A. 82;488). Variations in polymerase chain reaction (PCR) technology, described *infra*, also allow for the specific insertion of sequences (*i.e.*, restriction enzyme sites) and allow for the facile construction of hybrid molecules. Alternatively, PCR reactions could be used to prepare recombinant templates without the need of cloning. For example, PCR reactions could be used to prepare double-stranded DNA molecules containing a DNA-directed RNA polymerase promoter (*e.g.*, bacteriophage T3, T7 or SP6) and the hybrid sequence containing the heterologous gene and the PIV polymerase binding site. RNA templates could then be transcribed directly from this recombinant DNA. In yet another embodiment, the recombinant RNA templates may be prepared by ligating RNAs specifying the negative polarity of the heterologous gene and the viral polymerase binding site using an RNA ligase.

In addition, one or more nucleotides can be added in the untranslated region to adhere to the "Rule of Six" which may be important in obtaining virus rescue. The "Rule of Six" applies to many paramyxoviruses and states that the RNA nucleotide genome must be divisible by six to be functional. The addition of nucleotides can be accomplished by

techniques known in the art such as using a commercial mutagenesis kits such as the QuikChange mutagenesis kit (Stratagene). After addition of the appropriate number of nucleotides, the correct DNA fragment can then be isolated by digestion with appropriate restriction enzyme and gel purification. Sequence requirements for viral polymerase activity and constructs which may be used in accordance with the invention are described in the subsections below.

Without being bound by theory, several parameters affect the rate of replication of the recombinant virus and the level of expression of the heterologous sequence. In particular, the position of the heterologous sequence in hMPV, APV, hMPV/APV or APV/hMPV and the length of the intergenic region that flanks the heterologous sequence determine rate of replication and expression level of the heterologous sequence.

In certain embodiments, the leader and or trailer sequence of the virus are modified relative to the wild type virus. In certain more specific embodiments, the lengths of the leader and/or trailer are altered. In other embodiments, the sequence(s) of the leader and/or trailer are mutated relative to the wild type virus. For more detail, see section 5.7.

The production of a recombinant virus of the invention relies on the replication of a partial or full-length copy of the negative sense viral RNA (vRNA) genome or a complementary copy thereof (cRNA). This vRNA or cRNA can be isolated from infectious virus, produced upon in-vitro transcription, or produced in cells upon transfection of nucleic acids. Second, the production of recombinant negative strand virus relies on a functional polymerase complex. Typically, the polymerase complex of pneumoviruses consists of N, P, L and possibly M2 proteins, but is not necessarily limited thereto.

Polymerase complexes or components thereof can be isolated from virus particles, isolated from cells expressing one or more of the components, or produced upon transfection of specific expression vectors.

Infectious copies of MPV can be obtained when the above mentioned vRNA, cRNA, or vectors expressing these RNAs are replicated by the above mentioned polymerase complex 16 (Schnell et al., 1994, EMBO J 13: 4195-4203; Collins, et al., 1995, PNAS 92: 11563-11567; Hoffmann, et al., 2000, PNAS 97: 6108-6113; Bridgen, et al., 1996, PNAS 93: 15400-15404; Palese, et al., 1996, PNAS 93: 11354-11358; Peeters, et al., 1999, J.Virol. 73: 5001-5009; Durbin, et al., 1997, Virology 235: 323-332).

The invention provides a host cell comprising a nucleic acid or a vector according to the invention. Plasmid or viral vectors containing the polymerase components of MPV (presumably N, P, L and M2, but not necessarily limited thereto) are generated in prokaryotic cells for the expression of the components in relevant cell types (bacteria, insect cells, eukaryotic cells). Plasmid or viral vectors containing full-length or partial copies of the MPV genome will be generated in prokaryotic cells for the expression of viral nucleic acids in-vitro or in-vivo. The latter vectors may contain other viral sequences for the generation of chimeric viruses or chimeric virus proteins, may lack parts of the viral genome for the generation of replication defective virus, and may contain mutations, deletions or insertions for the generation of attenuated viruses.

Infectious copies of MPV (being wild type, attenuated, replication-defective or chimeric) can be produced upon co-expression of the polymerase components according to the state-of-the-art technologies described above.

In addition, eukaryotic cells, transiently or stably expressing one or more full-length or partial MPV proteins can be used. Such cells can be made by transfection (proteins or nucleic acid vectors), infection (viral vectors) or transduction (viral vectors) and may be useful for complementation of mentioned wild type, attenuated, replication-defective or chimeric viruses.

5.4.1 HETEROLOGOUS GENE SEQUENCES TO BE INSERTED

In accordance with the present invention the viral vectors of the invention may be further engineered to express a heterologous sequence. In an embodiment of the invention, the heterologous sequence is derived from a source other than the viral vector. By way of example, and not by limitation, the heterologous sequence encodes an antigenic protein, polypeptide or peptide of a virus belonging to a different species, subgroup or variant of metapneumovirus than the species, subgroup or variant from which the viral vector is derived. By way of example, and not by limitation, the heterologous sequence encodes an antigenic protein, polypeptide or peptide of a virus other than a metapneumovirus. By way of example, and not by limitation, the heterologous sequence is not viral in origin. In accordance with this embodiment, the heterologous sequence may encode a moiety, peptide, polypeptide or protein possessing a desired biological property or activity. Such a

heterologous sequence may encode a tag or marker. Such a heterologous sequence may encode a biological response modifier, examples of which include, lymphokines, interleukines, granulocyte macrophage colony stimulating factor and granulocyte colony stimulating factor.

In certain embodiments, the heterologous nucleotide sequence to be inserted is derived from a metapneumovirus. More specifically, the heterologous nucleotide sequence to be inserted is derived from a human metapneumovirus and/or an avian pneumovirus.

In certain embodiments, the heterologous sequence encodes PIV nucleocapsid phosphoprotein, PIV L protein, PIV matrix protein, PIV HN glycoprotein, PIV RNA-dependent RNA polymerase, PIV Y1 protein, PIV D protein, PIV C protein, PIV F protein or PIV P protein. In certain embodiments, the heterologous nucleotide sequence encodes a protein that is at least 90 %, at least 95 %, at least 98%, or at least 99 % homologous to PIV nucleocapsid phosphoprotein, PIV L protein, PIV matrix protein, PIV HN glycoprotein, PIV RNA-dependent RNA polymerase, PIV Y1 protein, PIV D protein, PIV C protein, PIV F protein or PIV P protein. The heterologous sequence can be obtained from PIV type 1, PIV type 2, or PIV type 3. In more specific embodiments, the heterologous sequence is obtained from human PIV type 1, PIV type 2, or PIV type 3. In other embodiments, the heterologous sequence encodes RSV nucleoprotein, RSV phosphoprotein, RSV matrix protein, RSV small hydrophobic protein, RSV RNA-dependent RNA polymerase, RSV F protein, RSV G protein, or RSV M2-1 or M2-2 protein. In certain embodiments, the heterologous sequence encodes a protein that is at least 90%, at least 95 %, at least 98 %, or at least 99 % homologous to RSV nucleoprotein, RSV phosphoprotein, RSV matrix protein, RSV small hydrophobic protein, RSV RNA-dependent RNA polymerase, RSV F protein, or RSV G protein. The heterologous sequence can be obtained from RSV subtype A and RSV subtype B. In more specific embodiments, the heterologous sequence is obtained from human RSV subtype A and RSV subtype B. In other embodiments, the heterologous sequence encodes APV nucleoprotein, APV phosphoprotein, APV matrix protein, APV small hydrophobic protein, APV RNA-dependent RNA polymerase, APV F protein, APV G protein or APV M2-1 or M2-2 protein. In certain embodiments, the heterologous sequence encodes a protein that is at least 90%, at least 95 %, at least 98 %, or at least 99 % homologous to APV nucleoprotein, APV phosphoprotein, APV matrix protein, APV small hydrophobic protein,

APV RNA-dependent RNA polymerase, APV F protein, or APV G protein. The avian pneumovirus can be APV subgroup A, APV subgroup B, or APV subgroup C. In other embodiments, the heterologous sequence encodes hMPV nucleoprotein, hMPV phosphoprotein, hMPV matrix protein, hMPV small hydrophobic protein, hMPV RNA-dependent RNA polymerase, hMPV F protein, hMPV G protein or hMPV M2-1 or M2-2. In certain embodiments, the heterologous sequence encodes a protein that is at least 90%, at least 95 %, at least 98 %, or at least 99 % homologous to hMPV nucleoprotein, hMPV phosphoprotein, hMPV matrix protein, hMPV small hydrophobic protein, hMPV RNA-dependent RNA polymerase, hMPV F protein, or hMPV G protein. The human metapneumovirus can be hMPV variant A1, hMPV variant A2, hMPV variant B1, or hMPV variant B2.

In certain embodiments, any combination of different heterologous sequence from PIV, RSV, human metapneumovirus, or avian pneumovirus can be inserted into the virus of the invention.

In certain preferred embodiments of the invention, the heterologous nucleotide sequence to be inserted is derived from a F gene from RSV, PIV, APV or hMPV.

In certain embodiments, the heterologous nucleotide sequence encodes a chimeric protein. In more specific embodiments, the heterologous nucleotide sequence encodes a chimeric F protein of RSV, PIV, APV or hMPV. A chimeric F protein can comprise parts of F proteins from different viruses, such as a human metapneumovirus, avian pneumovirus, respiratory syncytial virus, and parainfluenza virus. In certain other embodiments, the heterologous sequence encodes a chimeric G protein. A chimeric G protein comprises parts of G proteins from different viruses, such as a human metapneumovirus, avian pneumovirus, respiratory syncytial virus, and parainfluenza virus. In a specific embodiment, the F protein comprises an ectodomain of a F protein of a metapneumovirus, a transmembrane domain of a F protein of a parainfluenza virus, and luminal domain of a F protein of a parainfluenza virus.

In certain specific embodiments, the heterologous nucleotide sequence of the invention is any one of SEQ ID NO:1 through SEQ ID NO:5, SEQ ID NO:14, and SEQ ID NO:15. In certain specific embodiments, the nucleotide sequence encodes a protein of any one of SEQ ID NO:6 through SEQ ID NO:13, SEQ ID NO:16, and SEQ ID NO:17.

For heterologous nucleotide sequences derived from respiratory syncytial virus see, *e.g.*, PCT/US98/20230.

In a preferred embodiment, heterologous gene sequences that can be expressed into the recombinant viruses of the invention include but are not limited to antigenic epitopes and glycoproteins of viruses which result in respiratory disease, such as influenza glycoproteins, in particular hemagglutinin H5, H7, respiratory syncytial virus epitopes, New Castle Disease virus epitopes, Sendai virus and infectious Laryngotracheitis virus (ILV). In a preferred embodiment, the heterologous nucleotide sequences are derived from a RSV or PIV. In yet another embodiment of the invention, heterologous gene sequences that can be engineered into the chimeric viruses of the invention include, but are not limited to, viral epitopes and glycoproteins of viruses, such as hepatitis B virus surface antigen, hepatitis A or C virus surface glycoproteins of Epstein Barr virus, glycoproteins of human papilloma virus, simian virus 5 or mumps virus, West Nile virus, Dengue virus, glycoproteins of herpes viruses, VPI of poliovirus, and sequences derived from a lentivirus, preferably, but not limited to human immunodeficiency virus (HIV) type 1 or type 2. In yet another embodiment, heterologous gene sequences that can be engineered into chimeric viruses of the invention include, but are not limited to, Marek's Disease virus (MDV) epitopes, epitopes of infectious Bursal Disease virus (IBDV), epitopes of Chicken Anemia virus, infectious laryngotracheitis virus (ILV), Avian Influenza virus (AIV), rabies, feline leukemia virus, canine distemper virus, vesicular stomatitis virus, and swinepox virus (*see* Fields et al., (ed.), 1991, Fundamental Virology, Second Edition, Raven Press, New York).

Other heterologous sequences of the present invention include antigens that are characteristic of autoimmune disease. These antigens will typically be derived from the cell surface, cytoplasm, nucleus, mitochondria and the like of mammalian tissues, including antigens characteristic of diabetes mellitus, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, pernicious anemia, Addison's disease, scleroderma, autoimmune atrophic gastritis, juvenile diabetes, and discoid lupus erythematosus.

Antigens that are allergens generally include proteins or glycoproteins, including antigens derived from pollens, dust, molds, spores, dander, insects and foods. In addition, antigens that are characteristic of tumor antigens typically will be derived from the cell surface, cytoplasm, nucleus, organelles and the like of cells of tumor tissue. Examples

include antigens characteristic of tumor proteins, including proteins encoded by mutated oncogenes; viral proteins associated with tumors; and glycoproteins. Tumors include, but are not limited to, those derived from the types of cancer: lip, nasopharynx, pharynx and oral cavity, esophagus, stomach, colon, rectum, liver, gall bladder, pancreas, larynx, lung and bronchus, melanoma of skin, breast, cervix, uterine, ovary, bladder, kidney, uterus, brain and other parts of the nervous system, thyroid, prostate, testes, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma and leukemia.

In one specific embodiment of the invention, the heterologous sequences are derived from the genome of human immunodeficiency virus (HIV), preferably human immunodeficiency virus-1 or human immunodeficiency virus-2. In another embodiment of the invention, the heterologous coding sequences may be inserted within a gene coding sequence of the viral backbone such that a chimeric gene product is expressed which contains the heterologous peptide sequence within the metapneumoviral protein. In such an embodiment of the invention, the heterologous sequences may also be derived from the genome of a human immunodeficiency virus, preferably of human immunodeficiency virus-1 or human immunodeficiency virus-2.

In instances whereby the heterologous sequences are HIV-derived, such sequences may include, but are not limited to sequences derived from the env gene (*i.e.*, sequences encoding all or part of gp160, gp120, and/or gp41), the pol gene (*i.e.*, sequences encoding all or part of reverse transcriptase, endonuclease, protease, and/or integrase), the gag gene (*i.e.*, sequences encoding all or part of p7, p6, p55, p17/18, p24/25) tat, rev, nef, vif, vpu, vpr, and/or vpx.

In yet another embodiment, heterologous gene sequences that can be engineered into the chimeric viruses include those that encode proteins with immunopotentiating activities. Examples of immunopotentiating proteins include, but are not limited to, cytokines, interferon type 1, gamma interferon, colony stimulating factors, and interleukin -1, -2, -4, -5, -6, -12.

In addition, other heterologous gene sequences that may be engineered into the chimeric viruses include antigens derived from bacteria such as bacterial surface glycoproteins, antigens derived from fungi, and antigens derived from a variety of other pathogens and parasites. Examples of heterologous gene sequences derived from bacterial

pathogens include, but are not limited to, antigens derived from species of the following genera: *Salmonella*, *Shigella*, *Chlamydia*, *Helicobacter*, *Yersinia*, *Bordatella*, *Pseudomonas*, *Neisseria*, *Vibrio*, *Haemophilus*, *Mycoplasma*, *Streptomyces*, *Treponema*, *Coxiella*, *Ehrlichia*, *Brucella*, *Streptobacillus*, *Fusospirocheta*, *Spirillum*, *Ureaplasma*, *Spirochaeta*, *Mycoplasma*, *Actinomyces*, *Borrelia*, *Bacteroides*, *Trichomonas*, *Branhamella*, *Pasteurella*, *Clostridium*, *Corynebacterium*, *Listeria*, *Bacillus*, *Erysipelothrix*, *Rhodococcus*, *Escherichia*, *Klebsiella*, *Pseudomonas*, *Enterobacter*, *Serratia*, *Staphylococcus*, *Streptococcus*, *Legionella*, *Mycobacterium*, *Proteus*, *Campylobacter*, *Enterococcus*, *Acinetobacter*, *Morganella*, *Moraxella*, *Citrobacter*, *Rickettsia*, *Rochlimaeae*, as well as bacterial species such as: *P. aeruginosa*; *E. coli*, *P. cepacia*, *S. epidermis*, *E. faecalis*, *S. pneumonias*, *S. aureus*, *N. meningitidis*, *S. pyogenes*, *Pasteurella multocida*, *Treponema pallidum*, and *P. mirabilis*.

Examples of heterologous gene sequences derived from pathogenic fungi, include, but are not limited to, antigens derived from fungi such as *Cryptococcus neoformans*; *Blastomyces dermatitidis*; *Aiellomyces dermatitidis*; *Histoplasma capsulatum*; *Coccidioides immitis*; *Candida* species, including *C. albicans*, *C. tropicalis*, *C. parapsilosis*, *C. guilliermondii* and *C. krusei*, *Aspergillus* species, including *A. fumigatus*, *A. flavus* and *A. niger*, *Rhizopus* species; *Rhizomucor* species; *Cunninghamella* species; *Apophysomyces* species, including *A. saksenaea*, *A. mucor* and *A. absidia*; *Sporothrix schenckii*, *Paracoccidioides brasiliensis*; *Pseudallescheria boydii*, *Torulopsis glabrata*; *Trichophyton* species, *Microsporum* species and *Dermatophyres* species, as well as any other yeast or fungus now known or later identified to be pathogenic.

Finally, examples of heterologous gene sequences derived from parasites include, but are not limited to, antigens derived from members of the Apicomplexa phylum such as, for example, *Babesia*, *Toxoplasma*, *Plasmodium*, *Eimeria*, *Isospora*, *Atoxoplasma*, *Cystoisospora*, *Hammondia*, *Besnotia*, *Sarcocystis*, *Frenkelia*, *Haemoproteus*, *Leucocytozoon*, *Theileria*, *Perkinsus* and *Gregarina* spp.; *Pneumocystis carinii*; members of the Microspora phylum such as, for example, *Nosema*, *Enterocytozoon*, *Encephalitozoon*, *Septata*, *Mrazekia*, *Amblyospora*, *Ameson*, *Glugea*, *Pleistophora* and *Microsporidium* spp.; and members of the Ascetospora phylum such as, for example, *Haplosporidium* spp., as well as species including *Plasmodium falciparum*, *P. vivax*, *P. ovale*, *P. malaria*; *Toxoplasma gondii*; *Leishmania mexicana*, *L. tropica*, *L. major*, *L. aethiopica*, *L. donovani*, *Trypanosoma*

cruzi, *T. brucei*, *Schistosoma mansoni*, *S. haematobium*, *S. japonium*; *Trichinella spiralis*; *Wuchereria bancrofti*; *Brugia malayi*; *Entamoeba histolytica*; *Enterobius vermicularis*; *Taenia solium*, *T. saginata*, *Trichomonas vaginalis*, *T. hominis*, *T. tenax*; *Giardia lamblia*; *Cryptosporidium parvum*; *Pneumocystis carinii*, *Babesia bovis*, *B. divergens*, *B. microti*, *Isospora belli*, *L. hominis*; *Dientamoeba fragilis*; *Onchocerca volvulus*; *Ascaris lumbricoides*; *Necator americanus*; *Ancylostoma duodenale*; *Strongyloides stercoralis*; *Capillaria philippinensis*; *Angiostrongylus cantonensis*; *Hymenolepis nana*; *Diphyllobothrium latum*; *Echinococcus granulosus*, *E. multilocularis*; *Paragonimus westermani*, *P. caliensis*; *Chlonorchis sinensis*; *Opisthorchis felinus*, *G. Viverini*, *Fasciola hepatica*, *Sarcoptes scabiei*, *Pediculus humanus*; *Phthirus pubis*; and *Dermatobia hominis*, as well as any other parasite now known or later identified to be pathogenic.

5.4.2 INSERTION OF THE HETEROLOGOUS GENE SEQUENCE

Insertion of a foreign gene sequence into a viral vector of the invention can be accomplished by either a complete replacement of a viral coding region with a heterologous sequence or by a partial replacement or by adding the heterologous nucleotide sequence to the viral genome. Complete replacement would probably best be accomplished through the use of PCR-directed mutagenesis. Briefly, PCR-primer A would contain, from the 5' to 3' end: a unique restriction enzyme site, such as a class IIS restriction enzyme site (*i.e.*, a "shifter" enzyme; that recognizes a specific sequence but cleaves the DNA either upstream or downstream of that sequence); a stretch of nucleotides complementary to a region of the gene that is to be replaced; and a stretch of nucleotides complementary to the carboxy-terminus coding portion of the heterologous sequence. PCR-primer B would contain from the 5' to 3' end: a unique restriction enzyme site; a stretch of nucleotides complementary to the gene that is to be replaced; and a stretch of nucleotides corresponding to the 5' coding portion of the heterologous or non-native gene. After a PCR reaction using these primers with a cloned copy of the heterologous or non-native gene, the product may be excised and cloned using the unique restriction sites. Digestion with the class IIS enzyme and transcription with the purified phage polymerase would generate a RNA molecule containing the exact untranslated ends of the viral gene that carries now a heterologous or non-native gene insertion. In an alternate embodiment, PCR-primed reactions could be used to prepare double-stranded DNA

containing the bacteriophage promoter sequence, and the hybrid gene sequence so that RNA templates can be transcribed directly without cloning.

A heterologous nucleotide sequence can be added or inserted at various positions of the virus of the invention. In one embodiment, the heterologous nucleotide sequence is added or inserted at position 1. In another embodiment, the heterologous nucleotide sequence is added or inserted at position 2. In another embodiment, the heterologous nucleotide sequence is added or inserted at position 3. In another embodiment, the heterologous nucleotide sequence is added or inserted at position 4. In another embodiment, the heterologous nucleotide sequence is added or inserted at position 5. In yet another embodiment, the heterologous nucleotide sequence is added or inserted at position 6. As used herein, the term "position" refers to the position of the heterologous nucleotide sequence on the viral genome to be transcribed, *e.g.*, position 1 means that it is the first gene to be transcribed, and position 2 means that it is the second gene to be transcribed. Inserting heterologous nucleotide sequences at the lower-numbered positions of the virus generally results in stronger expression of the heterologous nucleotide sequence compared to insertion at higher-numbered positions due to a transcriptional gradient that occurs across the genome of the virus. However, the transcriptional gradient also yields specific ratios of viral mRNAs. Insertion of foreign genes will perturb these ratios and result in the synthesis of different amounts of viral proteins that may influence virus replication. Thus, both the transcriptional gradient and the replication kinetics must be considered when choosing an insertion site. Inserting heterologous nucleotide sequences at lower-numbered positions is the preferred embodiment of the invention if strong expression of the heterologous nucleotide sequence is desired. In a preferred embodiment, the heterologous sequence is added or inserted at position 1, 2 or 3.

When inserting a heterologous nucleotide sequence into the virus of the invention, the intergenic region between the end of the coding sequence of the heterologous gene and the start of the coding sequence of the downstream gene can be altered to achieve a desired effect. As used herein, the term "intergenic region" refers to nucleotide sequence between the stop signal of one gene and the start codon (*e.g.*, AUG) of the coding sequence of the next downstream open reading frame. An intergenic region may comprise a non-coding region of a gene, *i.e.*, between the transcription start site and the start of the coding sequence (AUG) of the gene. This non-coding region occurs naturally in some viral genes.

In various embodiments, the intergenic region between the heterologous nucleotide sequence and the downstream gene can be engineered, independently from each other, to be at least 10 nt in length, at least 20 nt in length, at least 30 nt in length, at least 50 nt in length, at least 75 nt in length, at least 100 nt in length, at least 125 nt in length, at least 150 nt in length, at least 175 nt in length or at least 200 nt in length. In certain embodiments, the intergenic region between the heterologous nucleotide sequence and the downstream gene can be engineered, independently from each other, to be at most 10 nt in length, at most 20 nt in length, at most 30 nt in length, at most 50 nt in length, at most 75 nt in length, at most 100 nt in length, at most 125 nt in length, at most 150 nt in length, at most 175 nt in length or at most 200 nt in length. In various embodiments, the non-coding region of a desired gene in a virus genome can also be engineered, independently from each other, to be at least 10 nt in length, at least 20 nt in length, at least 30 nt in length, at least 50 nt in length, at least 75 nt in length, at least 100 nt in length, at least 125 nt in length, at least 150 nt in length, at least 175 nt in length or at least 200 nt in length. In certain embodiments, the non-coding region of a desired gene in a virus genome can also be engineered, independently from each other, to be at most 10 nt in length, at most 20 nt in length, at most 30 nt in length, at most 50 nt in length, at most 75 nt in length, at most 100 nt in length, at most 125 nt in length, at most 150 nt in length, at most 175 nt in length or at most 200 nt in length.

When inserting a heterologous nucleotide sequence, the positional effect and the intergenic region manipulation can be used in combination to achieve a desirable effect. For example, the heterologous nucleotide sequence can be added or inserted at a position selected from the group consisting of position 1, 2, 3, 4, 5, and 6, and the intergenic region between the heterologous nucleotide sequence and the next downstream gene can be altered (*see* Table 3). Some of the combinations encompassed by the present invention are shown by way of example in Table 3.

Table 3. Examples of mode of insertion of heterologous nucleotide sequences

	Position 1	Position 2	Position 3	Position 4	Position 5	Position 6
IGR ^a	10-20	10-20	10-20	10-20	10-20	10-20
IGR	21-40	21-40	21-40	21-40	21-40	21-40
IGR	41-60	41-60	41-60	41-60	41-60	41-60
IGR	61-80	61-80	61-80	61-80	61-80	61-80
IGR	81-100	81-100	81-100	81-100	81-100	81-100
IGR	101-120	101-120	101-120	101-120	101-120	101-120
IGR	121-140	121-140	121-140	121-140	121-140	121-140
IGR	141-160	141-160	141-160	141-160	141-160	141-160
IGR	161-180	161-180	161-180	161-180	161-180	161-180
IGR	181-200	181-200	181-200	181-200	181-200	181-200
IGR	201-220	201-220	201-220	201-220	201-220	201-220
IGR	221-240	221-240	221-240	221-240	221-240	221-240
IGR	241-260	241-260	241-260	241-260	241-260	241-260
IGR	261-280	261-280	261-280	261-280	261-280	261-280
IGR	281-300	281-300	281-300	281-300	281-300	281-300

^a Intergenic Region, measured in nucleotide.

Depending on the purpose (*e.g.*, to have strong immunogenicity) of the inserted heterologous nucleotide sequence, the position of the insertion and the length of the intergenic region of the inserted heterologous nucleotide sequence can be determined by various indexes including, but not limited to, replication kinetics and protein or mRNA expression levels, measured by following non-limiting examples of assays: plaque assay, fluorescent-focus assay, infectious center assay, transformation assay, endpoint dilution assay, efficiency of plating, electron microscopy, hemagglutination, measurement of viral enzyme activity, viral neutralization, hemagglutination inhibition, complement fixation, immunostaining, immunoprecipitation and immunoblotting, enzyme-linked immunosorbent assay, nucleic acid detection (*e.g.*, Southern blot analysis, Northern blot analysis, Western blot analysis), growth curve, employment of a reporter gene (*e.g.*, using a reporter gene, such as Green Fluorescence Protein (GFP) or enhanced Green Fluorescence Protein (eGFP), integrated to the viral genome the same fashion as the interested heterologous gene to observe the protein expression), or a combination thereof. Procedures of performing these assays are well known in the art (*see, e.g.*, Flint et al., PRINCIPLES OF VIROLOGY, MOLECULAR BIOLOGY, PATHOGENESIS, AND CONTROL, 2000, ASM Press pp 25 - 56),

and non-limiting examples are given in the Example sections, *infra*.

For example, expression levels can be determined by infecting cells in culture with a virus of the invention and subsequently measuring the level of protein expression by, *e.g.*, Western blot analysis or ELISA using antibodies specific to the gene product of the heterologous sequence, or measuring the level of RNA expression by, *e.g.*, Northern blot analysis using probes specific to the heterologous sequence. Similarly, expression levels of the heterologous sequence can be determined by infecting an animal model and measuring the level of protein expressed from the heterologous sequence of the recombinant virus of the invention in the animal model. The protein level can be measured by obtaining a tissue sample from the infected animal and then subjecting the tissue sample to Western blot analysis or ELISA, using antibodies specific to the gene product of the heterologous sequence. Further, if an animal model is used, the titer of antibodies produced by the animal against the gene product of the heterologous sequence can be determined by any technique known to the skilled artisan, including but not limited to, ELISA.

As the heterologous sequences can be homologous to a nucleotide sequence in the genome of the virus, care should be taken that the probes and the antibodies are indeed specific to the heterologous sequence or its gene product.

In certain specific embodiments, expression levels of F-protein of hMPV from chimeric avian-human metapneumovirus can be determined by any technique known to the skilled artisan. Expression levels of the F-protein can be determined by infecting cells in a culture with the chimeric virus of the invention and measuring the level of protein expression by, *e.g.*, Western blot analysis or ELISA using antibodies specific to the F-protein and/or the G-protein of hMPV, or measuring the level of RNA expression by, *e.g.*, Northern blot analysis using probes specific to the F-gene and/or the G-gene of human metapneumovirus. Similarly, expression levels of the heterologous sequence can be determined using an animal model by infecting an animal and measuring the level of F-protein and/or G-protein in the animal model. The protein level can be measured by obtaining a tissue sample from the infected animal and then subjecting the tissue sample to Western blot analysis or ELISA using antibodies specific to F-protein and/or G-protein of the heterologous sequence. Further, if an animal model is used, the titer of antibodies produced by the animal against F-protein

and/or G-protein can be determined by any technique known to the skilled artisan, including but not limited to, ELISA.

The rate of replication of a recombinant virus of the invention can be determined by any technique known to the skilled artisan.

In certain embodiments, to facilitate the identification of the optimal position of the heterologous sequence in the viral genome and the optimal length of the intergenic region, the heterologous sequence encodes a reporter gene. Once the optimal parameters are determined, the reporter gene is replaced by a heterologous nucleotide sequence encoding an antigen of choice. Any reporter gene known to the skilled artisan can be used with the methods of the invention. For more detail, see section 5.8.

The rate of replication of the recombinant virus can be determined by any standard technique known to the skilled artisan. The rate of replication is represented by the growth rate of the virus and can be determined by plotting the viral titer over the time post infection. The viral titer can be measured by any technique known to the skilled artisan. In certain embodiments, a suspension containing the virus is incubated with cells that are susceptible to infection by the virus. Cell types that can be used with the methods of the invention include, but are not limited to, Vero cells, LLC-MK-2 cells, Hep-2 cells, LF 1043 (HEL) cells, MRC-5 cells, WI-38 cells, tMK cells, 293 T cells, QT 6 cells, QT 35 cells, or chicken embryo fibroblasts (CEF). Subsequent to the incubation of the virus with the cells, the number of infected cells is determined. In certain specific embodiments, the virus comprises a reporter gene. Thus, the number of cells expressing the reporter gene is representative of the number of infected cells. In a specific embodiment, the virus comprises a heterologous nucleotide sequence encoding for eGFP, and the number of cells expressing eGFP, *i.e.*, the number of cells infected with the virus, is determined using FACS.

In certain embodiments, the replication rate of the recombinant virus of the invention is at most 20 % of the replication rate of the wild type virus from which the recombinant virus is derived under the same conditions. The same conditions refer to the same initial titer of virus, the same strain of cells, the same incubation temperature, growth medium, number of cells and other test conditions that may affect the replication rate. For example, the replication rate of APV/hMPV with PIV's F gene in position 1 is at most 20 % of the replication rate of APV.

In certain embodiments, the replication rate of the recombinant virus of the invention is at most 5 %, at most 10 %, at most 20 %, at most 30 %, at most 40 %, at most 50 %, at most 75 %, at most 80 %, at most 90 % of the replication rate of the wild type virus from which the recombinant virus is derived under the same conditions. In certain embodiments, the replication rate of the recombinant virus of the invention is at least 5 %, at least 10 %, at least 20 %, at least 30 %, at least 40 %, at least 50 %, at least 75 %, at least 80 %, at least 90 % of the replication rate of the wild type virus from which the recombinant virus is derived under the same conditions. In certain embodiments, the replication rate of the recombinant virus of the invention is between 5 % and 20 %, between 10 % and 40 %, between 25 % and 50 %, between 40 % and 75 %, between 50 % and 80 %, or between 75 % and 90 % of the replication rate of the wild type virus from which the recombinant virus is derived under the same conditions.

In certain embodiments, the expression level of the heterologous sequence in the recombinant virus of the invention is at most 20 % of the expression level of the F-protein of the wild type virus from which the recombinant virus is derived under the same conditions. The same conditions refer to the same initial titer of virus, the same strain of cells, the same incubation temperature, growth medium, number of cells and other test conditions that may affect the replication rate. For example, the expression level of the heterologous sequence of the F-protein of PIV3 in position 1 of hMPV is at most 20 % of the expression level of the F-protein of hMPV.

In certain embodiments, the expression level of the heterologous sequence in the recombinant virus of the invention is at most 5 %, at most 10 %, at most 20 %, at most 30 %, at most 40 %, at most 50 %, at most 75 %, at most 80 %, at most 90 % of the expression level of the F-protein of the wild type virus from which the recombinant virus is derived under the same conditions. In certain embodiments, the expression level of the heterologous sequence in the recombinant virus of the invention is at least 5 %, at least 10 %, at least 20 %, at least 30 %, at least 40 %, at least 50 %, at least 75 %, at least 80 %, at least 90 % of the expression level of the F-protein of the wild type virus from which the recombinant virus is derived under the same conditions. In certain embodiments, the expression level of the heterologous sequence in the recombinant virus of the invention is between 5 % and 20 %, between 10 % and 40 %, between 25 % and 50 %, between 40 % and 75 %, between 50 % and 80 %, or

between 75 % and 90 % of the expression level of the F-protein of the wild type virus from which the recombinant virus is derived under the same conditions.

5.4.3 INSERTION OF THE HETEROLOGOUS GENE SEQUENCE INTO THE G GENE

The G protein is a transmembrane protein of metapneumoviruses. In a specific embodiment, the heterologous sequence is inserted into the region of the G-ORF that encodes for the ectodomain, such that it is expressed on the surface of the viral envelope. In one approach, the heterologous sequence may be inserted within the antigenic site without deleting any viral sequences. In another approach, the heterologous sequences replaces sequences of the G-ORF. Expression products of such constructs may be useful in vaccines against the foreign antigen, and may indeed circumvent problems associated with propagation of the recombinant virus in the vaccinated host. An intact G molecule with a substitution only in antigenic sites may allow for G function and thus allow for the construction of a viable virus. Therefore, this virus can be grown without the need for additional helper functions. The virus may also be attenuated in other ways to avoid any danger of accidental escape.

Other hybrid constructions may be made to express proteins on the cell surface or enable them to be released from the cell.

5.4.4 CONSTRUCTION OF BICISTRONIC RNA

Bicistronic mRNA could be constructed to permit internal initiation of translation of viral sequences and allow for the expression of foreign protein coding sequences from the regular terminal initiation site. Alternatively, a bicistronic mRNA sequence may be constructed wherein the viral sequence is translated from the regular terminal open reading frame, while the foreign sequence is initiated from an internal site. Certain internal ribosome entry site (IRES) sequences may be utilized. The IRES sequences which are chosen should be short enough to not interfere with MPV packaging limitations. Thus, it is preferable that the IRES chosen for such a bicistronic approach be no more than 500 nucleotides in length. In a specific embodiment, the IRES is derived from a picornavirus and does not include any additional picornaviral sequences. Specific IRES elements include, but are not limited to the mammalian BiP IRES and the hepatitis C virus IRES.

Alternatively, a foreign protein may be expressed from a new internal transcriptional unit in which the transcriptional unit has an initiation site and polyadenylation site. In another embodiment, the foreign gene is inserted into a MPV gene such that the resulting expressed protein is a fusion protein.

5.5 EXPRESSION OF HETEROLOGOUS GENE PRODUCTS USING RECOMBINANT cDNA AND RNA TEMPLATES

The viral vectors and recombinant templates prepared as described above can be used in a variety of ways to express the heterologous gene products in appropriate host cells or to create chimeric viruses that express the heterologous gene products. In one embodiment, the recombinant cDNA can be used to transfect appropriate host cells and the resulting RNA may direct the expression of the heterologous gene product at high levels. Host cell systems which provide for high levels of expression include continuous cell lines that supply viral functions such as cell lines superinfected with APV or MPV, respectively, cell lines engineered to complement APV or MPV functions, etc.

In an alternate embodiment of the invention, the recombinant templates may be used to transfect cell lines that express a viral polymerase protein in order to achieve expression of the heterologous gene product. To this end, transformed cell lines that express a polymerase protein such as the L protein may be utilized as appropriate host cells. Host cells may be similarly engineered to provide other viral functions or additional functions such as G or N.

In another embodiment, a helper virus may provide the RNA polymerase protein utilized by the cells in order to achieve expression of the heterologous gene product. In yet another embodiment, cells may be transfected with vectors encoding viral proteins such as the N, P, L, and M2-1 proteins.

5.6 RESCUE OF RECOMBINANT VIRUS PARTICLES

In order to prepare the chimeric and recombinant viruses of the invention, a cDNA encoding the genome of a recombinant or chimeric virus of the invention in the plus or minus sense may be used to transfect cells which provide viral proteins and functions required for replication and rescue. Alternatively, cells may be transfected with helper virus before, during, or after transfection by the DNA or RNA molecule coding for the recombinant virus of the invention. The synthetic recombinant plasmid DNAs and RNAs of the invention can

be replicated and rescued into infectious virus particles by any number of techniques known in the art, as described, *e.g.*, in U.S. Patent No. 5,166,057 issued November 24, 1992; in U.S. Patent No. 5,854,037 issued December 29, 1998; in European Patent Publication EP 0702085A1, published February 20, 1996; in U.S. Patent No. 6,146,642; in International Patent Publications PCT WO97/12032 published April 3, 1997; WO96/34625 published November 7, 1996; in European Patent Publication EP-A780475; WO 99/02657 published January 21, 1999; WO 98/53078 published November 26, 1998; WO 98/02530 published January 22, 1998; WO 99/15672 published April 1, 1999; WO 98/13501 published April 2, 1998; WO 97/06270 published February 20, 1997; and EPO 780 47SA1 published June 25, 1997.

In one embodiment, of the present invention, synthetic recombinant viral RNAs may be prepared that contain the non-coding regions of the negative strand virus RNA which are essential for the recognition by viral polymerases and for packaging signals necessary to generate a mature virion. There are a number of different approaches which may be used to apply the reverse genetics approach to rescue negative strand RNA viruses. First, the recombinant RNAs are synthesized from a recombinant DNA template and reconstituted *in vitro* with purified viral polymerase complex to form recombinant ribonucleoproteins (RNPs) which can be used to transfect cells. In another approach, a more efficient transfection is achieved if the viral polymerase proteins are present during transcription of the synthetic RNAs either *in vitro* or *in vivo*. With this approach the synthetic RNAs may be transcribed from cDNA plasmids which are either co-transcribed *in vitro* with cDNA plasmids encoding the polymerase proteins, or transcribed *in vivo* in the presence of polymerase proteins, *i.e.*, in cells which transiently or constitutively express the polymerase proteins.

In additional approaches described herein, the production of infectious chimeric or recombinant virus may be replicated in host cell systems that express a metapneumoviral polymerase protein (*e.g.*, in virus/host cell expression systems; transformed cell lines engineered to express a polymerase protein, etc.), so that infectious chimeric or recombinant virus are rescued. In this instance, helper virus need not be utilized since this function is provided by the viral polymerase proteins expressed.

In accordance with the present invention, any technique known to those of skill in the art may be used to achieve replication and rescue of recombinant and chimeric viruses. One

approach involves supplying viral proteins and functions required for replication *in vitro* prior to transfecting host cells. In such an embodiment, viral proteins may be supplied in the form of wildtype virus, helper virus, purified viral proteins or recombinantly expressed viral proteins. The viral proteins may be supplied prior to, during or post transcription of the synthetic cDNAs or RNAs encoding the chimeric virus. The entire mixture may be used to transfect host cells. In another approach, viral proteins and functions required for replication may be supplied prior to or during transcription of the synthetic cDNAs or RNAs encoding the chimeric virus. In such an embodiment, viral proteins and functions required for replication are supplied in the form of wildtype virus, helper virus, viral extracts, synthetic cDNAs or RNAs which express the viral proteins are introduced into the host cell via infection or transfection. This infection/transfection takes place prior to or simultaneous to the introduction of the synthetic cDNAs or RNAs encoding the chimeric virus.

In a particularly desirable approach, cells engineered to express all viral genes or chimeric or recombinant virus of the invention, *i.e.*, APV, MPV, MPV/APV or APV/MPV, may result in the production of infectious virus which contain the desired genotype; thus eliminating the need for a selection system. Theoretically, one can replace any one of the ORFs or part of any one of the ORFs encoding structural proteins of MPV with a foreign sequence. However, a necessary part of this equation is the ability to propagate the defective virus (defective because a normal viral gene product is missing or altered). A number of possible approaches exist to circumvent this problem. In one approach a virus having a mutant protein can be grown in cell lines which are constructed to constitutively express the wild type version of the same protein. By this way, the cell line complements the mutation in the virus. Similar techniques may be used to construct transformed cell lines that constitutively express any of the MPV genes. These cell lines which are made to express the viral protein may be used to complement the defect in the chimeric or recombinant virus and thereby propagate it. Alternatively, certain natural host range systems may be available to propagate chimeric or recombinant virus.

In yet another embodiment, viral proteins and functions required for replication may be supplied as genetic material in the form of synthetic cDNAs or RNAs so that they are co-transcribed with the synthetic cDNAs or RNAs encoding the chimeric virus. In a particularly desirable approach, plasmids which express the chimeric virus and the viral polymerase

and/or other viral functions are co-transfected into host cells. For example, plasmids encoding the genomic or antigenomic APV, MPV, MPV/APV or APV/MPV RNA, with or without one or more heterologous sequences, may be co-transfected into host cells with plasmids encoding the metapneumoviral polymerase proteins N, P, L, or M2-1. Alternatively, rescue of the recombinant viruses of the invention may be accomplished by the use of Modified Vaccinia Virus Ankara (MVA) encoding T7 RNA polymerase, or a combination of MVA and plasmids encoding the polymerase proteins (N, P, and L). For example, MVA-T7 or Fowl Pox-T7 can be infected into Vero cells, LLC-MK-2 cells, Hep-2 cells, LF 1043 (HEL) cells, tMK cells, LLC-MK2, HUT 292, FRHL-2 (rhesus), FCL-1 (green monkey), WI-38 (human), MRC-5 (human) cells, 293 T cells, QT 6 cells, QT 35 cells and CEF cells. After infection with MVA-T7 or Fowl Pox-T7, a full length antigenomic cDNA encoding the recombinant virus of the invention may be transfected into the cells together with the N, P, L, and M2-1 encoding expression plasmids. Alternatively, the polymerase may be provided by plasmid transfection. The cells and cell supernatant can subsequently be harvested and subjected to a single freeze-thaw cycle. The resulting cell lysate may then be used to infect a fresh HeLa or Vero cell monolayer in the presence of 1-beta-D-arabinofuranosylcytosine (ara C), a replication inhibitor of vaccinia virus, to generate a virus stock. The supernatant and cells from these plates can then be harvested, freeze-thawed once and the presence of recombinant virus particles of the invention can be assayed by immunostaining of virus plaques using antiserum specific to the particular virus.

Another approach to propagating the chimeric or recombinant virus may involve co-cultivation with wild-type virus. This could be done by simply taking recombinant virus and co-infecting cells with this and another wild-type virus. The wild-type virus should complement for the defective virus gene product and allow growth of both the wild-type and recombinant virus. Alternatively, a helper virus may be used to support propagation of the recombinant virus.

In another approach, synthetic templates may be replicated in cells co-infected with recombinant viruses that express the metapneumovirus polymerase protein. In fact, this method may be used to rescue recombinant infectious virus in accordance with the invention. To this end, the metapneumovirus polymerase protein may be expressed in any expression vector/host cell system, including but not limited to viral expression vectors (*e.g.*, vaccinia

virus, adenovirus, baculovirus, etc.) or cell lines that express a polymerase protein (*e.g.*, *see* Krystal *et al.*, 1986, *Proc. Natl. Acad. Sci. USA* 83: 2709-2713). Moreover, infection of host cells expressing all metapneumovirus proteins may result in the production of infectious chimeric virus particles. It should be noted that it may be possible to construct a recombinant virus without altering virus viability. These altered viruses would then be growth competent and would not need helper functions to replicate.

Transfection procedures are well-known to the skill artisan and include, but are not limited to, DEAE-dextran-mediated, Calcium phosphate-mediated, Electroporation, and Liposome-mediated transfection.

A full-length viral genome can be assembled from several smaller PCR fragments. Restriction maps of different isolates of hMPV are shown in Figure 28. The restriction sites can be used to assemble the full-length construct. In certain embodiments, PCR primers are designed such that the fragment resulting from the PCR reaction has a restriction site close to its 5' end and a restriction site close to its 3' end. The PCR product can then be digested with the respective restriction enzymes and subsequently ligated to the neighboring PCR fragments.

5.7 ATTENUATION OF RECOMBINANT VIRUSES

The recombinant viruses of the invention can be further genetically engineered to exhibit an attenuated phenotype. In particular, the recombinant viruses of the invention exhibit an attenuated phenotype in a subject to which the virus is administered as a vaccine. Attenuation can be achieved by any method known to a skilled artisan. Without being bound by theory, the attenuated phenotype of the recombinant virus can be caused, *e.g.*, by using a virus that naturally does not replicate well in an intended host (*e.g.*, using an APV in human), by reduced replication of the viral genome, by reduced ability of the virus to infect a host cell, or by reduced ability of the viral proteins to assemble to an infectious viral particle relative to the wild type strain of the virus. The viability of certain sequences of the virus, such as the leader and the trailer sequence can be tested using a minigenome assay (*see* section 5.8).

The attenuated phenotypes of a recombinant virus of the invention can be tested by any method known to the artisan (*see, e.g.*, section 5.8). A candidate virus can, for example, be tested for its ability to infect a host or for the rate of replication in a cell culture system. In

certain embodiments, a mimi-genome system is used to test the attenuated virus when the gene that is altered is N, P, L, M2, F, G, M2-1, M2-2 or a combination thereof. In certain embodiments, growth curves at different temperatures are used to test the attenuated phenotype of the virus. For example, an attenuated virus is able to grow at 35°C, but not at 39°C or 40°C. In certain embodiments, different cell lines can be used to evaluate the attenuated phenotype of the virus. For example, an attenuated virus may only be able to grow in monkey cell lines but not the human cell lines, or the achievable virus titers in different cell lines are different for the attenuated virus. In certain embodiments, viral replication in the respiratory tract of a small animal model, including but not limited to, hamsters, cotton rats, mice and guinea pigs, is used to evaluate the attenuated phenotypes of the virus. In other embodiments, the immune response induced by the virus, including but not limited to, the antibody titers (*e.g.*, assayed by plaque reduction neutralization assay or ELISA) is used to evaluate the attenuated phenotypes of the virus. In a specific embodiment, the plaque reduction neutralization assay or ELISA is carried out at a low dose. In certain embodiments, the ability of the recombinant virus to elicit pathological symptoms in an animal model can be tested. A reduced ability of the virus to elicit pathological symptoms in an animal model system is indicative of its attenuated phenotype. In a specific embodiment, the candidate viruses are tested in a monkey model for nasal infection, indicated by mucous production.

The viruses of the invention can be attenuated such that one or more of the functional characteristics of the virus are impaired. In certain embodiments, attenuation is measured in comparison to the wild type strain of the virus from which the attenuated virus is derived. In other embodiments, attenuation is determined by comparing the growth of an attenuated virus in different host systems. Thus, for a non-limiting example, an APV is said to be attenuated when grown in a human host if the growth of the APV in the human host is reduced compared to the growth of the APV in an avian host.

In certain embodiments, the attenuated virus of the invention is capable of infecting a host, is capable of replicating in a host such that infectious viral particles are produced. In comparison to the wild type strain, however, the attenuated strain grows to lower titers or grows more slowly. Any technique known to the skilled artisan can be used to determine the growth curve of the attenuated virus and compare it to the growth curve of the wild type virus. For exemplary methods see Example section, *infra*. In a specific embodiment, the

attenuated virus grows to a titer of less than 10^5 pfu/ml, of less than 10^4 pfu/ml, of less than 10^3 pfu/ml, or of less than 10^2 pfu/ml in Vero cells under conditions as described in, *e.g.*, Example 22.

In certain embodiments, the attenuated virus of the invention (*e.g.*, a chimeric mammalian MPV) cannot replicate in human cells as well as the wild type virus (*e.g.*, wild type mammalian MPV) does. However, the attenuated virus can replicate well in a cell line that lack interferon functions, such as Vero cells.

In other embodiments, the attenuated virus of the invention is capable of infecting a host, of replicating in the host, and of causing proteins of the virus of the invention to be inserted into the cytoplasmic membrane, but the attenuated virus does not cause the host to produce new infectious viral particles. In certain embodiments, the attenuated virus infects the host, replicates in the host, and causes viral proteins to be inserted in the cytoplasmic membrane of the host with the same efficiency as the wild type mammalian virus. In other embodiments, the ability of the attenuated virus to cause viral proteins to be inserted into the cytoplasmic membrane into the host cell is reduced compared to the wild type virus. In certain embodiments, the ability of the attenuated mammalian virus to replicate in the host is reduced compared to the wild type virus. Any technique known to the skilled artisan can be used to determine whether a virus is capable of infecting a mammalian cell, of replicating within the host, and of causing viral proteins to be inserted into the cytoplasmic membrane of the host. For illustrative methods see section 5.8.

In certain embodiments, the attenuated virus of the invention is capable of infecting a host. In contrast to the wild type mammalian MPV, however, the attenuated mammalian MPV cannot be replicated in the host. In a specific embodiment, the attenuated mammalian virus can infect a host and can cause the host to insert viral proteins in its cytoplasmic membranes, but the attenuated virus is incapable of being replicated in the host. Any method known to the skilled artisan can be used to test whether the attenuated mammalian MPV has infected the host and has caused the host to insert viral proteins in its cytoplasmic membranes.

In certain embodiments, the ability of the attenuated mammalian virus to infect a host is reduced compared to the ability of the wild type virus to infect the same host. Any

technique known to the skilled artisan can be used to determine whether a virus is capable of infecting a host. For illustrative methods see section 5.8.

In certain embodiments, mutations (*e.g.*, missense mutations) are introduced into the genome of the virus to generate a virus with an attenuated phenotype. Mutations (*e.g.*, missense mutations) can be introduced into the N-gene, the P-gene, the M-gene, the F-gene, the M2-gene, the SH-gene, the G-gene or the L-gene of the recombinant virus. Mutations can be additions, substitutions, deletions, or combinations thereof. In specific embodiments, a single amino acid deletion mutation for the N, P, L, F, G, M2-1, M2-2 or M2 proteins is introduced, which can be screened for functionality in the mini-genome assay system and be evaluated for predicted functionality in the virus. In more specific embodiments, the missense mutation is a cold-sensitive mutation. In other embodiments, the missense mutation is a heat-sensitive mutation. In one embodiment, major phosphorylation sites of P protein of the virus is removed. In another embodiment, a mutation or mutations are introduced into the L gene of the virus to generate a temperature sensitive strain. In yet another embodiment, the cleavage site of the F gene is mutated in such a way that cleavage does not occur or occurs at very low efficiency.

In other embodiments, deletions are introduced into the genome of the recombinant virus. In more specific embodiments, a deletion can be introduced into the N-gene, the P-gene, the M-gene, the F-gene, the M2-gene, the SH-gene, the G-gene or the L-gene of the recombinant virus. In specific embodiments, the deletion is in the M2-gene of the recombinant virus of the present invention. In other specific embodiments, the deletion is in the SH-gene of the recombinant virus of the present invention. In yet another specific embodiment, both the M2-gene and the SH-gene are deleted.

In certain embodiments, the intergenic region of the recombinant virus is altered. In one embodiment, the length of the intergenic region is altered. In another embodiment, the intergenic regions are shuffled from 5' to 3' end of the viral genome.

In other embodiments, the genome position of a gene or genes of the recombinant virus is changed. In one embodiment, the F or G gene is moved to the 3' end of the genome. In another embodiment, the N gene is moved to the 5' end of the genome.

In certain embodiments, attenuation of the virus is achieved by replacing a gene of the wild type virus with a gene of a virus of a different species, of a different subgroup, or of a

different variant. In illustrative embodiments, the N-gene, the P-gene, the M-gene, the F-gene, the M2-gene, the SH-gene, the G-gene or the L-gene of a mammalian MPV is replaced with the N-gene, the P-gene, the M-gene, the F-gene, the M2-gene, the SH-gene, the G-gene or the L-gene, respectively, of an APV. In other illustrative embodiments, the N-gene, the P-gene, the M-gene, the F-gene, the M2-gene, the SH-gene, the G-gene or the L-gene of APV is replaced with the N-gene, the P-gene, the M-gene, the F-gene, the M2-gene, the SH-gene, the G-gene or the L-gene, respectively, of a mammalian MPV. In a preferred embodiment, attenuation of the virus is achieved by replacing one or more polymerase associated genes (*e.g.*, N, P, L or M2) with genes of a virus of a different species.

In certain embodiments, attenuation of the virus is achieved by replacing one or more specific domains of a protein of the wild type virus with domains derived from the corresponding protein of a virus of a different species. In an illustrative embodiment, the ectodomain of a F protein of APV is replaced with an ectodomain of a F protein of a mammalian MPV. In a preferred embodiment, one or more specific domains of L, N, or P protein are replaced with domains derived from corresponding proteins of a virus of a different species. In certain other embodiments, attenuation of the virus is achieved by deleting one or more specific domains of a protein of the wild type virus. In a specific embodiment, the transmembrane domain of the F-protein is deleted.

In certain embodiments of the invention, the leader and/or trailer sequence of the recombinant virus of the invention can be modified to achieve an attenuated phenotype. In certain, more specific embodiments, the leader and/or trailer sequence is reduced in length relative to the wild type virus by at least 1 nucleotide, at least 2 nucleotides, at least 3 nucleotides, at least 4 nucleotides, at least 5 nucleotides or at least 6 nucleotides. In certain other, more specific embodiments, the sequence of the leader and/or trailer of the recombinant virus is mutated. In a specific embodiment, the leader and the trailer sequence are 100% complementary to each other. In other embodiments, 1 nucleotide, 2 nucleotides, 3 nucleotides, 4 nucleotides, 5 nucleotides, 6 nucleotides, 7 nucleotides, 8 nucleotides, 9 nucleotides, or 10 nucleotides are not complementary to each other where the remaining nucleotides of the leader and the trailer sequences are complementary to each other. In certain embodiments, the non-complementary nucleotides are identical to each other. In certain other embodiments, the non-complementary nucleotides are different from each other.

In other embodiments, if the non-complementary nucleotide in the trailer is purine, the corresponding nucleotide in the leader sequence is also a purine. In other embodiments, if the non-complementary nucleotide in the trailer is pyrimidine, the corresponding nucleotide in the leader sequence is also a purine.

When a live attenuated vaccine is used, its safety must also be considered. The vaccine must not cause disease. Any techniques known in the art that can make a vaccine safe may be used in the present invention. In addition to attenuation techniques, other techniques may be used. One non-limiting example is to use a soluble heterologous gene that cannot be incorporated into the virion membrane. For example, a single copy of the soluble RSV F gene, a version of the RSV gene lacking the transmembrane and cytosolic domains, can be used. Since it cannot be incorporated into the virion membrane, the virus tropism is not expected to change.

Various assays can be used to test the safety of a vaccine. *See* section 5.8, *infra*. Particularly, sucrose gradients and neutralization assays can be used to test the safety. A sucrose gradient assay can be used to determine whether a heterologous protein is inserted in a virion. If the heterologous protein is inserted in the virion, the virion should be tested for its ability to cause symptoms even if the parental strain does not cause symptoms. Without being bound by theory, if the heterologous protein is incorporated in the virion, the virus may have acquired new, possibly pathological, properties.

5.8 ASSAYS FOR USE WITH THE INVENTION

A number of assays may be employed in accordance with the present invention in order to determine the rate of growth of a chimeric or recombinant virus in a cell culture system, an animal model system or in a subject. A number of assays may also be employed in accordance with the present invention in order to determine the requirements of the chimeric and recombinant viruses to achieve infection, replication and packaging of virions.

The assays described herein may be used to assay viral titre over time to determine the growth characteristics of the virus. In a specific embodiment, the viral titre is determined by obtaining a sample from the infected cells or the infected subject, preparing a serial dilution of the sample and infecting a monolayer of cells that are susceptible to infection with the virus at a dilution of the virus that allows for the emergence of single plaques. The plaques

can then be counted and the viral titre express as plaque forming units per milliliter of sample. In a specific embodiment of the invention, the growth rate of a virus of the invention in a subject is estimated by the titer of antibodies against the virus in the subject. Without being bound by theory, the antibody titer in the subject reflects not only the viral titer in the subject but also the antigenicity. If the antigenicity of the virus is constant, the increase of the antibody titer in the subject can be used to determine the growth curve of the virus in the subject. In a preferred embodiment, the growth rate of the virus in animals or humans is best tested by sampling biological fluids of a host at multiple time points post-infection and measuring viral titer.

The expression of heterologous gene sequence in a cell culture system or in a subject can be determined by any technique known to the skilled artisan. In certain embodiments, the expression of the heterologous gene is measured by quantifying the level of the transcript. The level of the transcript can be measured by Northern blot analysis or by RT-PCR using probes or primers, respectively, that are specific for the transcript. The transcript can be distinguished from the genome of the virus because the virus is in the antisense orientation whereas the transcript is in the sense orientation. In certain embodiments, the expression of the heterologous gene is measured by quantifying the level of the protein product of the heterologous gene. The level of the protein can be measured by Western blot analysis using antibodies that are specific to the protein.

In a specific embodiment, the heterologous gene is tagged with a peptide tag. The peptide tag can be detected using antibodies against the peptide tag. The level of peptide tag detected is representative for the level of protein expressed from the heterologous gene. Alternatively, the protein expressed from the heterologous gene can be isolated by virtue of the peptide tag. The amount of the purified protein correlates with the expression level of the heterologous gene. Such peptide tags and methods for the isolation of proteins fused to such a peptide tag are well known in the art. A variety of peptide tags known in the art may be used in the modification of the heterologous gene, such as, but not limited to, the immunoglobulin constant regions, polyhistidine sequence (Petty, 1996, Metal-chelate affinity chromatography, in Current Protocols in Molecular Biology, volume 1-3 (1994-1998). Ed. by Ausubel, F.M., Brent, R., Kunston, R.E., Moore, D.D., Seidman, J.G., Smith, J.A. and Struhl, K. Published by John Wiley and sons, Inc., USA, Greene Publish. Assoc. & Wiley

Interscience), glutathione S-transferase (GST; Smith, 1993, Methods Mol. Cell Bio. 4:220-229), the *E. coli* maltose binding protein (Guan et al., 1987, Gene 67:21-30), various cellulose binding domains (U.S. patent 5,496,934; 5,202,247; 5,137,819; Tomme et al., 1994, Protein Eng. 7:117-123), and the FLAG epitope (Short Protocols in Molecular Biology, 1999, Ed. Ausubel et al., John Wiley & Sons, Inc., Unit 10.11) etc. Other peptide tags are recognized by specific binding partners and thus facilitate isolation by affinity binding to the binding partner, which is preferably immobilized and/or on a solid support. As will be appreciated by those skilled in the art, many methods can be used to obtain the coding region of the above-mentioned peptide tags, including but not limited to, DNA cloning, DNA amplification, and synthetic methods. Some of the peptide tags and reagents for their detection and isolation are available commercially.

Samples from a subject can be obtained by any method known to the skilled artisan. In certain embodiments, the sample consists of nasal aspirate, throat swab, sputum or broncho-alveolar lavage.

5.8.1 MINIREPLICON CONSTRUCTS

Minireplicon constructs can be generated to contain an antisense reporter gene. Any reporter gene known to the skilled artisan can be used with the invention (*see* section 5.8.2). In a specific embodiment, the reporter gene is CAT. In certain embodiments, the reporter gene can be flanked by the negative-sense hMPV or APV leader linked to the hepatitis delta ribozyme (Hep-d Ribo) and T7 polymerase termination (T-T7) signals, and the hMPV or APV trailer sequence preceded by the T7 RNA polymerase promoter.

In certain embodiments, the plasmid encoding the minireplicon is transfected into a host cell. The host cell expresses T7 RNA polymerase, the N gene, the P gene, the L gene, and the M2.1 gene. In certain embodiments, the host cell is transfected with plasmids encoding T7 RNA polymerase, the N gene, the P gene, the L gene, and the M2.1 gene. In other embodiments, the plasmid encoding the minireplicon is transfected into a host cell and the host cell is infected with a helper virus.

The expression level of the reporter gene and/or its activity can be assayed by any method known to the skilled artisan, such as, but not limited to, the methods described in section 5.8.2.

In certain, more specific, embodiments, the minireplicon comprises the following elements, in the order listed: T7 RNA Polymerase or RNA polymerase I, leader sequence, gene start, GFP, trailer sequence, Hepatitis delta ribozyme sequence or RNA polymerase I termination sequence. If T7 is used as RNA polymerase, Hepatitis delta ribozyme sequence should be used as termination sequence. If RNA polymerase I is used, RNA polymerase I termination sequence may be used as a termination signal. Dependent on the rescue system, the sequence of the minireplicon can be in the sense or antisense orientation. In certain embodiments, the leader sequence can be modified relative to the wild type leader sequence of hMPV. The leader sequence can optionally be preceded by an AC. The T7 promoter sequence can be with or without a G-doublet or triplet, where the G-doublet or triplet provides for increased transcription.

In a specific embodiment, a cell is infected with hMPV at T0. 24 hours later, at T24, the cell is transfected with a minireplicon construct. 48 hours after T0 and 72 hours after T0, the cells are tested for the expression of the reporter gene. If a fluorescent reporter gene product is used (*e.g.*, GFP), the expression of the reporter gene can be tested using FACS.

In another embodiment, a cell is transfected with six plasmids at T=0 hours. Cells are then harvested at T=40 hours and T=60 hours and analyzed for CAT or GFP expression. (*See* Figure 25.)

In another specific embodiment, a cell is infected with MVA-T7 at T0. 1 hour later, at T1, the cell is transfected with a minireplicon construct. 24 hours after T0, the cell is infected with hMPV. 72 hours after T0, the cells are tested for the expression of the reporter gene. If a fluorescent reporter gene product is used (*e.g.*, GFP), the expression of the reporter gene can be tested using FACS.

5.8.2 REPORTER GENES

In certain embodiments, assays for measurement of reporter gene expression in tissue culture or in animal models can be used with the methods of the invention. The nucleotide sequence of the reporter gene is cloned into the virus, such as APV, hMPV, hMPV/APV or APV/hMPV, wherein (i) the position of the reporter gene is changed and (ii) the length of the intergenic regions flanking the reporter gene are varied. Different combinations are tested to

determine the optimal rate of expression of the reporter gene and the optimal replication rate of the virus comprising the reporter gene.

In certain embodiments, minireplicon constructs are generated to include a reporter gene. The construction of minireplicon constructs is described herein.

The abundance of the reporter gene product can be determined by any technique known to the skilled artisan. Such techniques include, but are not limited to, Northern blot analysis or Western blot analysis using probes or antibodies, respectively, that are specific to the reporter gene.

In certain embodiments, the reporter gene emits a fluorescent signal that can be detected in a FACS. FACS can be used to detect cells in which the reporter gene is expressed.

Techniques for practicing the specific aspect of this invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, and recombinant DNA manipulation and production, which are routinely practiced by one of skill in the art. *See, e.g.*, Sambrook et al., *Molecular cloning, a laboratory manual*, second ed., vol. 1-3. (Cold Spring Harbor Laboratory, 1989), *A Laboratory Manual, Second Edition; DNA Cloning, Volumes I and II* (Glover, Ed. 1985); and *Transcription and Translation* (Hames & Higgins, Eds. 1984).

The biochemical activity of the reporter gene product represents the expression level of the reporter gene. The total level of reporter gene activity depends also on the replication rate of the recombinant virus of the invention. Thus, to determine the true expression level of the reporter gene from the recombinant virus, the total expression level should be divided by the titer of the recombinant virus in the cell culture or the animal model.

Reporter genes that can be used with the methods of invention include, but are not limited to, the genes listed in the Table 4 below:

TABLE 4: Reporter genes and the biochemical properties of the respective reporter gene products

Reporter Gene	Protein Activity & Measurement
CAT (chloramphenicol acetyltransferase)	Transfers radioactive acetyl groups to chloramphenicol or detection by thin layer chromatography and autoradiography
GAL (β -galactosidase)	Hydrolyzes colorless galactosides to yield colored products.
GUS (β -glucuronidase)	Hydrolyzes colorless glucuronides to yield colored products.
LUC (luciferase)	Oxidizes luciferin, emitting photons
GFP (green fluorescent protein)	fluorescent protein without substrate
SEAP (secreted alkaline phosphatase)	luminescence reaction with suitable substrates or with substrates that generate chromophores
HRP (horseradish peroxidase)	in the presence of hydrogen oxide, oxidation of 3,3',5,5'-tetramethylbenzidine to form a colored complex
AP (alkaline phosphatase)	luminescence reaction with suitable substrates or with substrates that generate chromophores

The abundance of the reporter gene can be measured by, *inter alia*, Western blot analysis or Northern blot analysis or any other technique used for the quantification of transcription of a nucleotide sequence, the abundance of its mRNA its protein (*see* Short Protocols in Molecular Biology, Ausubel et al., (editors), John Wiley & Sons, Inc., 4th edition, 1999). In certain embodiments, the activity of the reporter gene product is measured as a readout of reporter gene expression from the recombinant virus. For the quantification of the activity of the reporter gene product, biochemical characteristics of the reporter gene product can be employed (*see* Table 4). The methods for measuring the biochemical activity of the reporter gene products are well-known to the skilled artisan. A more detailed description of

illustrative reporter genes that can be used with the methods of the invention is set forth below.

5.8.3 MEASUREMENT OF INCIDENCE OF INFECTION RATE

The incidence of infection can be determined by any method well-known in the art, for example, but not limited to, clinical samples (e.g., nasal swabs) can be tested for the presence of a virus of the invention by immunofluorescence assay (IFA) using an anti-APV-antigen antibody, an anti-hMPV-antigen antibody, an anti-APV-antigen antibody, and/or an antibody that is specific to the gene product of the heterologous nucleotide sequence, respectively.

In certain embodiments, samples containing intact cells can be directly processed, whereas isolates without intact cells should first be cultured on a permissive cell line (e.g. HEp-2 cells). In an illustrative embodiment, cultured cell suspensions should be cleared by centrifugation at, e.g., 300xg for 5 minutes at room temperature, followed by a PBS, pH 7.4 (Ca⁺⁺ and Mg⁺⁺ free) wash under the same conditions. Cell pellets are resuspended in a small volume of PBS for analysis. Primary clinical isolates containing intact cells are mixed with PBS and centrifuged at 300xg for 5 minutes at room temperature. Mucus is removed from the interface with a sterile pipette tip and cell pellets are washed once more with PBS under the same conditions. Pellets are then resuspended in a small volume of PBS for analysis. Five to ten microliters of each cell suspension are spotted per 5 mm well on acetone washed 12-well HTC supercured glass slides and allowed to air dry. Slides are fixed in cold (-20°C) acetone for 10 minutes. Reactions are blocked by adding PBS - 1% BSA to each well followed by a 10 minute incubation at room temperature. Slides are washed three times in PBS - 0.1% Tween-20 and air dried. Ten microliters of each primary antibody reagent diluted to 250 ng/ml in blocking buffer is spotted per well and reactions are incubated in a humidified 37°C environment for 30 minutes. Slides are then washed extensively in three changes of PBS - 0.1% Tween-20 and air dried. Ten microliters of appropriate secondary conjugated antibody reagent diluted to 250 ng/ml in blocking buffer are spotted per respective well and reactions are incubated in a humidified 37°C environment for an additional 30 minutes. Slides are then washed in three changes of PBS - 0.1% Tween-20. Five microliters of PBS-50% glycerol-10 mM Tris pH 8.0-1 mM EDTA are spotted per reaction well, and

slides are mounted with cover slips. Each reaction well is subsequently analyzed by fluorescence microscopy at 200X power using a B-2A filter (EX 450-490 nm). Positive reactions are scored against an autofluorescent background obtained from unstained cells or cells stained with secondary reagent alone. Positive reactions are characterized by bright fluorescence punctuated with small inclusions in the cytoplasm of infected cells.

5.8.4 MEASUREMENT OF SERUM TITER

Antibody serum titer can be determined by any method well-known in the art, for example, but not limited to, the amount of antibody or antibody fragment in serum samples can be quantitated by a sandwich ELISA. Briefly, the ELISA consists of coating microtiter plates overnight at 4°C with an antibody that recognizes the antibody or antibody fragment in the serum. The plates are then blocked for approximately 30 minutes at room temperature with PBS-Tween-0.5% BSA. Standard curves are constructed using purified antibody or antibody fragment diluted in PBS-TWEEN-BSA, and samples are diluted in PBS-BSA. The samples and standards are added to duplicate wells of the assay plate and are incubated for approximately 1 hour at room temperature. Next, the non-bound antibody is washed away with PBS-TWEEN and the bound antibody is treated with a labeled secondary antibody (e.g., horseradish peroxidase conjugated goat-anti-human IgG) for approximately 1 hour at room temperature. Binding of the labeled antibody is detected by adding a chromogenic substrate specific for the label and measuring the rate of substrate turnover, e.g., by a spectrophotometer. The concentration of antibody or antibody fragment levels in the serum is determined by comparison of the rate of substrate turnover for the samples to the rate of substrate turnover for the standard curve at a certain dilution.

5.8.5 SEROLOGICAL TESTS

In certain embodiments of the invention, the presence of antibodies that bind to a component of a mammalian MPV is detected. In particular the presence of antibodies directed to a protein of a mammalian MPV can be detected in a subject to diagnose the presence of a mammalian MPV in the subject. Any method known to the skilled artisan can be used to detect the presence of antibodies directed to a component of a mammalian MPV.

In an illustrative embodiment, components of mammalian MPV are linked to a solid support. In a specific embodiment, the component of the mammalian MPV can be, but is not limited to, the F protein or the G protein. Subsequently, the material that is to be tested for the presence of antibodies directed to mammalian MPV is incubated with the solid support under conditions conducive to the binding of the antibodies to the mammalian MPV components. Subsequently, the solid support is washed under conditions that remove any unspecifically bound antibodies. Following the washing step, the presence of bound antibodies can be detected using any technique known to the skilled artisan. In a specific embodiment, the mammalian MPV protein-antibody complex is incubated with detectably labeled antibody that recognizes antibodies that were generated by the species of the subject, *e.g.*, if the subject is a cotton rat, the detectably labeled antibody is directed to rat antibodies, under conditions conducive to the binding of the detectably labeled antibody to the antibody that is bound to the component of mammalian MPV. In a specific embodiment, the detectably labeled antibody is conjugated to an enzymatic activity. In another embodiment, the detectably labeled antibody is radioactively labeled. The complex of mammalian MPV protein-antibody-detectably labeled antibody is then washed, and subsequently the presence of the detectably labeled antibody is quantified by any technique known to the skilled artisan, wherein the technique used is dependent on the type of label of the detectably labeled antibody.

5.8.6 BIACORE ASSAY

Determination of the kinetic parameters of antibody binding can be determined for example by the injection of 250 μ L of monoclonal antibody ("mAb") at varying concentration in HBS buffer containing 0.05% Tween-20 over a sensor chip surface, onto which has been immobilized the antigen. The antigen can be any component of a mammalian MPV. In a specific embodiment, the antigen can be, but is not limited to, the F protein or the G protein of a mammalian MPV. The flow rate is maintained constant at 75 μ L/min. Dissociation data is collected for 15 min, or longer as necessary. Following each injection/dissociation cycle, the bound mAb is removed from the antigen surface using brief, 1 min pulses of dilute acid, typically 10-100 mM HCl, though other regenerants are employed as the circumstances warrant.

More specifically, for measurement of the rates of association, k_{on} , and dissociation, k_{off} , the antigen is directly immobilized onto the sensor chip surface through the use of standard amine coupling chemistries, namely the EDC/NHS method (EDC= N-diethylaminopropyl)-carbodiimide). Briefly, a 5-100 nM solution of the antigen in 10 mM NaOAc, pH4 or pH5 is prepared and passed over the EDC/NHS-activated surface until approximately 30-50 RU's (Biacore Resonance Unit) worth of antigen are immobilized. Following this, the unreacted active esters are "capped" off with an injection of 1M Et-NH₂. A blank surface, containing no antigen, is prepared under identical immobilization conditions for reference purposes. Once a suitable surface has been prepared, an appropriate dilution series of each one of the antibody reagents is prepared in HBS/Tween-20, and passed over both the antigen and reference cell surfaces, which are connected in series. The range of antibody concentrations that are prepared varies depending on what the equilibrium binding constant, K_D , is estimated to be. As described above, the bound antibody is removed after each injection/dissociation cycle using an appropriate regenerant.

Once an entire data set is collected, the resulting binding curves are globally fitted using algorithms supplied by the instrument manufacturer, BIAcore, Inc. (Piscataway, NJ). All data are fitted to a 1:1 Langmuir binding model. These algorithm calculate both the k_{on} and the k_{off} , from which the apparent equilibrium binding constant, K_D , is deduced as the ratio of the two rate constants (*i.e.* k_{off}/k_{on}). More detailed treatments of how the individual rate constants are derived can be found in the BIAevaluation Software Handbook (BIAcore, Inc., Piscataway, NJ).

5.8.7 MICRONEUTRALIZATION ASSAY

The ability of antibodies or antigen-binding fragments thereof to neutralize virus infectivity is determined by a microneutralization assay. This microneutralization assay is a modification of the procedures described by Anderson et al., (1985, J. Clin. Microbiol. 22:1050-1052).

The procedure is also described in Johnson et al., 1999, J. Infectious Diseases 180:35-40.

Antibody dilutions are made in triplicate using a 96-well plate. 10^6 TCID₅₀ of a mammalian MPV are incubated with serial dilutions of the antibody or antigen-binding

fragments thereof to be tested for 2 hours at 37°C in the wells of a 96-well plate. Cells susceptible to infection with a mammalian MPV, such as, but not limited to Vero cells (2.5×10^4) are then added to each well and cultured for 5 days at 37°C in 5% CO₂. After 5 days, the medium is aspirated and cells are washed and fixed to the plates with 80% methanol and 20% PBS. Virus replication is then determined by viral antigen, such as F protein expression. Fixed cells are incubated with a biotin-conjugated anti-viral antigen, such as anti-F protein monoclonal antibody (*e.g.*, pan F protein, C-site-specific MAb 133-1H) washed and horseradish peroxidase conjugated avidin is added to the wells. The wells are washed again and turnover of substrate TMB (thionitrobenzoic acid) is measured at 450 nm. The neutralizing titer is expressed as the antibody concentration that causes at least 50% reduction in absorbency at 450 nm (the OD₄₅₀) from virus-only control cells.

The microneutralization assay described here is only one example. Alternatively, standard neutralization assays can be used to determine how significantly the virus is affected by an antibody.

5.8.8 VIRAL FUSION INHIBITION ASSAY

This assay is in principle identical to the microneutralization assay, except that the cells are infected with the respective virus for four hours prior to addition of antibody and the read-out is in terms of presence or absence of fusion of cells (Taylor et al., 1992, J. Gen. Virol. 73:2217-2223).

5.8.9 ISOTHERMAL TITRATION CALORIMETRY

Thermodynamic binding affinities and enthalpies are determined from isothermal titration calorimetry (ITC) measurements on the interaction of antibodies with their respective antigen.

Antibodies are diluted in dialysate and the concentrations were determined by UV spectroscopic absorption measurements with a Perkin-Elmer Lambda 4B Spectrophotometer using an extinction coefficient of $217,000 \text{ M}^{-1} \text{ cm}^{-1}$ at the peak maximum at 280 nm. The diluted mammalian MPV-antigen concentrations are calculated from the ratio of the mass of the original sample to that of the diluted sample since its extinction coefficient is too low to determine an accurate concentration without employing and losing a large amount of sample.

ITC Measurements

The binding thermodynamics of the antibodies are determined from ITC measurements using a Microcal, Inc. VP Titration Calorimeter. The VP titration calorimeter consists of a matched pair of sample and reference vessels (1.409 ml) enclosed in an adiabatic enclosure and a rotating stirrer-syringe for titrating ligand solutions into the sample vessel. The ITC measurements are performed at 25°C and 35°C. The sample vessel contained the antibody in the phosphate buffer while the reference vessel contains just the buffer solution. The phosphate buffer solution is saline 67 mM PO₄ at pH 7.4 from HyClone, Inc. Five or ten µl aliquots of the 0.05 to 0.1 mM RSV-antigen, PIV-antigen, and/or hMPV-antigen solution are titrated 3 to 4 minutes apart into the antibody sample solution until the binding is saturated as evident by the lack of a heat exchange signal.

A non-linear, least square minimization software program from Microcal, Inc., Origin 5.0, is used to fit the incremental heat of the i-th titration ($\Delta Q(i)$) of the total heat, Q_t , to the total titrant concentration, X_t , according to the following equations (I),

$$Q_t = nC_t \Delta H_b^\circ V \{1 + X_t/nC_t + 1/nK_b C_t - [(1 + X_t/nC_t + 1/nK_b C_t)^2 - 4X_t/nC_t]^{1/2}\} / 2 \quad (1a)$$

$$\Delta Q(i) = Q(i) + dV_i/2V \{Q(i) + Q(i-1)\} - Q(i-1) \quad (1b)$$

where C_t is the initial antibody concentration in the sample vessel, V is the volume of the sample vessel, and n is the stoichiometry of the binding reaction, to yield values of K_b , ΔH_b° , and n . The optimum range of sample concentrations for the determination of K_b depends on the value of K_b and is defined by the following relationship.

$$C_t K_b n \leq 500 \quad (2)$$

so that at 1 µM the maximum K_b that can be determined is less than $2.5 \times 10^8 \text{ M}^{-1}$. If the first titrant addition does not fit the binding isotherm, it was neglected in the final analysis since it may reflect release of an air bubble at the syringe opening-solution interface.

5.8.10 IMMUNOASSAYS

Immunoprecipitation protocols generally comprise lysing a population of cells in a lysis buffer such as RIPA buffer (1 % NP-40 or TritonTM X-100, 1% sodium deoxycholate, 0.1 % SDS, 0.15 M NaCl, 0.01 M sodium phosphate at pH 7.2, 1 % TrasylolTM) supplemented with protein phosphatase and/or protease inhibitors (*e.g.*, EDTA, PMSF, 159 aprotinin, sodium vanadate), adding the antibody of interest to the cell lysate, incubating for a period of time (*e.g.*, to 4 hours) at 4 degrees C, adding protein A and/or protein G sepharoseTM beads to the cell lysate, incubating for about an hour or more at 4 degrees C, washing the beads in lysis buffer and re-suspending the beads in SDS/sample buffer. The ability of the antibody of interest to immunoprecipitate a particular antigen can be assessed by, *e.g.*, western blot analysis. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the binding of the antibody to an antigen and decrease the background (*e.g.*, pre-clearing the cell lysate with sepharoseTM beads). For further discussion regarding immunoprecipitation protocols see, *e.g.*, Ausubel *et al.*, eds., 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at pages 10, 16, 1.

Western blot analysis generally comprises preparing protein samples, electrophoresis of the protein samples in a polyacrylamide gel (*e.g.*, 8%- 20% SDS-PAGE depending on the molecular weight of the antigen), transferring the protein sample from the polyacrylamide gel to a membrane such as nitrocellulose, PVDF or nylon, blocking the membrane, in blocking solution (*e.g.*, PBS with 3% BSA or non-fat milk), washing the membrane in washing buffer (*e.g.*, PBSTweenTM20), incubating the membrane with primary antibody (the antibody of interest) diluted in blocking buffer, washing the membrane in washing buffer, incubating the membrane with a secondary antibody (which recognizes the primary antibody, *e.g.*, an anti-human antibody) conjugated to an enzymatic substrate (*e.g.*, horseradish peroxidase or alkaline phosphatase) or radioactive molecule (*e.g.*, ¹²⁵I or ¹²⁵P) diluted in blocking buffer, washing the membrane in wash buffer, and detecting the presence of the antigen. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected and to reduce the background noise. For further discussion regarding western blot protocols see, *e.g.*, Ausubel *et al.*, eds., 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.8.1.

ELISAs comprise preparing antigen, coating the well of a 96-well microtiter plate with the antigen, washing away antigen that did not bind the wells, adding the antibody of interest conjugated to a detectable compound such as an enzymatic substrate (*e.g.*, horseradish peroxidase or alkaline phosphatase) to the wells and incubating for a period of time, washing away unbound antibodies or non-specifically bound antibodies, and detecting the presence of the antibodies specifically bound to the antigen coating the well. In ELISAs the antibody of interest does not have to be conjugated to a detectable compound; instead, a second antibody (which recognizes the antibody of interest) conjugated to a detectable compound may be added to the well. Further, instead of coating the well with the antigen, the antibody may be coated to the well. In this case, the detectable molecule could be the antigen conjugated to a detectable compound such as an enzymatic substrate (*e.g.*, horseradish peroxidase or alkaline phosphatase). The parameters that can be modified to increase signal detection and other variations of ELISAs are well known to one of skill in the art. For further discussion regarding ELISAs *see, e.g.*, Ausubel *et al.*, eds, 1994, Current Protocols in Molecular Biology, Vol. I, John Wiley & Sons, Inc., New York at 11.2.1.

The binding affinity of an antibody (including a scFv or other molecule comprising, or alternatively consisting of, antibody fragments or variants thereof) to an antigen and the off-rate of an antibody-antigen interaction can be determined by competitive binding assays. One example of a competitive binding assay is a radioimmunoassay comprising the incubation of labeled antigen (*e.g.*, ^3H or ^{125}I) with the antibody of interest in the presence of increasing amounts of unlabeled antigen, and the detection of the antibody bound to the labeled antigen.

5.8.11 SUCROSE GRADIENT ASSAY

The question of whether the heterologous proteins are incorporated into the virion can be further investigated by use of any biochemical assay known to the skilled artisan. In a specific embodiment, a sucrose gradient assay is used to determine whether a heterologous protein is incorporated into the virion.

Infected cell lysates can be fractionated in 20 - 60% sucrose gradients, various fractions are collected and analyzed for the presence and distribution of heterologous proteins and the vector proteins by, *e.g.*, Western blot analysis. The fractions and the virus proteins

can also be assayed for peak virus titers by plaque assay. If the heterologous protein co-migrates with the virion the heterologous protein is associated with the virion.

5.9 METHODS TO IDENTIFY NEW ISOLATES OF MPV

The present invention relates to mammalian MPV, in particular hMPV. While the present invention provides the characterization of two serological subgroups of MPV, A and B, and the characterization of four variants of MPV A1, A2, B1 and B2, the invention is not limited to these subgroups and variants. The invention encompasses any yet to be identified isolates of MPV, including those which are characterized as belonging to the subgroups and variants described herein, or belonging to a yet to be characterized subgroup or variant.

Immunoassays can be used in order to characterize the protein components that are present in a given sample. Immunoassays are an effective way to compare viral isolates using peptides components of the viruses for identification. For example, the invention provides herein a method to identify further isolates of MPV as provided herein, the method comprising inoculating an essentially MPV-uninfected or specific-pathogen-free guinea pig or ferret (in the detailed description the animal is inoculated intranasally but other was of inoculation such as intramuscular or intradermal inoculation, and using an other experimental animal, is also feasible) with the prototype isolate I-2614 or related isolates. Sera are collected from the animal at day zero, two weeks and three weeks post inoculation. The animal specifically seroconverted as measured in virus neutralization (VN) assay (For an example of a VN assay, *see* Example 16) and indirect IFA (For an example of IFA, *see* Example 11 or 14) against the respective isolate I-2614 and the sera from the seroconverted animal are used in the immunological detection of said further isolates. As an example, the invention provides the characterization of a new member in the family of *Paramyxoviridae*, a human metapneumovirus or metapneumovirus-like virus (since its final taxonomy awaits discussion by a viral taxonomy committee the MPV is herein for example described as taxonomically corresponding to APV) (MPV) which may cause severe RTI in humans. The clinical signs of the disease caused by MPV are essentially similar to those caused by hRSV, such as cough, myalgia, vomiting, fever broncheolitis or pneumonia, possible conjunctivitis, or combinations thereof. As is seen with hRSV infected children, specifically very young children may require hospitalization. As an example an MPV which was deposited

January 19, 2001 as I-2614 with CNCM, Institute Pasteur, Paris or a virus isolate phylogenetically corresponding therewith is herewith provided. Therewith, the invention provides a virus comprising a nucleic acid or functional fragment phylogenetically corresponding to a nucleic acid sequence of SEQ. ID NO:19, or structurally corresponding therewith. In particular the invention provides a virus characterized in that after testing it in phylogenetic tree analysis wherein maximum likelihood trees are generated using 100 bootstraps and 3 jumbles it is found to be more closely phylogenetically corresponding to a virus isolate deposited as I-2614 with CNCM, Paris than it is related to a virus isolate of avian pneumovirus (APV) also known as turkey rhinotracheitis virus (TRTV), the aetiological agent of avian rhinotracheitis. It is particularly useful to use an AVP-C virus isolate as outgroup in said phylogenetic tree analysis, it being the closest relative, albeit being an essentially non-mammalian virus.

5.9.1 BIOINFORMATICS ALIGNMENT OF SEQUENCES

Two or more amino acid sequences can be compared by BLAST (Altschul, S.F. *et al.*, 1990, J. Mol. Biol. 215:403-410) to determine their sequence homology and sequence identities to each other. Two or more nucleotide sequences can be compared by BLAST (Altschul, S.F. *et al.*, 1990, J. Mol. Biol. 215:403-410) to determine their sequence homology and sequence identities to each other. BLAST comparisons can be performed using the Clustal W method (MacVector(tm)). In certain specific embodiments, the alignment of two or more sequences by a computer program can be followed by manual re-adjustment.

The determination of percent identity between two sequences can be accomplished using a mathematical algorithm. A preferred, non-limiting example of a mathematical algorithm utilized for the comparison of two sequences is the algorithm of Karlin and Altschul, 1990, Proc. Natl. Acad. Sci. USA 87:2264-2268, modified as in Karlin and Altschul, 1993, Proc. Natl. Acad. Sci. USA 90:5873-5877. Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul *et al.*, 1990, J. Mol. Biol. 215:403-410. BLAST nucleotide comparisons can be performed with the NBLAST program. BLAST amino acid sequence comparisons can be performed with the XBLAST program. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul *et al.*, 1997, Nucleic Acids Res.25:3389-3402. Alternatively, PSI-Blast can be used

to perform an interated search which detects distant relationships between molecules (Altschul *et al.*, 1997, *supra*). When utilizing BLAST, Gapped BLAST, and PSI-Blast programs, the default parameters of the respective programs (*e.g.*, XBLAST and NBLAST) can be used (See the website of the National Center for Biotechnology Information). Another preferred, non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller, 1988, CABIOS 4:11-17. Such an algorithm is incorporated into the ALIGN program (version 2.0) which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table can be used. The gap length penalty can be set by the skilled artisan. The percent identity between two sequences can be determined using techniques similar to those described above, with or without allowing gaps. In calculating percent identity, typically only exact matches are counted.

5.9.2 HYBRIDIZATION CONDITIONS

A nucleic acid which is hybridizable to a nucleic acid of a mammalian MPV, or to its reverse complement, or to its complement can be used in the methods of the invention to determine their sequence homology and identities to each other. In certain embodiments, the nucleic acids are hybridized under conditions of high stringency. By way of example and not limitation, procedures using such conditions of high stringency are as follows.

Prehybridization of filters containing DNA is carried out for 8 h to overnight at 65 C in buffer composed of 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 µg/ml denatured salmon sperm DNA. Filters are hybridized for 48 h at 65 C in prehybridization mixture containing 100 µg/ml denatured salmon sperm DNA and 5-20 X 10⁶ cpm of ³²P-labeled probe. Washing of filters is done at 37 C for 1 h in a solution containing 2X SSC, 0.01% PVP, 0.01% Ficoll, and 0.01% BSA. This is followed by a wash in 0.1X SSC at 50 C for 45 min before autoradiography. Other conditions of high stringency which may be used are well known in the art. In other embodiments of the invention, hybridization is performed under moderate of low stringency conditions, such conditions are well-known to the skilled artisan (*see e.g.*, Sambrook *et al.*, 1989, Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York; *see also*, Ausubel *et al.*, eds., in the Current Protocols in Molecular Biology series of

laboratory technique manuals, 1987-1997 Current Protocols, © 1994-1997 John Wiley and Sons, Inc.).

5.9.3 PHYLOGENETIC ANALYSIS

This invention relates to the inference of phylogenetic relationships between isolates of mammalian MPV. Many methods or approaches are available to analyze phylogenetic relationship; these include distance, maximum likelihood, and maximum parsimony methods (Swofford, DL., et. al., Phylogenetic Inference. In Molecular Systematics. Eds. Hillis, DM, Mortiz, C, and Mable, BK. 1996. Sinauer Associates: Massachusetts, USA. pp. 407 - 514; Felsenstein, J., 1981, J. Mol. Evol. 17:368-376). In addition, bootstrapping techniques are an effective means of preparing and examining confidence intervals of resultant phylogenetic trees (Felsenstein, J., 1985, Evolution. 29:783-791). Any method or approach using nucleotide or peptide sequence information to compare mammalian MPV isolates can be used to establish phylogenetic relationships, including, but not limited to, distance, maximum likelihood, and maximum parsimony methods or approaches. Any method known in the art can be used to analyze the quality of phylogenetic data, including but not limited to bootstrapping. Alignment of nucleotide or peptide sequence data for use in phylogenetic approaches, include but are not limited to, manual alignment, computer pairwise alignment, and computer multiple alignment. One skilled in the art would be familiar with the preferable alignment method or phylogenetic approach to be used based upon the information required and the time allowed.

In one embodiment, a DNA maximum likelihood method is used to infer relationships between hMPV isolates. In another embodiment, bootstrapping techniques are used to determine the certainty of phylogenetic data created using one of said phylogenetic approaches. In another embodiment, jumbling techniques are applied to the phylogenetic approach before the input of data in order to minimize the effect of sequence order entry on the phylogenetic analyses. In one specific embodiment, a DNA maximum likelihood method is used with bootstrapping. In another specific embodiment, a DNA maximum likelihood method is used with bootstrapping and jumbling. In another more specific embodiment, a DNA maximum likelihood method is used with 50 bootstraps. In another specific embodiment, a DNA maximum likelihood method is used with 50 bootstraps and 3 jumbles.

In another specific embodiment, a DNA maximum likelihood method is used with 100 bootstraps and 3 jumbles.

In one embodiment, nucleic acid or peptide sequence information from an isolate of hMPV is compared or aligned with sequences of other hMPV isolates. The amino acid sequence can be the amino acid sequence of the L protein, the M protein, the N protein, the P protein, or the F protein. In another embodiment, nucleic acid or peptide sequence information from an hMPV isolate or a number of hMPV isolates is compared or aligned with sequences of other viruses. In another embodiment, phylogenetic approaches are applied to sequence alignment data so that phylogenetic relationships can be inferred and/or phylogenetic trees constructed. Any method or approach that uses nucleotide or peptide sequence information to compare hMPV isolates can be used to infer said phylogenetic relationships, including, but not limited to, distance, maximum likelihood, and maximum parsimony methods or approaches.

Other methods for the phylogenetic analysis are disclosed in International Patent Application PCT/NL02/00040, published as WO 02/057302.

In particular, PCT/NL02/00040 discloses nucleic acid sequences that are suitable for phylogenetic analysis at page 12, line 27 to page 19, line 29.

For the phylogenetic analyses it is most useful to obtain the nucleic acid sequence of a non-MPV as outgroup with which the virus is to be compared, a very useful outgroup isolate can be obtained from avian pneumovirus serotype C (APV-C), see, *e.g.*, Figure 16.

Many methods and programs are known in the art and can be used in the inference of phylogenetic relationships, including, but not limited to BioEdit, ClustalW, TreeView, and NJPlot. Methods that would be used to align sequences and to generate phylogenetic trees or relationships would require the input of sequence information to be compared. Many methods or formats are known in the art and can be used to input sequence information, including, but not limited to, FASTA, NBRF, EMBL/SWISS, GDE protein, GDE nucleotide, CLUSTAL, and GCG/MSF. Methods that would be used to align sequences and to generate phylogenetic trees or relationships would require the output of results. Many methods or formats can be used in the output of information or results, including, but not limited to, CLUSTAL, NBRF/PIR, MSF, PHYLIP, and GDE. In one embodiment, ClustalW is used in

conjunction with DNA maximum likelihood methods with 100 bootstraps and 3 jumbles in order to generate phylogenetic relationships.

5.10 GENERATION OF ANTIBODIES

The invention also relates to the generation of antibodies against a protein encoded by a mammalian MPV. In particular, the invention relates to the generation of antibodies against all MPV antigens, including the F protein, N protein, M2-1 protein, M2-2 protein, G protein, or P protein of a mammalian MPV. According to the invention, any protein encoded by a mammalian MPV, derivatives, analogs or fragments thereof, may be used as an immunogen to generate antibodies which immunospecifically bind such an immunogen. Antibodies of the invention include, but are not limited to, polyclonal, monoclonal, multispecific, human, humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab') fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies (including, e.g., anti-Id antibodies to antibodies of the invention), and epitope-binding fragments. The term "antibody," as used herein, refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, *i.e.*, molecules that contain an antigen binding site that immunospecifically binds an antigen. The immunoglobulin molecules of the invention can be of any type (*e.g.*, IgG, IgE, IgM, IgD, IgA and IgY), class (*e.g.*, IgG₁, IgG₂, IgG₃, IgG₄, IgA₁ and IgA₂) or subclass of immunoglobulin molecule. Examples of immunologically active portions of immunoglobulin molecules include F(ab) and F(ab')₂ fragments which can be generated by treating the antibody with an enzyme such as pepsin or papain. In a specific embodiment, antibodies to a protein encoded by human MPV are produced. In another embodiment, antibodies to a domain a protein encoded by human MPV are produced.

Various procedures known in the art may be used for the production of polyclonal antibodies against a protein encoded by a mammalian MPV, derivatives, analogs or fragments thereof. For the production of antibody, various host animals can be immunized by injection with the native protein, or a synthetic version, or derivative (*e.g.*, fragment) thereof, including but not limited to rabbits, mice, rats, *etc.* Various adjuvants may be used to increase the immunological response, depending on the host species, and including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active

substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and corynebacterium parvum.

For preparation of monoclonal antibodies directed toward a protein encoded by a mammalian MPV, derivatives, analogs or fragments thereof, any technique which provides for the production of antibody molecules by continuous cell lines in culture may be used. For example, the hybridoma technique originally developed by Kohler and Milstein (1975, *Nature* 256:495-497), as well as the trioma technique, the human B-cell hybridoma technique (Kozbor *et al.*, 1983, *Immunology Today* 4:72), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole *et al.*, 1985, in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96). In an additional embodiment of the invention, monoclonal antibodies can be produced in germ-free animals utilizing recent technology (PCT/US90/02545). According to the invention, human antibodies may be used and can be obtained by using human hybridomas (Cote *et al.*, 1983, *Proc. Natl. Acad. Sci. U.S.A.* 80:2026-2030) or by transforming human B cells with EBV virus in vitro (Cole *et al.*, 1985, in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, pp. 77-96). In fact, according to the invention, techniques developed for the production of "chimeric antibodies" (Morrison *et al.*, 1984, *Proc. Natl. Acad. Sci. U.S.A.* 81:6851-6855; Neuberger *et al.*, 1984, *Nature* 312:604-608; Takeda *et al.*, 1985, *Nature* 314:452-454) by splicing the genes from a mouse antibody molecule specific for a protein encoded by a mammalian MPV, derivatives, analogs or fragments thereof together with genes from a human antibody molecule of appropriate biological activity can be used; such antibodies are within the scope of this invention.

According to the invention, techniques described for the production of single chain antibodies (U.S. Patent No. 4,946,778) can be adapted to produce specific single chain antibodies. An additional embodiment of the invention utilizes the techniques described for the construction of Fab expression libraries (Huse *et al.*, 1989, *Science* 246:1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity for a protein encoded by a mammalian MPV, derivatives, analogs or fragments thereof.

Antibody fragments which contain the idiotype of the molecule can be generated by known techniques. For example, such fragments include but are not limited to: the F(ab')₂

fragment which can be produced by pepsin digestion of the antibody molecule; the Fab' fragments which can be generated by reducing the disulfide bridges of the F(ab')₂ fragment, the Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent, and Fv fragments.

In the production of antibodies, screening for the desired antibody can be accomplished by techniques known in the art, *e.g.* ELISA (enzyme-linked immunosorbent assay). For example, to select antibodies which recognize a specific domain of a protein encoded by a mammalian MPV, one may assay generated hybridomas for a product which binds to a fragment of a protein encoded by a mammalian MPV containing such domain.

The antibodies provided by the present invention can be used for detecting MPV and for therapeutic methods for the treatment of infections with MPV.

The specificity and binding affinities of the antibodies generated by the methods of the invention can be tested by any technique known to the skilled artisan. In certain embodiments, the specificity and binding affinities of the antibodies generated by the methods of the invention can be tested as described in sections 5.8.5, 5.8.6, 5.8.7, 5.8.8 or 5.8.9.

5.11 SCREENING ASSAYS TO IDENTIFY ANTIVIRAL AGENTS

The invention provides methods for the identification of a compound that inhibits the ability of a mammalian MPV to infect a host or a host cell. In certain embodiments, the invention provides methods for the identification of a compound that reduces the ability of a mammalian MPV to replicate in a host or a host cell. Any technique well-known to the skilled artisan can be used to screen for a compound that would abolish or reduce the ability of a mammalian MPV to infect a host and/or to replicate in a host or a host cell. In a specific embodiment, the mammalian MPV is a human MPV.

In certain embodiments, the invention provides methods for the identification of a compound that inhibits the ability of a mammalian MPV to replicate in a mammal or a mammalian cell. More specifically, the invention provides methods for the identification of a compound that inhibits the ability of a mammalian MPV to infect a mammal or a mammalian cell. In certain embodiments, the invention provides methods for the identification of a compound that inhibits the ability of a mammalian MPV to replicate in a mammalian cell. In

a specific embodiment, the mammalian cell is a human cell. For a detailed description of assays that can be used to determine virus titer see section 5.7.

In certain embodiments, a cell is contacted with a test compound and infected with a mammalian MPV. In certain embodiments, a control culture is infected with a mammalian virus in the absence of a test compound. The cell can be contacted with a test compound before, concurrently with, or subsequent to the infection with the mammalian MPV. In a specific embodiment, the cell is a mammalian cell. In an even more specific embodiment, the cell is a human cell. In certain embodiments, the cell is incubated with the test compound for at least 1 minute, at least 5 minutes at least 15 minutes, at least 30 minutes, at least 1 hour, at least 2 hours, at least 5 hours, at least 12 hours, or at least 1 day. The titer of the virus can be measured at any time during the assay. In certain embodiments, a time course of viral growth in the culture is determined. If the viral growth is inhibited or reduced in the presence of the test compound, the test compound is identified as being effective in inhibiting or reducing the growth or infection of a mammalian MPV. In a specific embodiment, the compound that inhibits or reduces the growth of a mammalian MPV is tested for its ability to inhibit or reduce the growth rate of other viruses to test its specificity for mammalian MPV.

In certain embodiments, a test compound is administered to a model animal and the model animal is infected with a mammalian MPV. In certain embodiments, a control model animal is infected with a mammalian virus in without the administration of a test compound. The test compound can be administered before, concurrently with, or subsequent to the infection with the mammalian MPV. In a specific embodiment, the model animal is a mammal. In an even more specific embodiment, the model animal can be, but is not limited to, a cotton rat, a mouse, or a monkey. The titer of the virus in the model animal can be measured at any time during the assay. In certain embodiments, a time course of viral growth in the culture is determined. If the viral growth is inhibited or reduced in the presence of the test compound, the test compound is identified as being effective in inhibiting or reducing the growth or infection of a mammalian MPV. In a specific embodiment, the compound that inhibits or reduces the growth of a mammalian MPV in the model animal is tested for its ability to inhibit or reduce the growth rate of other viruses to test its specificity for mammalian MPV.

5.12 FORMULATIONS OF VACCINES, ANTIBODIES AND ANTIVIRALS

In a preferred embodiment, the invention provides a proteinaceous molecule or metapneumovirus-specific viral protein or functional fragment thereof encoded by a nucleic acid according to the invention. Useful proteinaceous molecules are for example derived from any of the genes or genomic fragments derivable from a virus according to the invention. Such molecules, or antigenic fragments thereof, as provided herein, are for example useful in diagnostic methods or kits and in pharmaceutical compositions such as sub-unit vaccines. Particularly useful are the F, SH and/or G protein or antigenic fragments thereof for inclusion as antigen or subunit immunogen, but inactivated whole virus can also be used. Particularly useful are also those proteinaceous substances that are encoded by recombinant nucleic acid fragments that are identified for phylogenetic analyses, of course preferred are those that are within the preferred bounds and metes of ORFs useful in phylogenetic analyses, in particular for eliciting MPV specific antibody or T cell responses, whether in vivo (e.g. for protective purposes or for providing diagnostic antibodies) or in vitro (e.g. by phage display technology or another technique useful for generating synthetic antibodies).

Also provided herein are antibodies, be it natural polyclonal or monoclonal, or synthetic (e.g. (phage) library-derived binding molecules) antibodies that specifically react with an antigen comprising a proteinaceous molecule or MPV-specific functional fragment thereof according to the invention. Such antibodies are useful in a method for identifying a viral isolate as an MPV comprising reacting said viral isolate or a component thereof with an antibody as provided herein. This can for example be achieved by using purified or non-purified MPV or parts thereof (proteins, peptides) using ELISA, RIA, FACS or different formats of antigen detection assays (Current Protocols in Immunology). Alternatively, infected cells or cell cultures may be used to identify viral antigens using classical immunofluorescence or immunohistochemical techniques.

A pharmaceutical composition comprising a virus, a nucleic acid, a proteinaceous molecule or fragment thereof, an antigen and/or an antibody according to the invention can for example be used in a method for the treatment or prevention of a MPV infection and/or a respiratory illness comprising providing an individual with a pharmaceutical composition according to the invention. This is most useful when said individual comprises a human,

specifically when said human is below 5 years of age, since such infants and young children are most likely to be infected by a human MPV as provided herein. Generally, in the acute phase patients will suffer from upper respiratory symptoms predisposing for other respiratory and other diseases. Also lower respiratory illnesses may occur, predisposing for more and other serious conditions. The compositions of the invention can be used for the treatment of immuno-compromised individuals including cancer patients, transplant recipients and the elderly.

The invention also provides methods to obtain an antiviral agent useful in the treatment of respiratory tract illness comprising establishing a cell culture or experimental animal comprising a virus according to the invention, treating said culture or animal with an candidate antiviral agent, and determining the effect of said agent on said virus or its infection of said culture or animal. An example of such an antiviral agent comprises a MPV-neutralising antibody, or functional component thereof, as provided herein, but antiviral agents of other nature are obtained as well. The invention also provides use of an antiviral agent according to the invention for the preparation of a pharmaceutical composition, in particular for the preparation of a pharmaceutical composition for the treatment of respiratory tract illness, specifically when caused by an MPV infection or related disease, and provides a pharmaceutical composition comprising an antiviral agent according to the invention, useful in a method for the treatment or prevention of an MPV infection or respiratory illness, said method comprising providing an individual with such a pharmaceutical composition.

In certain embodiments of the invention, the vaccine of the invention comprises mammalian metapneumovirus as defined herein. In certain, more specific embodiments, the mammalian metapneumovirus is a human metapneumovirus. In a preferred embodiment, the mammalian metapneumovirus to be used in a vaccine formulation has an attenuated phenotype. For methods to achieve an attenuated phenotype, see section 5.6.

The invention provides vaccine formulations for the prevention and treatment of infections with PIV, RSV, APV, and/or hMPV. In certain embodiments, the vaccine of the invention comprises recombinant and chimeric viruses of the invention. In certain embodiments, the virus is attenuated.

In a specific embodiment, the vaccine comprises APV and the vaccine is used for the prevention and treatment for hMPV infections in humans. Without being bound by theory, because of the high degree of homology of the F protein of APV with the F protein of hMPV, infection with APV will result in the production of antibodies in the host that will cross-react with hMPV and protect the host from infection with hMPV and related diseases.

In another specific embodiment, the vaccine comprises hMPV and the vaccine is used for the prevention and treatment for APV infection in birds, such as, but not limited to, in turkeys. Without being bound by theory, because of the high degree of homology of the F protein of APV with the F protein of hMPV, infection with hMPV will result in the production of antibodies in the host that will cross-react with APV and protect the host from infection with APV and related diseases.

In a specific embodiment, the invention encompasses the use of recombinant and chimeric APV/hMPV viruses which have been modified in vaccine formulations to confer protection against APV and/or hMPV. In certain embodiments, APV/hMPV is used in a vaccine to be administered to birds, to protect the birds from infection with APV. Without being bound by theory, the replacement of the APV gene or nucleotide sequence with a hMPV gene or nucleotide sequence results in an attenuated phenotype that allows the use of the chimeric virus as a vaccine. In other embodiments the APV/hMPV chimeric virus is administered to humans. Without being bound by theory the APV viral vector provides the attenuated phenotype in humans and the expression of the hMPV sequence elicits a hMPV specific immune response.

In a specific embodiment, the invention encompasses the use of recombinant and chimeric hMPV/APV viruses which have been modified in vaccine formulations to confer protection against APV and/or hMPV. In certain embodiments, hMPV/APV is used in a vaccine to be administered to humans, to protect the human from infection with hMPV. Without being bound by theory, the replacement of the hMPV gene or nucleotide sequence with a APV gene or nucleotide sequence results in an attenuated phenotype that allows the use of the chimeric virus as a vaccine. In other embodiments the hMPV/APV chimeric virus is administered to birds. Without being bound by theory the hMPV backbone provides the attenuated phenotype in birds and the expression of the APV sequence elicits an APV specific immune response.

In certain preferred embodiments, the vaccine formulation of the invention is used to protect against infections by a metapneumovirus and related diseases. More specifically, the vaccine formulation of the invention is used to protect against infections by a human metapneumovirus and/or an avian pneumovirus and related diseases. In certain embodiments, the vaccine formulation of the invention is used to protect against infections by (a) a human metapneumovirus and a respiratory syncytial virus; and/or (b) an avian pneumovirus and a respiratory syncytial virus.

In certain embodiments, the vaccine formulation of the invention is used to protect against infections by (a) a human metapneumovirus and a human parainfluenza virus; and/or (b) an avian pneumovirus and a human parainfluenza virus, and related diseases.

In certain embodiments, the vaccine formulation of the invention is used to protect against infections by (a) a human metapneumovirus, a respiratory syncytial virus, and a human parainfluenza virus; and/or (b) an avian pneumovirus, a respiratory syncytial virus, and a human parainfluenza virus, and related diseases.

In certain embodiments, the vaccine formulation of the invention is used to protect against infections by a human metapneumovirus, a respiratory syncytial virus, and a human parainfluenza virus and related diseases. In certain other embodiments, the vaccine formulation of the invention is used to protect against infections by an avian pneumovirus, a respiratory syncytial virus, and a human parainfluenza virus and related diseases.

Due to the high degree of homology among the F proteins of different viral species, for exemplary amino acid sequence comparisons see Figure 9, the vaccine formulations of the invention can be used for protection from viruses different from the one from which the heterologous nucleotide sequence encoding the F protein was derived. In a specific exemplary embodiment, a vaccine formulation contains a virus comprising a heterologous nucleotide sequence derived from an avian pneumovirus type A, and the vaccine formulation is used to protect from infection by avian pneumovirus type A and avian pneumovirus type B.

The invention encompasses vaccine formulations to be administered to humans and animals which are useful to protect against APV, including APV-C and APV-D, hMPV, PIV, influenza, RSV, Sendai virus, mumps, laryngotracheitis virus, simianvirus 5, human papillomavirus, measles, mumps, as well as other viruses and pathogens and related diseases. The invention further encompasses vaccine formulations to be administered to humans and

animals which are useful to protect against human metapneumovirus infections and avian pneumovirus infections and related diseases.

In one embodiment, the invention encompasses vaccine formulations which are useful against domestic animal disease causing agents including rabies virus, feline leukemia virus (FLV) and canine distemper virus. In yet another embodiment, the invention encompasses vaccine formulations which are useful to protect livestock against vesicular stomatitis virus, rabies virus, rinderpest virus, swinepox virus, and further, to protect wild animals against rabies virus.

Attenuated viruses generated by the reverse genetics approach can be used in the vaccine and pharmaceutical formulations described herein. Reverse genetics techniques can also be used to engineer additional mutations to other viral genes important for vaccine production -- *i.e.*, the epitopes of useful vaccine strain variants can be engineered into the attenuated virus. Alternatively, completely foreign epitopes, including antigens derived from other viral or non-viral pathogens can be engineered into the attenuated strain. For example, antigens of non-related viruses such as HIV (gp160, gp120, gp41) parasite antigens (*e.g.*, malaria), bacterial or fungal antigens or tumor antigens can be engineered into the attenuated strain. Alternatively, epitopes which alter the tropism of the virus *in vivo* can be engineered into the chimeric attenuated viruses of the invention.

Virtually any heterologous gene sequence may be constructed into the chimeric viruses of the invention for use in vaccines. Preferably moieties and peptides that act as biological response modifiers. Preferably, epitopes that induce a protective immune response to any of a variety of pathogens, or antigens that bind neutralizing antibodies may be expressed by or as part of the chimeric viruses. For example, heterologous gene sequences that can be constructed into the chimeric viruses of the invention include, but are not limited to influenza and parainfluenza hemagglutinin neuraminidase and fusion glycoproteins such as the HN and F genes of human PIV3. In yet another embodiment, heterologous gene sequences that can be engineered into the chimeric viruses include those that encode proteins with immuno-modulating activities. Examples of immuno-modulating proteins include, but are not limited to, cytokines, interferon type 1, gamma interferon, colony stimulating factors, interleukin -1, -2, -4, -5, -6, -12, and antagonists of these agents.

In addition, heterologous gene sequences that can be constructed into the chimeric viruses of the invention for use in vaccines include but are not limited to sequences derived from a human immunodeficiency virus (HIV), preferably type 1 or type 2. In a preferred embodiment, an immunogenic HIV-derived peptide which may be the source of an antigen may be constructed into a chimeric PIV that may then be used to elicit a vertebrate immune response. Such HIV-derived peptides may include, but are not limited to sequences derived from the env gene (*i.e.*, sequences encoding all or part of gp160, gp120, and/or gp41), the pol gene (*i.e.*, sequences encoding all or part of reverse transcriptase, endonuclease, protease, and/or integrase), the gag gene (*i.e.*, sequences encoding all or part of p7, p6, p55, p17/18, p24/25), tat, rev, nef, vif, vpr, and/or vpx.

Other heterologous sequences may be derived from hepatitis B virus surface antigen (HBsAg); hepatitis A or C virus surface antigens, the glycoproteins of Epstein Barr virus; the glycoproteins of human papillomavirus; the glycoproteins of respiratory syncytial virus, parainfluenza virus, Sendai virus, simianvirus 5 or mumps virus; the glycoproteins of influenza virus; the glycoproteins of herpesviruses; VP1 of poliovirus; antigenic determinants of non-viral pathogens such as bacteria and parasites, to name but a few. In another embodiment, all or portions of immunoglobulin genes may be expressed. For example, variable regions of anti-idiotypic immunoglobulins that mimic such epitopes may be constructed into the chimeric viruses of the invention.

Other heterologous sequences may be derived from tumor antigens, and the resulting chimeric viruses be used to generate an immune response against the tumor cells leading to tumor regression *in vivo*. These vaccines may be used in combination with other therapeutic regimens, including but not limited to chemotherapy, radiation therapy, surgery, bone marrow transplantation, etc. for the treatment of tumors. In accordance with the present invention, recombinant viruses may be engineered to express tumor-associated antigens (TAAs), including but not limited to, human tumor antigens recognized by T cells (Robbins and Kawakami, 1996, Curr. Opin. Immunol. 8:628-636), melanocyte lineage proteins, including gp100, MART-1/MelanA, TRP-1 (gp75), tyrosinase; Tumor-specific widely shared antigens, MAGE-1, MAGE-3, BAGE, GAGE-1, GAGE-1, N-acetylglucosaminyltransferase-V, p15; Tumor-specific mutated antigens,

β -catenin, MUM-1, CDK4; Nonmelanoma antigens for breast, ovarian, cervical and pancreatic carcinoma, HER-2/neu, human papillomavirus -E6, -E7, MUC-1.

In even other embodiments, a heterologous nucleotide sequence is derived from a metapneumovirus, such as human metapneumovirus and/or avian pneumovirus. In even other embodiments, the virus of the invention contains two different heterologous nucleotide sequences wherein one is derived from a metapneumovirus, such as human metapneumovirus and/or avian pneumovirus, and the other one is derived from a respiratory syncytial virus. The heterologous nucleotide sequence encodes a F protein or a G protein of the respective virus. In a specific embodiment, a heterologous nucleotide sequences encodes a chimeric F protein, wherein the chimeric F protein contains the ectodomain of a F protein of a metapneumovirus and the transmembrane domain as well as the luminal domain of a F protein of a parainfluenza virus.

Either a live recombinant viral vaccine or an inactivated recombinant viral vaccine can be formulated. A live vaccine may be preferred because multiplication in the host leads to a prolonged stimulus of similar kind and magnitude to that occurring in natural infections, and therefore, confers substantial, long-lasting immunity. Production of such live recombinant virus vaccine formulations may be accomplished using conventional methods involving propagation of the virus in cell culture or in the allantois of the chick embryo followed by purification.

In a specific embodiment, the recombinant virus is non-pathogenic to the subject to which it is administered. In this regard, the use of genetically engineered viruses for vaccine purposes may desire the presence of attenuation characteristics in these strains. The introduction of appropriate mutations (*e.g.*, deletions) into the templates used for transfection may provide the novel viruses with attenuation characteristics. For example, specific missense mutations which are associated with temperature sensitivity or cold adaption can be made into deletion mutations. These mutations should be more stable than the point mutations associated with cold or temperature sensitive mutants and reversion frequencies should be extremely low.

Alternatively, chimeric viruses with "suicide" characteristics may be constructed. Such viruses would go through only one or a few rounds of replication within the host. When used as a vaccine, the recombinant virus would go through limited replication cycle(s) and

induce a sufficient level of immune response but it would not go further in the human host and cause disease. Recombinant viruses lacking one or more of the genes of wild type APV and hMPV, respectively, or possessing mutated genes as compared to the wild type strains would not be able to undergo successive rounds of replication. Defective viruses can be produced in cell lines which permanently express such a gene(s). Viruses lacking an essential gene(s) will be replicated in these cell lines but when administered to the human host will not be able to complete a round of replication. Such preparations may transcribe and translate -- in this abortive cycle -- a sufficient number of genes to induce an immune response.

Alternatively, larger quantities of the strains could be administered, so that these preparations serve as inactivated (killed) virus vaccines. For inactivated vaccines, it is preferred that the heterologous gene product be expressed as a viral component, so that the gene product is associated with the virion. The advantage of such preparations is that they contain native proteins and do not undergo inactivation by treatment with formalin or other agents used in the manufacturing of killed virus vaccines. Alternatively, recombinant virus of the invention made from cDNA may be highly attenuated so that it replicates for only a few rounds.

In certain embodiments, the vaccine of the invention comprises an attenuated mammalian MPV. Without being bound by theory, the attenuated virus can be effective as a vaccine even if the attenuated virus is incapable of causing a cell to generate new infectious viral particles because the viral proteins are inserted in the cytoplasmic membrane of the host thus stimulating an immune response.

In another embodiment of this aspect of the invention, inactivated vaccine formulations may be prepared using conventional techniques to "kill" the chimeric viruses. Inactivated vaccines are "dead" in the sense that their infectivity has been destroyed. Ideally, the infectivity of the virus is destroyed without affecting its immunogenicity. In order to prepare inactivated vaccines, the chimeric virus may be grown in cell culture or in the allantois of the chick embryo, purified by zonal ultracentrifugation, inactivated by formaldehyde or β -propiolactone, and pooled. The resulting vaccine is usually inoculated intramuscularly.

Inactivated viruses may be formulated with a suitable adjuvant in order to enhance the immunological response. Such adjuvants may include but are not limited to mineral gels, *e.g.*, aluminum hydroxide; surface active substances such as lysolecithin, pluronic polyols,

polyanions; peptides; oil emulsions; and potentially useful human adjuvants such as BCG, *Corynebacterium parvum*, ISCOMS and virosomes.

Many methods may be used to introduce the vaccine formulations described above, these include but are not limited to oral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, percutaneous, and intranasal and inhalation routes. It may be preferable to introduce the chimeric virus vaccine formulation via the natural route of infection of the pathogen for which the vaccine is designed.

In certain embodiments, the invention relates to immunogenic compositions. The immunogenic compositions comprise a mammalian MPV. In a specific embodiment, the immunogenic composition comprises a human MPV. In certain embodiments, the immunogenic composition comprises an attenuated mammalian MPV or an attenuated human MPV. In certain embodiments, the immunogenic composition further comprises a pharmaceutically acceptable carrier.

5.13 DOSAGE REGIMENS, ADMINISTRATION AND FORMULATIONS

The present invention provides vaccines and immunogenic preparations comprising MPV and APV, including attenuated forms of the virus, recombinant forms of MPV and APV, and chimeric MPV and APV expressing one or more heterologous or non-native antigenic sequences. The vaccines or immunogenic preparations of the invention encompass single or multivalent vaccines, including bivalent and trivalent vaccines. The vaccines or immunogenic formulations of the invention are useful in providing protections against various viral infections. Particularly, the vaccines or immunogenic formulations of the invention provide protection against respiratory tract infections in a host.

A recombinant virus and/or a vaccine or immunogenic formulation of the invention can be administered alone or in combination with other vaccines. Preferably, a vaccine or immunogenic formulation of the invention is administered in combination with other vaccines or immunogenic formulations that provide protection against respiratory tract diseases, such as but not limited to, respiratory syncytial virus vaccines, influenza vaccines, measles vaccines, mumps vaccines, rubella vaccines, pneumococcal vaccines, rickettsia vaccines, staphylococcus vaccines, whooping cough vaccines or vaccines against respiratory tract cancers. In a preferred embodiment, the virus and/or vaccine of the invention is

administered concurrently with pediatric vaccines recommended at the corresponding ages. For example, at two, four or six months of age, the virus and/or vaccine of the invention can be administered concurrently with DtaP (IM), Hib (IM), Polio (IPV or OPV) and Hepatitis B (IM). At twelve or fifteen months of age, the virus and/or vaccine of the invention can be administered concurrently with Hib (IM), Polio (IPV or OPV), MMRII® (SubQ); Varivax® (SubQ), and hepatitis B (IM). The vaccines that can be used with the methods of invention are reviewed in various publications, e.g., The Jordan Report 2000, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States.

A vaccine or immunogenic formulation of the invention may be administered to a subject per se or in the form of a pharmaceutical or therapeutic composition. Pharmaceutical compositions comprising an adjuvant and an immunogenic antigen of the invention (e.g., a virus, a chimeric virus, a mutated virus) may be manufactured by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes. Pharmaceutical compositions may be formulated in conventional manner using one or more physiologically acceptable carriers, diluents, excipients or auxiliaries which facilitate processing of the immunogenic antigen of the invention into preparations which can be used pharmaceutically. Proper formulation is, amongst others, dependent upon the route of administration chosen.

When a vaccine or immunogenic composition of the invention comprises adjuvants or is administered together with one or more adjuvants, the adjuvants that can be used include, but are not limited to, mineral salt adjuvants or mineral salt gel adjuvants, particulate adjuvants, microparticulate adjuvants, mucosal adjuvants, and immunostimulatory adjuvants. Examples of adjuvants include, but are not limited to, aluminum hydroxide, aluminum phosphate gel, Freund's Complete Adjuvant, Freund's Incomplete Adjuvant, squalene or squalene oil-in-water adjuvant formulations, biodegradable and biocompatible polyesters, polymerized liposomes, triterpenoid glycosides or saponins (e.g., QuilA and QS-21, also sold under the trademark STIMULON, ISCOPREP), N-acetyl-muramyl-L-threonyl-D-isoglutamine (Threonyl-MDP, sold under the trademark TERMURTIDE), LPS, monophosphoryl Lipid A (3D-MLA sold under the trademark MPL).

The subject to which the vaccine or an immunogenic composition of the invention is administered is preferably a mammal, most preferably a human, but can also be a non-human animal, including but not limited to, primates, cows, horses, sheep, pigs, fowl (e.g., chickens, turkeys), goats, cats, dogs, hamsters, mice and rodents.

Many methods may be used to introduce the vaccine or the immunogenic composition of the invention, including but not limited to, oral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, percutaneous, intranasal and inhalation routes, and via scarification (scratching through the top layers of skin, e.g., using a bifurcated needle).

For topical administration, the vaccine or immunogenic preparations of the invention may be formulated as solutions, gels, ointments, creams, suspensions, etc. as are well-known in the art.

For administration intranasally or by inhalation, the preparation for use according to the present invention can be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, e.g., gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

For injection, the vaccine or immunogenic preparations may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer. The solution may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the proteins may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

Determination of an effective amount of the vaccine or immunogenic formulation for administration is well within the capabilities of those skilled in the art, especially in light of the detailed disclosure provided herein.

An effective dose can be estimated initially from in vitro assays. For example, a dose can be formulated in animal models to achieve an induction of an immunity response using techniques that are well known in the art. One having ordinary skill in the art could readily optimize administration to all animal species based on results described herein. Dosage

amount and interval may be adjusted individually. For example, when used as an immunogenic composition, a suitable dose is an amount of the composition that when administered as described above, is capable of eliciting an antibody response. When used as a vaccine, the vaccine or immunogenic formulations of the invention may be administered in about 1 to 3 doses for a 1-36 week period. Preferably, 1 or 2 doses are administered, at intervals of about 2 weeks to about 4 months, and booster vaccinations may be given periodically thereafter. Alternate protocols may be appropriate for individual animals. A suitable dose is an amount of the vaccine formulation that, when administered as described above, is capable of raising an immunity response in an immunized animal sufficient to protect the animal from an infection for at least 4 to 12 months. In general, the amount of the antigen present in a dose ranges from about 1 pg to about 100 mg per kg of host, typically from about 10 pg to about 1 mg, and preferably from about 100 pg to about 1 μ g. Suitable dose range will vary with the route of injection and the size of the patient, but will typically range from about 0.1 mL to about 5 mL.

In a specific embodiment, the viruses and/or vaccines of the invention are administered at a starting single dose of at least 10^3 TCID₅₀, at least 10^4 TCID₅₀, at least 10^5 TCID₅₀, at least 10^6 TCID₅₀. In another specific embodiment, the virus and/or vaccines of the invention are administered at multiple doses. In a preferred embodiment, a primary dosing regimen at 2, 4, and 6 months of age and a booster dose at the beginning of the second year of life are used. More preferably, each dose of at least 10^5 TCID₅₀, or at least 10^6 TCID₅₀ is given in a multiple dosing regimen.

5.13.1 CHALLENGE STUDIES

This assay is used to determine the ability of the recombinant viruses of the invention and of the vaccines of the invention to prevent lower respiratory tract viral infection in an animal model system, such as, but not limited to, cotton rats or hamsters. The recombinant virus and/or the vaccine can be administered by intravenous (IV) route, by intramuscular (IM) route or by intranasal route (IN). The recombinant virus and/or the vaccine can be administered by any technique well-known to the skilled artisan. This assay is also used to correlate the serum concentration of antibodies with a reduction in lung titer of the virus to which the antibodies bind.

On day 0, groups of animals, such as, but not limited to, cotton rats (*Sigmodon hispidus*, average weight 100 g) cynomolgous macaques (average weight 2.0 kg) are administered the recombinant or chimeric virus or the vaccine of interest or BSA by intramuscular injection, by intravenous injection, or by intranasal route. Prior to, concurrently with, or subsequent to administration of the recombinant virus or the vaccine of the invention, the animals are infected with wild type virus wherein the wild type virus is the virus against which the vaccine was generated. In certain embodiments, the animals are infected with the wild type virus at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, 1 week or 1 or more months subsequent to the administration of the recombinant virus and/or the vaccine of the invention.

After the infection, cotton rats are sacrificed, and their lung tissue is harvested and pulmonary virus titers are determined by plaque titration. Bovine serum albumin (BSA) 10 mg/kg is used as a negative control. Antibody concentrations in the serum at the time of challenge are determined using a sandwich ELISA. Similarly, in macaques, virus titers in nasal and lung lavages can be measured.

5.13.2 TARGET POPULATIONS

In certain embodiments of the invention, the target population for the therapeutic and diagnostic methods of the invention is defined by age. In certain embodiments, the target population for the therapeutic and/or diagnostic methods of the invention is characterized by a disease or disorder in addition to a respiratory tract infection.

In a specific embodiment, the target population encompasses young children, below 2 years of age. In a more specific embodiment, the children below the age of 2 years do not suffer from illnesses other than respiratory tract infection.

In other embodiments, the target population encompasses patients above 5 years of age. In a more specific embodiment, the patients above the age of 5 years suffer from an additional disease or disorder including cystic fibrosis, leukaemia, and non-Hodgkin lymphoma, or recently received bone marrow or kidney transplantation.

In a specific embodiment of the invention, the target population encompasses subjects in which the hMPV infection is associated with immunosuppression of the hosts. In a specific embodiment, the subject is an immunocompromised individual.

In certain embodiments, the target population for the methods of the invention encompasses the elderly.

In a specific embodiment, the subject to be treated or diagnosed with the methods of the invention was infected with hMPV in the winter months.

5.13.3 CLINICAL TRIALS

Vaccines of the invention or fragments thereof tested in in vitro assays and animal models may be further evaluated for safety, tolerance and pharmacokinetics in groups of normal healthy adult volunteers. The volunteers are administered intramuscularly, intravenously or by a pulmonary delivery system a single dose of a recombinant virus of the invention and/or a vaccine of the invention. Each volunteer is monitored at least 24 hours prior to receiving the single dose of the recombinant virus of the invention and/or a vaccine of the invention and each volunteer will be monitored for at least 48 hours after receiving the dose at a clinical site. Then volunteers are monitored as outpatients on days 3, 7, 14, 21, 28, 35, 42, 49, and 56 postdose.

Blood samples are collected via an indwelling catheter or direct venipuncture using 10 ml red-top Vacutainer tubes at the following intervals: (1) prior to administering the dose of the recombinant virus of the invention and/or a vaccine of the invention; (2) during the administration of the dose of the recombinant virus of the invention and/or a vaccine of the invention; (3) 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, and 48 hours after administering the dose of the recombinant virus of the invention and/or a vaccine of the invention; and (4) 3 days, 7 days 14 days, 21 days, 28 days, 35 days, 42 days, 49 days, and 56 days after administering the dose of the recombinant virus of the invention and/or a vaccine of the invention. Samples are allowed to clot at room temperature and serum will be collected after centrifugation.

The amount of antibodies generated against the recombinant virus of the invention and/or a vaccine of the invention in the samples from the patients can be quantitated by ELISA. T-cell immunity (cytotoxic and helper responses) in PBMC and lung and nasal lavages can also be monitored.

The concentration of antibody levels in the serum of volunteers are corrected by subtracting the predose serum level (background level) from the serum levels at each

collection interval after administration of the dose of recombinant virus of the invention and/or a vaccine of the invention. For each volunteer the pharmacokinetic parameters are computed according to the model-independent approach (Gibaldi et al., eds., 1982, Pharmacokinetics, 2nd edition, Marcel Dekker, New York) from the corrected serum antibody or antibody fragment concentrations.

5.14 METHODS FOR DETECTING AND DIAGNOSING MAMMALIAN MPV

The invention provides means and methods for the diagnosis and/or detection of MPV, said means and methods to be employed in the detection of MPV, its components, and the products of its transcription, translation, expression, propagation, and metabolic processes. More specifically, this invention provides means and methods for the diagnosis of an MPV infection in animals and in humans, said means and methods including but not limited to the detection of components of MPV, products of the life cycle of MPV, and products of a host's response to MPV exposure or infection.

In one embodiment, the invention provides means and methods for the diagnosis and detection of MPV, said means and methods including but not limited to the detection of genomic material and other nucleic acids that are associated with or complimentary to MPV, the detection of transcriptional and translational products of MPV, said products being both processed and unprocessed, and the detection of components of a host response to MPV exposure or infection.

In one embodiment, the invention relates to the detection of MPV through the preparation and use of oligonucleotides that are complimentary to nucleic acid sequences and transcriptional products of nucleic acid sequences that are present within the genome of MPV. Furthermore, the invention relates to the detection of nucleic acids, or sequences thereof, that are present in the genome of MPV and its transcription products, using said oligonucleotides as primers for copying or amplification of specific regions of the MPV genome and its transcripts. The regions of the MPV genome and its transcripts that can be copied or amplified include but are not limited to complete and incomplete stretches of one or more of the following: the N-gene, the P-gene, the M-gene, the F-gene, the M2-gene, the SH-gene, the G-gene, and the L-gene. In a specific embodiment, oligonucleotides are used as primers in conjunction with methods to copy or amplify the N-gene of MPV, or transcripts thereof, for

identification purposes. Said methods include but are not limited to RT-PCR assays, primer extension or run on assays, and other methods that employ the genetic material of MPV or transcripts and compliments thereof as templates for the extension of nucleic acid sequences from said oligonucleotides.

In another embodiment, the invention relates to detection of MPV through the preparation and use of oligonucleotides that are complimentary to nucleic acid sequences and transcriptional products of nucleic acid sequences that are present within the genome of MPV. Furthermore, the invention relates to the detection of nucleic acids, or sequences thereof, that are present in or complimentary to the genome of MPV and its transcription products, using said oligonucleotide sequences as probes for hybridization to and detection of specific regions within or complimentary to the MPV genome and its transcripts. The regions of the MPV genome and its transcripts that can be detected using hybridization probes include but are not limited to complete and incomplete stretches of one or more of the following: the N-gene, the P-gene, the M-gene, the F-gene, the M2-gene, the SH-gene, the G-gene, and the L-gene. In a specific embodiment, oligonucleotides are used as probes in conjunction with methods to detect, anneal, or hybridize to the N-gene of MPV, or transcripts thereof, for identification purposes. Said methods include but are not limited to, Northern blots, Southern blots and other methods that employ the genetic material of MPV or transcripts and compliments thereof as targets for the hybridization, annealing, or detection of sequences or stretches of sequences within or complimentary to the MPV genome.

A nucleic acid which is hybridizable to a nucleic acid of a mammalian MPV, or to its reverse complement, or to its complement can be used in the methods of the invention to detect the presence of a mammalian MPV. In certain embodiments, the nucleic acids are hybridized under conditions of high stringency. By way of example and not limitation, procedures using such conditions of high stringency are as follows. Prehybridization of filters containing DNA is carried out for 8 h to overnight at 65 C in buffer composed of 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 µg/ml denatured salmon sperm DNA. Filters are hybridized for 48 h at 65 C in prehybridization mixture containing 100 µg/ml denatured salmon sperm DNA and 5-20 X 10⁶ cpm of 32P-labeled probe. Washing of filters is done at 37 C for 1 h in a solution containing 2X SSC, 0.01% PVP, 0.01% Ficoll, and 0.01% BSA. This is followed by a wash in 0.1X SSC at 50 C

for 45 min before autoradiography. Other conditions of high stringency which may be used are well known in the art. In other embodiments of the invention, hybridization is performed under moderate or low stringency conditions, such conditions are well-known to the skilled artisan (*see e.g.*, Sambrook et al., 1989, *Molecular Cloning, A Laboratory Manual*, 2d Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York; *see also*, Ausubel et al., eds., in the *Current Protocols in Molecular Biology* series of laboratory technique manuals, 1987-1997 *Current Protocols*, © 1994-1997 John Wiley and Sons, Inc.).

In another embodiment, the invention relates to the detection of an MPV infection in an animal or human host through the preparation and use of antibodies, e.g., monoclonal antibodies (MAbs), that are specific to and can recognize peptides or nucleic acids that are characteristic of MPV or its gene products. The epitopes or antigenic determinants recognized by said MAbs include but are not limited to proteinaceous and nucleic acid products that are synthesized during the life cycle and metabolic processes involved in MPV propagation. The proteinaceous or nucleic acid products that can be used as antigenic determinants for the generation of suitable antibodies include but are not limited to complete and incomplete transcription and expression products of one or more of the following components of MPV: the N-gene, the P-gene, the M-gene, the F-gene, the M2-gene, the SH-gene, the G-gene, and the L-gene. In one specific embodiment, MAbs raised against proteinaceous products of the G-gene or portions thereof are used in conjunction with other methods to detect or confirm the presence of the MPV expressed G peptide in a biological sample, e.g. body fluid. Said methods include but are not limited to ELISA, Radio-Immuno or Competition Assays, Immuno-precipitation and other methods that employ the transcribed or expressed gene products of MPV as targets for detection by MAbs raised against said targets or portions and relatives thereof.

In another embodiment, the invention relates to the detection of factors that are associated with and characteristic of a host's immunologic response to MPV exposure or infection. Upon exposure or infection by MPV, a host's immune system elicits a response to said exposure or infection that involves the generation by the host of antibodies directed at eliminating or attenuating the effects and/or propagation of virus. This invention provides means and methods for the diagnosis of MPV related disease through the detection of said antibodies that may be produced as a result of MPV exposure to or infection of the host. The

epitopes recognized by said antibodies include but are not limited to peptides and their exposed surfaces that are accessible to a host immune response and that can serve as antigenic determinants in the generation of an immune response by the host to the virus. Some of the proteinaceous and nuclear material used by a host immune response as epitopes for the generation of antibodies include but are not limited to products of one or more of the following components of MPV: the N-gene, the P-gene, the M-gene, the F-gene, the M2-gene, the SH-gene, the G-gene, and the L-gene. In one embodiment, antibodies to partially or completely accessible portions of the N-gene encoded peptides of MPV are detected in a host sample. In a specific embodiment, proteinaceous products of the G-gene or portions thereof are used in conjunction with other methods to detect the presence of the host derived antibodies in a biological sample, e.g. body fluid. Said methods include but are not limited to ELISA, Radio-Immuno or Competition Assays, and other methods that employ the transcribed or expressed gene products of MPV as targets for detection by host antibodies that recognize said products and that are found in biological samples.

This invention also provides means and methods for diagnostic assays or test kits and for methods to detect agents of an MPV infection from a variety of sources including but not limited to biological samples, e.g., body fluids. In one embodiment, this invention relates to assays, kits, protocols, and procedures that are suitable for identifying an MPV nucleic acid or a complement thereof. In another embodiment, this invention relates to assays, kits, protocols, and procedures that are suitable for identifying an MPV expressed peptide or a portion thereof. In another embodiment, this invention relates to assays, kits, protocols, and procedures that are suitable for identifying components of a host immunologic response to MPV exposure or infection.

In addition to diagnostic confirmation of MPV infection of a host, the present invention also provides for means and methods to classify isolates of MPV into distinct phylogenetic groups or subgroups. In one embodiment, this feature can be used advantageously to distinguish between the different variant of MPV, variant A1, A2, B1 and B2, in order to design more effective and subgroup specific therapies. Variants of MPV can be differentiated on the basis of nucleotide or amino acid sequences of one or more of the following: the N-gene, the P-gene, the M-gene, the F-gene, the M2-gene, the SH-gene, the G-gene, and the L-gene. In a specific embodiment, MPV can be differentiated into a specific

subgroup using the nucleotide or amino acid sequence of the G gene or glycoprotein and neutralization tests using monoclonal antibodies that also recognize the G glycoprotein.

In one embodiment, the diagnosis of an MPV infection in a human is made using any technique well known to one skilled in the art, *e.g.*, immunoassays. Immunoassays which can be used to analyze immunospecific binding and cross-reactivity include, but are not limited to, competitive and non-competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), sandwich immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitation reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, and fluorescent immunoassays, to name but a few. Such assays are routine and well known in the art (see, *e.g.*, Ausubel *et al.*, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York) and non-limiting examples of immunoassays are described in section 5.8.

In one embodiment, the invention relates to the detection of an MPV infection using oligonucleotides in conjunction with PCR or primer extension methods to copy or amplify regions of the MPV genome, said regions including but not limited to genes or parts of genes, *e.g.*, the N, M, F, G, L, M, P, and M2 genes. In a specific embodiment, oligonucleotides are used in conjunction with RT-PCR methods. In a further embodiment, the amplification products and/or genetic material can be probed with oligonucleotides that are complimentary to specific sequences that are either conserved between various hMPV strains or are distinct amongst various hMPV strains. The latter set of oligonucleotides would allow for identification of the specific strain of hMPV responsible for the infection of the host.

The invention provides methods for distinguishing between different subgroups and variants of hMPV that are capable of infecting a host. In one specific embodiment, the hMPV that is responsible for a host infection is classified into a specific subgroup, *e.g.*, subgroup A or subgroup B. In another specific embodiment, the hMPV that is responsible for a host infection is classified as a specific variant of a subgroup, *e.g.*, variant A1, A2, B1, or B2. In another embodiment, the invention provides means and methods for the classification of an hMPV that is responsible for a host infection into a new subgroup and/or into a new variant of a new or existing subgroup. The methods that are able to distinguish hMPV strains into subgroups and/or variant groups would be known to one skilled in the art. In one

embodiment, a polyclonal antibody is used to identify the etiological agent of an infection as a strain of hMPV, and a secondary antibody is used to distinguish said strain as characteristic of a new or known subgroup and/or new or known variant of hMPV. In one embodiment, antibodies that are selective for hMPV are used in conjunction with immunoreactive assays, e.g. ELISA or RIA, to identify the presence of hMPV exposure or infection in biological samples. In a further embodiment, secondary antibodies that are selective for specific epitopes in the peptide sequence of hMPV proteins are used to further classify the etiological agents of said identified hMPV infections into subgroups or variants. In one specific embodiment, an antibody raised against peptide epitopes that are shared between all subgroups of hMPV is used to identify the etiological agent of an infection as an hMPV. In a further specific embodiment, antibodies raised against peptide epitopes that are unique to the different subgroups and/or variants of hMPV are used to classify the hMPV that is responsible for the host infection into a known or new subgroup and/or variant. In one specific embodiment, the antibody that is capable of distinguishing between different subgroups and/or variants of hMPV recognizes segments of hMPV peptides that are unique to the subgroup or variant, said peptides including but not limited to those encoded by the N, M, F, G, L, M, P, and M2 genes. The peptides or segments of peptides that can be used to generate antibodies capable of distinguishing between different hMPV subgroups or variants can be selected using differences in known peptide sequences of various hMPV proteins in conjunction with hydrophilicity plots to identify suitable peptide segments that would be expected to be solvent exposed or accessible in a diagnostic assay. In one embodiment, the antibody that is capable of distinguishing between the different subgroups of hMPV recognizes differences in the F protein that are unique to different subgroups of hMPV, e.g. the amino acids at positions 286, 296, 312, 348, and 404 of the full length F protein. In another specific embodiment, the antibody that is capable of distinguishing between different subgroups and/or variants of hMPV recognizes segments of the G protein of hMPV that are unique to specific subgroups or variants, e.g., the G peptide sequence corresponding to amino acids 50 through 60 of SEQ ID:119 can be used to distinguish between subgroups A and B as well as between variants A1, A2, B1, and B2. In another embodiment of the invention, the nucleotide sequence of hMPV isolates are used to distinguish between different subgroups and/or different variants of hMPV. In one embodiment, oligonucleotide sequences, primers, and/or probes that are complimentary

to sequences in the hMPV genome are used to classify the etiological agents of hMPV infections into distinct subgroups and/or variants in conjunction with methods known to one skilled in the art, e.g. RT-PCR, PCR, primer run on assays, and various blotting techniques. In one specific embodiment, a biological sample is used to copy or amplify a specific segment of the hMPV genome, using RT-PCR. In a further embodiment, the sequence of said segment is obtained and compared with known sequences of hMPV, and said comparison is used to classify the hMPV strain into a distinct subgroup or variant or to classify the hMPV strain into a new subgroup or variant. In another embodiment, the invention relates to diagnostic kits that can be used to distinguish between different subgroups and/or variants of hMPV.

In a preferred embodiment, diagnosis and/or treatment of a specific viral infection is performed with reagents that are most specific for said specific virus causing said infection. In this case this means that it is preferred that said diagnosis and/or treatment of an MPV infection is performed with reagents that are most specific for MPV. This by no means however excludes the possibility that less specific, but sufficiently crossreactive reagents are used instead, for example because they are more easily available and sufficiently address the task at hand. Herein it is for example provided to perform virological and/or serological diagnosis of MPV infections in mammals with reagents derived from APV, in particular with reagents derived from APV-C, in the detailed description herein it is for example shown that sufficiently trustworthy serological diagnosis of MPV infections in mammals can be achieved by using an ELISA specifically designed to detect APV antibodies in birds. A particular useful test for this purpose is an ELISA test designed for the detection of APV antibodies (e.g. in serum or egg yolk), one commercially available version of which is known as APV-Ab SVANOVIR ® which is manufactured by SVANOVA Biotech AB, Uppsala Science Park Glunten SE-751 83 Uppsala Sweden. The reverse situation is also the case, herein it is for example provided to perform virological and/or serological diagnosis of APV infections in mammals with reagents derived from MPV, in the detailed description herein it is for example shown that sufficiently trustworthy serological diagnosis of APV infections in birds can be achieved by using an ELISA designed to detect MPV antibodies. Considering that antigens and antibodies have a lock-and-key relationship, detection of the various antigens can be achieved by selecting the appropriate antibody having sufficient cross-reactivity. Of course, for relying on such cross-reactivity, it is best to select the reagents (such as antigens or

antibodies) under guidance of the amino acid homologies that exist between the various (glyco)proteins of the various viruses, whereby reagents relating to the most homologous proteins will be most useful to be used in tests relying on said cross-reactivity.

For nucleic acid detection, it is even more straightforward, instead of designing primers or probes based on heterologous nucleic acid sequences of the various viruses and thus that detect differences between the essentially mammalian or avian *Metapneumoviruses*, it suffices to design or select primers or probes based on those stretches of virus-specific nucleic acid sequences that show high homology. In general, for nucleic acid sequences, homology percentages of 90% or higher guarantee sufficient cross-reactivity to be relied upon in diagnostic tests utilizing stringent conditions of hybridisation.

The invention for example provides a method for virologically diagnosing a MPV infection of an animal, in particular of a mammal, more in particular of a human being, comprising determining in a sample of said animal the presence of a viral isolate or component thereof by reacting said sample with a MPV specific nucleic acid or antibody according to the invention, and a method for serologically diagnosing an MPV infection of a mammal comprising determining in a sample of said mammal the presence of an antibody specifically directed against an MPV or component thereof by reacting said sample with a MPV-specific proteinaceous molecule or fragment thereof or an antigen according to the invention. The invention also provides a diagnostic kit for diagnosing an MPV infection comprising an MPV, an MPV-specific nucleic acid, proteinaceous molecule or fragment thereof, antigen and/or an antibody according to the invention, and preferably a means for detecting said MPV, MPV-specific nucleic acid, proteinaceous molecule or fragment thereof, antigen and/or an antibody, said means for example comprising an excitable group such as a fluorophore or enzymatic detection system used in the art (examples of suitable diagnostic kit format comprise IF, ELISA, neutralization assay, RT-PCR assay). To determine whether an as yet unidentified virus component or synthetic analogue thereof such as nucleic acid, proteinaceous molecule or fragment thereof can be identified as MPV-specific, it suffices to analyse the nucleic acid or amino acid sequence of said component, for example for a stretch of said nucleic acid or amino acid, preferably of at least 10, more preferably at least 25, more preferably at least 40 nucleotides or amino acids (respectively), by sequence homology comparison with known MPV sequences and with known non-MPV sequences. APV-C is

preferably used) using for example phylogenetic analyses as provided herein. Depending on the degree of relationship with said MPV or non-MPV sequences, the component or synthetic analogue can be identified.

The invention also provides method for virologically diagnosing an MPV infection of a mammal comprising determining in a sample of said mammal the presence of a viral isolate or component thereof by reacting said sample with a cross-reactive nucleic acid derived from APV (preferably serotype C) or a cross-reactive antibody reactive with said APV, and a method for serologically diagnosing an MPV infection of a mammal comprising determining in a sample of said mammal the presence of a cross-reactive antibody that is also directed against an APV or component thereof by reacting said sample with a proteinaceous molecule or fragment thereof or an antigen derived from APV. Furthermore, the invention provides the use of a diagnostic kit initially designed for AVP or AVP-antibody detection for diagnosing an MPV infection, in particular for detecting said MPV infection in humans.

The invention also provides methods for virologically diagnosing an APV infection in a bird comprising determining in a sample of said bird the presence of a viral isolate or component thereof by reacting said sample with a cross-reactive nucleic acid derived from MPV or a cross-reactive antibody reactive with said MPV, and a method for serologically diagnosing an APV infection of a bird comprising determining in a sample of said bird the presence of a cross-reactive antibody that is also directed against an MPV or component thereof by reacting said sample with a proteinaceous molecule or fragment thereof or an antigen derived from MPV. Furthermore, the invention provides the use of a diagnostic kit initially designed for MPV or MPV-antibody detection for diagnosing an APV infection, in particular for detecting said APV infection in poultry such as a chicken, duck or turkey.

For diagnosis as for treatment, use can be made of the high degree of homology among different mammalian MPVs and between MPV and other viruses, such as, *e.g.*, APV, in particular when circumstances at hand make the use of the more homologous approach less straightforward. Vaccinations that can not wait, such as emergency vaccinations against MPV infections can for example be performed with vaccine preparations derived from APV(preferably type C) isolates when a more homologous MPV vaccine is not available, and, vice versa, vaccinations against APV infections can be contemplated with vaccine preparations derived from MPV. Also, reverse genetic techniques make it possible to generate chimeric

APV-MPV virus constructs that are useful as a vaccine, being sufficiently dissimilar to field isolates of each of the respective strains to be attenuated to a desirable level. Similar reverse genetic techniques will make it also possible to generate chimeric paramyxovirus-metapneumovirus constructs, such as RSV-MPV or P13-MPV constructs for use in a vaccine preparation. Such constructs are particularly useful as a combination vaccine to combat respiratory tract illnesses.

Since MPV CPE was virtually indistinguishable from that caused by hRSV or hPIV-1 in tMK or other cell cultures, the MPV may have well gone unnoticed until now. tMK (tertiary monkey kidney cells, *i.e.* MK cells in a third passage in cell culture) are preferably used due to their lower costs in comparison to primary or secondary cultures. The CPE is, as well as with some of the classical *Paramyxoviridae*, characterized by syncytium formation after which the cells showed rapid internal disruption, followed by detachment of the cells from the monolayer. The cells usually (but not always) displayed CPE after three passages of virus from original material, at day 10 to 14 post inoculation, somewhat later than CPE caused by other viruses such as hRSV or hPIV-1.

As an example, the invention provides a not previously identified paramyxovirus from nasopharyngeal aspirate samples taken from 28 children suffering from severe RTI. The clinical symptoms of these children were largely similar to those caused by hRSV. Twenty-seven of the patients were children below the age of five years and half of these were between 1 and 12 months old. The other patient was 18 years old. All individuals suffered from upper RTI, with symptoms ranging from cough, myalgia, vomiting and fever to broncheolitis and severe pneumonia. The majority of these patients were hospitalised for one to two weeks.

The virus isolates from these patients had the paramyxovirus morphology in negative contrast electron microscopy but did not react with specific antisera against known human and animal paramyxoviruses. They were all closely related to one another as determined by indirect immunofluorescence assays (IFA) with sera raised against two of the isolates. Sequence analyses of nine of these isolates revealed that the virus is somewhat related to APV. Based on virological data, sequence homology as well as the genomic organisation we propose that the virus is a member of *Metapneumovirus* genus. Serological surveys showed that this virus is a relatively common pathogen since the seroprevalence in the Netherlands approaches

100% of humans by the age of five years. Moreover, the seroprevalence was found to be equally high in sera collected from humans in 1958, indicating this virus has been circulating in the human population for more than 40 years. The identification of this proposed new member of the *Metapneumovirus* genus now also provides for the development of means and methods for diagnostic assays or test kits and vaccines or serum or antibody compositions for viral respiratory tract infections, and for methods to test or screen for antiviral agents useful in the treatment of MPV infections.

Methods and means provided herein are particularly useful in a diagnostic kit for diagnosing a MPV infection, be it by virological or serological diagnosis. Such kits or assays may for example comprise a virus, a nucleic acid, a proteinaceous molecule or fragment thereof, an antigen and/or an antibody according to the invention. Use of a virus, a nucleic acid, a proteinaceous molecule or fragment thereof, an antigen and/or an antibody according to the invention is also provided for the production of a pharmaceutical composition, for example for the treatment or prevention of MPV infections and/or for the treatment or prevention of respiratory tract illnesses, in particular in humans. Attenuation of the virus can be achieved by established methods developed for this purpose, including but not limited to the use of related viruses of other species, serial passages through laboratory animals or/and tissue/cell cultures, site directed mutagenesis of molecular clones and exchange of genes or gene fragments between related viruses.

5.15 COMPOSITIONS OF THE INVENTION AND COMPONENTS OF MAMMALIAN METAPNEUMOVIRUS

The invention relates to nucleic acid sequences of a mammalian MPV, proteins of a mammalian MPV, and antibodies against proteins of a mammalian MPV. The invention further relates to homologs of nucleic acid sequences of a mammalian MPV and homologs of proteins of a mammalian MPV. The invention further relates to nucleic acid sequences encoding fusion proteins, wherein the fusion protein contains a protein of a mammalian MPV or a fragment thereof and one or more peptides or proteins that are not derived from mammalian MPV. In a specific embodiment, a fusion protein of the invention contains a protein of a mammalian MPV or a fragment thereof and a peptide tag, such as, but not limited to a polyhistidine tag. The invention further relates to fusion proteins, wherein the fusion

protein contains a protein of a mammalian MPV or a fragment thereof and one or more peptides or proteins that are not derived from mammalian MPV. The invention also relates to derivatives of nucleic acids encoding a protein of a mammalian MPV. The invention also relates to derivatives of proteins of a mammalian MPV. A derivative can be, but is not limited to, mutant forms of the protein, such as, but not limited to, additions, deletions, truncations, substitutions, and inversions. A derivative can further be a chimeric form of the protein of the mammalian MPV, wherein at least one domain of the protein is derived from a different protein. A derivative can also be a form of a protein of a mammalian MPV that is covalently or non-covalently linked to another molecule, such as, *e.g.*, a drug.

The viral isolate termed NL/1/00 (also 00-1) is a mammalian MPV of variant A1 and its genomic sequence is shown in SEQ ID NO:19. The viral isolate termed NL/17/00 is a mammalian MPV of variant A2 and its genomic sequence is shown in SEQ ID NO:20. The viral isolate termed NL/1/99 (also 99-1) is a mammalian MPV of variant B1 and its genomic sequence is shown in SEQ ID NO:18. The viral isolate termed NL/1/94 is a mammalian MPV of variant B2 and its genomic sequence is shown in SEQ ID NO:21. A list of sequences disclosed in the present application and the corresponding SEQ ID Nos is set forth in Table 14.

The protein of a mammalian MPV can be a an N protein, a P protein, a M protein, a F protein, a M2-1 protein or a M2-2 protein or a fragment thereof. A fragment of a protein of a mammalian MPV can be at least 25 amino acids, at least 50 amino acids, at least 75 amino acids, at least 100 amino acids, at least 125 amino acids, at least 150 amino acids, at least 175 amino acids, at least 200 amino acids, at least 225 amino acids, at least 250 amino acids, at least 275 amino acids, at least 300 amino acids, at least 325 amino acids, at least 350 amino acids, at least 375 amino acids, at least 400 amino acids, at least 425 amino acids, at least 450 amino acids, at least 475 amino acids, at least 500 amino acids, at least 750 amino acids, at least 1000 amino acids, at least 1250 amino acids, at least 1500 amino acids, at least 1750 amino acids, at least 2000 amino acids or at least 2250 amino acids in length. A fragment of a protein of a mammalian MPV can be at most 25 amino acids, at most 50 amino acids, at most 75 amino acids, at most 100 amino acids, at most 125 amino acids, at most 150 amino acids, at most 175 amino acids, at most 200 amino acids, at most 225 amino acids, at most 250 amino acids, at most 275 amino acids, at most 300 amino acids, at most 325

amino acids, at most 350 amino acids, at most 375 amino acids, at most 400 amino acids, at most 425 amino acids, at most 450 amino acids, at most 475 amino acids, at most 500 amino acids, at most 750 amino acids, at most 1000 amino acids, at most 1250 amino acids, at most 1500 amino acids, at most 1750 amino acids, at most 2000 amino acids or at most 2250 amino acids in length.

In certain embodiments of the invention, the protein of a mammalian MPV is a N protein, wherein the N protein is phylogenetically closer related to a N protein of a mammalian MPV, such as the N protein encoded by, *e.g.*, the viral genome of SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, or SEQ ID NO:21, (see also Table 14 for a description of the SEQ ID Nos) than it is related to the N protein of APV type C. In certain embodiments of the invention, the protein of a mammalian MPV is a P protein, wherein the P protein is phylogenetically closer related to a P protein of a mammalian MPV, such as the P protein encoded by, *e.g.*, the viral genome of SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, or SEQ ID NO:21, than it is related to the N protein of APV type C. In certain embodiments of the invention, the protein of a mammalian MPV is a M protein, wherein the M protein is closer related to a M protein of a mammalian MPV, such as the M protein encoded by, *e.g.*, the viral genome of SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, or SEQ ID NO:21, than it is related to the M protein of APV type C. In certain embodiments of the invention, the protein of a mammalian MPV is a F protein, wherein the F protein is phylogenetically closer related to a F protein of a mammalian MPV, such as the F protein encoded by, *e.g.*, the viral genome of SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, or SEQ ID NO:21, than it is related to the F protein of APV type C. In certain embodiments of the invention, the protein of a mammalian MPV is a M2-1 protein, wherein the M2-1 protein is phylogenetically closer related to a M2-1 protein of a mammalian MPV, such as the M2-1 protein encoded by, *e.g.*, the viral genome of SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, or SEQ ID NO:21, than it is related to the M2-1 protein of APV type C. In certain embodiments of the invention, the protein of a mammalian MPV is a M2-2 protein, wherein the M2-2 protein is phylogenetically closer related to a M2-2 protein of a mammalian MPV, such as the M2-2 protein encoded by, *e.g.*, the viral genome of SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, or SEQ ID NO:21, than it is related to the M2-2 protein of APV type C. In certain embodiments of the invention, the protein of a mammalian MPV is a G protein, wherein the G protein is phylogenetically closer

related to a G protein of a mammalian MPV, such as the G protein encoded by, *e.g.*, the viral genome of SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, or SEQ ID NO:21, than it is related to any protein of APV type C. In certain embodiments of the invention, the protein of a mammalian MPV is a SH protein, wherein the SH protein is phylogenetically closer related to a SH protein of a mammalian MPV, such as the SH protein encoded by, *e.g.*, the viral genome of SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, or SEQ ID NO:21, than it is related to any protein of APV type C. In certain embodiments of the invention, the protein of a mammalian MPV is a L protein, wherein the L protein is phylogenetically closer related to a L protein of a mammalian MPV, such as the SH protein encoded by, *e.g.*, the viral genome of SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, or SEQ ID NO:21, than it is related to any protein of APV type C.

In certain embodiments of the invention, the protein of a mammalian MPV is a N protein, wherein the N protein is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of a N protein encoded by the viral genome of SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, or SEQ ID NO:21 (the amino acid sequences of the respective N proteins are disclosed in SEQ ID NO:366-369; see also Table 14). In certain embodiments of the invention, the protein of a mammalian MPV is a N protein, wherein the P protein is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of a P protein encoded by the viral genome of SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, or SEQ ID NO:21 (the amino acid sequences of the respective P proteins are disclosed in SEQ ID NO:374-377; see also Table 14). In certain embodiments of the invention, the protein of a mammalian MPV is a M protein, wherein the M protein is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of a M protein encoded by the viral genome of SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, or SEQ ID NO:21 (the amino acid sequences of the respective M proteins are disclosed in SEQ ID NO:358-361; see also Table 14). In certain embodiments of the invention, the protein of a mammalian MPV is a F protein, wherein the F protein is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least

99%, or at least 99.5% identical to the amino acid sequence of a F protein encoded by the viral genome of SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, or SEQ ID NO:21 (the amino acid sequences of the respective F proteins are disclosed in SEQ ID NO:314-317; see also Table 14). In certain embodiments of the invention, the protein of a mammalian MPV is a M2-1 protein, wherein the M2-1 protein is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of a M2-1 protein encoded by the viral genome of SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, or SEQ ID NO:21 (the amino acid sequences of the respective M2-1 proteins are disclosed in SEQ ID NO:338-341; see also Table 14). In certain embodiments of the invention, the protein of a mammalian MPV is a M2-2 protein, wherein the M2-2 protein is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of a M2-2 protein encoded by the viral genome of SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, or SEQ ID NO:21 (the amino acid sequences of the respective M2-2 proteins are disclosed in SEQ ID NO:346-349; see also Table 14). In certain embodiments of the invention, the protein of a mammalian MPV is a G protein, wherein the G protein is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of a G protein encoded by the viral genome of SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, or SEQ ID NO:21 (the amino acid sequences of the respective G proteins are disclosed in SEQ ID NO:322-325; see also Table 14). In certain embodiments of the invention, the protein of a mammalian MPV is a SH protein, wherein the SH protein is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of a SH protein encoded by the viral genome of SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, or SEQ ID NO:21 (the amino acid sequences of the respective SH proteins are disclosed in SEQ ID NO:382-385; see also Table 14). In certain embodiments of the invention, the protein of a mammalian MPV is a L protein, wherein the L protein is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of a L protein encoded by the viral genome of SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, or

SEQ ID NO:21 (the amino acid sequences of the respective L proteins are disclosed in SEQ ID NO:330-333; see also Table 14).

A fragment of a protein of mammalian MPV is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.5% identical to the homologous protein encoded by the virus of SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, or SEQ ID NO:21 over the portion of the protein that is homologous to the fragment. In a specific, illustrative embodiment, the invention provides a fragment of the F protein of a mammalian MPV that contains the ectodomain of the F protein and homologs thereof. The homolog of the fragment of the F protein that contains the ectodomain is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.5% identical to the corresponding fragment containing the ectodomain of the F protein encoded by a virus of SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, or SEQ ID NO:21 (the amino acid sequences of the respective F proteins are disclosed in SEQ ID NO:314-317; see also Table 14).

In certain embodiments, the invention provides a protein of a mammalian MPV of subgroup A and fragments thereof. The invention provides a N protein of a mammalian MPV of subgroup A, wherein the N protein is phylogenetically closer related to the N protein encoded by a virus of SEQ ID NO:19 or SEQ ID NO:20 than it is related to the N protein encoded by a virus encoded by SEQ ID NO:18 or SEQ ID NO:21. The invention provides a G protein of a mammalian MPV of subgroup A, wherein the G protein is phylogenetically closer related to the G protein encoded by a virus of SEQ ID NO:19 or SEQ ID NO:20 than it is related to the G protein encoded by a virus encoded by SEQ ID NO:18 or SEQ ID NO:21. The invention provides a P protein of a mammalian MPV of subgroup A, wherein the P protein is phylogenetically closer related to the P protein encoded by a virus of SEQ ID NO:19 or SEQ ID NO:20 than it is related to the P protein encoded by a virus encoded by SEQ ID NO:18 or SEQ ID NO:21. The invention provides a M protein of a mammalian MPV of subgroup A, wherein the M protein is phylogenetically closer related to the M protein encoded by a virus of SEQ ID NO:19 or SEQ ID NO:20 than it is related to the M protein encoded by a virus encoded by SEQ ID NO:18 or SEQ ID NO:21. The invention provides a N protein of a mammalian MPV of subgroup A, wherein the F protein is phylogenetically closer related to the F protein encoded by a virus of SEQ ID NO:19 or SEQ ID NO:20 than it is related to the F

protein encoded by a virus encoded by SEQ ID NO:18 or SEQ ID NO:21. The invention provides a M2-1 protein of a mammalian MPV of subgroup A, wherein the M2-1 protein is phylogenetically closer related to the M2-1 protein encoded by a virus of SEQ ID NO:19 or SEQ ID NO:20 than it is related to the M2-1 protein encoded by a virus encoded by SEQ ID NO:18 or SEQ ID NO:21. The invention provides a M2-2 protein of a mammalian MPV of subgroup A, wherein the M2-2 protein is phylogenetically closer related to the M2-2 protein encoded by a virus of SEQ ID NO:19 or SEQ ID NO:20 than it is related to the M2-2 protein encoded by a virus encoded by SEQ ID NO:18 or SEQ ID NO:21. The invention provides a SH protein of a mammalian MPV of subgroup A, wherein the SH protein is phylogenetically closer related to the SH protein encoded by a virus of SEQ ID NO:19 or SEQ ID NO:20 than it is related to the SH protein encoded by a virus encoded by SEQ ID NO:18 or SEQ ID NO:21. The invention provides a L protein of a mammalian MPV of subgroup A, wherein the L protein is phylogenetically closer related to the L protein encoded by a virus of SEQ ID NO:19 or SEQ ID NO:20 than it is related to the L protein encoded by a virus encoded by SEQ ID NO:18 or SEQ ID NO:21.

In other embodiments, the invention provides a protein of a mammalian MPV of subgroup B or fragments thereof. The invention provides a N protein of a mammalian MPV of subgroup B, wherein the N protein is phylogenetically closer related to the N protein encoded by a virus of SEQ ID NO:18 or SEQ ID NO:21 than it is related to the N protein encoded by a virus encoded by SEQ ID NO:19 or SEQ ID NO:20. The invention provides a G protein of a mammalian MPV of subgroup A, wherein the G protein is phylogenetically closer related to the G protein encoded by a virus of SEQ ID NO:18 or SEQ ID NO:21 than it is related to the G protein encoded by a virus encoded by SEQ ID NO:19 or SEQ ID NO:20. The invention provides a P protein of a mammalian MPV of subgroup A, wherein the P protein is phylogenetically closer related to the P protein encoded by a virus of SEQ ID NO:18 or SEQ ID NO:21 than it is related to the P protein encoded by a virus encoded by SEQ ID NO:19 or SEQ ID NO:20. The invention provides a M protein of a mammalian MPV of subgroup A, wherein the M protein is phylogenetically closer related to the M protein encoded by a virus of SEQ ID NO:18 or SEQ ID NO:21 than it is related to the M protein encoded by a virus encoded by SEQ ID NO:19 or SEQ ID NO:20. The invention provides a N protein of a mammalian MPV of subgroup A, wherein the F protein is phylogenetically closer related to

the F protein encoded by a virus of SEQ ID NO:18 or SEQ ID NO:21 than it is related to the F protein encoded by a virus encoded by SEQ ID NO:19 or SEQ ID NO:20. The invention provides a M2-1 protein of a mammalian MPV of subgroup A, wherein the M2-1 protein is phylogenetically closer related to the M2-1 protein encoded by a virus of SEQ ID NO:18 or SEQ ID NO:21 than it is related to the M2-1 protein encoded by a virus encoded by SEQ ID NO:19 or SEQ ID NO:20. The invention provides a M2-2 protein of a mammalian MPV of subgroup A, wherein the M2-2 protein is phylogenetically closer related to the M2-2 protein encoded by a virus of SEQ ID NO:18 or SEQ ID NO:21 than it is related to the M2-2 protein encoded by a virus encoded by SEQ ID NO:19 or SEQ ID NO:20. The invention provides a SH protein of a mammalian MPV of subgroup A, wherein the SH protein is phylogenetically closer related to the SH protein encoded by a virus of SEQ ID NO:18 or SEQ ID NO:21 than it is related to the SH protein encoded by a virus encoded by SEQ ID NO:19 or SEQ ID NO:20. The invention provides a L protein of a mammalian MPV of subgroup A, wherein the L protein is phylogenetically closer related to the L protein encoded by a virus of SEQ ID NO:18 or SEQ ID NO:21 than it is related to the L protein encoded by a virus encoded by SEQ ID NO:19 or SEQ ID NO:20.

The invention further provides proteins of a mammalian MPV of variant A1, A2, B1 or B2. In certain embodiments of the invention, the proteins of the different variants of mammalian MPV can be distinguished from each other by way of their amino acid sequence identities (see, *e.g.*, Figure 42b). A variant of mammalian MPV can be, but is not limited to, A1, A2, B1 or B2. The invention, however, also contemplates isolates of mammalian MPV that are members of another variant.

The invention provides a G protein of a mammalian MPV variant B1, wherein the G protein of a mammalian MPV variant B1 is phylogenetically closer related to the G protein of the prototype of variant B1, isolate NL/1/99, than it is related to the G protein of the prototype of variant A1, isolate NL/1/00, the G protein of the prototype of A2, isolate NL/17/00, or the G protein of the prototype of B2, isolate NL/1/94. The invention provides a G protein of a mammalian MPV variant B1, wherein the amino acid sequence of the G protein is at least 66%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% or at least 99.5% identical to the G protein of a mammalian MPV variant B1 as represented by the prototype NL/1/99 (SEQ ID NO:324). The invention provides a N

protein of a mammalian MPV variant B1, wherein the N protein of a mammalian MPV variant B1 is phylogenetically closer related to the N protein of the prototype of variant B1, isolate NL/1/99, than it is related to the N protein of the prototype of variant A1, isolate NL/1/00, the N protein of the prototype of A2, isolate NL/17/00, or the N protein of the prototype of B2, isolate NL/1/94. The invention provides a N protein of a mammalian MPV variant B1, wherein the amino acid sequence of the N protein is at least 98.5% or at least 99% or at least 99.5% identical to the N protein of a mammalian MPV variant B1 as represented by the prototype NL/1/99 (SEQ ID NO:368). The invention provides a P protein of a mammalian MPV variant B1, wherein the P protein of a mammalian MPV variant B1 is phylogenetically closer related to the P protein of the prototype of variant B1, isolate NL/1/99, than it is related to the P protein of the prototype of variant A1, isolate NL/1/00, the P protein of the prototype of A2, isolate NL/17/00, or the P protein of the prototype of B2, isolate NL/1/94. The invention provides a P protein of a mammalian MPV variant B1, wherein the amino acid sequence of the P protein is at least 96%, at least 98%, or at least 99% or at least 99.5% identical the P protein of a mammalian MPV variant B1 as represented by the prototype NL/1/99 (SEQ ID NO:376). The invention provides a M protein of a mammalian MPV variant B1, wherein the M protein of a mammalian MPV variant B1 is phylogenetically closer related to the M protein of the prototype of variant B1, isolate NL/1/99, than it is related to the M protein of the prototype of variant A1, isolate NL/1/00, the M protein of the prototype of A2, isolate NL/17/00, or the M protein of the prototype of B2, isolate NL/1/94. The invention provides a M protein of a mammalian MPV variant B1, wherein the amino acid sequence of the M protein is identical the M protein of a mammalian MPV variant B1 as represented by the prototype NL/1/99 (SEQ ID NO:360). The invention provides a F protein of a mammalian MPV variant B1, wherein the F protein of a mammalian MPV variant B1 is phylogenetically closer related to the F protein of the prototype of variant B1, isolate NL/1/99, than it is related to the F protein of the prototype of variant A1, isolate NL/1/00, the F protein of the prototype of A2, isolate NL/17/00, or the F protein of the prototype of B2, isolate NL/1/94. The invention provides a F protein of a mammalian MPV variant B1, wherein the amino acid sequence of the F protein is at least 99% identical to the F protein of a mammalian MPV variant B1 as represented by the prototype NL/1/99 (SEQ ID NO:316). The invention provides a M2-1 protein of a mammalian MPV variant B1, wherein the M2-1 protein of a

mammalian MPV variant B1 is phylogenetically closer related to the M2-1 protein of the prototype of variant B1, isolate NL/1/99, than it is related to the M2-1 protein of the prototype of variant A1, isolate NL/1/00, the M2-1 protein of the prototype of A2, isolate NL/17/00, or the M2-1 protein of the prototype of B2, isolate NL/1/94. The invention provides a M2-1 protein of a mammalian MPV variant B1, wherein the amino acid sequence of the M2-1 protein is at least 98% or at least 99% or at least 99.5% identical the M2-1 protein of a mammalian MPV variant B1 as represented by the prototype NL/1/99 (SEQ ID NO:340). The invention provides a M2-2 protein of a mammalian MPV variant B1, wherein the M2-2 protein of a mammalian MPV variant B1 is phylogenetically closer related to the M2-2 protein of the prototype of variant B1, isolate NL/1/99, than it is related to the M2-2 protein of the prototype of variant A1, isolate NL/1/00, the M2-2 protein of the prototype of A2, isolate NL/17/00, or the M2-2 protein of the prototype of B2, isolate NL/1/94. The invention provides a M2-2 protein of a mammalian MPV variant B1, wherein the amino acid sequence of the M2-2 protein is at least 99% or at least 99.5% identical the M2-2 protein of a mammalian MPV variant B1 as represented by the prototype NL/1/99 (SEQ ID NO:348). The invention provides a SH protein of a mammalian MPV variant B1, wherein the SH protein of a mammalian MPV variant B1 is phylogenetically closer related to the SH protein of the prototype of variant B1, isolate NL/1/99, than it is related to the SH protein of the prototype of variant A1, isolate NL/1/00, the SH protein of the prototype of A2, isolate NL/17/00, or the SH protein of the prototype of B2, isolate NL/1/94. The invention provides a SH protein of a mammalian MPV variant B1, wherein the amino acid sequence of the SH protein is at least 83%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% or at least 99.5% identical the SH protein of a mammalian MPV variant B1 as represented by the prototype NL/1/99 (SEQ ID NO:384). The invention provides a L protein of a mammalian MPV variant B1, wherein the L protein of a mammalian MPV variant B1 is phylogenetically closer related to the L protein of the prototype of variant B1, isolate NL/1/99, than it is related to the L protein of the prototype of variant A1, isolate NL/1/00, the L protein of the prototype of A2, isolate NL/17/00, or the L protein of the prototype of B2, isolate NL/1/94. The invention provides a L protein of a mammalian MPV variant B1, wherein the amino acid sequence of the L protein is at least 99% or at least 99.5% identical the L protein a mammalian MPV variant B1 as represented by the prototype NL/1/99 (SEQ ID NO:332).

The invention provides a G protein of a mammalian MPV variant A1, wherein the G protein of a mammalian MPV variant A1 is phylogenetically closer related to the G protein of the prototype of variant A1, isolate NL/1/00, than it is related to the G protein of the prototype of variant B1, isolate NL/1/99, the G protein of the prototype of A2, isolate NL/17/00, or the G protein of the prototype of B2, isolate NL/1/94. The invention provides a G protein of a mammalian MPV variant A1, wherein the amino acid sequence of the G protein is at least 66%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% or at least 99.5% identical to the G protein of a mammalian MPV variant A1 as represented by the prototype NL/1/00 (SEQ ID NO:322). The invention provides a N protein of a mammalian MPV variant A1, wherein the N protein of a mammalian MPV variant A1 is phylogenetically closer related to the N protein of the prototype of variant A1, isolate NL/1/00, than it is related to the N protein of the prototype of variant B1, isolate NL/1/99, the N protein of the prototype of A2, isolate NL/17/00, or the N protein of the prototype of B2, isolate NL/1/94. The invention provides a N protein of a mammalian MPV variant A1, wherein the amino acid sequence of the N protein is at least 99.5% identical to the N protein of a mammalian MPV variant A1 as represented by the prototype NL/1/00 (SEQ ID NO:366). The invention provides a P protein of a mammalian MPV variant A1, wherein the P protein of a mammalian MPV variant A1 is phylogenetically closer related to the P protein of the prototype of variant A1, isolate NL/1/00, than it is related to the P protein of the prototype of variant B1, isolate NL/1/99, the P protein of the prototype of A2, isolate NL/17/00, or the P protein of the prototype of B2, isolate NL/1/94. The invention provides a P protein of a mammalian MPV variant A1, wherein the amino acid sequence of the P protein is at least 96%, at least 98%, or at least 99% or at least 99.5% identical to the P protein of a mammalian MPV variant A1 as represented by the prototype NL/1/00 (SEQ ID NO:374). The invention provides a M protein of a mammalian MPV variant A1, wherein the M protein of a mammalian MPV variant A1 is phylogenetically closer related to the M protein of the prototype of variant A1, isolate NL/1/00, than it is related to the M protein of the prototype of variant B1, isolate NL/1/99, the M protein of the prototype of A2, isolate NL/17/00, or the M protein of the prototype of B2, isolate NL/1/94. The invention provides a M protein of a mammalian MPV variant A1, wherein the amino acid sequence of the M protein is at least 99% or at least 99.5% identical to the M protein of a mammalian MPV variant A1 as

represented by the prototype NL/1/00 (SEQ ID NO:358). The invention provides a F protein of a mammalian MPV variant A1, wherein the F protein of a mammalian MPV variant A1 is phylogenetically closer related to the F protein of the prototype of variant A1, isolate NL/1/00, than it is related to the F protein of the prototype of variant B1, isolate NL/1/99, the F protein of the prototype of A2, isolate NL/17/00, or the F protein of the prototype of B2, isolate NL/1/94. The invention provides a F protein of a mammalian MPV variant A1, wherein the amino acid sequence of the F protein is at least 98% or at least 99% or at least 99.5% identical to the F protein of a mammalian MPV variant A1 as represented by the prototype NL/1/00 (SEQ ID NO:314). The invention provides a M2-1 protein of a mammalian MPV variant A1, wherein the M2-1 protein of a mammalian MPV variant A1 is phylogenetically closer related to the M2-1 protein of the prototype of variant A1, isolate NL/1/00, than it is related to the M2-1 protein of the prototype of variant B1, isolate NL/1/99, the M2-1 protein of the prototype of A2, isolate NL/17/00, or the M2-1 protein of the prototype of B2, isolate NL/1/94. The invention provides a M2-1 protein of a mammalian MPV variant A1, wherein the amino acid sequence of the M2-1 protein is at least 99% or at least 99.5% identical to the M2-1 protein of a mammalian MPV variant A1 as represented by the prototype NL/1/00 (SEQ ID NO:338). The invention provides a M2-2 protein of a mammalian MPV variant A1, wherein the M2-2 protein of a mammalian MPV variant A1 is phylogenetically closer related to the M2-2 protein of the prototype of variant A1, isolate NL/1/00, than it is related to the M2-2 protein of the prototype of variant B1, isolate NL/1/99, the M2-2 protein of the prototype of A2, isolate NL/17/00, or the M2-2 protein of the prototype of B2, isolate NL/1/94. The invention provides a M2-2 protein of a mammalian MPV variant A1, wherein the amino acid sequence of the M2-2 protein is at least 96% or at least 99% or at least 99.5% identical to the M2-2 protein of a mammalian MPV variant A1 as represented by the prototype NL/1/00 (SEQ ID NO:346). The invention provides a SH protein of a mammalian MPV variant A1, wherein the SH protein of a mammalian MPV variant A1 is phylogenetically closer related to the SH protein of the prototype of variant A1, isolate NL/1/00, than it is related to the SH protein of the prototype of variant B1, isolate NL/1/99, the SH protein of the prototype of A2, isolate NL/17/00, or the SH protein of the prototype of B2, isolate NL/1/94. The invention provides a SH protein of a mammalian MPV variant A1, wherein the amino acid sequence of the SH protein is at least 84%, at least 90%, at least 95%, at least 98%, or at

least 99% or at least 99.5% identical to the SH protein of a mammalian MPV variant A1 as represented by the prototype NL/1/00 (SEQ ID NO:382). The invention provides a L protein of a mammalian MPV variant A1, wherein the L protein of a mammalian MPV variant A1 is phylogenetically closer related to the L protein of the prototype of variant A1, isolate NL/1/00, than it is related to the L protein of the prototype of variant B1, isolate NL/1/99, the L protein of the prototype of A2, isolate NL/17/00, or the L protein of the prototype of B2, isolate NL/1/94. The invention provides a L protein of a mammalian MPV variant A1, wherein the amino acid sequence of the L protein is at least 99% or at least 99.5% identical to the L protein of a virus of a mammalian MPV variant A1 as represented by the prototype NL/1/00 (SEQ ID NO:330).

The invention provides a G protein of a mammalian MPV variant A2, wherein the G protein of a mammalian MPV variant A2 is phylogenetically closer related to the G protein of the prototype of variant A2, isolate NL/17/00, than it is related to the G protein of the prototype of variant B1, isolate NL/1/99, the G protein of the prototype of A1, isolate NL/1/00, or the G protein of the prototype of B2, isolate NL/1/94. The invention provides a G protein of a mammalian MPV variant A2, wherein the amino acid sequence of the G protein is at least 66%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or at least 99.5% identical to the G protein of a mammalian MPV variant A2 as represented by the prototype NL/17/00 (SEQ ID NO:332). The invention provides a N protein of a mammalian MPV variant A2, wherein the N protein of a mammalian MPV variant A2 is phylogenetically closer related to the N protein of the prototype of variant A2, isolate NL/17/00, than it is related to the N protein of the prototype of variant B1, isolate NL/1/99, the N protein of the prototype of A1, isolate NL/1/00, or the N protein of the prototype of B2, isolate NL/1/94. The invention provides a N protein of a mammalian MPV variant A2, wherein the amino acid sequence of the N protein at least 99.5% identical to the N protein of a mammalian MPV variant A2 as represented by the prototype NL/17/00 (SEQ ID NO:367). The invention provides a P protein of a mammalian MPV variant A2, wherein the P protein of a mammalian MPV variant A2 is phylogenetically closer related to the P protein of the prototype of variant A2, isolate NL/17/00, than it is related to the P protein of the prototype of variant B1, isolate NL/1/99, the P protein of the prototype of A1, isolate NL/1/00, or the P protein of the prototype of B2, isolate NL/1/94. The invention provides a P protein of a

mammalian MPV variant A2, wherein the amino acid sequence of the P protein is at least 96%, at least 98%, at least 99% or at least 99.5% identical to the P protein of a mammalian MPV variant A2 as represented by the prototype NL/17/00 (SEQ ID NO:375). The invention provides a M protein of a mammalian MPV variant A2, wherein the M protein of a mammalian MPV variant A2 is phylogenetically closer related to the M protein of the prototype of variant A2, isolate NL/17/00, than it is related to the M protein of the prototype of variant B1, isolate NL/1/99, the M protein of the prototype of A1, isolate NL/1/00, or the M protein of the prototype of B2, isolate NL/1/94. The invention provides a M protein of a mammalian MPV variant A2, wherein the the amino acid sequence of the M protein is at least 99%, or at least 99.5% identical to the M protein of a mammalian MPV variant A2 as represented by the prototype NL/17/00 (SEQ ID NO:359). The invention provides a F protein of a mammalian MPV variant A2, wherein the F protein of a mammalian MPV variant A2 is phylogenetically closer related to the F protein of the prototype of variant A2, isolate NL/17/00, than it is related to the F protein of the prototype of variant B1, isolate NL/1/99, the F protein of the prototype of A1, isolate NL/1/00, or the F protein of the prototype of B2, isolate NL/1/94. The invention provides a F protein of a mammalian MPV variant A2, wherein the amino acid sequence of the F protein is at least 98%, at least 99% or at least 99.5% identical to the F protein of a mammalian MPV variant A2 as represented by the prototype NL/17/00 (SEQ ID NO:315). The invention provides a M2-1 protein of a mammalian MPV variant A2, wherein the M2-1 protein of a mammalian MPV variant A2 is phylogenetically closer related to the M2-1 protein of the prototype of variant A2, isolate NL/17/00, than it is related to the M2-1 protein of the prototype of variant B1, isolate NL/1/99, the M2-1 protein of the prototype of A1, isolate NL/1/00, or the M2-1 protein of the prototype of B2, isolate NL/1/94. The invention provides a M2-1 protein of a mammalian MPV variant A2, wherein the amino acid sequence of the M2-1 protein is at least 99%, or at least 99.5% identical to the M2-1 protein of a mammalian MPV variant A2 as represented by the prototype NL/17/00 (SEQ ID NO: 339). The invention provides a M2-2 protein of a mammalian MPV variant A2, wherein the M2-2 protein of a mammalian MPV variant A2 is phylogenetically closer related to the M2-2 protein of the prototype of variant A2, isolate NL/17/00, than it is related to the M2-2 protein of the prototype of variant B1, isolate NL/1/99, the M2-2 protein of the prototype of A1, isolate NL/1/00, or the M2-2 protein of the prototype of B2, isolate

NL/1/94. The invention provides a M2-2 protein of a mammalian MPV variant A2, wherein the amino acid sequence of the M2-2 protein is at least 96%, at least 98%, at least 99% or at least 99.5% identical to the M2-2 protein of a mammalian MPV variant A2 as represented by the prototype NL/17/00 (SEQ ID NO:347). The invention provides a SH protein of a mammalian MPV variant A2, wherein the SH protein of a mammalian MPV variant A2 is phylogenetically closer related to the SH protein of the prototype of variant A2, isolate NL/17/00, than it is related to the SH protein of the prototype of variant B1, isolate NL/1/99, the SH protein of the prototype of A1, isolate NL/1/00, or the SH protein of the prototype of B2, isolate NL/1/94. The invention provides a SH protein of a mammalian MPV variant A2, wherein the amino acid sequence of the SH protein is at least 84%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or at least 99.5% identical to the SH protein of a mammalian MPV variant A2 as represented by the prototype NL/17/00 (SEQ ID NO:383). The invention provides a L protein of a mammalian MPV variant A2, wherein the L protein of a mammalian MPV variant A2 is phylogenetically closer related to the L protein of the prototype of variant A2, isolate NL/17/00, than it is related to the L protein of the prototype of variant B1, isolate NL/1/99, the L protein of the prototype of A1, isolate NL/1/00, or the L protein of the prototype of B2, isolate NL/1/94. The invention provides a L protein of a mammalian MPV variant A2, wherein the amino acid sequence of the L protein is at least 99% or at least 99.5% identical to the L protein of a mammalian MPV variant A2 as represented by the prototype NL/17/00 (SEQ ID NO:331).

The invention provides a G protein of a mammalian MPV variant B2, wherein the G protein of a mammalian MPV variant B2 is phylogenetically closer related to the G protein of the prototype of variant B2, isolate NL/1/94, than it is related to the G protein of the prototype of variant B1, isolate NL/1/99, the G protein of the prototype of A1, isolate NL/1/00, or the G protein of the prototype of A2, isolate NL/17/00. The invention provides a G protein of a mammalian MPV variant B2, wherein the amino acid sequence of the G protein is at least 66%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% or at least 99.5% identical to the G protein of a mammalian MPV variant B2 as represented by the prototype NL/1/94 (SEQ ID NO:325). The invention provides a N protein of a mammalian MPV variant B2, wherein the N protein of a mammalian MPV variant B2 is phylogenetically closer related to the N protein of the prototype of variant B2, isolate

NL/1/94, than it is related to the N protein of the prototype of variant B1, isolate NL/1/99, the N protein of the prototype of A1, isolate NL/1/00, or the N protein of the prototype of A2, isolate NL/17/00. The invention provides a N protein of a mammalian MPV variant B2, wherein the amino acid sequence of the N protein is at least 99% or at least 99.5% identical to the N protein of a mammalian MPV variant B2 as represented by the prototype NL/1/94 (SEQ ID NO:369). The invention provides a P protein of a mammalian MPV variant B2, wherein the P protein of a mammalian MPV variant B2 is phylogenetically closer related to the P protein of the prototype of variant B2, isolate NL/1/94, than it is related to the P protein of the prototype of variant B1, isolate NL/1/99, the P protein of the prototype of A1, isolate NL/1/00, or the P protein of the prototype of A2, isolate NL/17/00. The invention provides a P protein of a mammalian MPV variant B2, wherein the amino acid sequence of the P protein is at least 96%, at least 98%, or at least 99% or at least 99.5% identical to the P protein of a mammalian MPV variant B2 as represented by the prototype NL/1/94 (SEQ ID NO:377). The invention provides a M protein of a mammalian MPV variant B2, wherein the M protein of a mammalian MPV variant B2 is phylogenetically closer related to the M protein of the prototype of variant B2, isolate NL/1/94, than it is related to the M protein of the prototype of variant B1, isolate NL/1/99, the M protein of the prototype of A1, isolate NL/1/00, or the M protein of the prototype of A2, isolate NL/17/00. The invention provides a M protein of a mammalian MPV variant B2, wherein the amino acid sequence of its M protein is identical to the M protein of a mammalian MPV variant B2 as represented by the prototype NL/1/94 (SEQ ID NO:361). The invention provides a F protein of a mammalian MPV variant B2, wherein the F protein of a mammalian MPV variant B2 is phylogenetically closer related to the F protein of the prototype of variant B2, isolate NL/1/94, than it is related to the F protein of the prototype of variant B1, isolate NL/1/99, the F protein of the prototype of A1, isolate NL/1/00, or the F protein of the prototype of A2, isolate NL/17/00. The invention provides a F protein of a mammalian MPV variant B2, wherein the amino acid sequence of the F protein is at least 99% or at least 99.5% identical to the F protein of a mammalian MPV variant B2 as represented by the prototype NL/1/94 (SEQ ID NO:317). The invention provides a M2-1 protein of a mammalian MPV variant B2, wherein the M2-1 protein of a mammalian MPV variant B2 is phylogenetically closer related to the M2-1 protein of the prototype of variant B2, isolate NL/1/94, than it is related to the M2-1 protein of the prototype of variant B1, isolate

NL/1/99, the M2-1 protein of the prototype of A1, isolate NL/1/00, or the M2-1 protein of the prototype of A2, isolate NL/17/00. The invention provides a M2-1 protein of a mammalian MPV variant B2, wherein the amino acid sequence of the M2-1 protein is at least 98% or at least 99% or at least 99.5% identical to the M2-1 protein of a mammalian MPV variant B2 as represented by the prototype NL/1/94 (SEQ ID NO:341). The invention provides a M2-2 protein of a mammalian MPV variant B2, wherein the M2-2 protein of a mammalian MPV variant B2 is phylogenetically closer related to the M2-2 protein of the prototype of variant B2, isolate NL/1/94, than it is related to the M2-2 protein of the prototype of variant B1, isolate NL/1/99, the M2-2 protein of the prototype of A1, isolate NL/1/00, or the M2-2 protein of the prototype of A2, isolate NL/17/00. The invention provides a M2-2 protein of a mammalian MPV variant B2, wherein the amino acid sequence is at least 99% or at least 99.5% identical to the M2-2 protein of a mammalian MPV variant B2 as represented by the prototype NL/1/94 (SEQ ID NO:350). The invention provides a SH protein of a mammalian MPV variant B2, wherein the SH protein of a mammalian MPV variant B2 is phylogenetically closer related to the SH protein of the prototype of variant B2, isolate NL/1/94, than it is related to the SH protein of the prototype of variant B1, isolate NL/1/99, the SH protein of the prototype of A1, isolate NL/1/00, or the SH protein of the prototype of A2, isolate NL/17/00. The invention provides a SH protein of a mammalian MPV variant B2, wherein the amino acid sequence of the SH protein is at least 84%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% or at least 99.5% identical to the SH protein of a mammalian MPV variant B2 as represented by the prototype NL/1/94 (SEQ ID NO:385). The invention provides a L protein of a mammalian MPV variant B2, wherein the L protein of a mammalian MPV variant B2 is phylogenetically closer related to the L protein of the prototype of variant B2, isolate NL/1/94, than it is related to the L protein of the prototype of variant B1, isolate NL/1/99, the L protein of the prototype of A1, isolate NL/1/00, or the L protein of the prototype of A2, isolate NL/17/00. The invention provides a L protein of a mammalian MPV variant B2, wherein the and/or if the amino acid sequence of the L protein is at least 99% or at least 99.5% identical to the L protein of a mammalian MPV variant B2 as represented by the prototype NL/1/94 (SEQ ID NO:333).

In certain embodiments, the percentage of sequence identity is based on an alignment of the full length proteins. In other embodiments, the percentage of sequence identity is based

on an alignment of contiguous amino acid sequences of the proteins, wherein the amino acid sequences can be 25 amino acids, 50 amino acids, 75 amino acids, 100 amino acids, 125 amino acids, 150 amino acids, 175 amino acids, 200 amino acids, 225 amino acids, 250 amino acids, 275 amino acids, 300 amino acids, 325 amino acids, 350 amino acids, 375 amino acids, 400 amino acids, 425 amino acids, 450 amino acids, 475 amino acids, 500 amino acids, 750 amino acids, 1000 amino acids, 1250 amino acids, 1500 amino acids, 1750 amino acids, 2000 amino acids or 2250 amino acids in length.

In certain, specific embodiments, the invention provides a G protein of a mammalian MPV wherein the G protein has one of the amino acid sequences set forth in SEQ ID NO:119-153; SEQ ID NO:322-325 or a fragment thereof. In certain, specific embodiments, the invention provides a F protein of a mammalian MPV wherein the F protein has one of the amino acid sequences set forth in SEQ ID NO:234-317. In certain, specific embodiments, the invention provides a L protein of a mammalian MPV wherein the L protein has one of the amino acid sequences set forth in SEQ IDNO:330-333 or a fragment thereof. In certain, specific embodiments, the invention provides a M2-1 protein of a mammalian MPV wherein the M2-1 protein has one of the amino acid sequences set forth in SEQ ID NO:338-341 or a fragment thereof. In certain, specific embodiments, the invention provides a M2-2 protein of a mammalian MPV wherein the M2-2 protein has one of the amino acid sequences set forth in SEQ ID NO:346-349 or a fragment thereof. In certain, specific embodiments, the invention provides a M protein of a mammalian MPV wherein the M protein has one of the amino acid sequences set forth in SEQ ID NO:358-361 or a fragment thereof. In certain, specific embodiments, the invention provides a N protein of a mammalian MPV wherein the N protein has one of the amino acid sequences set forth in SEQ ID NO:366-369 or a fragment thereof. In certain, specific embodiments, the invention provides a P protein of a mammalian MPV wherein the P protein has one of the amino acid sequences set forth in SEQ ID NO:374-377 or a fragment thereof. In certain, specific embodiments, the invention provides a SH protein of a mammalian MPV wherein the SH protein has one of the amino acid sequences set forth in SEQ ID NO:382-385 or a fragment thereof.

In certain embodiments of the invention, a fragment is at least 25 amino acids, 50 amino acids, 75 amino acids, 100 amino acids, 125 amino acids, 150 amino acids, 175 amino acids, 200 amino acids, 225 amino acids, 250 amino acids, 275 amino acids, 300 amino acids,

325 amino acids, 350 amino acids, 375 amino acids, 400 amino acids, 425 amino acids, 450 amino acids, 475 amino acids, 500 amino acids, 750 amino acids, 1000 amino acids, 1250 amino acids, 1500 amino acids, 1750 amino acids, 2000 amino acids or 2250 amino acids in length. In certain embodiments of the invention, a fragment is at most 25 amino acids, 50 amino acids, 75 amino acids, 100 amino acids, 125 amino acids, 150 amino acids, 175 amino acids, 200 amino acids, 225 amino acids, 250 amino acids, 275 amino acids, 300 amino acids, 325 amino acids, 350 amino acids, 375 amino acids, 400 amino acids, 425 amino acids, 450 amino acids, 475 amino acids, 500 amino acids, 750 amino acids, 1000 amino acids, 1250 amino acids, 1500 amino acids, 1750 amino acids, 2000 amino acids or 2250 amino acids in length.

The invention further provides nucleic acid sequences derived from a mammalian MPV. The invention also provides derivatives of nucleic acid sequences derived from a mammalian MPV. In certain specific embodiments the nucleic acids are modified.

In certain embodiments, a nucleic acid of the invention encodes a G protein, a N protein, a P protein, a M protein, a F protein, a M2-1 protein, a M2-2 protein, a SH protein, or a L protein of a mammalian MPV as defined above. In certain embodiments, a nucleic acid of the invention encodes a G protein, a N protein, a P protein, a M protein, a F protein, a M2-1 protein, a M2-2 protein, a SH protein, or a L protein of subgroup A of a mammalian MPV as defined above. In certain embodiments, a nucleic acid of the invention encodes a G protein, a N protein, a P protein, a M protein, a F protein, a M2-1 protein, a M2-2 protein, a SH protein, or a L protein of subgroup B of a mammalian MPV as defined above. In certain embodiments, a nucleic acid of the invention encodes a G protein, a N protein, a P protein, a M protein, a F protein, a M2-1 protein, a M2-2 protein, a SH protein, or a L protein of variant A1 of a mammalian MPV as defined above. In certain embodiments, a nucleic acid of the invention encodes a G protein, a N protein, a P protein, a M protein, a F protein, a M2-1 protein, a M2-2 protein, a SH protein, or a L protein of variant A2 of a mammalian MPV as defined above. In certain embodiments, a nucleic acid of the invention encodes a G protein, a N protein, a P protein, a M protein, a F protein, a M2-1 protein, a M2-2 protein, a SH protein, or a L protein of variant B1 of a mammalian MPV as defined above. In certain embodiments, a nucleic acid of the invention encodes a G protein, a N protein, a P protein, a M protein, a F protein, a M2-1

protein, a M2-2 protein, a SH protein, or a L protein of variant B2 of a mammalian MPV as defined above.

In certain embodiments, the invention provides a nucleotide sequence that is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.5% identical to the nucleotide sequence of SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, or SEQ ID NO:21. In certain embodiments, the nucleic acid sequence of the invention, is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.5% identical to a fragment of the nucleotide sequence of SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, or SEQ ID NO:21, wherein the fragment is at least 25 nucleotides, at least 50 nucleotides, at least 75 nucleotides, at least 100 nucleotides, at least 150 nucleotides, at least 200 nucleotides, at least 250 nucleotides, at least 300 nucleotides, at least 400 nucleotides, at least 500 nucleotides, at least 750 nucleotides, at least 1,000 nucleotides, at least 1,250 nucleotides, at least 1,500 nucleotides, at least 1,750 nucleotides, at least 2,000 nucleotides, at least 2,00 nucleotides, at least 3,000 nucleotides, at least 4,000 nucleotides, at least 5,000 nucleotides, at least 7,500 nucleotides, at least 10,000 nucleotides, at least 12,500 nucleotides, or at least 15,000 nucleotides in length. In a specific embodiment, the nucleic acid sequence of the invention is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.5% or 100% identical to one of the nucleotide sequences of SEQ ID NO:84-118; SEQ ID NO:154-233; SEQ ID NO:318-321; SEQ ID NO:326-329; SEQ ID NO:334-337; SEQ ID NO:342-345; SEQ ID NO:350-353; SEQ ID NO:354-357; SEQ ID NO:362-365; SEQ ID NO:370-373; SEQ ID NO:378-381; or SEQ ID NO:386-389.

In specific embodiments of the invention, a nucleic acid sequence of the invention is capable of hybridizing under low stringency, medium stringency or high stringency conditions to one of the nucleic acid sequences of SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, or SEQ ID NO:21. In specific embodiments of the invention, a nucleic acid sequence of the invention is capable of hybridizing under low stringency, medium stringency or high stringency conditions to one of the nucleic acid sequences of SEQ ID NO:84-118; SEQ ID NO:154-233; SEQ ID NO:318-321; SEQ ID NO:326-329; SEQ ID NO:334-337; SEQ ID

NO:342-345; SEQ ID NO:350-353; SEQ ID NO:354-357; SEQ ID NO:362-365; SEQ ID NO:370-373; SEQ ID NO:378-381; or SEQ ID NO:386-389. In certain embodiments, a nucleic acid hybridizes over a length of at least 25 nucleotides, at least 50 nucleotides, at least 75 nucleotides, at least 100 nucleotides, at least 150 nucleotides, at least 200 nucleotides, at least 250 nucleotides, at least 300 nucleotides, at least 400 nucleotides, at least 500 nucleotides, at least 750 nucleotides, at least 1,000 nucleotides, at least 1,250 nucleotides, at least 1,500 nucleotides, at least 1,750 nucleotides, at least 2,000 nucleotides, at least 2,000 nucleotides, at least 3,000 nucleotides, at least 4,000 nucleotides, at least 5,000 nucleotides, at least 7,500 nucleotides, at least 10,000 nucleotides, at least 12,500 nucleotides, or at least 15,000 nucleotides with the nucleotide sequence of SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, or SEQ ID NO:21.

The invention further provides antibodies and antigen-binding fragments that bind specifically to a protein of a mammalian MPV. An antibody of the invention binds specifically to a G protein, a N protein, a P protein, a M protein, a F protein, a M2-1 protein, a M2-2 protein, a SH protein, or a L protein of a mammalian MPV. In specific embodiments, the antibody is a human antibody or a humanized antibody. In certain embodiments, an antibody of the invention binds specifically to a G protein, a N protein, a P protein, a M protein, a F protein, a M2-1 protein, a M2-2 protein, a SH protein, or a L protein of a virus of subgroup A of a mammalian MPV. In certain other embodiments, an antibody of the invention binds specifically to a G protein, a N protein, a P protein, a M protein, a F protein, a M2-1 protein, a M2-2 protein, a SH protein, or a L protein of a virus of subgroup B of a mammalian MPV. In certain, more specific, embodiments, an antibody of the invention binds specifically to a G protein, a N protein, a P protein, a M protein, a F protein, a M2-1 protein, a M2-2 protein, a SH protein, or a L protein of a virus of variant A1 of a mammalian MPV. In other embodiments, the antibody of the invention binds specifically to a G protein, a N protein, a P protein, a M protein, a F protein, a M2-1 protein, a M2-2 protein, a SH protein, or a L protein of a virus of subgroup A2 of a mammalian MPV. In certain embodiments, an antibody of the invention binds specifically to a G protein, a N protein, a P protein, a M protein, a F protein, a M2-1 protein, a M2-2 protein, a SH protein, or a L protein of a virus of subgroup B1 of a mammalian MPV. In certain other embodiments, an antibody of the invention binds

specifically to a G protein, a N protein, a P protein, a M protein, a F protein, a M2-1 protein, a M2-2 protein, a SH protein, or a L protein of a virus of subgroup B2 of a mammalian MPV.

6. VIRUS ISOLATION AND CHARACTERIZATION

6.1 EXAMPLE 1: SPECIMEN COLLECTION, VIRUS ISOLATION, VIRUS CHARACTERIZATION

Samples of nasopharyngeal aspirates were obtained from hosts to assay for the presence of viruses, and also to characterize those identified. Nasopharyngeal aspirates were collected from children suffering from respiratory tract infection (RTI). In order to determine the identity of the cause of illness, all nasopharyngeal aspirates were tested by direct immunofluorescence assays (DIF) (See method in Example 9), using fluorescence labeled antibodies against influenza virus types A and B, hRSV, and human parainfluenza virus (hPIV) types 1, 2, and 3. Viruses were also isolated from nasopharyngeal aspirates using rapid shell vial techniques, (Rothbarth *et. al.*, 1999, J of Virol. Methods 78:163-169) on various cell lines, including VERO cells, tertiary cynomolgous monkey kidney (tMK) cells, human endothelial lung (HEL) cells and marbin dock kidney (MDCK) cells. Samples showing cytopathic effects (CPE) after two to three passages, that were negative in DIF assays, were tested by indirect immunofluorescence assays (IFA) (See method in Example 11), using virus specific antibodies against influenza virus types A, B and C, hRSV types A and B, measles virus, mumps virus, human parainfluenza virus (hPIV) types 1 to 4, sendai virus, simian virus type 5, and New-Castle disease virus. Although for many cases the aetiological agent could be identified, some specimens were negative for all of the viruses tested.

These 28 unidentified virus isolates grew slowly in tMK cells, poorly in VERO cells and A549 cells and barely in MDCK or chicken embryonated fibroblast cells. Most of the virus isolates induced CPE on tMK cells, between days ten and fourteen. This was somewhat later than the CPE caused by other viruses such as hRSV or hPIV. The CPE were virtually indistinguishable from that caused by hRSV or hPIV in tMK or other cell cultures, and were characterized by syncytium formation. Some of the effects observed on the cells included rapid internal disruption, followed by detachment of the cells from the monolayer.

The supernatants of infected tMK cells were used for Electron Microscopy (EM) analysis, and they revealed the presence of paramyxovirus-like virus particles ranging from

150 to 600 nanometers in diameter, with short envelope projections ranging from 13 to 17 nanometers. Consistent with the biochemical properties of enveloped viruses such as the *Paramyxoviridae* family of viruses, standard chloroform or ether treatment (Osterhaus *et al.*, 1985, Arch. of Virol. 86:239-25) resulted in a greater than 10^4 TCID₅₀ reduction in infectivity of tMK cells. Virus-infected tMK cell culture supernatants did not display hemagglutinating activity with turkey, chicken and guinea pig erythrocytes. During culture, the virus replication appeared to be trypsin dependent. These combined virological data demonstrated that the newly identified virus was a taxonomic member of the *Paramyxoviridae* family.

RNA from tMK cells infected with 15 of the unidentified virus isolates was extracted for use in reverse transcription and polymerase chain reaction (RT-PCR) analyses, using primer-sets specific for *Paramyxovirinae* (K.B. Chua *et al.*, 2000, Science 288:1432-1435) such as: hPIV 1-4, sendai virus, simian virus type 5, New-Castle disease virus, hRSV, morbilli, mumps, Nipah, Hendra, Tupaia and Mapuera viruses. RT-PCR assays were performed under conditions of low stringency in order to detect potentially related viruses. RNA isolated from homologous virus stocks was used as a control. Whereas the available controls reacted positive with the respective virus-specific primers, the newly identified virus isolates did not react with any primer set, indicating the virus was not closely related to the viruses tested.

Two of the virus-infected tMK cell culture supernatants were used to inoculate guinea pigs and ferrets intranasally. Sera samples were collected from these animals at day zero, two weeks, and three weeks post inoculation. The animals displayed no clinical symptoms, however, the seroconversion of all of the animals was detected and measured in virus neutralization (VN) (See method in Example 16) assays and indirect IFA against the homologous viruses. The sera did not react in indirect IFA with any of the known paramyxoviruses described above or with pneumovirus of mice (PVM). The so far unidentified virus isolates were screened, using the guinea pig and ferret pre-and post-infection sera. Of these, 28 were clearly positive by indirect IFA, with the post-infection sera suggesting that, the thus far unidentified viral isolates, were closely related or identical.

In order further characterize the virus, the phenotypic effects of virus infection on a cell line was examined. In short, tMK cells were cultured in 24 well plates containing glass slides (Costar, Cambridge, UK), with the medium described below supplemented with 10% fetal

bovine serum (BioWhittaker, Vervier, Belgium). Before inoculation, the plates were washed with PBS and supplied with Eagle's MEM with Hanks' salt (ICN, Costa mesa, CA), of which 0.5L was supplemented with 0.26 g of NaHCO₃, 0.025 M Hepes (Biowhittaker), 2 mM L-glutamine (Biowhittaker), 100 units penicillin, 100 µg streptomycin (Biowhittaker), 0.5 g lactalbumin (Sigma-Aldrich, Zwijndrecht, The Netherlands), 1.0 g D-glucose (Merck, Amsterdam, The Netherlands), 5.0 g peptone (Oxoid, Haarlem, The Netherlands) and 0.02% trypsin (Life Technologies, Bethesda, MD). The plates were inoculated with the supernatant of the nasopharyngeal aspirate samples (0.2 ml per well in triplicate), followed by centrifuging at 840x g for one hour. After inoculation, the plates were incubated at 37°C for a maximum of 14 days, and the medium was changed once a week while cultures were checked daily for CPE. After 14 days, the cells were scraped from the second passage and incubated for 14 days. This step was repeated for the third passage. The glass slides were used to demonstrate the presence of the virus by indirect IFA as described below.

CPE were generally observed after the third passage, between days 8 to 14, depending on the isolate. The CPE were virtually indistinguishable from that caused by hRSV or hPIV in tMK or other cell cultures, except that hRSV induces CPE at around day 4. CPE were characterized by syncytia formation, after which the cells showed rapid internal disruption, followed by detachment of the cells from the monolayer. For some isolates, CPE were difficult to observe, and IFA was used to confirm the presence of the virus in these cultures. The observation that the CPE were indistinguishable from those of other viruses indicated that diagnosis could not be made from a visual examination of clinical symptoms.

6.2 EXAMPLE 2: SEROPREVALENCE IN THE HUMAN POPULATION

To study the seroprevalence of this virus in the human population, sera from humans in different age categories were analyzed by indirect IFA using tMK cells infected with one of the unidentified virus isolates. Studies revealed that antibodies to the virus could be detected in 25% of the children between six and twelve months. Furthermore, by the age of five, nearly 100% of the children were seropositive. In total, 56 sera samples examined by indirect IFA and by VN assay. For 51 of the samples or 91%, the results of the VN assay, *i.e.*, a titer greater than 8, coincided with the results obtained with indirect IFA, *i.e.*, a titer greater than 32. Four samples that were found to be positive by IFA, were negative by the VN assay, *i.e.*,

titer less than 8, whereas one serum sample was negative by IFA, *i.e.*, titer less than 32, and was positive by the VN test, *i.e.*, a titer of 16 (Figure 2).

IFA conducted on 72 sera samples taken from humans in 1958, with ages ranging from 8-99 years, revealed a 100% seroprevalence rate, indicating the virus has been circulating in the human population for more than 40 years. In addition, a number of these sera samples were used in VN assays to confirm the IFA data (Figure 2). The seroprevalence data indicate that the virus has been a significant source of infection in the human population for many years.

The repeated isolation of this virus from clinical samples from children with severe RTI indicates that the clinical and economic impact of MPV may be high. New diagnostic assays based on virus detection and serology would yield a more detailed analysis of the incidence rate and also of the clinical and economical impact of this viral pathogen.

The slight differences between the IFA and VN results (5 samples) may have been due to the fact that in the IFA, only IgG serum antibodies were detected, whereas the VN assay detects both classes and sub-classes of antibodies. Alternatively, differences may have been due to the differences in sensitivity between both assays. For IFA, a threshold value of 16 was used, whereas for VN a value of 8 was used.

Differences between results in the IFA and VN assays may also indicate possible differences between serotypes of this newly identified virus. Since MPV seems to be most closely related to APV, it was speculated that the human virus may have originated from birds. Analysis of serum samples taken from humans in 1958 revealed that MPV has been widespread in the human population for more than 40 years, indicating that a tentative zoonosis event must have taken place long before 1958.

6.3 EXAMPLE 3: GENOMIC SEQUENCE OF HMPV ISOLATE 00-1

In order to obtain sequence information for the unknown virus isolates, a random PCR amplification strategy known as RAP-PCR (Welsh *et. al.*, 1992, NAR 20:4965-4970) (See Example 19). In short, tMK cells were infected with one of the virus isolates (isolate 00-1) as well as with hPIV- 1 that served as a positive control. After both cultures displayed similar levels of CPE, virus in the culture supernatants was purified on continuous 20-60% sucrose gradients. The gradient fractions were inspected for virus-like particles by EM, and RNA was

isolated from the fraction that contained approximately 50% sucrose, in which nucleocapsids were observed. Equivalent amounts of RNA isolated from both virus fractions were used for RAP-PCR, after which samples were run side by side on a 3% NuSieve agarose gel. Twenty differentially displayed bands specific for the unidentified virus were subsequently purified from the gel, cloned in plasmid pCR2.1 (Invitrogen) and sequenced (See Example 20) with vector-specific primers. A search for homologies against sequences in the Genbank database, using the BLAST program available through the National Library of Medicine, found that 10 out of 20 fragments displayed resemblance to APV/TRTV sequences.

These 10 fragments were located in the genes coding for the nucleoprotein (N; fragment 1 and 2), the matrix protein (M; fragment 3), the fusion protein (F; fragment 4, 5, 6, 7) and the polymerase protein (L; fragment 8, 9, 10) (Figure 3). PCR primers were designed to complete the sequence information for the 3' end of the viral genome based on our RAP PCR fragments as well as published leader and trailer sequences for the *Pneumovirinae* (Randhawa, et.al., 1997, *J.Virol.* 71:9849-9854). Three fragments were amplified, of which fragment A spanned the extreme 3' end of the N open reading frame (ORF), fragment B spanned the phosphoprotein (F) ORF and fragment C closed the gap between the M and F ORFs (Figure 16). Sequence analyses of these three fragments revealed the absence of NS1 and NS2 ORFs at the extreme 3' end of the viral genome and positioning of the F ORF immediately adjacent to the M ORF. This genomic organization resembled that of the metapneumovirus APV, which was also consistent with the sequence homology. Relation between different viruses could be deduced by comparing the amino acid sequence of Figure 4 with the amino acid sequence of the respective N proteins of other viruses. Overall the translated sequences for the N, P, M and F ORFs showed an average of 30-33% homology with members of the genus *Pneumovirus* and 66-68% with members of the genus *Metapneumovirus*. For the SH and G ORFs, no discernable homology was found with members of either genera. The amino acid homologies found for the amino acid sequence of the N ORF showed about 40% homology with hRSV and 88% with APV-C, its closest relative genetically. The amino acid sequence for the P ORF showed about 25% homology with hRSV and about 66-68% with APV-C, the M ORF showed about 36-39% with hRSV and about 87-89% with APV-C, the F ORF showed about 40% homology with hRSV and about 81% with APV-C, the M2-1 ORF showed about 34-36% homology with pneumoviruses and 84-86 % with APV-C, the M2-2 ORF showed 15-

17% homology with pneumoviruses and 56% with APV-C and the fragments obtained from the L ORF showed an average of 44% with pneumoviruses and 64% with APV-C.

Genetic analyses of the N, M, P and F genes revealed that MPV has higher sequence homology to the recently proposed genus *Metapneumovirinae* as compared to the genus *Pneumovirinae* and thus demonstrates a genomic organization similar to and resembling that of APV/TRTV. In contrast to the genomic organization of the RSVs ('3-NS1-NS2-N-P-M-SH-G-F-M2-L-5'), metapneumoviruses lack NS1 and NS2 genes and also have a different genomic organization, specifically between the M and L ('3-N-P-M-F-M2-SH-G-L-5') genes. The lack of ORFs between the M and F genes in the virus isolates of the invention, the lack of NS1 and NS2 adjacent to N, and the high amino acid sequence homology found within APV led to the proposed classification of MPV isolated from humans as the first member of the *Metapneumovirus* genus of mammals, and more specifically of humans.

Phylogenetic analyses revealed that the nine MPV isolates, from which sequence information was obtained, are closely related. Although sequence information was limited, they appeared to be more closely related to one another than to any of the avian metapneumoviruses. Of the four serotypes of APV that have been described, serotype C appeared to be most closely related to MPV. This conclusion was based upon the nucleotide sequence similarities of the N, P, M and F genes. It should be noted however, that for serotype D, only partial sequences of the F gene were available from Genbank, and for serotype B, only M, N, and F sequences were available. Our MPV isolates formed two clusters in phylogenetic trees. For both hRSV and APV, different genetic and serological subtypes have been described. Whether the two genetic clusters of MPV isolates represent serological subgroups that are also functionally different remains unknown at present. Our serological surveys showed that MPV is a common human pathogen.

6.4 EXAMPLE 4: FURTHER CHARACTERIZATION OF ASSOCIATED GENES

Sequence analyses of the nucleoprotein (N), phosphoprotein (P), matrixprotein (M) and fusion protein (F) genes of MPV revealed the highest degree of sequence homology with APV serotype C, the avian pneumovirus found primarily in birds in the United States. These analyses also revealed the absence of non-structural proteins NS1 and NS2 at the 3'end of the viral genome and positioning of the fusion protein immediately adjacent to the matrix protein.

The sequences of the 22K (M2) gene, the small hydrophobic (SH) gene, the attachment (G) gene, the polymerase (L) gene, the intergenic regions, and the trailer sequences were determined. In combination with the sequences described previously, the sequences presented here completed the genomic sequence of MPV with the exception of the extreme 12-15 nucleotides of the genomic termini and establish the genomic organization of MPV. Side by side comparisons of the sequences of the MPV genome with those of APV subtype A, B and C, RSV subtype A and B, PVM and other paramyxoviruses provides strong evidence for the classification of MPV in the *Metapneumovirus* genus.

GENE ENCODING THE NUCLEOPROTEIN (N): As shown above, the first gene in the genomic map of MPV codes for a 394 amino acid (aa) protein and shows extensive homology with the N protein of other pneumoviruses. The length of the N ORF is identical to the length of the N ORF of APV-C (Table 5) and is smaller than those of other paramyxoviruses (Barr *et al.*, 1991, J Gen Virol 72:677 - 85). Analysis of the amino acid sequence revealed the highest homology with APV-C (88%), and only 7-11% with other paramyxoviruses (Table 6).

Three regions of similarity between viruses belonging to the order Mononegavirales were identified: A, B and C (Figure 22) (Barr *et al.*, 1991, J Gen Virol 72: 677 - 85). Although similarities are highest within a virus family, these regions are highly conserved between virus families observed. In all three regions MPV revealed 97% aa sequence identity with APV-C, 89% with APV-B, 92% with APV-A, and 66-73% with RSV and PYM. The region between aa residues 160 and 340 appears to be highly conserved among metapneumoviruses and to a somewhat lesser extent the *Pneumovirinae* (Miyahara *et al.*, 1991, Arch Viral 124:255-68; Li *et al.*, 1996, Virus Res 41:185-91; Barr, 1991, J Gen Virol 72:677-85).

GENE ENCODING THE PHOSPHOPROTEIN (P): The second ORF in the genome map codes for a 294 aa protein which shares 68% aa sequence homology with the P protein of APV-C, and only 22-26% with the P protein of RSV (Table 7). The P gene of MPV contains one substantial ORF and in that respect is similar to P from many other paramyxoviruses (Reviewed in Lamb *et al.*, Fields virology, (B. N. Knipe, Hawley, P.M., ed., LippencottRaven), Philadelphia, 1996; Sedlmeier *et al.*, 1998, Adv Virus Res 50:101-39).

In contrast to APV A and B and PVM and similar to RSV and APV-C the MPV P ORF lacks cysteine residues. A region of high similarity between all pneumoviruses (amino acids 185-241) plays a role in either the RNA synthesis process or in maintaining the structural integrity of the nucleocapsid complex (Ling *et al.*, 1995, Virus Res 36:247-57). This region of high similarity is also found in MPV (Figure 6) especially when conservative substitutions are taken into account, showing 100% similarity with APYC, 93 % with APV-A and B, and approximately 81% with RSV. The C-terminus of the MPV P protein is rich in glutamate residues as has been described for APVs (Ling, *et al.*, 1995, Virus Res 36:247-57).

GENE ENCODING THE MATRIX (M) PROTEIN: The third ORF of the MPV genome encodes a 254 aa protein, which resembles the M ORFs of other pneumoviruses. The M ORF of MPV has exactly the same size as the M ORFs of other metapneumoviruses and shows high aa sequence homology with the matrix proteins of APV (78-87%), lower homology with those of iRSV and PVM (37-38%), and 10% or less homology with those of other paramyxoviruses (Table 6).

The sequences of matrix proteins of all pneumoviruses were compared and a conserved heptadpeptide at residue 14 to 19 was found to also conserved in MPV (Figure 7) (Easton *et al.* 1997, Virus Res, 48:27-33). For RSV, PVM and APV, small secondary ORFs within or overlapping with the major ORF of M have been identified (52 aa and 51 aa in bRSV, 75 aa in RSV, 46 aa in PVM and 51 aa in APV) (Yu *et al.*, 1992, Virology 186:426-34; Easton *et al.*, 1997, Virus Res 48:27-33; Samal *et al.*, 1991, J Gen Virol 72:715-20; Satake *et al.*, 1995, J Virol 50:92-9). One small ORF of 54 aa residues was found within the major M ORF (fragment 1, Figure 8), starting at nucleotide 2281 and one small ORF of 33 aa residues was found overlapping with the major ORF of M starting at nucleotide 2893 (fragment 2, Figure 8). Similar to the secondary ORFs of RSV and APV there is no significant homology between these secondary ORFs and secondary ORFs of the other pneumoviruses, and apparent start or stop signals are lacking. Furthermore, there have not been any report of protein synthesis occurring from these secondary ORFs.

GENE ENCODING THE FUSION PROTEIN: The F ORF of MPV is located adjacent to the M ORF, a feature that is characteristic of members of the *Metapneumovirus* genus. The

F gene of MPV encodes a 539 aa protein, which is two aa residues longer than F of APV-C. Analysis of the aa sequence revealed 81% homology with APV-C, 67% with APV-A and B, 33-39% with pneumovirus F proteins and only 10-18% with other paramyxoviruses (Table 6). One of the conserved features among F proteins of paramyxoviruses, and also seen in MPV is the distribution of cysteine residues (Morrison *et al.*, 1988, Virus Res 10:113-35; Yu *et al.*, 1991, J. Gen Virol 72:75-81). The metapneumoviruses share 12 cysteine residues in E1 (7 are conserved among all paramyxoviruses), and two in E2 (1 is conserved among all paramyxoviruses). Of the 3 potential N-linked glycosylation sites present in the F ORF of MPV, none are shared with RSV and two (position 74 and 389) are shared with APV. The third, unique, potential N-linked glycosylation site for MPV is located at position 206 (Figure 9).

Despite the low sequence homology with other paramyxoviruses, the F protein of MPV revealed typical fusion protein characteristics consistent with those described for the F proteins of other Paramyxoviridae family members (Morrison *et al.*, 1988, Virus Res 10:113-35). F proteins of Paramyxoviridae members are synthesized as inactive precursors (F0) that are cleaved by host cell proteases which generate amino terminal E2 subunits and large carboxy terminal F1 subunits. The proposed cleavage site (Collins *et al.*, Fields virology, (B. N. Knipe, Howley, P.M., ed., Lippencott-Raven), Philadelphia, 1996) is conserved among all members of the Paramyxoviridae family. The cleavage site of MPV contains the residues RQSR. Both arginine (R) residues are shared with APV and RSV, but the glutamine (Q) and serine (S) residues are shared with other paramyxoviruses such as human parainfluenza virus type 1, Sendai virus and morbilliviruses.

The hydrophobic region at the amino terminus of F1 is thought to function as the membrane fusion domain and shows high sequence similarity among paramyxoviruses and morbilliviruses and to a lesser extent the pneumoviruses (Morrison *et al.*, 1988, Virus Res 10:113-35). These 26 residues (position 137-163, Figure 9) are conserved between MPV and APV-C, which is in agreement with this region being highly conserved among the metapneumoviruses (Naylor *et al.*, 1998, J. Gen Virol 79:1393 - 1398; Seal *et al.*, 2000, Virus Res 66:139-47).

As is seen for the F2 subunits of APV and other paramyxoviruses, MPV revealed a deletion of 22 aa residues compared with RSV (position 107-128, Figure 9). Furthermore, for

RSV and APV, the signal peptide and anchor domain were found to be conserved within subtypes and displayed high variability between subtypes (Plows *et al.*, 1995, *Virus Genes* 11:37-45; Naylor *et al.*, 1998, *J. Gen Virol* 79:1393-1398). The signal peptide of MPV (aa 10-35, Figure 9) at the amino terminus of F2 exhibits some sequence similarity with APV-C (18 out of 26 aa residues are similar), and less conservation with other APVs or RSV. Much more variability between subtypes is seen in the membrane anchor domain at the carboxy terminus of E1, although some homology is still seen with APV-C.

GENE ENCODING THE M2 PROTEIN: The M2 gene is unique to the *Pneumovirinae* and two overlapping ORFs have been observed in all pneumoviruses. The first major ORF represents the M2-1 protein which enhances the processivity of the viral polymerase (Collins *et al.*, 1995, *Proc Natl Acad Sci U S A* 92:11563-7; Collins *et al.*, *Fields virology* (B. N. Knipe, Howley, P.M., ed., Lippencott-Raven), Philadelphia, 1996) and its readthrough of intergenic regions (Hardy *et al.*, 1998, *J Virol* 72:520-6; Fearn *et al.*, 1999, *J Virol* 73:5852-64). The M2-1 gene for MPV, located adjacent to the F gene, encodes a 187 aa protein, and reveals the highest (84%) homology with M2-1 of APV-C. Comparison of all pneumovirus M2-1 proteins revealed the highest conservation in the amino-terminal half of the protein (Collins *et al.*, 1990, *J. Gen Virol* 71:3015-20; Zamora *et al.*, 1992, *J. Gen Virol* 73:737-41; Ahmadian *et al.*, 1999, *J. Gen Virol* 80:2011-6), which is in agreement with the observation that MPV displays 100% similarity with APV-C in the first 80 aa residues of the protein (Figure 10). The MPV M2-1 protein contains 3 cysteine residues located within the first 30 aa residues that are conserved among all pneumoviruses. Such a concentration of cysteines is frequently found in zinc-binding proteins (Cuesta *et al.*, 2000, *Gen Virol*:74, 9858-67).

The secondary ORFs (M2-2) that overlap with the M2-1 ORFs of pneumoviruses are conserved in location but not in sequence and are thought to be involved in the control of the switch between virus RNA replication and transcription (Collins *et al.*, 1985, *J Virol* 54:65-71; Elango *et al.*, 1985, *J Virol* 55:101-10; Baybutt *et al.*, 1987, *J Gen Virol* 68:2789-96; Collins *et al.*, 1990, *J. Gen Virol* 71:3015-20; Ling *et al.*, 1992, *J. Gen Virol* 73:1709-15; Zamora *et al.*, 1992, *J. Gen Virol* 73:737-41; Alansari *et al.*, 1994, *J. Gen Virol*:75:401-404; Ahmadian *et al.*, 1999, *J. Gen Virol* 80: 2011-6). For MPV, the M2-2 ORF starts at nucleotide 512 in the M2-1 ORF (Figure 8), which is exactly the same start position as for APV-C. The length of the M2-2 ORFs are the same for APV-C and MPV, 71 aa residues. Sequence comparison of the

M2-2 ORF (Figure 10) revealed 64% aa sequence homology between MPV and APV-C and only 44-48% aa sequence homology between MPV and APV-A and B.

SMALL HYROPHOBIC (SH) GENE ORF: The gene located adjacent to M2 of hMPV probably encodes a 183 aa SH protein (Figure 8). There is no discernible sequence identity between this ORF and other RNA virus genes or gene products. This is not surprising since sequence similarity between pneumovirus SH proteins is generally low. The aa composition of the SH ORF is relatively similar to that of APV, RSV and PVM, with a high percentage of threonine and serine residues (22%, 18%, 19%, 20.0%, 21% and 28% for hMPV, APV, RSV A, RSV B, bRSV and PVM respectively). The SH ORF of hMPV contains 10 cysteine residues, whereas APV SH contains 16 cysteine residues. The SH ORF of hMPV contains two potential *N*-linked glycosylation sites (aa 76 and 121), whereas APV has one, RSV has two or three and PVM has four.

The hydrophilicity profiles for the putative hMPV SH protein and SH of APV and RSV revealed similar characteristics (Figure 11B). The SH ORFs of APV and hMPV have a hydrophilic *N*-terminus, a central hydrophobic domain which can serve as a potential membrane spanning domain (aa 30-53 for hMPV), a second hydrophobic domain (aa 155-170) and a hydrophilic C-terminus. In contrast, RSV SH appears to lack the C-terminal part of the APV and hMPV ORFs. In all pneumovirus SH proteins the hydrophobic domain is flanked by basic aa residues, which are also found in the SH ORF for hMPV (aa 29 and 54).

GENE ENCODING THE ATTACHMENT GLYCOPROTEIN (G): The putative G ORF of hMPV is located adjacent to the putative SH gene and encodes a 236 aa protein (nt 6262-6972, Figure 8). A secondary small ORF is found immediately following this ORF, potentially coding for 68 aa residues (nt 6973-7179) but lacking a start codon. A third potential ORF in the second reading frame of 194 aa residues is overlapping with both of these ORFs but also lacks a start codon (nt 6416-7000). This ORF is followed by a potential fourth ORF of 65 aa residues in the same reading frame (nt 7001-7198), again lacking a start codon. Finally, a potential ORF of 97 aa residues (but lacking a start codon) is found in the third reading frame (nt 6444-6737, Figure 8). Unlike the first ORF, the other ORFs do not have apparent gene start or gene end sequences (see below). Although the 236 aa G ORF probably

represents at least a part of the hMPV attachment protein it can not be excluded that the additional coding sequences are expressed as separate proteins or as part of the attachment protein through some RNA editing event. It should be noted that for APV and RSV no secondary ORFs after the primary G ORF have been identified but that both APV and RSV have secondary ORFs within the major ORF of G. However, evidence for expression of these ORFs is lacking and there is no sequence identity between the predicted aa sequences for different viruses (Ling *et al.*, 1992, J Gen Virol 73:1709-15). The secondary ORFs in hMPV G do not reveal characteristics of other G proteins and whether the additional ORFs are expressed requires further investigation.

BLAST analyses with all ORFs revealed no discernible sequence identity at the nucleotide or aa sequence level with other known virus genes or gene products. This is in agreement with the low percentage sequence identity found for other G proteins such as those of hRSV A and B (53%) (Johnson *et al.*, 1987, J Virol 61:163-6) and APV A and B (38%) (Juhasz and Easton, 1994, J Gen Virol 75:2873-80).

Whereas most of the hMPV ORFs resemble those of APV both in length and sequence, the putative G ORF of 236 aa residues of hMPV is considerably smaller than the G ORF of APV (Table 4). The aa sequence revealed a serine and threonine content of 34%, which is even higher than the 32% for RSV and 24% for APV. The putative G ORF also contains 8.5% proline residues, which is higher than the 8% for RSV and 7% for APV. The unusual abundance of proline residues in the G proteins of APV, RSV and hMPV has also been observed in glycoproteins where it is a major determinant of the proteins three dimensional structure (Collins and Wertz, 1983, PNAS 80:3208-12; Wertz *et al.*, 1985, PNAS 82:4075-9; Jentoft, 1990, Trends Biochem Sci 15:291-4.). The G ORF of hMPV contains five potential *N*-linked glycosylation sites, whereas hRSV has seven, bRSV has five and APV has three to five.

The predicted hydrophilicity profile of hMPV G revealed characteristics similar to the other pneumoviruses. The *N*-terminus contains a hydrophilic region followed by a short hydrophobic area (aa 33-53 for hMPV) and a mainly hydrophilic C-terminus (Figure 12B). This overall organization corresponds well with regions in the G protein of APV and RSV. The putative G ORF of hMPV contains only 1 cysteine residue in contrast to RSV and APV (5 and 20 respectively). Of note, only two of the four secondary ORFs in the G gene contained

one additional cysteine residue and these four potential ORFs revealed 12-20% serine and threonine residues and 6-11% proline residues.

POLYMERASE GENE (L): In analogy to other negative strand viruses, the last ORF of the MPV genome is the RNA-dependent RNA polymerase component of the replication and transcription complexes. The L gene of MPV encodes a 2005 aa protein, which is one residue longer than the APV-A protein (Table 5). The L protein of MPV shares 64% homology with APV-A, 42-44% with RSV, and approximately 13% with other paramyxoviruses (Table 6). Six conserved domains within the L proteins of non-segmented negative strand RNA viruses were identified; it was found that the domain three contained the four core polymerase motifs that are thought to be essential for polymerase function (Poch *et al.*, 1990, J Gen Virol 71:1153-62; Poch *et al.*, 1989, EMBO J 8:3867-74). These motifs (A, B, C and D) are well conserved in the MPV L protein: in motifs A, B and C: MPV shares 100% similarity with all pneumoviruses and in motif D MPV shares 100 % similarity with APV and 92% with RSVs. For all of domain III (aa 627- 903 in the L ORF), MPV shares 77% identity with APV, 61-62% with RSV and 23-27% with other paramyxoviruses (Figure 13). In addition to the polymerase motifs the pneumovirus L proteins contain a sequence which conforms to a consensus ATP binding motif K(X)₂₁GEGAGN(X)₂₀K (Stec *et al.*, 1991, Virology 183:273-87). The MPV L ORF contains a similar motif as APV, in which the spacing of the intermediate residues is shifted by one residue: K(X)₂₂GEGAGN(X)₁₉K.

TABLE 5: LENGTHS OF THE ORFs OF MPV AND OTHER PARAMYXOVIRUSES

	N ^I	P	M	F	M2-1	M2-2	SH	G	L
MPV	394	294	254	539	187	71	183	236	2005
APV A	391	278	254	538	186	73	174	391	2004
APV B	391	279	254	538	186	73	**	414	**
APV C	394	294	254	537	184	71	**	**	**
APV D	**	**	**	**	**	**	**	389	**
hRSVA	391	241	256	574	194	90	64	298	2165
hRSV B	391	241	249	574	195	93	65	299	2166

	N ¹	P	M	F	M2-1	M2-2	SH	G	L
bRSV	391	241	256	569	186	93	81	257	2162
PVM	393	295	257	537	176	77	92	396	**
others ³	418- 542	225- 709	335-393	539-565	****	****	****	****	2183- 2262

Legend for Table 5: * = length in amino acid residues, ** = sequences not available, *** = others: human parainfluenza virus type 2 and 3, Sendai virus, measles virus, nipah virus, phocine distemper virus, and New Castle Disease virus, **** = ORF not present in viral genome.

TABLE 6: AMINO ACID SEQUENCE IDENTITY BETWEEN THE ORFs
OF MPV AND THOSE OF OTHER PARAMYXOVIRUSES

	N	P	M	F	M2-1	M2-2	L
APV A	69	55	78	67	72	26	64
APV B	69	51	76	67	71	27	**
APV C	88	68	87	81	84	56	**
hRSVA	42	24	38	34	36	18	42
hRSV B	41	23	37	33	35	19	44
bRSV	42	22	38	34	35	13	44
PVM	45	26	37	39	33	12	**
others ³	7-11	4-9	7-10	10-18	****	****	13-14

Legend for Table 6: * = No sequence homologies were found with known G and SH proteins and were thus excluded, ** = Sequences not available, *** = See list in table 4, denoted by same (***), **** = ORF absent in viral genome.

6.5 EXAMPLE 5: GENOMIC SEQUENCING OF HMPV ISOLATE 1-99

Another isolate of hMPV (1-99) was also identified and sequenced. In order to do so, the hMPV isolate 1-99 was propagated on tertiary monkey kidney cells exactly as described before (van den Hoogen *et al.*, 2001, Nature Medicine 7(6):719-724). Viral RNA was isolated using the MagnaPure LC isolation system (Roche Applied Science) and the total nucleic acid kit protocol. RNA was converted into cDNA using standard protocols, with random hexamers

(Progenia Inc. Leiden) as primers. This cDNA was kept at -20°C or lower until used for sequence analysis. Primers used throughout this project were based on the sequences available from the prototype hMPV 1-00 strain, or obtained after sequence analysis using the hMPV strain 1-99.

PCR fragments were made ranging in size up to 1600 base-pairs to generate overlapping fragments. Sequence analysis was performed on the PCR fragments using standard technology and an ABI 3100 capillary sequence instrument (Applied Biosystems, Nieuwerkerk Issel). The nucleotide sequences generated were compared initially with the prototype hMPV strain 1-00 for comparison. Blast software was used for comparison with related sequences in the GenBank database. For further analysis of the sequences, DNASTAR software was used (DNASTAR Inc, Madison WI, U.S.A.) and for phylogenetic analysis, the ClustalW software program was used.

Initially, sequences for the 1-99 isolate were obtained using primers that were designed based on sequence information from the 1-00 isolate. However, since some parts of the genome could not be sequenced based on the information from the 1-00 isolate, new primers based on sequence information from the 1-99 isolate, as well from information made available through the sequencing of the 3' and 5' end of the 1-00 isolate, were used.

The prototype sequence of the hMPV isolate 1-99 contained 13,223 base-pairs, sequenced in a total of 227 individual sequences, with an average length of 404 base-pairs. The sequence is SEQ ID NO:18.

The length of the open reading frames of hMPV 1-99 and other Paramyxoviruses, both in absolute size and percentage amino acid identity are shown in Table 7.

Most identity between the 1-99 and 1-00 strains was observed in the genes coding for N protein (95.2%), M (97.3%), F (93.7%), L (94.1%) and M2-1 (94.1%) with percentages homology of over 90%. The homology of the P and M2-2 genes between both strains was found to be 86.1 and 88.9% respectively. Also, the isolate is mostly related to the subtype C of the avian Metapneumovirus, with amino acid identities in the N protein (88.6%), M protein (87.1%) and M2-1 protein (84.3%). The identity with the P and M2-2 proteins is lower at 67.8% and 56.9% respectively.

The genes of the prototype 1-00 and 1-99 strains are identical on the genomic map, with the same number of amino acids for N, P, M, F, M21 and M2-2 protein. The putative SH

gene is 6 amino acids shorter, the G protein is 12 amino acids shorter, and the L gene of the 1-00 and 1-99 strain are the same size.

Finally, the start of the genes on the genomic map and the non-coding sequences located between the genes, have been summarized in Table 8.

In summary, the sequence information of the 1-99 strain of the human Metapneumovirus clearly demonstrates the genetic relation of 1-99 with the prototype strain 1-00, sharing identical genomic map organization. Less phylogenetic relation is observed with the subtype C of APV.

TABLE 7:

LENGTH OF THE ORFS OF HMPV 1-99 AND OTHER PARAMYXOVIRUSES (NO. OF AMINO ACID RESIDUES)									
	N	P	M	F	M21	M22	SH	G	L
1-99	394	294	254	539	187	71	177	224	1937
1-00	394	294	254	539	187	71	183	236	2005
APV-A	391	278	254	538	186	73	174	391	2004
APV-B	391	279	254	538	186	73		414	
APV-C	394	294	254	537	184	71			
hRSV-A	391	241	256	574	194	90	64	298	2165
hRSV-B	391	241	256	574	195	90	65	299	2166
bRSV	391	241	256	574	186	90	81	257	2162
PVM	393	295	257	537	176	98	92	396	

PERCENTAGE OF THE AMINO ACID SEQUENCE IDENTITY BETWEEN HMPV 1-99 AND OTHER PARAMYXOVIRUSES									
	N	P	M	F	M21	M22	SH	G	L
1-00	95,2	86,1	97,3	93,7	94,1	88,9	59	32,4	94,1
APV-A	68,9	58,1	76,1	67,5	69	25	13,1	14,2	63,7
APV-B	69,1	53,9	76,5	66,8	65,8	26,4			
APV-C	88,6	67,8	87,1	80,5	84,3	56,9			
bRSV	41,1	28,1	36,9	35	32,6	9,7	12,2	15,6	46,5
hRSV-A	41,1	26	37,6	32,2	35,6		6,2	16	46,9
hRSV-B	40,6	26	36,9	34,4	34	13,9	21,2	15,6	47
PVM	43,7	22,4	39,2	38,8			5,4	8	

TABLE 8: SUMMARY OF GENE START SEQUENCES ON THE GENOMIC MAP AND THE NON-CODING SEQUENCES LOCATED BETWEEN THE GENES.

Pos.	ORF	Stop	Non-coding sequence	Gene start	Start	Pos	ORF
1	Le		ACGAGAAAAAACGCGUAUAAUUAUU UCCAAACAAAAC	GGGACAAAUAAAA	AUG	54	N
1238	N	UAA	UUAAAAACU	GGGACAAGUCAAA	AUG	1262	P
2146	P	UAG	UUUAAUAAAAUAAACAAU	GGGACAAGUCAAG	AUG	2179	M
2943	M	UAA	AAUUAACUGUCUUAUCAUAAUUGCUU AUUAACUCUAG AGAUUAAUAAGCUUAUUUUUAUAGUUU AUAAAAUAAU UAGAAUUAGAAGGGCAUCAUAGAAAGC	GGGACAAAUAAAA	AUG	3065	F
4684	F	UAG	UUAAUUAAAAAU	GGGACAAAUCAUC	AUG	4711	M2
5437	M2	UAG	UAAAAAUAAAAUAGAAU	GGGAUAAUUGACA	AUG	5470	SH
6003	SH	UAA	AAUAACACGGSUUUSAACAUUAAAAUSA GAACAACCUCCA CCCAGGUCUAUCAUACAGUGGUUUAG CCAUUUAAAAACC GAAUAUUUUCUAGGCUGCACGACACUUU GCAUUAUAUGC AAUAGUCAAUAGUUAAACCACUGCUGCA AACUCAUCCAUA AUUAUACACUGAGUAAUACAAAACAAG AAAAU	GGGACAAGUGGCU	AUG	6210	G
6884	G	UAG	AGAGGUGCAAAACUCAAUUGAGCACAAC ACACAAACAUYC CAUCCAAGUAGUUAACAAAAAACACAA AAUAACCUUGAA AACCAAAAAACCAAAACAUAAACCCAGA CCCAGAAAAACA UAGACACCAUAUGGAAGGUUCUAGCAUA UGCACCAUUGAG AUGGCAUCUGUUCAUGUAUCAUAGCAC CACCAUCAUUCA AGGAAUAAGAAGAGGCGAAAAUUUAA	GGGAUAAUUGACA	AUG	7124	L
13009	L	UGA	AUUAAACUAUGAUUUCUUUGAAGCAUUA GAGAACACAUAC CCCAUAUGAUCAAGCUUAUAGAUAAUU UGGGAAAUGCAG AAUUAAGAAACUAAUCMAGGUCMCUG GGUAUAUGCUUGU GAGUAAGAAGUAAUAAUAAUGAUAAUGA UUAACCAUAAUC UCMCMCMACUGAGAAAAUAAUCGUCUA ACAGUUUAGUUGA UCAUUAGUUUUUUAAAAUUUAAAAUAG UAACUA		AUG	13243	Tr

6.6 EXAMPLE 6: PHYLOGENETIC RELATIONSHIPS

Phylogenetic approaches can be used in order to identify the relationships among groups of viruses, i.e. between MPV and other viruses. Additionally, phylogenetic relationships can be determined for different isolates of the same type of virus. Phylogenetic trees were determined to determine relationships between MPV and other viruses, and also to determine relationships between the different isolates of hMPV. For example, phylogenetic trees can be generated, using nucleotide or protein sequence data, in order to illustrate the relationship between MPV and different viruses. Alternatively, phylogenetic trees can be generated, using nucleotide or protein sequence data, in order to illustrate the relationship between various isolates of hMPV.

PHYLOGENETIC RELATIONSHIPS BETWEEN HMPV AND DIFFERENT VIRUSES: Although BLAST searches using nucleotide sequences obtained from the unidentified virus isolates revealed homologies primarily with members of *Pneumovirinae*, homologies that were based on protein sequences revealed some resemblance with other paramyxoviruses as well. As an indication of the relationship between the newly identified virus isolates and members of *Pneumovirinae*, phylogenetic trees were constructed based on the N, P, M and F ORFs of these viruses. In all four phylogenetic trees, the newly identified virus isolate was most closely related to APV (Figure 14). From the four serotypes of APV that have been described (Bayon-Auboyer *et al.*, 2000, J Gen. Virol 81:2723-2733), APV serotype C, the metapneumovirus found primarily in birds in the USA, showed the closest resemblance to the newly identified virus. It should be noted however, that only partial sequence information for APV serotype D is available.

For all phylogenetic trees, DNA sequences were aligned using the ClustalW software package and maximum likelihood trees were generated using the DNA-ML software package of the Phylip 3.5 program using 50 or 100 bootstraps and 3 jumbles (Brandenburg *et al.*, 1997, J Med Virol 52:97-104). Previously published sequences that were used for the generation of phylogenetic trees are available from Genbank under accessions numbers : For all ORFs: hRSV: NC001781; bRSV: NC001989; For the F ORF: PYM, D11128; MV-A, D00850; MV-B, Y14292; MV-C, AF187152; For the N ORF: PVM, D10331; MV-A, U39295; MV-B, U39296; MV-C, M176590; For the M ORF: PMV, U66893; MV-A, X58639;

MV-B, U37586; MV-C, AE262571; For the P ORF: PVM, 09649; MV-A, U22110, MV-C, AF176591.

As an indicator of the relationship between MPV and members of the *Pneumovirinae*, phylogenetic trees based on the N, P, M, and F ORFs were constructed previously (van den Hoogen *et al.*, 2001, Nat Med 7(6):19-24) and revealed a close relationship between MPV and APV-C. Because of the low homology of the MPV SH and G genes with those genes of other paramyxoviruses, reliable phylogenetic trees for these genes cannot be constructed. In addition, the distinct genomic organization between members of the *Pneumovirus* and *Metapneumovirus* genera make it impossible to generate phylogenetic trees based on the entire genomic sequence. Trees for the M2 and L genes were constructed in addition to those previously published. Both these trees confirmed the close relation between APV and MPV within the *Pneumovirinae* subfamily (Figure 15).

To construct phylogenetic trees, DNA sequences were aligned using the ClustalW software package and maximum likelihood trees were generated using the DNA-ML software package of the Phylip 3.5 program using 100 bootstraps and 3 jumbles. Bootstrap values were computed for consensus trees created with the PHYLIP consensus package.

Based upon phylogenetic analyses of the different isolates of hMPV obtained so far, two major genotypes have been identified with virus isolate 00-1 being the prototype of genotype A and isolate 99-1 the prototype of genotype B.

It is hypothesized that the genotypes are related to subtypes and that re-infection with viruses from both subgroups occur in the presence of pre-existing immunity and the antigenic variation may not be strictly required to allow re-infection. Furthermore, hMPV appears to be closely related to avian pneumovirus, a virus primarily found in poultry. The nucleotide sequences of both viruses show high percentages of homology, with the exception of the SH and G proteins. The viruses appear to cross-react in tests that are based primarily on the nucleoprotein and matrixprotein, however, they respond differently in tests that are based on the attachment proteins. The differences in virus neutralization titer provide further proof that the two genotypes of hMPV are two different serotypes of one virus, where APV is a different virus.

PHYLOGENETIC RELATIONSHIPS BETWEEN DIFFERENT HMPV ISOLATES:

Phylogenetic approaches can also be used in order to identify the relationships among different isolates of MPV. For example, phylogenetic trees can be generated, using nucleotide or protein sequence data of MPV, in order to illustrate the relationship between a number of MPV isolates that are obtained from different subjects. This approach is useful in understanding the differences that occur within the population of MPV viruses.

To determine the relationship of our various newly identified virus isolates, phylogenetic trees were constructed based on sequence information obtained from eight to nine isolates (8 for F, 9 for N, M and L). RT-PCR was used with primers designed to amplify short fragments in the N, M, F, P, SH and L ORFs, that were subsequently sequenced directly. The nine virus isolates that were previously found to be related in serological terms (see above) were also found to be closely related genetically. In fact, all nine isolates were more closely related to one another than to APV. Although the sequence information used for these phylogenetic trees was limited, it appears that the nine isolates can be divided in two groups, with isolate 94-1, 99-1 and 99-2 clustering in one group and the other six isolates (94-2; 93-1; 93-2; 93-3; 93-4; 00-1) in the other (Figure 16).

An alignment of the F genes of different isolates of hMPV of all four variants, variant A1, A2, B1, or B2, is shown in Figure 17.

An alignment of the F proteins of different isolates of hMPV of all four variants, variant A1, A2, B1, or B2, is shown in Figure 18.

An alignment of the G genes of different isolates of hMPV of all four variants, variant A1, A2, B1, or B2, is shown in Figure 19.

An alignment of the G proteins of different isolates of hMPV of all four variants, variant A1, A2, B1, or B2, is shown in Figure 20.

A phylogenetic tree based on the F gene sequences showing the phylogenetic relationship of the different hMPV isolates and their association with the respective variants of hMPV is shown in Figure 21. Further, a phylogenetic tree based on the G gene sequences showing the phylogenetic relationship of the different hMPV isolates and their association with the respective variants of hMPV is shown in Figure 22. The phylogenetic trees were calculated using DNA maximum likelihood with 50 bootstraps and 3 jumbles.

Sequence identities between different genes of hMPV isolate 00-1 with different genes of hMPV isolate 99-1, APV serotype C, and APV serotype A are listed in Table 9.

TABLE 9

ORF SEQUENCE IDENTITY BETWEEN HMPV
ISOLATE 00-1 AND OTHER VIRUSES

	N	P	M	F	M2.1	M2.2	SH	G	L
hMPV isolate 99-1	95	86	98	94	95	90	57	33	94
APV serotype C	88	68	87	81	84	56	N.A.	N.A.	N.A.
APV serotype A	69	55	78	68	72	25	18	9	64

Originally, phylogenetic relationships were inferred for only nine different isolates. Two potential genetic clusters were identified by analyses of partial nucleotide sequences in the N, M, F and L ORFs of virus isolates. Nucleotide identity of 90 - 100% was observed within a cluster, and 81-88% identity was observed between the clusters. Sequence information obtained on more virus isolates confirmed the existence of two genotypes. Virus isolate 00-1, as a prototype of cluster A, and virus isolate 99-1 as a prototype of cluster B, have been used in cross neutralization assays to test whether the genotypes are related to different serotypes or subgroups.

Using RT-PCR assays with primers located in the polymerase gene, thirty additional virus isolates were identified from nasopharyngeal aspirate samples. Sequence information of parts of the matrix and polymerase genes of these new isolates together with those of the previous nine isolates were used to construct phylogenetic trees (Figure 15). Analyses of these trees confirmed the presence of two genetic clusters, with virus isolate 00-1, as the prototype

virus in group A and virus isolate 99-1 as the prototype virus in group B. The nucleotide sequence identity within a group was more than 92%, while between the clusters the identity was 81-85%.

6.7 EXAMPLE 7: LEADER SEQUENCES OF HUMAN METAPNEUMOVIRUS (HMPV) NL/1/00 GENOMIC RNA

While the majority of genomic composition was determined, the authentic terminal sequences at the extreme ends were lacking. Using ligation of the viral RNA and subsequent PCR amplification of the ligated junction and a combination of polyadenylation and 3' RACE methods, the authentic nucleotide sequences were determined (Figure 54). The sequence analysis of PCR fragments generated by ligation of viral RNA ends revealed the Leader and Trailer sequences displayed in Figure 26 (See, SEQ IDs 18-21). The trailer sequences obtained this way were consistent with the sequences expected from the trailer sequences of other paramyxoviruses, including APV. However, the leader sequence of only 2 out of 71 clones sequenced, contained AC as the terminal nucleotide residues that are found in all paramyxoviruses to date. Therefore, the terminal nucleotide sequences of the hMPV/NL/1/00 leader were subsequently confirmed using a combination of polyadenylation and 3' RACE methods. Furthermore, two extra nucleotides at the 3' leader terminus of hMPV NL/1/00 were identified.

Vero-grown hMPV NL/1/00 virus was used in this study. As a control, a related negative sense RNA virus, respiratory syncytial virus (RSV) A2, that has a similar genomic size with identified terminal sequences, was included. Viral RNA was isolated using the QIAamp Viral RNA Mini Kit (Qiagen), following the manufacturer's instructions.

Viral RNA was polyadenylated by incubating the viral RNA with poly (A) polymerase (Ambion) at 37 °C for 1 hr, followed by clean up using a NucAway spin column (Ambion). The viral RNA was then reverse transcribed using a primer complementary to the poly (A) tail region and the reverse transcriptase, SuperscriptTM I (Invitrogen). PCR and Nested PCR reactions were carried out using hMPV specific primers, juxtaposed to the terminal ends, to amplify the desired products with expected sizes for sequencing analysis. PCR products were further cloned into pCRII vector using a TA cloning kit (Invitrogen). To reveal the authentic

nucleotide sequences for the terminus, direct sequencing of PCR DNA as well as the cloned PCR products were conducted.

Only hMPV data are shown in Figure 55. Control experiments, using RSV-A2 RNA, indicated that the leader sequences of RSV-A2 remained intact and detectible with the same approach. Sequencing analyses on PCR products directly (Figure 55) and on PCR clones both indicated that the leader region of hMPV consisted of 5' ACG CGA AAA AAA CGC GTA TA (expressed as positive sense cDNA orientation) at the 3' most proximal 20 nucleotides in the leader sequence. The two newly identified nucleotides are underlined in Figure 101.

6.8 EXAMPLE 8: SEROTYPING AND SUBGROUPING OF MPV ISOLATES

Virus neutralization assays (See, *e.g.*, Example 16) were used to determine if the virus isolates of hMPV could be distinguished by serotype or genotype. Virus isolates 00-1 and 99-1 were used to inoculate ferrets in order to raise virus-specific antisera. For the 00-1 isolate, ferret and guinea pig specific antisera for the virus were generated by experimental intranasal infection of two specific pathogen free ferrets and two guinea pigs, housed in separate pressurized glove boxes. Two to three weeks later all the animals were bled by cardiac puncture, and their sera were used as reference sera. The sera were tested for all previous described viruses with indirect IFA as described below. These antisera, along with antisera prepared using the 99-1 isolate, were used in virus neutralization assays with both viruses (Table 10).

TABLE 10: VIRUS NEUTRALIZATION TITERS

	ISOLATE 00-1	ISOLATE 99-1
PRESERUM FERRET A (00-1)	2	2
FERRET A 22 DPI (00-1)	64	2
PRESERUM FERRET B (99-1)	2	2
FERRET B 22 DPI (99-1)	4	64

For isolate 00-1 the titer differs 32 (64/2) fold
 For isolate 99-1 the titer differs 16 (64/4) fold

In addition, six guinea pigs were inoculated with either one of the viruses, *i.e.*, 00-1 and 99-1). RT-PCR assays on nasopharyngeal aspirate samples showed virus replication from day 2 through day 10 post infection. At day 70 post infection the guinea pigs were challenged with either the homologous or the heterologous virus, and in all four cases virus replication was noticed.

Virus neutralization assays with anti sera after the first challenge showed essentially the same results as in the VN assays performed with the ferrets (> 16-fold difference in VN titer).

The results presented in this example confirm the existence of two genotypes, that correspond to two serotypes of MPV, and show the possibility of repeated infection with heterologous and homologous virus (Table 11).

Table 11

	primary infection	virus replication	secondary infection	virus replication
guinea pig 1-3	00-1	2 out of 3	99-1	1 out of 2
guinea pig 4-6	00-1	3 out of 3	00-1	1 out of 3
guinea pig 7-9	99-1	3 out of 3	00-1	2 out of 2
guinea pig 10-12	99-1	3 out of 3	99-1	1 out of 3
Note: for the secondary infection guinea pig 2 and 9 were not there any more.				

7. DIAGNOSTIC ASSAYS/DETECTION METHODS

7.1 EXAMPLE 9: DIRECT IMMUNOFLUORESCENCE ASSAY (DIF) METHOD

Nasopharyngeal aspirate samples from patients suffering from RTI were analyzed by DIF as described (Rothbarth *et. al.*, 1999, J. of Virol. Methods 78:163-169). Samples were stored at -70°C. In short, nasopharyngeal aspirates were diluted with 5 ml Dulbecco MEM (BioWhittaker, Walkersville, MD) and thoroughly mixed on a vortex mixer for one minute.

The suspension was centrifuged for ten minutes at 840 x g. The sediment was spread on a multispot slide (Nutacon, Leimuiden, The Netherlands) and the supernatant was used for virus isolation. After drying, the cells were fixed in acetone for one minute at room temperature. After the slides were washed, they were incubated for 15 minutes at 37°C with commercially available FITC-labeled anti-sera specific for viruses such as influenza A and B, hRSV and hPIV 1 to 3 (Dako, Glostrup, Denmark). After three washings in PBS and one in tap water, the slides were submerged in a glycerol/PBS solution (Citifluor, UKO, Canterbury, UK) and covered. The slides were then analyzed using a Axioscop fluorescence microscope.

7.2 EXAMPLE 10: VIRUS CULTURE OF MPV

The detection of the virus in a cultivated sample from a host is a direct indication of the host's current and/or past exposure or infection with the virus.

Samples that displayed CPE after the first passage were used to inoculate sub-confluent mono-layers of tMK cells in media in 24 well plates. Cultures were checked for CPE daily and the media was changed once a week. Since CPE differed for each isolate, all cultures were tested at day 12 to 14 with indirect IFA using ferret antibodies against the new virus isolate. Positive cultures were freeze-thawed three times, after which the supernatants were clarified by low-speed centrifugation, aliquoted and stored frozen at -70°C. The 50% tissue culture infectious doses (TCID₅₀) of virus in the culture supernatants were determined as described (Lennette, D.A. *et al.* In: DIAGNOSTIC PROCEDURES FOR VIRAL, RICKETTSIAL, AND CHLAMYDIAL INFECTIONS, 7th ed. (eds. Lennette, E.H., Lennette, D.A. & Lennette, E.T.) 3-25; 37-138; 431-463; 481-494; 539-563 (American Public Health Association, Washington, 1995)).

7.3 EXAMPLE 11: ANTIGEN DETECTION BY INDIRECT IMMUNOFLUORESCENCE ASSAYS (IFA)

Antibodies can be used to visualize viral proteins in infected cells or tissues. Indirect immunofluorescence assay (IFA) is a sensitive approach in which a second antibody coupled to a fluorescence indicator recognizes a general epitope on the virus-specific antibody. IFA is more advantageous than DIF because of its higher level of sensitivity.

In order to perform the indirect IFA, collected specimens were diluted with 5 ml Dulbecco MEM medium (BioWhittaker, Walkersville, MD) and thoroughly mixed on a vortex mixer for one minute. The suspension was then centrifuged for ten minutes at 840 x g. The sediment was spread on a multispot slide. After drying, the cells were fixed in acetone for 1 minute at room temperature. Alternatively, virus was cultured on tMK cells in 24 well slides containing glass slides. These glass slides were washed with PBS and fixed in acetone for 1 minute at room temperature.

Two indirect IFAs were performed. In the first indirect IFA, slides containing infected tMK cells were washed with PBS, and then incubated for 30 minutes at 37°C with virus specific antisera. Monoclonal antibodies against influenza A, B and C, hPIV type 1 to 3, and hRSV were used. For hPIV type 4, mumps virus, measles virus, sendai virus, simian virus type 5, and New-Castle Disease virus, polyclonal antibodies (RIVM) and ferret and guinea pig reference sera were used. After three washings with PBS and one wash with tap water, the slides were stained with secondary antibodies directed against the sera used in the first incubation. Secondary antibodies for the polyclonal antisera were goat-anti-ferret (KPL, Guilford, UK, 40 fold diluted), mouse-anti-rabbit (Dako, Glostrup, Denmark, 20 fold diluted), rabbit-anti-chicken (KPL, 20 fold dilution) and mouse-anti-guinea pig (Dako, 20 fold diluted).

In the second IFA, after washing with PBS, the slides were incubated for 30 minutes at 37°C with 20 polyclonal antibodies at a dilution of 1:50 to 1:100 in PBS. Immunized ferrets and guinea pigs were used to obtain polyclonal antibodies, but these antibodies can be raised in various animals, and the working dilution of the polyclonal antibody can vary for each immunization. After three washes with PBS and one wash with tap water, the slides were incubated at 37°C for 30 minutes with FITC labeled goat-anti-ferret antibodies (KPL, Guilford, UK, 40 fold diluted). After three washes in PBS and one in tap water, the slides were included in a glycerol/PBS solution (Citifluor, UKO, Canterbury, UK) and covered. The slides were analyzed using an Axioscop fluorescence microscope (Carl Zeiss B.V., Weesp, the Netherlands).

7.4 EXAMPLE 12: HAEMAGGLUTINATION ASSAYS, CHLOROFORM SENSITIVITY TESTS AND ELECTRON MICROSCOPY

Different characteristics of a virus can be utilized for the detection of the virus. For example, many virus contain proteins that can bind to erythrocytes resulting in a lattice. This property is called hemagglutination and can be used in hemagglutination assays for detection of the virus. Virus may also be visualized under an electron microscope (EM) or detected by PCR techniques.

Hemagglutination assays and chloroform sensitivity tests were performed as described (Osterhaus *et al.*, 1985, *Arch.of Virol* 86:239-25; Rothbarth *et al.*, J of Virol Methods 78:163-169).

For EM analyses, virus was concentrated from infected cell culture supernatants in a micro-centrifuge at 4°C at 17000 x g, after which the pellet was resuspended in PBS and inspected by negative contrast EM.

7.5 EXAMPLE 13: DETECTION OF hMPV/AVP ANTIBODIES OF IgG, IgA AND IgM CLASSES

Specific antibodies to viruses rise during the course of infection/illness. Thus, detection of virus-specific antibodies in a host is an indicator of current and/or past infections of the host with that virus.

The indirect enzyme immunoassay (EIA) was used to detect the IgG class of hMPV antibodies. This assay was performed in microtitre plates essentially as described previously (Rothbarth *et al.*, 1999, J. of Vir. Methods 78:163-169). Briefly, concentrated hMPV was solubilized by treatment with 1% Triton X-100. After determination of the optimal working dilution by checkerboard titration, it was coated for 16 hr at room temperature into microtitre plates in PBS. Subsequently, 100 ul volumes of 1:100 diluted human serum samples in EIA buffer were added to the wells and incubated for 1 hour at 37°C. Binding of human IgG was detected by adding a goat anti-human IgG peroxidase conjugate (Biosource, USA), adding TMB as substrate developed plates and Optical Density (OD) was measured at 450 nm. The results were expressed as the S(ignal)/N(egative) ratio of the OD. A serum was considered positive for IgG if the S/N ratio was beyond the negative control plus three times the standard.

The hMPV antibodies of the IgM and IgA classes were detected in sera by capture EIA essentially as described previously (Rothbarth *et al.*, 1999, J Vir Methods 78:163-169). For the detection of IgA and IgM, commercially available microtiter plates coated with anti human

IgM or IgA specific monoclonal antibodies were used. Sera were diluted 1:100. After incubation of 1 hour at 37°C, an optimal working dilution of hMPV was added to each well (100 µl) before incubation for 1 hour at 37°C. After washing, polyclonal anti-hMPV antibody labeled with peroxidase was added, and the plate was incubated 1 hour at 37°C. Adding TMB as a substrate the plates were developed, and OD was measured at 450 nm. The results were expressed as the S(ignal)/N(egative) ratio of the OD. A positive result was indicated for IgG when the S/N ratio was beyond the negative control plus three times the standard.

AVP antibodies were detected in an AVP inhibition assay. The protocol for the APV inhibition test is included in the APV-Ab SVANOVIR® enzyme immunoassay that is manufactured by SVANOVA Biotech AB, Uppsala Science Park Glunten SE-751 83 Uppsala Sweden. The results were expressed as the S(ignal)/N(egative) ratio of the OD. A serum was considered positive for IgG, if the S/N ratio was beyond the negative control plus three times the standard.

7.6 EXAMPLE 14: DETECTION OF ANTIBODIES IN HUMANS, MAMMALS, RUMINANTS OR OTHER ANIMALS BY INDIRECT IFA

For the detection of virus specific antibodies, infected tMK cells with MPV were fixed with acetone on coverslips (as described above), washed with PBS and incubated 30 minutes at 37°C with serum samples at a 1 to 16 dilution. After two washes with PBS and one with tap water, the slides were incubated for 30 minutes at 37°C with FITC-labeled secondary antibodies to the species used (Dako). Slides were processed as described above.

Antibodies can be labeled directly with a fluorescent dye, which will result in a direct immunofluorescence assay. FITC can be replaced with any fluorescent dye.

7.7 EXAMPLE 15: DETECTION OF ANTIBODIES IN HUMANS, MAMMALS, RUMINANTS OR OTHER ANIMALS BY ELISA

In *Paramyxoviridae*, the N protein is the most abundant protein, and the immune response to this protein occurs early in infection. For these reasons, a recombinant source of the N proteins is preferably used for developing an ELISA assay for detection of antibodies to MPV. Antigens suitable for antibody detection include any MPV protein that combines with any MPV-specific antibody of a patient exposed to or infected with MPV virus. Preferred

antigens of the invention include those that predominantly engender the immune response in patients exposed to MPV, thus, typically are recognized most readily by antibodies of a patient. Particularly preferred antigens include the N, F, M and G proteins of MPV. Antigens used for immunological techniques can be native antigens or can be modified versions thereof. Well known techniques of molecular biology can be used to alter the amino acid sequence of a MPV antigen to produce modified versions of the antigen that may be used in immunologic techniques.

Methods for cloning genes, for manipulating the genes to and from expression vectors, and for expressing the protein encoded by the gene in a heterologous host are well-known, and these techniques can be used to provide the expression vectors, host cells, and the for expressing cloned genes encoding antigens in a host to produce recombinant antigens for use in diagnostic assays. *See e.g.*, MOLECULAR CLONING, A LABORATORY MANUAL AND CURRENT PROTOCOLS IN MOLECULAR BIOLOGY.

A variety of expression systems may be used to produce MPV antigens. For instance, a variety of expression vectors suitable to produce proteins in *E. Coli*, *B.subtilis*, yeast, insect cells, and mammalian cells have been described, any of which might be used to produce a MPV antigen suitable to detect anti-MPV antibodies in exposed patients.

The baculovirus expression system has the advantage of providing necessary processing of proteins, and is therefor preferred. The system utilizes the polyhedrin promoter to direct expression of MPV antigens. (Matsuura *et al.*, 1987, J. Gen.Virol. 68:1233-1250).

Antigens produced by recombinant baculo-viruses can be used in a variety of immunological assays to detect anti-MPV antibodies in a patient. It is well established that recombinant antigens can be used instead of natural virus in practically any immunological assay for detection of virus specific antibodies. The assays include direct and indirect assays, sandwich assays, solid phase assays such as those using plates or beads among others, and liquid phase assays. Assays suitable include those that use primary and secondary antibodies, and those that use antibody binding reagents such as protein A. Moreover, a variety of detection methods can be used in the invention, including colorimetric, fluorescent, phosphorescent, chemiluminescent, luminescent and radioactive methods.

For example, an indirect IgG EIA using a recombinant N protein (produced with recombinant baculo-virus in insect (Sf9) cells) as antigen can be performed. For antigen

preparation, Sf9 cells are infected with the recombinant baculovirus and harvested 3-7 days post infection. The cell suspension is washed twice in PBS, pH 7.2, adjusted to a cell density of 5.0×10^6 cells/ml, and freeze-thawed three times. Large cellular debris is pelleted by low speed centrifugation (500 x g for 15 minutes) and the supernatant is collected and stored at -70°C until use. Uninfected cells are processed similarly for negative control antigen.

Once the antigen is prepared, 100 µl of a freeze-thaw lysate is used to coat microtiter plates at dilutions ranging from 1:50 to 1:1000. An uninfected cell lysate is run in duplicate wells and serves as a negative control. After incubation overnight, plates are washed twice with PBS/0.05% Tween. Test sera are diluted 1:50 to 1:200 in ELISA buffer (PBS, supplemented to 2% with normal goat sera, and with 0.5% bovine serum albumin and 0.1% milk), followed by incubation wells for 1 hour at 37°C.

Plates are washed two times with PBS/0.05% Tween. Horseradish peroxidase labeled goat anti-human (or against other species) IgG, diluted 1:3000 to 1:5000 in ELISA buffer, is added to wells, and incubated for 1 hour at 37°C. The plates are then washed two times with PBS/0.05% Tween and once with tap water, incubated for 15 minutes at room temperature with the enzyme substrate TMB, 3,3',5,5' tetramethylbenzidine, such as that obtained from Sigma, and the reaction is stopped with 100 µl of 2 M phosphoric acid. Colorimetric readings are measured at 450 nm using an automated microtiter plate reader.

7.8 EXAMPLE 16: VIRUS NEUTRALIZATION ASSAY

When a subject is infected with a virus, an array of antibodies against the virus are produced. Some of these antibodies can bind virus particles and neutralize their infectivity. Virus neutralization assays (VN) are usually conducted by mixing dilutions of serum or monoclonal antibody with virus, incubating them, and assaying for remaining infectivity with cultured cells, embryonated eggs, or animals. Neutralizing antibodies can be used to define type-specific antigens on the virus particle, e.g., neutralizing antibodies could be used to define serotypes of a virus. Additionally, broadly neutralizing antibodies may also exist.

VN assays were performed with serial two-fold dilutions of human and animal sera starting at an eight-fold dilution. Diluted sera were incubated for one hour with 100 TCID₅₀ of virus before inoculation of tMK cells grown in 96 well plates, after which the plates were centrifuged at 840 x g. The media was changed after three and six days and IFA was

conducted with FTIC-labeled ferret antibodies against MPV 8 days after inoculation. The VN titre was defined as the lowest dilution of the serum sample resulting in negative IFA and inhibition of CPE in cell cultures.

7.9 EXAMPLE 17: RNA ISOLATION

The presence of viruses in a host can also be diagnosed by detecting the viral nucleic acids in samples taken from the host (See *e.g.*, RT-PCR in Example 18 and RAP-PCR in Example 19).

RNA was isolated from the supernatants of infected cell cultures or sucrose gradient fractions using a High Pure RNA Isolation kit, according to instructions from the manufacturer (Roche Diagnostics, Ahnere, The Netherlands). RNA can also be isolated following other procedures known in the art (*see, e.g.*, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, volume 1-3 (1994-1998). Ed. by Ausubel, F.M. *et al.*, Published by John Wiley and sons, Inc., USA).

7.10 EXAMPLE 18: RT-PCR TO DETECT/DIAGNOSE MPV

Detection of the virus in a biological sample can be done using methods that copy or amplify the genomic material of the virus. Virus-specific oligonucleotide sequences for RT-PCR assays on known paramyxoviruses are described below in this Example. A one-step RT-PCR was performed in 50 µl reactions containing 50 mM Tris.HCl pH 8.5, 50 mM NaCl, 4 mM MgCl₂, 2 mM dithiothreitol, 200 µM each dNTP, 10 units recombinant RNAsin (Promega, Leiden, the Netherlands), 10 units AMV RT (Promega, Leiden, The Netherlands), 5 units Amplitaq Gold DNA polymerase (PE Biosystems, Nieuwerkerk aan de IJssel, The Netherlands) and 5 µl RNA. Cycling conditions were 45 min. at 42°C and 7 min. at 95°C once, 1 min at 95°C, 2 min. at 42°C and 3 min. at 72°C repeated 40 times and 10 min. at 72°C once. Primers sequences are provided in the sequence listing. More specifically, the primers used for the nucleoprotein gene were N3 and N4, having nucleotide sequences corresponding to SEQ ID NOs:28 and 29 respectively, and were used to amplify a 151 nucleotide fragment. The primers used for the matrix protein gene were M3 and M4, having nucleotide sequences corresponding to SEQ ID NOs: 30 and 31 respectively, and were used to amplify a 252 nucleotide fragment. The primers used for the polymerase protein gene were L6

and L7, corresponding to SEQ ID NOs: 34 and 35 respectively, and were used to amplify a 173 nucleotide fragment. The primers used for the F protein gene were F7 and F8, corresponding to SEQ IS NOs: 32 and 33 respectively, and were used to amplify a 221 nucleotide fragment.

Furthermore, probes were used to confirm the presence of hMPV genome sequences. The probe used to detect the M gene had a nucleotide sequence corresponding to SEQ ID NO: 36. The probe used to detect the N gene had a nucleotide sequence corresponding to SEQ ID NO: 37. The probe used to detect the L gene had a nucleotide sequence corresponding to SEQ ID NO:38.

In another example, primers and probes can be designed based on MPV sequences that are known or obtained through sequencing. Likewise, different sequences of primers and difference buffer and assay conditions to be used for specific purposes would be known to one skilled in the art.

RT-PCR was used for the detection of known paramyxoviruses as well. Primers for hPIV-1 to 4, mumps, measles, Tupsia, Mapuera, and Hendra were developed in house and based on alignments of available sequences. Primers for New Castle Disease Virus were taken from Seal, J., J. *et al*; Clin. Microb., 2624-2630, 1995. Primers for Nipah and general paramyxovirus-PCR were taken from Chua, *et al.*, 2000, *Science*, 288. The primers used to detect other known paramyxoviruses were as follows: hPIV-1 was detected with primers corresponding to the sequences of SEQ ID NO: 58 and 59 for the forward and reverse primers respectively, hPIV-2 was detected with primers corresponding to the sequences of SEQ ID NO: 60 and 61 for the forward and reverse primers respectively, hPIV-3 was detected with primers corresponding to the sequences of SEQ ID NO: 62 and 63 for the forward and reverse primers respectively, hPIV-4 was detected with primers corresponding to the sequences of SEQ ID NO: 64 and 65 for the forward and reverse primers respectively, Mumps was detected with primers corresponding to the sequences of SEQ ID NO: 66 and 67 for the forward and reverser primers respectively, NDV was detected with primers corresponding to the sequences of SEQ ID NO: 68 and 69 for the forward and reverse primers respectively, Tupaia was detected with primers corresponding to the sequences of SEQ ID NO: 70 and 71 for the forward and reverse primers respectively, Mapuera was detected with primers corresponding to the sequences of SEQ ID NO: 72 and 73 for the forward and reverse primers respectively,

Hendra was detected with primers corresponding to the sequences of SEQ ID NO: 74 and 75 for the forward and reverse primers respectively, Nipah was detected with primers corresponding to the sequences of SEQ ID NO: 76 and 77 for the forward and reverse primers respectively, HRSV was detected with primers corresponding to the sequences of SEQ ID NO: 78 and 79 for the forward and reverse primers respectively, Measles was detected with primers corresponding to the sequences of SEQ ID NO: 80 and 81 for the forward and reverse primers respectively, and general *Paramyxoviridae* viruses were detected with primers corresponding to the sequences of SEQ ID NO: 82 and 83 for the forward and reverse primers respectively.

7.11 EXAMPLE 19: RAP-PCR

The genetic material of MPV or another virus can be detected or amplified using primers that hybridize to regions within the genome and that extend in a particular direction so that the genetic material is amplified. This type of technique is useful when specific sequence information is unavailable or when performing an initial amplification of genetic material in a sample. One such technique is called RAP-PCR.

RAP-PCR was performed essentially as described (Welsh *et al.*, 1992, *NAR* 20:4965-4970). For the RT reaction, 2 µl of RNA was used in a 10 µl reaction containing 10 ng/µl oligonucleotide, 10 mM dithiothreitol, 500 µM each dNTP, 25 mM Tris-HCl pH 8.3, 75 mM KCl and 3 mM MgCl₂. The reaction mixture was incubated for 5 minutes at 70°C and 5 minutes at 37°C, after which 200 units Superscript RT enzyme (LifeTechnologies) were added. The incubation at 37 °C was continued for 55 minutes and the reaction was terminated by a 5 minute incubation at 72 °C. The RT mixture was diluted to give a 50 µl PCR reaction containing 8 ng/µl oligonucleotide, 300 µl each dNTP, 15 mM Tris-HCl pH 8.3, 65 mM KCl, 3.0 mM MgCl₂ and 5 units Taq DNA polymerase (FE Biosystems). Cycling conditions were 5 minutes at 94 °C, 5 minutes at 40 °C, and 1 minute at 72 °C once, followed by 1 minute at 94 °C, 2 minutes at 56 °C and 1 minute at 72 °C repeated 40 times, and 5 minutes at 72°C once.

Primers used for RAP-PCR were: primer ZF1 with a nucleotide sequence corresponding to SEQ ID NO: 46, primer ZF4 with a nucleotide sequence corresponding to SEQ ID NO: 47, primer ZF7 with a nucleotide sequence corresponding to SEQ ID NO: 48,

primer ZF10 with a nucleotide sequence corresponding to SEQ ID NO: 49, primer ZF13 with a nucleotide sequence corresponding to SEQ ID NO: 50, primer ZF16 with a nucleotide sequence corresponding to SEQ ID NO: 51, primer CS1 with a nucleotide sequence corresponding to SEQ ID NO: 52, CS4 with a nucleotide sequence corresponding to SEQ ID NO: 53, primer CS7 with a nucleotide sequence corresponding to SEQ ID NO: 54, primer CS10 with a nucleotide sequence corresponding to SEQ ID NO: 55, primer CS13 with a nucleotide sequence corresponding to SEQ ID NO: 56, and primer CS16 with a nucleotide sequence corresponding to SEQ ID NO: 57. Products were run side by side on a 3% NuSieve agarose gel (FMC BioProducts, Heerhugowaard, The Netherlands). Differentially displayed fragments specific for MPV were purified from the gel with a Qiaquick Gel Extraction kit (Qiagen, Leusden, The Netherlands) and cloned in pCR2.1 vector (Invitrogen, Groningen, The Netherlands), according to instructions from the manufacturer. Twenty fragments were successfully purified and sequenced. Sequence homology to APV was found in ten fragments, i.e. fragment 1 isolated using the ZF7 primer yielded a 335 bp fragment with homology to the N gene, fragment 2 isolated using the ZF10 primer yielded a 235 bp fragment with homology to the N gene, fragment 3 isolated using the ZF10 primer yielded a 800 bp fragment with homology to the M gene, fragment 4 isolated using the CS1 primer yielded a 1250 bp fragment with homology to the F gene, fragment 5 isolated using the CS10 primer yielded a 400 bp fragment with homology to the F gene, fragment 6 isolated using the CS13 primer yielded a 1450 bp fragment with homology to the F gene, fragment 7 isolated using primer CS13 yielded a 750 bp fragment with homology to the F gene, fragment 8 isolated using the ZF4 primer yielded a 780 bp fragment with homology to the L gene (protein level), fragment 9 isolated using the ZF10 primer yielded a 330 bp fragment with homology to the L gene (protein level), and fragment 10 isolated using the ZF10 primer yielded a 250bp fragment with homology to the L gene (protein level).

TaqMan assays can be used to measure the level of expression of a gene. TaqMan assays were adapted to examine the expression of the L-gene and the N-gene. The primers that were used in these assays are not required to be specific to any one of the hMPV groups, however, examples are shown below. Reactions were carried out with a 500 nM concentration of a forward primer, 250 nM concentration of a reverse primer, 250 nM concentration of an oligonucleotide probe, 25 µl of a universal PCR mastermix (available from ABI), and 5 µl of

cDNA in a 50 µl total reaction volume. Cycling conditions were: a first step of 10 minutes at 95 °C, followed by a second step of 45 cycles consisting of 30 seconds at 95 °C and 60 seconds at 60 °C on an ABI 7000 sequence detection system.

Other examples of primers for the N gene of hMPV to be used in TaqMan assays are as follows: For isolates NL/1/00, BI/1/01, FI/4/01, NL/8/01, and FI/2/01, all of the subgroup A1, primers with the nucleotide sequence of SEQ ID NO: 39 could be used. For isolate NL/30/01, of the subgroup A1, a primer with the nucleotide sequence of SEQ ID NO: 40 could be used. For isolates NL/22/01 and NL/23/01, of the subgroup A2, a primer with the nucleotide sequence of SEQ ID NO: 41 could be used. For isolates NL/17/01, of the subgroup A2, a primer with the nucleotide sequence of SEQ ID NO: 42 could be used. For isolate NL/17/00, of the subgroup A2, a primer with the nucleotide sequence of SEQ ID NO: 43 could be used. For isolates NL/1/99, NL/5/01, NL/21/01, and NL/9/01, of the subgroup B1, a primer with the nucleotide sequence of SEQ ID NO: 44. For isolates FI/1/01 and FI/10/01, of subgroup B1, a primer with the nucleotide sequence of SEQ ID NO: 45 could be used.

A potential probe that can be used for the A1 subgroup corresponds to SEQ ID NO:390, a probe that can be used for the B1 subgroup corresponds to SEQ ID NO:391, and a probe that can be used for the B2 subgroup corresponds to SEQ ID NO:392.

7.12 EXAMPLE 20: SEQUENCE ANALYSIS OF RAP-PCR PRODUCTS

After segments are amplified using RAP-PCR, sequence information can be obtained on the amplified segments. In order to do so, it is advantageous to clone the generated fragments into vectors before sequencing.

RAP-PCR products cloned in vector pCR2.1 (Invitrogen) were sequenced with M13-specific oligonucleotides. DNA fragments obtained by RT-PCR were purified from agarose gels using Qiaquick Gel Extraction kit (Qiagen, Leusden, The Netherlands), and sequenced directly with the same oligonucleotides used for PCR. Sequence analyses were performed using a Dyenamic ET terminator sequencing kit (Amersham Pharmacia Biotech, Roosendaal, The Netherlands) and an ABI 373 automatic DNA sequencer (PE Biosystem). All techniques were performed according to the instructions of the manufacturer.

7.13 EXAMPLE 21: GENERATING GENOMIC FRAGMENTS BY RT-PCR

The RAP-PCR method can leave gaps in the sequence that have not be amplified or copied. In order to obtain a complete sequence, the sequence information of the gaps can be obtained using RT-PCR.

To generate PCR fragments spanning gaps A, B and C between the RAP-PCR fragments (Figure 3), RT-PCR assays were used as described previously on RNA samples isolated from virus isolate 00-1.

The following primers were used to generate fragment A: TR1 designed in the leader, corresponding to the nucleotide sequence of SEQ ID NO:22 and N1 designed at the 3' end of the RAP-PCR fragments obtained in N and corresponding to the sequence of SEQ ID NO:23. The following primers were used to generate fragment B: N2 designed at the 5' end of the RAP-PCR fragments obtained in N and corresponding to the nucleotide sequence of SEQ ID NO:24 and M1 designed at the 3' end of the RAP-PCR fragments obtained in M and corresponding to the nucleotide sequence of SEQ ID NO:25. The following primers were used to generate fragment C: M2 designed at the 5' end of the RAP-PCR fragment obtained in M and corresponding to the nucleotide sequence of SEQ ID NO:26 and F1 designed at the 3' end of the RAP-PCR fragments obtained in F and corresponding to the nucleotide sequence of SEQ ID NO: 27.

Fragments were purified after gel electrophoresis and cloned and sequenced as described previously.

7.14 EXAMPLE 25: CAPTURE ANTI-MPV IgM EIA USING A RECOMBINANT NUCLEOPROTEIN.

In order to detect the hMPV virus, an immunological assay that detects the presence of the antibodies in a variety of hosts. In one example, antibodies to the N protein are used because it is the most abundant protein that is produced. This feature is due the transcriptional gradient that occurs across the genome of the virus.

A capture IgM EIA using the recombinant nucleoprotein or any other recombinant protein as antigen can be performed by modification of assays as previously described by Erdman et al., 1990, J.Clin.Microb. 29: 1466-1471.

Affinity purified anti-human IgM capture antibody (or against other species), such as that obtained from Dako, is added to wells of a microtiter plate in a concentration of 250 ng

per well in 0.1 M carbonate buffer pH 9.6. After overnight incubation at room temperature, the plates are washed two times with PBS/0.05% Tween. 100 µl of test serum diluted 1:200 to 1:1000 in ELISA buffer is added to triplicate wells and incubated for 1 hour at 37°C. The plates are then washed two times with in PBS/0.05% Tween.

The freeze-thawed (infected with recombinant virus) Sf21 cell lysate is diluted 1:100 to 1:500 in ELISA buffer is added to the wells and incubated for 2 hours at 37°C. Uninfected cell lysate serves as a negative control and is run in duplicate wells. The plates are then washed three times in PBS/0.05% Tween and incubated for 1 hour at 37°C with 100 µl of a polyclonal antibody against MPV in a optimal dilution in ELISA buffer. After 2 washes with PBS/0.05% Tween , the plates are incubated with horseradish peroxide labeled secondary antibody (such as rabbit anti ferret), and the plates are incubated 20 minutes at 37°C.

The plates are then washed five times in PBS/0/05% Tween, incubated for 15 minutes at room temperature with the enzyme substrate TMB, 3,3 ,5,5 tetramethylbenzidine, as, for instance obtained from "Sigma", and the reaction is stopped with 100 µl of 2M phosphoric acid. Colormetric readings are measured at 450 nm using automated microtiter plate reader.

The sensitivities of the capture IgM ELAs using the recombinant nucleoprotein (or other recombinant protein) and whole MPV virus are compared using acute-and convalescent-phase serum pairs form persons with clinical MPV virus infection. The specificity of the recombinant nucleoprotein capture ELA is determined by testing serum specimens from healthy persons and persons with other paramyxovirus infections.

Potential for ELAs for using recombinant MPV fusion and glycoprotein proteins produced by the baculovirus expression.

The glycoproteins G and F are the two transmembraneous envelope glycoproteins of the MPV virion and represent the major neutralisation and protective antigens. The expression of these glycoproteins in a vector virus system such as a baculovirus system provides a source of recombinant antigens for use in assays for detection of MPV specific antibodies. Moreover, their use in combination with the nucleoprotein, for instance, further enhances the sensitivity of enzyme immunoassays in the detection of antibodies against MPV.

A variety of other immunological assays (*Current Protocols in Immunology*, volume 1-3. Ed. by Coligan, J.E., Kruisbeek, A.M., Margulies, D.H., Shevach, E.M. and Strobe, W.

Published by John Wiley and sons, Inc., USA) may be used as alternative methods to those described here.

In order to find virus isolates nasopharyngeal aspirates, throat and nasal swabs, broncho alveolar lavages and throat swabs preferable from but not limited to humans, carnivores (dogs, cats, seals etc.), horses, ruminants (cattle, sheep, goats etc.), pigs, rabbits, birds (poultry, ostridges, etc) can be examined. From birds, cloaca and intestinal swabs and droppings can be examined as well. For all samples, serology (antibody and antigen detection etc.), virus isolation and nucleic acid detection techniques can be performed for the detection of virus. Monoclonal antibodies can be generated by immunizing mice (or other animals) with purified MPV or parts thereof (proteins, peptides) and subsequently using established hybridoma technology (*Current Protocols in Immunology*, Published by John Wiley and sons, Inc., USA). Alternatively, phage display technology can be used for this purpose (*Current Protocols in Immunology*, Published by John Wiley and sons, Inc., USA). Similarly, polyclonal antibodies can be obtained from infected humans or animals, or from immunised humans or animals (*Current Protocols in Immunology*, Published by John Wiley and sons, Inc., USA).

The detection of the presence or absence of NS1 and NS2 proteins can be performed using western-blotting, IFA, immuno precipitation techniques using a variety of antibody preparations. The detection of the presence or absence of NS1 and NS2 genes or homologues thereof in virus isolates can be performed using PCR with primer sets designed on the basis of known NS1 and/or NS2 genes as well as with a variety of nucleic acid hybridisation techniques.

To determine whether NS1 and NS2 genes are present at the 3' end of the viral genome, a PCR can be performed with primers specific for this 3' end of the genome. In our case, we used a primer specific for the 3' untranslated region of the viral genome and a primer in the N ORF. Other primers may be designed for the same purpose. The absence of the NS1/NS2 genes is revealed by the length and/or nucleotide sequence of the PCR product. Primers specific for NS1 and/or NS2 genes may be used in combination with primers specific for other parts of the 3' end of the viral genome (such as the untranslated region or N, M or F ORFs) to allow a positive identification of the presence of NS1 or NS2 genes. In addition to PCR, a variety of

techniques such as molecular cloning, nucleic acid hybridisation may be used for the same purpose.

8. CELL CULTURE SYSTEMS AND ANIMAL MODELS FOR MPV AND RECOMBINANT ENGINEERING OF MPV

8.1 EXAMPLE 22: HMPV GROWTH IN DIFFERENT CELL LINES

Virus isolates can be cultured in different cell lines in order to examine characteristics of each virus. For example, the infectivity of different virus isolates can be characterized and distinguished on the basis of titer levels measured in culture. Alternatively, cells can be used to propagate or amplify strains of the virus in culture for further analysis.

In one example, tertiary monkey kidney cells were used to amplify hMPV. However, tertiary monkey kidney cells are derived from primary cells which may only be passaged a limited number of times and have been passaged three times in vivo. It was not known which kind of immortalized cell line would support hMPV virus growth to high titers. A number of monkey cell lines such as Vero, LLC-MK2, HEp-2, and lung fibroblast (LF1043) cells, were tested to see whether they could support hMPV virus replication (Table 12). Trypsin used was TPCK-trypsin (Worthington) at a concentration of 0.001 mg/ml. The growth of this virus in fertilized 10 day old chicken eggs was also tested. The infected eggs were incubated for 2 and 3 days at 37°C prior to AF harvest. Virus titers were determined by plaque assay of infected cell lysates on Vero cells without trypsin, incubated for 10 days at 35°C, and immunostained using the guinea pig hMPV antiserum. The results showed that Vero cells and LLC-MK2 cells were the cell substrates most suitable for hMPV virus replication, resulting in virus stock titers of $10^6 - 10^7$ pfu/ml. These titers were similar to those obtained from tMK cells. The addition of trypsin at a concentration of 0.01 mg/ml did not increase virus titers appreciably (Table 12).

TABLE 12: HMPV VIRUS GROWTH IN DIFFERENT CELL LINES

<u>Cell Substrate</u>	<u>Trypsin used to grow virus</u>	<u>Virus titers on Vero cells (pfu/ml)</u>
Vero	yes	2.1×10^7
	no	1.1×10^7
LLC-MK2	yes	2.3×10^5
Hep-2	yes	cells died
LF 1043 (HEL)	yes	no virus recovered
	no	no virus recovered
tMK	yes	1.0×10^7
eggs (10 days)	no	no virus recovered

In order to study the virus kinetics of hMPV viral growth in Vero cells, a growth curve was performed using an MOI of 0.1 (Figure 23). Cells and cell supernatants were harvested every 24 hours, and analyzed by plaque assay for quantification of virus titers. The results showed that at day 5, near peak titers of hMPV were observed. The absolute peak titer of $5.4 \log_{10}$ pfu/ml was achieved on Day 8. The virus titer was very stable up to day 10. A growth curve carried out at the same time with solely the cell supernatants, showed only very low virus titers. This data demonstrated that hMPV replication, under the conditions used (MOI of 0.1) peaked on day 8 post-infection and that hMPV was largely, a cell-associated RNA virus.

TRANSFECTION OF 293 CELLS: 293 cells (human kidney epithelial cells) were passed in DMEM and supplemented with FCS (10 %), L-Glutamine (1:100) and Pen/Strep (1:100) and split 1:10 every 3-4 days. Care was taken not to let the cells grow to confluency in order to enhance transfectability. Cells were not very adherent; a very brief (2 min. or less) incubation in Trypsin-EDTA was usually sufficient to release them from plastic surfaces. Cells were diluted in culture media immediately after trypsin-treatment.

Cells were split the day before transfection. Cell confluency approximated 50 – 75 % when transfected. Gelatinized plasticware was used to prevent cells from detaching throughout

the transfection procedure. Plates or flasks were covered with 0.1 % gelatinin (1:20 dilution of 2 % stock) for 10 minutes and rinsed one time with PBS once. To achieve the correct cell density; cells were used at a concentration of 1×10^7 cells per T75 flask or 100 mm plate (in 10 ml) or 1×10^6 cells per well of a 6-well plate (in 2 ml).

Transfection lasted for a minimum of 7 hours, however, it was preferable to allow the transfection to occur overnight. The following were combined in a sterile tube: 30 mg DNA with 62 ml 2 M CaCl_2 and H_2O to 500 ml (T75) or 3 mg DNA with 6.2 ml 2 M CaCl_2 and H_2O to 50 ml (6-well plate); with brief mixing. Addition of 500 or 50 ml 2xHBS occurred dropwise and the solutions were allowed to mix for 5 minutes until a precipitate formed. Gentle care was used, *i.e.* no vortexing was applied. The old media was replaced with fresh prewarmed media (10 ml per T75 flask or 1 ml per well of a 6-well plate). The DNA was mixed carefully by blowing airbubbles through the tube with a Gilson pipet and the precipitate was added dropwise to the media covering the cells. The cells were incubated in a 37°C CO_2 atmosphere.

The cells appeared to be covered with little specks (the precipitate). The transfection media was removed from the cells, and the cells were rinsed carefully with PBS, and then replaced with fresh media.

The cells were incubated in a 37°C CO_2 atmosphere until needed, usually between 8 - 24 hours.

A 10x stock of HBS was prepared with 8.18 % NaCl, 5.94 % Hepes and 0.2 % Na_2HPO_4 (all w/v). The solution was filter sterilized and stored at 4°C . A 2x solution was prepared by diluting the 10x stock with H_2O and adjusting the pH to 7.12 with 1 M NaOH. The solution was stored in aliquots at -20°C . Care was taken to exactly titrate the pH of the solution. The pH was adjusted immediately before the solution was used for the transfection procedure.

8.2 EXAMPLE 23: MINIREPLICON CONSTRUCT OF MPV

Minireplicon constructs can be generated to contain an antisense reporter gene. An example of a minireplicon, CAT-hMPV, is shown in Figure 24. The leader and trailer sequences that were used for the generation of the minireplicon construct are shown in Figure 26. For comparison, an alignment of APV, RSV and PIV3 leader and trailer sequences are also shown in Figure 26.

Two versions of the minireplicon constructs were tested: one with terminal AC residues at the leader end (Le+AC), and one without terminal AC residues at the leader end (Le-AC). The two constructs were both functional in the assay (Figure 25). It can be seen in Figure 25 that much higher CAT expression occurred after 48 hours than after 24 hours. After 48 hours, around 14 ng CAT per 500,000 cells transfected was observed. This experiment was entirely plasmid driven: the minireplicon was cotransfected with a T7 polymerase plasmid, and the N, P, L, M2.1 genes were expressed from pCITE-2a/3a (the pCite plasmids have a T7 promoter followed by the IRES element derived from the encephalomyocarditis virus (EMCV)). The CAT expression was completely abolished when L, P and N were excluded. A significant reduction in CAT expression was noted when M2.1 expression was excluded from the vector.

The specificity (attributes to heterologous viruses) and the effect of the terminal residues of the leader (attributes to homologous virus) of the minireplicon system can also be tested by superinfecting the minireplicon-transfected cells with hMPV polymerase components (NL/1/00 and NL/1/99) or polymerase components from APV-A, APV-C, RSV or PIV. The different amount of each of the six plasmids can also be tested in order to determine the optimal conditions.

Other reporter genes can be used instead of CAT. In other examples, GFP can be inserted into the minireplicon construct instead of CAT.

8.3 EXAMPLE 24: GENERATION OF FULL LENGTH INFECTIOUS cDNA

Full length cDNAs that express the genes of the hMPV virus can be constructed so that infectious viruses can be produced. For example, a cDNA encoding all of the genes or all of the essential genes of hMPV can be constructed; the genome can then be expressed to produce infectious viruses.

In order to genetically manipulate hMPV, the genome of this RNA virus was cloned. For the 00-1 isolate of hMPV, eight PCR fragments varying in length from 1-3 kb were generated (Figure 27). The PCR fragments were sequenced and analyzed for sequence errors by comparison to the hMPV sequence deposited in Genbank. Two silent mutations (nucleotide 5780 ile:ile in the SH gene, nucleotide 12219 cys:cys in the L gene) were not

corrected. Another change in the L gene at nucleotide 8352 (trp:leu) was not changed since this mutation was observed in two independently generated PCR fragments (C and H), as well as in the hMPV 99-1 sequence. Similarly, a 5 nucleotide insertion at nucleotide 4715 in the F-M2 intergenic region was not corrected. Both of these changes may be reflected in the wild type sequence of hMPV. In contrast, at nucleotide 1242, a single A residue was removed in the N-P intergenic region; at nucleotide 3367, a ser:pro was corrected in the F gene; at nucleotide 6296, an asp:val was changed in the G gene; and at nucleotide 7332 a stop codon was changed to a glu in the L gene.

Restriction maps of different isolates of hMPV are shown in Figure 28. The restriction sites can be used to assemble the full-length construct.

The eight corrected PCR fragments were then assembled in sequence, taking advantage of unique restriction enzyme sites (Figure 29). A genetic marker was introduced at nucleotide 75 generating an AflII restriction enzyme site without altering the amino acid sequence. A unique restriction enzyme site, XhoI, was added at the 3' end of the hMPV sequence. A phage T7 polymerase promoter followed by two G residues was also added to the 3' end of the hMPV sequence. At the 5' end of the hMPV genome, a Hepatitis delta ribozyme sequence and BssHII restriction enzyme site were added.

Helper plasmids encoding the hMPV L, N, P and M2-1 gene in a pCITE plasmid were also generated. Once the full-length hMPV cDNA was generated, virus recovery by reverse genetics was performed in Vero cells using fowl-pox T7 or MVA-T7 as a source of T7 polymerase.

8.4 EXAMPLE 26: INFECTION OF ANIMAL HOSTS WITH SUBTYPES OF hMPV

Animal hosts can be infected in order to characterize the virulence of MPV strains. For example, different hosts can be used in order to determine how infectious each strain is in an organism.

A small animal model for hMPV had not been identified. Balb/c mice, cotton rats, and Syrian Golden hamsters were infected with hMPV using a dose of 1.3×10^6 pfu/animal. The animals were inoculated intranasally with 1.3×10^6 pfu of hMPV in a 0.1 ml volume. The tissue samples were quantified by plaque assays that were immunostained on Day 9 with the

hMPV guinea pig antiserum. Four days post-infection, the animals were sacrificed, and the nasal turbinates and lungs were isolated and quantified for hMPV titers by plaque assays that were immunostained (Table 13).

TABLE 13: HMPV TITERS IN INFECTED ANIMALS

<u>Animals</u>	<u>Number of animals</u>	<u>Mean virus titer on day 4 post-infection ($\log_{10}$ PFU/g tissue +/- Standard Error</u>	
		Nasal turbinates	Lungs
mice (Balb c)	6	2.7 +/- 0.4	2.2 +/- 0.6
cotton rats	5	<1.7 +/- 0.0	<1.8 +/- 0.0
Syrian Golden hamsters	6	5.3 +/- 0.2	2.3 +/- 0.6

The results showed that hMPV replicated to high titers in Syrian Golden hamsters. Titers of 5.3 and 2.3 $\log_{10}$ pfu/g tissue were obtained in the nasal turbinates and lungs, respectively. hMPV did not replicate to any appreciable titer levels in the respiratory tracts of cotton rats. Mice showed titers of 2.7 and 2.2 $\log_{10}$ pfu/g tissue in the upper and lower respiratory tracts, respectively. These results suggested that Syrian Golden hamsters would be a suitable small animal model to study hMPV replication and immunogenicity as well as to evaluate hMPV vaccine candidates.

INFECTION OF GUINEA PIGS. Two virus isolates, 00-1 (subtype A) and 99-1 (subtype B), were used to inoculate six guinea pigs per subtype (intratracheal, nose and eyes). Six guinea pigs were infected with hMPV 00-1 ($10^{6.5}$ TCID₅₀). Six guinea pigs were infected with hMPV 99-1 ($10^{4.1}$ TCID₅₀). The primary infection was allowed to progress for fifty-four days when the guinea pigs were inoculated with the homologous and heterologous subtypes (10^4 TCID₅₀/ml), i.e., two guinea pigs had a primary infection with 00-1 and a secondary infection with 99-1 in order to achieve a heterologous infection, three guinea pigs had a primary infection with 00-1 and a secondary infection with 00-1 to achieve a homologous infection, two guinea pigs had a primary infection with 99-1 and a secondary

infection with 00-1 to achieve a heterologous infection and three guinea pigs had a primary infection with 99-1 and a secondary infection with 99-1 to achieve a homologous infection.

Throat and nose swabs were collected for 12 days (primary infection) or 8 days (secondary infection) post infection, and were tested for the presence of the virus by RT-PCR assays. The results (Figure 32) of the RT-PCR assays showed that guinea pigs inoculated with virus isolate 00-1 showed infection of the upper respiratory tract on days 1 through 10 post infection. Guinea pigs inoculated with 99-1 showed infection of the upper respiratory tract day 1 to 5 post infection. Infection of guinea pigs with 99-1 appeared to be less severe than infection with 00-1. A second inoculation of the guinea pigs with the heterologous virus, as commented on above, resulted in re-infection in 3 out of 4 of the guinea pigs. Likewise, reinfection in the case of the homologous virus occurred in 2 out of 6 guinea pigs. Little or no clinical symptoms were noted in those animals that became re-infected, and no clinical symptoms were seen in those animals that were protected against the re-infections, demonstrating that even with the wild-type virus, a protective effect due to the first infection may have occurred. This also showed that heterologous and homologous isolates could be used as a vaccine.

Both subtypes of hMPV were able to infect guinea pigs, although infection with subtype B (99-1) seemed less severe, i.e., the presence of the virus in nose and throat was for a shorter period than infection with subtype A (00-1). This may have been due to the higher dose given for subtype A, or to the lower virulence of subtype B. Although the presence of pre-existing immunity did not completely protect against re-infection with both the homologous and heterologous virus, the infection appeared to be less prominent, in that a shorter period of presence of virus was noted and not all animals became virus positive.

The serology of guinea pigs that were infected with both subtypes of hMPV was examined. At days 0, 52, 70, 80, 90, 110, 126 and 160, sera were collected from the guinea pigs and tested at a 1:100 dilution in a whole virus ELISA against 00-1 and 99-1 antigens. (See Figure 33 A and B showing the IgG response against 00-1 and 99-1 for each individual guinea pig. See also Figure 34 showing the specificity of the 00-1 and 99-1 ELISA but note that only data from homologous reinfected guinea pigs was used. See also Figure 35 showing the mean IgG response against 00-1 and 99-1 ELISA of three homologous, i.e. 00-1 and 00-1, two

homologous, i.e., 99-1 and 99-1, two heterologous, i.e., 99-1 and 00-1, and 2 heterologous, i.e., 00-1 and 99-1 infected guinea pigs).

Only a minor difference in response to the two different ELISAs was observed. Whole virus ELISA against 00-1 or 99-1 could not be used to discriminate between the two subtypes.

The reactivity of sera raised against hMPV in guinea pigs with APV antigen was examined. Sera were collected from the infected guinea pigs and tested with an APV inhibition ELISA. (See Figure 36, showing the mean percentage of APV inhibition of hMPV infected guinea pigs). Sera raised against hMPV in guinea pigs reacted in the APV inhibition test in a manner similar to their reaction in the hMPV IgG ELISA's. Sera raised against 99-1 revealed a lower percentage of inhibition in the APV inhibition ELISA than sera raised against 00-1. Guinea pigs infected with 99-1 may have had a lower titer than that seen in the hMVP ELISAs. Alternatively, the cross-reaction of 99-1 with APV could have been less than that of 00-1. Nevertheless, the APVAb inhibition ELISA could be used to detect hMPV antibodies in guinea pigs.

Virus neutralization assays were performed with sera raised against hMPV in guinea pigs. Sera were collected at day 0, day 52, day 70 and day 80 post infection and used in a virus cross-neutralization assay with 00-1, 99-1, and APV-C. The starting dilution used was 1 to 10 and 100 TCID₅₀ virus per well. After neutralization, the virus was exposed to tMK cells (15 mm.) and centrifuged at 3500 RPM, after which the media was refreshed. The APV cultures were grown for 4 days and the hMPV cultures were grown for 7 days. Cells were fixed with 80% acetone, and IFAs were conducted with labeled monkey-anti hMPV. Wells that were negative upon staining were defined as the neutralizing titer. For each virus, a 10-log titration of the virus stock and a 2 fold titration of the working solution was included. (See Figure 37 showing the virus neutralization titers of 00-01 and 99-1 infected guinea pigs against 00-1, 99-1, and APV-C).

INFECTION OF CYNOMOLOGOUS MACAQUES. Virus isolates 00-1 (subtype A) and 99-1 (subtype B) (1e5 TCID₅₀) was used to inoculate two cynomologous macaques per subtype (intratracheal, nose and eyes). Six months after the primary infection, the macaques were inoculated for the second time with 00-1. Throat swabs were collected for 14 days

(primary infection) or 8 days (secondary infection) post infection, and were tested for presence of the virus by RT-PCR assays (Figure 38).

Cynomologous macaques inoculated with virus isolate 00-1 showed infection of the upper respiratory tract day 1 to 10 post infection. Clinical symptoms included a suppurative rhinitis. A second inoculation of the macaques with the homologous virus results in re-infection, as demonstrated by PCR, however, no clinical symptoms were seen.

Sera were collected from the macaques that received 00-1 during six months after the primary infection (re-infection occurred at day 240 for monkey 3 and day 239 for monkey 6). Sera were used to test for the presence of IgG (Figure 39B) antibodies against either 00-1 or APV, and for the presence of IgA and IgM antibodies against 00-1 (Figure 39A).

Two macaques were successfully infected with 00-1 and in the presence of antibodies against 00-1 were reinfected with the homologous virus. The response to IgA and IgM antibodies showed the raise in IgM antibodies after the first infection, and the absence of it after the reinfection. IgA antibodies were only detected after the re-infection, showing the immediacy of the immune response after a first infection. Sera raised against hMPV in macaques that were tested in an APV inhibition ELISA showed a similar response as to the hMPV IgG ELISA.

Antibodies to hMPV in cynomologous macaques were detected with the APV inhibition ELISA using a similar sensitivity as that with the hMPV ELISA, and therefore the APV inhibition ELISA was suitable for testing human samples for the presence of hMPV antibodies.

Virus cross-neutralization assays were performed on sera collected from hMPV infected cynomologous macaques. The sera were taken from day 0 to day 229 post primary infection and showed only low virus neutralization titers against 00-1 (0-80), the sera taken after the secondary infection showed high neutralisation titers against 00-1, i.e., greater than 1280. Only sera taken after the secondary infection showed neutralization titers against 99-1 (80-640), and none of the sera were able to neutralize the APV C virus. There was no cross reaction between APV-C and hMPV in virus cross-neutralization assays, however, there was a cross reaction between 00-1 and 99-1 after a boost of the antibody response.

INFECTION OF HUMANS. The sera of patients ranging in ages under six months or greater than twenty years of age were previously tested using IFA and virus neutralization assays against 00-1. These sera were tested for the presence of IgG, IgM and IgA antibodies in an ELISA against 00-1. The samples were also tested for their ability to inhibit the APV ELISA. A comparison of the use of the hMPV ELISA and the APV inhibition ELISA for the detection of IgG antibodies in human sera was made and a strong correlation between the IgG hMPV test and the APV-Ab test was noted, therefore the APV-Ab test was essentially able to detect IgG antibodies to hMPV in humans (Figure 40).

INFECTION OF POULTRY. The APV inhibition ELISA and the 00-1 ELISA were used to test chickens for the presence of IgG antibodies against APV. Both the hMPV ELISA and the APV inhibition ELISA detected antibodies against APV.

8.5 EXAMPLE 27: APV AS A VACCINE IN HUMANS

APV can be used as a vaccine in humans to prevent infection by a human MPV, or to reduce the infectivity of human MPV in human hosts. The vaccine can be a whole APV or a chimeric or recombinant version or derivative thereof, that is comprised of heterologous sequences of another metapneumovirus in addition to sequences of APV. The genome of APV can be used as a backbone to create a recombinant virus vaccine. For example, a vaccine can be made where the F-gene and/or the G-gene of APV is substituted by the F-gene or the G-gene of human MPV. Alternatively, a vaccine can be made that includes sequences from PIV substituted for or added to sequences of an APV backbone. For more on the construction of a recombinant/chimeric vaccine, see, *e.g.*, Construction of the Recombinant cDNA and RNA.

The vaccine can be administered to a candidate by a variety of methods known to those skilled in the art, (*see*, Section 5.13, *infra*) including but not limited to, subcutaneous injection, intranasal administration, or inhalation. The viruses and/or vaccines of the invention are administered at a starting dosage of at least between 10^3 TCID₅₀ and 10^6 TCID₅₀. The viruses and/or vaccines are administered in either single or multiple dosages, *e.g.*, a primary dose can be administered with one or more subsequent or booster doses administered at periodic time intervals throughout the host life. In a clinical trial, the replication rate of the virus can be used as an index to adjust the dosage of the vaccine so that an effective dosage regimen can be

determined. A comparison can be made between the replication rate of the virus in the study population and a predetermined rate that is known to be effective.

The present invention is not to be limited in scope by the specific described embodiments that are intended as single illustrations of individual aspects of the invention, and any constructs, viruses or enzymes that are functionally equivalent are within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings.

8.6 EXAMPLE 28: MPV AS A VACCINE IN BIRDS

Human MPV can be used as a vaccine in birds to prevent infection by an APV, or to reduce the infectivity of APV in avian hosts. The vaccine can be a whole MPV or a chimeric or recombinant version or derivative thereof, that is comprised of heterologous sequences of another metapneumovirus in addition to sequences of MPV. The genome of human MPV can be used as a backbone to create a recombinant virus vaccine. For example, a vaccine can be made where the F-gene and/or the G-gene of human MPV is substituted by the F-gene or the G-gene of APV. For more on the construction of a recombinant/chimeric vaccine, see, *e.g.*, Construction of the Recombinant cDNA and RNA.

The vaccine can be administered to a candidate by a variety of methods, including but not limited to, subcutaneous injection, intranasal administration, or inhalation. The viruses and/or vaccines of the invention are administered at a starting dosage of at least between 10^3 TCID₅₀ and 10^6 TCID₅₀. The viruses and/or vaccines are administered in either single or multiple dosages, *e.g.*, a primary dose can be administered with one or more subsequent or booster doses administered at periodic time intervals throughout the host life. In a clinical trial, the replication rate of the virus can be used as an index to adjust the dosage of the vaccine so that an effective dosage regimen can be determined. A comparison can be made between the replication rate of the virus in the study population and a predetermined rate that is known to be effective.

Various publications are cited herein.

TABLE 14: LEGEND FOR SEQUENCE LISTING

SEQ ID NO:1	Human metapneumovirus isolate 00-1 matrix protein (M) and fusion protein (F) genes
SEQ ID NO:2	Avian pneumovirus fusion protein gene, partial cds
SEQ ID NO:3	Avian pneumovirus isolate 1b fusion protein mRNA,complete cds
SEQ ID NO:4	Turkey rhinotracheitis virus gene for fusion protein (F1 and F2 subunits), complete cds
SEQ ID NO:5	Avian pneumovirus matrix protein (M) gene, partial cds and Avian pneumovirus fusion glycoprotein (F) gene, complete cds
SEQ ID NO:6	paramyxovirus F protein hRSV B
SEQ ID NO:7	paramyxovirus F protein hRSV A2
SEQ ID NO:8	human metapneumovirus01-71 (partial sequence)
SEQ ID NO:9	Human metapneumovirus isolate 00-1 matrix protein(M) and fusion protein (F) genes
SEQ ID NO:10	Avian pneumovirus fusion protein gene, partial cds
SEQ ID NO:11	Avian pneumovirus isolate 1b fusion protein mRNA,complete cds
SEQ ID NO:12	Turkey rhinotracheitis virus gene for fusion protein (F1 and F2 subunits), complete cds
SEQ ID NO:13	Avian pneumovirus fusion glycoprotein (F) gene, complete cds
SEQ ID NO:14	Turkey rhinotracheitis virus (strain CVL14/1)attachment protien (G) mRNA, complete cds
SEQ ID NO:15	Turkey rhinotracheitis virus (strain 6574)attachment protein (G), complete cds
SEQ ID NO:16	Turkey rhinotracheitis virus (strain CVL14/1)attachment protein (G) mRNA, complete cds

SEQ ID NO:17	Turkey rhinotracheitis virus (strain 6574)attachment protein (G), complete cds
SEQ ID NO:18	isolate NL/1/99 (99-1) HMPV (Human Metapneumovirus)cDNA sequence
SEQ ID NO:19	isolate NL/1/00 (00-1) HMPV cDNA sequence
SEQ ID NO:20	isolate NL/17/00 HMPV cDNA sequence
SEQ ID NO:21	isolate NL/1/94 HMPV cDNA sequence
SEQ ID NO:22	RT-PCR primer TR1
SEQ ID NO:23	RT-PCR primer N1
SEQ ID NO:24	RT-PCR primer N2
SEQ ID NO:25	RT-PCR primer M1
SEQ ID NO:26	RT-PCR primer M2
SEQ ID NO:27	RT-PCR primer F1
SEQ ID NO:28	RT-PCR primer N3
SEQ ID NO:29	RT-PCR primer N4
SEQ ID NO:30	RT-PCR primer M3
SEQ ID NO:31	RT-PCR primer M4
SEQ ID NO:32	RT-PCR primer F7
SEQ ID NO:33	RT-PCR primer F8
SEQ ID NO:34	RT-PCR primer L6
SEQ ID NO:35	RT-PCR primer L7

SEQ ID NO:36	Oligonucleotide probe M
SEQ ID NO:37	Oligonucleotide probe N
SEQ ID NO:38	Oligonucleotide probe L
SEQ ID NO:39	TaqMan primer and probe sequences for isolates NL/1/00, BI/1/01, FI/4/01, NL/8/01, FI/2/01
SEQ ID NO:40	TaqMan primer and probe sequences for isolates NL/30/01
SEQ ID NO:41	TaqMan primer and probe sequences for isolates NL/22/01 and NL/23/01
SEQ ID NO:42	TaqMan primer and probe sequences for isolate NL/17/01
SEQ ID NO:43	TaqMan primer and probe sequences for isolate NL/17/00
SEQ ID NO:44	TaqMan primer and probe sequences for isolates NL/9/01, NL/21/01, and NL/5/01
SEQ ID NO:45	TaqMan primer and probe sequences for isolates FI/1/01 and FI/10/01
SEQ ID NO:46	Primer ZF1
SEQ ID NO:47	Primer ZF4
SEQ ID NO:48	Primer ZF7
SEQ ID NO:49	Primer ZF10
SEQ ID NO:50	Primer ZF13
SEQ ID NO:51	Primer ZF16
SEQ ID NO:52	Primer CS1
SEQ ID NO:53	Primer CS4
SEQ ID NO:54	Primer CS7

SEQ ID NO:55	Primer CS10
SEQ ID NO:56	Primer CS13
SEQ ID NO:57	Primer CS16
SEQ ID NO:58	Forward primer for amplification of HPIV-1
SEQ ID NO:59	Reverse primer for amplification of HPIV-1
SEQ ID NO:60	Forward primer for amplification of HPIV-2
SEQ ID NO:61	Reverse primer for amplification of HPIV-2
SEQ ID NO:62	Forward primer for amplification of HPIV-3
SEQ ID NO:63	Reverse primer for amplification of HPIV-3
SEQ ID NO:64	Forward primer for amplification of HPIV-4
SEQ ID NO:65	Reverse primer for amplification of HPIV-4
SEQ ID NO:66	Forward primer for amplification of Mumps
SEQ ID NO:67	Reverse primer for amplification of Mumps
SEQ ID NO:68	Forward primer for amplification of NDV
SEQ ID NO:69	Reverse primer for amplification of NDV
SEQ ID NO:70	Forward primer for amplification of Tupaia
SEQ ID NO:71	Reverse primer for amplification of Tupaia
SEQ ID NO:72	Forward primer for amplification of Mapuera
SEQ ID NO:73	Reverse primer for amplification of Mapuera

SEQ ID NO:74	Forward primer for amplification of Hendra
SEQ ID NO:75	Reverse primer for amplification of Hendra
SEQ ID NO:76	Forward primer for amplification of Nipah
SEQ ID NO:77	Reverse primer for amplification of Nipah
SEQ ID NO:78	Forward primer for amplification of HRSV
SEQ ID NO:79	Reverse primer for amplification of HRSV
SEQ ID NO:80	Forward primer for amplification of Measles
SEQ ID NO:81	Reverse primer for amplification of Measles
SEQ ID NO:82	Forward primer to amplify general paramyxoviridae viruses
SEQ ID NO:83	Reverse primer to amplify general paramyxoviridae viruses
SEQ ID NO:84	G-gene coding sequence for isolate NL/1/00 (A1)
SEQ ID NO:85	G-gene coding sequence for isolate BR/2/01 (A1)
SEQ ID NO:86	G-gene coding sequence for isolate FL/4/01 (A1)
SEQ ID NO:87	G-gene coding sequence for isolate FL/3/01 (A1)
SEQ ID NO:88	G-gene coding sequence for isolate FL/8/01 (A1)
SEQ ID NO:89	G-gene coding sequence for isolate FL/10/01 (A1)
SEQ ID NO:90	G-gene coding sequence for isolate NL/10/01 (A1)
SEQ ID NO:91	G-gene coding sequence for isolate NL/2/02 (A1)
SEQ ID NO:92	G-gene coding sequence for isolate NL/17/00 (A2)

SEQ ID NO:93	G-gene coding sequence for isolate NL/1/81 (A2)
SEQ ID NO:94	G-gene coding sequence for isolate NL/1/93 (A2)
SEQ ID NO:95	G-gene coding sequence for isolate NL/2/93 (A2)
SEQ ID NO:96	G-gene coding sequence for isolate NL/3/93 (A2)
SEQ ID NO:97	G-gene coding sequence for isolate NL/1/95 (A2)
SEQ ID NO:98	G-gene coding sequence for isolate NL/2/96 (A2)
SEQ ID NO:99	G-gene coding sequence for isolate NL/3/96 (A2)
SEQ ID NO:100	G-gene coding sequence for isolate NL/22/01 (A2)
SEQ ID NO:101	G-gene coding sequence for isolate NL/24/01 (A2)
SEQ ID NO:102	G-gene coding sequence for isolate NL/23/01 (A2)
SEQ ID NO:103	G-gene coding sequence for isolate NL/29/01 (A2)
SEQ ID NO:104	G-gene coding sequence for isolate NL/3/02 (A2)
SEQ ID NO:105	G-gene coding sequence for isolate NL/1/99 (B1)
SEQ ID NO:106	G-gene coding sequence for isolate NL/11/00 (B1)
SEQ ID NO:107	G-gene coding sequence for isolate NL/12/00 (B1)
SEQ ID NO:108	G-gene coding sequence for isolate NL/5/01 (B1)
SEQ ID NO:109	G-gene coding sequence for isolate NL/9/01 (B1)
SEQ ID NO:110	G-gene coding sequence for isolate NL/21/01 (B1)
SEQ ID NO:111	G-gene coding sequence for isolate NL/1/94 (B2)

SEQ ID NO:112	G-gene coding sequence for isolate NL/1/82 (B2)
SEQ ID NO:113	G-gene coding sequence for isolate NL/1/96 (B2)
SEQ ID NO:114	G-gene coding sequence for isolate NL/6/97 (B2)
SEQ ID NO:115	G-gene coding sequence for isolate NL/9/00 (B2)
SEQ ID NO:116	G-gene coding sequence for isolate NL/3/01 (B2)
SEQ ID NO:117	G-gene coding sequence for isolate NL/4/01 (B2)
SEQ ID NO:118	G-gene coding sequence for isolate UK/5/01 (B2)
SEQ ID NO:119	G-protein sequence for isolate NL/1/00 (A1)
SEQ ID NO:120	G-protein sequence for isolate BR/2/01 (A1)
SEQ ID NO:121	G-protein sequence for isolate FL/4/01 (A1)
SEQ ID NO:122	G-protein sequence for isolate FL/3/01 (A1)
SEQ ID NO:123	G-protein sequence for isolate FL/8/01 (A1)
SEQ ID NO:124	G-protein sequence for isolate FL/10/01 (A1)
SEQ ID NO:125	G-protein sequence for isolate NL/10/01 (A1)
SEQ ID NO:126	G-protein sequence for isolate NL/2/02 (A1)
SEQ ID NO:127	G-protein sequence for isolate NL/17/00 (A2)
SEQ ID NO:128	G-protein sequence for isolate NL/1/81 (A2)
SEQ ID NO:129	G-protein sequence for isolate NL/1/93 (A2)
SEQ ID NO:130	G-protein sequence for isolate NL/2/93 (A2)

SEQ ID NO:131	G-protein sequence for isolate NL/3/93 (A2)
SEQ ID NO:132	G-protein sequence for isolate NL/1/95 (A2)
SEQ ID NO:133	G-protein sequence for isolate NL/2/96 (A2)
SEQ ID NO:134	G-protein sequence for isolate NL/3/96 (A2)
SEQ ID NO:135	G-protein sequence for isolate NL/22/01 (A2)
SEQ ID NO:136	G-protein sequence for isolate NL/24/01 (A2)
SEQ ID NO:137	G-protein sequence for isolate NL/23/01 (A2)
SEQ ID NO:138	G-protein sequence for isolate NL/29/01 (A2)
SEQ ID NO:139	G-protein sequence for isolate NL/3/02 (A2)
SEQ ID NO:140	G-protein sequence for isolate NL/1/99 (B1)
SEQ ID NO:141	G-protein sequence for isolate NL/11/00 (B1)
SEQ ID NO:142	G-protein sequence for isolate NL/12/00 (B1)
SEQ ID NO:143	G-protein sequence for isolate NL/5/01 (B1)
SEQ ID NO:144	G-protein sequence for isolate NL/9/01 (B1)
SEQ ID NO:145	G-protein sequence for isolate NL/21/01 (B1)
SEQ ID NO:146	G-protein sequence for isolate NL/1/94 (B2)
SEQ ID NO:147	G-protein sequence for isolate NL/1/82 (B2)
SEQ ID NO:148	G-protein sequence for isolate NL/1/96 (B2)
SEQ ID NO:149	G-protein sequence for isolate NL/6/97 (B2)

SEQ ID NO:150	G-protein sequence for isolate NL/9/00 (B2)
SEQ ID NO:151	G-protein sequence for isolate NL/3/01 (B2)
SEQ ID NO:152	G-protein sequence for isolate NL/4/01 (B2)
SEQ ID NO:153	G-protein sequence for isolate NL/5/01 (B2)
SEQ ID NO:154	F-gene coding sequence for isolate NL/1/00
SEQ ID NO:155	F-gene coding sequence for isolate UK/1/00
SEQ ID NO:156	F-gene coding sequence for isolate NL/2/00
SEQ ID NO:157	F-gene coding sequence for isolate NL/13/00
SEQ ID NO:158	F-gene coding sequence for isolate NL/14/00
SEQ ID NO:159	F-gene coding sequence for isolate FL/3/01
SEQ ID NO:160	F-gene coding sequence for isolate FL/4/01
SEQ ID NO:161	F-gene coding sequence for isolate FL/8/01
SEQ ID NO:162	F-gene coding sequence for isolate UK/1/01
SEQ ID NO:163	F-gene coding sequence for isolate UK/7/01
SEQ ID NO:164	F-gene coding sequence for isolate FL/10/01
SEQ ID NO:165	F-gene coding sequence for isolate NL/6/01
SEQ ID NO:166	F-gene coding sequence for isolate NL/8/01
SEQ ID NO:167	F-gene coding sequence for isolate NL/10/01
SEQ ID NO:168	F-gene coding sequence for isolate NL/14/01

WO 03/072719**PCT/US03/05271**

SEQ ID NO:169	F-gene coding sequence for isolate NL/20/01
SEQ ID NO:170	F-gene coding sequence for isolate NL/25/01
SEQ ID NO:171	F-gene coding sequence for isolate NL/26/01
SEQ ID NO:172	F-gene coding sequence for isolate NL/28/01
SEQ ID NO:173	F-gene coding sequence for isolate NL/30/01
SEQ ID NO:174	F-gene coding sequence for isolate BR/2/01
SEQ ID NO:175	F-gene coding sequence for isolate BR/3/01
SEQ ID NO:176	F-gene coding sequence for isolate NL/2/02
SEQ ID NO:177	F-gene coding sequence for isolate NL/4/02
SEQ ID NO:178	F-gene coding sequence for isolate NL/5/02
SEQ ID NO:179	F-gene coding sequence for isolate NL/6/02
SEQ ID NO:180	F-gene coding sequence for isolate NL/7/02
SEQ ID NO:181	F-gene coding sequence for isolate NL/9/02
SEQ ID NO:182	F-gene coding sequence for isolate FL/1/02
SEQ ID NO:183	F-gene coding sequence for isolate NL/1/81
SEQ ID NO:184	F-gene coding sequence for isolate NL/1/93
SEQ ID NO:185	F-gene coding sequence for isolate NL/2/93
SEQ ID NO:186	F-gene coding sequence for isolate NL/4/93
SEQ ID NO:187	F-gene coding sequence for isolate NL/1/95

SEQ ID NO:188	F-gene coding sequence for isolate NL/2/96
SEQ ID NO:189	F-gene coding sequence for isolate NL/3/96
SEQ ID NO:190	F-gene coding sequence for isolate NL/1/98
SEQ ID NO:191	F-gene coding sequence for isolate NL/17/00
SEQ ID NO:192	F-gene coding sequence for isolate NL/22/01
SEQ ID NO:193	F-gene coding sequence for isolate NL/29/01
SEQ ID NO:194	F-gene coding sequence for isolate NL/23/01
SEQ ID NO:195	F-gene coding sequence for isolate NL/17/01
SEQ ID NO:196	F-gene coding sequence for isolate NL/24/01
SEQ ID NO:197	F-gene coding sequence for isolate NL/3/02
SEQ ID NO:198	F-gene coding sequence for isolate NL/3/98
SEQ ID NO:199	F-gene coding sequence for isolate NL/1/99
SEQ ID NO:200	F-gene coding sequence for isolate NL/2/99
SEQ ID NO:201	F-gene coding sequence for isolate NL/3/99
SEQ ID NO:202	F-gene coding sequence for isolate NL/11/00
SEQ ID NO:203	F-gene coding sequence for isolate NL/12/00
SEQ ID NO:204	F-gene coding sequence for isolate NL/1/01
SEQ ID NO:205	F-gene coding sequence for isolate NL/5/01
SEQ ID NO:206	F-gene coding sequence for isolate NL/9/01

WO 03/072719**PCT/US03/05271**

SEQ ID NO:207	F-gene coding sequence for isolate NL/19/01
SEQ ID NO:208	F-gene coding sequence for isolate NL/21/01
SEQ ID NO:209	F-gene coding sequence for isolate UK/11/01
SEQ ID NO:210	F-gene coding sequence for isolate FL/1/01
SEQ ID NO:211	F-gene coding sequence for isolate FL/2/01
SEQ ID NO:212	F-gene coding sequence for isolate FL/5/01
SEQ ID NO:213	F-gene coding sequence for isolate FL/7/01
SEQ ID NO:214	F-gene coding sequence for isolate FL/9/01
SEQ ID NO:215	F-gene coding sequence for isolate UK/10/01
SEQ ID NO:216	F-gene coding sequence for isolate NL/1/02
SEQ ID NO:217	F-gene coding sequence for isolate NL/1/94
SEQ ID NO:218	F-gene coding sequence for isolate NL/1/96
SEQ ID NO:219	F-gene coding sequence for isolate NL/6/97
SEQ ID NO:220	F-gene coding sequence for isolate NL/7/00
SEQ ID NO:221	F-gene coding sequence for isolate NL/9/00
SEQ ID NO:222	F-gene coding sequence for isolate NL/19/00
SEQ ID NO:223	F-gene coding sequence for isolate NL/28/00
SEQ ID NO:224	F-gene coding sequence for isolate NL/3/01
SEQ ID NO:225	F-gene coding sequence for isolate NL/4/01

SEQ ID NO:226	F-gene coding sequence for isolate NL/11/01
SEQ ID NO:227	F-gene coding sequence for isolate NL/15/01
SEQ ID NO:228	F-gene coding sequence for isolate NL/18/01
SEQ ID NO:229	F-gene coding sequence for isolate FL/6/01
SEQ ID NO:230	F-gene coding sequence for isolate UK/5/01
SEQ ID NO:231	F-gene coding sequence for isolate UK/8/01
SEQ ID NO:232	F-gene coding sequence for isolate NL/12/02
SEQ ID NO:233	F-gene coding sequence for isolate HK/1/02
SEQ ID NO:234	F-protein sequence for isolate NL/1/00
SEQ ID NO:235	F-protein sequence for isolate UK/1/00
SEQ ID NO:236	F-protein sequence for isolate NL/2/00
SEQ ID NO:237	F-protein sequence for isolate NL/13/00
SEQ ID NO:238	F-protein sequence for isolate NL/14/00
SEQ ID NO:239	F-protein sequence for isolate FL/3/01
SEQ ID NO:240	F-protein sequence for isolate FL/4/01
SEQ ID NO:241	F-protein sequence for isolate FL/8/01
SEQ ID NO:242	F-protein sequence for isolate UK/1/01
SEQ ID NO:243	F-protein sequence for isolate UK/7/01
SEQ ID NO:244	F-protein sequence for isolate FL/10/01

SEQ ID NO:245	F-protein sequence for isolate NL/6/01
SEQ ID NO:246	F-protein sequence for isolate NL/8/01
SEQ ID NO:247	F-protein sequence for isolate NL/10/01
SEQ ID NO:248	F-protein sequence for isolate NL/14/01
SEQ ID NO:249	F-protein sequence for isolate NL/20/01
SEQ ID NO:250	F-protein sequence for isolate NL/25/01
SEQ ID NO:251	F-protein sequence for isolate NL/26/01
SEQ ID NO:252	F-protein sequence for isolate NL/28/01
SEQ ID NO:253	F-protein sequence for isolate NL/30/01
SEQ ID NO:254	F-protein sequence for isolate BR/2/01
SEQ ID NO:255	F-protein sequence for isolate BR/3/01
SEQ ID NO:256	F-protein sequence for isolate NL/2/02
SEQ ID NO:257	F-protein sequence for isolate NL/4/02
SEQ ID NO:258	F-protein sequence for isolate NL/5/02
SEQ ID NO:259	F-protein sequence for isolate NL/6/02
SEQ ID NO:260	F-protein sequence for isolate NL/7/02
SEQ ID NO:261	F-protein sequence for isolate NL/9/02
SEQ ID NO:262	F-protein sequence for isolate FL/1/02
SEQ ID NO:263	F-protein sequence for isolate NL/1/81

SEQ ID NO:264	F-protein sequence for isolate NL/1/93
SEQ ID NO:265	F-protein sequence for isolate NL/2/93
SEQ ID NO:266	F-protein sequence for isolate NL/4/93
SEQ ID NO:267	F-protein sequence for isolate NL/1/95
SEQ ID NO:268	F-protein sequence for isolate NL/2/96
SEQ ID NO:269	F-protein sequence for isolate NL/3/96
SEQ ID NO:270	F-protein sequence for isolate NL/1/98
SEQ ID NO:271	F-protein sequence for isolate NL/17/00
SEQ ID NO:272	F-protein sequence for isolate NL/22/01
SEQ ID NO:273	F-protein sequence for isolate NL/29/01
SEQ ID NO:274	F-protein sequence for isolate NL/23/01
SEQ ID NO:275	F-protein sequence for isolate NL/17/01
SEQ ID NO:276	F-protein sequence for isolate NL/24/01
SEQ ID NO:277	F-protein sequence for isolate NL/3/02
SEQ ID NO:278	F-protein sequence for isolate NL/3/98
SEQ ID NO:279	F-protein sequence for isolate NL/1/99
SEQ ID NO:280	F-protein sequence for isolate NL/2/99
SEQ ID NO:281	F-protein sequence for isolate NL/3/99
SEQ ID NO:282	F-protein sequence for isolate NL/11/00

SEQ ID NO:283	F-protein sequence for isolate NL/12/00
SEQ ID NO:284	F-protein sequence for isolate NL/1/01
SEQ ID NO:285	F-protein sequence for isolate NL/5/01
SEQ ID NO:286	F-protein sequence for isolate NL/9/01
SEQ ID NO:287	F-protein sequence for isolate NL/19/01
SEQ ID NO:288	F-protein sequence for isolate NL/21/01
SEQ ID NO:289	F-protein sequence for isolate UK/11/01
SEQ ID NO:290	F-protein sequence for isolate FL/1/01
SEQ ID NO:291	F-protein sequence for isolate FL/2/01
SEQ ID NO:292	F-protein sequence for isolate FL/5/01
SEQ ID NO:293	F-protein sequence for isolate FL/7/01
SEQ ID NO:294	F-protein sequence for isolate FL/9/01
SEQ ID NO:295	F-protein sequence for isolate UK/10/01
SEQ ID NO:296	F-protein sequence for isolate NL/1/02
SEQ ID NO:297	F-protein sequence for isolate NL/1/94
SEQ ID NO:298	F-protein sequence for isolate NL/1/96
SEQ ID NO:299	F-protein sequence for isolate NL/6/97
SEQ ID NO:300	F-protein sequence for isolate NL/7/00
SEQ ID NO:301	F-protein sequence for isolate NL/9/00

SEQ ID NO:302	F-protein sequence for isolate NL/19/00
SEQ ID NO:303	F-protein sequence for isolate NL/28/00
SEQ ID NO:304	F-protein sequence for isolate NL/3/01
SEQ ID NO:305	F-protein sequence for isolate NL/4/01
SEQ ID NO:306	F-protein sequence for isolate NL/11/01
SEQ ID NO:307	F-protein sequence for isolate NL/15/01
SEQ ID NO:308	F-protein sequence for isolate NL/18/01
SEQ ID NO:309	F-protein sequence for isolate FL/6/01
SEQ ID NO:310	F-protein sequence for isolate UK/5/01
SEQ ID NO:311	F-protein sequence for isolate UK/8/01
SEQ ID NO:312	F-protein sequence for isolate NL/12/02
SEQ ID NO:313	F-protein sequence for isolate HK/1/02
SEQ ID NO:314	F protein sequence for HMPV isolate NL/1/00
SEQ ID NO:315	F protein sequence for HMPV isolate NL/17/00
SEQ ID NO:316	F protein sequence for HMPV isolate NL/1/99
SEQ ID NO:317	F protein sequence for HMPV isolate NL/1/94
SEQ ID NO:318	F-gene sequence for HMPV isolate NL/1/00
SEQ ID NO:319	F-gene sequence for HMPV isolate NL/17/00
SEQ ID NO:320	F-gene sequence for HMPV isolate NL/1/99

SEQ ID NO:321	F-gene sequence for HMPV isolate NL/1/94
SEQ ID NO:322	G protein sequence for HMPV isolate NL/1/00
SEQ ID NO:323	G protein sequence for HMPV isolate NL/17/00
SEQ ID NO:324	G protein sequence for HMPV isolate NL/1/99
SEQ ID NO:325	G protein sequence for HMPV isolate NL/1/94
SEQ ID NO:326	G-gene sequence for HMPV isolate NL/1/00
SEQ ID NO:327	G-gene sequence for HMPV isolate NL/17/00
SEQ ID NO:328	G-gene sequence for HMPV isolate NL/1/99
SEQ ID NO:329	G-gene sequence for HMPV isolate NL/1/94
SEQ ID NO:330	L protein sequence for HMPV isolate NL/1/00
SEQ ID NO:331	L protein sequence for HMPV isolate NL/17/00
SEQ ID NO:332	L protein sequence for HMPV isolate NL/1/99
SEQ ID NO:333	L protein sequence for HMPV isolate NL/1/94
SEQ ID NO:334	L-gene sequence for HMPV isolate NL/1/00
SEQ ID NO:335	L-gene sequence for HMPV isolate NL/17/00
SEQ ID NO:336	L-gene sequence for HMPV isolate NL/1/99
SEQ ID NO:337	L-gene sequence for HMPV isolate NL/1/94
SEQ ID NO:338	M2-1 protein sequence for HMPV isolate NL/1/00
SEQ ID NO:339	M2-1 protein sequence for HMPV isolate NL/17/00
SEQ ID NO:340	M2-1 protein sequence for HMPV isolate NL/1/99

SEQ ID NO:341	M2-1 protein sequence for HMPV isolate NL/1/94
SEQ ID NO:342	M2-1 gene sequence for HMPV isolate NL/1/00
SEQ ID NO:343	M2-1 gene sequence for HMPV isolate NL/17/00
SEQ ID NO:344	M2-1 gene sequence for HMPV isolate NL/1/99
SEQ ID NO:345	M2-1 gene sequence for HMPV isolate NL/1/94
SEQ ID NO:346	M2-2 protein sequence for HMPV isolate NL/1/00
SEQ ID NO:347	M2-2 protein sequence for HMPV isolate NL/17/00
SEQ ID NO:348	M2-2 protein sequence for HMPV isolate NL/1/99
SEQ ID NO:349	M2-2 protein sequence for HMPV isolate NL/1/94
SEQ ID NO:350	M2-2 gene sequence for HMPV isolate NL/1/00
SEQ ID NO:351	M2-2 gene sequence for HMPV isolate NL/17/00
SEQ ID NO:352	M2-2 gene sequence for HMPV isolate NL/1/99
SEQ ID NO:353	M2-2 gene sequence for HMPV isolate NL/1/94
SEQ ID NO:354	M2 gene sequence for HMPV isolate NL/1/00
SEQ ID NO:355	M2 gene sequence for HMPV isolate NL/17/00
SEQ ID NO:356	M2 gene sequence for HMPV isolate NL/1/99
SEQ ID NO:357	M2 gene sequence for HMPV isolate NL/1/94
SEQ ID NO:358	M protein sequence for HMPV isolate NL/1/00
SEQ ID NO:359	M protein sequence for HMPV isolate NL/17/00

SEQ ID NO:360	M protein sequence for HMPV isolate NL/1/99
SEQ ID NO:361	M protein sequence for HMPV isolate NL/1/94
SEQ ID NO:362	M gene sequence for HMPV isolate NL/1/00
SEQ ID NO:363	M gene sequence for HMPV isolate NL/17/00
SEQ ID NO:364	M gene sequence for HMPV isolate NL/1/99
SEQ ID NO:365	M gene sequence for HMPV isolate NL/1/94
SEQ ID NO:366	N protein sequence for HMPV isolate NL/1/00
SEQ ID NO:367	N protein sequence for HMPV isolate NL/17/00
SEQ ID NO:368	N protein sequence for HMPV isolate NL/1/99
SEQ ID NO:369	N protein sequence for HMPV isolate NL/1/94
SEQ ID NO:370	N gene sequence for HMPV isolate NL/1/00
SEQ ID NO:371	N gene sequence for HMPV isolate NL/17/00
SEQ ID NO:372	N gene sequence for HMPV isolate NL/1/99
SEQ ID NO:373	N gene sequence for HMPV isolate NL/1/94
SEQ ID NO:374	P protein sequence for HMPV isolate NL/1/00
SEQ ID NO:375	P protein sequence for HMPV isolate NL/17/00
SEQ ID NO:376	P protein sequence for HMPV isolate NL/1/99
SEQ ID NO:377	P protein sequence for HMPV isolate NL/1/94
SEQ ID NO:378	P gene sequence for HMPV isolate NL/1/00

SEQ ID NO:379	P gene sequence for HMPV isolate NL/17/00
SEQ ID NO:380	P gene sequence for HMPV isolate NL/1/99
SEQ ID NO:381	P gene sequence for HMPV isolate NL/1/94
SEQ ID NO:382	SH protein sequence for HMPV isolate NL/1/00
SEQ ID NO:383	SH protein sequence for HMPV isolate NL/17/00
SEQ ID NO:384	SH protein sequence for HMPV isolate NL/1/99
SEQ ID NO:385	SH protein sequence for HMPV isolate NL/1/94
SEQ ID NO:386	SH gene sequence for HMPV isolate NL/1/00
SEQ ID NO:387	SH gene sequence for HMPV isolate NL/17/00
SEQ ID NO:388	SH gene sequence for HMPV isolate NL/1/99
SEQ ID NO:389	SH gene sequence for HMPV isolate NL/1/94

DEMANDES OU BREVETS VOLUMINEUX

**LA PRÉSENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.**

CECI EST LE TOME __1__ DE __2__

NOTE: Pour les tomes additionels, veuillez contacter le Bureau Canadien des Brevets.

JUMBO APPLICATIONS / PATENTS

**THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.**

THIS IS VOLUME __1__ OF __2__

NOTE: For additional volumes please contact the Canadian Patent Office.

The embodiments of the present invention for which an exclusive property or privilege is claimed are defined as follows:

1. An in vitro diagnostic method for classifying a human metapneumovirus as a human metapneumovirus variant B2 virus of SEQ ID NO: 21, wherein said method comprises contacting an isolated sample containing the human metapneumovirus with an antibody, wherein the antibody specifically recognizes an amino acid sequence unique to human metapneumovirus variant B2 OF SEQ ID NO: 21.
2. An in vitro diagnostic method for classifying a human metapneumovirus as a human metapneumovirus variant B2 virus of SEQ ID NO: 21, wherein said method comprises contacting an isolated sample containing the human metapneumovirus with a nucleic acid or a complement thereof, wherein the nucleic acid or complement thereof hybridizes specifically under high stringency conditions to a nucleotide sequence of human metapneumovirus variant B2 comprising a nucleotide sequence according to SEQ ID NO: 21, wherein said high stringency conditions comprise prehybridization in buffer composed of 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll®, 0.02% BSA, and 500 µg/ml denatured salmon sperm DNA for 8 h to overnight at 65 °C, hybridization in a buffer composed of 6X SSC, 50 mM Tris-HCl (pH=7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll®, 0.02% BSA and 100 µg/ml denatured salmon sperm DNA for 48 hours at 65 °C, washing in a buffer consisting of 2X SSC, 0.01% PVP, 0.01% Ficoll and 0.01% BSA, for 1 h at 37 °C, and washing in a buffer consisting of 0.1X SSC, for 45 minutes at 50 °C.
3. The method of claim 1 or 2 wherein the sample is obtained from a human.
4. The method of claim 1, wherein the amino acid sequence is selected from the group consisting of SEQ ID NO: 325, SEQ ID NO: 369, SEQ ID NO: 377, SEQ ID NO: 317, SEQ ID NO: 341, SEQ ID NO: 349, SEQ ID NO: 385, and SEQ ID NO: 333.
5. The method of claim 2, wherein the nucleic acid is selected from the group consisting of SEQ ID NO: 329; SEQ ID NO: 373; SEQ ID NO: 381; SEQ ID NO: 321; SEQ ID NO: 345; SEQ ID NO: 353; SEQ ID NO: 389; and SEQ ID NO: 337.
6. The method of claim 1, wherein the amino acid sequence is a G protein selected from SEQ ID NO: 146-153 or F protein selected from SEQ ID NO: 297, SEQ ID NO: 298, SEQ ID NO: 299, SEQ ID NO:301, SEQ ID NO:304, SEQ ID NO:305 and SEQ ID NO:310.

7. The method of claim 2 wherein the nucleotide sequence is a G gene selected from SEQ ID NO: 111-118 or an F gene selected from SEQ ID NO: 217-219, SEQ ID NO:221, SEQ ID NO: 224, SEQ ID NO: 225 and SEQ ID NO: 230.

8. The method of claim 2, wherein the nucleic acid or complement thereof hybridizes specifically under high stringency conditions to a nucleotide sequence encoding a protein comprising:

(i) an amino acid sequence that is identical to the G protein of a human metapneumovirus variant B2 SEQ ID NO: 325;

(ii) an amino acid sequence that is identical to the N protein of a human metapneumovirus variant B2 SEQ ID NO: 369;

(iii) an amino acid sequence that is identical to the P protein of a human metapneumovirus variant B2 SEQ ID NO: 377;

(iv) an amino acid sequence that is identical to the F protein of a human metapneumovirus variant B2 SEQ ID NO: 317;

(v) an amino acid sequence that is identical to the M2-1 protein of a human metapneumovirus variant B2 SEQ ID NO: 341;

(vi) an amino acid sequence that is identical to the M2-2 protein of a human metapneumovirus variant B2 SEQ ID NO: 349;

(vii) an amino acid sequence that is identical to the SH protein of a human metapneumovirus variant B2 SEQ ID NO: 385; or

(viii) an amino acid sequence that is identical to the L protein a human metapneumovirus variant B2 SEQ ID NO: 333,

wherein said high stringency conditions comprise prehybridization in buffer composed of 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll®, 0.02% BSA, and 500 µg/ml denatured salmon sperm DNA for 8 h to overnight at 65 °C, hybridization in a buffer composed of 6X SSC, 50 mM Tris-HCl (pH=7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll®, 0.02% BSA and 100 µg/ml denatured salmon sperm DNA for 48 hours at 65 °C, washing in a buffer consisting of 2X SSC, 0.01% PVP, 0.01% Ficoll and 0.01% BSA, for 1 h at 37 °C, and washing in a buffer consisting of 0.1X SSC, for 45 minutes at 50 °C.

9. The method of claim 2, wherein the nucleic acid or complement thereof hybridizes specifically under high stringency conditions to a nucleotide sequence selected from the

group consisting of SEQ ID NO: 329; SEQ ID NO: 373; SEQ ID NO: 381; SEQ ID NO: 321; SEQ ID NO: 345; SEQ ID NO: 353; SEQ ID NO: 389; and SEQ ID NO: 337, wherein said high stringency conditions comprise prehybridization in buffer composed of 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll®, 0.02% BSA, and 500 µg/ml denatured salmon sperm DNA for 8 h to overnight at 65°C, hybridization in a buffer composed of 6X SSC, 50 mM Tris-HCl (pH=7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll®, 0.02% BSA and 100 µg/ml denatured salmon sperm DNA for 48 hours at 65 °C, washing in a buffer consisting of 2X SSC, 0.01% PVP, 0.01% Ficoll and 0.01% BSA, for 1 h at 37 °C, and washing in a buffer consisting of 0.1X SSC, for 45 minutes at 50 °C.

10. The method of claim 1, wherein the antibody binds specifically to a protein consisting of:

- (i) an amino acid sequence that is identical to the G protein of a human metapneumovirus variant B2 SEQ ID NO: 325;
- (ii) an amino acid sequence that is identical to the N protein of a human metapneumovirus variant B2 SEQ ID NO: 369;
- (iii) an amino acid sequence that is identical to the P protein of a human metapneumovirus variant B2 SEQ ID NO: 377;
- (iv) an amino acid sequence that is identical to the F protein of a human metapneumovirus variant B2 SEQ ID NO: 317;
- (v) an amino acid sequence that is identical to the M2-1 protein of a human metapneumovirus variant B2 SEQ ID NO: 341;
- (vi) an amino acid sequence that is identical to the M2-2 protein of a human metapneumovirus variant B2 SEQ ID NO: 349;
- (vii) an amino acid sequence that is identical to the SH protein of a human metapneumovirus variant B2 SEQ ID NO: 385; or
- (viii) an amino acid sequence that is identical to the L protein a human metapneumovirus variant B2 SEQ ID NO: 333.

11. A recombinant human metapneumovirus of variant B2, wherein the genome of the recombinant human metapneumovirus of variant B2 comprises a nucleotide sequence that is at least 99% identical to the nucleotide sequence of SEQ ID NO: 21.

12. The recombinant human metapneumovirus of claim 11, wherein the recombinant human metapneumovirus of variant B2 comprises a genome with the nucleotide sequence of SEQ ID NO: 21.
13. An isolated nucleic acid, wherein the nucleic acid encodes a protein comprising
 - (i) an amino acid sequence that is identical to the G protein of SEQ ID NO:325;
 - (ii) an amino acid sequence that is identical to the N protein of SEQ ID NO:369;
 - (iii) an amino acid sequence that is identical to the P protein of SEQ ID NO:377;
 - (iv) an amino acid sequence that is identical to the F protein of SEQ ID NO:317;
 - (v) an amino acid sequence that is identical to the M2-1 protein of SEQ ID NO:341;
 - (vi) an amino acid sequence that is identical to the M2-2 protein of SEQ ID NO:349;
 - (vii) an amino acid sequence that is identical to the SH protein of SEQ ID NO:385;
 or
 - (viii) an amino acid sequence that is identical to the L protein of SEQ ID NO:333.
14. An isolated protein, wherein the protein comprises:
 - (i) an amino acid sequence that is identical to the G protein of SEQ ID NO:325;
 - (ii) an amino acid sequence that is identical to the N protein of SEQ ID NO:369;
 - (iii) an amino acid sequence that is identical to the P protein of SEQ ID NO:377;
 - (iv) an amino acid sequence that is identical to the F protein of SEQ ID NO:317;
 - (v) an amino acid sequence that is identical to the M2-1 protein of SEQ ID NO:341;
 - (vi) an amino acid sequence that is identical to the M2-2 protein of SEQ ID NO:349;

- (vii) an amino acid sequence that is identical to the SH protein of SEQ ID NO:385;
or
 - (viii) an amino acid sequence that is identical to the L protein of SEQ ID NO:333.
15. An antibody, wherein the antibody binds specifically to a protein consisting of:
- (i) an amino acid sequence that is identical to the G protein of SEQ ID NO:325;
 - (ii) an amino acid sequence that is identical to the N protein of SEQ ID NO:369;
 - (iii) an amino acid sequence that is identical to the P protein of SEQ ID NO:377;
 - (iv) an amino acid sequence that is identical to the F protein of SEQ ID NO:317;
 - (v) an amino acid sequence that is identical to the M2-1 protein of SEQ ID NO:341;
 - (vi) an amino acid sequence that is identical to the M2-2 protein of SEQ ID NO:349;
 - (vii) an amino acid sequence that is identical to the SH protein of SEQ ID NO:385;
or
 - (viii) an amino acid sequence that is identical to the L protein of SEQ ID NO:333.
16. A method for detecting a human metapneumovirus of variant B2 in a sample, wherein the method comprises contacting the sample with the nucleic acid of claim 13 or the antibody of claim 15.
17. The method of claim 16, wherein the sample is obtained from a human.

M							
	00-1	hRSV	bRSV	PMV	APV-A	APV-C	APV-B
00-1	1,00	0,37	0,37	0,37	0,77	0,87	0,75
hRSV	---	1,00	0,91	0,41	0,37	0,37	0,37
bRSV	---	---	1,00	0,42	0,35	0,36	0,35
PMV	---	---	---	1,00	0,37	0,38	0,38
APV-A	---	---	---	---	1,00	0,78	0,89
APV-C	---	---	---	---	---	1,00	0,77
APV-B	---	---	---	---	---	---	1,00
N							
	00-1	hRSV	bRSV	PVM	APV-A	APV-C	APV-B
00-1	1,00	0,20	0,22	0,21	0,40	0,52	0,40
hRSV	---	1,00	0,59	0,30	0,18	0,21	0,18
bRSV	---	---	1,00	0,31	0,21	0,23	0,21
PVM	---	---	---	1,00	0,21	0,23	0,21
APVA	---	---	---	---	1,00	0,42	1,00
APVC	---	---	---	---	---	1,00	0,42
APVB	---	---	---	---	---	---	1,00
F							
	00-1	hRSV	bRSV	PVM	APV-A	APV-C	APV-B
00-1	1,00	0,32	0,33	0,37	0,67	0,80	0,66
hRSV	---	1,00	0,82	0,40	0,35	0,35	0,35
bRSV	---	---	1,00	0,41	0,34	0,36	0,34
PVM	---	---	---	1,00	0,38	0,38	0,39
APV-A	---	---	---	---	1,00	0,72	0,84
APV-C	---	---	---	---	---	1,00	0,72
APV-B	---	---	---	---	---	---	1,00
P							
	00-1	hRSV	bRSV	PMV	APV-A	APV-C	
00-1	1,00	0,25	0,26	0,27	0,55	0,67	
hRSV	---	1,00	0,81	0,30	0,28	0,26	
bRSV	---	---	1,00	0,29	0,28	0,26	
PMV	---	---	---	1,00	0,23	0,27	
APV-A	---	---	---	---	1,00	0,52	
APV-C	---	---	---	---	---	1,00	
L8							
	00-1	hRSV	bRSV	APV-A			
00-1	1,00	0,36	0,35	0,56			
hRSV	---	1,00	0,79	0,36			
bRSV	---	---	1,00	0,35			
APV-A	---	---	---	1,00			
L9/10							
	00-1	hRSV	bRSV	APV-A			
00-1	1,00	0,30	0,30	0,53			
hRSV	---	1,00	0,83	0,34			
bRSV	---	---	1,00	0,32			
APV-A	---	---	---	1,00			

FIGURE 1

Seroprevalence of hMPV in humans categorised by age group using immunofluorescence and virus neutralisation assays

Age (Years)	Immunofluorescence assays		Virus neutralisation assays		
	N tested	N positive	N tested	N positive	Titre range
< 1	20	5	12	3	16-32
1-2	20	11	13	4	16-32
2-5	20	14	8	3	16-512
5-10	20	20	4	4	32-256
10-20	20	20	4	3	32-128
> 20	20	20	4	3	32-128
8-99 ¹	72	72	11	11	16-128

¹Sero-archeological analysis using sera collected in 1958

FIGURE 2




FIGURE 3

Nucleo protein

00-1 NP MSIQGIHLSYKHAILKESQYTIKRDVGTITAVTPSSLQOEITLLCGEILYAKHADYKYAAEIGIQYISTALGSEVQVILRNSGSEVQVVLRTYSL 10
APV A ...ES.R...E.....ED.....R...A...I...E...PQVST...MV.F...T...EP...V.M.....AD.T...K.....G.M.KIVT. 10
APV B Q.....R.VS.....T...SH...V.M..V..T..A..T...K.....A...K... 10
APV C Q.....R.VS.....T...SH...V.M..V..T..A..T...K.....A...K... 10
bRSV .A.SKVK.N.TFN.DQL.ST.K...Q.ST.DNIDIPNYDV.KHLNK...ML.ITED.NH.FTGL..ML.AMSR..R.DTLK..KDA.YQ.RANGVDVITH 10
hRSV .A.SKVK.N.TFN.DQL.SS.K...Q.ST.DNIDIPNYDV.KHLNK...ML.ITED.NH.FTGL..ML.AMSR..R.DTLK..KDA.YH.KANGVDITTY 10
FVM ...DRLK.N.V.N.DSL.SNCK.SVT.ST.DV.S.SGHAM.KALARTL.MF.LTAFNRCEEV...L..AMSL..RDSIK...EA.YN.KC.D.QLKDF 10

00-1 NP GKIKNNKGEDLQMLDINGVEKSWVEEIDKARKMTATLLKESSGNIPQNRPSAPDTPILLCVGALIFTKLASTIEVGLETTVRRANRVLSDALKRYPR 20
APV A SAEGSVRKREV...N..D.GVG.ADDVERTT.EA.GAMVR.KV-QLTK..K...L.A.V...I.....V.....AI...S.....IS... 19
APV B ..G..S...E.....R..I..V.....SAT.DN..P.....S..A.....I.....A.....N.....F.. 20
APV C ..G..S...E.....R..I..V.....SAT.DN..P.....S..A.....I.....A.....N.....F.. 20
bRSV RQDV.G.EMKFEV.TLVSLTSEVQGN.EI.S..SYKKM...M-.EVAPEY.HDS..CGM.V...A..VI...AGDRS..TAVI...N..RNEM...KG 19
hRSV RQDI.G.EMKFEV.TLVSLTSEIQVN.EI.S..SYKKM...M-.EVAPEY.HDS..CGM.I..IA..VI...AGDRS..TAVI...N..RNEI...KG 19
FVM TIKLQG.EYKI.V...V.IDAANLADLEIQ..GVV.KE..TG-ARL.D.R.HD...CGV.V..IA..VVS...AGDRG..DAVE...LN..KAEGA...N 19

00-1 NP MDIPKIARSFYDLFEQKVYHRSLEFYGKALGSSSTGSKAESLFVNIEMQAYGAGQTMRLRWGLIARSSNNIMLGHVSVQAEIKQVTEVYDLVREMGPESG 30
APV A ...R..K..FE...K...Y.N.....T...RM.....R..S.....K..... 29
APV B I.....Y..... 30
APV C I.....Y..... 30
bRSV LIPKD..N...EV..KYPHYIDV.VHF.I.QS.TRG..RV.GI.AGL..N.....V.....L.K.VK.....A.....ME..V...EYAKQL.G.A. 29
hRSV LIPKD..N...EV..KHPHLIDV.VHF.I.QS.TRG..RV.GI.AGL..N...S..V.....L.K.VK.....A.....ME..V...EYAKQL.G.A. 29
FVM .EVKQ..E.....R.P.YIDV..TF.L.QS.VRG...V.G..SGL..N.....V.....LL.K.VK.....A.....ME..V...EYAKQL.G.A. 29

00-1 NP LLHLRQSPKAGLLSLANCPNFASVVLGNASGLIGMYRGRVPNTLFSAAESYAKSLKESNKNIFSSSLGLTDEEKEAAEHFLNVSDSDSDNDYE 39
APV A T.....A.....K..A..L..A.....RT.R.N...LAA...D.R...TSY.GGD.ERSSEK. 39
APV B N.....L.....A.....R.....E.....N...INEEG.... 39
APV C N.....L.....A.....R.....E.....N...INEEG.... 39
bRSV FY.I.LNN...S...TQF...S.....A...M.E...TPR.QD.YD..KA..EQ...NGV..Y.V.D..T..L..IKNQ..PK.N--DVEL 39
hRSV FY.I.LNN...S...TQF...S.....A...M.E...TPR.QD.YD..KA..EQ...NGV..Y.V.D..A..L..IKNQ..PKE--DVEL 39
FVM FY.I.LNN...S...T...T.....A.....S.K.APR.R...D..KD..ER..DN.V..Y.A.N..A..R.LISQQ..IV...TPD.DI 39

Phospho protein

00-1 P MS-FPEGKDILFMGNEAAKLAEAF-----QKSLRKPGHKRSQSIIGKVNVTSETLELPTISRPAKPTIPSEPKLAWTDKGGATKTEIKQAIVMDP 91
APV-A ...M..S...M.D.Y-----R...NTSAG-GR..S..PI..IA.KVP..PLCN.TT-----SCI.PNKAPVP..K-- 76
APV-C ...L.....A.....R..K.I..R.T...V.D.II...V.K...KST.V.T.P.R.N..GE.PDT.RSQTEE.RNEAT. 91
bRSV 80
hRSV .EK.APE---H.ED.NNK.TK.LES-----IKGKE-----ASSKDPKK.DS.IXVNS 45
FVM .EK.APE---V.ED.N.K..E.LKHRSFPSE.P.AGIPNTATHVTYKYNMPPILRSSEK..SPRVA.NL.E..A---PTTPPP.PPQN.EEQPKESD 92

00-1 P IEEESTETKVLPSDDGKTPEAKKLPSTNT-----KKKVSFTPNP-----GKYTKLEKDALLSDNEEDAE-SSILTFEE-RDTSSLSTEARLESTIE 18
APV-A --.I..IYP.LPTAPVATDTYTSTSTE.AKK-----S...K.DNPKV-----EEG.E...P..DND.K.....K..A.T.....A.. 16
APV-C EDASRLY.EVFA.T.....GKETPEKP-----T.KND.S--R.....ME..E.....DD...V.....K...A..L.....D 18
bRSV 16
hRSV .DI.VTK.SPITSGTNIIN.TSEADSTPETKANYPR.PL...KEDLTSPDNPF.S..Y.ETIETF--DNN--EE.SYSY..INDQ.-NDN.T...DR.D 13
FVM VDI.TMHVC..PONPEHSKKKCCSDDTD.KKT--R.PM.T.VEP.EKFV.LGAS.YRETMTTF--AADGYDEE.N.S...TNQEPG.S.V.Q..DR.. 18

00-1 P EKLSMILGLLRITINLATAGPTAARDGIRDAMIGVREELIADIKEA--KGKAAEM--MEEEMXQRSKIGNGSVKLTEKAKELANKIVEDESTSGESEE 27
APV-A M.K.....M.....NS.MT...D.I...K..DT..A..D.....L..Q.S.....S. 25
APV-C V.....V.L.....K..AK.K.....G..... 27
bRSV X..... 26
hRSV E...M.H..VV.S...S.....V.L..M.EK.RA..LMTNDRLEA.ARLN..SEKMA.OTSDE.P.NPTS.K.SDLL..N----- 23
FVM Y.I...N.DMV.....T...E...L..T...EM.KSDILTNDRIVA.EKLRD..CSRADTDDGSACY..DR.RI.D...SSNA----- 27

00-1 P EEPKDTQDNSQEDDIY---QLIM. 29
APV-A ..SGESESDEE.S...NLDL..L 28
APV-C ..EE.EEESNPD..L.SLTM..LIK 29
bRSV 28
hRSV ---.SNDLSL.---DF. 24
FVM ---EEAKEDLDV...MGINF..LI 29

FIGURE 4

Matrix protein

FIGURE 4, contd.

00-1 matrix MESYLVDVYQGIPTAAVQVDLIEKDLLPASLTIWFLPQANTPPAVLLDQLKLTITITLYAASQNGPILKVNASQGAAMEVLKPKFEVNAVAXDEYS 10
APV-B II....V.....V...NN..K..V.....SS..AP.....S...Q-TV..PE..V.Q...T.....SA.....S.S.PA..L.... 10
APV-A II....V.....SN..T..V.....SS..AP.....S...Q-TV..PE..V.Q...A.....SA.....A.S.A..L.... 10
APV-C V.....V.....T..V...Q...R..V.V...T...T...E.....T.....SA.....S.D.S.S..L.D.. 10
brSV ..T.VNKLHE..ST.....YNV....DD.....V.M..SSISADL.IKE..INVN.LVRQISTPK..S..IMNSRS.VLAQM.S..TIS.N.SL..R.. 10
hrSV ..T.VNKLHE..ST.....YNVL...DD.....V.M..SSV.ADL.IKE..ASIN.LVRQISTPK..S.R.TINSRS.VLAQM.SN.IIS.N.SL..R.. 10
FVM A...EM.H.V.....LN.V..HSANI...V.I.M..TSL.KNSVM.L.HDV.VICTQISTVH..MI..DL.SSN.GLATM.RQ.LI..II.L.DWG 10

00-1 matrix KLEFDKLTVCVKTVYLTIMKPYGMVSKFVSSAKSVGKTHDLIALCDFMDLEKNTPTTIPAFIKSVSIKESSESATVEAAISSEADQALTOAKIAPYAGL 20
APV-B ..D.GV....D.RA....L.....I.TMNT..R.....I.M.RGI.....Y..A...D.....G....I...R..... 20
APV-A R ..GT....D.RSI...L.....IMDVR..R.....I..I..GV.I...Y..A...D.....G....I...R..... 20
APV-C L.A.....N...A.....L.....GV.....Y.....G....I...R..... 20
brSV ..AY.IT.P..I.ACS..CL.VKN.LTTVKDLTKTFNP..EI...E.ENIMTSKR.V..T.LR.INV.AKDLSL.NIATT.FKN.I.N...I.... 20
hrSV ..AY.VT.P..I.ACS..CL.VKS.LTTVKDLTKTFNP..EI...E.ENIMTSKR.I..TYLRPI.V.NKDLNSL.NIATT.FKN.I.N...I.... 20
FVM NMDYEVFAFDK.SFCV..IL..KN.LYTV..ITPTN-RP..E...V.S.HNRVTLSKN..V..RALY.RQGLDS..Q....DV.H.I.T.RV..... 19

00-1 matrix IMIMTMNNPKGIFKGLGAGTQVIVELGAYVQAESISKICKTWSHQTRYVLKSR. 25
APV-B ..LL.A.....R.....P.....IG.....N..R...-I-L-K-SR 25
APV-A ..L.....M.....P.....IG.....N..R...-GYPK-A.-IC.C-YSQ.K 27
APV-C V.....R..RN.....-R 25
brSV VLVI.VTDN..A..YIKPQS.F..D...LEK...YYVTN.K.TA.KFSI.P-IED. 25
hrSV VLVI.VTDN..A..YIKPQS.F..D...LEK...YYVTN.K.TA..FSI.P-IED. 25
FVM TLVINITST..A..L.K..S.ILA...P.LTQV.LHDVTM.N.K.T..S.I...SS-TSG. 25

Fusion protein

00-1 F MSW-KVVIKESLLI-TPKHGLKESYLEESCSTITEGYLSVLRGTWYTNVFTLEVGDVENLTCADGPS-LIKTELDLTKSALRELRTVSADQ 88
APV-A .DV-RICLLF.IS-N.SSCIQ.T.N....V.R..K.....N..I.N..I.N...-D..V..N....K..... 88
APV-B .YL-LLLIY.VV-GASGKQ.T.S....V.R..K.....N..I.N..I.N...-S..S..QN.Q..... 88
APV-C ...-LLLV..A-..TG..E....Y..V.R.....T.....R...E..N..E..K..... 88
brSV .ATTAMRM.SIIFISTYVTH.LCONIT.EFYQST.AVSR...A.....S.V.I.LSKIQKNV.KSTD.RVK...Q..ERYNN.VV..QSLMQNE 10
hrSV .ELIHRLSAI.LT.AINALYL.SSQNT.EFYQST.AVSR..F.A.....S.I.I.LSNIKETK.NGTDTRVK...Q...KY.N.VT..QLIMQNT 10
FVM .-IPGR.FLV..VIFNTKPIHNT.T.K.Y.ST..VE.A..K.A....RMT.MSKLSQINIES.KSSN.-.IAH..AIYS..VD...L.SNA 93

00-1 F LAREEQ-IENPROSREVLGALVATAAATAGVAIAKTIRLESEVTAIKNAKKTNEAVSTLGMGVRVLATAVRELK 16
APV-A V.K.SR-LSS..AR.....L.....G..K.....RN.....ND.. 16
APV-B ITK.NR-LSH.KK.....T.....L.....G..K..L..RS.....I....ND.. 16
APV-C ..K.AR-MS..KA.....G..A..G..R.....ND.. 16
brSV P.SFSRAKRGIFELIHYTRNSTKTFYGLMGKK.KR..L-GFL..IG-S..AS..VS.VLH..G..NK....LS..K..VS.S..S..TSK.LD.. 19
hrSV P.ANNRARREAPQYMYTINTTKNLNVS.SKK.KR..L-GFL..G-S.IAS.I.VS.VLH..G..NK....LS..K..VS.S..S..TSK.LD.. 19
FVM -LKS.KK..L-GLI..LG-.....L..VQ...IAL.RD.VRN....VS.T..MS..KV.DD.. 16

00-1 F DFVSKNLTRAINKNKCDIADLKMAVFSQFNRRFLNVVRQFSDNAGITPAISLDLMTDAELARAVSNMPTSAGQIKIMLENRAMVRRKGFGFLIGVYGSS 26
APV-A E.I..K..P..Q..N..I..I..G.N.....S...S.V.....D..V..INR...S...S..N.....I....DGT 26
APV-B E.I..K..P..Q..N..IR..I..G.N.....S...S.V.....VK.INR...S...S..N.....I....GT 26
APV-C ..I..K..P..R...S.....G.Y.....V.....S..N.....I.... 26
brSV NYID.E.LPQV.NHD.R.SNIETVIE.Q.K.N.L.EIA.E..V....TPL.TYML.NS..LSLIND..ITND.K..SS.VQI..QSYSIMS.V.KEEV 29
hrSV NYINMQ.LPIV.QQS.R.SNIETVIE.Q.K.S.L.EIN.E..V....V.TPL.TYML.NS..LSLIND..ITND.K..SS.VQI..QSYSIMS.IKEEV 29
FVM N.I..E.LPK..RVS..VH.ITAVIR.Q.L.K.L.E.S.E..S...L.HTV.SFML..R..TST.GG.AV...KEI..SSK..IM..N.LAI.SS.NADT 26

00-1 F VIKMVQLPIFGVIDTPCWIVKAAPSC-SGKKGNACLLREDQGWYQCNAGSTVYYPNEKDCETRGDHFVFCUTAGINVAEQSKECNINISTTNYPKVS 36
APV-A .VY.....E...R.V..L-RKE.....I.....T....A...KD...V.D.Y.....LEVEQ..Y...SK..... 36
APV-B .VY.....E...R.V..L-RHERES.....T....A...D...V.D.Y.....SEVEQ..H...ST..... 36
APV-C .VYI.....K...L-..D.....E..V.S.....RE.E..R...K..... 36
brSV IAYV....Y.....KLHTS.L.TDN.E.SNI..T.T.R...D...VSFF.QTET.KVQSNR...MNSLTLPDNL..TD.FN.K.D..IM 39
hrSV IAYV....Y.....KLHTS.L.TNI.E.SNI..T.T.R...D...VSFF.QADT.KVQSNR...MNSLTLPSEVSL..TD.FNSK.D..IM 39
FVM LVYVI...L..M..D..VIRSSID-HNIADK...A.A.N...H...LS.F.SPT...IHNGYA...LKSILT.PVT.R...S.MY...D..I.. 35

00-1 F TGRHPISMVALSPLGALVACYKGVSCSIGSNRVLGILKQLKGCYSITNODADVTITDNTVYQLSKVEGEQHVIRKRPVSSSFDPKFPEDQFNVALDQVF 46
APV-A V....T...G..S..ES.....K.....G...TH.P.NE...I.....V...RT...A..VNN.N.IL..... 46
APV-B V....T...G..S..E.....K.....TH.P.NE...I.....I.....V...RT...A..VNN.N.LL..... 46
APV-C D.M.....K...RP.G...S.....T...K...N..IE.....I.... 46
brSV .SKTD..SSVITSI..I.S..GKTK.TASNKNR...TFSN..D.VS.KGV...SVG..L.YVN.L..KALY...E.IINYY..LV..S.E.DASIA..N 49
hrSV .SKTD..SSVITS...I.S..GKTK.TASNKNR...TFSN..D.VS.KGV...SVG..L.YVN.L..KNLYV..E.IINYY..LV..S.E.DASIS..N 49
FVM .SKTYV.TAV.TTM.C..S..GHN..TVIN.DK...RT.PD..H..S.KGV.R.QVG...Y...EV.KSI.VR.E.LVLKY..LS..D.K.D..IRD.E 45

00-1 F ESIENSQALVDQSNRILS-SAEKGNIGFII-VIILAVLGSTMILVSFIIIRKTKRPTGAP-PELSGVINNGFIPH-N. 54
APV-A ...DR..D.I.K..DL.G-ADA.SKA..IA-A.VVLVI..IFFL.AVIYYCSRVR.TKPKHDY.ATT.HSSMAY-S 53
APV-B ..VDK.KD.I.K..DL.D-IEV.S.I.AAL-A.TILV..SMLI.VGIAYV..R.AK.SNGY.RTT.QS.M.Y.S. 53
APV-C ..V.K..N.I...K..D-I...A..V-..V..VL.MLAAG.G..FVV..R.AAPKF..M.MN..N.K...-F.LLKKGKGGK 55
brSV AK.NQ.L.FIRR.DEL.H-SVDVG.ST.NVV.TTI..V.V.VIIML.A.GLLFYC.TKST.IMLGRDQ...IN.LS.S-K. 57
hrSV .K.NQ.L.FIRR.DEL.H-NVNTG.ST.NIM.TTI..V.I.VLLSL.AIGLLLYC.AKNT.VTLSEKQ...IN.IA.S-K. 57
FVM H..NQTRTFKA.DQL.DLSENREN.NLAKSY.LTLLFVVM.III.AVIGFIIYKVLK-MIRDNK.KSKSTP.IT-VLS 53

L polymerase RAP PCR fragment 8

```

00-1 fragment 8 -----TVNVYLPDSYLKGVISFSETNAIGSCLLRPYLKNDNTAKVAIENPVEHVRLKNAVNSKMKISDYK-----IVEFVNMQHE 77
APV-A      ME-ISNESV.....V.N...I.D.Y..H..MT.....Q..RALFK.LTISRE.R-----V...IMI.K. 84
bRSV      MDTLIHENST....T.....C..L..Y..DG.....Y.NIISROK.L...IN..KLSIIQSFTK.NKGELGLE..TYF.SL 90
hRSV      MDPIINGNSA....T.G.....C..L..YIFNG.....Y.NIISROK.L...MN..KLNTTQSL..K.HKGEIKLE..TYF.SL 90

00-1 fragment 8 IM-KNVHSCEL---TLLKQFLTRSKNISTKLNMICDWLQLK-----STSDPTSILSEIDVEFI----- 13
APV-A      LL--VAAGAR.---KK..KW.G...D..EV..K.VT...K.S-----Q.PGRGK.IDR.Q..NL----- 13
bRSV      L.TY.SLSTS..ITTT..F.KIIR.AIE..DV.VYA.LNK.G..EKGVKDRD---DDTN.TLSNIVRDNLSVISDNTPTKPPNNSCK 17
hRSV      L.TY.SMT.S.QIATN..KIIR.AIE..DV.VYA.LNK.G..EKDKIKSNNGQDE.NSV.TTI.KDDILSAVKDNQSHLKADKNHSTK 18

00-1 fragment 8 -----PSWVSNWFSNWNLNKLLLEFRKEEVIRTGSIL---CRSLGKLVFVSSYGCIVKSNKSKRVSFFTYNQLL 20
APV-A      -----D.LEH..DS.LI..DV.QSY.CL..SQ.SA..--RK.SLNEF.A...F...II.R..R.IC.C..... 20
bRSV      PDQPIKTTILCKLLSSMSHP.T.LIH..NLYTK..DILTQY.TN.ARNH.Y..IDT.T..EFQ.IINQ.....YHK.L.KITIT....F. 26
hRSV      QKDTIKTTLLKKLMCSMQHP...LIH..NLYTK..NILTQY.SN..KNH.FT.IDNQT.SGFQ.IINQ.....YHKEL..ITVT....F. 27

00-1 fragment 8 TWKDVMLSRFNANFCIWSNLSLNENQEGVGLRSNL-----Q 23
APV-A      ....LA.....L.V....C..SA.D.L....K.VGELLNR 24
bRSV      ....IS...L.VCMIT.I..C..TLNKS...C 30
hRSV      ....IS...L.VCLIT.I..C..TLNKS...C 30

```

L polymerase RAP-PCR fragment 9/10

```

00-1 fragment 9/10 --KLVDKITSQHFISPDKIDMLTLGKMLMP--TIKQKTDQ---FLNKRNYFHGNLIESLSAALAXHWGILTEQC 72
APV-A      -F.S.R..VT.....N..H..LVM...L.L.--VRSNINNN---KPAT..F.N...IV.A.TSC..C...TV.IILT 72
bRSV      -ICKLNQVIQK..M.L....SLSQYVELFLSNK.L.NSPHISSNLVLVH.MSD..LHKYV---.TN..G..IM.IQIMK 76
hRSV      DIHKLKQVIQK..M.L....SLTQYVELFLSNK.L.SGSHVNSNLILAH.ISD...NTYT---.TN..G..IL.IQIMK 77

00-1 fragment 9/10 IENNIFKKDWGDFISDHAFMDFKIFLCVFKTKLLC 10
APV-A      T..S..Q.E.....T....IN.TW..MS...Y...HW 11
bRSV      DSKG..E....E.Y.T..M.L.LNV.FDAY..Y. 11
hRSV      DSKG..E....E.Y.T..M.INL.V.FNAY..Y 11

```

FIGURE 4, contd.

50
HMPV MSLOGIHLSDLSYKHAILKESQYTIKRDVGTTTAVTPSSLOQEITLLCGE
APVC Q.....R.VS.....
APVB ...ES.R...E.....D.....R...A...I...E..PKVST...M
APVA ...ES.R...E.....ED.....R...A...I...E..POVST...M
HRSVA .A.SKVK.N.TLN.DQL.SS.K...Q.ST.DSIDTPNYDV.KH.NK...M
HRSVB .A.SKVK.N.TLN.DQL.SS.K...Q.ST.DNIDTPNYDV.KHLNK...M
BRSV .A.SKVK.N.TFN.DQL.ST.K...Q.ST.DNIDIPNYDV.KHLNK...M
PVM ...DRLK.N.V.N.DSL.SNCK.SVT.ST.DV.S.SGHAM.KALARTL.M
100
HMPV ILYAKHADYKYAAEIGIQYISTALGSEVQOILRNSGSEVQVVLTRTYSL
APVC T..SH...V.M..V..T..A..T....K.....A...K....
APVB ..F.....EP..QV.M.....ADKT....KS.....G.M.KIVT.
APVA V.F...T..EP...V.M.....AD.T....K.....G.M.KIVT.
HRSVA L.ITED.NH.FTGL..ML.AMSR..R.DTIK...DA.YH.KANGVDVTTH
HRSVB L.ITED.NH.FTGL..ML.AMSR..R.DTIK...KDA.YH.KANGVDITTY
BRSV L.ITED.NH.FTGL..ML.AMSR..R.DTLK...KDA.YQ.RANGVDVITH
PVM F.LTAFNRCEEV....L..AMSL..RDDSIC...EA.YN.KC.D.QLKDF
150
HMPV GKIKNNKGEDLOMLDINGVEKSWVEEIDKEARKTMATLLKESSGNIPONQ
APVC ..G..S...E.....R..I..V.....SAT.DN..P.....
APVB PAEGPIR--KREV.N..DIGPA.ADNVERT..E..SIMV..K-AQ..K..
APVA SAEGSVR--KREV.N..D.GVG.ADDVERTT.EA.GAMVR.K-VQLTK..
HRSVA RQDI.G.EMKFEV.TLASLTTEIQIN.EI.S..SYKKM...M-.EVAPEY
HRSVB RQDI.G.EMKFEV.TLSSLTSEIQVN.EI.S..SYKKM...M-.EVAPEY
BRSV RQDV.G.EMKFEV.TLVSLTSEVQGN.EI.S..SYKKM...M-.EVAPEY
PVM TIKLOG.EYKI.V...V.IDAANLADLEIQ..GVV.KE..TG-ARL.D.R
200
HMPV RPSAPDTPHLCVGAITFKITSTFEVGLTVEKRNVLSDAIKRYPR
APVC ...S..A...I.....A.....N.....F..
APVB K...L.A.V...I.....V.....AI...S.....IS...
APVA K...L.A.V...I.....V.....AI...S.....IS...
HRSVA .HDS..CGM.I..IA..VI....AGDRS..TAVI....N..KNEM...KG
HRSVB .HDS..CGM.I..IA..VI....AGDRS..TAVI....N..KNEI...KG
BRSV .HDS..CGM.V...A..VI....AGDRS..TAVI....N..RNEM...KG
PVM .HD...CGV.V...IA..VVS...AGDRG..DAVE...LN..KAEGA...N
250
HMPV MDLQKARSFEDFEOKVHRSFDEYKALGSSSTGSKAESLEVNEMO
APVC I.....Y.....
APVB R..K..FE...K...Y.N.....T.S..RM.....
APVA R..K..FE...K...Y.N.....T...RM.....
HRSVA LLPKD..N...EV..KHPHFIDV.VHF.I.QS.TRG..RV.GI.AGL..N
HRSVB LIPKD..N...EV..KHPHLIDV.VHF.I.QS.TRG..RV.GI.AGL..N
BRSV LIPKD..N...EV..KYPHYIDV.VHF.I.QS.TRG..RV.GI.AGL..N
PVM .EVKQ..E.....R.P.YIDV..TF.L.QS.VRG...V.G..SGL..N
300
HMPV AYCAGQPMERWGVFARSSNNIMCGHVAQAEIKVATLEVYDNRREMGPSG
APVC R..V.....R..S.....K.....
APVB R..S.....K.....
APVA R..S.....K.....
HRSVA V.....L.K.VK.....A...ME..V...EYAQKL.G.A.
HRSVB S..V.....L.K.VK.....A...ME..V...EYAQKL.G.A.
BRSV V.....L.K.VK.....A...ME..V...EYAQKL.G.A.
PVM V.....L.K.VK.....A...ME..V...EYAOKO.G.A.
350
HMPV LHLRQSPKQGLISEANENFESVUENASGEGICGMRGRVPNTELESA
APVC N.....L.....A..
APVB TS.....A.....K..A..L....
APVA T.....A.....K..A..L...A..
HRSVA FY.ILNN...S...TQF.H.S.....A...M.E...TPR.QD.YD.
HRSVB FY.ILNN...S...TQF...S.....A...M.E...TPR.QD.YD.
BRSV FY.ILNN...S...TQF...S.....A...M.E...TPR.QD.YD.
PVM FY.I.NN...S...T...T.....A.....S.K.APR.R...D.
395
HMPV AESYAKSLKESNKNINFSSLGLTDEEKEAAEHFLNVSDDS-QNDYE
APVC R.....E.....N...INEEG-.....
APVB R.....LAA...ED.R...TSY.GGDE.K-SQKF.
APVA RT.R.N...LAA...D.R...TSY.GGD.ER-SSKF.
HRSVA .KA..EQ...NGV..Y.V.D..A..L..IK.Q..PK.N--DVEL-
HRSVB .KA..EQ...NGV..Y.V.D..A..L..IKNQ..PKE.--DVEL-
BRSV .KA..EQ...NGV..Y.V.D..T..L..IKNQ..PK.N--DVEL-
PVM .KD..ER..DN.V..Y.A.N..A..R.LISQQ..IV..TPDD.I-

FIGURE 5

50
HMPV MSFPEGKDILFMGNEAAKLAEAFQKSLRKPGHKRS-----QSIIGEK
APVC L.....A.....R..K.I..R.T-----...V.D.
APVB ..L.....M..S.....Y.Q.IKNSTSV-----R..S.DP
APVA M..S....M.D.Y.R...NTSAGG-----R..S..P
HRSVA ---M.KFAPE.H.ED.NNR.TK.LE-----
HRSVB ---M.KFAPE.H.ED.NNK.TK.LE-----
BRSV ---M.KFAPE.H.ED.NTK.TK.LE-----
PVM ---M.KFAPE.V.ED.N.K..E.L.HRSF.SE.PLAGIPNTATHVTKYNM
100
HMPV VNTVSETLELPTISREPAKPTIPSEPKLAWTDKGGATKTEIKQAIKVMPI
APVC II.....V.K....KST.V.T.P.R.N..GE.PDT.RSQTEE.RNEAT.E
APVB .S....KVP..PLCSSETS-----R.ACIRPT-.STLPPIK--
APVA I..IA.KVP..PLCN.TT-----..SCI.PN-.APVPKVK--
HRSVA ---IKGKFTS-----KDPKK.DS.ISVNS.
HRSVB ---IKGKFSS-----KDPKK.DS.ISVNS.
BRSV ---LKGKFTSS-----KDSRK.DS.ISVNSV
PVM PPILRSSFK..SPRVA.NL.E..A.P---TTPPP.PPQN.EEQPKESDV
150
HMPV EEEESTEKKVLPSSDGKTPAEKKLPSTNTKKK-----VSFTPNPGKYT
APVC DASRLY.EVFA.T.....GKETPEKP.....T.KND.S.R..
APVB .V.SIYP.LPTAPP.AMIETAHPGAPKKAQ.R-----K.ESSKA...
APVA .I.SIYP.LPTAPVATD.YTSTSTESAKKS.....K.DNPKV...
HRSVA DI.VTK.SPITSN.TIIN.TNETDDTAG.KPNYQRKPL...KEDPTPSDN
HRSVB DI.VTK.SPITSGTNIIN.TSEADSTPETKANYPRKPL...KEDLTPSDN
BRSV DI.LPK.SPITSTNQINQNPSEINDTIATNQVHIRKPL...KEEL.SSEN
PVM DI.TMHVC..PDNPEHKKPCCSDDTD.KKT---RKPM.T.VEP.EKFVG
200
HMPV KLEKDALLDLS-NEEEDAESSILTFEERD--TSSLSIEARLESIEEKL
APVC ...ME..E....-..DD....V....K---A..L.....D...
APVB ...EE..E....PD.DN.EK..V....K---NAPS.....A.....
APVA ...EEG.E....PE.DN.EK.....K---A.T.....A.....
HRSVA PFS.LYKETIETFDNN--E.E.SYSY..INDQ.NDN-.T...DR.D...
HRSVB PFS.LYKETIETFDNN--E.E.SYSY..INDQ.NDN-.T...DR.D...
BRSV PFTRLYKETIETFDNN--E.E.SYSYD.INDQ.NDN-.T...DR.D...
PVM LGASLYRETMQTFAADGYD.E.N.S...TNQEPG.S.V.O..DR.....
250
HMPV MILGLLRLTNIATAGPTAARDGIRDAMIGVREELIADIIEAKGK-----
APVC V.....V.L.....
APVB ...M.K..S.....V.....NS.MA.....
APVA ...M.K.....M.....NS.MT...D.....
HRSVA E...M.H..VV.S....S.....L...M.EK.RT..LMTNDRLE
HRSVB E...M.H..VV.S....S.....V.L...M.EK.RA..LMTNDRLE
BRSV E.I.M.H..VV.S.....V.L...M.EK.RS..LMTNDRLE
PVM Y.I...N.IMV.....T...E...L..T....EM.KSIILTVNDRIV
300
HMPV -AAEMMEEEMSQRSKIGNSGSVKLTEKAKELNKIVEEESISGESEEEEPK
APVC K..AK.K.....G.....
APVB -I..IIK..DA..A...D.....R...RML..O.S...T.S.ET
APVA -I...K..DT..A...D.....L...O.S...T.S.ET
HRSVA AM.RLRN..SEKMA.DTSDE.S.NPTSEK..NLL.G-----N
HRSVB AM.RLRN..SEKMA.DTSDE.P.NPTS.K.SDLL-----N
BRSV AM.RLRD..SEKMT.DTSDE....PTSEK..MVL-----E
PVM AMEKLRD..C.RADTDGSAKY..DR.RI.D...SSNA-----E
316
HMPV DTQDNSQEDDIYOLIM
APVC :HEESNPT..L.S.T.
APVB EPDTDGEN....SFD.
APVA ESESDEEUS...N.DL
HRSVA .SDNDLSLE.F-----
HRSVB .SDNDLSL..F-----
BRSV SSDNDLSLE.F-----
PVM EAKEDLOV...MGINF

FIGURE 6


```

50
HMPV MESYLVDTYQGIPTAAVQVDLIEKDLLPASLTIWFPLFQANTPPAVLLD
APVC .....V.....T..V...Q...R..V.V....T....T...E
APVB ....II.....V.....V...NN..K..V.....SS..AP....
APVA ....II.....V.....V...SN..T..V.....SS..AP....
HRSVA ..T.VNKLHE.ST.....YNVL...DD.....V.M..SSM.ADL.IK
HRSVB ..T.VNKLHE.ST.....YNVL...DD.....V.M..SSV.ADL.IK
BRSV ..T.VNKLHE.ST.....YNV...DD.....V.M..SSISADL.IK
PVM ..A...EM.H.V.....LN.V..HSANI...V.I.M..TSL.KNSVM.
100
HMPV QLKTLTITTLYAASQNGPILKVNASQAQGAAMSVLPKKFEVNATVALDEYS
APVC .....T.....A...S.D.S.S....D..
APVB .....S...Q.TV.PE..V.Q...T.....A.....S.S.AA.....
APVA .....S...Q.T..PE..V.Q...A.....A.....A.S.A.....
HRSVA E..ANVN.LVKQISTPK..S.R.MINSRS.VLAQM.S..TIC.N.S...R.
HRSVB E..ASIN.LVKQISTPK..S.R.TINSRS.VLAQM.SN.IIS.N.S...R.
BRSV E..INVN.LVRQISTLK..S..IMINSRS.VLAQM.S..TIS.N.S...R.
PVM L.HDV.VICTQISTVH..MI..DL.SSN.GLATM.RQ.LI..II...DWG
150
HMPV KLEFDKLTVCVKTYLTMTKPYGMVSKFVSSAKSVGKKTTHDLLALCDEM
APVC .....L.A.....N...A.....L
APVB ..D.GV....D.RA....L.....I.TNMNT..R.....I
APVA R...GT....D.RSI....L.....IMTDVR...R.....I
HRSVA ..AY.VT.P..I.ACS..CL.SKN.LTTVKDLTMKTNP...I...E.E
HRSVB ..AY.VT.P..I.ACS..CL.VKS.LTTVKDLTMKTNP...EI...E.E
BRSV ..AY.IT.P..I.ACS..CL.VKN.LTTVKDLTMKTNP...EI...E.E
PVM NMDYEVPAFDK.SFCV.IL..KN.LYTVP.ITP-TNRP..E...V.S.R
200
HMPV DLEKNTFVTIPAFIKSVSIKESSESATVEAAISSEADQALTOAKIAPYAGL
APVC ....GV.....Y.....G.....I...R.....
APVB .M.RGI.....Y..A....D.....G.....I...R.....
APVA .I..GV.I....Y..A....D.....G.....I...R.....
HRSVA NIVTSKK.I..TYLR.I.VRNKDLN.L.NITTT.FKN.I.N...I..S..
HRSVB NIMTSKR.I..TYLRPI.V.NKDLNSL.NIATT.FKN.I.N...I....
BRSV NIMTSKR.V..T.LR.INV.AKDLDLSL.NIATT.FKN.I.N...I....
PVM NRVTLKSFN..V..RALY.RQGLDS..Q....DV.H.I.T.RV.....
250
HMPV IMIMTMNPNKGIFFKLGAGTQVIVELGAYVQAESISKICKTWSHQTRYV
APVC .....V.....R..RN.....
APVB .LL.A.....R.....P.....LG.....N..R...I
APVA .L.....M.....P.....LG.....N..R...
HRSVA LLVI.VTDN..A..YIKPOS.F..D...LEK...YYVTN.K.TA..FA
HRSVB VLVI.VTDN..A..YIKPOS.F..D...LEK...YYVTN.K.TA..FS
BRSV VLVI.VTDN..A..YIKPOS.F..D...LEK...YYVTN.K.TA..KFS
PVM TLVINITST..A..L.K..S.ILA...P.LTQV.LHDVIMN.K.T..S.I
258
HMPV LKSR----
APVC .....
APVB .....
APVA .R.....
HRSVA I.PMED--
HRSVB I.PLED--
BRSV I.PIED--
PVM ...SSTSG

```

FIGURE 7




FIGURE 8

Signal peptide

HMPV -----MSWKVVIIIFSLITPQHGLKESYLEESCTITEGYLSVLRTGWYTNVFTLEVGDVENLTCADGPS---LIKTELDLTSAALRELRTVSADQ 100
 APVC -----LLLV.A.TG.E.....Y.V.R.....T.....R...E...N...E...K.....
 APVB -----YL.LLL.IY.VVGASGKIQ.T.S.....V.R..K.....N..I.N..I.N.....S...S..QN..Q.....
 APVA -----DVRICLLF.ISN.SSCIQ.T.N.....V.R..K.....N..I.N..I.N.....D...V...N...K.....
 HRSVA MELLILKANAITTILTAFTCFASGQNT.EFYQST.AVSK....A.....S.I.I.LSNIKENH.NGTDKVK...Q...KY.N.VT..QLLMQST
 HRSVB MELLIRLSAIFLTLA.NA.YL.SSONIT.EFYQST.AVSR..F.A.....S.I.I.LSNIKETH.NGTDKVK...Q...KY.N.VT..QLLMQNT
 BRSV MATTAMRMII.IFISTYVTH..LCONIT.EFYQST.AVSR....A.....S.V.I.LSKIQKNV.KSTD.KVK...Q...ERYNN.VV..QSLMQNE
 PVM ----MIPGRIFLVLLV..NTKPIHPNT.T.K.Y.ST..VE.A..K.A....HMT.MSIKLSQINIES.KSSN.---LAH..AIYS..VD....L.SN-

Fusion domain

HMPV LAREEQ-----IENPROSRFVIGAIALGVATAAAVTAGVAIAKTIRLESEVTATKNALKKTNEAVSTLGNGVRVLATAVRELK 200
 APVC ..K.AR-----MS..K.....G..A...G..R.....ND..
 APVB ITK.NR-----LSH.KK.....T.....L.....G..K...L..RS.....I.....ND..
 APVA V.K.SR-----LSS..K.....L.....G..K.....RN.....ND..
 HRSVA PPTNNRARRELPRFMNYTLNNAKKTNTVLSKK.KR..LG--FL..G--S.IAS...VS.VLH..G..NK..S..LS..K..VS.S...S..TSK.LD..
 HRSVB P.ANNRARREAPQYMNNTINTTKNLNVS.SKK.KR..LG--FL..G--S.IAS.I.VS.VLH..G..NK....LS..K..VS.S...S..TSK.LD..
 BRSV P.SFSRAKRGIPELIHYTRNSTKKFYGLMGKK.KR..LG--FL..IG--S..AS...VS.VLH..G..NK....LS..K..VS.S...S..TSK.LD..
 PVM -----ALKSK-KK..LG--LI..LG--.....L...VQ....IAL.RD.VRN....VS.T..MS...KV.DD..

HMPV DEVSKNLTRAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDIMTDAELARAVSNMPTSAGQIKIMLENRAMVRRKGFGFLIGVYSS 300
 APVC ..I..K..P...R.....S.....G..Y.....V.....S...N.....I.....
 APVB E.I..K..P...Q...N...IR..I..G.N.....S...S.V.....VK.INR...S...S..N.....I.....GT
 APVA E.I..K..P...Q...N...I...I..G.N.....S...S.V.....D..V..INR...S...S..N.....I.....DGT
 HRSVA NYID.Q.LPIV..QS.S.SNIETVIE.Q.K.N.L.EIT.E..V...V.TPV.TYML.NS..LSLIND..ITND.K...SN.VQI..QQSYSIMSIIKEEV
 HRSVB NYINNQ.LPIV.QQS.R.SNIETVIE.Q.K.S.L.EIN.E..V...V.TPL.TYML.NS..LSLIND..ITND.K...SS.VQI..QQSYSIMSIIKEEV
 BRSV NYID.E.LPQV.NHL.R.SNIETVIE.Q.K.N.L.EIA.E..V....TPL.TYML.NS..LSLIND..ITND.K...SS.VQI..QQSYSIMSIIKEEV
 PVM N.I..E.LPK..RVS..VH.ITAVIR.Q.L.K.L.E.S.E..S...L.HTV.SFML..R..TSI.GG.AV...KEI..SSK.IM..N.LAI.SS.NADT

HMPV VIYMQVLPFEGVIDTHQWIVKAAPSGSG--KKGNYACLLREDQGWYQONAGSTVYYPNEKDCETRGDHVTCDDTAAGINVAEQSKHCNINISTTNYHCKVS 400
 APVC ..V.I.....K.....D.....E...V.S.....KE.E...R...K.....
 APVB ..V.....E...R.V...RH--ERES.....T...A...D...V.D.Y.....SEVEG...H...ST.....
 APVA ..V.....E...R.V...RK--E...I.....T...A...D...V.D.Y.....LEVEG...Y...SK.....
 HRSVA LA.V....LY....KLHTS.I.TTNT.E.SNI..T.T.R...D...VSFF.QAET.KVQSNR...MNSLTLPSEINI..VD.FNPK.I..IM
 HRSVB LA.V....Y....KLHTS.I.TTNI.E.SNI..T.T.R...D...VSFF.QAD.KVQSNR...MNSLTLPSEVSI..TD.FNSK.I..IM
 BRSV LA.V....Y....KLHTS.I.TTDN.E.SNI..T.T.R...D...VSFF.QTE.KVQSNR...MNSLTLPDVTNI..TD.FN.K.I..IM
 PVM LV.VI...L...M...H.VIRSSIHNN--IADK..A.A.N...H...LS.F.SPT..IHNGYA...LKSILT.PVT.RI..S.MY....I..I.

HMPV TGRHPISMVALSPLGALVHCYKGVSCSIGSNRVGIKQLNKGC SYITNQDADTVTIDNTVYQLSKVEGEQHVIGKRFVSSSFDPVKFPEDQFNVALDQVF 500
 APVC D.M.....K...RP.G.....S.....T...K...N...IE.....I.....
 APVB V.....T...G...S...E.....K.....TH.P.NE...I.....I.....V...RT...A..VNN.N.LL.....
 APVA V.....T...G...S...ES.....K.....G...TH.P.NE...I.....V...RT...A..VNN.N.LL.....
 HRSVA .SKTDV.SSVITS...I.S..GKTK.TASNKNR...TFSN..D.VS.KGM...SVG..L.YVN.Q..KSLYV..E.IINFY..LV..S.E.DASIS..N
 HRSVB .SKTD..SSVITS...I.S..GKTK.TASNKNR...TFSN..D.VS.KGV...SVG..L.YVN.L..KNLYV..E.IINY..LV..S.E.DASIS..N
 BRSV .SKTD..SSVITS...I.S..GKTK.TASNKNR...TFSN..D.VS.KGV...SVG..L.YVN.L..KALY...E.IINY..LV..S.E.DASIA..N
 PVM .SKTYV.TAV.TTM.C..S..GHN..TVIN.DK...RT.PD..H..S.KGV.R.QVG....Y...EV.KSI.VR.E.LVLKY..LS..D.K.D..IRD.E

HRB

HMPV ESIENSQALVDQSNRILSSAE----KGNTGFIIVIIILIAVLGSTMILVSVFIIKKTKKPTG---AP-PELSGVTNNGFIPHN 583
 APVC ..V.K..N.I....K..D.I-----A..V...V..VL.MLAAGV.G..FVV..R.AAPK---F.-M.MN..N.K....--
 APVB ..VDK.KD.I.K..DL.DIEV----S.I.AALA.TILV..SMLI.VGIAYYV..R.AK.S---NGY.KTT.QS.M.Y.S--
 APVA ...DR..D.I.K..DL.GADA----SKA.IA.A.VVLVI..IFFL.AVIYYCSRVR.TKPK---HDY.ATT.HSSMAYVS--
 HRSVA .K.NO..L.FIRK.DEL.HNVN--AG.ST.NIM.TT.I.VIIIVILLS.IA.GLLLYCKARS.P-VTLSKDQ...IN.IA.SN--
 HRSVB .K.NO..L.FIRR.DEL.HNVN--TG.ST.NIM.TT.I.VIIIVILLS.IAIGLLLYCKA.N.P-VTLSKDQ...IN.IA.SK--
 BRSV AK.NO..L.FIRR.DEL.H.VD--VG.ST.NV.VT.I.VIVVILM.IA.GLLFYCKT.S.P-IMLGKDQ...IN.LS.SK--
 PVM H..NOTRTFFKA.DQL.DLS.NREN.NLNKSY.LTT.LE.VMLII.MAVIGF.LY.VL.MIRDNKLKSKSTP.L.VLS-----

FIGURE 9

A

```

# # # 50
HMPV MSRKAPCKMVRGKCNBSSECKENHNYWSWDRYLLKSNYTLNQLHNT
APVC .....L.....
APVB ..GRN..R..T..R.....S.T.....HV..V.A..M...V...
APVA ...RN..R..I.....S.T.....HV..V.A..M.....
HRSVA ...RN...F.I..H.LN.KR.H.S...FE..PHA..V.Q.FM..RI.KSM
HRSVB ...RN...F.I..H.LN.RR.HYS...FE..PHA..V.Q.FM..KI.KSM
BRSV ...RN....I..H.LN.KK.H.S...FE..PHA..V.Q.FM..KI.KSM
PVM ...VR-...F..Q.F.S..RN..YS.K..E..LKT.ML.Q..M..RIY.FL
# 100
HMPV DEAHGSLSTISGAGREEDRTQDEVLTSTNYQGYIDDNQSITKAAACYS LH
APVC ..S-....L.....D.....N..N,EN....ST....Y
APVB ..T-....L.....A....N..EG.AT...S.....Y
APVA ..T-....L.....A....N..EG.TT...S.....Y
HRSVA .KSI.T..E....AEL...EEYA..VVG.LES..GSINN...QS..VAMS
HRSVB .KSI.T..E....AEL...EEYA..IVG.LES..GSINN...QS..VAMS
BRSV ..NN.T..E....AEL...EEYA..VIG.LES.LGSINN...QS..VAMS
PVM .TNT.AI.DV..FDAPO..AEYA..TIG.LKS.LEKTNN...SI..G..I
# 150
HMPV NIIKQLQEVEVRQARDNKLSDSKHVALHNLVLSYMEMS-KTPASLINNLK
APVC .....TD.....VD.....-.....
APVB .....ND.KS...LMVD.P.....ID..-..N..N...S..
APVA .....ND.KTS..SM.E.P.....I...VD..-..N.....S..
HRSVA KLLTE.NSDDIKKL...EELN.PKIRVY.T.I..I.SNR.NNKQT.HL..
HRSVB KLLTEINSDDIKKL...EELN.PKIRVY.T.I..I.SNR.NNKQT.HL..
BRSV KLLAEINNDIKRL.NKEVPT.PKIRIY.T.I..IDSNKRNKQT.HL..
PVM TVLQN.DVGL.I....SNTE.TNYLRSC.TI...IDKIL.K-RQI.HI..
# 195
HMPV RLPREKLKKLAKLIIDLSAGAE--NDSSYALQDSESTNQVQ----
APVC K..K.....E....V....TA.M...ANSD-----
APVB ...K.....I..Q....S.GE.AN.NT..KGD.S-----
APVA .....I..LQ....P.SD.A.GNT..KGD.N-----
HRSVA ...ADV...TI.NTL.IHKSITIN.PKESTVS.TNDHAKNNDTT-
HRSVB ...ADV...TI.NTL.IHKSIIIS.PKESTVN.QNDQTKNNDITG
BRSV ...ADV...TI.NT..IHNEINGN.QGDIIVNEQNE-----
PVM ...VGV.CN.IQSV.SIEEKINSSMKTE-----

```

B

```

# 50
HMPV -----MTLHMP-CKTVKALIKCS-----EHGPFVITIEVDDMIW
APVC -----...QL...I.QT...G-----...LI.LKMKL...V.
APVB -----PIVI...R.T.V.R.N-----TL.VCLFKRTYEHN.I
APVA -----PVVI...RR.T.I...N-----AL.LCMVRKIY.YS.A
HRSVA MTMPKIMILPKY.-.SITSI..TSRCRVTMYNQKNTLY.NQNNPNNHMY
HRSVB MTKPKIMILPKY:-.SISSI..SSESMIATFNHKNILQ.NHNHL.NHQR
BRSV MNNSNIIIFPEKY.-.SISSL...NENDVIVLSHQNVLDYLFQYPCNMY
PVM MQSDPICHLRGEDKFFYENRM.RLPKYYPAILHKMYIIRVNRNLTYDGS
# 97
HMPV THKDLKEA---L---SDGIVKSHTNIYNCYLENIEIIYVKAYLS---
APVC .KNE.VDI---I---TE...V.A..FK.R..D.....TF.---
APVB NLG..I.E---V---ARM.IID.I.RKQ.NECRKDFEF.AV.T.YT--
APVA SWS..I.E---V---ANMVLID.I.RKQ.VECRKDFEFIAI.T.YN--
HRSVA SPNQTFNE---IHWT.QELIDTIQ.FLQHLGIIED.YTIYILV.---
HRSVB LLNNIFDE---IHWT.PKNLLDATQQFLQHLNIPED.YTIYILV.---
BRSV SQNHMLDD---IYWT.QELIEDVLK.LHLSGIS.SKYVIYVLVL---
PVM GPSTIID.GKSVVWNRVDVLACVKEALC.IEFSWNNQVIIDFDYSQAR

```

FIGURE 10




FIGURE 11




FIGURE 12

A 674

HMPV NYIARASIVTDLSEKFNQAFRYETTAICADVADELHGTQSLFCWLHLIVPM
 APVA SV.....T.SS
 HRSVA ...SKC...I.....SC..S..L....V....F....AI..H
 HRSVB ...SKC...I.....SC..S..L....V....S....TI..L
 BRSV ...SKC...I.....SC..S..L....V....S....TI..F
 HPIV2 FELSAF.T...A.YCLQW...Q.IIHF.RTLNRMV.VPH..E.I..RLIR
 NDV RRRVATF.T...Q.YCLNW...Q.IKLF.HAINQ.M.LPHF.E.I..RLMD
 SV YETLSQFLT...K.YCLNW...F.S..LFGQRCN.IF.FKTF.N.M.FVLEK
 HPIV3 YETVSCFLT...K.YCLNW...S..LFGETCNQIF.LNK..N...PRLEG
 MV YETVS.F.T...K.YCLNW...ISLF.QRLN.IY.LP.F.Q...KRLET
 NIPAH FDTVS.FLT...K..CLNW...SM..F.ERL..IY.LPGF.N.M.KRLER

B 723

HMPV TTMICAYRHAPPETKG-EYDIDKIEEQSGLYRYHMGGIEGWCQKLWTMEA
 APVA T.....D.G.-I....Q.P.....F.....M.....
 HRSVA V.I..T.....YIRDHIV.LNNVD.....I..
 HRSVB V.I..T.....FI.DHVNLNEVD.....I..
 BRSV A.V..T.....YIRNHIT.LN.VD.....I..
 HPIV2 S.LYVGDPFN..AATD-AF.L.VLNGIIFIVSK-....L..M...IS
 NDV ...FVGDPFN..SDPT-DC.LSRVPNDIYIVSAR....L.....IS
 SV C.IYVGDPYC.VADRM-HRQLQDHADSCIFIHNPR....Y.....LIS
 HPIV3 S.IYVGDPYC..SD.E-HISLEDHPDSCFYVHNPR....F.....LIS
 MV SVLYVSDP.C..DLDA-HIPLY.VPNDQIFIK.P.....Y.....IST
 NIPAH SVIYV.DPNC..NIDK-HMELE.TP.DIIFIH.PK.....YS..T..IAT

C 772

HMPV ISLLDVSVKTRCQMTSLNGDNQSIDVSKFVKLSEG-LDEVKADYSLAV
 APVA RN.V.L.....R.TGA-QT.IQ.....I
 HRSVA LI.L.GKFSI.A.I.....I....R.M.-QTHAQ...L..L
 HRSVB LI.L.GKFSI.A.I.....I....R.I.-QTHAQ...L..L
 BRSV LI.I.GKFSI.A.I.....I....I..N.-QTHAQ...L..L
 HPIV2 ..VILLS.AESKTRVM.MVQ....A.A.TTR.PR.LPSIQKKELA.AASK
 NDV ..AAIQLAAARSH.RVACMVQ....V.A.TRE.RSDDSPENVLTQLHQASD
 SV ..AIHLAA.RVGVRSAMVQ....A.A.TSR.PVAQTYKQKKNHV.EEIT
 HPIV3 ..AIHLAA.RIGVRV.AMVQ....A.A.TTR.PNNYDYRIKKEIV.KDV.
 MV .PY.YLAAYESGVRIA..VQ....T.A.T.R.PSTWPYNLKKREARVTR
 NIPAH .PE.FLSAYE.NTRIPAIVO...E..AITQK.HPNLPYKVKKEICAKQ.Q

D 822

HMPV KMLKEIRDAYRNIGHKLKEGETYISRDLQFISKVIOSEGVMHPTPIKKIL
 APVA ...TAV....Y.....V.....M..T.....Y.AA...V..
 HRSVA NS..LLYKE.AG.....GT.....M..M..T..HN..YY.AS...V..
 HRSVB NS..LLYKE.AG.....GT.....M..M..T..HN..YY.AS...V..
 BRSV .S..LLYKE.AS.....GT.....M..M..T..HN..YY.AS...V..
 HPIV2 LFERL.ANNYGL..Q..AQ..I..STFFIY..RVFYQ.RILTQAL.NPS
 NDV NFF..LIHVNL..N..DR..IR.DTFFIY..R.FKD.AILSQVL.NSS
 SV RYFGAL.HVMED...E..LN..I..SKMEVY..R.YYD.KIL.QCL.AIT
 HPIV3 REFDL.EVMDL..E..LN..I..SKMEIY..R.YYD.RIL.QAL.AIS
 MV DYFVIL.QRLHD...H..AN..IV.SHFFVY..G.YYD.LLVSQL.S.A
 NIPAH LYFERL.MNL.AL..N..AT..I..TH.FIY..K..HYD.AVLSQAL.SMS

847

HMPV RVGPWINTILDDIKTSAESIGSLCQ
 APVA M.A.....
 HRSVA F.V.L.....T.
 HRSVB F.V.L.....T.
 BRSV F.V.M.....T.
 HPIV2 KLCLTADVLGECTQA.CSNSATTIM
 NDV KLVLVSGDLSENTVM.CAN.A.TVA
 SV .CVF.SE.LV.ENRSACSN.STSIA
 HPIV3 .CVF.SE.VI.ETRSASSNLATSFA
 MV .CVF.SE..V.ETRAACSN.ATTMA
 NIPAH .CCF.SE.LV.ETRSACSN.STTIA

FIGURE 13




FIGURE 14




FIGURE 15




FIGURE 16

Alignment: F DNA

						
	5	15	25	35	45	55
NL/1/00	ATAGGAGTTT	ACGGAAGCTC	CGTAATTTAC	ATGGTGCAAC	TGCCAATCTT	TGGGGTTATA
UK/1/00	ATAGGAGTTT	ACGGAAGCTC	CGTAATTTAC	ATGGTGCAAC	TGCCAATCTT	TGGGGTTATA
NL/2/00	ATAGGAGTTT	ACGGAAGCTC	CGTAATTTAC	ATGGTGCAAC	TGCCAATCTT	TGGGGTTATA
NL/13/00	ATAGGAGTTT	ACGGAAGCTC	CGTAATTTAC	ATGGTGCAAC	TGCCAATCTT	TGGGGTTATA
NL/14/00	ATAGGAGTTT	ACGGAAGCTC	CGTAATTTAC	ATGGTGCAAC	TGCCAATCTT	TGGGGTTATA
FL/3/01	ATAGGAGTTT	ACGGAAGCTC	CGTAATTTAC	ATGGTGCAAC	TGCCAATCTT	TGGGGTTATA
FL/4/01	ATAGGAGTTT	ACGGAAGCTC	CGTAATTTAC	ATGGTGCAAC	TGCCAATCTT	TGGGGTTATA
FL/8/01	ATAGGAGTTT	ACGGAAGCTC	CGTAATTTAC	ATGGTGCAAC	TGCCAATCTT	TGGGGTTATA
UK/1/01	ATAGGAGTTT	ACGGAAGCTC	CGTAATTTAC	ATGGTGCAAC	TGCCAATCTT	TGGGGTTATA
UK/7/01	ATAGGAGTTT	ACGGAAGCTC	CGTAATTTAC	ATGGTGCAAC	TGCCAATCTT	TGGAGTTATA
FL/10/01	ATAGGAGTTT	ACGGAAGCTC	CGTAATTTAC	ATGGTGCAAC	TGCCAATCTT	TGGGGTTATA
NL/6/01	ATAGGAGTTT	ACGGAAGCTC	CGTAATTTAC	ATGGTGCAAC	TGCCAATCTT	TGGAGTTATA
NL/8/01	ATAGGAGTTT	ACGGAAGCTC	CGTAATTTAC	ATGGTGCAAC	TGCCAATCTT	TGGGGTTATA
NL/10/01	ATAGGAGTTT	ACGGAAGCTC	CGTAATTTAC	ATGGTGCAAC	TGCCAATCTT	TGGAGTTATA
NL/14/01	ATAGGAGTTT	ATGGAAGCTC	CGTAATTTAC	ATGGTGCAAC	TGCCAATCTT	TGGAGTTATA
NL/20/01	ATAGGAGTTT	ATGGAAGCTC	CGTAATTTAC	ATGGTGCAAC	TGCCAATCTT	TGGAGTTATA
NL/25/01	ATAGGAGTTT	ACGGAAGCTC	CGTAATTTAC	ATGGTGCAAC	TGCCAATCTT	TGGAGTTATA
NL/26/01	ATAGGAGTTT	ATGGAAGCTC	CGTAATTTAC	ATGGTGCAAC	TGCCAATCTT	TGGAGTTATA
NL/28/01	ATAGGAGTTT	ATGGAAGCTC	CGTAATTTAC	ATGGTGCAAC	TGCCAATCTT	TGGAGTTATA
NL/30/01	ATAGGAGTTT	ATGGAAGCTC	CGTAATTTAC	ATGGTGCAAC	TGCCAATCTT	TGGAGTTATA
BR/2/01	ATAGGAGTTT	ACGGAAGCTC	CGTAATTTAC	ATGGTGCAAC	TGCCAATCTT	TGGGGTTATA
BR/3/01	ATAGGAGTTT	ACGGAAGCTC	CGTAATTTAC	ATGGTGCAAC	TGCCAATCTT	TGGGGTTATA
NL/2/02	ATAGGAGTTT	ACGGAAGCTC	CGTAATTTAC	ATGGTGCAAC	TGCCAATCTT	TGGAGTTATA
NL/4/02	ATAGGAGTTT	ACGGAAGCTC	CGTAATTTAC	ATGGTGCAAC	TGCCAATCTT	TGGGGTTATA
NL/5/02	ATAGGAGTTT	ACGGAAGCTC	CGTAATTTAC	ATGGTGCAAC	TGCCAATCTT	TGGAGTTATA
NL/6/02	ATAGGAGTTT	ACGGAAGCTC	CGTAATTTAC	ATGGTGCAAC	TGCCAATCTT	TGGAGTTATA
NL/7/02	ATAGGAGTTT	ACGGAAGCTC	CGTAATTTAC	ATGGTGCAAC	TGCCAATCTT	TGGGGTTATA
NL/9/02	ATAGGAGTTT	ATGGAAGCTC	CGTAATTTAC	ATGGTGCAAC	TGCCAATCTT	TGGAGTTATA
FL/1/02	ATAGGAGTTT	ACGGAAGCTC	CGTAATTTAC	ATGGTGCAAC	TGCCAATCTT	TGGGGTTATA
NL/1/81	ATAGGGGTCT	ACGGGAGCTC	TGTAATTTAC	ATGGTGCAGC	TGCCAATCTT	TGGCGTTATA
NL/1/93	ATAGGGGTCT	ACGGGAGCTC	CGTAATTTAC	ATGGTGCAGC	TGCCAATCTT	TGGCGTCATA
NL/2/93	ATAGGGGTCT	ACGGGAGCTC	CGTAATTTAC	ATGGTGCAGC	TGCCAATCTT	TGGCGTCATA
NL/4/93	ATAGGGGTCT	ACGGGAGCTC	CGTAATTTAC	ATGGTGCAGC	TGCCAATCTT	TGGCGTCATA
NL/1/95	ATAGGGGTCT	ACGGGAGCTC	CGTAATTTAC	ATGGTGCAGC	TGCCAATCTT	TGGCGTTATA
NL/2/96	ATAGGGGTCT	ACGGGAGCTC	CGTAATTTAC	ATGGTGCAGC	TGCCAATCTT	TGGCGTTATA
NL/3/96	ATAGGGGTCT	ACGGGAGCTC	CGTAATTTAC	ATGGTGCAGC	TGCCAATCTT	TGGCGTTATA
NL/1/98	ATAGGGGTCT	ACGGGAGCTC	CGTAATTTAC	ATGGTGCAGC	TGCCAATCTT	TGGCGTTATA
NL/17/00	ATAGGGGTCT	ACGGGAGCTC	CGTAATTTAC	ATGGTGCAGC	TGCCAATCTT	TGGCGTTATA
NL/22/01	ATAGGGGTCT	ACGGGAGCTC	CGTAATTTAC	ATGGTGCAGC	TGCCAATCTT	TGGCGTTATA
NL/29/01	ATAGGGGTCT	ACGGGAGCTC	CGTAATTTAC	ATGGTGCAGC	TGCCAATCTT	TGGCGTTATA
NL/23/01	ATAGGGGTCT	ACGGGAGCTC	CGTAATTTAC	ATGGTGCAGC	TGCCAATCTT	TGGCGTTATA
NL/17/01	ATAGGGGTCT	ACGGGAGCTC	CGTAATTTAC	ATGGTGCAGC	TGCCAATCTT	TGGCGTTATA
NL/24/01	ATAGGGGTCT	ACGGGAGCTC	CGTAATTTAC	ATGGTGCAGC	TGCCAATCTT	TGGCGTTATA
NL/3/02	ATAGGGGTCT	ACGGGAGCTC	CGTAATTTAC	ATGGTGCAGC	TGCCAATCTT	TGGCGTTATA
NL/3/98	ATAGGGGTCT	ACGGAAGCTC	CGTGATTTAC	ATGGTTCAAT	TGCCGATCTT	TGGTGTCATA
NL/1/99	ATAGGGGTCT	ACGGAAGCTC	TGTGATTTAC	ATGGTTCAAT	TGCCGATCTT	TGGTGTCATA
NL/2/99	ATAGGGGTCT	ACGGAAGCTC	TGTGATTTAC	ATGGTTCAAT	TGCCGATCTT	TGGTGTCATA
NL/3/99	ATAGGGGTCT	ACGGAAGCTC	TGTGATTTAC	ATGGTTCAAT	TGCCGATCTT	TGGTGTCATA
NL/11/00	ATAGGGGTCT	ACGGAAGCTC	TGTGATTTAC	ATGGTTCAAT	TGCCGATCTT	TGGTGTCATA
NL/12/00	ATAGGGGTCT	ACGGAAGCTC	CGTGATTTAC	ATGGTTCAAT	TGCCGATCTT	TGGTGTCATA
NL/1/01	ATAGGGGTCT	ACGGAAGCTC	TGTAATTTAC	ATGGTTCAAT	TGCCGATCTT	TGGTGTCATA
NL/5/01	ATAGGGGTCT	ACGGAAGCTC	CGTGATTTAC	ATGGTTCAAT	TGCCGATCTT	TGGTGTCATA
NL/9/01	ATAGGGGTCT	ACGGAAGCTC	CGTGATTTAC	ATGGTTCAAT	TGCCGATCTT	TGGTGTCATA
NL/19/01	ATAGGGGTCT	ACGGAAGCTC	TGTGATTTAC	ATGGTTCAAT	TGCCGATCTT	TGGTGTCATA

FIGURE 17

NL/21/01	ATAGGGGTCT	ACGGAAGCTC	CGTGATTTAC	ATGGTTCAAT	TGCCGATCTT	TGGTGTCTATA
UK/11/01	ATAGGGGTCT	ACGGAAGCTC	TGTGATTTAC	ATGGTTCAAT	TGCCGATCTT	TGGGGTCTATA
FL/1/01	ATAGGGGTCT	ACGGAAGCTC	TGTGATTTAC	ATGGTTCAAT	TGCCGATCTT	TGGTGTCTATA
FL/2/01	ATAGGGGTCT	ACGGAAGCTC	TGTGATTTAC	ATGGTTCAAT	TGCCGATCTT	TGGTGTCTATA
FL/5/01	ATAGGGGTCT	ACGGAAGCTC	TGTGATTTAC	ATGGTTCAAT	TGCCGATCTT	TGGTGTCTATA
FL/7/01	ATAGGGGTCT	ACGGAAGCTC	CGTGATTTAC	ATGGTTCAAT	TGCCGATCTT	TGGTGTCTATA
FL/9/01	ATAGGGGTCT	ACGGAAGCTC	TGTGATTTAC	ATGGTTCAAT	TGCCGATCTT	TGGTGTCTATA
UK/10/01	ATAGGGGTCT	ACGGAAGCTC	TGTGATTTAC	ATGGTTCAAT	TGCCGATCTT	TGGTGTCTATA
NL/1/02	ATAGGGGTCT	ACGGAAGCTC	CGTGATTTAC	ATGGTTCAAT	TGCCGATCTT	TGGTGTCTATA
NL/1/94	ATAGGGGTCT	ACGGAAGCTC	TGTGATTTAC	ATGGTCCAGC	TGCCGATCTT	TGGTGTCTATA
NL/1/96	ATAGGGGTCT	ACGGAAGCTC	TGTGATTTAC	ATGGTCCAGC	TGCCGATCTT	TGGTGTCTATA
NL/6/97	ATAGGGGTCT	ACGGAAGCTC	TGTGATTTAC	ATGGTCCAGC	TGCCGATCTT	TGGTGTCTATA
NL/7/00	ATAGGGGTCT	ACGGAAGCTC	CGTGATTTAC	ATGGTCCAGC	TGCCGATCTT	TGGTGTCTATA
NL/9/00	ATAGGGGTCT	ACGGAAGCTC	CGTGATTTAC	ATGGTCCAGC	TGCCGATCTT	TGGTGTCTATA
NL/19/00	ATAGGGGTCT	ACGGAAGCTC	CGTGATTTAC	ATGGTCCAGC	TGCCGATCTT	TGGTGTCTATA
NL/28/00	ATAGGGGTCT	ACGGAAGCTC	CGTGATTTAC	ATGGTCCAGC	TGCCGATCTT	TGGTGTCTATA
NL/3/01	ATAGGGGTCT	ACGGAAGCTC	CGTGATTTAC	ATGGTCCAGC	TGCCGATCTT	TGGTGTCTATA
NL/4/01	ATAGGGGTCT	ACGGAAGCTC	CGTGATTTAC	ATGGTCCAGC	TGCCGATCTT	TGGTGTCTATA
NL/11/01	ATAGGGGTCT	ACGGAAGCTC	CGTGATTTAC	ATGGTCCAGC	TGCCGATCTT	TGGTGTCTATA
NL/15/01	ATAGGGGTCT	ACGGAAGCTC	CGTGATTTAC	ATGGTCCAGC	TGCCGATCTT	TGGTGTCTATA
NL/18/01	ATAGGGGTCT	ACGGAAGCTC	CGTGATTTAC	ATGGTCCAGC	TGCCGATCTT	TGGTGTCTATA
FL/6/01	ATAGGGGTCT	ACGGAAGCTC	CGTGATTTAC	ATGGTCCAGC	TGCCGATCTT	TGGTGTCTATA
UK/5/01	ATAGGGGTCT	ACGGAAGCTC	TGTGATTTAC	ATGGTCCAGC	TGCCGATCTT	TGGTGTCTATA
UK/8/01	ATAGGGGTCT	ACGGAAGCTC	TGTGATTTAC	ATGGTCCAGC	TGCCGATCTT	TGGTGTCTATA
NL/12/02	ATAGGGGTCT	ACGGAAGCTC	CGTGATTTAC	ATGGTCCAGC	TGCCGATCTT	TGGTGTCTATA
HK/1/02	ATAGGGGTCT	ACGGAAGCTC	CGTGATTTAC	ATGGTCCAGC	TGCCGATCTT	TGGTGTCTATA

						
	65	75	85	95	105	115
NL/1/00	GACACGCCTT	GCTGGATAGT	AAAAGCAGCC	CCTTCTTGTT	CAGGAAAAAA	GGGAAACTAT
UK/1/00	GACACGCCTT	GCTGGATAGT	AAAAGCAGCC	CCTTCTTGCT	CAGAAAAAAA	GGGAAACTAT
NL/2/00	GACACGCCTT	GCTGGATAGT	AAAAGCAGCC	CCTTCTTGCT	CAGAAAAAAA	GGGAAACTAT
NL/13/00	GACACGCCTT	GCTGGATAGT	AAAAGCAGCC	CCTTCTTGCT	CAGAAAAAAA	GGGAAACTAT
NL/14/00	GACACGCCTT	GCTGGATAGT	AAAAGCAGCC	CCTTCTTGCT	CAGAAAAAAA	GGGAAACTAT
FL/3/01	GACACGCCTT	GCTGGATAGT	AAAAGCAGCC	CCTTCTTGTT	CAGAAAAAAA	GGGAAACTAT
FL/4/01	GACACGCCTT	GCTGGATAGT	AAAAGCAGCC	CCTTCTTGTT	CAGAAAAAAA	GGGAAACTAT
FL/8/01	GACACGCCTT	GCTGGATAGT	AAAAGCAGCC	CCTTCTTGTT	CAGAAAAAAA	GGGAAACTAT
UK/1/01	GACACGCCTT	GCTGGATAGT	AAAAGCAGCC	CCTTCTTGCT	CAGAAAAAAA	GGGAAACTAT
UK/7/01	GACACGCCTT	GCTGGATAGT	AAAAGCAGCC	CCTTCTTGCT	CAGAAAAAAA	GGGAAACTAT
FL/10/01	GACACGCCTT	GCTGGATAGT	AAAAGCAGCC	CCTTCTTGCT	CAGAAAAAAA	GGGAAACTAT
NL/6/01	GACACGCCTT	GCTGGATAGT	AAAAGCGGCC	CCTTCTTGCT	CAGAAAAAAA	GGGAAACTAT
NL/8/01	GACACGCCTT	GCTGGATAGT	AAAAGCAGCC	CCTTCTTGCT	CAGAAAAAAA	GGGAAACTAT
NL/10/01	GACACGCCTT	GCTGGATAGT	AAAAGCGGCC	CCTTCTTGCT	CGGAAAAAAA	GGGAAACTAT
NL/14/01	GACACGCCTT	GCTGGATAGT	AAAAGCGGCC	CCTTCTTGCT	CAGAAAAAAA	GGGAAACTAT
NL/20/01	GACACGCCTT	GCTGGATAGT	AAAAGCGGCC	CCTTCTTGCT	CAGAAAAAAA	GGGAAACTAT
NL/25/01	GACACGCCTT	GCTGGATAGT	AAAAGCGGCC	CCTTCTTGCT	CAGAAAAAAA	GGGAAACTAT
NL/26/01	GACACGCCTT	GCTGGATAGT	AAAAGCGGCC	CCTTCTTGCT	CAGAAAAAAA	GGGAAACTAT
NL/28/01	GACACGCCTT	GCTGGATAGT	AAAAGCGGCC	CCTTCTTGCT	CAGAAAAAAA	GGGAAACTAT
NL/30/01	GACACGCCTT	GCTGGATAGT	AAAAGCGGCC	CCTTCTTGCT	CAGAAAAAAA	GGGAAACTAT
BR/2/01	GACACGCCTT	GCTGGATAGT	AAAAGCAGCC	CCTTCTTGTT	CAGGAAAAAA	GGGAAACTAT
BR/3/01	GACACGCCTT	GCTGGATAGT	AAAAGCAGCC	CCTTCTTGTT	CAGGAAAAAA	GGGAAACTAT
NL/2/02	GACACGCCTT	GCTGGATAGT	AAAAGCGGCC	CCTTCTTGCT	CAGAAAAAAA	GGGAAACTAT
NL/4/02	GACACGCCTT	GCTGGATAGT	AAAAGCAGCC	CCTTCTTGCT	CAGAAAAAAA	GGGAAACTAT
NL/5/02	GACACGCCTT	GCTGGATAGT	AAAAGCGGCC	CCTTCTTGCT	CAGAAAAAAA	GGGAAACTAT
NL/6/02	GACACGCCTT	GCTGGATAGT	AAAAGCGGCC	CCTTCTTGCT	CAGAAAAAAA	GGGAAACTAT
NL/7/02	GACACGCCTT	GCTGGATAGT	AAAAGCAGCC	CCTTCTTGTT	CAGGAAAAAA	GGGAAACTAT
NL/9/02	GACACGCCTT	GCTGGATAGT	AAAAGCGGCC	CCTTCTTGCT	CAGAAAAAAA	GGGAAACTAT
FL/1/02	GACACGCCTT	GCTGGATAGT	AAAAGCAGCC	CCTTCTTGTT	CAGGAAAAAA	GGGAAACTAT
NL/1/81	GACACGCCTT	GCTGGATAGT	AAAAGCAGCC	CCCTCTTGTT	CCGAAAAAAA	GGGAAACTAT
NL/1/93	GACACGCCTT	GCTGGATAGT	AAAAGCAGCC	CCCTCTTGTT	CCGAAAAAAA	GGGAAACTAT
NL/2/93	GACACGCCTT	GCTGGATAGT	AAAAGCAGCC	CCCTCTTGTT	CCGAAAAAAA	GGGAAACTAT

NL/4/93	GACACGCCTT	GCTGGATAGT	AAAAGCAGCC	CCCTCTTGTT	CCGAAAAAAA	GGGAAACTAT
NL/1/95	GACACGCCCT	GCTGGATAGT	AAAAGCAGCC	CCCTCTTGTT	CCGAAAAAAA	GGGAAACTAT
NL/2/96	GACACGCCTT	GCTGGATAGT	AAAAGCAGCC	CCCTCTTGTT	CCGAAAAAAA	GGGAAACTAT
NL/3/96	GACACGCCCT	GCTGGATAGT	AAAAGCAGCC	CCCTCTTGTT	CCGAAAAAAA	GGGAAACTAT
NL/1/98	GACACGCCTT	GCTGGATAGT	AAAAGCAGCC	CCTTCTTGTT	CCGAAAAAAA	GGGAAACTAT
NL/17/00	GACACGCCTT	GCTGGATAGT	AAAAGCAGCC	CCTTCTTGTT	CCGAAAAAAA	GGGAAACTAT
NL/22/01	GACACGCCTT	GCTGGATAGT	AAAAGCAGCC	CCTTCTTGTT	CCGAAAAAAA	GGGAAACTAT
NL/29/01	GACACGCCTT	GCTGGATAGT	AAAAGCAGCC	CCTTCTTGTT	CCGAAAAAAA	GGGAAACTAT
NL/23/01	GACACGCCTT	GCTGGATAGT	AAAAGCAGCC	CCTTCTTGTT	CCGAAAAAAA	GGGAAACTAT
NL/17/01	GACACACCTT	GCTGGATAGT	AAAAGCAGCC	CCTTCTTGTT	CCGAAAAAAA	GGGAAATTAT
NL/24/01	GACACGCCTT	GCTGGATAGT	AAAAGCAGCC	CCTTCTTGTT	CCGAAAAAAA	GGGAAACTAT
NL/3/02	GACACGCCTT	GCTGGATAGT	AAAAGCAGCC	CCTTCTTGTT	CCGAAAAAAA	GGGAAACTAT
NL/3/98	GATACACCTT	GTTGGATAAT	CAAGGCAGCT	CCCTCTTGCT	CAGAAAAAAA	CGGGAATTAT
NL/1/99	GATACACCTT	GTTGGATCAT	CAAGGCAGCT	CCCTCTTGCT	CAGAAAAAAA	CGGGAATTAT
NL/2/99	GATACACCTT	GTTGGATCAT	CAAGGCAGCT	CCCTCTTGCT	CAGAAAAAAA	CGGGAATTAT
NL/3/99	GATACACCTT	GTTGGATCAT	CAAGGCAGCT	CCCTCTTGCT	CAGAAAAAAA	CGGGAATTAT
NL/11/00	GATACACCTT	GTTGGATAAT	CAAGGCAGCT	CCCTCTTGCT	CAGAAAAAAA	CGGGAATTAT
NL/12/00	GATACACCTT	GTTGGATAAT	CAAGGCAGCT	CCCTCTTGCT	CAGAAAAAAA	CGGGAATTAT
NL/1/01	GATACACCTT	GTTGGATAAT	CAAGGCAGCT	CCCTCTTGCT	CAGAAAAAAA	CGGGAATTAT
NL/5/01	GATACACCTT	GTTGGATAAT	CAAGGCAGCT	CCCTCTTGCT	CAGAAAAAAA	CGGGAATTAT
NL/9/01	GATACACCTT	GTTGGATAAT	CAAGGCAGCT	CCCTCTTGCT	CAGAAAAAAA	CGGGAATTAT
NL/19/01	GATACACCTT	GTTGGATAAT	CAAGGCAGCT	CCCTCTTGCT	CAGAAAAAAA	CGGGAATTAT
NL/21/01	GATACACCTT	GTTGGATAAT	CAAGGCAGCT	CCCTCTTGCT	CAGAAAAAAA	CGGGAATTAT
UK/11/01	GATACACCTT	GTTGGATAAT	CAAGGCAGCT	CCCTCTTGCT	CAGAAAAAAA	CGGGAATTAT
FL/1/01	GATACACCTT	GTTGGATAAT	CAAGGCAGCC	CCCTCTTGCT	CAGAGAAAAA	CGGGAATTAT
FL/2/01	GATACACCTT	GTTGGATAAT	CAAGGCAGCT	CCCTCTTGCT	CAGAGAAAAA	CGGGAATTAT
FL/5/01	GATACACCTT	GTTGGATAAT	CAAGGCAGCT	CCCTCTTGCT	CAGAAAAAAA	CGGGAATTAT
FL/7/01	GATACACCTT	GTTGGATAAT	CAAGGCAGCT	CCCTCTTGCT	CAGAAAAAAA	CGGGAATTAT
FL/9/01	GATACACCTT	GTTGGATAAT	CAAGGCAGCT	CCCTCTTGCT	CAGAGAAAAA	CGGGAATTAT
UK/10/01	GATACACCTT	GTTGGATAAT	CAAGGCAGCT	CCCTCTTGCT	CAGAAAAAAA	CGGGAATTAT
NL/1/02	GATACACCTT	GTTGGATAAT	CAAGGCAGCT	CCCTCTTGCT	CAGAAAAAAA	CGGGAATTAT
NL/1/94	GATACACCTT	GTTGGATAAT	CAAGGCAGCT	CCCTCTTGTT	CAGAAAAAGA	TGGAAATTAT
NL/1/96	GATACACCTT	GTTGGATAAT	CAAGGCAGCT	CCCTCTTGTT	CAGAAAAAGA	TGGAAATTAT
NL/6/97	GATACACCTT	GTTGGATAAT	CAAGGCAGCT	CCCTCTTGTT	CAGAAAAAGA	TGGAAATTAT
NL/7/00	GATACACCTT	GTTGGATAAT	CAAGGCAGCT	CCCTCTTGTT	CAGAAAAAGA	TGGAAATTAT
NL/9/00	GATACACCTT	GTTGGATAAT	CAAGGCAGCT	CCCTCTTGTT	CAGAAAAAGA	TGGAAATTAT
NL/19/00	GATACACCTT	GTTGGATAAT	CAAGGCAGCT	CCCTCTTGTT	CAGAAAAAGA	TGGAAATTAT
NL/28/00	GATACACCTT	GTTGGATAAT	CAAGGCAGCT	CCCTCTTGTT	CAGAAAAAGA	TGGAAATTAT
NL/3/01	GATACACCTT	GTTGGATAAT	CAAGGCAGCT	CCCTCTTGTT	CAGAAAAAGA	TGGAAATTAT
NL/4/01	GATACACCTT	GTTGGATAAT	CAAGGCAGCT	CCCTCTTGTT	CAGAAAAAGA	TGGAAATTAT
NL/11/01	GATACACCTT	GTTGGATAAT	CAAGGCAGCT	CCCTCTTGTT	CAGAAAAAGA	TGGAAATTAT
NL/15/01	GATACACCTT	GTTGGATAAT	CAAGGCAGCT	CCCTCTTGTT	CAGAAAAAGA	TGGAAATTAT
NL/18/01	GATACACCTT	GTTGGATAAT	CAAGGCAGCT	CCCTCTTGTT	CAGAAAAAGA	TGGAAATTAT
FL/6/01	GATACACCTT	GTTGGATAAT	CAAGGCAGCT	CCCTCTTGTT	CAGAAAAAGA	TGGAAATTAT
UK/5/01	GATACACCTT	GTTGGATAAT	CAAGGCAGCT	CCCTCTTGTT	CAGAAAAAGA	TGGAAATTAT
UK/8/01	GATACACCTT	GTTGGATAAT	CAAGGCAGCT	CCCTCTTGTT	CAGAAAAAGA	TGGAAATTAT
NL/12/02	GATACACCTT	GTTGGATAAT	CAAGGCAGCT	CCCTCTTGTT	CAGAAAAAGA	TGGAAATTAT
HK/1/02	GATACACCTT	GTTGGATAAT	CAAGGCAGCT	CCCTCTTGTT	CAGAAAAAGA	TGGAAATTAT
						
	125	135	145	155	165	175
NL/1/00	GCTTGCCTCT	TAAGAGAAGA	CCAAGGATGG	TATTGTCAAA	ATGCAGGGTC	AACTGTTTAC
UK/1/00	GCTTGCCTCT	TAAGAGAAGA	TCAAGGATGG	TATTGTCAGA	ATGCAGGGTC	AACTGTTTAC
NL/2/00	GCTTGCCTCT	TAAGAGAAGA	TCAAGGATGG	TATTGTCAGA	ATGCAGGGTC	AACTGTTTAC
NL/13/00	GCTTGCCTCT	TAAGAGAAGA	TCAAGGATGG	TATTGTCAGA	ATGCAGGGTC	AACTGTTTAC
NL/14/00	GCTTGCCTCT	TAAGAGAAGA	TCAAGGATGG	TATTGTCAGA	ATGCAGGGTC	AACTGTTTAC
FL/3/01	GCTTGCCTCT	TAAGAGAAGA	CCAAGGATGG	TATTGTCAGA	ATGCAGGGTC	AACTGTTTAC
FL/4/01	GCTTGCCTCT	TAAGAGAAGA	CCAAGGATGG	TATTGTCAGA	ATGCAGGGTC	AACTGTTTAC
FL/8/01	GCTTGCCTCT	TAAGAGAAGA	CCAAGGATGG	TATTGTCAGA	ATGCAGGGTC	AACTGTTTAC
UK/1/01	GCTTGCCTCT	TAAGAGAAGA	TCAGGGATGG	TATTGTCAGA	ATGCAGGGTC	AACTGTTTAC
UK/7/01	GCTTGCCTCT	TAAGAGAAGA	TCAAGGATGG	TATTGTCAGA	ATGCAGGGTC	AACTGTTTAC

[illegible]

NL/4/01	GCTTGCCTCC	TAAGAGAGGA	TCAAGGGTGG	TATTGTAAAA	ATGCAGGATC	CACTGTTTAC
NL/11/01	GCTTGCCTCC	TAAGAGAGGA	TCAAGGGTGG	TATTGTAAAA	ATGCAGGATC	CACTGTTTAC
NL/15/01	GCTTGCCTCC	TAAGAGAGGA	TCAAGGGTGG	TATTGTAAAA	ATGCAGGATC	CACTGTTTAC
NL/18/01	GCTTGCCTCC	TAAGAGAGGA	TCAAGGGTGG	TATTGTAAAA	ATGCAGGATC	CACTGTTTAC
FL/6/01	GCTTGCCTCC	TAAGAGAGGA	TCAAGGGTGG	TATTGTAAAA	ATGCAGGATC	CACTGTTTAC
UK/5/01	GCTTGCCTCC	TAAGAGAGGA	TCAAGGGTGG	TATTGTAAAA	ATGCAGGATC	CACTGTTTAC
UK/8/01	GCTTGCCTCC	TAAGAGAGGA	TCAAGGGTGG	TATTGTAAAA	ATGCAGGATC	CACTGTTTAC
NL/12/02	GCTTGCCTCC	TAAGAGAGGA	TCAAGGGTGG	TATTGTAAAA	ATGCAGGATC	CACTGTTTAC
HK/1/02	GCTTGCCTCC	TAAGAGAGGA	TCAAGGGTGG	TATTGTAAAA	ATGCAGGATC	CACTGTTTAC

						
	185	195	205	215	225	235
NL/1/00	TACCCAAATG	AAAAAGACTG	TGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
UK/1/00	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
NL/2/00	TACCCAAATG	AAAAAGATTG	CGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
NL/13/00	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
NL/14/00	TACCCAAATG	AAAAAGATTG	CGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
FL/3/01	TACCCAAATG	AAAAAGACTG	TGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
FL/4/01	TACCCAAATG	AAAAAGACTG	TGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
FL/8/01	TACCCAAATG	AAAAAGACTG	TGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
UK/1/01	TACCCAAATG	AAAAAGACTG	TGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
UK/7/01	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
FL/10/01	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
NL/6/01	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
NL/8/01	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
NL/10/01	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
NL/14/01	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
NL/20/01	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
NL/25/01	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
NL/26/01	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
NL/28/01	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
NL/30/01	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
BR/2/01	TACCCAAATG	AAAAAGACTG	TGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
BR/3/01	TACCCAAATG	AAAAAGACTG	TGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
NL/2/02	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
NL/4/02	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
NL/5/02	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
NL/6/02	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
NL/7/02	TACCCAAATG	AAAAAGACTG	TGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
NL/9/02	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
FL/1/02	TACCCAAATG	AAAAAGACTG	TGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
NL/1/81	TACCCAAATG	AGAAAGACTG	TGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
NL/1/93	TACCCAAATG	AGAAAGACTG	TGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
NL/2/93	TACCCAAATG	AGAAAGACTG	TGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGTAGCA
NL/4/93	TACCCAAATG	AGAAAGACTG	TGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
NL/1/95	TACCCAAATG	AGAAGGACTG	TGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
NL/2/96	TACCCAAATG	AGAAAGACTG	TGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
NL/3/96	TACCCAAATG	AGAAGGACTG	TGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
NL/1/98	TACCCAAATG	AGAAAGACTG	TGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
NL/17/00	TACCCAAATG	AGAAAGACTG	TGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
NL/22/01	TACCCAAATG	AGAAAGACTG	TGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
NL/29/01	TACCCAAATG	AGAAAGACTG	TGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
NL/23/01	TACCCAAATG	AGAAAGACTG	TGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
NL/17/01	TACCCAAATG	AGAAAGACTG	TGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
NL/24/01	TACCCAAATG	AGAAAGACTG	TGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
NL/3/02	TACCCAAATG	AGAAAGACTG	TGAAACAAGA	GGAGACCATG	TCTTTTGCGA	CACAGCAGCA
NL/3/98	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGTGATCATG	TTTTTTGTGA	CACAGCAGCA
NL/1/99	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGTGATCATG	TTTTTTGTGA	CACAGCAGCA
NL/2/99	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGTGATCATG	TTTTTTGTGA	CACAGCAGCA
NL/3/99	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGTGATCATG	TTTTTTGTGA	CACAGCAGCA
NL/11/00	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGTGATCATG	TTTTTTGTGA	CACAGCAGCA

NL/12/00	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGTGATCATG	TTTTTTGTGA	CACAGCAGCA
NL/1/01	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGTGATCATG	TTTTTTGTGA	CACAGCAGCA
NL/5/01	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGTGATCATG	TTTTTTGTGA	CACAGCAGCA
NL/9/01	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGTGATCATG	TTTTTTGTGA	CACAGCAGCA
NL/19/01	TACCCAAATG	AAAAAGACTG	TGAAACAAGA	GGTGATCATG	TTTTTTGTGA	CACAGCAGCA
NL/21/01	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGTGATCATG	TTTTTTGTGA	CACAGCAGCA
UK/11/01	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGTGATCATG	TTTTTTGTGA	TACAGCAGCA
FL/1/01	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGTGATCATG	TGTTTTGTGA	CACAGCAGCA
FL/2/01	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGTGATCATG	TGTTTTGTGA	CACAGCAGCA
FL/5/01	TACCCAAATG	AAAAAGACTG	TGAAACAAGA	GGTGATCATG	TTTTTTGTGA	CACAGCAGCA
FL/7/01	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGTGATCATG	TTTTTTGTGA	CACAGCAGCA
FL/9/01	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGTGATCATG	TGTTTTGTGA	CACAGCAGCA
UK/10/01	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGTGATCATG	TTTTTTGTGA	TACAGCAGCA
NL/1/02	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGTGATCATG	TTTTTTGTGA	CACAGCAGCA
NL/1/94	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGTGATCATG	TTTTTTGTGA	CACAGCAGCA
NL/1/96	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGTGATCATG	TTTTTTGTGA	CACAGCAGCA
NL/6/97	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGTGATCATG	TTTTTTGTGA	CACAGCAGCA
NL/7/00	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGTGATCATG	TTTTTTGTGA	CACAGCAGCA
NL/9/00	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGTGATCATG	TTTTTTGTGA	CACAGCTGCA
NL/19/00	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGTGATCATG	TTTTTTGTGA	CACAGCAGCA
NL/28/00	TACCCAAATG	AAAAAGACTG	TGAAACAAGA	GGTGATCATG	TTTTTTGTGA	CACAGCAGCA
NL/3/01	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGTGATCATG	TTTTTTGTGA	CACAGCAGCA
NL/4/01	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGTGATCATG	TTTTTTGTGA	CACAGCAGCA
NL/11/01	TACCCAAATG	AAAAAGACTG	TGAAACAAGA	GGTGATCATG	TTTTTTGTGA	CACAGCAGCA
NL/15/01	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGTGATCATG	TTTTTTGTGA	CACAGCTGCA
NL/18/01	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGTGATCATG	TTTTTTGTGA	CACAGCTGCA
FL/6/01	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGTGATCATG	TTTTTTGTGA	CACAGCTGCA
UK/5/01	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGTGATCATG	TTTTTTGTGA	CACAGCTGCA
UK/8/01	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGTGATCATG	TTTTTTGTGA	CACAGCAGCA
NL/12/02	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGTGATCATG	TTTTTTGTGA	CACAGCTGCA
HK/1/02	TACCCAAATG	AAAAAGACTG	CGAAACAAGA	GGTGATCATG	TTTTTTGTGA	CACAGCAGCA

	 245	 255	 265	 275	 285	 295
NL/1/00	GGAATCAATG	TTGCTGAGCA	GTCAAAGGAG	TGCAACATAA	ACATATCTAC	TACTAATTAC
UK/1/00	GGAATCAATG	TTGCTGAGCA	GTCAAAGGAG	TGCAACATCA	ACATATCCAC	TACTAATTAC
NL/2/00	GGAATCAATG	TTGCTGAGCA	GTCAAAGGAG	TGCAACATCA	ACATATCCAC	TACTAATTAC
NL/13/00	GGAATCAATG	TTGCTGAGCA	GTCAAAGGAG	TGCAACATCA	ACATATCCAC	TACTAATTAC
NL/14/00	GGAATCAATG	TTGCTGAGCA	GTCAAAGGAG	TGCAACATCA	ACATATCCAC	TACTAATTAC
FL/3/01	GGAATCAATG	TTGCTGAGCA	GTCAAAGGAG	TGCAACATAA	ACATATCTAC	TACTAATTAC
FL/4/01	GGAATCAATG	TTGCTGAGCA	GTCAAAGGAG	TGCAACATAA	ACATATCTAC	TACTAATTAC
FL/8/01	GGAATCAATG	TTGCTGAGCA	GTCAAAGGAG	TGCAACATAA	ACATATCTAC	TACTAATTAC
UK/1/01	GGAATCAATG	TTGCTGAGCA	GTCAAAGGAG	TGCAACATCA	ACATATCCAC	TACTAATTAC
UK/7/01	GGAATCAATG	TTGCTGAGCA	GTCAAAGGAG	TGCAACATCA	ACATATCCAC	TACTAATTAC
FL/10/01	GGAATCAATG	TTGCTGAGCA	GTCAAAGGAG	TGCAACATCA	ACATATCCAC	TACTAATTAC
NL/6/01	GGAATCAATG	TTGCTGAGCA	GTCAAAGGAG	TGCAACATCA	ACATATCCAC	TACTAATTAC
NL/8/01	GGAATCAATG	TTGCTGAGCA	GTCAAAGGAG	TGCAACATCA	ATATATCCAC	TACTAATTAC
NL/10/01	GGAATCAATG	TTGCTGAGCA	GTCAAAGGAG	TGCAACATCA	ACATATCCAC	TACTAATTAC
NL/14/01	GGAATCAATG	TTGCTGAGCA	GTCAAAGGAG	TGCAACATCA	ACATATCCAC	TACTAATTAC
NL/20/01	GGAATCAATG	TTGCTGAGCA	GTCAAAGGAG	TGCAACATCA	ACATATCCAC	TACTAATTAC
NL/25/01	GGAATCAATG	TTGCTGAGCA	GTCAAAGGAG	TGCAACATCA	ACATATCCAC	CACTAATTAC
NL/26/01	GGAATCAATG	TTGCTGAGCA	GTCAAAGGAG	TGCAACATCA	ACATATCCAC	TACTAATTAC
NL/28/01	GGAATCAATG	TTGCTGAGCA	GTCAAAGGAG	TGCAACATCA	ACATATCCAC	TACTAATTAC
NL/30/01	GGAATCAATG	TTGCTGAGCA	GTCAAAGGAG	TGCAACATCA	ACATATCCAC	TACTAATTAC
BR/2/01	GGAATCAATG	TTGCTGAGCA	GTCAAAGGAG	TGCAACATAA	ACATATCTAC	TACTAATTAC
BR/3/01	GGAATCAATG	TTGCTGAGCA	GTCAAAGGAG	TGCAACATAA	ACATATCTAC	TACTAATTAC
NL/2/02	GGAATCAATG	TTGCTGAGCA	GTCAAAGGAG	TGCAACATCA	ACATATCCAC	CACTAATTAC
NL/4/02	GGAATCAATG	TTGCTGAGCA	GTCAAAGGAG	TGCAACATCA	ACATATCCAC	TACTAATTAC
NL/5/02	GGAATCAATG	TTGCTGAGCA	GTCAAAGGAG	TGCAACATCA	ACATATCCAC	CACTAATTAC
NL/6/02	GGAATCAATG	TTGCTGAGCA	GTCAAAGGAG	TGCAACATCA	ACATATCCAC	CACTAATTAC
NL/7/02	GGAATCAATG	TTGCTGAGCA	GTCAAAGGAG	TGCAACATAA	ACATATCTAC	TACTAATTAC

NL/9/02	GGAATCAATG	TTGCTGAGCA	GTCAAAGGAG	TGCAACATCA	ACATATCCAC	TACTAATTAC
FL/1/02	GGAATCAATG	TTGCTGAGCA	GTCAAAGGAG	TGCAACATAA	ACATATCTAC	TACTAATTAC
NL/1/81	GGAATTAATG	TTGCTGAGCA	ATCAAAGGAG	TGCAACATCA	ACATATCCAC	TACAAATTAC
NL/1/93	GGAATTAATG	TTGCTGAGCA	ATCAAAGGAG	TGCAACATCA	ACATATCCAC	TACAAATTAC
NL/2/93	GGAATTAATG	TTGCTGAGCA	ATCAAAGGAG	TGCAACATCA	ACATATCCAC	TACAAATTAC
NL/4/93	GGAATTAATG	TTGCTGAGCA	ATCAAAGGAG	TGCAACATCA	ACATATCCAC	TACAAATTAC
NL/1/95	GGAATTAATG	TTGCTGAGCA	ATCAAAGGAG	TGCAACATCA	ACATATCCAC	CACAAATTAC
NL/2/96	GGAATTAATG	TTGCTGAGCA	ATCAAAGGAG	TGCAACATCA	ACATATCCAC	TACAAATTAC
NL/3/96	GGAATTAATG	TTGCTGAGCA	ATCAAAGGAG	TGCAACATCA	ACATATCCAC	CACAAATTAC
NL/1/98	GGAATTAATG	TTGCTGAGCA	ATCAAAGGAG	TGCAACATCA	ACATATCCAC	TACAAATTAC
NL/17/00	GGAATTAATG	TTGCTGAGCA	ATCAAAGGAG	TGCAACATCA	ACATATCCAC	TACAAATTAC
NL/22/01	GGAATTAATG	TTGCTGAGCA	ATCAAAGGAG	TGCAACATCA	ACATATCCAC	CACAAATTAC
NL/29/01	GGAATTAATG	TTGCTGAGCA	ATCAAAGGAG	TGCAACATCA	ACATATCCAC	TACAAATTAC
NL/23/01	GGAATTAATG	TTGCTGAGCA	ATCAAAGGAG	TGCAACATCA	ACATATCCAC	CACAAATTAC
NL/17/01	GGAATTAATG	TTGCTGAGCA	ATCAAAGGAA	TGCAACATCA	ACATATCCAC	TACAAATTAC
NL/24/01	GGAATTAATG	TTGCTGAGCA	ATCAAAGGAG	TGCAACATCA	ACATATCCAC	CACAAATTAC
NL/3/02	GGAATTAATG	TTGCTGAGCA	ATCAAAGGAG	TGCAACATCA	ACATATCCAC	TACAAATTAC
NL/3/98	GGGATCAATG	TTGCTGAGCA	ATCAAGAGAA	TGCAACATCA	ACATATCTAC	TACCAACTAC
NL/1/99	GGGATCAATG	TTGCTGAGCA	ATCAAGAGAA	TGCAACATCA	ACATATCTAC	TACCAACTAC
NL/2/99	GGGATCAATG	TTGCTGAGCA	ATCAAGAGAA	TGCAACATCA	ACATATCTAC	TACCAACTAC
NL/3/99	GGGATCAATG	TTGCTGAGCA	ATCAAGAGAA	TGCAACATCA	ACATATCTAC	TACCAACTAC
NL/11/00	GGGATCAATG	TTGCTGAGCA	ATCAAGAGAA	TGCAACATCA	ACATATCTAC	TACCAACTAC
NL/12/00	GGGATCAATG	TTGCTGAGCA	ATCAAGAGAA	TGCAACATCA	ACATATCTAC	TACCAACTAC
NL/1/01	GGGATCAATG	TTGCTGAGCA	ATCAAGAGAA	TGCAACATCA	ACATATCTAC	TACCAACTAC
NL/5/01	GGGATCAATG	TTGCTGAGCA	ATCAAGAGAA	TGCAACATCA	ACATATCTAC	TACCAACTAC
NL/9/01	GGGATCAATG	TTGCTGAGCA	ATCAAGAGAA	TGCAACATCA	ACATATCTAC	TACCAACTAC
NL/19/01	GGGATCAATG	TTGCTGAGCA	ATCAAGAGAA	TGCAACATCA	ACATATCTAC	TACCAACTAC
NL/21/01	GGGATCAATG	TTGCTGAGCA	ATCAAGAGAA	TGCAACATCA	ACATATCTAC	TACCAACTAC
UK/11/01	GGGATCAATG	TTGCTGAGCA	ATCAAGAGAA	TGCAACATCA	ACATATCTAC	TACCAACTAC
FL/1/01	GGGATCAATG	TTGCTGAGCA	ATCAAGAGAA	TGCAACATCA	ACATATCTAC	TACCAACTAC
FL/2/01	GGGATCAATG	TTGCTGAGCA	ATCAAGAGAA	TGCAACATCA	ACATATCTAC	TACCAACTAC
FL/5/01	GGGATCAATG	TTGCTGAGCA	ATCAAGAGAA	TGCAACATCA	ACATATCTAC	TACCAACTAC
FL/7/01	GGGATCAATG	TTGCTGAGCA	ATCAAGAGAA	TGCAACATCA	ACATATCTAC	TACCAACTAC
FL/9/01	GGGATCAATG	TTGCTGAGCA	ATCAAGAGAA	TGCAACATCA	ACATATCTAC	TACCAACTAC
UK/10/01	GGGATCAATG	TTGCTGAGCA	ATCAAGAGAA	TGCAACATCA	ACATATCTAC	TACCAACTAC
NL/1/02	GGGATCAATG	TTGCTGAGCA	ATCAAGAGAA	TGCAACATCA	ACATATCTAC	TACCAACTAC
NL/1/94	GGGATCAATG	TTGCTGAGCA	ATCAAGAGAA	TGCAACATCA	ACATATCTAC	CACCAACTAC
NL/1/96	GGGATCAATG	TTGCTGAGCA	ATCAAGAGAA	TGCAACATCA	ACATATCTAC	CACCAACTAC
NL/6/97	GGGATCAATG	TTGCTGAGCA	ATCAAGAGAA	TGCAACATCA	ACATATCTAC	CACCAACTAC
NL/7/00	GGGATCAATG	TTGCTGAGCA	ATCAAGAGAA	TGCAACATCA	ACATATCTAC	AACCAACTAC
NL/9/00	GGGATCAATG	TTGCTGAGCA	ATCAAGAGAA	TGCAACATCA	ACATATCCAC	AACCAACTAC
NL/19/00	GGGATCAATG	TTGCTGAGCA	ATCAAGAGAA	TGCAACATCA	ACATATCTAC	TACCAACTAC
NL/28/00	GGGATCAATG	TTGCTGAGCA	ATCAAGAGAA	TGCAACATCA	ACATATCTAC	AACCAACTAC
NL/3/01	GGGATCAATG	TTGCTGAGCA	ATCAAGAGAA	TGCAACATCA	ACATATCTAC	AACCAACTAC
NL/4/01	GGGATCAATG	TTGCTGAGCA	ATCAAGAGAA	TGCAACATCA	ACATATCTAC	AACCAACTAC
NL/11/01	GGGATCAATG	TTGCTGAGCA	ATCAAGAGAA	TGCAACATCA	ACATATCTAC	AACCAACTAC
NL/15/01	GGGATCAATG	TTGCTGAGCA	ATCAAGAGAA	TGCAACATCA	ACATATCTAC	AACCAACTAC
NL/18/01	GGGATCAATG	TTGCTGAGCA	ATCAAGAGAA	TGCAACATCA	ACATATCTAC	AACCAACTAC
FL/6/01	GGGATCAATG	TTGCTGAGCA	ATCAAGAGAA	TGCAACATCA	ACATATCTAC	AACCAACTAC
UK/5/01	GGGATCAATG	TTGCTGAGCA	ATCAAGAGAA	TGCAACATCA	ACATATCCAC	AACCAACTAC
UK/8/01	GGGATCAACG	TTGCTGAGCA	ATCAAGAGAA	TGCAACATCA	ACATATCTAC	CACCAACTAT
NL/12/02	GGGATCAATG	TTGCTGAGCA	ATCAAGAGAA	TGCAACATCA	ACATATCTAC	AACCAACTAC
HK/1/02	GGGATCAATG	TTGCTGAGCA	ATCAAGAGAA	TGCAACATCA	ACATATCTAC	AACCAACTAC

....					
305	315	325	335	345	355

NL/1/00	CCATGCAAAG	TTAGCACAGG	AAGACATCCT	ATCAGTATGG	TTGCACTATC	TCCTCTTGGG
UK/1/00	CCATGCAAAG	TTAGCACAGG	AAGACATCCT	ATCAGTATGG	TTGCACTGTC	TCCTCTTGGG
NL/2/00	CCATGCAAAG	TTAGCACAGG	AAGACATCCT	ATCAGTATGG	TTGCACTGTC	TCCTCTTGGG
NL/13/00	CCATGCAAAG	TTAGCACAGG	AAGACATCCT	ATCAGTATGG	TTGCACTGTC	TCCTCTTGGG
NL/14/00	CCATGCAAAG	TTAGCACAGG	AAGACATCCT	ATCAGTATGG	TTGCACTGTC	TCCTCTTGGG

[illegible]

NL/7/00	CCATGCAAAG	TCAGCACAGG	AAGACACCCT	ATCAGCATGG	TTGCACTATC	ACCTCTCGGT
NL/9/00	CCATGCAAAG	TCAGCACAGG	AAGACACCCT	ATCAGCATGG	TTGCACTGTC	ACCTCTCGGC
NL/19/00	CCATGCAAAG	TCAGCACAGG	AAGACACCCT	ATCAGCATGG	TTGCACTATC	ACCTCTCGGT
NL/28/00	CCATGCAAAG	TCAGCACAGG	AAGACACCCT	ATCAGCATGG	TTGCACTATC	ACCTCTCGGT
NL/3/01	CCATGCAAAG	TCAGCACAGG	AAGACACCCT	ATCAGCATGG	TTGCACTATC	ACCTCTCGGT
NL/4/01	CCATGCAAAG	TCAGCACAGG	AAGACACCCT	ATCAGCATGG	TTGCACTATC	ACCTCTCGGT
NL/11/01	CCATGCAAAG	TCAGCACAGG	AAGACACCCT	ATCAGCATGG	TTGCACTATC	ACCTCTCGGT
NL/15/01	CCATGCAAAG	TCAGCACAGG	AAGACACCCT	ATCAGCATGG	TTGCACTATC	ACCTCTCGGT
NL/18/01	CCATGCAAAG	TCAGCACAGG	AAGACACCCT	ATCAGCATGG	TTGCACTATC	ACCTCTCGGT
FL/6/01	CCATGCAAAG	TCAGCACAGG	AAGACACCCT	ATCAGCATGG	TTGCACTATC	ACCTCTCGGT
UK/5/01	CCATGCAAAG	TCAGCACAGG	AAGACACCCT	ATCAGCATGG	TTGCACTGTC	ACCTCTCGGC
UK/8/01	CCGTGCAAAG	TCAGCACAGG	AAGACACCCT	ATCAGCATGG	TTGCACTATC	ACCTCTCGGT
NL/12/02	CCATGCAAAG	TCAGCACAGG	AAGACACCCT	ATCAGCATGG	TTGCACTATC	ACCTCTCGGT
HK/1/02	CCATGCAAAG	TCAGCACAGG	AAGACACCCT	ATCAGCATGG	TTGCACTATC	ACCTCTCGGT

						
	365	375	385	395	405	415
NL/1/00	GCTTTGGTTG	CTTGCTACAA	GGGAGTGAGC	TGTTCCATTG	GCAGCAACAG	AGTAGGGATC
UK/1/00	GCTTTGGTTG	CTTGCTACAA	GGGAGTGAGC	TGTTCCATTG	GCAGCAACAG	AGTAGGGATC
NL/2/00	GCTTTGGTTG	CTTGCTACAA	GGGAGTGAGC	TGTTCCATTG	GCAGCAACAG	AGTAGGGATC
NL/13/00	GCTTTGGTTG	CTTGCTACAA	GGGAGTGAGC	TGTTCCATTG	GCAGCAACAG	AGTAGGGATC
NL/14/00	GCTTTGGTTG	CTTGCTACAA	GGGAGTGAGC	TGTTCCATTG	GTAGCAACAG	AGTAGGGATC
FL/3/01	GCTTTGGTTG	CTTGCTACAA	GGGAGTGAGC	TGTTCCATTG	GCAGCAACAG	AGTAGGGATC
FL/4/01	GCTTTGGTTG	CTTGCTACAA	GGGAGTGAGC	TGTTCCATTG	GCAGCAACAG	AGTAGGGATC
FL/8/01	GCTTTGGTTG	CTTGCTACAA	GGGAGTGAGC	TGTTCCATTG	GCAGCAACAG	AGTAGGGATC
UK/1/01	GCTTTGGTTG	CTTGCTACAA	GGGAGTGAGC	TGTTCCATTG	GCAGCAACAG	AGTAGGAATC
UK/7/01	GCTTTGGTTG	CTTGCTACAA	GGGAGTGAGC	TGTTCCATTG	GCAGCAACAG	AGTAGGGATC
FL/10/01	GCTTTGGTTG	CTTGCTACAA	GGGAGTGAGC	TGTTCCATTG	GCAGCAACAG	AGTAGGGATC
NL/6/01	GCTTTGGTTG	CTTGCTACAA	GGGAGTGAGC	TGTTCCATTG	GCAGCAACAG	AGTAGGGATC
NL/8/01	GCTTTGGTTG	CTTGCTACAA	GGGAGTGAGC	TGTTCCATTG	GCAGCAACAG	AGTAGGGATC
NL/10/01	GCTTTGGTTG	CTTGCTACAA	GGGAGTGAGC	TGTTCCATTG	GCAGCAACAG	AGTAGGGATC
NL/14/01	GCTTTGGTTG	CTTGCTACAA	GGGAGTGAGC	TGTTCTATTG	GCAGCAACAG	AGTAGGGATC
NL/20/01	GCTTTGGTTG	CTTGCTACAA	GGGAGTGAGC	TGTTCCATTG	GCAGCAACAG	AGTAGGGATC
NL/25/01	GCTTTGGTTG	CTTGCTACAA	GGGAGTGAGC	TGTTCCATTG	GCAGCAACAG	AGTAGGGATC
NL/26/01	GCTTTGGTTG	CTTGCTACAA	GGGAGTGAGC	TGTTCCATTG	GCAGCAACAG	AGTAGGGATC
NL/28/01	GCTTTGGTTG	CTTGCTACAA	GGGAGTGAGC	TGTTCCATTG	GCAGCAACAG	AGTAGGGATC
NL/30/01	GCTTTGGTTG	CTTGCTACAA	GGGAGTGAGC	TGTTCCATTG	GCAGCAACAG	AGTAGGGATC
BR/2/01	GCTTTGGTTG	CTTGCTaCAA	GGGAGTGAGC	TGTTCCATTG	GCAGCAACAG	AGTAGGGATC
BR/3/01	GCTTTGGTTG	CTTGCTACAA	GGGAGTGAGC	TGTTCCATTG	GCAGCAACAG	AGTAGGGATC
NL/2/02	GCTTTGGTTG	CTTGCTACAA	GGGAGTGAGC	TGTTCCATTG	GCAGCAACAG	AGTAGGGATC
NL/4/02	GCTCTGGTTG	CTTGCTACAA	GGGAGTGAGC	TGCTCCATTG	GCAGCAACAG	AGTAGGGATC
NL/5/02	GCTTTGGTTG	CTTGCTACAA	GGGAGTGAGC	TGTTCCATTG	GCAGCAACAG	AGTAGGGATC
NL/6/02	GCTTTGGTTG	CTTGCTACAA	GGGAGTGAGC	TGTTCCATTG	GCAGCAACAG	AGTAGGGATC
NL/7/02	GCTTTGGTTG	CTTGCTACAA	GGGAGTGAGC	TGTTCCATTG	GCAGCAACAG	AGTAGGGATC
NL/9/02	GCTTTGGTTG	CTTGCTACAA	GGGAGTGAGC	TGTTCCATTG	GCAGCAACAG	AGTAGGGATC
FL/1/02	GCTTTGGTTG	CTTGCTACAA	GGGAGTGAGC	TGTTCCATTG	GCAGCAACAG	AGTAGGGATC
NL/1/81	GCTCTGGTTG	CTTGCTACAA	AGGAGTAAGC	TGTTCCATTG	GCAGCAATAG	AGTAGGGATT
NL/1/93	GCTCTAGTTG	CTTGCTACAA	AGGAGTAAGC	TGTTCCATTG	GCAGCAATAG	AGTAGGGATC
NL/2/93	GCTCTAGTTG	CTTGCTACAA	AGGAGTAAGC	TGTTCCATTG	GCAGCAATAG	AGTAGGGATC
NL/4/93	GCTCTAGTTG	CTTGCTACAA	AGGAGTAAGC	TGTTCCATTG	GCAGCAATAG	AGTAGGGATC
NL/1/95	GCTCTGGTTG	CTTGTTACAA	AGGAGTAAGC	TGTTCTATTG	GCAGCAATAG	AGTAGGGATC
NL/2/96	GCTCTAGTTG	CTTGCTACAA	AGGAGTAAGC	TGTTCCATTG	GCAGCAACAG	AGTAGGGATC
NL/3/96	GCTCTGGTTG	CTTGTTACAA	AGGAGTAAGC	TGTTCTATTG	GCAGCAATAG	AGTAGGGATC
NL/1/98	GCTCTGGTTG	CTTGCTACAA	AGGAGTAAGC	TGTTCCATTG	GCAGCAACAG	AGTAGGGATC
NL/17/00	GCTCTGGTTG	CTTGCTACAA	AGGAGTAAGC	TGTTCCATTG	GCAGCAACAG	AGTAGGGATC
NL/22/01	GCTCTGGTTG	CCTGTTACAA	AGGAGTAAGT	TGTTCCATTG	GCAGCAATAG	AGTAGGGATC
NL/29/01	GCTCTGGTTG	CTTGCTACAA	AGGAGTAAGC	TGTTCCATTG	GCAGCAACAG	AGTAGGGATC
NL/23/01	GCTCTGGTTG	CCTGTTACAA	AGGAGTAAGT	TGTTCCATTG	GCAGCAATAG	AGTAGGGATC
NL/17/01	GCTCTGGTTG	CTTGCTACAA	AGGAGTAAGC	TGTTCCATTG	GCAGCAACAG	AGTAGGGATC
NL/24/01	GCTCTGGTTG	CCTGTTACAA	AGGAGTAAGT	TGTTCCATTG	GCAGCAATAG	AGTAGGGATC
NL/3/02	GCTCTGGTTG	CTTGCTACAA	AGGAGTAAGC	TGTTCCATTG	GCAGCAACAG	AGTAGGGATC

NL/3/98	GCTTTGGTGG	CTTGCTATAA	AGGGGTAAGC	TGCTCGATTG	GCAGCAATCG	GGTTGGAATC
NL/1/99	GCTTTGGTGG	CTTGCTATAA	AGGGGTAAGC	TGCTCGATTG	GCAGCAATCG	GGTTGGAATC
NL/2/99	GCTTTGGTGG	CTTGCTATAA	AGGGGTAAGC	TGCTCGATTG	GCAGCAATCG	GGTTGGAATC
NL/3/99	GCTTTGGTGG	CTTGCTATAA	AGGGGTAAGC	TGCTCGATTG	GCAGCAATCG	GGTTGGAATC
NL/11/00	GCTTTGGTGG	CTTGCTATAA	AGGGGTAAGC	TGCTCGATTG	GCAGCAATCG	GGTTGGAATC
NL/12/00	GCTTTGGTGG	CTTGCTATAA	AGGGGTAAGC	TGCTCGATTG	GCAGCAATCG	GGTTGGAATC
NL/1/01	GCTTTGGTGG	CTTGCTATAA	AGGGGTAAGC	TGCTCGATTG	GCAGCAATCG	GGTTGGAATC
NL/5/01	GCTTTGGTGG	CTTGCTATAA	AGGGGTAAGC	TGCTCGATTG	GCAGCAATCG	GGTTGGAATC
NL/9/01	GCTTTGGTGG	CTTGCTATAA	AGGGGTAAGC	TGCTCGATTG	GCAGCAATCG	GGTTGGAATC
NL/19/01	GCTTTGGTGG	CTTGCTATAA	AGGGGTAAGC	TGCTCGATTG	GCAGCAATCG	GGTTGGAATC
NL/21/01	GCTTTGGTGG	CTTGCTATAA	AGGGGTAAGC	TGCTCGATTG	GCAGCAATCG	GGTTGGAATC
UK/11/01	GCTTTGGTGG	CTTGCTATAA	AGGGGTAAGC	TGCTCGATTG	GCAGCAATCG	GGTTGGAATC
FL/1/01	GCTTTGGTGG	CTTGCTATAA	AGGGGTAAGC	TGCTCGATTG	GCAGCAATCG	GGTTGGAATT
FL/2/01	GCTTTGGTGG	CTTGCTATAA	AGGGGTAAGC	TGCTCGATTG	GCAGCAATCG	GGTTGGAATC
FL/5/01	GCTTTGGTGG	CTTGCTATAA	AGGGGTAAGC	TGCTCGATTG	GCAGCAATCG	GGTTGGAATC
FL/7/01	GCTTTGGTGG	CTTGCTATAA	AGGGGTAAGC	TGCTCGATTG	GCAGCAATCG	GGTTGGAATC
FL/9/01	GCTTTGGTGG	CTTGCTATAA	AGGGGTAAGC	TGCTCGATTG	GCAGCAATCG	GGTTGGAATC
UK/10/01	GCTTTGGTGG	CTTGCTATAA	AGGGGTAAGC	TGCTCGATTG	GCAGCAATCG	GGTTGGAATC
NL/1/02	GCTTTGGTGG	CTTGCTATAA	AGGGGTAAGC	TGCTCGATTG	GCAGCAATCG	GGTTGGAATC
NL/1/94	GCTTTGGTaG	CTTGcTaCaA	GGGGGTTAGC	TGCTCGATTG	GCAGTAATCG	GGTTGGAATA
NL/1/96	GCTTTGGTAG	CTTGCTACAA	AGGGGTTAGC	TGCTCGATTG	GCAGTAATCG	GGTTGGAATA
NL/6/97	GCTTTGGTAG	CTTGCTACAA	AGGGGTTAGC	TGCTCGATTG	GCAGTAATCG	GGTTGGAATA
NL/7/00	GCTTTGGTAG	CTTGCTACAA	AGGGGTTAGC	TGTTTCGATTG	GCAGTAATCG	GGTTGGAATA
NL/9/00	GCTTTGGTAG	CTTGCTACAA	AGGGGTTAGC	TGTTTCGATTG	GCAGTAATCG	GGTTGGAATA
NL/19/00	GCTTTGGTAG	CTTGCTACAA	AGGGGTTAGC	TGTTTCGATTG	GCAGTAATCG	GGTTGGAATA
NL/28/00	GCTTTGGTAG	CTTGCTACAA	AGGGGTTAGC	TGTTTCGATTG	GCAGTAATCG	GGTTGGAATA
NL/3/01	GCTTTGGTAG	CTTGCTACAA	AGGGGTTAGC	TGTTTCGATTG	GCAGTAATCG	GGTTGGAATA
NL/4/01	GCTTTGGTAG	CTTGCTACAA	AGGGGTTAGC	TGTTTCGATTG	GCAGTAATCG	GGTTGGAATA
NL/11/01	GCTTTGGTAG	CTTGCTACAA	AGGGGTTAGC	TGTTTCGATTG	GCAGTAATCG	GGTTGGAATA
NL/15/01	GCTTTGGTAG	CTTGCTACAA	AGGGGTTAGC	TGTTCAATTG	GCAGTAATCG	GGTTGGAATA
NL/18/01	GCTTTGGTAG	CTTGCTACAA	AGGGGTTAGC	TGTTCAATTG	GCAGTAATCG	GGTTGGAATA
FL/6/01	GCTTTGGTAG	CTTGCTACAA	GGGGGTTAGC	TGTTTCGATTG	GCAGTAATCG	GGTTGGAATA
UK/5/01	GCTTTGGTAG	CTTGCTACAA	AGGGGTTAGC	TGTTTCGATTG	GCAGTAATCG	GGTTGGAATA
UK/8/01	GCTTTGGTAG	CTTGCTACAA	AGGGGTTAGC	TGCTCGATTG	GCAGTAATCG	GGTTGGAATA
NL/12/02	GCTTTGGTAG	CTTGCTACAA	AGGGGTTAGC	TGTTCAATTG	GCAGTAATCG	GGTTGGAATA
HK/1/02	GCTTTGGTAG	CTTGCTACAA	AGGGGTTAGC	TGTTTCGATTG	GCAGTAATCG	GGTTGGAATA

....		
425	435	445

NL/1/00	ATCAAGCAAC	TGAACAAAGG	CTGCTCTTA
UK/1/00	ATCAAGCAAC	TGAACAAAGG	CTGCTCTTA
NL/2/00	ATCAAGCAAC	TGAACAAAGG	CTGCTCTTA
NL/13/00	ATCAAGCAAC	TGAACAAAGG	CTGCTCTTA
NL/14/00	ATCAAGCAAC	TGAACAAAGG	CTGCTCTTA
FL/3/01	ATCAAGCAAC	TGAACAAAGG	CTGCTCTTA
FL/4/01	ATCAAGCAAC	TGAACAAAGG	CTGCTCTTA
FL/8/01	ATCAAGCAAC	TGAACAAAGG	CTGCTCTTA
UK/1/01	ATCAAGCAAC	TGAACAAAGG	CTGCTCTTA
UK/7/01	ATCAAGCAAC	TGAACAAAGG	CTGCTCTTA
FL/10/01	ATCAAGCAAC	TGAACAAAGG	CTGCTCTTA
NL/6/01	ATCAAGCAAC	TGAACAAAGG	CTGCTCTTA
NL/8/01	ATCAAGCAAC	TGAACAAAGG	CTGCTCTTA
NL/10/01	ATCAAGCAAC	TGAACAAAGG	CTGCTCTTA
NL/14/01	ATCAAGCAAC	TGAACAAAGG	CTGCTCTTA
NL/20/01	ATCAAGCAAC	TGAACAAAGG	CTGCTCTTA
NL/25/01	ATCAAGCAAC	TGAACAAAGG	CTGCTCTTA
NL/26/01	ATCAAGCAAC	TGAACAAAGG	CTGCTCTTA
NL/28/01	ATCAAGCAAC	TGAACAAAGG	CTGCTCTTA
NL/30/01	ATCAAGCAAC	TGAACAAAGG	CTGCTCTTA
BR/2/01	ATCAAGCAAC	TGAACAAAGG	CTGCTCTTA
BR/3/01	ATCAAGCAAC	TGAACAAAGG	CTGCTCTTA

NL/2/02	ATCAAGCAAC	TGAACAAAGG	CTGCTCTTA
NL/4/02	ATCAAGCAAC	TGAACAAAGG	CTGCTCTTA
NL/5/02	ATCAAGCAAC	TGAACAAAGG	CTGCTCTTA
NL/6/02	ATCAAGCAAC	TGAACAAAGG	CTGCTCTTA
NL/7/02	ATCAAGCAAC	TGAACAAAGG	CTGCTCTTA
NL/9/02	ATCAAGCAAC	TGAACAAAGG	CTGCTCTTA
FL/1/02	ATCAAGCAAC	TGAACAAAGG	CTGCTCTTA
NL/1/81	ATCAAGCAGC	TGAACAAAGG	TTGCTCTTA
NL/1/93	ATCAAGCAGC	TGAACAAAGG	TTGCTCCTA
NL/2/93	ATCAAGCAGC	TGAACAAAGG	TTGCTCCTA
NL/4/93	ATCAAGCAGC	TGAACAAAGG	TTGCTCCTA
NL/1/95	ATCAAGCAGC	TGAACAAAGG	TTGCTCTTA
NL/2/96	ATCAAGCAGC	TGAACAAAGG	TTGCTCCTA
NL/3/96	ATCAAGCAGC	TGAACAAAGG	TTGCTCTTA
NL/1/98	ATCAAGCAGC	TGAACAAAGG	TTGCTCCTA
NL/17/00	ATCAAGCAGC	TGAACAAAGG	TTGCTCCTA
NL/22/01	ATCAAGCAGC	TGAACAAAGG	TTGCTCTTA
NL/29/01	ATAAGCAGC	TGAACAAAGG	TTGCTCCTA
NL/23/01	ATCAAGCAGC	TGAACAAAGG	TTGCTCTTA
NL/17/01	ATCAAGCAGC	TGAACAAAGG	TTGCTCCTA
NL/24/01	ATCAAGCAGC	TGAACAAAGG	TTGCTCTTA
NL/3/02	ATAAGCAGC	TGAACAAAGG	TTGCTCCTA
NL/3/98	ATCAAACAAT	TACCTAAAGG	CTGCTCATA
NL/1/99	ATCAAACAAT	TACCCAAAGG	CTGCTCATA
NL/2/99	ATCAAACAAT	TACCCAAAGG	CTGCTCATA
NL/3/99	ATCAAACAAT	TACCCAAAGG	CTGCTCATA
NL/11/00	ATCAAACAAT	TACCTAAAGG	CTGCTCATA
NL/12/00	ATCAAACAAT	TACCTAAAGG	CTGCTCATA
NL/1/01	ATCAAACAAT	TACCTAAAGG	CTGCTCATA
NL/5/01	ATCAAACAAT	TACCTAAAGG	CTGCTCATA
NL/9/01	ATCAAACAAT	TACCTAAAGG	CTGCTCATA
NL/19/01	ATCAAACAAT	TACCTAAAGG	CTGCTCATA
NL/21/01	ATCAAACAAT	TACCTAAAGG	CTGCTCATA
UK/11/01	ATCAAACAAT	TACCCAAAGG	CTGCTCATA
FL/1/01	ATCAAACAAT	TACCTAAAGG	CTGCTCATA
FL/2/01	ATCAAACAAT	TACCTAAAGG	CTGCTCATA
FL/5/01	ATCAAACAAT	TACCTAAAGG	CTGCTCATA
FL/7/01	ATCAAACAAT	TACCTAAAGG	CTGCTCATA
FL/9/01	ATCAAACAAT	TACCTAAAGG	CTGCTCATA
UK/10/01	ATCAAACAAT	TACCCAAAGG	CTGCTCATA
NL/1/02	ATCAAACAAT	TACCTAAAGG	CTGCTCATA
NL/1/94	ATCAAACAAC	TACCTAAAGG	CTGCTCATA
NL/1/96	ATCAAACAAC	TACCTAAAGG	CTGCTCATA
NL/6/97	ATCAAACAAC	TACCTAAAGG	CTGCTCATA
NL/7/00	ATCAAACAAC	TACCTAAAGG	CTGCTCATA
NL/9/00	ATCAAACAAC	TACCTAAAGG	CTGCTCATA
NL/19/00	ATCAAACAAC	TACCTAAAGG	CTGCTCATA
NL/28/00	ATCAAACAAC	TACCTAAAGG	CTGCTCATA
NL/3/01	ATCAAACAAC	TACCTAAAGG	CTGCTCATA
NL/4/01	ATCAAACAAC	TACCTAAAGG	CTGCTCATA
NL/11/01	ATCAAACAAC	TACCTAAAGG	CTGCTCATA
NL/15/01	ATCAAACAAC	TACCTAAAGG	CTGCTCATA
NL/18/01	ATCAAACAAC	TACCTAAAGG	CTGCTCATA
FL/6/01	ATCAAACAAC	TACCTAAAGG	CTGCTCATA
UK/5/01	ATCAAACAAC	TACCTAAAGG	CTGCTCATA
UK/8/01	ATCAAACAAC	TACCTAAAGG	CTGCTCATA
NL/12/02	ATCAAACAAC	TACCTAAAGG	CTGCTCATA
HK/1/02	ATCAAACAAC	TACCTAAAGG	CTGCTCATA

Alignment: F proteins

						
	5	15	25	35	45	55
NL/1/00	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSGKKGNY	ACLLREDQGW	YCQNAGSTVY
UK/1/00	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSEKKGNY	ACLLREDQGW	YCQNAGSTVY
NL/2/00	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSEKKGNY	ACLLREDQGW	YCQNAGSTVY
NL/13/00	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSEKKGNY	ACLLREDQGW	YCQNAGSTVY
NL/14/00	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSEKKGNY	ACLLREDQGW	YCQNAGSTVY
FL/3/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSEKKGNY	ACLLREDQGW	YCQNAGSTVY
FL/4/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSEKKGNY	ACLLREDQGW	YCQNAGSTVY
FL/8/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSEKKGNY	ACLLREDQGW	YCQNAGSTVY
UK/1/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSEKKGNY	ACLLREDQGW	YCQNAGSTVY
UK/7/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSEKKGNY	ACLLREDQGW	YCQNAGSTVY
FL/10/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSEKKGNY	ACLLREDQGW	YCQNAGSTVY
NL/6/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSEKKGNY	ACLLREDQGW	YCQNAGSTVY
NL/8/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSEKKGNY	ACLLREDQGW	YCQNAGSTVY
NL/10/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSEKKGNY	ACLLREDQGW	YCQNAGSTVY
NL/14/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSEKKGNY	ACLLREDQGW	YCQNAGSTVY
NL/20/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSEKKGNY	ACLLREDQGW	YCQNAGSTVY
NL/25/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSEKKGNY	ACLLREDQGW	YCQNAGSTVY
NL/26/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSEKKGNY	ACLLREDQGW	YCQNAGSTVY
NL/28/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSEKKGNY	ACLLREDQGW	YCQNAGSTVY
NL/30/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSEKKGNY	ACLLREDQGW	YCQNAGSTVY
BR/2/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSGKKGNY	ACLLREDQGW	YCQNAGSTVY
BR/3/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSGKKGNY	ACLLREDQGW	YCQNAGSTVY
NL/2/02	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSEKKGNY	ACLLREDQGW	YCQNAGSTVY
NL/4/02	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSEKKGNY	ACLLREDQGW	YCQNAGSTVY
NL/5/02	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSEKKGNY	ACLLREDQGW	YCQNAGSTVY
NL/6/02	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSEKKGNY	ACLLREDQGW	YCQNAGSTVY
NL/7/02	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSGKKGNY	ACLLREDQGW	YCQNAGSTVY
NL/9/02	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSEKKGNY	ACLLREDQGW	YCQNAGSTVY
*1 FL/1/02	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSGKKGNY	ACLLREDQGW	YCQNAGSTVY
*2 NL/1/81	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSEKKGNY	ACLLREDQGW	YCQNAGSTVY
NL/1/93	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSEKKGNY	ACLLREDQGW	YCQNAGSTVY
NL/2/93	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSEKKGNY	ACLLREDQGW	YCQNAGSTVY
NL/4/93	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSEKKGNY	ACLLREDQGW	YCQNAGSTVY
NL/1/95	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSEKKGNY	ACLLREDQGW	YCQNAGSTVY
NL/2/96	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSEKKGNY	ACLLREDQGW	YCQNAGSTVY
NL/3/96	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSEKKGNY	ACLLREDQGW	YCQNAGSTVY
NL/1/98	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSEKKGNY	ACLLREDQGW	YCQNAGSTVY
NL/17/00	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSEKKGNY	ACLLREDQGW	YCQNAGSTVY
NL/22/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSEKKGNY	ACLLREDQGW	YCQNAGSTVY
NL/29/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSEKKGNY	ACLLREDQGW	YCQNAGSTVY
NL/23/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSEKKGNY	ACLLREDQGW	YCQNAGSTVY
NL/17/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSEKKGNY	ACLLREDQGW	YCQNAGSTVY
NL/24/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSEKKGNY	ACLLREDQGW	YCQNAGSTVY
NL/3/02	IGVYGSSVIY	MVQLPIFGVI	DTPCWIVKAA	PSCSEKKGNY	ACLLREDQGW	YCQNAGSTVY
NL/3/98	IGVYGSSVIY	MVQLPIFGVI	DTPCWIKAA	PSCSEKNGNY	ACLLREDQGW	YCKNAGSTVY
NL/1/99	IGVYGSSVIY	MVQLPIFGVI	DTPCWIKAA	PSCSEKNGNY	ACLLREDQGW	YCKNAGSTVY
NL/2/99	IGVYGSSVIY	MVQLPIFGVI	DTPCWIKAA	PSCSEKNGNY	ACLLREDQGW	YCKNAGSTVY
NL/3/99	IGVYGSSVIY	MVQLPIFGVI	DTPCWIKAA	PSCSEKNGNY	ACLLREDQGW	YCKNAGSTVY
NL/11/00	IGVYGSSVIY	MVQLPIFGVI	DTPCWIKAA	PSCSEKNGNY	ACLLREDQGW	YCKNAGSTVY
NL/12/00	IGVYGSSVIY	MVQLPIFGVI	DTPCWIKAA	PSCSEKNGNY	ACLLREDQGW	YCKNAGSTVY
NL/1/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIKAA	PSCSEKNGNY	ACLLREDQGW	YCKNAGSTVY
NL/5/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIKAA	PSCSEKNGNY	ACLLREDQGW	YCKNAGSTVY
NL/9/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIKAA	PSCSEKNGNY	ACLLREDQGW	YCKNAGSTVY
NL/19/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIKAA	PSCSEKNGNY	ACLLREDQGW	YCKNAGSTVY

FIGURE 18

NL/21/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIIKAA	PSCSEKNGNY	ACLLREDQGW	YCKNAGSTVY
UK/11/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIIKAA	PSCSEKNGNY	ACLLREDQGW	YCKNAGSTVY
FL/1/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIIKAA	PSCSEKNGNY	ACLLREDQGW	YCKNAGSTVY
FL/2/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIIKAA	PSCSEKNGNY	ACLLREDQGW	YCKNAGSTVY
FL/5/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIIKAA	PSCSEKNGNY	ACLLREDQGW	YCKNAGSTVY
FL/7/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIIKAA	PSCSEKNGNY	ACLLREDQGW	YCKNAGSTVY
FL/9/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIIKAA	PSCSEKNGNY	ACLLREDQGW	YCKNAGSTVY
UK/10/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIIKAA	PSCSEKNGNY	ACLLREDQGW	YCKNAGSTVY
NL/1/02	IGVYGSSVIY	MVQLPIFGVI	DTPCWIIKAA	PSCSEKNGNY	ACLLREDQGW	YCKNAGSTVY
NL/1/94	IGVYGSSVIY	MVQLPIFGVI	DTPCWIIKAA	PSCSEKNGNY	ACLLREDQGW	YCKNAGSTVY
NL/1/96	IGVYGSSVIY	MVQLPIFGVI	DTPCWIIKAA	PSCSEKNGNY	ACLLREDQGW	YCKNAGSTVY
NL/6/97	IGVYGSSVIY	MVQLPIFGVI	DTPCWIIKAA	PSCSEKNGNY	ACLLREDQGW	YCKNAGSTVY
NL/7/00	IGVYGSSVIY	MVQLPIFGVI	DTPCWIIKAA	PSCSEKNGNY	ACLLREDQGW	YCKNAGSTVY
NL/9/00	IGVYGSSVIY	MVQLPIFGVI	DTPCWIIKAA	PSCSEKNGNY	ACLLREDQGW	YCKNAGSTVY
NL/19/00	IGVYGSSVIY	MVQLPIFGVI	DTPCWIIKAA	PSCSEKNGNY	ACLLREDQGW	YCKNAGSTVY
NL/28/00	IGVYGSSVIY	MVQLPIFGVI	DTPCWIIKAA	PSCSEKNGNY	ACLLREDQGW	YCKNAGSTVY
NL/3/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIIKAA	PSCSEKNGNY	ACLLREDQGW	YCKNAGSTVY
NL/4/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIIKAA	PSCSEKNGNY	ACLLREDQGW	YCKNAGSTVY
NL/11/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIIKAA	PSCSEKNGNY	ACLLREDQGW	YCKNAGSTVY
NL/15/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIIKAA	PSCSEKNGNY	ACLLREDQGW	YCKNAGSTVY
NL/18/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIIKAA	PSCSEKNGNY	ACLLREDQGW	YCKNAGSTVY
FL/6/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIIKAA	PSCSEKNGNY	ACLLREDQGW	YCKNAGSTVY
UK/5/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIIKAA	PSCSEKNGNY	ACLLREDQGW	YCKNAGSTVY
UK/8/01	IGVYGSSVIY	MVQLPIFGVI	DTPCWIIKAA	PSCSEKNGNY	ACLLREDQGW	YCKNAGSTVY
NL/12/02	IGVYGSSVIY	MVQLPIFGVI	DTPCWIIKAA	PSCSEKNGNY	ACLLREDQGW	YCKNAGSTVY
HK/1/02	IGVYGSSVIY	MVQLPIFGVI	DTPCWIIKAA	PSCSEKNGNY	ACLLREDQGW	YCKNAGSTVY

						
	65	75	85	95	105	115
NL/1/00	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
UK/1/00	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/2/00	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/13/00	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/14/00	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
FL/3/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
FL/4/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
FL/8/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
UK/1/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
UK/7/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
FL/10/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/6/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/8/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/10/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/14/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/20/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/25/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/26/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/28/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/30/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
BR/2/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
BR/3/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/2/02	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/4/02	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/5/02	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/6/02	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/7/02	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/9/02	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
FL/1/02	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/1/81	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/1/93	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/2/93	YPNEKDCETR	GDHVFCDTVA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG

NL/4/93	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/1/95	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/2/96	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/3/96	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/1/98	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/17/00	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/22/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/29/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/23/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/17/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/24/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/3/02	YPNEKDCETR	GDHVFCDTAA	GINVAEQSKE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/3/98	YPNEKDCETR	GDHVFCDTAA	GINVAEQSRE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/1/99	YPNEKDCETR	GDHVFCDTAA	GINVAEQSRE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/2/99	YPNEKDCETR	GDHVFCDTAA	GINVAEQSRE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/3/99	YPNEKDCETR	GDHVFCDTAA	GINVAEQSRE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/11/00	YPNEKDCETR	GDHVFCDTAA	GINVAEQSRE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/12/00	YPNEKDCETR	GDHVFCDTAA	GINVAEQSRE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/1/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSRE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/5/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSRE	CNINISTTNY	PCKVSTGRHS	ISMVALSPLG
NL/9/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSRE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/19/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSRE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/21/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSRE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
UK/11/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSRE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
FL/1/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSRE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
FL/2/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSRE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
FL/5/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSRE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
FL/7/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSRE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
FL/9/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSRE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
UK/10/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSRE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/1/02	YPNEKDCETR	GDHVFCDTAA	GINVAEQSRE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/1/94	YPNEKDCETR	GDHVFCDTAA	GINVAEQSRE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/1/96	YPNEKDCETR	GDHVFCDTAA	GINVAEQSRE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/6/97	YPNEKDCETR	GDHVFCDTAA	GINVAEQSRE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/7/00	YPNEKDCETR	GDHVFCDTAA	GINVAEQSRE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/9/00	YPNEKDCETR	GDHVFCDTAA	GINVAEQSRE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/19/00	YPNEKDCETR	GDHVFCDTAA	GINVAEQSRE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/28/00	YPNEKDCETR	GDHVFCDTAA	GINVAEQSRE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/3/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSRE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/4/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSRE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/11/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSRE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/15/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSRE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/18/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSRE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
FL/6/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSRE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
UK/5/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSRE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
UK/8/01	YPNEKDCETR	GDHVFCDTAA	GINVAEQSRE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
NL/12/02	YPNEKDCETR	GDHVFCDTAA	GINVAEQSRE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG
HK/1/02	YPNEKDCETR	GDHVFCDTAA	GINVAEQSRE	CNINISTTNY	PCKVSTGRHP	ISMVALSPLG

....|....||....||....
125 135 145

NL/1/00	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
UK/1/00	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
NL/2/00	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
NL/13/00	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
NL/14/00	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
FL/3/01	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
FL/4/01	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
FL/8/01	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
UK/1/01	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
UK/7/01	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS

FL/10/01	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
NL/6/01	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
NL/8/01	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
NL/10/01	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
NL/14/01	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
NL/20/01	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
NL/25/01	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
NL/26/01	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
NL/28/01	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
NL/30/01	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
BR/2/01	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
BR/3/01	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
NL/2/02	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
NL/4/02	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
NL/5/02	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
NL/6/02	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
NL/7/02	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
NL/9/02	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
FL/1/02	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
NL/1/81	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
NL/1/93	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
NL/2/93	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
NL/4/93	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
NL/1/95	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
NL/2/96	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
NL/3/96	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
NL/1/98	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
NL/17/00	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
NL/22/01	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
NL/29/01	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
NL/23/01	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
NL/17/01	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
NL/24/01	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
NL/3/02	ALVACYKGV	CSIGSNRVGI	IKQLNKGCS
NL/3/98	ALVACYKGV	CSIGSNRVGI	IKQLPKGCS
NL/1/99	ALVACYKGV	CSIGSNRVGI	IKQLPKGCS
NL/2/99	ALVACYKGV	CSIGSNRVGI	IKQLPKGCS
NL/3/99	ALVACYKGV	CSIGSNRVGI	IKQLPKGCS
NL/11/00	ALVACYKGV	CSIGSNRVGI	IKQLPKGCS
NL/12/00	ALVACYKGV	CSIGSNRVGI	IKQLPKGCS
NL/1/01	ALVACYKGV	CSIGSNRVGI	IKQLPKGCS
NL/5/01	ALVACYKGV	CSIGSNRVGI	IKQLPKGCS
NL/9/01	ALVACYKGV	CSIGSNRVGI	IKQLPKGCS
NL/19/01	ALVACYKGV	CSIGSNRVGI	IKQLPKGCS
NL/21/01	ALVACYKGV	CSIGSNRVGI	IKQLPKGCS
UK/11/01	ALVACYKGV	CSIGSNRVGI	IKQLPKGCS
FL/1/01	ALVACYKGV	CSIGSNRVGI	IKQLPKGCS
FL/2/01	ALVACYKGV	CSIGSNRVGI	IKQLPKGCS
FL/5/01	ALVACYKGV	CSIGSNRVGI	IKQLPKGCS
FL/7/01	ALVACYKGV	CSIGSNRVGI	IKQLPKGCS
FL/9/01	ALVACYKGV	CSIGSNRVGI	IKQLPKGCS
UK/10/01	ALVACYKGV	CSIGSNRVGI	IKQLPKGCS
NL/1/02	ALVACYKGV	CSIGSNRVGI	IKQLPKGCS
NL/1/94	ALVACYKGV	CSIGSNRVGI	IKQLPKGCS
NL/1/96	ALVACYKGV	CSIGSNRVGI	IKQLPKGCS
NL/6/97	ALVACYKGV	CSIGSNRVGI	IKQLPKGCS
NL/7/00	ALVACYKGV	CSIGSNRVGI	IKQLPKGCS
NL/9/00	ALVACYKGV	CSIGSNRVGI	IKQLPKGCS
NL/19/00	ALVACYKGV	CSIGSNRVGI	IKQLPKGCS
NL/28/00	ALVACYKGV	CSIGSNRVGI	IKQLPKGCS
NL/3/01	ALVACYKGV	CSIGSNRVGI	IKQLPKGCS

NL/4/01	ALVACYKGV	CSIGSNRVGI	IKQLPKGCS
NL/11/01	ALVACYKGV	CSIGSNRVGI	IKQLPKGCS
NL/15/01	ALVACYKGV	CSIGSNRVGI	IKQLPKGCS
NL/18/01	ALVACYKGV	CSIGSNRVGI	IKQLPKGCS
FL/6/01	ALVACYKGV	CSIGSNRVGI	IKQLPKGCS
UK/5/01	ALVACYKGV	CSIGSNRVGI	IKQLPKGCS
UK/8/01	ALVACYKGV	CSIGSNRVGI	IKQLPKGCS
NL/12/02	ALVACYKGV	CSIGSNRVGI	IKQLPKGCS
HK/1/02	ALVACYKGV	CSIGSNRVGI	IKQLPKGCS

Alignment: G DNA

							
		5	15	25	35	45	55
NL/1/00	(p	ATGGAGGTGA	AAGTGGAGAA	CATTCGAACA	ATAGATATGC	TCAAAGCAAG	AGTAAAAAAT
BR/2/01	(A	ATGGAGGTGA	AAGTGGAGAA	CATTCGAACA	ATAGATATGC	TCAAAGCAAG	TGTAAAAAAT
FL/4/01	(A	ATGGAGGTGA	AAGTGGAGAA	CATTCGAACA	ATAGATATGC	TCAAAGCAAG	AGTAAAAAAT
FL/3/01	(A	ATGGAGGTGA	AAGTGGAGAA	CATTCGAACA	ATAGATATGC	TCAAAGCAAG	AGTAAAAAAT
FL/8/01	(A	ATGGAGGTGA	AAGTGGAGAA	CATTCGAACA	ATAGATATGC	TCAAAGCAAG	AGTAAAAAAT
FL/10/01	(	ATGGAGGTGA	AAGTGGAGAA	CATTCGAACA	ATAGATATGC	TCAAAGCAAG	AGTAAAAAAT
NL/10/01	(	ATGGAGGTGA	AAGTGGAGAA	CATTCGAACA	ATAGATATGC	TCAAAGCAAG	AGTAAAAAAT
NL/2/02	(A	ATGGAGGTGA	AAGTGGAGAA	CATTCGAACA	ATAGATATGC	TCAAAGCAAG	AGTAAAAAAT
NL/17/00	(	ATGGAGGTGA	AAGTAGAGAA	CATTCGAGCA	ATAGACATGC	TCAAAGCAAG	AGTAAAAAAT
NL/1/81	(A	ATGGAGGTGA	AAGTAGAGAA	CATTCGAGCA	ATAGACATGC	TCAAAGCAAG	AGTAAAAAAT
NL/1/93	(A	ATGGAGGTGA	AAGTAGAGAA	CATCCGAGCA	GTAGACATGC	TCAAAGCAAG	AGTCAAAAAT
NL/2/93	(A	ATGGAGGTGA	AAGTAGAGAA	CATCCGAGCA	GTAGACATGC	TCAAAGCAAG	AGTTAAAAAT
NL/3/93	(A	ATGGAGGTGA	AAGTAGAGAA	CATTCGAGCA	ATAGACATGC	TCAAAGCAAG	AATGAAAAAT
NL/1/95	(A	ATGGAGGTGA	AAGTAGAGAA	CATTCGAGCA	ATAGACATGC	TCAAAGCAAG	AGTAAAAAAT
NL/2/95	(A	ATGGAGGTGA	AAGTAGAGAA	CATTCGAGCA	ATAGACATGC	TCAAAGCAAG	AGTAAAAAAT
NL/3/96	(A	ATGGAGGTGA	AAGTAGAGAA	CATTCGAGCA	ATAGACATGC	TCAAAGCAAG	AGTAAAAAAT
NL/22/01	(	ATGGAGGTGA	AAGTAGAGAA	CATTCGAGCA	ATAGACATGC	TCAAAGCAAG	AGTAAAAAAT
NL/24/01	(	ATGGAGGTGA	AAGTAGAGAA	CATTCGAGCA	ATAGACATGC	TCAAAGCAAG	AGTAAAAAAT
NL/23/01	(	ATGGAGGTGA	AAGTAGAGAA	TATTCGAGCA	ATAGACATGC	TCAAAGCAAG	AGTAAAAAAT
NL/29/01	(	ATGGAGGTGA	AAGTAGAGAA	CATTCGAGCA	ATAGACATGC	TCAAAGCAAG	AGTAAAAAAT
NL/3/02	(A	ATGGAGGTGA	AAGTAGAGAA	CATTCGAGCA	ATAGACATGC	TCAAAGCAAG	AGTAAAAAAT
NL/1/99	(p	ATGGAAGTAA	GAGTGGAGAA	CATTCGAGCG	ATAGACATGT	TCAAAGCAAA	GATAAAAAAC
NL/11/00	(	ATGGAAGTAA	GAGTGGAGAA	CATTCGAGCG	ATAGACATGT	TCAAAGCAAA	GATAAAGAAC
NL/12/00	(	ATGGAAGTAA	GAGTGGAGAA	CATTCGAGCG	ATAGACATGT	TCAAAGCAAA	GATAAAAAAC
NL/5/01	(B	ATGGAAGTAA	GAGTGGAGAA	CATTCGAGCG	ATAGACATGT	TCAAAGCAAA	GATAAAAAAC
NL/9/01	(B	ATGGAAGTAA	GAGTGGAGAA	CATTCGAGCG	ATAGACATGT	TCAAAGCAAA	GATAAAAAAC
NL/21/01	(	ATGGAAGTAA	GAGTGGAGAA	CATTCGAGCG	ATAGACATGT	TCAAAGCAAA	GATAAAAAAC
NL/1/94	(p	ATGGAAGTAA	GAGTGGAGAA	CATTCGGGCA	ATAGACATGT	TCAAAGCAAA	AATGAAAAAC
NL/1/82	(B	ATGGAAGTAA	GAGTGGAGAA	CATTCGGACA	ATAGACATGT	TCAAAGCAAA	GATGAAAAAC
NL/1/96	(B	ATGGAAGTAA	GAGTGGAGAA	CATTCGGGCA	ATAGACATGT	TCAAAGCAAA	GATGAAAAAC
NL/6/97	(B	ATGGAAGTAA	GAGTGGAGAA	CATTCGGGCA	ATAGACATGT	TCAAAGCAAA	GATGAAAAAC
NL/9/00	(B	ATGGAAGTAA	GAGTGGAGAA	CATTCGGGCA	ATAGACATGT	TCAAAGCAAA	GATGAAAAAC
NL/3/01	(B	ATGGAAGTAA	GAGTGGAGAA	CATTCGGGCA	ATAGACATGT	TCAAAGCAAA	GATGAAAAAC
NL/4/01	(B	ATGGAAGTAA	GAGTGGAGAA	CATTCGGGCA	ATAGACATGT	TCAAAGCAAA	GATGAAAAAC
UK/5/01	(B	ATGGAAGTAA	GAGTGGAGAA	CATTCGGGCA	ATAGACATGT	TCAAAGCAAA	GATGAAAAAC
							
		65	75	85	95	105	115
NL/1/00	(p	CGTGTGGCAC	GCAGCAAATG	CTTTAAAAAT	GCCTCTTTGG	TCCTCATAGG	AATAACTACA
BR/2/01	(A	CGTGTGGCAC	GCAGCAAATG	CTTTAAAAAT	GCCTCTTTGG	TCCTCATAGG	AATAACTACA
FL/4/01	(A	CGTGTGGCAC	GCAGCAAATG	CTTTAAAAAT	GCCTCTTTGG	TCCTCATAGG	AATAACTACA
FL/3/01	(A	CGTGTGGCAC	GCAGCAAATG	CTTTAAAAAT	GCCTCTTTGG	TCCTCATAGG	AATAACTACA
FL/8/01	(A	CGTGTGGCAC	GCAGCAAATG	CTTTAAAAAT	GCCTCTTTGG	TCCTCATAGG	AATAACTACA
FL/10/01	(	CGTGTGGCAC	GCAGCAAATG	CTTTAAAAAT	GCCTCTTTGA	TCCTAATAGG	AATAACTACA
NL/10/01	(	CGTGTGGCAC	GCAGCAAATG	CTTTAAAAAT	GCCTCTTTGA	TCCTAATAGG	AATAACTACA
NL/2/02	(A	CGTGTGGCAC	GCAGCAAATG	CTTTAAAAAT	GCCTCTTTGA	TCCTAATAGG	AATAACTACA
NL/17/00	(	CGTGTGGCAC	GTAGCAAATG	CTTTAAAAAT	GCTTCTTTAA	TCCTCATAGG	AATAACTACA
NL/1/81	(A	CGTGTGGCAC	GCAGCAAATG	CTTTAAAAAT	GCTTCTTTAA	TCCTCATAGG	AATAACTACA
NL/1/93	(A	CGTGTGGCAC	GCAGCAAATG	CTTTAAAAAT	GCCTCCTTAA	TCCTCGTAGG	AATAACTACA
NL/2/93	(A	CGTGTGGCAC	GCAGCAAATG	CTTTAAAAAT	GCCTCTTTAA	TCCTCGTAGG	AATAACTACA
NL/3/93	(A	CGTGTGGCAC	GCAGCAAATG	CTTTAAAAAT	GCTTCTTTAA	TCCTCATAGG	AATAACTACT
NL/1/95	(A	CGTGTGGCAC	GCAGCAAATG	CTTTAAAAAT	GCTTCTTTAA	TCCTCATAGG	AATAACTACT
NL/2/96	(A	CGTGTGGCAC	GTAGCAAATG	CTTTAAAAAT	GCTTCTTTAA	TCCTCATAGG	AATAACTACA
NL/3/96	(A	CGTGTGGCAC	GCAGCAAATG	CTTTAAAAAT	GCTTCTTTAA	TCCTCATAGG	AATAACTACT
NL/22/01	(	CGTGTGGCAC	GCAGCAAATG	CTTTAAAAAT	GCTTCTTTAA	TCCTCATAGG	AATAACTACT

FIGURE 19

NL/24/01 (	CGTGTGGCAC	GCAGCAAATG	CTTTAAAAAT	GCTTCTTTAA	TCCTCATAGG	AATAACTACT
NL/23/01 (	CGTGTGGCAC	GCAGCAAATG	CTTTAAAAAT	GCTTCTTTAA	TCCTCATAGG	AATAACTACT
NL/29/01 (	CGTGTGGCAC	G TAGCAAATG	CTTTAAAAAT	GCTTCTTTAA	TCCTCATAGG	AATAACTACA
NL/3/02 (A	CGTGTGGCAC	G TAGCAAATG	CTTTAAAAAT	GCTTCTTTAA	TCCTCATAGG	AATAACTACA
NL/1/99 (p	CGTATAAGAA	GCAGCAGGTG	CTATAGAAAT	GCTACACTGA	TCCTTATTGG	ACTAACAGCG
NL/11/00 (	CGTATAAGAA	GCAGCAGGTG	CTATAGAAAT	GCTACACTGA	TCCTTATTGG	ACTAACAGCG
NL/12/00 (	CGTATAAGAA	GCAGCAGGTG	CTATAGAAAT	GCTACACTGA	TCCTTATTGG	ACTAACAGCG
NL/5/01 (B	CGTATAAGAA	GCAGCAGGTG	CTATAGAAAT	GCTACACTGA	TCCTTATTGG	ACTAACAGCG
NL/9/01 (B	CGTATAAGAA	GCAGCAGGTG	CTATAGAAAT	GCTACATTGA	TCCTTATTGG	ACTAACAGCG
NL/21/01 (	CGTATAAGAA	GCAGCAGGTG	CTATAGAAAT	GCTACACTGA	TCCTTATTGG	ACTAACAGCG
NL/1/94 (p	CGTATAAGAA	G TAGCAAGTG	CTATAGAAAT	GCTACACTGA	TCCTTATTGG	ATTAACAGCA
NL/1/82 (B	CGTATAAGAA	GCAGCAAGTG	CTATAGAAAT	GCTACACTGA	TCCTTATTGG	ACTGACAGCA
NL/1/96 (B	CGTATAAGAA	G TAGCAAGTG	CTATAGAAAT	GCTACACTGA	TCCTTATTGG	ATTAACAGCA
NL/6/97 (B	CGCATAAGAA	G TAGCAAGTG	CTATAGAAAT	GCTACACTGA	TCCTTATTGG	ATTAACAGCA
NL/9/00 (B	CGTATAAGAA	G TAGCAAGTG	CTATAGAAAT	GCTACACTGA	TCCTTATTGG	ATTAACAGCA
NL/3/01 (B	CGTATAAGAA	G TAGCAAGTG	CTATAGAAAT	GCTACACTGA	TCCTTATTGG	ATTATCAGCA
NL/4/01 (B	CGTATAAGAA	G TAGCAAGTG	CTATAGAAAT	GCTACACTGA	TCCTTATTGG	ATTATCAGCA
UK/5/01 (B	CGTATAAGAA	G TAGCAAGTG	CTATAGAAAT	GCTACACTGA	TCCTTATTGG	ATTAACAGCA

						
	125	135	145	155	165	175
NL/1/00 (p	TTGAGTATTG	CCCTCAATAT	CTATCTGATC	ATAAACTATA	AAATGCAAAA	AAACACATCT
BR/2/01 (A	TTGAGTATTG	CCCTCAATAT	CTATCTGATC	ATAAACTATA	AAATGCAAAA	AAACACATCT
FL/4/01 (A	CTGAGTATTG	CCCTCAATAT	CTATCTGATC	ATAAACTATA	AAATGCAAAA	AAACACATCT
FL/3/01 (A	TTGAGTATTG	CCCTCAATAT	CTATCTGATC	ATAAACTATA	AAATGCAAAA	AAACACATCT
FL/8/01 (A	TTGAGTATTG	CCCTCAATAT	CTATCTGATC	ATAAACTATA	AAATGCAAAA	AAACACATCT
FL/10/01 (	TTGAGTATAG	CCCTCAATAT	CTATCTGATC	ATAAACTATA	CAATGCAAGA	AAACACATCC
NL/10/01 (	TTGAGTATAG	CCCTCAATAT	CTATCTGATC	ATAAACTATA	CAATGCAAGA	AAACACATCC
NL/2/02 (A	TTGAGTATAG	CCCTCAATAT	CTATCTGATC	ATAAACTATA	CAATGCAAGA	AAACACATCC
NL/17/00 (	CTGAGTATAG	CTCTCAATAT	CTATCTGATC	ATAAACTACA	CAATACAAAA	AACCACATCC
NL/1/81 (A	CTGAGTATAG	CCCTCAATAT	CTATCTGATC	ATAAACTACA	CAATACAAAA	AACCACATCT
NL/1/93 (A	CTGAGCATAG	CCCTCAATAT	CTATCTGATC	G TAAACTACA	CAATACAAAA	AACCACATCC
NL/2/93 (A	CTGAGTATAG	CCCTCAATAT	CTATCTGATC	G TAAACTACA	CAATACAAAA	AACCACATCC
NL/3/93 (A	CTGAGTATAG	CCCTCAATAT	CTATCTGATC	ATAAACTACA	CAATACAAAA	AACCACATCT
NL/1/95 (A	CTGAGTATAG	CCCTCAACAT	CTATCTGATC	ATAAACTACA	CAATACAAAA	AACCACATCT
NL/2/96 (A	CTGAGTATAG	CTCTCAATAT	CTATCTGATC	ATAAACTACA	CAATACAAAA	AACCACATCT
NL/3/96 (A	CTGAGTATAG	CCCTCAACAT	CTATCTGATC	ATAAACTACA	CAATACAAAA	AACCACATCT
NL/22/01 (	CTGAGTATAG	CCCTCAATAT	CTATCTGATC	ATAAACTACA	CAATACAAAA	AACCACATCT
NL/24/01 (	CTGAGTATAG	CCCTCAATAT	CTATCTGATC	ATAAACTACA	CAATACAAAA	AACCACATCT
NL/23/01 (	CTGAGTATAG	CCCTCAATAT	CTATCTGATC	ATAAACTACA	CAATACAAAA	AACCACATCT
NL/29/01 (	CTGAGCATAG	CCCTCAATAT	CTATCTGATC	ATAAACTACA	CAATACAAAA	AACCACATCT
NL/3/02 (A	CTGAGCATAG	CCCTCAATAT	CTATCTGATC	ATAAACTACA	CAATACAAAA	AACCACATCT
NL/1/99 (p	TTAAGCATGG	CACTTAATAT	TTTCCTGATC	ATCGATCATG	CAACATTAAG	AAACATGATC
NL/11/00 (	TTAAGCATGG	CACTTAATAT	TTTCCTGATC	ATTGATCATG	CAACATTAAG	AAACATGATC
NL/12/00 (	TTAAGCATGG	CACTTAATAT	TTTCCTGATC	ATCGATCATG	CAACATTAAG	AAACATGATC
NL/5/01 (B	TTAAGCATGG	CACTTAATAT	TTTCCTGATC	ATCGATCATG	CAACATTAAG	AAACATGATC
NL/9/01 (B	TTAAGCATGG	CACTTAATAT	TTTCCTGATC	ATCGATCATG	CAACATTAAG	AAACATGATC
NL/21/01 (	TTAAGCATGG	CACTTAATAT	TTTCCTGATC	ATCGATCATG	CAACATTAAG	AAACATGATC
NL/1/94 (p	TTAAGTATGG	CACTTAATAT	TTTTTTAATC	ATTGATTATG	CAATGT TAAA	AAACATGACC
NL/1/82 (B	TTAAGTATGG	CACTTAATAT	TTTCTTGATC	ATCGATTATG	CAACATTTAA	AAACATGACC
NL/1/96 (B	TTAAGTATGG	CACTTAATAT	TTTTTTAATC	ATTGATTATG	CAATGT TAAA	AAACATGACC
NL/6/97 (B	TTAAGTATGG	CACTTAATAT	TTTTTTAATC	ATTGATTATG	CAACAT TAAA	AAACATGACC
NL/9/00 (B	CTAAGTATGG	CACTTAATAT	TTTTTTAATC	ATTGATTATG	CAACAT TAAA	AAACATGACC
NL/3/01 (B	CTAAGTATGG	CACTTAATAT	TTTTTTAATC	ATTGATTATG	CAAAATCAAA	AAACATGACC
NL/4/01 (B	CTAAGTATGG	CACTTAATAT	TTTTTTAATC	ATTGATTATG	CAAAATCAAA	AACCATGACC
UK/5/01 (B	CTAAGTATGG	CACTTAATAT	TTTTTTAATC	ATTGATTATG	CAACAT TAAA	AAACATGACC

						
	185	195	205	215	225	235
NL/1/00 (p	GAATCAGAAC	ATCACACCAG	CTCATCACCC	ATGGAATCCA	GCAGAGAAAC	TCCAACGGTC
BR/2/01 (A	GAATCAGAAC	ATCACACCAG	CTCATCACCC	ATGGAATCCA	GCAGAGAAAC	TCCAACGGTC

FL/4/01 (A	GAATCAGAAC	ATCACACCAG	CTCATCACCC	ATGGAATCCA	GCAGAGAAAC	TCCAACGGTC
FL/3/01 (A	GAATCAGAAC	ATCACACCAG	CTCATCACCC	ATGGAATCCA	GCAGAGAAAC	TCCAACGGTC
FL/8/01 (A	GAATCAGAAC	ATCACACCAG	CTCATCACCC	ATGGAATCCA	GCAGAGAAAC	TCCAACGGTC
FL/10/01 (	GAATCAGAAC	ATCACACCAG	CTCATCACCC	ATGGAATCCA	GCAGGGAAAC	TCCAACGGTC
NL/10/01 (	GAATCAGAAC	ATCACACCAG	TTCATCACCC	ATGGAATCCA	GCAGGGAAAC	TCCAACGGTC
NL/2/02 (A	GAATCAGAAC	ATCACACCAG	CTCATCACCC	ATGGAATCCA	GCAGAGAAAC	TCCAACGGTC
NL/17/00 (	GAATCAGAAC	ACCACACCAG	CTCACCACCC	ACAGAACCCTA	ACAAGGAAGC	TTCAACAATC
NL/1/81 (A	GAATCAGAAC	ACCACACTAG	CTCACCACCC	ACAGAATCCA	ACAAAGAAAC	TTCAACAATC
NL/1/93 (A	GAATCAGAAC	ACCACACCAG	CTCATCACCC	ACAGAATCCA	ACAAAGGAAC	TTCAACAATC
NL/2/93 (A	GAATCAGAAC	ACCACACTAG	CTCATCACCC	ACAGAATCCA	ACAAAGGAAC	TTCAACAATC
NL/3/93 (A	GAATCAGAAC	ACCACACTAG	CTCACCACCC	ACAGAATCCA	ACAAAGAAAC	TTCAACAATC
NL/1/95 (A	GAATCAGAAC	ACCACACTAG	CTCACCACCC	ACAGAATCTA	ACAAAGAAAC	TTCAACAATC
NL/2/96 (A	GAATCAGAAC	ACCACACCAG	CTCACCACCC	ACAGAATCCA	ACAAGGAAGC	TTCAACAATC
NL/3/96 (A	GAATCAGAAC	ACCACACTAG	CTCACCACCC	ACAGAATCTA	ACAAAGAAAC	TTCAACAATC
NL/22/01 (	GAATCAGAAC	ACCACACTAG	CTCACCACCC	ACAGAATCTA	ACAAGGAAGC	TTCAACAATC
NL/24/01 (	GAATCAGAAC	ACCACACTAG	CTCACCACCC	ACAGAATCTA	ACAAGGAAGC	TTCAACAATC
NL/23/01 (	GAATCAGAAC	ACCACACTAG	CTCACCACCC	ACAGAATCTA	ACAAGGAAGC	TTCAACAATC
NL/29/01 (	GAATCAGAAC	ACCACACCAG	CTCACCACCC	ACAGAATCCA	ACAAGGAAGC	TTCAACAATC
NL/3/02 (A	GAATCAGAAC	ACCACACCAG	CTCACCACCC	ACAGAATCCA	ACAAGGAAGC	TTCAACAATC
NL/1/99 (p	AAAACAGAAA	ACTGTGCTAA	CATGCCGTCG	GCAGAACCAA	GCAAAAAGAC	CCCAATGACC
NL/11/00 (	AAAACAGAAA	ACTGTGCTAA	CATGCCATCG	GCAGAACCAA	GCAAAAAGAC	CCCAATGACC
NL/12/00 (	AAAACAGAAA	ATTGTGCTAA	CATGCCGCCG	GCAGAACCAA	GCAAAAAGAC	CCCAATGACC
NL/5/01 (B	AAAACAGAAA	ATTGTGCTAA	CATGCCGCCG	GCAGAACCAA	GCAGAAAGAC	CCCAATGACC
NL/9/01 (B	AAAACAGAAA	ATTGTGCTAA	CATGCCACCG	GCAGAACCAA	GCAAAAAGAC	CCCAATGACC
NL/21/01 (	AAAACAGAAA	ATTGTGCTAA	CATGCCGCCG	GCAGAACCAA	GCAAAAAGAC	CCCAATGACC
NL/1/94 (p	AAAGTGGAAC	ACTGTGTTAA	TATGCCGCCG	GTAGAACCAA	GCAAGAAGAC	CCCAATGACC
NL/1/82 (B	AAAGTGGAAC	ACTGTGCTAA	TATGCCGCCG	GTAGAACCGA	GTAAGAAGAC	CCCAATGACC
NL/1/96 (B	AAAGTGGAAC	ACTGTGTTAA	TATGCCGCCG	GTAGAACCAA	GCAAGAAGAC	CCCAATGACC
NL/6/97 (B	AAAGTGGAAC	ACTGTGTTAA	TATGCCGCCG	GTAGAACCAA	GCAAGAAGAC	CCCAATGACC
NL/9/00 (B	AAAGTGGAAC	ACTGTGTTAA	TATGCCGCCG	GTAGAACCAA	GCAAGAAGAC	CCCAATGACC
NL/3/01 (B	AGAGTGGAAC	ACTGTGTCAA	TATGCCGCCG	GTAGAACCAA	GCAAGAAGAC	CCCAATGACC
NL/4/01 (B	AGAGTGGAAC	ACTGTGTTAA	TATGCCGCCG	GTAGAACCAA	GCAAGAAGAC	CCCAATGACC
UK/5/01 (B	AAAGTGGAAC	ACTGTGTTAA	TATGCCGCCG	GTAGAACCAA	GCAAGAAGAC	CCCAATGACC

						
	245	255	265	275	285	295
NL/1/00 (p	CCCACAGACA	ACTCAGACAC	CAACTCAAGC	CCACAGCATC	CAACTCAACA	GTCCACAGAA
BR/2/01 (A	CCCACAGACA	ACTCAGACAC	CAACTCAAGC	CCACAGCATC	CAACTCAACA	GTCCACAGAA
FL/4/01 (A	CCCACAGATA	ATTCAGACAC	CAACTCAAGC	CCACAACATC	CAACTCAACA	GTCCACAGAA
FL/3/01 (A	CCCACAGATA	ATTCAGACAC	CAACTCAAGC	CCACAACATC	CAACTCAACA	GTCCACAGAA
FL/8/01 (A	CCCACAGATA	ATTCAGACAC	CAACTCAAGC	CCACAACATC	CAACTCAACA	GTCCACAGAA
FL/10/01 (	CCCATAGACA	ACTCAGACAC	CAATCCAGGC	TCACAGTATC	CAACTCAACA	GTCCACAGAA
NL/10/01 (	CCTATGGACA	ACTCAGACAC	CAATCCAGGC	TCACAGTATC	CAACTCAACA	GTCCACAGAA
NL/2/02 (A	CCTATGGACA	ACTCAGACAC	CAATCCAGGC	TCACAGTATC	CAACTCAACA	GTCCACAGAA
NL/17/00 (	TCCACAGACA	ACCCAGACAT	CAATCCAAAGC	TCACAGCATC	CAACTCAACA	GTCCACAGAA
NL/1/81 (A	CCCATAGACA	ACCCAGACAT	CAATCCAAAC	TCACAGCATC	CAACCCAACA	GTCCACAGAA
NL/1/93 (A	CCCACAGACA	ACCCAGACAT	CAATCCAAAT	TCACAACATC	CAACTCAACA	GTCCACAGAA
NL/2/93 (A	CC-ACAGACA	ACCCAGACAT	CAATCCAAAT	TCACAACATC	CAACTCAACA	GTCCACAGAA
NL/3/93 (A	CCTATAGACA	ACCCAGACAT	CAATCCAAAC	TCACAGCATC	CAACTCAACA	GTCCACAGAA
NL/1/95 (A	TCTATAGACA	ACCCAGACAT	CAATCCAAAC	TCACAGCATC	CAACTCAACA	GTCCACAGAA
NL/2/96 (A	TCCACAGACA	ATCCAGACAT	CAATCCAAAC	TCACAGCATC	CAACTCAACA	GTCCACAGAA
NL/3/96 (A	TCTATAGACA	ACTCAGACAT	CAATCCAAAC	TCACAGCATC	CAACTCAACA	GTCCACAGAA
NL/22/01 (	CCTATAGACA	ACCCAGACAT	CAATCCAAAC	TCACAGCATC	CAACTCAACA	GTCCACAGAA
NL/24/01 (	CCTATAGACA	ACCCAGACAT	CAATCCAAAC	TCACAGCATC	CAACTCAACA	GTCCGCAGAA
NL/23/01 (	CCTATAGACA	ACCCAGACAT	CAATCCAAAC	TCACAGCATC	CAACTCAACA	GTCCACAGAA
NL/29/01 (	TCCACAGACA	ACCCAGACAT	CAATCCAAAC	TCACAGCATC	CAACTCAACA	GTCCACAGAA
NL/3/02 (A	TCCACAGACA	ACCCAGACAT	CAATCCAAAC	TCACAGCATC	CAACTCAACA	GTCCACAGAA
NL/1/99 (p	TCCACAGCAG	GCCCAAACAC	CAAACCCAAT	CCACAGCAAG	CAACACAGTG	GACCACAGAG
NL/11/00 (	TCCACAGCAG	GCCCAAAGCAC	CGAACCCAAT	CCACAGCAAG	CAACACAATG	GACCACAGAG
NL/12/00 (	TCTACAGCAG	GCCCAAACAC	CAAACCCAAT	CCACAGCAAG	CAACACAGTG	GACCACGGAG
NL/5/01 (B	TCCACAGCAG	GCCCAAACAC	CAAACCCAAT	CCACAGCAAG	CAACACAGTG	GACCACGGAG

NL/9/01 (B	TCCACAGCAG	GCCTAAACAC	TAAACCCAAT	CCACAGCAAG	CAACACAGTG	GACCACGGAG
NL/21/01 (	TCCACAGCAG	GCCCAAACAC	CAAACCCAAT	CCACAGCAAG	CAACACAGTG	GACCACGGAG
NL/1/94 (p	TCTGCAGTAG	ACTTAAACAC	CAAACCCAAT	CCACAGCAGG	CAACACAGTT	GGCCGCAGAG
NL/1/82 (B	TCTACAGTAG	ACTCAAGCAC	CGGACCCAAT	CCACAGCAGA	CAACACAGTG	GACCACAGAG
NL/1/96 (B	TCTGCAGTAG	ACTTAAACAC	CAAACCTCAAT	CCACAGCAGG	CAACACAGTT	GACCACAGAG
NL/6/97 (B	TCTGCAGTAG	ACTTAAACAC	CAAACCTCAAT	CCACAGCAGG	CAACACAGTT	GACCACAGAG
NL/9/00 (B	TCTGCAGTAG	ACTCAAAACAC	CAAACCCAAT	CCACAGCAGG	CAACACAGTT	GACCACAGAG
NL/3/01 (B	TCTGCAGTAG	ACTTAAACAC	CAAACCCAAT	CCACAGCGGG	CAACACAGTT	GACCACAGAG
NL/4/01 (B	TCTGCAGTAG	ACTTAAACAC	CAAACCCAAT	CCACAGCAGG	CAACACAGTT	GACCACAGAG
UK/5/01 (B	TCTGCAGTAG	ACTTAAACAC	CAAACCCAAT	CCACAGCAGG	CAACACAGTT	GACCACAGAG

						
	305	315	325	335	345	355
NL/1/00 (p	GGCTCCACAC	TCTACTTTGC	AGCCTCAGCA	AGCTCACCAG	AGACAGAACC	AACATCAACA
BR/2/01 (A	GGCTCCACAC	TCTACTTTGC	AGCCTCAGCA	AGCTCACCAG	AGACAGAACC	AACATCAACA
FL/4/01 (A	GGCTCCACAC	TCTACTTTGC	AGCCTCAGCA	AACTCACCAG	AGACAGAACC	AACATCAACA
FL/3/01 (A	GGCTCCACAC	TCTACTTTGC	AGCCTCAGCA	AACTCACCAG	AGACAGAACC	AACATCAACA
FL/8/01 (A	GGCTCCACAC	TCTACTTTGC	AGCCTCAGCA	AGCTCACCAG	AGACAGAACC	AACATCAACA
FL/10/01 (	GACTCCACAC	TCCACTTCTGC	AGCTTCAGCA	AGCTCACCAG	AGACAGAACC	AACATCAACA
NL/10/01 (	GGCTCCACAC	TCCACTTTGC	AGCCTCAGCA	AGCTCACCAG	AGACAGAACC	AACATCAACA
NL/2/02 (A	GGCTCCACAC	TCCACTTTGC	AGCCTCAGCA	AGCTCACCAG	AGACAGAACC	AACATCAACA
NL/17/00 (	AACCCACAC	TCAACCCCGC	AGCATCAGCG	AGCCCATCAG	AAACAGAACC	AGCATCAACA
NL/1/81 (A	AGCCCCACAC	TCAACCCCGC	AGCCTCGGTG	AGCCCATCAG	AAACAGAACC	AGCATCAACA
NL/1/93 (A	AGCCCCACAC	TCAACACCGC	AGCCTCGGTG	AGCCCATCAG	AAACAGAACC	AGCATCAACA
NL/2/93 (A	AGCCCCACAC	TCAACACCGC	AGCCTCGGTG	AGCCCATCAG	AAACAGAACC	AGCATCAACA
NL/3/93 (A	AGCCTCACAC	TCAACCCCGC	AGCCTCGGTG	AGCCCATCAG	AAACAGAACC	AGCATCAACA
NL/1/95 (A	AGCCTCACAC	TCAGCCCCAC	AGCCTCGGTG	AGCCCATCAG	AAACAGAACC	AGCATCAACA
NL/2/96 (A	AACCCACAC	TAAACCCCGC	AGCATCAGGTG	AGCTCATCAG	AAACAGAACC	AGCATCAACA
NL/3/96 (A	AGCCTCACAC	TCAGCCCCAC	AGCCTCGGTG	AGCCCATCAG	AAACAGAACC	AGCATCAACA
NL/22/01 (	AGCCTCACAC	TCTACCCAC	ATCCTCGGTG	AGCTCATCAG	AAACAGAACC	AGCATCAACA
NL/24/01 (	AGCCTCACAC	TCTACCCAC	ATCCTCGGTG	AGCTCATCAG	AAACAGAACC	AGCATCAACA
NL/23/01 (	AGCCTCACAC	TCTACCCAC	ATCCTCGGTG	AGCTCATCAG	AAACAGAACC	AGCATCAACA
NL/29/01 (	AACCCACAC	TCAACCCAGC	AGCATCAGCG	AGCCCATCAG	AAACAGAATC	AGCATCAACA
NL/3/02 (A	AACCCACAC	TCAACCCAGC	AGCATCAGCG	AGCCCATCAG	AAACAGAATC	AGCATCAACA
NL/1/99 (p	AACTCAACAT	CCCCAGTAGC	AACCCAGAG	GGCCATCCAT	ACACAGGGAC	AACTCAAACA
NL/11/00 (	AACTCAACAT	CCCCAGCAGC	AACCCTAGAG	AGCCATCCAT	ACACAGGGAC	AACCCAAACA
NL/12/00 (	AACTCAACAT	TCCCAGCAGC	AACCTCAGAG	GGCCATCTAC	ACACAGGGAC	AACTCAAACA
NL/5/01 (B	AACTCAACAT	CCCCAGCAGC	AACCCAGAG	GGCCATCTAC	ACACAGGGAC	AACTCAAACA
NL/9/01 (B	AACTCAACAT	CCCCAGCAGC	AACCCAGAG	GGCCATCTAC	ACACAGGGAC	AACTCAAACA
NL/21/01 (	AACTCAACAT	CCCCAGCAGC	AACCCAGAG	GGCCATCTAC	ACACAGGGAC	AACTCAAACA
NL/1/94 (p	GATTCAACAT	CTCTAGCAGC	AACCTCAGAG	GACCATCTAC	ACACAGGGAC	AACTCCAACA
NL/1/82 (B	GATTCAACAT	CTCTAGCAGC	AACCTCAGAG	GACCATCTAC	ACACAGGGAC	AACTCCAACA
NL/1/96 (B	GATTCAACAT	CTCTAGCAGC	AACCTCGGAG	GATCATTTC	TCACAGGGAC	AACTCCAACA
NL/6/97 (B	GATTCAACAT	CTCTAGCAGC	AACCTCAGAG	GGCCATCCAC	ACACAGGAAC	AACTCCAACA
NL/9/00 (B	GATTCTACAT	CTTTAGCAGC	AACCCTAGAG	GACCATCCAC	ACACAGGGAC	AACTCCAACA
NL/3/01 (B	GATTCAACAT	CTCTAGCAGC	AACCCTAGAG	GGCCATCTAC	ACACAGGGAC	AACTCCAACA
NL/4/01 (B	GATTCAACAT	CTCCAGCAGC	AACCCTAGAG	GGCCATCTAC	ACACAGGGAC	AACTCCAACA
UK/5/01 (B	GACTCTACAT	CTTTAGCAGC	AACCCTAGAG	GACCATCCAC	ACACAGGGAC	AACTCCAACA

						
	365	375	385	395	405	415
NL/1/00 (p	CCAGATACAA	CAAACCGCCC	GCCCTTCGTC	GACACACACA	CAACACCACC	AAGCGCAAGC
BR/2/01 (A	CCAGATACAA	CAAACCGCCC	GCCCTTCGTC	GACACACACA	CAACACCACC	AAGCGCAAGC
FL/4/01 (A	CCAGACACAA	CAAACCGCCC	GCCCTTCGTC	GACACACACA	CAACACCACC	AAGCGCAAGC
FL/3/01 (A	CCAGACACAA	CAGACCGCCC	GCCCTTCGTC	GACACACACA	CAACACCACC	AAGCGCAAGC
FL/8/01 (A	CCAGACACAA	CAGACCGCCC	GCCCTTCGTC	GACACACACA	CAACACCACC	AAGCGCAAGC
FL/10/01 (	CCAGACACAA	CAAGCCGCCC	GCCCTTCGTC	GACACACACA	CAACACCACC	AAGTGCAAGC
NL/10/01 (	CCAGACACAA	CAAGCCGCCC	GCCCTTCGTC	GACACACACA	CAACACCACC	AAGTGCAAGC
NL/2/02 (A	CCAGACACAA	CAAGCCGCCC	GCCCTTCGTC	GACACACACA	CAACACCACC	AAGTGCAAGC
NL/17/00 (	CCAGACACAA	CAAACCGCCT	GTCCTCCGTA	GACAGGTCCA	CAGCACAACC	AAGTGAAAGC
NL/1/81 (A	CCAGACACAA	CAAACCGCCT	GTCCTCCGTA	GACAGATCCA	CAACACAACC	AAGTGAAAGC

NL/1/93 (A -	CCAGACACAA	CAAACCGCCT	GTCTTCCGTA	GACAGATCCA	CAACACAACC	AAGTGAAAGC
NL/2/93 (A	CCAGACACAA	CAAACCGCCT	GTCTTCCGTA	GACAGATCCA	CAACACAACC	AAGTGAAAGC
NL/3/93 (A	CCAGACACAA	CAAACCGCCT	GTCTTCCGTA	GACAGATCCA	CAACACAACC	AAGTGAAAGC
NL/1/95 (A	TCAGACACAA	CAAGCCGCCT	GTCTTCCGTA	GACAGATCCA	CAACACAACC	AAGTGAAAGC
NL/2/96 (A	CCAGACACAA	CAAACCGCCT	GTCTTCCGTA	GACAGGTCCA	CAGCACAACC	AAGTGAAAGC
NL/3/96 (A	TCAGACACAA	CAAACCGCCT	GTCTTCCGTA	GACAGATCCA	CAACACAACC	AAGTGAAAGC
NL/22/01 (	CCAGGCATAA	CAAACACCT	GTCTTTTGTA	GACAGATCCA	CAACACAACC	AAGTGAAAGC
NL/24/01 (	CCAGGCATAA	CAAACACCT	GTCTTTTGTA	GACAGATCCA	CAACACAACC	AAGTGAAAGC
NL/23/01 (	CCAGGCATAA	CAAACACCT	GTCTTTTGTA	GACAGATCCA	CAACACAACC	AAGTGAAAGC
NL/29/01 (	CCAGATACAA	CAAACCGCCT	GTCTTCCGTA	GACAGGTCCA	CGGTACAACC	AAGTGAAAAC
NL/3/02 (A	CCAGATACAA	CAAACCGCCT	GTCTTCCGTA	GACAGGTCCA	CGGTACAACC	AAGTGAAAAC
NL/1/99 (p	TCAGACACAA	CAGTCCCCA	GCAAACCACA	GACAAACACA	CAGCACCCT	AAAATCAACC
NL/11/00 (	CCAGACATAA	CAGTCCCCA	ACAAACCACA	GACAAACACA	CAGCACTGCC	AAAATCAACC
NL/12/00 (	CCAGACACAA	CAGTCTCTCA	GCAAACCACA	GACAAACACA	CAGCACTGCC	AAAATCAACC
NL/5/01 (B	CCAGACACAA	CAGTCTCTCA	GCAAACCACA	GACAAACACA	CAGCACTGCC	AAAATCAACC
NL/9/01 (B	CCAGACACAA	CAGTCTCTCA	GCAAACCACA	GACAAACACA	CAGCACTGCC	AAAATCAACC
NL/21/01 (	CCAGACACAA	CAGTCTCTCA	GCAAACCACA	GACAAACACA	CAGCACTGCC	AAAATCAACC
NL/1/94 (p	CCAGATGCAA	CAGTCTCTCA	GCAAACCACA	GACGAGTACA	CAACATTGCT	GAGATCAACC
NL/1/82 (B	CTAGATGCAA	CAGTTTCTCA	GCAAACCCCA	GACAAGCACA	CAACACCGCT	GAGATCAACC
NL/1/96 (B	CCAGATGCAA	CAGTCTCTCA	GCAAACCACA	GACGAGCACA	CAACACTGCT	GAGATCAACC
NL/6/97 (B	CCAGACGCAA	CAGTCTCTCA	GCAAACCACA	GACGAGCACA	CAACACTGCT	GAGATCAACC
NL/9/00 (B	CCAGATGCAA	CAGTCTCTCA	GCAAACCACA	GACGAGCACA	CAACACTGCT	GAGATCAACC
NL/3/01 (B	CCAGATGTAA	CAGTCTCTCA	GCAAACCACA	GACGAGCACA	CAACACTGCT	GAGATCAACC
NL/4/01 (B	CCAGATGCAA	CAGTCTCTCA	GCAAACCACA	GACGAGCACA	CAACACTGCT	GAGATCAACC
UK/5/01 (B	CCAGATGCAA	CAGTCTCTCA	GCAAACCACA	GACGAGCACA	CAACACTGCT	GAGATCAACC

						
	425	435	445	455	465	475
NL/1/00 (p	AGAACAAAGA	CAAGTCCGGC	AGTC-CACAC	AAAAAA-CAA	CCCAAGGACA	AGCTCTAG--
BR/2/01 (A	AGAACAAAGA	CAAGTCCGGC	AGTC-CACAC	AAAAAA-CAA	CCCAAGGACA	AGCTCTAG--
FL/4/01 (A	AGAACAAAGA	CAAGTCCGGC	AGTC-CACAC	AAAAAA-CAA	CCCAAGGATA	AGCTCCAG--
FL/3/01 (A	AGAACAAAGA	CAAGTCCGGC	AGTC-CACAC	AAAAAA-CAA	CCCAAGGATA	AGCTCCAG--
FL/8/01 (A	AGAACAAAGA	CAAGTCCGGC	AGTC-CACAC	AAAAAA-CAA	CCCAAGGATA	AGCTCCAG--
FL/10/01 (	AGGACAAGGA	CAAGTCCGGC	AGTC-CACAC	AAAAAA-CAA	TCCAAGGGTA	AGCCCCAG--
NL/10/01 (	AGAACAAAGA	CAAGTCCGGC	AGTC-CACAC	AAAAAA-CAA	TCTAAGGATA	AGCCCCAG--
NL/2/02 (A	AGAATAAGGA	CAAGTCCGGC	AGTC-CACAC	AAAAAA-CAA	TCTAAGGATA	AGCCCCAG--
NL/17/00 (	AGAACAAAGA	CAAAACCGAC	AGTC-CACAC	AATCAA-CAA	CCCAAACACA	GCTTCCAG--
NL/1/81 (A	AGAACAAAGA	CAAAACCAAC	AGTC-CACAC	AAAAAA-CAA	TCCAAGTACA	GTTTCCAG--
NL/1/93 (A	AGAACAAAGA	CAAAGCTGAC	AGTC-CACAC	AAAAAA-CAA	CCTAAGTACA	GCCTCCAG--
NL/2/93 (A	AGAACAAAGA	CAAAGCTGAC	AGTC-CACAC	AAAAAA-CAA	CCTAAGTACA	GCCTCCAG--
NL/3/93 (A	AGAACAAAGA	CAAAACTGAC	AGTC-CACAA	AAAAAA-CAT	CCCAAGTACA	GTCTCTAG--
NL/1/95 (A	AGAGCAAGGA	CAAAACCGAC	AGTC-CACAA	GAAAAA-CAT	CCCAAGTACA	GTTTCTAG--
NL/2/96 (A	AGAACAAAGA	CAAAACCGAC	AGTC-CACAC	AAGAAA-CAA	CCCAAGCACA	GCTTCCAG--
NL/3/96 (A	AGAGCAAGAA	CAAAACCGAC	AGTC-CACAA	GAAAAA-CAT	CCCAAGTACA	GTTTCTAG--
NL/22/01 (	AGAACAAAGA	CAAAACCGAC	AGTC-CACAA	AAAAAA-CAT	CTCAAGTACA	GTTTCTAG--
NL/24/01 (	AGAACAAAGA	CAAAACCGAC	AGTC-CACAA	AAAAAA-CAT	CTCAAGTACA	GTTTCTAG--
NL/23/01 (	AGAACAAAGA	CAAAACCGAC	AGTC-CACAA	AAAAAA-CAT	CTCAAGTACA	GTTTCTAG--
NL/29/01 (	AGAACAAAGA	CAAAACTGAC	AGTC-CACAC	AAGAAA-CAA	CCTAAGCACA	GCCTCCAG--
NL/3/02 (A	AGAACAAAGA	CAAAACTGAC	AGTC-CACAC	AAGAAA-CAA	CCTAAGCACA	GCCTCCAG--
NL/1/99 (p	AATGAACAGA	TCACCCAGAC	AACCACAGAG	AAAAAGACAA	TCAGAGCAAC	AACCCAAAAA
NL/11/00 (	AATGAACAGA	TCACCCAGAC	AACCACAGAG	AAAAAGACAA	CCAGAGCAAC	AACCCAAAAA
NL/12/00 (	AATGAACAAA	TCACCCAGAC	AACCACAGAG	AAAAAGACAA	CCAGAGCAAC	AACCCAAAGA
NL/5/01 (B	AATGAACAGA	TCACCCAGGC	AACCACAGAG	AAAAAGACAA	CCAGAGAAAC	AACCCAAAGA
NL/9/01 (B	AATGAACAGA	TCACCCAGAC	AACCACAGAG	AAAAAGACAA	CCAGAGCAAC	AACCCAAAGA
NL/21/01 (	AATGAACAGA	TCACCCAGAC	AACCACAGAG	AAAAAGACAA	CCAGAGCAAC	AACCCAAAGA
NL/1/94 (p	AACAGACAGA	CCACCCAAAC	AACCACAGAG	AAAAAGCCAA	CCGGAGCAAC	AACCAAAA--
NL/1/82 (B	AATGGACAGA	CCACCCAGAC	AACCACAGAG	AAAAAGCCAA	CCAGAGCAAT	AGCCAAAA--
NL/1/96 (B	AACAGACAGA	CCACCCAAAC	AACCACAGAG	AAAAAGCCAA	CCGGAGCAAC	AACCAAAA--
NL/6/97 (B	AACAGACAGA	CCACCCAAAC	AGCCACAGAG	AAAAAGCCAA	CTGGAGCAAC	AACCAAAA--
NL/9/00 (B	AACAGACAGA	CCACCCAAAC	AACTGCAGAG	AAAAAGCCAA	CCAGGGCAAC	AACCAAAA--
NL/3/01 (B	AACAGACAGA	CCACCCAAAC	AGCCGCAGAG	AAAAAGCCAA	CCAGAGTAAC	AACTAACA--

NL/4/01 (B .	AACAGACAGA	CCACCCAAAC	AACCGCAGAG	AAAAAGCCAA	CCAGAGCAAC	AACCAAAA--
UK/5/01 (B	AACAGACAGA	CCACCCAAAC	AACTGCAGAG	AAAAAGCCAA	CCAGAGCAAC	AACCAAAA--

						
	485	495	505	515	525	535

NL/1/00 (p	-----	-AACACATTC	TCCACCACGG	GCAACGACAA	GGACGGC--A	CGCAG-AACC
BR/2/01 (A	-----	-AACACATTC	TCCACCACGG	GCAACGACAA	GGACGGC--A	CGCAGGAACC
FL/4/01 (A	-----	-AACACACTC	TCCACCATGG	GCAACGACAA	GGACGGC--A	CGCAG-AACC
FL/3/01 (A	-----	-AACACATTC	TCCACCATGG	GCAACGACAA	GGACGGC--A	CGCAG-AACC
FL/8/01 (A	-----	-AACACATTC	TCCACCATGG	GCAACGACAA	GGACGGC--A	CGCAG-AACC
FL/10/01 (	-----	-AACACATTC	CCCACCATGG	GCAATGACAA	GGACGGT--C	CGCGG-AACC
NL/10/01 (	-----	-AACACATTC	CCCACCATGG	GCAATGACAA	GGACGGT--C	CGTGG-AACC
NL/2/02 (A	-----	-AACACATTC	CCCACCATGG	GCAATGACAA	GGACGGT--C	CGTGG-AACC
NL/17/00 (	-----	-TACACAATC	CCCACCACGG	ACAACAACGA	AGGCAAT--C	CGCAG-AGCC
NL/1/81 (A	-----	-AACACAATC	CCCCTACGG	GCAACAACGA	AGGCGGT--C	CTCAG-AGCC
NL/1/93 (A	-----	-AACACAATC	ACCACCACGG	GCAACAACGA	AGGCGGT--C	CTCAG-AGAC
NL/2/93 (A	-----	-AACACAATC	ACCACCACGG	GCAACAACGA	AGGCGGT--C	CTCAG-AGAC
NL/3/93 (A	-----	-AACACAATC	CTCAATACGG	GCAACAACGA	AGGCGGT--C	CTCAG-AGCC
NL/1/95 (A	-----	-AACACAATC	CCCCTACGG	GCAACAACGA	AGGCGGT--C	CTCAG-AGCC
NL/2/96 (A	-----	-CACACAATC	CCCACCACGG	GTAACAACGA	AGGCAAT--C	CTCAG-AGCC
NL/3/96 (A	-----	-AACACAATC	CCCCTACGG	GCAACAACGA	AGGCGGT--C	CTCAG-AGCC
NL/22/01 (	-----	-AACACAGTC	CCCACCACGG	ACAACAGCGA	AGGCGGT--C	CCCAG-AGCC
NL/24/01 (	-----	-AACACAGTC	CCCACCACGG	ACAACAGCGA	AGGCGGT--C	CCCAG-AGCC
NL/23/01 (	-----	-AACACAGTC	CCCACCACGG	ACAACAGCGA	AGGCGGT--C	CCCAG-AGCC
NL/29/01 (	-----	-TACACAATC	CCCACCACGG	GCAACAACGA	AGGCAAT--C	CGCAG-AGCC
NL/3/02 (A	-----	-TACACAATC	CCCACCACGG	GCAACAACGA	AGGCAAT--C	CGCAG-AGCC
NL/1/99 (p	AGGGAAAAAG	GAAAAGAAAA	CACAAACCAA	ACCACAAGCA	CAGCTGCAAC	CCAAACAACC
NL/11/00 (	AGGGAAAAAG	GAAAAGAAAA	CACAAACCAA	ACCACAAGCA	CAGCTGCAAC	CCAAACAACC
NL/12/00 (	AGGGAAAAAG	GAAAAGAAAA	CACAAACCAA	ACCACAAGCA	CAGCTGCTAC	CCAAACAACC
NL/5/01 (B	AGGGAAAAAG	GAAAAGAAAA	CACAAACCAA	ACCACAAGCA	CAGCTGCAAC	CCAAACAACC
NL/9/01 (B	AGGGAAAAAG	GAAAAGAAAA	CACAAACCAA	ACCACAAGCA	CAGCTGCAAC	CCAAACAACC
NL/21/01 (	AGGGAAAAAG	GAAAAGAAAA	CACAAACCAA	ACCACAAGCA	CAGCTGCAAC	CCAAACAACC
NL/1/94 (p	-----	---AAGAAAC	CACAACTCGA	ACTACAAGCA	CAGCTGCAAC	CCAAACACTC
NL/1/82 (B	-----	---AAGAAAC	CACAAACCAA	ACCACAAGCA	CAGCTGCAAC	CCAAACATTC
NL/1/96 (B	-----	---AAGAAAC	CACAACTCGA	ACCACAAGCA	CAGCTGCAAC	CCAAACACTC
NL/6/97 (B	-----	---AAGAAAC	CACAACCCGA	ACTACAAGTA	CAGCTGCAAC	CCAAACACCC
NL/9/00 (B	-----	---AAGAAAC	CACAACTCGA	ACCACAAGCA	CAGCTGCAAC	CCAAACACTC
NL/3/01 (B	-----	---AAGAAAC	CATAACTCGA	ACCACAAGCA	CAGCCGCAAC	CCAAACACTC
NL/4/01 (B	-----	---AAGAAAC	CATAACTCGA	ACCACAAGCA	CAGCTGCAAC	CCAAACACTC
UK/5/01 (B	-----	---AAGAAAC	CACAACTCGA	ACCACAAGCA	CAGCTGCAAC	CCAAACACTC

						
	545	555	565	575	585	595

NL/1/00 (p	ACCACTCTCC	GCACAAGCAG	CACAAGAAAG	AGACCGTCCA	CAGCATCAGT	CCAACCTGAC
BR/2/01 (A	ACCACTCTCC	GCACAAGCAG	CACAAGAAAG	AGACCGTCCA	CAGCATCAGT	CCAACCTGAC
FL/4/01 (A	ACCACTCTCC	GCACAAGCAG	CACAAGAAAG	AGACCGTCCA	CAGCATCAGC	CCAACCCGAC
FL/3/01 (A	ACCACTCTCC	GCACAAGCAG	CACAAGAAAG	AGACCGTCCA	CAGCATCAGT	CCAACCCGAC
FL/8/01 (A	ACCACTCTCC	GCACAAGCAG	CACAAGAAAG	AGACCGTCCA	CAGCATCAGT	CCAACCCGAC
FL/10/01 (	ACCACTCTCC	GCACAAGCAG	CACAAGAAAA	AGACTGTCTA	CAGCATCAGT	CCAACCCGAC
NL/10/01 (	ACCACTCTCC	GCACAAGCAG	CATAAGAAAA	AGACCGTCCA	CAGCATCAGT	CCAACCTGAC
NL/2/02 (A	ACCACTCTCC	GCACAAGCAG	CATAAGAAAA	AGACCGTCCA	CAGCATCAGT	CCAACCTGAC
NL/17/00 (	ACCACTTTCC	GCATGAGCAG	CACAGGAAAA	AGACCAACCA	CAACATTAGT	CCAGTCCGAC
NL/1/81 (A	ACCGCTTTCC	GCACGAGCAG	CACAAGAAAA	AGACCAACCA	CAACATCAGT	CCAGTCTGAC
NL/1/93 (A	ACCGCCTTCC	ACACGAGCAG	CACAGGAAAA	AGACCAACCA	CAACATCAGT	CCAGTCTGGC
NL/2/93 (A	ACCGCCTTCC	ACACGAGCAG	CACAGGAAAA	AGACCAACCA	CAACATCAGT	CCAGTCTGGC
NL/3/93 (A	ACCGCCTTTC	GCACGAGCAG	CACAGGAGAA	AGACCAACTA	CAACATCAGT	CCAGTCTGAC
NL/1/95 (A	ACCGCCTTTC	GCACGAGCAG	CACAGGAGAG	GGACCAACCA	CAACATCGGT	CCAGTCTGAC
NL/2/96 (A	ACCGTCTTCC	GCATGAGCAG	CACAGGAAAA	AGACCAGCCA	CAACATTAGT	CCAGTCCGAC
NL/3/96 (A	ACCGCCTTTC	GCATGAGCAG	CACAGGAGAG	GGACCAACCA	CAACATCGGT	CCAGTCTGAC
NL/22/01 (	ACCGCCCTTC	GCACGAGCAG	CACAGGAGAA	AGACCAACCA	CAACACCAGT	CCAGCCCGAT
NL/24/01 (	ACCGCCCTTC	GCACGAGCAG	CACAGGAGAA	AGACCAACCA	CAACACCAGT	CCAGCCCGAT

NL/23/01 (	ACCGCCCTTC	GCACGAGCAG	CACAGGAGAA	AGACCAACCA	CAACACCAGT	CCAGCCCGAT
NL/29/01 (	ACCACCCTCC	GCATGAGCAG	CACAGGAAGA	AGACCAACCA	CAACACTAGT	CCAGTCCGAC
NL/3/02 (A	ACCACCCTCC	GCATGAGCAG	CACAGGAAGA	AGACCAACCA	CAACACTAGT	CCAGTCCGAC
NL/1/99 (p	AACACCACCA	ACCAAATCAG	AAATGCAAGT	GAGACAATCA	CAACATCCGA	CAGACCCAGA
NL/11/00 (	AACACCACCA	ACCAAACCAG	AAATGCAAGT	GAGACAATCA	CAACATCCGA	CAGACCCAGA
NL/12/00 (	AACACCACCA	ACCAAATCAG	AAATGCAAGC	GAGACAATCA	CAACATCCGA	CAGACCCAGA
NL/5/01 (B	AACACCACCA	ACCAAATCAG	AAATGCAAGC	GAGACAATCA	CAACATCCGA	CAGACCCAGA
NL/9/01 (B	AACACCACCA	ACCAAATCAG	AAATGCAAGC	GAGACAATCA	CAACATCCGA	CAGACCCAGA
NL/21/01 (	AACACCACCA	ACCAAATCAG	AAATGCAATT	GAGACAATCA	CAACATCCGA	CAGACCCAGA
NL/1/94 (p	AACACTACCA	ACCAAACCTAG	CTATGTGAGA	GAGGCAACCA	CAACATCCGC	CAGATCCAGA
NL/1/82 (B	AACACCACCA	ATCAAACCAG	AAATGGAAGA	GAGACAACCA	TAACATCTGC	CAGATCCAGA
NL/1/96 (B	AACACCACCA	ACCAAACCTAG	CAATGGAAGA	GAGGCAACCA	CAACATCCAC	CAGATCCAGA
NL/6/97 (B	AACACCACCA	ACCAAACCAG	CAATGGAAGA	GAGGCAACCA	CAACATCCGC	CAGGTCCAGA
NL/9/00 (B	AACACCACCA	ACCAAACCTAG	CAATGGAAGA	GAGGCAACCA	CAACATCTGC	CAGATCCAGA
NL/3/01 (B	AACACCACCA	ACCAAACCAA	CAATGGAAGA	GAGGCAACCA	CAACATCTGC	CAGATCCAGA
NL/4/01 (B	AACACCACCA	ACCAAACCAG	CAATGGAAGA	GAGGCAACCA	CAACATCTGC	CAGATCCAGA
UK/5/01 (B	AACACCACCA	ACCAAACCTAG	CAATGGAAGA	GAGGCAACCA	CAACATCTGC	CAGATCCAGA

						
	605	615	625	635	645	655
NL/1/00 (p	ATCAGCGCAA	CAACCCACAA	AAACGAAGAA	GCAAGTCCAG	CGAGCCCACA	AACATCTGCA
BR/2/01 (A	ATCAGCGCAA	CAACCCACAA	AAACGAAGAA	GCAAGTCCAG	CGAGCCCACA	AACATCTGCA
FL/4/01 (A	ATCAGCGCAA	CAACCCACAA	AAACGAAGAA	GCAAGTCCAG	CGAGCCCACA	AACATCTGCA
FL/3/01 (A	ATCAGCGCAA	CAACCCACAA	AAACGAAGAA	GCAAGTCCAG	CGAGCCCACA	AACATCTGCA
FL/8/01 (A	ATCAGCGCAA	CAACCCACAA	AAACGAAGAA	GCAAGTCCAG	CGAGCCCACA	AACATCTGCA
FL/10/01 (	AGCAGCGCAA	CAACCCACAA	ACACGAAGAA	ACAAGCCCAG	TGAGCCCACA	AACATCTGCA
NL/10/01 (	AGCAGCGCAA	CAACCCACAA	ACACGAAGAA	GCAAGCCCAG	TGAGCCCAGCA	AGCATCTGCA
NL/2/02 (A	AGCAGCGCAA	CAACCCACAA	ACACGAAGAA	GCAAGCCCAG	TGAGCCCAGCA	AGCATCTGCA
NL/17/00 (	AGCAGCACCA	CAACCCAAAA	TCATGAAGAA	ACAGGTTTCAG	CGAACCCACA	GGCGTCTGCA
NL/1/81 (A	AGCAGCACCA	CAACCCAAAA	TCATGAAGAA	ACAAGTTTCAT	CGAACCCACA	GGCATCTGCA
NL/1/93 (A	AGCAGCACCA	CAACTCAAAA	TCATGAAGAA	ACAAGTTTCAT	CGAACCCACA	GGCATCTGCA
NL/2/93 (A	AGCAGCACCA	CAACTCAAAA	TCATGAAGAA	ACAAGTTTCAT	CGAACCCACA	GGCATCTGCA
NL/3/93 (A	AGCAGCACCA	CAACCCAAAA	TCATGAAGAA	ACAGGTTTCAG	CGAACCCACA	GGCATCTGCA
NL/1/95 (A	AGCAGCACCA	CAACCCAAAA	TCATGAAGAA	ACAGGTTTCAG	CGAACCCACA	GGCATCTGCA
NL/2/96 (A	AGCAGCACCA	CAACCCAAAA	TCATGAAGAA	ACAGGTTTCAG	CAAACCTCACA	GGCATCTGCA
NL/3/96 (A	AGCAGCACCA	CAACCCAAAA	TCATGAAGAA	ACAGGTTTCAG	CGAACCCACA	GGCATCTGCA
NL/22/01 (	AGCAGCACCA	CAACACAAAA	TCATGAAGAA	ACAGGTTTCAG	CGAACCCACA	GGCATCCGCA
NL/24/01 (	AGCAGCACCA	CAACACAAAA	TCATGAAGAA	ACAGGTTTCAG	CGAACCCACA	GGCATCCGCA
NL/23/01 (	AGCAGCACCA	CAACACAAAA	TCATGAAGAA	ACAGGTTTCAG	CGAACCCACA	GGCATCCGCA
NL/29/01 (	AGCAGCACCA	CAACCCAAAA	TCATGAAGAA	ACAGGTTTCAG	CGAACCCACA	GGCATCTGCA
NL/3/02 (A	AGCAGCACCA	CAACCCAAAA	TCATGAAGAA	ACAGGTTTCAG	CGAACCCACA	GGCATCTGCA
NL/1/99 (p	ACTGACACCA	CAACCCAAAG	CAGCGAACAG	ACAA-CCCGG	GCAACAGACC	CAAGCTCCCC
NL/11/00 (	ATTGACACCA	CAACCCAAAG	CAGCGATCAG	ACAA-CCCGG	GCAACAGACC	CAAGCTCCCC
NL/12/00 (	ACTGACTCCA	CAACCCAAAG	CAGCGAACAG	ACAA-CCCGG	GCAACAGACC	CAAGCTCCCC
NL/5/01 (B	ACTGACTCCA	CAACCCAAAG	CAGCGAACAG	ACAA-CCCGG	GCAACAGACC	CAAGCTCCCC
NL/9/01 (B	ACTGACTCCA	CAACCCAAAG	CAGCGAACAG	ACAA-CCCGG	GCAACAGACC	CAAGCTCCCC
NL/21/01 (	ACTGACTCCA	CAACCCAAAG	CAGCGAACAG	ACAA-CCCGG	GCAACAGACC	CAAGCTCCCC
NL/1/94 (p	AACAGTGCCA	CAACTCAAAG	CAGCGACCAA	ACAA-CCCGG	GCAACAGACC	CAAGCTCCCC
NL/1/82 (B	AACGAGGCCA	CAACTCAAAG	CAGCGAACAA	ACAA-ACCAG	ACAACAGACC	CAAGCTCCCC
NL/1/96 (B	AACGGTGCCA	CAACTCAAAG	CAGCGATCAA	ACAA-CCTAG	ACAGCAGACC	CAAGCTCCCC
NL/6/97 (B	AACGGTGCCA	CAACTCAAAG	CAGCGATCAA	ATAA-CCCGG	GCAGCAGACT	CAAGCTCCCC
NL/9/00 (B	AACAATGCCA	CAACTCAAAG	CAGCGATCAA	ACAA-CCCGG	GCAGCAGAAC	CAAGCTCCCC
NL/3/01 (B	AACAATGCCA	CAACTCAAAG	CAGCGACCAA	ACAA-CCCGG	GCAGCAGACC	CAAGCTCCCC
NL/4/01 (B	AACAATGCCA	CAACTCAAAG	CAGCGACCAA	ACAA-CCCGG	GCAGCAGACC	CAAGCTCCCC
UK/5/01 (B	AACAATGCCA	CAACTCAAAG	CAGCGATCAA	ACAA-CCCAA	GCAGCAGAAC	CAAACCTCCA

						
	665	675	685	695	705	715
NL/1/00 (p	AGCACAACAA	GAATACAAAG	GAAAAGCGTG	GAGGCCAACA	CATCAACAAC	ATACAACCAA
BR/2/01 (A	AGCACAACAA	GAATACAAAG	GAAAAGCGTG	GAGGCCAACA	CATCAACAAC	ATACAACCAA
FL/4/01 (A	AGCACAACAA	GAACACAAAG	GAAAAGCGTG	GAGGCCAACA	CATCAACAAC	ATACAACCAA

FL/3/01 (A	AGCACAACAA	GAACACAAAG	GAAAAGCGTG	GAGGCCAACA	CATCAACAAC	ATACAACCAA
FL/8/01 (A	AGCACAACAA	GAACACAAAG	GAAAAGCGTG	GAGGCCAACA	CATCAACAAC	ATACAACCAA
FL/10/01 (	AGCACAGCAA	GACCACAAAG	GAAGGGCATG	GAGGCCAGCA	CATCAACAAC	ATACAACCAA
NL/10/01 (	AGCACAGCAA	GACCACAAAG	GAAGGGCATG	GAGGCCAGCA	CATCAACAAC	ATACAACCAA
NL/2/02 (A	AGCACAGCAA	GACCACAAAG	GAAGGGCATG	GAGGCCAGCA	CATCAACAAC	ATACAACCAA
NL/17/00 (	AGCACAATG-	-----CAAAA	-----	----CTAGCA	CACCAATAAT	ATAAAACCAA
NL/1/81 (A	AGCACAATG-	-----CAAAG	-----	----CCAGCA	CACCAACAAC	ATAAAACCAA
NL/1/93 (A	AGCACAATG-	-----CAAGA	-----	----CCAGGA	CACCAACAAT	ACAAAACAAA
NL/2/93 (A	AGCACAATG-	-----CAAGA	-----	----CCAGGA	CACCAACAAT	ACAAAACAAA
NL/3/93 (A	AGCACAATG-	-----CAAAA	-----	----CTAGCA	CACCAACATT	GTAAAACCAA
NL/1/95 (A	AGCACAATG-	-----CAAAA	-----	----CTAGCA	CACCAACATT	GTAAAACCAA
NL/2/96 (A	AGCACAATG-	-----CAAAA	-----	----CTAGCA	CTCCAACAAT	ATAAAACCAA
NL/3/96 (A	AGCACAATG-	-----CAAAA	-----	----CCAGCA	CACCAACATT	GCAAAACCAA
NL/22/01 (	AGCACAATG-	-----CAAAA	-----	----CCAGCA	CACCAACATT	GCAAGACCAA
NL/24/01 (	AGCACAATG-	-----CAAAA	-----	----CCAGCA	CACCAACATT	GCAAGACCAA
NL/23/01 (	AGCACAATG-	-----CAAAA	-----	----CCAGCA	CACCAACATT	GCAAGACCAA
NL/29/01 (	AGCACAATG-	-----CAAAA	-----	----CCAGCA	CACCAACAAT	ATAAAACCAA
NL/3/02 (A	AGCACAATG-	-----CAAAA	-----	----CCAGCA	CACCAACAAT	ATAAAACCAA
NL/1/99 (p	ACCACACCAT	GCATAGAGAG	GTGCA-----	-AAACTCAAA	TGAGCACAAC	ACACAAACAT
NL/11/00 (	ACCACACCAT	GCACAGAGTG	GTGCA-----	-AAACCCAAA	TGAACACAAC	ACACAAACAT
NL/12/00 (	ACCACATCAT	GCACAGGGAA	GTGCA-----	-AAACCCAAA	TGAACACAAC	ACACAAACAT
NL/5/01 (B	AGCACACCAT	GCACAGGGAA	GTGCA-----	-AAACCCAAA	TGAACACAAC	ACACAAACAT
NL/9/01 (B	ACCACACCAT	GCACAGGGAA	GTGCA-----	-AAACCCAAA	TGAACACAAC	ACACAAACAT
NL/21/01 (	CCCACACCAT	GCACAGGGAA	GTGCA-----	-AAACCCAAA	TGAACACAAC	ACACAAACAT
NL/1/94 (p	ACCACACCAT	ACACAGAAAA	GCACA-----	-ACAACAACA	T----ACAAC	ACAGACACAT
NL/1/82 (B	ACCACATCAT	GCATAGATAA	GCACA-----	-ATAACAATA	TGAACACAAC	ACAGACACAT
NL/1/96 (B	ACCACACCAT	ACACAGAAAA	GCACA-----	-ACAACAACA	T----ACAAC	ACAGACACAT
NL/6/97 (B	ACCACACCAT	ACACAGAAAA	GCACA-----	-ACAACAGCA	T----ACAAC	ACAGACACAT
NL/9/00 (B	ATCACAACAT	ACACAGAAAA	GCACA-----	-ACAACAACA	T----ACAAC	ACAGACACAT
NL/3/01 (B	ATCACAACAT	ACACAGAAAA	GCATA-----	-ACAACAACA	T----ACAAC	ACAGACACAT
NL/4/01 (B	ATCACAACAT	ACAAAGAAAA	GCACA-----	-ACAACAACA	T----ACAAC	ACAGACACAT
UK/5/01 (B	ATCACAACAT	ACACAGAAAA	GCACA-----	-ACAACAACA	T----ACAAC	ACAGACACAT

						
	725	735	745	755	765	775
NL/1/00 (p	ACTAGTTAAC	AAAAAATACA	AAATAACTCT	AAGATAAACC	ATGCAGACAC	CAACAATGGA
BR/2/01 (A	ACTAGTTAAC	AAAAAATACA	AAATAACTCT	AAGATAAACC	ATGCAGACAC	CAACAATGGA
FL/4/01 (A	ACTAGTTAAC	AAAAAATACA	AAATAACTCT	AAGATAAACC	ATGCAGACAC	CAACAATGGA
FL/3/01 (A	ACTAGTTAAC	AAAAAATACA	AAATAACTCT	AAGATAAACC	ATGCAGACAC	CAACAATGGA
FL/8/01 (A	ACTAGTTAAC	AAAAAATACA	AAATAACTCT	AAGATAAACC	ATGCAGACAC	CAACAATGGA
FL/10/01 (	ACTAGTTAAC	AAAAAATACA	AAATAACTCT	AAGATAAACC	ATGTAGACAC	CAACAATTGA
NL/10/01 (	ACTAGTTAAC	AAAAAATATA	AAATAACTCT	AAGATAAACC	ATGTAGACAC	CAACAATTGA
NL/2/02 (A	ACTAGTTAAC	AAAAAATATA	CAATAACTCT	AAGATAAACC	ATGTAGACAC	CAACAATTGA
NL/17/00 (	ATTAGTTAAC	AAAAAATGCG	AGATAGCTCT	AAAGCAAAAC	ATGTAGGTAC	CAACAATCAA
NL/1/81 (A	ATTAGTTAAC	AAAAAATACG	AGATAGCTCT	AAAGTAAAAC	ATGTAGGTAC	CAACAATCAA
NL/1/93 (A	ATTAGTTAAC	AAAAAATACA	AGATAGCTCT	AAAGTAAAAC	ATGTAGGTAC	CAACAGTAAA
NL/2/93 (A	ATTAGTTAAC	AAAAAATACA	AGATAGCTCT	AAAGTAAAAC	ATGTAGGTAC	CAACAGTAAA
NL/3/93 (A	ATTAGTTAAC	AAAAAATATG	AAATAGCTCT	AAAGTAAAAC	ATGTAGGTGC	TAACAATCAA
NL/1/95 (A	ATTAGTTAAC	AAAAAATATG	AAATAGTTCT	AAAGTAAAAC	ATGTAGGTGC	TAACAATCAA
NL/2/96 (A	ATTAGTTAAC	AAAAAATACG	AGATAGCTCT	AAAGTAAAAC	ATGTAGGCAC	CAACAATCAG
NL/3/96 (A	ATTAGTTAAC	AAAAAATATG	AAATAGTTCT	AAAGTAAAAC	ATGTAGGTGC	CAACAATCAA
NL/22/01 (	ATTAGTTAAC	AAAAAATATG	AAATAGCTCT	AAAGTAAAAC	ATGTAGGTGC	CAACAATCAA
NL/24/01 (	ATTAGTTAAC	AAAAAATATG	AAATAGCTCT	AAAGTAAAAC	ATGTAGGTGC	CAACAATCAA
NL/23/01 (	ATTAGTTAAC	AAAAAATATG	AAATAGCTCT	AAAGTAAAAC	ATGTAGGTGC	CAACAATCAA
NL/29/01 (	ATTAGTTAAC	AAAAAATACG	AGATAGCTCT	AAAGTAAAAC	ATGTAGGCAC	CAACAATCAA
NL/3/02 (A	ATTAGTTAAC	AAAAAATACG	AGATAGCTCT	AAAGTAAAAC	ATGTAGGCAC	CAACAATCAA
NL/1/99 (p	CCCATCCAAG	TAGTTA-ACA	AAAAA-CCAC	AAAATAA-CC	TTGAAAAC-C	AAAAAA--CC
NL/11/00 (	CTCATCCAAG	TAGTTA-ACA	AAAAA-CCAC	AAAATAA-CC	TTGAAAAC-C	AAAAAA--CC
NL/12/00 (	CCCATCCAAG	TAGTTA-ACA	AAAAA-----	-----	-----	-----
NL/5/01 (B	CCCATCCAAG	TAGTTA-ACA	AAAAA-A---	-----	-----	-----
NL/9/01 (B	CCCATCCAAG	TAGTTA-ACA	AAAAA-----	-----	-----	-----

NL/21/01 (	CCCCATCCAAG	TAGTTA-ACA	AAAAA-----	-----	-----	-----
NL/1/94 (p	CCTCTCCAAG	TAGTTA-ACA	AAAAAACTAT	AAAATAA-TC	ATGAAAAC-C	GAAAAA-CTA
NL/1/82 (B	CTTCTCCAAG	TAGTTA-ACA	AAAAA-CTAT	AAAATAA-CC	ATGAAAAC-C	AAAAAA-CTA
NL/1/96 (B	CTTCTCCAAG	TAGTTA-ACA	AAAAA-CTAT	AAAATAA-CC	ATGAAAAC-T	AAAAAA-CTA
NL/6/97 (B	CTTTTCCAAG	TAGTTA-ACA	AAAAA-CTAT	AAAATAA-CC	ATGAAAAC-C	AAAAAA-CTA
NL/9/00 (B	CTTCTCTAAG	TAGTTA-ACA	AAAAAACTAT	AAAATAA-CC	ATGAAAAC-C	AAAAAA-CTA
NL/3/01 (B	CTTCTCCAAG	TAGTTA-ACA	AAAAAACTAT	AAAATAA-CC	ATGAAAAC-C	AAAAAACTA
NL/4/01 (B	CTTCTCCAAG	TAGTTA-ACA	AAAAAACTAT	AAAATAA-CC	ATGAAAAC-C	AAAAAACTA
UK/5/01 (B	CTTCTCTAAG	TAGTTA-ACA	AAAAAACTAT	AAAATAA-CC	ATGAAAAC-C	AAAAAA-CTA

						
	785	795	805	815	825	835
NL/1/00 (p	GAAGCCAAAA	GACAATTCAC	AATCTCCCCA	AAAAGGCAAC	AACACCATAT	TAGC--TCTG
BR/2/01 (A	GAAGCCAAAA	GACAATTCAC	AATCTCCCCA	AAAAGGCAAC	AACACCATAT	TAGC--TCTG
FL/4/01 (A	GAAGTCAAAA	GACAATTCAC	AATCTCCCCA	AAAAGGCAAC	AACACCATAT	TAGC--TCTG
FL/3/01 (A	GAAGTCAAAA	GACAATTCAC	AATCTCCCCA	AAAAGGCAAC	AACACCATAT	TAGC--TCTG
FL/8/01 (A	GAAGTCAAAA	GACAATTCAC	AATCTCCCCA	AAAAGGCAAC	AACACCATAT	TAGC--TCTG
FL/10/01 (	GAAGCCAAAA	GGCAATTCAC	AATCTCCC-A	AAAAAGCAAC	AACACCATAT	TAGC--TCCG
NL/10/01 (	GAAGCCAAAA	GGCAATTCAC	AATCTCCCCA	AAAAGGCAAC	AACACCATAT	TAGC--TCCG
NL/2/02 (A	GAAGCCAAAA	GGCAATTCAC	AATCTCCCCA	AAAAGGCAAC	AACACCATAT	TAGC--TCCG
NL/17/00 (	GAAACCAAAA	GACAATTCAC	AATCTCCCTA	AAACAGCAAC	GACACCATGT	CAGC--TTTG
NL/1/81 (A	GGAATCAAAA	GACAATTCAC	AATCTCCCTA	AAACAGCAAC	AACATCATGT	CAGT--TTTG
NL/1/93 (A	GAAATCAAAA	GACAATTCAC	AATCTCCCCA	AAACAGCAAC	AACATCATGT	CAGC--TTTG
NL/2/93 (A	GAAATCAAAA	GACAATTCAT	AATCTCCCCA	AAACAGCAAC	AACATCATGT	CAGC--TTTG
NL/3/93 (A	GAAATCAAAA	GACATCTCAT	AATCTCTCCA	AAACAGCAAC	AACATCATGT	CAAC--TTTG
NL/1/95 (A	GAAATCAAAA	GACAATTCAT	AATCTCCCTA	AAACAGCAAC	AACATCATGT	CAAC--TTTG
NL/2/96 (A	GAAATTAAAA	GACAATTCAC	AACCTCCCTA	AAACAGCAAC	GACACCATGT	CAAC--TTTG
NL/3/96 (A	GAAATCAAAA	GACAATTCAC	AATCTCCCTA	AAACAGCAAC	AACATCATGC	CAAC--TTTG
NL/22/01 (	GAAATCAAAA	GATAACTCAT	AATCTCTCTA	AAACATCAAC	AACATCATGT	TAAC--TTTG
NL/24/01 (	GAAATCAAAA	GATAACTCAT	AATCTCTCTA	AAACATCAAC	AACATCATGT	TAAC--TTTG
NL/23/01 (	GAAATCAAAA	GATAACTCAT	AATCTCTCTA	AAACATCAAC	AACATCATGT	TAAC--TTTG
NL/29/01 (	GAAACCAAAA	GATAACTCAC	AATCCCCCCA	AAACAGCAAC	GACACCATGT	CAGC--TTTG
NL/3/02 (A	GAAACCAAAA	GATAACTCAC	AATCCCCCCA	AAACAGCAAC	GACACCATGT	CAGC--TTTG
NL/1/99 (p	A-----AAAC	ATAAACCCAG	A---CCCAGA	AA--AACATA	GACACCATAT	GGAAGGTTCT
NL/11/00 (	A-----AACC	ACAAACTTAG	A---CCCAGA	AA--AACATA	GACACTATAT	GGAAGGTTTG
NL/12/00 (	-----	-----TCAG	A---CCCAGA	AA--AACATA	GACACTATAT	GGAAGGTCCG
NL/5/01 (B	-----	-----TCAG	A---CCCAGA	AA--AACACA	GACACTATAT	GGAAGGTCCG
NL/9/01 (B	-----	-----TCAG	A---CCCAGA	AA--AACATA	GACACTATAT	GGAAGGTCCG
NL/21/01 (	-----	-----TCAG	A---CCCAGA	AA--AACATA	GACACTATAT	GGAAGGTCCG
NL/1/94 (p	G-----AAAA	GTTAATTTGA	A---CTCAGA	AAAGAACACA	AACACTATAT	GAATTGTTTG
NL/1/82 (B	G-----AAAA	GTTAATTTGA	A---CTCAGA	AAAGAACACA	AACACTAAAT	GAATTGTTTG
NL/1/96 (B	G-----AAAA	GTTAATTTGA	A---CTCAGA	AAAGAACACA	AACACTATAT	GAATTGTTTG
NL/6/97 (B	G-----AAAA	GTTAATTTGA	A---CTCAGA	AAAGAACACA	AACACTATAT	GAATTGTTTG
NL/9/00 (B	G-----AAAA	GTTAATTTGA	A---CTCAGA	AAAGAACACA	AACACTATAT	GAATTATTTG
NL/3/01 (B	G-----AAAA	GTTAATTTGA	A---CTCAGA	AAAGAACACA	AACACTATAT	GAATTGTTTG
NL/4/01 (B	G-----AAAA	GTTAATTTGA	A---CTCAGA	AAAGAACACA	AACACTATAT	GAATTGTTTG
UK/5/01 (B	G-----AAAA	GTTAATTTGA	A---CTCAGA	AAGGAACACA	AACACTATAT	GAATTATTTG

						
	845	855	865	875	885	895
NL/1/00 (p	CCCAAATCTC	CCTGGAAAA-	AACACTCGCC	CATATACCAA	AAATACCACA	ACCACCCCAA
BR/2/01 (A	CCCAAATCTC	CCTGGAAAA-	AACACTCGCC	CATATACCAA	AAATACCACA	ACCACCCCAA
FL/4/01 (A	CCCAAATCTC	CCTGGAAAA-	AACACTCGCC	CATATACCAA	AAATACCACA	ACCACCCCAA
FL/3/01 (A	CCCAAATCTC	CCTGGAAAA-	AACACTCGCC	CATATACCAA	AAATACCACA	ACCACCCCAA
FL/8/01 (A	CCCAAATCTC	CCTGGAAAA-	AACACTCGCC	CATATACCAA	AAATACCACA	ACCACCCCAA
FL/10/01 (	CTTAAATCTC	CCTGAAAAA-	AACACTCACC	CATATACCAA	CTATACCACA	ACCATCCCAA
NL/10/01 (	CTTAAATCTC	CCTGGAAAA-	AACACTCGCC	CATATACCAA	CTATACCACA	ACCATCCCAA
NL/2/02 (A	CTTAAAGTCTC	CCTGGAAAA-	AACACTCGCC	CATATACCAA	CTATACCACA	ACCATCCCAA
NL/17/00 (	CTCAAATCTC	TCTGGGAGA-	AACTTCTACC	CACATACTAA	CAACATCACA	ACCATCTCAA
NL/1/81 (A	CTCAAATCTC	CCTGGGAGA-	AACTTCTGCC	CACATACTAA	CAACATCACA	ACCATCTCAA
NL/1/93 (A	CTCAAATCTC	CCTGGGAGA-	AACTCTCGCC	CACATACTAA	CAACATCACA	ACTATCTCAA

NL/2/93 (A	CTCAAATCTC	CCTGGGAGA-	AACTCTCGCC	CACATACTAA	CAACATCACA	ACTATCTCAA
NL/3/93 (A	CTCAAATCTC	CCTGGGAGA-	AACTTTTCGCC	CCCATACTGA	CAACATCACA	ATCATCTCAA
NL/1/95 (A	CTCAAATCTC	CCTGGGAGA-	AACTTTTCGCC	CCCATACTGA	CAACATCACA	ATCATCTCAA
NL/2/96 (A	CTCAAATCTC	TCTGGGAGA-	AACTTTTGCC	CACATACTAA	CAACATCACA	ATCATCTCAA
NL/3/96 (A	CTCAAATCTC	CCTGGGAGA-	AACCCTCGCC	CCCATACTGA	CAACATCACA	ATCATCTCAA
NL/22/01 (	CTCAAATCTC	TCTGGGAGA-	AACCTTCGCC	CCCATACTGG	CAACATCACA	ATCATCTCAA
NL/24/01 (	CTCAAATCTC	TCTGGGAGA-	AACCTTCGCC	CCCATACTGG	CAACATCACA	ATCATCTCAA
NL/23/01 (	CTCAAATCTC	TCTGGGAGA-	AACCTTCGCC	CCCATACTGG	CAACATCACA	ATCATCTCAA
NL/29/01 (	CTCAAATCTC	TCTGGGAGA-	AACTTTTGCC	CACATACTAA	CAACATCACA	ACCATCTCAA
NL/3/02 (A	CTCAAATCTC	TCTGGGAGA-	AACTTTTGCC	CACATACTAA	CAACATCACA	ACCATCTCAA
NL/1/99 (p	AGCATATGCA	CCAATGAGAT	GGCATCTGTT	CATGTATCAA	TAGCACCACC	ATCAT-TCAA
NL/11/00 (	AGCATATGCA	CCAATGAAAT	GGTATCTGTT	CATGTATCAA	TAGCGCCACC	ATTAT-TTAA
NL/12/00 (	AGCATATGCA	CCGATGAAAT	GGCATTGTT	CATGTATCAA	TAGCGCCACC	ATTAT-TTAA
NL/5/01 (B	AGCATATGCA	CCGATGAAAT	GGCATCTGTT	CATGTATCAA	TAGCACCACC	ATTAT-TTAA
NL/9/01 (B	AGCATATGCA	CCGATGAAAT	GGCATCTGTT	CATGTATCAA	TAGCGCCACC	ATTAT-TTAA
NL/21/01 (	AGCATATGCA	CCGATGAAAT	GGCATCTGTT	CATGTATCAA	TAGCGCCACC	ATTAT-TTAA
NL/1/94 (p	AGCGTATATA	CTAATGAAAT	AGCATCTGTT	TGTGCATCAA	TAATACCATC	ATTAT-TTAA
NL/1/82 (B	AGCATATATA	CTAATGAAAT	AGCATCTGTT	CATGCATCAA	TAATACCATC	ATTAC-TTAA
NL/1/96 (B	AGCGTATATA	CTAATGAAAT	AGCATCTGTT	TGTGCATCAA	TAATACCATC	ATTAT-TTAA
NL/6/97 (B	AGCGTATATA	CTAATGAAAT	AGCATCTGTT	TGTGCATCAA	TAATACCATC	ATTAT-TTAA
NL/9/00 (B	AGCGTATATA	CTAATGAAAT	AGCATCTGTT	TGTGCATCAA	TAATACCATC	ATTAT-TTAA
NL/3/01 (B	AGCGTATATA	CTAATGAAAT	AGCATCTGTT	TGTGCATCAA	TAATACCATC	ATTAT-TTAA
NL/4/01 (B	AGCGTATATA	CTAATGAAAT	AGCATCTGTT	TGTGCATCAA	TAATACCATC	ATTAT-TTAA
UK/5/01 (B	AGCGTATATA	CTAATGAAAT	AGCATCTGTT	TGTGCATCAA	TAATACCATC	ATTAT-TTAA

....		
905	915	925

NL/1/00 (p	GAAAAAAA-C	TGGGCAAAAC	AACACCCAA
BR/2/01 (A	GAAAAAAA-C	TGGGCAAAAC	AACACCCAA
FL/4/01 (A	GAAAAAAA-C	TGGGCAAAAC	AACACCCAA
FL/3/01 (A	GAAAAAAA-C	TGGGCAAAAC	AACACCCAA
FL/8/01 (A	GAAAAAAA-C	TGGGCAAAAC	AACACCCAA
FL/10/01 (	GAAAAAAGGC	TGGGCAAAAC	AACACCCAA
NL/10/01 (	GGAAAAAAGC	TGGGTAAAC	AACACCCAA
NL/2/02 (A	GAAAAAAGC	TGGGCAAAAC	AACACCCAA
NL/17/00 (	GAAAAGAAAC	TGGGCAAAAC	AGCATCCAA
NL/1/81 (A	GAAAAGAAAC	TGGGCAAAAC	AGCACCCAA
NL/1/93 (A	GAAAAGAAAC	TGGGCAAAAA	AACACTCAA
NL/2/93 (A	GAAAAGAAAC	TGGGCAAAAA	AACACTCAA
NL/3/93 (A	GAAAAGAAAC	TGGGCAAAAC	AGCACCAA
NL/1/95 (A	GAAAAGAAAC	TGGGCAAAAC	AGCACCAA
NL/2/96 (A	GAAAAGAAAC	TGGGCAAAAC	AGCATCCAA
NL/3/96 (A	GAAAAGAAAC	TGGGCAAAAC	AGCACCAA
NL/22/01 (	GAAAAGAAAC	TGGGCAAAAC	AACACCAA
NL/24/01 (	GAAAAGAAAC	TGGGCAAAAC	AACACCAA
NL/23/01 (	GAAAAGAAAC	TGGGCAAAAC	AACACCCAA
NL/29/01 (	GAAAAGAAAC	TGGGCAAAAC	AGCATCCAA
NL/3/02 (A	GAAAAGAAAC	TGGGCAAAAC	AGCATCCAA
NL/1/99 (p	GGAATAAGAA	GAGGCAAAA-	---ATTCAA
NL/11/00 (	GGAATAAGAA	GAGGCAAAA-	---ATTCAA
NL/12/00 (	GGAATAAGAA	GAGGCAAAA-	---ATTCAA
NL/5/01 (B	GGAATAAGAA	GAGGCAAAA-	---ATTCAA
NL/9/01 (B	GGAATAAGAA	GAGGCAAAA-	---ATTCAA
NL/21/01 (	GGAATAAGAA	GAGGCAAGA-	---ATTCAA
NL/1/94 (p	GAAATAAGAA	GAAGCTAAA-	---ATTCAA
NL/1/82 (B	GAAATAAGAA	GAAGCTAAA-	---ATTCAA
NL/1/96 (B	GAAATAAGAA	GAAGCTAAA-	---ATTCAA
NL/6/97 (B	GAAATAAGAA	GAAGCTAAA-	---ATTCAA
NL/9/00 (B	GAAATAAGAA	GAAGCTAAA-	---ATTCAA
NL/3/01 (B	GAATTAAGAA	GAAGCTAAA-	---ATTCAA
NL/4/01 (B	GAATTAAGAA	GAAGCTAAA-	---ATTCAA

WO 03/072719

PCT/US03/05271

45/132

UK/5/01 (B . GAAATAAGAA GAAGCTAAA- ---ATTCAA

Alignment: G Protein

							
		5	15	25	35	45	55
NL/1/00 (p	MEVKVENIRT	IDMLKARVKN	RVARSKCFKN	ASLVLIGITT	LSIALNIYLI	INYKMQKNTS	
BR/2/01 (A	MEVKVENIRT	IDMLKASVKN	RVARSKCFKN	ASLVLIGITT	LSIALNIYLI	INYKMQKNTS	
FL/4/01 (A	MEVKVENIRT	IDMLKARVKN	RVARSKCFKN	ASLVLIGITT	LSIALNIYLI	INYKMQKNTS	
FL/3/01 (A	MEVKVENIRT	IDMLKARVKN	RVARSKCFKN	ASLVLIGITT	LSIALNIYLI	INYKMQKNTS	
FL/8/01 (A	MEVKVENIRT	IDMLKARVKN	RVARSKCFKN	ASLVLIGITT	LSIALNIYLI	INYKMQKNTS	
FL/10/01 (	MEVKVENIRT	IDMLKARVKN	RVARSKCFKN	ASLILIGITT	LSIALNIYLI	INYTMQENTS	
NL/10/01 (	MEVKVENIRT	IDMLKARVKN	RVARSKCFKN	ASLILIGITT	LSIALNIYLI	INYTMQENTS	
NL/2/02 (A	MEVKVENIRT	IDMLKARVKN	RVARSKCFKN	ASLILIGITT	LSIALNIYLI	INYTMQENTS	
NL/17/00 (	MEVKVENIRA	IDMLKARVKN	RVARSKCFKN	ASLILIGITT	LSIALNIYLI	INYTIQKTTS	
NL/1/81 (A	MEVKVENIRA	IDMLKARVKN	RVARSKCFKN	ASLILIGITT	LSIALNIYLI	INYTIQKTTS	
NL/1/93 (A	MEVKVENIRA	VDMLKARVKN	RVARSKCFKN	ASLILVGITT	LSIALNIYLI	VNYTIQKTTS	
NL/2/93 (A	MEVKVENIRA	VDMLKARVKN	RVARSKCFKN	ASLILVGITT	LSIALNIYLI	VNYTIQKTTS	
NL/3/93 (A	MEVKVENIRA	IDMLKARMKN	RVARSKCFKN	ASLILIGITT	LSIALNIYLI	INYTIQKTTS	
NL/1/95 (A	MEVKVENIRA	IDMLKARVKN	RVARSKCFKN	ASLILIGITT	LSIALNIYLI	INYTIQKTTS	
NL/2/96 (A	MEVKVENIRA	IDMLKARVKN	RVARSKCFKN	ASLILIGITT	LSIALNIYLI	INYTIQKTTS	
NL/3/96 (A	MEVKVENIRA	IDMLKARVKN	RVARSKCFKN	ASLILIGITT	LSIALNIYLI	INYTIQKTTS	
NL/22/01 (	MEVKVENIRA	IDMLKARVKN	RVARSKCFKN	ASLILIGITT	LSIALNIYLI	INYTIQKTTS	
NL/24/01 (	MEVKVENIRA	IDMLKARVKN	RVARSKCFKN	ASLILIGITT	LSIALNIYLI	INYTIQKTTS	
NL/23/01 (	MEVKVENIRA	IDMLKARVKN	RVARSKCFKN	ASLILIGITT	LSIALNIYLI	INYTIQKTTS	
NL/29/01 (	MEVKVENIRA	IDMLKARVKN	RVARSKCFKN	ASLILIGITT	LSIALNIYLI	INYTIQKTTS	
NL/3/02 (A	MEVKVENIRA	IDMLKARVKN	RVARSKCFKN	ASLILIGITT	LSIALNIYLI	INYTIQKTTS	
NL/1/99 (p	MEVRVENIRA	IDMFKAKIKN	RIRSSRCYRN	ATLILIGLTA	LSMALNIFLI	IDHATLRNMI	
NL/11/00 (	MEVRVENIRA	IDMFKAKIKN	RIRSSRCYRN	ATLILIGLTA	LSMALNIFLI	IDHATLRNMI	
NL/12/00 (	MEVRVENIRA	IDMFKAKIKN	RIRSSRCYRN	ATLILIGLTA	LSMALNIFLI	IDHATLRNMI	
NL/5/01 (B	MEVRVENIRA	IDMFKAKIKN	RIRSSRCYRN	ATLILIGLTA	LSMALNIFLI	IDHATLRNMI	
NL/9/01 (B	MEVRVENIRA	IDMFKAKIKN	RIRSSRCYRN	ATLILIGLTA	LSMALNIFLI	IDHATLRNMI	
NL/21/01 (	MEVRVENIRA	IDMFKAKIKN	RIRSSRCYRN	ATLILIGLTA	LSMALNIFLI	IDHATLRNMI	
NL/1/94 (p	MEVRVENIRA	IDMFKAKMKN	RIRSSKCYRN	ATLILIGLTA	LSMALNIFLI	IDYAMLKNMT	
NL/1/82 (B	MEVRVENIRT	IDMFKAKMKN	RIRSSKCYRN	ATLILIGLTA	LSMALNIFLI	IDYATFKNMT	
NL/1/96 (B	MEVRVENIRA	IDMFKAKMKN	RIRSSKCYRN	ATLILIGLTA	LSMALNIFLI	IDYAMLKNMT	
NL/6/97 (B	MEVRVENIRA	IDMFKAKMKN	RIRSSKCYRN	ATLILIGLTA	LSMALNIFLI	IDYATLKNMT	
NL/9/00 (B	MEVRVENIRA	IDMFKAKMKN	RIRSSKCYRN	ATLILIGLTA	LSMALNIFLI	IDYATLKNMT	
NL/3/01 (B	MEVRVENIRA	IDMFKAKMKN	RIRSSKCYRN	ATLILIGLSA	LSMALNIFLI	IDYAKSKNMT	
NL/4/01 (B	MEVRVENIRA	IDMFKAKMKN	RIRSSKCYRN	ATLILIGLSA	LSMALNIFLI	IDYAKSKTMT	
UK/5/01 (B	MEVRVENIRA	IDMFKAKMKN	RIRSSKCYRN	ATLILIGLTA	LSMALNIFLI	IDYATLKNMT	
							
		65	75	85	95	105	115
NL/1/00 (p	ESEHHTSSSP	MESSRETPTV	PTDNSDTNSS	PQHPTQQSTE	GSTLYFAASA	SSPETEPTST	
BR/2/01 (A	ESEHHTSSSP	MESSRETPTV	PTDNSDTNSS	PQHPTQQSTE	GSTLYFAASA	SSPETEPTST	
FL/4/01 (A	ESEHHTSSSP	MESSRETPTV	PTDNSDTNSS	PQHPTQQSTE	GSTLYFAASA	NSPETEPTST	
FL/3/01 (A	ESEHHTSSSP	MESSRETPTV	PTDNSDTNSS	PQHPTQQSTE	GSTLYFAASA	NSPETEPTST	
FL/8/01 (A	ESEHHTSSSP	MESSRETPTV	PTDNSDTNSS	PQHPTQQSTE	GSTLYFAASA	SSPETEPTST	
FL/10/01 (	ESEHHTSSSP	MESSRETPTV	PIDNSDTNPG	SQYPTQQSTE	DSTLHSAASA	SSPETEPTST	
NL/10/01 (	ESEHHTSSSP	MESSRETPTV	PMDNSDTNPG	SQYPTQQSTE	GSTLHFAASA	SSPETEPTST	
NL/2/02 (A	ESEHHTSSSP	MESSRETPTV	PMDNSDTNPG	SQYPTQQSTE	GSTLHFAASA	SSPETEPTST	
NL/17/00 (	ESEHHTSSPP	TEPNKEASTI	STDNPDINPS	SQHPTQQSTE	NPTLNPAASA	SPSETEPAST	
NL/1/81 (A	ESEHHTSSPP	TESNKETSTI	PIDNPDINPN	SQHPTQQSTE	SPTLNPAASV	SPSETEPAST	
NL/1/93 (A	ESEHHTSSSP	TESNKGSTSTI	PTDNPDINPN	SQHPTQQSTE	SPTLNPAASV	SPSETEPAST	
NL/2/93 (A	ESEHHTSSSP	TESNKGSTSTI	XTDNPDINPN	SQHPTQQSTE	SPTLNPAASV	SPSETEPAST	
NL/3/93 (A	ESEHHTSSPP	TESNKETSTI	PIDNPDINPN	SQHPTQQSTE	SLTLNPAASV	SPSETEPAST	
NL/1/95 (A	ESEHHTSSPP	TESNKETSTI	SIDNPDINPN	SQHPTQQSTE	SLTLSPTASV	SPSETEPAST	
NL/2/96 (A	ESEHHTSSPP	TESNKEASTI	STDNPDINPN	SQHPTQQSTE	NPTLNPAASV	SSSETEPAST	
NL/3/96 (A	ESEHHTSSPP	TESNKETSTI	SIDNSDINPN	SQHPTQQSTE	SLTLSPTASV	SPSETEPAST	
NL/22/01 (	ESEHHTSSPP	TESNKETSTI	PIDNPDINPN	SQHPTQQSTE	SLTLYPTSSV	SSSETEPAST	

FIGURE 20

NL/24/01 (	ESEHHTSSPP	TESNKETSTI	PIDNPDINPN	SQHPTQQSAE	SLTLYPTSSV	SSSETEPAST
NL/23/01 (	ESEHHTSSPP	TESNKETSTI	PIDNPDINPN	SQHPTQQSTE	SLTLYPTSSV	SSSETEPAST
NL/29/01 (	ESEHHTSSPP	TESNKEASTI	STDNPDINPN	SQHPTQQSTE	NPTLNPAASA	SPSETESAST
NL/3/02 (A	ESEHHTSSPP	TESNKEASTI	STDNPDINPN	SQHPTQQSTE	NPTLNPAASA	SPSETESAST
NL/1/99 (p	KTENCANMPS	AEPSKKTTPMT	STAGPNTKPN	PQQATQWTE	NSTSPVATPE	GHPYTGTQT
NL/11/00 (	KTENCANMPS	AEPSKKTTPMT	STAGPSTEPN	PQQATQWTE	NSTSPAATLE	SHPYTGTQT
NL/12/00 (	KTENCANMPP	AEPSKKTTPMT	STAGPNTKPN	PQQATQWTE	NSTFPAATSE	GHLHTGTQT
NL/5/01 (B	KTENCANMPP	AEPSRKTPMT	STAGPNTKPN	PQQATQWTE	NSTSPAATPE	GHLHTGTQT
NL/9/01 (B	KTENCANMPP	AEPSKKTTPMT	STAGLNTKPN	PQQATQWTE	NSTSPAATPE	GHLHTGTQT
NL/21/01 (	KTENCANMPP	AEPSKKTTPMT	STAGPNTKPN	PQQATQWTE	NSTSPAATPE	GHLHTGTQT
NL/1/94 (p	KVEHCVMPP	VEPSKKTTPMT	SAVDLNTKPN	PQQATQLAAE	DSTSLAATSE	DHLHTGTPT
NL/1/82 (B	KVEHCANMPP	VEPSKKTTPMT	STVDSSTGPN	PQQATQWTE	DSTSLAATSE	DHLHTGTPT
NL/1/96 (B	KVEHCVMPP	VEPSKKTTPMT	SAVDLNTKLN	PQQATQLTTE	DSTSLAATSE	DHLHTGTPT
NL/6/97 (B	KVEHCVMPP	VEPSKKTTPMT	SAVDLNTKLN	PQQATQLTTE	DSTSLAATSE	GHPHTGTPT
NL/9/00 (B	KVEHCVMPP	VEPSKKTTPMT	SAVDSNTKPN	PQQATQLTTE	DSTSLAATLE	DHPHTGTPT
NL/3/01 (B	RVEHCVMPP	VEPSKKTTPMT	SAVDLNTKPN	PQRATQLTTE	DSTSLAATLE	GHLHTGTPT
NL/4/01 (B	RVEHCVMPP	VEPSKKTTPMT	SAVDLNTKPN	PQQATQLTTE	DSTSPAATLE	GHLHTGTPT
UK/5/01 (B	KVEHCVMPP	VEPSKKTTPMT	SAVDLNTKPN	PQQATQLTTE	DSTSLAATLE	DHPHTGTPT

						
	125	135	145	155	165	175
NL/1/00 (p	PDTTNRPPFV	DTHHTPPSAS	RTKTSPAVHT	KNNPRTSSR-	-----THSPP	RATTRTARRT
BR/2/01 (A	PDTTNRPPFV	DTHHTPPSAS	RTKTSPAVHT	KNNPRTSSR-	-----THSPP	RATTRTARRT
FL/4/01 (A	PDTTNRPPFV	DTHHTPPSAS	RTKTSPAVHT	KNNPRISSR-	-----THSPP	WATTRTARRT
FL/3/01 (A	PDTTDRPPFV	DTHHTPPSAS	RTKTSPAVHT	KNNPRISSR-	-----THSPP	WATTRTARRT
FL/8/01 (A	PDTTDRPPFV	DTHHTPPSAS	RTKTSPAVHT	KNNPRISSR-	-----THSPP	WATTRTARRT
FL/10/01 (	PDTTSRPPFV	DTHHTPPSAS	RTRTSPAVHT	KNNPRVSPR-	-----THSPP	WAMTRTVRG
NL/10/01 (	PDTTSRPPFV	DTHHTPPSAS	RTKTSPAVHT	KNNLRISPR-	-----THSPP	WAMTRTVRG
NL/2/02 (A	PDTTSRPPFV	DTHHTPPSAS	RIRTSPAVHT	KNNLRISPR-	-----THSPP	WAMTRTVRG
NL/17/00 (	PDTTNRLSSV	DRSTAQPSES	RTKTKPTVHT	INNPNNTASS-	-----TQSPP	RTTAKAIRRA
NL/1/81 (A	PDTTNRLSSV	DRSTTQPSES	RTKTKPTVHT	KNNPSTVSR-	-----TQSPL	RATTKAVLRA
NL/1/93 (A	PDTTNRLSSA	DRSTTQPSES	RTKTKLTVHT	KNNLSTASR-	-----TQSPP	RATTKAVLRD
NL/2/93 (A	PDTTNRLSSA	DRSTTQPSES	RTKTKLTVHT	KNNLSTASR-	-----TQSPP	RATTKAVLRD
NL/3/93 (A	PDTTNRLSSV	DRSTTQPSES	RTKTKLTVHK	KNIPSTVSR-	-----TQSSI	RATTKAVLRA
NL/1/95 (A	SDTTSRLSSV	DRSTTQPSES	RARTKPTVHK	KNIPSTVSR-	-----TQSPL	RATTKAVLRA
NL/2/96 (A	PDTTNRLSSV	DRSTAQPSES	RTKTKPTVHT	RNNPSTASS-	-----TQSPP	RVTTKAILRA
NL/3/96 (A	SDTTNRLSSV	DRSTTQPSES	RARTKPTVHK	KNIPSTVSR-	-----TQSPL	RATTKAVLRA
NL/22/01 (	PGITNHLFV	DRSTTQPSES	RTKTNRTVHK	KNISSTVSR-	-----TQSPP	RTTAKAVPRA
NL/24/01 (	PGITNHLFV	DRSTTQPSES	RTKTNRTVHK	KNISSTVSR-	-----TQSPP	RTTAKAVPRA
NL/23/01 (	PGITNHLFV	DRSTTQPSES	RTKTNRTVHK	KNISSTVSR-	-----TQSPP	RTTAKAVPRA
NL/29/01 (	PDTTNRLSSV	DRSTVQPSN	RTKTKLTVHT	RNNLSTASS-	-----TQSPP	RATTKAIRRA
NL/3/02 (A	PDTTNRLSSV	DRSTVQPSN	RTKTKLTVHT	RNNLSTASS-	-----TQSPP	RATTKAIRRA
NL/1/99 (p	SDTTAPQQT	DKHTALPKST	NEQITQTTTE	KKTIRATTQK	REKGKENTNQ	TTSTAATQTT
NL/11/00 (	PDITAPQQT	DKHTALPKST	NEQITQTTTE	KKTTRATTQK	REKEKENTNQ	TTSTAATQTT
NL/12/00 (	PDTTAPQQT	DKHTALPKST	NEQITQTTTE	KKTTRATTQR	REKGKENTNQ	TTSTAATQTT
NL/5/01 (B	PDTTAPQQT	DKHTALPKST	NEQITQATTE	KKTTRATTQR	REKGKENTNQ	TTSTAATQTT
NL/9/01 (B	PDTTAPQQT	DKHTALPKST	NEQITQTTTE	KKTTRATTQR	REKGKENTNQ	TTSTAATQTT
NL/21/01 (	PDTTAPQQT	DKHTALPKST	NEQITQTTTE	KKTTRATTQR	REKGKENTNQ	TTSTAATQTT
NL/1/94 (p	PDATVSQQT	DEHTTLLRST	NRQTTQTTTE	KKPTGATTK-	----KETTTR	TTSTAATQTL
NL/1/82 (B	LDATVSQQT	DKHTTPLRST	NGQTTQTTTE	KKPTRAIK-	----KETTTR	TTSTAATQTF
NL/1/96 (B	PDATVSQQT	DEHTTLLRST	NRQTTQTTTE	KKPTGATTK-	----KETTTR	TTSTAATQTL
NL/6/97 (B	PDATVSQQT	DEHTTLLRST	NRQTTQTATE	KKPTGATTK-	----KETTTR	TTSTAATQTP
NL/9/00 (B	PDATVSQQT	DEHTTLLRST	NRQTTQTAAE	KKPTRATTK-	----KETTTR	TTSTAATQTL
NL/3/01 (B	PDVTVSQQT	DEHTTLLRST	NRQTTQTAAE	KKPTRVTTN-	----KETITR	TTSTAATQTL
NL/4/01 (B	PDATVSQQT	DEHTTLLRST	NRQTTQTAAE	KKPTRATTK-	----KETITR	TTSTAATQTL
UK/5/01 (B	PDATVSQQT	DEHTTLLRST	NRQTTQTAAE	KKPTRATTK-	----KETTTR	TTSTAATQTL

						
	185	195	205	215	225	235
NL/1/00 (p	TTLRTSSTRK	RPSTASVQPD	ISATTHKNEE	ASPASPQTS	STTRIQRKSV	EANTSTTYNQ
BR/2/01 (A	TTLRTSSTRK	RPSTASVQPD	ISATTHKNEE	ASPASPQTS	STTRIQRKSV	EANTSTTYNQ

FL/4/01 (A	TTLRTSSTRK	RPSTASAQPD	ISATTHKNEE	ASPASPQ TSA	STTRTQRKSV	EANTSTTYNQ
FL/3/01 (A	TTLRTSSTRK	RPSTASVQPD	ISATTHKNEE	ASPASPQ TSA	STTRTQRKSV	EANTSTTYNQ
FL/8/01 (A	TTLRTSSTRK	RPSTASVQPD	ISATTHKNEE	ASPASPQ TSA	STTRTQRKSV	EANTSTTYNQ
FL/10/01 (	TTLRTSSTRK	RLSTASVQPD	SSATTHKHEE	TSPVSPQ TSA	STARPQRKGM	EASTSTTYNQ
NL/10/01 (	TTLRTSSIRK	RPSTASVQPD	SSATTHKHEE	ASPVSPQ ASA	STARPQRKGM	EASTSTTYNQ
NL/2/02 (A	TTLRTSSIRK	RPSTASVQPD	SSATTHKHEE	ASPVSPQ ASA	STARPQRKGM	EASTSTTYNQ
NL/17/00 (	TTFRMSSTGK	RPTTTLVQSD	SSTTTQNHEE	TGSANPQ ASA	STMQN-----	----HTNNIK
NL/1/81 (A	TAFRTSSTRK	RPTTTSVQSD	SSTTTQNHEE	TSSANPQ ASA	STMQS-----	----HTNNIK
NL/1/93 (A	TAFHTSSTGK	RPTTTSVQSG	SSTTTQNHEE	TSSSNPQ ASA	STMQD-----	----DTNNTK
NL/2/93 (A	TAFHTSSTGK	RPTTTSVQSG	SSTTTQNHEE	TSSSNPQ ASA	STMQD-----	----DTNNTK
NL/3/93 (A	TAFRTSSTGE	RPTTTSVQSD	SSTTTQNHEE	TGSANPQ ASA	STMQN-----	----HTNIVK
NL/1/95 (A	TAFRTSSTGE	GPTTTSVQSD	SSTTTQNHEE	TGSANPQ ASA	STMQN-----	----HTNIVK
NL/2/96 (A	TVFRMSSTGK	RPATTLVQSD	SSTTTQNHEE	TGSANSQ ASA	STMQN-----	----HSNNIK
NL/3/96 (A	TAFRMSSTGE	GPTTTSVQSD	SSTTTQNHEE	TGSANPQ ASA	STMQN-----	----HTNIAK
NL/22/01 (	TALRTSSTGE	RPTTTPVQPD	SSTTTQNHEE	TGSANPQ ASA	STMQN-----	----HTNIAR
NL/24/01 (	TALRTSSTGE	RPTTTPVQPD	SSTTTQNHEE	TGSANPQ ASA	STMQN-----	----HTNIAR
NL/23/01 (	TALRTSSTGE	RPTTTPVQPD	SSTTTQNHEE	TGSANPQ ASA	STMQN-----	----HTNIAR
NL/29/01 (	TTLRMSSTGR	RPTTTLVQSD	SSTTTQNHEE	TGSANPQ ASA	STMQN-----	----HTNNIK
NL/3/02 (A	TTLRMSSTGR	RPTTTLVQSD	SSTTTQNHEE	TGSANPQ ASA	STMQN-----	----HTNNIK
NL/1/99 (p	NTTNQIRNAS	ETITTSRPR	TDTTTQSSEQ	TTRATDPSSP	PHHAR-----	----GAKLK-
NL/11/00 (	NTTNQIRNAS	ETITTSRPR	IDTTTQSSDQ	TTRATDPSSP	PHHAQS-----	----GAKPK-
NL/12/00 (	NTTNQIRNAS	ETITTSRPR	TDSTTQSSEQ	TTRATDPSSP	PHHAQG-----	----SAKPK-
NL/5/01 (B	NTTNQIRNAS	ETITTSRPR	TDSTTQSSEQ	TTQATDPSSP	AHHAQG-----	----SAKPK-
NL/9/01 (B	NTTNQIRNAS	ETITTSRPR	TDSTTQSSEQ	TTRATDPSSP	PHHAQG-----	----SAKPK-
NL/21/01 (	NTTNQIRNAI	ETITTSRPR	TDSTTQSSEQ	TTRATDPSSH	PHHAQG-----	----SAKPK-
NL/1/94 (p	NTTNQTSYVR	EATTTARSR	NSATTQSSDQ	TTQAADPSSQ	PHHTQK-----	----STTTY
NL/1/82 (B	NTTNQTRNGR	ETTITSARSR	NDATTQSSEQ	TNQTDPSSQ	PHHAIS-----	----TITITQ
NL/1/96 (B	NTTNQTSNGR	EATTTSTRSR	NGATTQNSDQ	TT-TADPSSQ	PHHTQK-----	----STTTY
NL/6/97 (B	NTTNQTSNGR	EATTTARSR	NGATTQNSDQ	ITQAADSSSQ	PHHTQK-----	----STTAY
NL/9/00 (B	NTTNQTSNGR	EATTTARSR	NNATTQSSDQ	TTQAAEPSSQ	SQHTQK-----	----STTTY
NL/3/01 (B	NTTNQTNNGR	EATTTARSR	NNATTQSSDQ	TTQAADPSSQ	SQHTQK-----	----SITTY
NL/4/01 (B	NTTNQTSNGR	EATTTARSR	NNATTQSSDQ	TTQAADPSSQ	SQHTKK-----	----STTTY
UK/5/01 (B	NTTNQTSNGR	EATTTARSR	NNATTQSSDQ	TTQAAEPNSQ	SQHTQK-----	----STTTY

....|....
245

NL/1/00 (p	TS-----
BR/2/01 (A	TS-----
FL/4/01 (A	TS-----
FL/3/01 (A	TS-----
FL/8/01 (A	TS-----
FL/10/01 (	TS-----
NL/10/01 (	TS-----
NL/2/02 (A	TS-----
NL/17/00 (	PN-----
NL/1/81 (A	PN-----
NL/1/93 (A	QN-----
NL/2/93 (A	QN-----
NL/3/93 (A	PN-----
NL/1/95 (A	PN-----
NL/2/96 (A	PN-----
NL/3/96 (A	PN-----
NL/22/01 (	PN-----
NL/24/01 (	PN-----
NL/23/01 (	PN-----
NL/29/01 (	PN-----
NL/3/02 (A	PN-----
NL/1/99 (p	-----
NL/11/00 (	-----
NL/12/00 (	-----
NL/5/01 (B	-----

NL/9/01	(B .	-----
NL/21/01	(	-----
NL/1/94	(p	NTDTSSPSS
NL/1/82	(B	HRHIFSK--
NL/1/96	(B	NTDTSSPSS
NL/6/97	(B	NTDTSPFPSS
NL/9/00	(B	NTDTSSLSS
NL/3/01	(B	NTDTSSPSS
NL/4/01	(B	NTDTSSPSS
UK/5/01	(B	NTDTSSLSS

Phylogenetic analysis of hMPV F sequences




FIGURE 21

Phylogenetic analysis of G sequences




FIGURE 22

Growth Curve for hMPV001 in Vero Cells MOI = 0.1




FIGURE 22




FIGURE 24

CTTTAGGGAAATAGGCCAGGTTTTACCGTAACACGCCACATCTTGCGAATATATGTGTAGAACTGCCGGAAATC 532
GAAATCCCTTTATCCGGTCCAAAAGTGGCATTGTGCGGTGTAGAACGCTTATATACACATCTTTGACGGCCTTTAG

K P F Y A L N E G Y C A V D O S Y I H L F Q R F D
CAT

GTCGTGGTATTCACTCCAGAGCGATGAAAACGTTTTCAGTTTGCTCATGGAAAACGGTGTAACAAGGGTGAACACTA 608
CAGCACCATAAGTGAGGTCTCGCTACTTTTGCAAAGTCAAACGAGTACCTTTTGCCACATTGTTCCCACTTGTGAT

D H Y E S W L S S F T E T O E H F V T Y C P H V S
CAT

EcoRI

TCCCATATCACCAGCTCACCCTCTTTTCATTGCCATACGGAATTCGGGATGAGCATTTCATCAGGCGGGCAAGAATGT 684
AGGSTATAGTGGTTCGAGTGGCAGAAAGTAACGGTATGCCTTAAGGCCTACTCGTAAGTAGTCCGCCCGTTCTTACA

D W I V L E G D K M A M R F E P H A N M L R A L I H
CAT

DraI

PvuII

GAATAAAGGCCGGATAAACTTGTGCTTATTTTTCTTTACGGTCTTTAAAAAGGCCGTAATATCCAGCTGAACGGT 760
CTTATTTCCGGCCTATTTTGAACACGAATAAAAAGAAATGCCAGAAATTTTCCGGCATTATAGGTGCGACTTGCCA

I F A P Y F K H K N K K V T K L F A T I D L Q V T
CAT

CTGGTTATAGGTACATTGAGCAAGTGACTGAAATGCCTCAAAATGTTCTTTACGATGCGATTGGGATATATCAACG 836
GACCAATATCCATGTAACCTCGTTCACTGACTTTACGGAGTTTACAAGAAATGCTACGCTAACCTATATAGTTGC



Q N Y T C Q A L S Q F A E F H E K R H S Q S I D V
CAT

AccI

AflIII
MluI

GNGGTATACCCAGTGATTTTTTCTCCATTTTCACTTGTCCCATATTTTTTTGGAATCTAATTTATACGCGTTTTT 912
CNCCATATGGGTCACTAAAAAAGAGGTAAAAGTGAACAGGGTATAAAAAACCTTAGATTAAATATGCGCAAAAA

? T Y G T I K K E M Le+AC
CAT







FIGURE 25

Leader and Trailer Sequence Comparison

hMPV le	ACG CGA AAA AAA C GC GTA TA
hMPV tr	TGC CTT TTT TTT G GC ATA T
APV le	ACG AGA AAA AAA C GC ATT CAA GCA GG
APV tr	TGC TCT TTT TTT G GC ATA AGT AGT TT
RSV A2 le	ACG GGA AAA AAT GCG TAC AAC AAA CTT
RSV A2 tr	TGC TCT TTT TTT CAC AGT TTT T
BRSV le	ACG CGA AAA AAT GCG TAT AAC AAA CCT GT
BRSV tr	TGC TCT TTT TTT CAT AGT TTT TG
HPIV3 le	ACC AAA CAA GAG AAG A GA CTT
HPIV3 tr	TGG TTT GTT CTC TTC T TG AGA
BPIV3 le	ACC AAA CAA GAG AAG A GA CTT
BPIV3 tr	TGG TTT GTT CTC TTT T TG AGA


Yellow color are non-complementary nucleotides between leader and trailer sequences

Green color is a nucleotide to be tested next: change C to A or G



FIGURE 2C

hMPV Genome Sequence Analysis



Silent mutations: nt 5780 ile:ile SH gene
nt 12219 cys:cys L gene
Other changes: nt 8352 trp:leu L gene (leu in 99-1)
(in Frag C and H)



FIGURE 27

hMPV full length clones

Erasmus MC

Erasmus




FIGURE 28

hMPV cDNA Assembly Progress





FIGURE 29A


hMPV cDNA Assembly Progress

13378



4480 G H C B A 13378/RZ/Bssh2

Xho1/pT7 * D E F 4480



* Genetic marker = AfIII
at nt 75 (silent) in N gene



FIGURE 29B

[illegible]

225C GTCAAGAGATGACATTACCAAGTTAAATATGATGTTAAATAAAATAAACAATGGGACAAATGAGTCTCTACCTAGTAGACACCATATCAAGGCATTCTCTACACGACGCTGTTCAAGTTGATCTAATAGAAAAGGACCTGTT
S Q E O D I Y O L I M GS GS M E S Y L V D T Y O G I P Y T A A V O V D L I E K D L L
240C ACCTGCAACCCTAACAATATGTTGCTTTTCAGGCCAACACACACGAGCTGCTCCATCAGCTAAACCCCTGACAATAACCCACTCTGTATGCTGCATCACAATAATGCTCCAAATACTCAAAAGTGAATGCAATCAGCCCAAGG
P A S L T I W F P L F O A N T P P A V L L O Q L K T L T I T L Y A A S Q N G P I L K V N A S A O G
255C TCAGCAATGTTCTACTTCCCAAAAATTTCAAGTCAATGCGACTGTAGCANTCGATGATATAGCAAACTGGAAATTTGACAAACTCAGCTCTGTAAGTAAAAACAGTTTACTTAACAACCATAGAAACCATACGGGATGGTATCAAA
A A H F V L P K K F E V N A T V A ? D E Y S K L E F D K L T V C E V K T V Y L T T M K P Y G H V S K
270C ATTGTGAGCTCAGCCAAATCAGTTGGCAAAAACACATGATCTAATGCACTATGTTATGGATCTAGAAAAGAACACACACCTGTTACAATACCAGCATTCATCAAAATCAGTTTCAATCAAGAGAGTGAGTCAAGTACTGTTGA
F V S S A K S V G K K T H D L I A L C D F H D L E K N T P V T I P A F I K S Y S I K E S E S A T Y E
285C AGCTGTATAAGCAGTGAAGCAGACCAAGCTCTAACACAGGCCAAAATTCACCTTATGCGGATTAATATGATCATGACTATGAACAATCCCAAGGCATATTCAAAAGCTTGGAGTGGGACTCAAGTCAATAGTAGAACTAGGAGC
A A I S S E A O O A L T Q A K I A P Y A G L I M I M T H N N P K G I F K K L Q A G T O V I Y E L G A
300C ATATGTCAGGCTCAAAAGCATAAGCAAAATATGCAAGACTTGGAGCCATCAAGGACACAGATATGCTTGAAGTCCAGATAACAACCAACACCTTGGCCCAAGGCTACTAACCTTATCTCATAGATCATAAAGTCACCATCTAGTTAT
Y V O A E S I S K I C K T W S H O G T R Y V L K S R GS
315C ATAAAAATCAAGTTAGAACAGAAATTAATCAATCAAGAACGGACAAATAAAATGCTTTGAAAAGTGGTGATCAKTTTTTCATTGTTAATAACACCTCRACACGGTCTTAAAGAGAGCTACTTAGAGAGTCTAGTACACTATAACT
GS GS M S W K V V I ? F S L L I T P ? H G L K E S Y L E E S C S T I T
330C GAAGGATATCTCAGTGTCTGAGGACAGGTTGTTACACCAATGTTTACACTGGAGTAGGCGATGTAGAGACCTTACATGTCCGATGACCCAGCTTAATAAAACAGAAATTAGACCTGACCAAAAGTGCCTAAGAGAGCTCAGA
E G Y L S V L R T G W Y T N V F T L E V G D V E N L T C A D G P S L I K T E L D L T K S A L R E L R
345C ACAGTTCTGCTGATCAACTGGCAAGAGAGGACAAATGAAAATCCCAAGCAATCTAGATTGCTTAGGACCAATAGCACTCGGTGTGCAACTGCGAGTTCAGAGAGGTGTGCAATTGCCAAAACCATCGCGCTTGAAGT
T Y S A D O L A R E E O I E N P R O S R F V L G A I A L G V A T A A A V T A G V A I A K T I R L E S
360C GAAGTAACAGCAATTAAGATSCCTCAAAAAGCAATCAAGCAGTATCTACATTTGGGCAATGGAGTTGCTGTGTGGCAACTGCGAGTGAAGAACTGAAGCAATTTGTGAGCAAGAATCTAACACGTGCAATCAACAAAACAAGTGC
E V T A I K N A L K K T N E A V S T L G N G V R V L A T A V R E L K D F V S K N L T R A I N K N X C
375C GACATTTGCTGACCTGAATGSCGTTAGCTTCAGTCAATTCACAGAGGTTCTTAATGTTGTGGGCAATTTTCACACACACCTGGAATAACACCAAGCAATATCTTTGGACTTAATGCACAGATGCTGAAGTACCCAGAGCTGTTTCC
O I A D L K H A V S F S Q F N R R F L N V Y R O F S D N A Q I T P A I S L D L M T O A E L A R A V S
390C AACATGECACATCTGCAGACAAATAAAACTGATGTTGAGAACCGTGCAATGGTAAGAGAAAGGTTCCGATTCCTCATAGGAGTTTACGGAAGCTCCGTAATYACATGGTGCACCTGCCAAATCTTTGGGGTATAGACAGGCTT
N H P T S A G O I K L H L E N R A H V R R K G F G F L I G V Y G S S V I ? H V Q L P I F G V I O T P
405C TGTGAGTAGTAAAGCAGCCCCCTCTCTGTGAGGAAAAGGAACTATGCTTGCCCTTAAGAGAGACCAAGATGGTATGTGCAAAATGCGAGGTCAACTGTTTACTACCCAATGAAAAGACTGTGAACAGAGGAGACCAT
C W I Y K A A P S C S G K X G N Y A C L L R E D O G W Y C O N A G S T V Y Y P N E K D C E T R G O H
420C GTCTTTTGGCACACAGCAGCAAGTAATGTTGCTGAGCAGTCAARBGAGTGCACATAACATATCTACTACTAATTACCCATGCAAGGAGTGCATGAGTATGCTTATGAGTATGGTTGCACTATCTCTCTTGGGGCTTGGT
V F C D T A A G I N V A E O S ? E C N I N I S T T N Y P C K Y S T G R H P I S H Y A L S P L G A L V

FIGURE 30 contd.

[illegible]

CAAGAAAAAAGTGTCCACTGTGTTAATGTCTATCTCC1GACTCATATCTTAAAGGAGTGATTCCTTTAGTGAGACTAATGCAATTGGTTCATGTCCTTAAAGAGACCTTACCTAAAAAATGACAACACTGCAAAAGTTGCCATAGAG 15C
Q E X N C S T V N V Y L P D S Y L K G V J S F S E T N A I G S C L L K R P Y L K N D N T A K V A I E
AATCCTGTATCGAGCATGTAGACTCAAAAATGCCAGTCAATTC TAAGATCAAAATATACATTACAAGTACTAGAGCCAGTAACATGCAAAATTTATGAAGAATGTACACAGTTGTGAGCTCAGCTTATTAACACAGTTTITA 30C
N P V I E H V R L K N A V N S K M K I S D Y K I V E P V N H Q H E I M K N V H S C E L T L L K Q F L
ACAAGGTAAAAAATATTAGCACTCTCAAAATTAATATGATATGATGCTGAGTTAAGTCTAAGTCTACATCAGATGATACCTCAATCTAAGTTTATAGATGTAGAATTTATACCTAGTGGGTAAAGCAATTGGTTAGTAATTGGTAC 45C
T R S K N I S Y L K L N M I C D W L O L K S T S D D T S I L S F I D V E F I P S W V S N W F S N W Y
AATCTCAACAAGTTGATTCGGAAATTCAGCAAAAGAGAGAGTAATAAGAACTGGTTCACATCTGTGTAGGTGATTCGGGTAAATTAGTTTGTGTGTATCATATGATGTATAGTCAAGAGCAACAAAAGCAAAAGAGTCAAGCTTCTTC 60C
N L N K L I L E F R K E E V I R T G S I L C R S L G K L V F V Y S S Y G C I V K S N K S K R V S F F
ACATACAATCAACTGTTAACTGGAAAGATGTGATGTTAAGTAGATTCAATGCAAAATTTTGTATATGGGTAAAGCAACACTCTCAATGCAAAATCAAGAGGGTACGGTTGAGAGAGTAATTTCCAAAGCCATATTAACTAATAAGCTATAT 75C
T Y N O L L T W K O V M L S R F N A N F C I W V S N S L N E N O E G V G L R S N L O G I L T N K L Y
GAAACGTAGATTATATGCTTAGTTTATGTT 781
E T V O Y M L S L C

FIGURE 31 A

ATAAGCTAGTAGATAAGATAAAGTCTGTGATCAACATATCTTCAGTCCAGACAAATAAGATATGTTAACACTGGGGAAAAATGCTCATGCCCCACTATAAAGGTCAAGAAACAGATCAGTTCCTGACAGAGAGAGAGATTTATTCATGGGA 15C
K L V D K I T S D Q H I F S P I D K J D M L T L G K M L M P T I K G Q K T D Q F L N K R E N Y F H G
ATAATCTTATTGAGTCTTTGTGAGCAGCGTTAGCATGTGCTATGCTGCGATATTACAGAGCAATGTATAGAAAATAATTTTCAAGAAAGACTGGCGGTTCATATCGGATCATGCTTTTATCGACTTCAAAATATTCCTAT 30C
N N L J E S L S A A L A C W W C G I L T E Q C I E N N I F K K O W G D G F I S O H A F H O F K I F L
GIGTCTTTAAAGCTAAACITTTATGTA 327
C Y F K T K L L C

FIGURE 31 B

+ = positive; - = negative; T = throatswabs; NO = nose swab; N = not done; ? = not sure; D = dead; 0 to 12: days post infection. 2e infection is only tested on nose swabs.

nr	1 ^e infection	swab	0	1	2	3	4	5	8	10	11	12	2 ^e infection	0	1	2	3	4	5
1	00-1	T	-	+	+	+	-	+	+	+	-	-	99-1	N	N	N	N	N	N
		NO	-	+	+	+	+	+	N	+	-	-		-	-	-	-	-	-
2	00-1	T	-	+	+	+	+	+	-	-	-	D		N	N	N	N	N	N
		NO		+	+	+	+	+	N	+	-	D		-	-	-	-	-	-
3	00-1	T	-	-	?	-	-	-	-	-	-	N	99-1	N	N	?	N	N	N
		NO		+	?	?		-	N	-	-	-		-	-	?	+	+	-
4	00-1	T	-	+	+	+	+	+	-	?	-	N	00-1	N	N	N	N	N	N
		NO	-	+	+	+	+	+	N	?	-	-		-	-	-	+	-	-
5	00-1	T	-	?	+	+	+	+	+	+	-	N	00-1	N	N	N	N	N	N
		NO		+	+	+	+	+	N	+	-	-		-	-	-	-	-	-
6	00-1	T	-	-	+	+	+	+	-	+	-	N	00-1	N	N	N	N	N	N
		NO	-	+	+	+	+	+	N	+	+	?		-	-	-	-	-	-
7	99-1	T	-	-	-	+	+	-	+	D	-	-		N	N	N	N	N	N
		NO	-	-	-	+	+	+	N	D	-	-		-	-	-	-	-	-
8	99-1	T	-	-	+	+	-	-	-	-	-	N	00-1	N	N	N	N	N	N
		NO	-	?	-	+	+	?	N	-	-	-		-	-	+	+	+	+
9	99-1	T	-	-	-	-	-	-	-	-	-	N	00-1	N	N	N	N	N	N
		NO	-	-	-	-	+	+	N	-	-	-		-	?	+	+	-	-
10	99-1	T	-	-	-	+	+	-	-	-	-	N	99-1	N	N	N	N	N	N
		NO	-	+	+	+	+	+	N	-	-	-		-	-	-	-	-	-
11	99-1	T	-	-	+	+	+	-	-	-	-	N	99-1	N	N	N	N	N	N
		NO	-	+	?	+	+	+	N	-	-	-		-	-	-	+	-	-
12	99-1	T	-	-	+	+	?	-	-	-	-	N	99-1	N	N	N	N	N	N
		NO	-	+	+	+	+	+	N	-	-	-		-	-	-	-	-	-

FIGURE 32




FIGURE 33A




FIGURE 33B




FIGURE 34




FIGURE 35




FIGURE 36

	Against 00-1	Against 99-1	Against APV-C
1 infection with 00-1	20-60	< 10	< 10
2 infections with 00-1	>320-1280	40-80	< 10-60
1 infection with 99-1	<10-60	10-80	< 10
2 infections with	20-40	80-400	<10-40

FIGURE 37

+ = positive; - = negative; N = not done; ? = not sure; 0 to 10: days post infection

nr	1 st infection	0	2	3	4	5	6	7	8	9	11	2 nd infect ion	0	1	2	3	4	5	7	10
3	00-1	-	-	-	+	+	+	+	+	N	-		-	+	+	+	+	-	?	-
6	00-1	-	+	+	+	+	+	+	-	-	-		-	+	+	+	+	+	-	-

FIGURE 38

FIGURE 39A





FIGURE 39B






FIGURE 40

FIGURE 41

Comparison of two prototypic hMPV isolates with APV-A and APV-CDNA similarity matrices

<u>N</u>	00-1	99-1	APVC	APVA
00-1	1,000	0,862	0,757	0,660
99-1	---	1,000	0,757	0,663
APVC	---	---	1,000	0,656
APVA	---	---	---	1,000

<u>P</u>	00-1	99-1	APVC	APVA
00-1	1,000	0,811	0,677	0,588
99-1	---	1,000	0,674	0,593
APVC	---	---	1,000	0,584
APVA	---	---	---	1,000

<u>M</u>	00-1	99-1	APVC	APVA
00-1	1,000	0,865	0,766	0,695
99-1	---	1,000	0,773	0,707
APVC	---	---	1,000	0,705
APVA	---	---	---	1,000

<u>F</u>	00-1	99-1	APVC	APVA
00-1	1,000	0,838	0,706	0,662
99-1	---	1,000	0,716	0,655
APVC	---	---	1,000	0,685
APVA	---	---	---	1,000

<u>M2-1</u>	00-1	99-1	APVC	APVA
00-1	1,000	0,863	0,764	0,668
99-1	---	1,000	0,744	0,657
APVC	---	---	1,000	0,670
APVA	---	---	---	1,000

<u>M2-2</u>	00-1	99-1	APVC	APVA
00-1	1,000	0,861	0,648	0,486
99-1	---	1,000	0,675	0,486
APVC	---	---	1,000	0,463
APVA	---	---	---	1,000

<u>SH</u>	00-1	99-1	APVC	APVA
00-1	1,000	0,688	N.A.	0,421
99-1	---	1,000	N.A.	0,380
APVC	---	---	N.A.	N.A.
APVA	---	---	---	1,000

<u>G</u>	00-1	99-1	APVC	APVA
00-1	1,000	0,543	N.A.	0,262
99-1	---	1,000	N.A.	0,263
APVC	---	---	N.A.	N.A.
APVA	---	---	---	1,000

<u>5'L</u>	00-1	99-1	APVC	APVA
00-1	1,000	0,835	N.A.	0,596
99-1	---	1,000	N.A.	0,605
APVC	---	---	N.A.	N.A.
APVA	---	---	---	1,000

5'L: only the first 1500 nucleotides of 99-1 were available.
N.A.: sequence not available.

Protein similarity matrices

<u>N</u> 00-1	99-1	APVC	APVA	
00-1	1,000	0,949	0,880	0,685
99-1	---	1,000	0,883	0,682
APVC	---	---	1,000	0,700
APVA	---	---	---	1,000

<u>P</u> 00-1	99-1	APVC	APVA	
00-1	1,000	0,860	0,683	0,552
99-1	---	1,000	0,676	0,549
APVC	---	---	1,000	0,528
APVA	---	---	---	1,000

<u>M</u> 00-1	99-1	APVC	APVA	
00-1	1,000	0,976	0,874	0,775
99-1	---	1,000	0,874	0,763
APVC	---	---	1,000	0,775
APVA	---	---	---	1,000

<u>F</u> 00-1	99-1	APVC	APVA	
00-1	1,000	0,938	0,810	0,677
99-1	---	1,000	0,803	0,674
APVC	---	---	1,000	0,719
APVA	---	---	---	1,000

<u>M2-1</u>	00-1	99-1	APVC	APVA
00-1	1,000	0,946	0,844	0,719
99-1	---	1,000	0,834	0,703
APVC	---	---	1,000	0,704
APVA	---	---	---	1,000

<u>M2-2</u>	00-1	99-1	APVC	APVA
00-1	1,000	0,901	0,563	0,246
99-1	---	1,000	0,577	0,232
APVC	---	---	1,000	0,191
APVA	---	---	---	1,000

<u>SH</u>	00-1	99-1	APVC	APVA
00-1	1,000	0,570	N.A.	0,178
99-1	---	1,000	N.A.	0,162
APVC	---	---	N.A.	N.A.
APVA	---	---	---	1,000

<u>G</u> 00-1	99-1	APVC	APVA	
00-1	1,000	0,326	N.A.	0,094
99-1	---	1,000	N.A.	0,107
APVC	---	---	N.A.	N.A.
APVA	---	---	---	1,000

<u>5'L</u>	00-1	99-1	APVC	APVA
00-1	1,000	0,921	N.A.	0,600
99-1	---	1,000	N.A.	0,594
APVC	---	---	N.A.	N.A.
APVA	---	---	---	1,000

5'L: only the first 500 amino acid residues of 99-1 were available.

N.A.: sequence not available.

FIGURE 42A

Comparison of the coding sequences of 4 hMPV prototypes

N nt	NL/17/00	NL/1/99	NL/1/94	N aa	NL/17/00	NL/1/99	NL/1/94
NL/1/00	0.938	0.864	0.854	NL/1/00	0.994	0.954	0.961
NL/17/00		0.870	0.861	NL/17/00		0.956	0.964
NL/1/99			0.944	NL/1/99			0.984
P nt	NL/17/00	NL/1/99	NL/1/94	P aa	NL/17/00	NL/1/99	NL/1/94
NL/1/00	0.923	0.812	0.818	NL/1/00	0.955	0.863	0.867
NL/17/00		0.807	0.811	NL/17/00		0.857	0.863
NL/1/99			0.932	NL/1/99			0.959
M nt	NL/17/00	NL/1/99	NL/1/94	M aa	NL/17/00	NL/1/99	NL/1/94
NL/1/00	0.938	0.860	0.861	NL/1/00	0.988	0.976	0.976
NL/17/00		0.848	0.852	NL/17/00		0.972	0.972
NL/1/99			0.942	NL/1/99			1.000
F nt	NL/17/00	NL/1/99	NL/1/94	F aa	NL/17/00	NL/1/99	NL/1/94
NL/1/00	0.937	0.840	0.840	NL/1/00	0.979	0.940	0.946
NL/17/00		0.838	0.840	NL/17/00		0.942	0.949
NL/1/99			0.943	NL/1/99			0.987
M2 nt	NL/17/00	NL/1/99	NL/1/94	M2.1 aa	NL/17/00	NL/1/99	NL/1/94
NL/1/00	0.943	0.854	0.854	NL/1/00	0.983	0.946	0.951
NL/17/00		0.863	0.851	NL/17/00		0.951	0.957
NL/1/99			0.943	NL/1/99			0.978
M2.1 nt	NL/17/00	NL/1/99	NL/1/94	M2.2 aa	NL/17/00	NL/1/99	NL/1/94
NL/1/00	0.943	0.863	0.861	NL/1/00	0.957	0.901	0.915
NL/17/00		0.870	0.852	NL/17/00		0.887	0.901
NL/1/99			0.939	NL/1/99			0.985
M2.2 nt	NL/17/00	NL/1/99	NL/1/94	SH aa	NL/17/00	NL/1/99	NL/1/94
NL/1/00	0.953	0.861	0.865	NL/1/00	0.836	0.570	0.576
NL/17/00		0.870	0.875	NL/17/00		0.605	0.622
NL/1/99			0.967	NL/1/99			0.830
SH nt	NL/17/00	NL/1/99	NL/1/94	G aa	NL/17/00	NL/1/99	NL/1/94
NL/1/00	0.884	0.682	0.673	NL/1/00	0.652	0.309	0.341
NL/17/00		0.688	0.685	NL/17/00		0.337	0.338
NL/1/99			0.887	NL/1/99			0.651
G nt	NL/17/00	NL/1/99	NL/1/94	L aa	NL/17/00	NL/1/99	NL/1/94
NL/1/00	0.762	0.530	0.575	NL/1/00	0.986	0.942	0.938
NL/17/00		0.573	0.546	NL/17/00		0.944	0.939
NL/1/99			0.765	NL/1/99			0.985
L nt	NL/17/00	NL/1/99	NL/1/94				
NL/1/00	0.944	0.843	0.843				
NL/17/00		0.843	0.843				
NL/1/99			0.952				

FIGURE 42B

Amino acid sequence alignment of two prototype hMPV isolatesNucleoprotein (N)

	10	20	30	40	50	60	
00-1	MSLQGIHLS	DL	SYKHAILKESQYTIKRDVGTTTAVTPSS	LQ	QEITLLC	GEILYAKH	ADYK 60
99-1	MSLQGIHLS	DL	SYKHAILKESQYTIKRDVGTTTAVTPSS	LQ	QEITLLC	GEILYTKH	TDYK 60
	70	80	90	100	110	120	
00-1	YAAEIGIQYI	STALG	SERVQQILRNSGSEVQVVLTRTYS	LGKIKNNK	GEDLQML	DIHGVE	120
99-1	YAAEIGIQYI	CTALG	SERVQQILRNSGSEVQVVLTKTYS	LGKIKNSK	GEELQML	DIHGVE	120
	130	140	150	160	170	180	
00-1	KSWVEEIDKEARKTM	ATLLK	ESSGNIPQNQRPSAPDTP	II	LLCVGALIFTK	LASTIEVGL	180
99-1	KSWIEEIDKEARKTM	VTLLK	ESSGNIPQNQRPSAPDTP	II	LLCVGALIFTK	LASTIEVGL	180
	190	200	210	220	230	240	
00-1	ETTVRRANRVLS	DALKRYP	RM	DI	PKIARSFYDLFEQKVYHRSLFIEYGKALGSSSTGSKA	240	
99-1	ETTVRRANRVLS	DALKRYP	RI	DI	PKIARSFYELFEQKVYYRSLFIEYGKALGSSSTGSKA	240	
	250	260	270	280	290	300	
00-1	ESL	FNIFMQAYGAGQTMLRWGV	IARSSNNIMLGHVSVQ	AE	LKQVTEVYDLVREMPESG	300	
99-1	ESL	FNIFMQAYGAGQTLLRWGV	IARSSNNIMLGHVSVQ	SELKQVTEVYDLVREMPESG	300		
	310	320	330	340	350	360	
00-1	LLHLRQSPKAGLLSLANCPNFASVVLGNASGLGIIGMYRGRVPNTE	LFSA	AE	SYAKSLKE	360		
99-1	LLHLRQSPKAGLLSLANCPNFASVVLGNASGLGIIGMYRGRVPNTE	LFSA	AE	SYARSLKE	360		
	370	380	390				
00-1	SNKINFSSLGLTDEEKEAAEHFLNVS	DD	SQNDYE	394			
99-1	SNKINFSSLGLTDEEKEAAEHFLNMS	GD	NQDDYE	394			

FIGURE 43

Phosphoprotein (P)

	10	20	30	40	50	60
00-1	MSFPEGKDILFMGNEAAKLAFAFQKSLRKF	GHKRSQSIIGKVN	TVSETLELPTIS	RP	AK	60
99-1	MSFPEGKDILFMGNEAAKIAFAFQKSLKKS	GHKRTQSIVGEKV	NTISETLELPTIS	KPAR		60

	70	80	90	100	110	120
00-1	PTIPSEPKLAWTDKGGATKTEIKQAIKVM	DP	PIEEEEEST	EKKVLPSSDGKTP	AEKKIKPST	120
99-1	STILLEPKLAWADNSGITKITEKPAKTKTT	DP	VEEEEEFNEKKVLPSSDGKTP	AEKKISKEST		120

	130	140	150	160	170	180
00-1	NTKKKVSFTFNEPGKYTKLEKDALD	LLSDNEEEDAESSILT	FEERDTSSLSIE	ARLESIE		180
99-1	SVKKKVSFTSNEPGKYTKLEKDALD	LLSDNEEEDAESSILT	FEEDTSSLSIE	ARLESIE		180

	190	200	210	220	230	240
00-1	EKLSMILGLLRTLNIATAGPTAARDGIRDAMIGVREELIADI	IKEAKGKAAEMMEE	EMSQ			240
99-1	EKLSMILGLLRTLNIATAGPTAARDGIRDAMIGIREELIAEI	IKEAKGKAAEMMEE	EMNQ			240

	250	260	270	280	290
00-1	RSKIGNGSVKLTEKAKELNKIVEDESTSGESEEEEEPKDTQD	NSQEDDIYQLIM			294
99-1	RSKIGNGSVKLTEKAKELNKIVEDESTSGESEEEEEPKETQD	NNQGEDDIYQLIM			294

FIGURE 44

Matrix protein (M)

	10	20	30	40	50	60
						
00-1	MESYLVD	TYQGIPY	TAAVQVD	LIEKD	LLPASLT	IWFPLFQANTPPAVLLDQLKTLTITTL 60
99-1	MESYLVD	TYQGIPY	TAAVQVD	LVEKD	LLPASLT	IWFPLFQANTPPAVLLDQLKTLTITTL 60
	70	80	90	100	110	120
						
00-1	YAASQNG	PILKVN	ASAQGA	MSVLP	KKFEV	NATVALDEYSKLEFDKLTVC
99-1	YAASQNG	PILKVN	ASAQGA	MSVLP	KKFEV	NATVALDEYSKLEFDKLTVC
	130	140	150	160	170	180
						
00-1	KPYGMV	SKFVSS	AKSVG	KKTHD	LIALC	DFMDLEKNIPVTIPAFIKSVSIKESESATVEAA 180
99-1	KPYGMV	SKFVSS	AKSVG	KKTHD	LIALC	DFMDLEKNIPVTIPAFIKSVSIKESESATVEAA 180
	190	200	210	220	230	240
						
00-1	ISSEAD	QALTQ	AKIAP	YAGLI	MIMTM	NNPKGIFKKLGAGTQVIVELGAYVQAESISKICK 240
99-1	ISSEAD	QALTQ	AKIAP	YAGLI	MIMTM	NNPKGIFKKLGAGTQVIVELGAYVQAESISRICK 240
	250					
						
00-1	TWSHQG	TRYVL	KSR	254		
99-1	SWSHQG	TRYVL	KSR	254		

FIGURE 45

Fusion protein (F)

	10	20	30	40	50	60	
							
00-1	MSWKVVII	ESLLITPQHGLKESYLEESCSTITEGYLSVLRTGWYTNVFTL	EVGDVENLTC	60			
99-1	MSWKVMI	ESLLITPQHGLKESYLEESCSTITEGYLSVLRTGWYTNVFTL	EVGDVENLTC	60			
	70	80	90	100	110	120	
							
00-1	ADGPSLIKTELDLT	KSALRELRTVSADQLAREEQIENPRQSRFVLGAIALGVATAAAVTA	120				
99-1	TDGPSLIKTELDLT	KSALRELKTVSADQLAREEQIENPRQSRFVLGAIALGVATAAAVTA	120				
	130	140	150	160	170	180	
							
00-1	GVAIAKTIRLESEV	TAIKNALKKTNEAVSTLGNGVRVLATAVRELKDFVSKNLT	RAINKN	180			
99-1	GIAIAKTIRLESEV	NAIKGALKQTNEAVSTLGNGVRVLATAVRELKEFVSKNLT	SAINRN	180			
	190	200	210	220	230	240	
							
00-1	KCDIADLKMAVSFSQ	FNRRFLNVVRQFSDNAGITPAISLDLMTDAELARAVSN	MPTSAGQ	240			
99-1	KCDIADLKMAVSFSQ	FNRRFLNVVRQFSDNAGITPAISLDLMTDAELARAVS	YMPTSAGQ	240			
	250	260	270	280	290	300	
							
00-1	IKLMLENRAMVRRKG	FGFLIGVYGSSVIYMVQLPIFGVIDTPCWIVKAAPSCS	GKKGNYA	300			
99-1	IKLMLENRAMVRRKG	FGFLIGVYGSSVIYMVQLPIFGVIDTPCWIKAAPSCS	EKGNYA	300			
	310	320	330	340	350	360	
							
00-1	CLLREDQGWYCQ	NAGSTVYYPNEKDCETRGDHVFCDTAAGINVAEQSKECNINISTTNYP	360				
99-1	CLLREDQGWYCK	NAGSTVYYPNEKDCETRGDHVFCDTAAGINVAEQSRECNINISTTNYP	360				
	370	380	390	400	410	420	
							
00-1	CKVSTGRHPISM	VALSPLGALVACYKGVSCSIGSNRVGIIKQLNKGCSYITNQDADTVTI	420				
99-1	CKVSTGRHPISM	VALSPLGALVACYKGVSCSIGSNWVGIIKQLNKGCSYITNQDADTVTI	420				
	430	440	450	460	470	480	
							
00-1	DNTVYQLSKVEGEQ	HVIKGRPVSSSFDPVKFPEDQFNVALDQVFESIENSQALVDQSNRI	480				
99-1	DNTVYQLSKVEGEQ	HVIKGRPVSSSFDPVKFPEDQFNVALDQVFESIENSQALVDQSNKI	480				
	490	500	510	520	530		
							
00-1	LSSAEKGNTGFI	IVILIAVLGSTMIIVSVFIIIIKKTKKPTGAPPELSGVTNNGFIPHN	539				
99-1	LNSAEKGNTGFI	IVILIAVLGLTMIISVSIIIIIKKTKKPTGAPPELNGVTNNGFIPHS	539				

FIGURE 46

22K protein (M2-1)

	10	20	30	40	50	60
						
00-1	MSRKAPCKYEVRGKCNRGSECKFNHNYWSWPD	RYLLIRSNYLLNQLLRNTDRADGLSIIS	60			
99-1	MSRKAPCKYEVRGKCNRGSDCKFNHNYWSWPD	RYLLIRSNYLLNQLLRNTDKADGLSIIS	60			
	70	80	90	100	110	120
						
00-1	GAGREDRTQDFVLGSTNVVQGYIDDNQ	SITKAAACYSLHNI	IKQLQE	VEVRQARDNKLSD	120	
99-1	GAGREDRTQDFVLGSTNVVQGYIDDNQ	GITKAAACYSLHNI	IKQLQE	TEVRQARDNKLSD	120	
	130	140	150	160	170	180
						
00-1	SKHVALHNLVLSYMEMSKTPASLINNLKRLPREKLKKLAKLIIDLSAG	AENDSSYALQDS	180			
99-1	SKHVALHNLILSYMEMSKTPASLINNLKRLPREKLKKLARLIIDLSAG	TDNDSSYALQDS	180			
						
00-1	ESTNQVQ	187				
99-1	ESTNQVQ	187				

FIGURE 47

M2-2 protein (M2-2)

	10	20	30	40	50	60
						
00-1	MTLHMPCKTVKALIKCSEHG	PV	FITIEV	DDMIWTHKDLKE	ALSDGIVKSHTNIY	NCYLEN 60
99-1	MTLHMPCKTVKALIKCSKHG	PK	FITIEA	DDMIWTHKELKE	ALSDGIVKSHTNIY	SCYLEN 60
		70				
						
00-1	IEIIYVK	AYLS	71			
99-1	IEIIYVK	AYLS	71			

FIGURE 48

Short hydrophobic protein (SH)

	10	20	30	40	50	60		
00-1		MTLDVIKSDGSSKTC	THLKKI IK	DHSGKVLIV	LKLILALLTF	ITVTITINYIKVENNLQ	60	
99-1		MKTLDVIKSDGSSETCN	QLKKI IK	KHSGKVLIAL	KLILALLTF	ETATITVNYIKVENNLQ	60	
	70	80	90	100	110	120		
00-1		ICQSKTESDKK	DSSNTTSV	TKTTLNHDIT	QYFKSLIQRYTNS	AIN-SDTCWKINRNQC	119	
99-1		ACQPKNESDKKV	TKPNTTST	TIRPTDPTV	VHHLKRRLIQRHTNS	VTKDSDTCWRIHKNQR	120	
	130	140	150	160	170	180		
00-1		TNI	TTYKFLC	EKSEDTKT	NNCDKLTDL	CRNKP	KPAVGVYHIVECHCIYTVKWKCYHYPTD	179
99-1		TNI	KIYKFLC	SGFTNSK	GTDCEEPT	ALCDKKL	KTIIVEKHKAECHCLHTTEWGCLHP---	177
00-1		ETQS	183					
99-1		----	177					

FIGURE 49

Attachment glycoprotein (G)

	10	20	30	40	50	60	
00-1	MEVKVENIR	TIDML	KARVKNRV	ARSKCFKN	ASLVLIGIT	TL	SIALNIYLIINYKMQKNTS 60
99-1	MEVRVENIRA	IDMFK	KAKIKNRIR	SSRCYRNAT	LILIGLTA	LSMALNIFLIIDHATLRNMI 60	

	70	80	90	100	110	120	
00-1	ESEHHTSS	SPMESS	RETP	TVPTD	NSDTN	SSPOHPTQ	STEGSTLYFAASASSPETEPTST 120
99-1	KTENCAN	MPSAEP	SKKTP	MTSTAG	PNTKPN	PQOATQ	WTTENSTSPVATPEGHPYTGTQT 120

	130	140	150	160	170	180	
00-1	PDTTNR	PPFVD	THTP	PPSAS	RTKTS	PAVHTK	NNPRTSSRTHSPPRATRTARRTTTLRTS 180
99-1	SDTTAP	QOTTD	KHTAP	LKSTNE	QITQ	TTEKKT	IRATTOKREKGKENTNQTSTAATQTT 180

	190	200	210	220	230		
00-1	STRKR	PSTAS	VQPD	ISAT	THKNEE	ASPAS	PQTSASTTRIQRKSVEANTSTTYNQTS 236
99-1	NTTNQ	IRNASE	T-----	ITTS	DRPRT	DTTQ	SSQOTTRATDPSPPHHA----- 224

FIGURE 50

N-terminus of polymerase protein (L)

	10	20	30	40	50	60
						
00-1	MDP	IN	ESTVNVYLPDSYLKGVISFSETNAIGSCLLKRPYLKNDNTAKVAIENPVI			EHVRL 60
99-1	MDP	EC	ESTVNVYLPDSYLKGVISFSETNAIGSCLLKRPYLKNDNTAKVAIENPVI			EHVRL 60
	70	80	90	100	110	120
						
00-1	KNA	VNS	KMKISDYKIVEPVNMQHEIMKNVHSC	ELTLLKQFLTRSKNISTL		KLNMICDWLQ 120
99-1	RNA	VM	TKMKISDYKVVEPVNMQHEIMKNIHSC	ELTLLKQFLTRSKNISS		LKLNMICDWLQ 120
	130	140	150	160	170	180
						
00-1	LKST	SDD	TSILSFIDVEFIP	SWVSNWF	SNWYNL	NKLILEFRKEEVIRTGSILCRSLGKLV 180
99-1	LKST	S	DNTSILNFIDVEFIP	VWVSNWF	SNWYNL	NKLILEFRREEVIRTGSILCRSLGKLV 180
	190	200	210	220	230	240
						
00-1	FVV	SSYGCIVKSNKSKRVSFFT	YNQLLTWKDVMLSRFNANFCIWVSN	SLNENQ		EGLGLRS 240
99-1	FIV	SSYGCIVKSNKSKRVSFFT	YNQLLTWKDVMLSRFNANFCIWVSN	NNLNKNQ		EGLGLRS 240
	250	260	270	280	290	300
						
00-1	NLQ	GIL	TNKLYETVDYMLSLCCNEGFS	LVKEFE	GFMSEIL	RITEHAQFSTRFRNTLLNG 300
99-1	NLQ	G	MLTNKLYETVDYMLSLCCNEGFS	LVKEFE	GFMSEIL	KITEHAQFSTRFRNTLLNG 300
	310	320	330	340	350	360
						
00-1	LTD	QLT	KLKKNR	LRVH	GTVLE	NNDYPMYEVVLKLLGDTLRCIKLLINKNLENAAE
99-1	LTE	QLS	VLKAKNRS	RVL	GTILE	NNNYPMYEVVLKLLGDTLRSIKLLINKNLENAAE
	370	380	390	400	410	420
						
00-1	FRI	FGH	PMVDERDAMDAVKLNNEITKILR	WESL	TEL	RGAFILRIIKGFVDNNKRWPKIKN 420
99-1	FRI	FGH	PMVDEREAMDAVKLNNEITKILK	LES	TEL	RGAFILRIIKGFVDNNKRWPKIKN 420
	430	440	450	460	470	480
						
00-1	LKV	LSK	RW	MYF	KA	SYPSQLELS
99-1	LKV	LSK	RW	MYF	KA	SYPSQLELS
	490					
						
00-1	KRL	IWS	VYPKNYLPE	KIKN		499
99-1	KKL	IWS	VYPKNYLPE	TIKN		499

FIGURE 51

hMPV Le: 3' UGCUCUUUUUUUGCGCADAUUUAACUAAGGUUUUUUUUAUACCCU
 ||||| ||||| ||||| || ||| || ||| ||
 hMPV Tr: 5' ACGAGAAAAAAC CGUAUACAUCCAAUUAUAUUUCUUAUUUUU
 hMPV Tr: 5' ACGAGAAAAAACCGUAUACAUCCAAUUAUAUUUCUUAUUUUUA
 ||||| ||||| ||||| ||||| ||||| || ||| |||||
 hMPV Tr: 5' ACGAGAAAAAACCGUAUACAUCCAAAUUUUUAGCUUUUAUUUUUU
 hMPV Le: 3' UGCUCUUUUUUUGCGCCAUAUUUAUAUCUAAGGUUUUUUUUAU-ACCC
 ||||| ||||| ||||| || ||| || ||||| ||||| |||||
 hMPV Le: 3' UGCUCUUUUUUUGCGUA-AGUUCGUCCAAGAUUUUUUAUUUACCC

90/132

1 10	 30	
00-1 1-9000 - - - - -	- - - - - G T A T A	A A T T A G A T T C
99-1 1-9000 A C G C G A A A A A	A A C G C G T A T A	A A T T A A A T T C
. 40	 50	 60
00-1 1-9000 C A A A A A A T A	T G G G A C A A G T	G A A A A T G T C T
99-1 1-9000 C A A A C A A A - A	C G G G A C A A A T	A A A A A T G T C T
. 70	 80	 90
00-1 1-9000 C T T C A A G G G A	T T C A C C T G A G	T G A T T T A T C A
99-1 1-9000 C T T C A A G G G A	T T C A C C T A A G	T G A T C T A T C A
. 100	 110	 120
00-1 1-9000 T A C A A G C A T G	C T A T A T T A A A	A G A G T C T C A G
99-1 1-9000 T A T A A A C A T G	C T A T A T T A A A	A G A G T C T C A A
. 130	 140	 150
00-1 1-9000 T A C A C A A T A A	A A A G A G A T G T	G G G T A C A A C A
99-1 1-9000 T A C A C A A T A A	A A A G A G A T G T	A G G C A C C A C A
. 160	 170	 180
00-1 1-9000 A C T G C A G T G A	C A C C C T C A T C	A T T G C A A C A A
99-1 1-9000 A C T G C A G T G A	C A C C T T C A T C	A T T A C A A C A A
. 190	 200	 210
00-1 1-9000 G A A A T A A C A C	T G T T G T G T G G	A G A A A T T C T G
99-1 1-9000 G A A A T A A C A C	T T T T G T G T G G	G G A A A T A C T T
. 220	 230	 240
00-1 1-9000 T A T G C T A A A C	A T G C T G A C T A	C A A A T A T G C T
99-1 1-9000 T A C A C T A A A C	A C A C T G A T T A	C A A A T A T G C T
. 250	 260	 270
00-1 1-9000 G C A G A A A T A G	G A A T A C A A T A	T A T T A G C A C A
99-1 1-9000 G C T G A G A T A G	G A A T A C A A T A	T A T T T G C A C A
. 280	 290	 300
00-1 1-9000 G C T T T A G G A T	C A G A G A G A G T	G C A G C A G A T T
99-1 1-9000 G C T C T A G G A T	C A G A A A G A G T	A C A A C A G A T T
. 310	 320	 330
00-1 1-9000 C T G A G G A A C T	C A G G C A G T G A	A G T C C A A G T G
99-1 1-9000 T T G A G A A A C T	C A G G T A G T G A	A G T T C A G G T G
. 340	 350	 360
00-1 1-9000 G T C T T A A C C A	G A A C G T A C T C	T C T G G G G A A A
99-1 1-9000 G T T C T A A C C A	A A A C A T A C T C	C T T A G G G A A A
. 370	 380	 390
00-1 1-9000 A T T A A A A A C A	A T A A A G G A G A	A G A T T T A C A G
99-1 1-9000 G G C A A A A A C A	G T A A A G G G G A	A G A G C T G C A G

Figure 53

WO 03/072719

PCT/US03/05271

91/132

00-1 1-9000	A T G T T A G A C A	400	T A C A C G G G G T	430	A G A G A A G A G C
99-1 1-9000	A T G T T A G A T A		T A C A T G G A G T		G G A A A A G A G T
00-1 1-9000	T G G G T A G A A G	430	A G A T A G A C A A	440	A G A A G C A A G G
99-1 1-9000	T G G A T A G A A G		A A A T A G A C A A		A G A G G C A A G A
00-1 1-9000	A A A A C A A T G G	460	C A A C C T T G C T	470	T A A G G A A T C A
99-1 1-9000	A A G A C A A T G G		T A A C T T T G C T		T A A G G A A T C A
00-1 1-9000	T C A G G T A A T A	490	T C C C A C A A A A	500	T C A G A G G C C C
99-1 1-9000	T C A G G T A A C A		T C C C A C A A A A		C C A G A G A C C T
00-1 1-9000	T C A G C A C C A G	520	A C A C A C C C A T	530	A A T C T T A T T A
99-1 1-9000	T C A G C A C C A G		A C A C A C C A A T		A A T T T T A T T A
00-1 1-9000	T G T G T A G G T G	550	C C T T A A T A T T	560	C A C T A A A C T A
99-1 1-9000	T G T G T A G G T G		C C C T A A T A T T		C A C T A A A C T A
00-1 1-9000	G C A T C A A C C A	580	T A G A A G T G G G	590	A C T A G A G A C C
99-1 1-9000	G C A T C A A C A A		T A G A A G T T G G		A T T A G A G A C T
00-1 1-9000	A C A G T C A G A A	610	G G G C T A A C C G	620	T G T A C T A A G T
99-1 1-9000	A C A G T T A G A A		G A G C T A A T A G		A G T G C T A A G T
00-1 1-9000	G A T G C A C T C A	640	A G A G A T A C C C	650	T A G A A T G G A C
99-1 1-9000	G A T G C A C T C A		A A A G A T A C C C		A A G G A T A G A T
00-1 1-9000	A T A C C A A A G A	670	T T G C C A G A T C	680	C T T C T A T G A C
99-1 1-9000	A T A C C A A A G A		T T G C T A G A T C		T T T T T A T G A A
00-1 1-9000	T T A T T T G A A C	700	A A A A A G T G T A	710	T C A C A G A A G T
99-1 1-9000	C T A T T T G A A C		A A A A A G T G T A		C T A C A G A A G T
00-1 1-9000	T T G T T C A T T G	730	A G T A T G G C A A	740	A G C A T T A G G C
99-1 1-9000	T T A T T C A T T G		A G T A C G G A A A		A G C T T T A G G C
00-1 1-9000	T C A T C A T C T A	760	C A G G C A G C A A	770	A G C A G A A A G T
99-1 1-9000	T C A T C T T C A A		C A G G A A G C A A		A G C A G A A A G T

Figure 53 cont'd

00-1 1-9000	CTATTTGTTA	ATATATT CAT	GCAAGCTTAT
99-1 1-9000	TTGTTTGTAA	ATATATT TAT	GCAAGCTTAT
00-1 1-9000	GGGGCCGGTC	AAACAATGCT	AAGGTGGGGG
99-1 1-9000	GGAGCTGGCC	AAACA CTGCT	AAGGTGGGGT
00-1 1-9000	GTCA TTGCCA	GGTCATCCAA	CAATATAATG
99-1 1-9000	GTCA TTGCCA	GATCATCCAA	CAACATAATG
00-1 1-9000	TTAGGACATG	TATCCGTCCA	AGCTGAGTTA
99-1 1-9000	CTAGGGCATG	TATCTGTGCA	ATCTGAATTG
00-1 1-9000	AAACAGGTCA	CAGAA GTCTA	TGACTTGGTG
99-1 1-9000	AAGCAAGTTA	CAGAG GTTTA	TGACTTGGTG
00-1 1-9000	CGAGAAATGG	GCCCTGAATC	TGGACTTCTA
99-1 1-9000	AGAGAAATGG	GTCCTGAATC	TGGGCTTTTA
00-1 1-9000	CATTTAAGGC	AAAGCCCAAA	AGCTGGACTG
99-1 1-9000	CATCTAAGAC	AAAGTCCAAA	GGCAGGGCTG
00-1 1-9000	TTATCACTAG	CCA ACTGTCC	CAACTTTGCA
99-1 1-9000	TTATCATTTGG	CCAATTGCCC	CAATTTTGCT
00-1 1-9000	AGTGTTGTTC	TCGGAAATGC	CTCAGGCTTA
99-1 1-9000	AGTGTTGTTC	TTGGCAATGC	TTCAGGTCTA
00-1 1-9000	GGCATAATCG	G TATGTATCG	AGGGAGAGTA
99-1 1-9000	GGCATAATCG	G AATGTACAG	AGGGAGAGTA
00-1 1-9000	CCA AACACAG	AAT TATTTTC	AGCAGCTGAA
99-1 1-9000	CCA AACACAG	AGCTATTTTC	TGCAGCAGAA
00-1 1-9000	AGTTATGCCA	AAAGTTTGAA	AGAAAGCAAT
99-1 1-9000	AGTTATGCCA	G AAGCTTAAA	AGAAAGCAAT
00-1 1-9000	AAAATAAATT	TCTCTTCA TT	AGGACTTACA
99-1 1-9000	AAAATCAACT	TCTCTT CGTT	AGGGCTTACA

Figure 53 cont'd

00-1 1-9000	1180 G A T G A A G A G A	1190 A A G A G G C T G C	1200 A G A A C A T T T C
99-1 1-9000	G A T G A A G A A A	A A G A A G C T G C	A G A A C A C T T C
00-1 1-9000	1210 T T A A A T G T G A	1220 G T G A C G A C A G	1230 T C A A A A T G A T
99-1 1-9000	T T A A A C A T G A	G T G G T G A C A A	T C A A G A T G A T
00-1 1-9000	1240 T A T G A G T A A T	1250 T A A A A A A G T G	1260 G G A C A A G T C A
99-1 1-9000	T A T G A G T A A T	T A A A A A A C T G	G G A C A A G T C A
00-1 1-9000	1270 A A A T G T C A T T	1280 C C C T G A A G G A	1290 A A A G A T A T T C
99-1 1-9000	A A A T G T C A T T	C C C T G A A G G A	A A G G A T A T T C
00-1 1-9000	1300 T T T T C A T G G G	1310 T A A T G A A G C A	1320 G C A A A A T T A G
99-1 1-9000	T G T T C A T G G G	T A A T G A A G C A	G C A A A A A T A G
00-1 1-9000	1330 C A G A A G C T T T	1340 C C A G A A A T C A	1350 T T A A G A A A A C
99-1 1-9000	C C G A A G C T T T	C C A G A A A T C A	C T G A A A A A A T
00-1 1-9000	1360 C A G G T C A T A A	1370 A A G A T C T C A A	1380 T C T A T T A T A G
99-1 1-9000	C A G G T C A C A A	G A G A A C T C A A	T C T A T T G T A G
00-1 1-9000	1390 G A G A A A A A G T	1400 G A A T A C T G T A	1410 T C A G A A A C A T
99-1 1-9000	G G G A A A A A G T	T A A C A C T A T A	T C A G A A A C T C
00-1 1-9000	1420 T G G A A T T A C C	1430 T A C T A T C A G T	1440 A G A C C T G C A A
99-1 1-9000	T A G A A C T A C C	T A C C A T C A G C	A A A C C T G C A C
00-1 1-9000	1450 A A C C A A C C A T	1460 A C C G T C A G A A	1470 C C A A A G T T A G
99-1 1-9000	G A T C A T C T A C	A C T G C T G G A A	C C A A A A T T G G
00-1 1-9000	1480 C A T G G A C A G A	1490 T A A A G G T G G G	1500 G C A A C C A A A A
99-1 1-9000	C A T G G G C A G A	C A A C A G C G G A	A T C A C C A A A A
00-1 1-9000	1510 C T G A A A T A A A	1520 G C A A G C A A T C	1530 A A A G T C A T G G
99-1 1-9000	T C A C A G A A A A	A C C A G C A A C C	A A A A C A A C A G
00-1 1-9000	1540 A T C C C A T T G A	1550 A G A A G A A G A G	1560 T C T A C C G A G A
99-1 1-9000	A T C C T G T T G A	A G A A G A G G A A	T T C A A T G A A A

Figure 53 cont'd

00-1 1-9000	1570 A G A A G G T G C T	1580 A C C C T C C A G T	1590 G A T G G G A A A A
99-1 1-9000	A G A A A G T G T T	A C C T T C C A G T	G A T G G G A A G A
00-1 1-9000	1600 C C C C T G C A G A	1610 A A A G A A A C T G	1620 A A A C C A T C A A
99-1 1-9000	C T C C T G C A G A	G A A A A A A T C A	A A G T T T T C A A
00-1 1-9000	1630 C T A A C A C C A A	1640 A A A G A A G G T T	1650 T C A T T T A C A C
99-1 1-9000	C C A G T G T A A A	A A A G A A A G T T	T C C T T T A C A T
00-1 1-9000	1660 C A A A T G A A C C	1670 A G G G A A A T A T	1680 A C A A A G T T G G
99-1 1-9000	C A A A T G A A C C	A G G G A A A T A C	A C C A A A C T A G
00-1 1-9000	1690 A A A A A G A T G C	1700 T C T A G A T T T G	1710 C T C T C A G A T A
99-1 1-9000	A G A A A G A T G C	C C T A G A T T T G	C T C T C A G A C A
00-1 1-9000	1720 A T G A A G A A G A	1730 A G A T G C A G A A	1740 T C T T C A A T C T
99-1 1-9000	A T G A G G A A G A	A G A C G C A G A A	T C C T C A A T C C
00-1 1-9000	1750 T A A C C T T T G A	1760 A G A A A G A G A T	1770 A C T T C A T C A T
99-1 1-9000	T A A C T T T T G A	G G A G A A A G A T	A C A T C A T C A C
00-1 1-9000	1780 T A A G C A T T G A	1790 G G C C A G A T T G	1800 G A A T C A A T A G
99-1 1-9000	T A A G C A T T G A	A G C T A G A C T A	G A A T C T A T A G
00-1 1-9000	1810 A G G A G A A A T T	1820 A A G C A T G A T A	1830 T T A G G G C T A T
99-1 1-9000	A A G A G A A G T T	G A G C A T G A T A	T T A G G A C T G C
00-1 1-9000	1840 T A A G A A C A C T	1850 C A A C A T T G C T	1860 A C A G C A G G A C
99-1 1-9000	T T C G T A C A C T	T A A C A T T G C A	A C A G C A G G A C
00-1 1-9000	1870 C C A C A G C A G C	1880 A A G A G A T G G G	1890 A T C A G A G A T G
99-1 1-9000	C A A C A G C T G C	A C G A G A T G G A	A T T A G G G A T G
00-1 1-9000	1900 C A A T G A T T G G	1910 C G T A A G A G A G	1920 G A A T T A A T A G
99-1 1-9000	C A A T G A T T G G	T A T A A G A G A A	G A G C T A A T A G
00-1 1-9000	1930 C A G A C A T A A T	1940 A A A G G A A G C T	1950 A A A G G G A A A G
99-1 1-9000	C A G A G A T A A T	T A A G G A A G C C	A A G G G A A A A G

Figure 53 cont'd

00-1 1-9000	1960 C A G C A G A A A T	1970 G A T G G A A G A G	1980 G A A A T G A G T C
99-1 1-9000	C A G C T G A A A T	G A T G G A A G A A	G A G A T G A A T C
00-1 1-9000	1990 A A C G A T C A A A	2000 A A T A G G A A A T	2010 G G T A G T G T A A
99-1 1-9000	A A A G A T C A A A	A A T A G G A A A T	G G C A G T G T A A
00-1 1-9000	2020 A A T T A A C A G A	2030 A A A A G C A A A A	2040 G A G C T C A A C A
99-1 1-9000	A A C T A A C C G A	G A A G G C A A A A	G A G C T C A A C A
00-1 1-9000	2050 A A A T T G T T G A	2060 A G A T G A A A G C	2070 A C A A G T G G A G
99-1 1-9000	A A A T T G T T G A	A G A C G A G A G C	A C A A G C G G T G
00-1 1-9000	2080 A A T C C G A A G A	2090 A G A A G A A G A A	2100 C C A A A A G A C A
99-1 1-9000	A A T C A G A A G A	A G A A G A A G A A	C C A A A A G A A A
00-1 1-9000	2110 C A C A A G A C A A	2120 T A G T C A A G A A	2130 G A T G A C A T T T
99-1 1-9000	C T C A G G A T A A	C A A T C A A G G A	G A A G A T A T T T
00-1 1-9000	2140 A C C A G T T A A T	2150 T A T G T A G T T T	2160 A A T A A A A A T A
99-1 1-9000	A T C A G T T A A T	C A T G T A G T T T	A A T A A A A A T A
00-1 1-9000	2170 A A C A A T G G G A	2180 C A A G T A A A A A	2190 T G G A G T C C T A
99-1 1-9000	A A C A A T G G G A	C A A G T C A A G A	T G G A G T C C T A
00-1 1-9000	2200 C C T A G T A G A C	2210 A C C T A T C A A G	2220 G C A T T C C T T A
99-1 1-9000	T C T A G T A G A C	A C T T A T C A A G	G C A T T C C A T A
00-1 1-9000	2230 C A C A G C A G C T	2240 G T T C A A G T T G	2250 A T C T A A T A G A
99-1 1-9000	T A C A G C T G C T	G T T C A A G T T G	A C C T G G T A G A
00-1 1-9000	2260 A A A G G A C C T G	2270 T T A C C T G C A A	2280 G C C T A A C A A T
99-1 1-9000	A A A A G A T T T A	C T G C C A G C A A	G T T T G A C A A T
00-1 1-9000	2290 A T G G T T C C C T	2300 T T G T T T C A G G	2310 C C A A C A C A C C
99-1 1-9000	A T G G T T T C C T	T T A T T T C A G G	C C A A C A C A C C
00-1 1-9000	2320 A C C A G C A G T G	2330 C T G C T C G A T C	2340 A G C T A A A A A C
99-1 1-9000	A C C A G C A G T T	C T G C T T G A T C	A G C T A A A A A C

Figure 53 cont'd

00-1 1-9000	2350 C C T G A C A A T A	2360 A C C A C T C T G T	2370 A T G C T G C A T C
99-1 1-9000	C C T G A C A A T A	A C C A C T C T G T	A T G C T G C A T C
00-1 1-9000	2380 A C A A A A T G G T	2390 C C A A T A C T C A	2400 A A G T G A A T G C
99-1 1-9000	A C A G A A T G G T	C C A A T A C T C A	A G G T A A A T G C
00-1 1-9000	2410 A T C A G C C C A A	2420 G G T G C A G C A A	2430 T G T C T G T A C T
99-1 1-9000	A T C T G C C C A A	G G T G C T G C C A	T G T C T G T A C T
00-1 1-9000	2440 T C C C A A A A A A	2450 T T T G A A G T C A	2460 A T G C G A C T G T
99-1 1-9000	T C C C A A A A A A	T T C G A G G T A A	A T G C A A C T G T
00-1 1-9000	2470 A G C A C T C G A T	2480 G A A T A T A G C A	2490 A A C T G G A A T T
99-1 1-9000	A G C A C T T G A T	G A A T A C A G T A	A A C T T G A T T T
00-1 1-9000	2500 T G A C A A A C T C	2510 A C A G T C T G T G	2520 A A G T A A A A A C
99-1 1-9000	T G A C A A G C T G	A C G G T C T G C G	A T G T T A A A A C
00-1 1-9000	2530 A G T T T A C T T A	2540 A C A A C C A T G A	2550 A A C C A T A C G G
99-1 1-9000	A G T T T A T T T G	A C A A C T A T G A	A A C C G T A C G G
00-1 1-9000	2560 G A T G G T A T C A	2570 A A A T T T G T G A	2580 G C T C A G C C A A
99-1 1-9000	G A T G G T G T C A	A A A T T T G T G A	G T T C A G C C A A
00-1 1-9000	2590 A T C A G T T G G C	2600 A A A A A A A C A C	2610 A T G A T C T A A T
99-1 1-9000	A T C A G T T G G C	A A A A A G A C A C	A T G A T C T A A T
00-1 1-9000	2620 C G C A C T A T G T	2630 G A T T T T A T G G	2640 A T C T A G A A A A
99-1 1-9000	T G C A C T A T G T	G A C T T C A T G G	A C C T A G A G A A
00-1 1-9000	2650 G A A C A C A C C T	2660 G T T A C A A T A C	2670 C A G C A T T C A T
99-1 1-9000	A A A T A T A C C T	G T G A C A A T A C	C A G C A T T C A T
00-1 1-9000	2680 C A A A T C A G T T	2690 T C A A T C A A A G	2700 A G A G T G A G T C
99-1 1-9000	A A A G T C A G T T	T C A A T C A A A G	A G A G T G A A T C
00-1 1-9000	2710 A G C T A C T G T T	2720 G A A G C T G C T A	2730 T A A G C A G T G A
99-1 1-9000	A G C C A C T G T T	G A A G C T G C A A	T A A G C A G C G A

Figure 53 cont'd

WO 03/072719

PCT/US03/05271

00-1 1-9000	A G C A G A C C A A	97/132 G C T C T A A C A C	A G G C C A A A A T
99-1 1-9000	A G C C G A C C A A	G C C T T G A C A C	A A G C C A A G A T
00-1 1-9000	T G C A C C T T A T	G C G G G A T T A A	T T A T G A T C A T
99-1 1-9000	T G C G C C C T A T	G C A G G A C T A A	T T A T G A T C A T
00-1 1-9000	G A C T A T G A A C	A A T C C C A A A G	G C A T A T T C A A
99-1 1-9000	G A C C A T G A A C	A A T C C A A A A G	G T A T A T T C A A
00-1 1-9000	A A A G C T T G G A	G C T G G G A C T C	A A G T C A T A G T
99-1 1-9000	G A A A C T A G G G	G C T G G A A C A C	A A G T G A T A G T
00-1 1-9000	A G A A C T A G G A	G C A T A T G T C C	A G G C T G A A A G
99-1 1-9000	A G A G C T G G G G	G C A T A T G T T C	A G G C T G A G A G
00-1 1-9000	C A T A A G C A A A	A T A T G C A A G A	C T T G G A G C C A
99-1 1-9000	C A T C A G T A G G	A T C T G C A A G A	G C T G G A G T C A
00-1 1-9000	T C A A G G G A C A	A G A T A T G T C T	T G A A G T C C A G
99-1 1-9000	C C A A G G A A C A	A G A T A C G T A C	T A A A A T C C A G
00-1 1-9000	A T A A C A A C C A	A G C A C C T T G G	C C A A G A G C T A
99-1 1-9000	A T A A - A A A T A	A C T G T C T T A A	T C A A T A A T T G
00-1 1-9000	C T A A C C C T A T	C T C A T A G A T C	A - T A A A G T C A
99-1 1-9000	C T T A T A T A A C	T C T A G A G A T T	A A T A A G C T T A
00-1 1-9000	C C A T T C T A G T	T A T A T A A A A A	T C A A G T T A G A
99-1 1-9000	T T A T T A T A G T	T A T A T A A A A A	T - A A A T T A G A
00-1 1-9000	A C A A G A A T T A	A A T C A A T C A A	G A A C G G G A C A
99-1 1-9000	A T T A G A A G G G	C A T C A A T A G A	A A G C G G G A C A
00-1 1-9000	A A T A A A A A T G	T C T T G G A A A G	T G G T G A T C A T
99-1 1-9000	A A T A A A A A T G	T C T T G G A A A G	T G A T G A T C A T
00-1 1-9000	T T T T T C A T T G	T T A A T A A C A C	C T C A A C A C G G
99-1 1-9000	C A T T T C G T T A	C T C A T A A C A C	C C C A G C A C G G

Figure 53 cont'd

WO 03/072719

PCT/US03/05271

00-1 1-9000	3130	98/132	3140	3150
99-1 1-9000				
T C T T A A A G A G	A G C T A C T T A G	A A G A G T C A T G		
G C T A A A G G A G	A G T T A T T T G G	A A G A A T C A T G		
00-1 1-9000	3160	3170	3180	
99-1 1-9000				
T A G C A C T A T A	A C T G A A G G A T	A T C T C A G T G T		
T A G T A C T A T A	A C T G A G G G A T	A C C T C A G T G T		
00-1 1-9000	3190	3200	3210	
99-1 1-9000				
T C T G A G G A C A	G G T T G G T A C A	C C A A T G T T T T		
T T T A A G A A C A	G G C T G G T A C A	C T A A T G T C T T		
00-1 1-9000	3220	3230	3240	
99-1 1-9000				
T A C A C T G G A G	G T A G G C G A T G	T A G A G A A C C T		
C A C A T T A G A A	G T T G G T G A T G	T T G A A A A T C T		
00-1 1-9000	3250	3260	3270	
99-1 1-9000				
T A C A T G T G C C	G A T G G A C C C A	G C T T A A T A A A		
T A C A T G T A C T	G A T G G A C C T A	G C T T A A T C A A		
00-1 1-9000	3280	3290	3300	
99-1 1-9000				
A A C A G A A T T A	G A C C T G A C C A	A A A G T G C A C T		
A A C A G A A C T T	G A T C T A A C A A	A A A G T G C T T T		
00-1 1-9000	3310	3320	3330	
99-1 1-9000				
A A G A G A G C T C	A G A A C A G T T T	C T G C T G A T C A		
A A G G G A A C T C	A A A A C A G T C T	C T G C T G A T C A		
00-1 1-9000	3340	3350	3360	
99-1 1-9000				
A C T G G C A A G A	G A G G A G C A A A	T T G A A A A T C C		
G T T G G C G A G A	G A G G A G C A A A	T T G A A A A T C C		
00-1 1-9000	3370	3380	3390	
99-1 1-9000				
C A G A C A A T C T	A G A T T C G T T C	T A G G A G C A A T		
C A G A C A A T C A	A G A T T T G T C T	T A G G T G C G A T		
00-1 1-9000	3400	3410	3420	
99-1 1-9000				
A G C A C T C G G T	G T T G C A A C T G	C A G C T G C A G T		
A G C T C T C G G A	G T T G C T A C A G	C A G C A G C A G T		
00-1 1-9000	3430	3440	3450	
99-1 1-9000				
T A C A G C A G G T	G T T G C A A T T G	C C A A A A C C A T		
C A C A G C A G G C	A T T G C A A T A G	C C A A A A C C A T		
00-1 1-9000	3460	3470	3480	
99-1 1-9000				
C C G G C T T G A A	A G T G A A G T A A	C A G C A A T T A A		
A A G G C T T G A G	A G T G A G G T G A	A T G C A A T T A A		
00-1 1-9000	3490	3500	3510	
99-1 1-9000				
G A A T G C C C T C	A A A A A G A C C A	A T G A A G C A G T		
A G G T G C T C T C	A A A C A A A C T A	A T G A A G C A G T		

Figure 53 cont'd

WO 03/072719

PCT/US03/05271

00-1 1-9000	ATCTACATTG	GGGAATGGAG	TCGTGTGTT
99-1 1-9000	ATCCACATTA	GGGAATGGTG	TGCGGGTCTT
00-1 1-9000	GGCAACTGCA	GTGAGAGAGC	TGAAAGATT
99-1 1-9000	AGCCAAGTCA	GTGAGAGAGC	TAAAAGAAAT
00-1 1-9000	TGTGAGCAAG	AATCTAACAC	GTGCAATCAA
99-1 1-9000	TGTGAGCAAA	AACCTGACTA	GTGCAATCAA
00-1 1-9000	CAAAACAAG	TGCGACATTG	CTGACCTGAA
99-1 1-9000	CAGGAACA	TGTGACATTG	CTGATCTGAA
00-1 1-9000	AATGGCCGTT	AGCTTTCAGTC	AATTCAACAG
99-1 1-9000	GATGGCTGTC	AGCTTTCAGTC	AATTCAACAG
00-1 1-9000	AAGGTTCCTA	AATGTTGTGC	GGCAATTTTC
99-1 1-9000	AAGATTTCCTA	AATGTTGTGC	GGCAGTTTTC
00-1 1-9000	AGACAACGCT	GGAAATAACAC	CAGCAATATC
99-1 1-9000	AGACAATGCA	GGGATAACAC	CAGCAATATC
00-1 1-9000	TTTGGAAGCTTA	ATGACAGATG	CTGAAGTAGC
99-1 1-9000	ATTGGAAGCTG	ATGACTGATG	CTGAGTTGGC
00-1 1-9000	CAGAGCTGTT	TCCAACATGC	CAACATCTGC
99-1 1-9000	CAGAGCTGTA	TCAATACATGC	CAACATCTGC
00-1 1-9000	AGGACAATAA	AAACTGATGT	TGGAGAACCG
99-1 1-9000	AGGGCAGATA	AAACTGATGT	TGGAGAACCG
00-1 1-9000	TGCAATGGTA	AGAAAGAAAAG	GGTTCGGATT
99-1 1-9000	CGCAATGGTA	AGGAGAAAAG	GATTTGGAAT
00-1 1-9000	CCTGATAGGA	GTTTACGGAA	GCTCCGTAAT
99-1 1-9000	CCTGATAGGG	GTCTACGGAA	GCTCTGTGAT
00-1 1-9000	TTACATGGTG	CAACTGCCAA	TCTTTGGGGT
99-1 1-9000	TTACATGGTT	CAATTGCCGA	TCTTTGGTGT

Figure 53 cont'd

00-1 1-9000	T A T A G A C A C G	3910	00-1 1-9000	C C T T G C T G G A	3920	00-1 1-9000	T A G T A A A A G C	3930
99-1 1-9000	C A T A G A T A C A		99-1 1-9000	C C T T G T T G G A		99-1 1-9000	T C A T C A A G G C	
00-1 1-9000	A G C C C C T T C T	3940	00-1 1-9000	T G T T C A G G A A	3950	00-1 1-9000	A A A A G G G A A A	3960
99-1 1-9000	A G C T C C C T C T		99-1 1-9000	T G C T C A G A A A		99-1 1-9000	A A A A C G G G A A	
00-1 1-9000	C T A T G C T T G C	3970	00-1 1-9000	C T C T T A A G A G	3980	00-1 1-9000	A A G A C C A A G G	3990
99-1 1-9000	T T A T G C T T G C		99-1 1-9000	C T C C T A A G A G		99-1 1-9000	A G G A T C A A G G	
00-1 1-9000	A T G G T A T T G T	4000	00-1 1-9000	C A A A A T G C A G	4010	00-1 1-9000	G G T C A A C T G T	4020
99-1 1-9000	G T G G T A T T G T		99-1 1-9000	A A A A A T G C A G		99-1 1-9000	G A T C T A C T G T	
00-1 1-9000	T T A C T A C C C A	4030	00-1 1-9000	A A T G A A A A A G	4040	00-1 1-9000	A C T G T G A A A C	4050
99-1 1-9000	T T A C T A C C C A		99-1 1-9000	A A T G A A A A A G		99-1 1-9000	A C T G C G A A A C	
00-1 1-9000	A A G A G G A G A C	4060	00-1 1-9000	C A T G T C T T T T	4070	00-1 1-9000	G C G A C A C A G C	4080
99-1 1-9000	A A G A G G T G A T		99-1 1-9000	C A T G T T T T T T		99-1 1-9000	G T G A C A C A G C	
00-1 1-9000	A G C A G G A A T C	4090	00-1 1-9000	A A T G T T G C T G	4100	00-1 1-9000	A G C A G T C A A A	4110
99-1 1-9000	A G C A G G G A T C		99-1 1-9000	A A T G T T G C T G		99-1 1-9000	A G C A A T C A A G	
00-1 1-9000	G G A G T G C A A C	4120	00-1 1-9000	A T A A A C A T A T	4130	00-1 1-9000	C T A C T A C T A A	4140
99-1 1-9000	A G A A T G C A A C		99-1 1-9000	A T C A A C A T A T		99-1 1-9000	C T A C T A C C A A	
00-1 1-9000	T T A C C C A T G C	4150	00-1 1-9000	A A A G T T A G C A	4160	00-1 1-9000	C A G G A A G A C A	4170
99-1 1-9000	C T A C C C A T G C		99-1 1-9000	A A A G T C A G C A		99-1 1-9000	C A G G A A G A C A	
00-1 1-9000	T C C T A T C A G T	4180	00-1 1-9000	A T G G T T G C A C	4190	00-1 1-9000	T A T C T C C T C T	4200
99-1 1-9000	C C C T A T A A G C		99-1 1-9000	A T G G T T G C A C		99-1 1-9000	T A T C A C C T C T	
00-1 1-9000	T G G G G C T T T G	4210	00-1 1-9000	G T T G C T T G C T	4220	00-1 1-9000	A C A A G G G A G T	4230
99-1 1-9000	C G G T G C T T T G		99-1 1-9000	G T G G C T T G C T		99-1 1-9000	A T A A A G G G G T	
00-1 1-9000	G A G C T G T T C C	4240	00-1 1-9000	A T T G G C A G C A	4250	00-1 1-9000	A C A G A G T A G G	4260
99-1 1-9000	A A G C T G C T C G		99-1 1-9000	A T T G G C A G C A		99-1 1-9000	A T T G G G T T G G	
00-1 1-9000	G A T C A T C A A G	4270	00-1 1-9000	C A A C T G A A C A	4280	00-1 1-9000	A A G G C T G C T C	4290
99-1 1-9000	A A T C A T C A A A		99-1 1-9000	C A A T T A C C C A		99-1 1-9000	A A G G C T G C T C	

Figure 53 cont'd

101/132

00-1 1-9000	TTATATAACC	4300	AACCAAGACG	4310	CAGACACAGT	4320
99-1 1-9000	ATACATAACC		AACCAAGGATG		CAGACACTGT	
00-1 1-9000	GACAATAGAC	4330	AACACTGTAT	4340	ACCAGCTAAG	4350
99-1 1-9000	AACAATTGAC		AATACCGTGT		ATCAACTAAG	
00-1 1-9000	CAAGTTGAA	4360	GGCGAACAGC	4370	ATGTTATAAA	4380
99-1 1-9000	CAAGTTGAA		GGTGAACAGC		ATGTAATAAA	
00-1 1-9000	AGGAAGGCCA	4390	GTGTCAAGCA	4400	GCTTTGACCC	4410
99-1 1-9000	AGGGAGACCA		GTTTCAAGCA		GTTTTGATCC	
00-1 1-9000	AGTCAAGTTT	4420	CCTGAAGATC	4430	AATTCAATGT	4440
99-1 1-9000	AATCAAGTTT		CCTGAGGATC		AGTTCAATGT	
00-1 1-9000	TGCACTTGAC	4450	CAAGTTTTCG	4460	AGAGCATTTGA	4470
99-1 1-9000	TGCGCTTGAT		CAAGTCTTCG		AAAGCATTTGA	
00-1 1-9000	GAACAGTCAG	4480	GCCTTGGTGG	4490	ATCAATCAAA	4500
99-1 1-9000	GAACAGTCAG		GCACTAGTGG		ACCAGTCAAA	
00-1 1-9000	CAGAATCCTA	4510	AGCAGTGCAG	4520	AGAAAGGAAA	4530
99-1 1-9000	CAAAATTCTA		AACAGTGCAG		AAAAAGGAAA	
00-1 1-9000	CACTGGCTTC	4540	ATCATTTGTA	4550	TAATTCTAAT	4560
99-1 1-9000	CACTGGTTTC		ATTATCGTAG		TAATTTTGGT	
00-1 1-9000	TGCTGTCCTT	4570	GGCTCTACCA	4580	TGATCCTAGT	4590
99-1 1-9000	TGCTGTTCTT		GGTCTAACCA		TGATTTTCAGT	
00-1 1-9000	GAGTGTTTTT	4600	ATCATAATAA	4610	AGAAAACAAA	4620
99-1 1-9000	GAGCATCATC		ATCATAATCA		AGAAAACAAG	
00-1 1-9000	GAAACCCACA	4630	GGAGCACCTC	4640	CAGAGCTGAG	4650
99-1 1-9000	GAAAGCCACA		GGAGCACCTC		CAGAGCTGAA	
00-1 1-9000	TGGTGTCACA	4660	AACAATGGCT	4670	TCATACCACA	4680
99-1 1-9000	TGGTGTCACC		AACGGCGGTT		TCATACCACA	

Figure 53 cont'd

00-1 1-9000	4690 T A A T T A G T T A	4700 A T T A A A A A T A	4710 A A G T A A A T T A
99-1 1-9000	T A G T T A G T T A	A T T A A A A A - -	- - - - A - - - -
00-1 1-9000	4720 A A A T A A A T T A	4730 A A A T T A A A A A	4740 T A A A A A T T T G
99-1 1-9000	- - - - -	- - - - -	- - - - T G
00-1 1-9000	4750 G G A C A A A T C A	4760 T A A T G T C T C G	4770 C A A G G C T C C G
99-1 1-9000	G G A C A A A T C A	T C A T G T C T C G	T A A G G C T C C A
00-1 1-9000	4780 T G C A A A T A T G	4790 A A G T G C G G G G	4800 C A A A T G C A A T
99-1 1-9000	T G C A A A T A T G	A A G T G C G G G G	C A A A T G C A A C
00-1 1-9000	4810 A G A G G A A G T G	4820 A G T G C A A G T T	4830 T A A C C A C A A T
99-1 1-9000	A G A G G G A G T G	A T T G C A A A T T	C A A T C A C A A T
00-1 1-9000	4840 T A C T G G A G T T	4850 G G C C A G A T A G	4860 A T A C T T A T T A
99-1 1-9000	T A C T G G A G T T	G G C C T G A T A G	A T A T T T A T T G
00-1 1-9000	4870 A T A A G A T C A A	4880 A T T A T T T A T T	4890 A A A T C A A C T T
99-1 1-9000	T T A A G A T C A A	A T T A T C T C T T	A A A T C A G C T T
00-1 1-9000	4900 T T A A G G A A C A	4910 C T G A T A G A G C	4920 T G A T G G C T T A
99-1 1-9000	T T A A G A A A C A	C A G A T A A G G C	T G A T G G T T T G
00-1 1-9000	4930 T C A A T A A T A T	4940 C A G G A G C A G G	4950 C A G A G A A G A T
99-1 1-9000	T C A A T A A T A T	C A G G A G C A G G	T A G A G A A G A T
00-1 1-9000	4960 A G G A C A C A A G	4970 A T T T T G T C C T	4980 A G G T T C C A C C
99-1 1-9000	A G A A C T C A A G	A C T T T G T T C T	T G G T T C T A C T
00-1 1-9000	4990 A A T G T G G T T C	5000 A A G G T T A T A T	5010 T G A T G A T A A C
99-1 1-9000	A A T G T G G T T C	A A G G G T A C A T	T G A T G A C A A C
00-1 1-9000	5020 C A A A G C A T A A	5030 C A A A A G C T G C	5040 A G C C T G T T A C
99-1 1-9000	C A A G G A A T A A	C C A A G G C T G C	A G C T T G C T A T
00-1 1-9000	5050 A G T C T A C A T A	5060 A T A T A A T C A A	5070 A C A A C T A C A A
99-1 1-9000	A G T C T A C A C A	A C A T A A T C A A	G C A A C T A C A A

Figure 53 cont'd

WO 03/072719

PCT/US03/05271

103/132

	5080	5090	5100
00-1 1-9000	G A A G T T G A A G	T T A G G C A G G C	T A G A G A T A A C
99-1 1-9000	G A A A C A G A A G	T A A G A C A G G C	T A G A G A C A A C
	5110	5120	5130
00-1 1-9000	A A A C T A T C T G	A C A G C A A A C A	T G T A G C A C T T
99-1 1-9000	A A G C T T T C T G	A T A G C A A A C A	T G T G G C G C T C
	5140	5150	5160
00-1 1-9000	C A C A A C T T A G	T C C T A T C T T A	T A T G G A G A T G
99-1 1-9000	C A C A A C T T G A	T A T T A T C C T A	T A T G G A G A T G
	5170	5180	5190
00-1 1-9000	A G C A A A A C T C	C T G C A T C T T T	A A T C A A C A A T
99-1 1-9000	A G C A A A A C T C	C T G C A T C T C T	A A T C A A C A A C
	5200	5210	5220
00-1 1-9000	C T C A A G A G A C	T G C C G A G A G A	G A A A C T G A A A
99-1 1-9000	C T A A A G A A A C	T A C C A A G G G A	A A A A C T G A A G
	5230	5240	5250
00-1 1-9000	A A A T T A G C A A	A G C T C A T A A T	T G A C T T A T C A
99-1 1-9000	A A A T T A G C A A	G A T T A A T A A T	T G A T T T A T C A
	5260	5270	5280
00-1 1-9000	G C A G G T G C T G	A A A A T G A C T C	T T C A T A T G C C
99-1 1-9000	G C A G G A A C T G	A C A A T G A C T C	T T C A T A T G C C
	5290	5300	5310
00-1 1-9000	T T G C A A G A C A	G T G A A A G C A C	T A A T C A A G T G
99-1 1-9000	T T G C A A G A C A	G T G A A A G C A C	T A A T C A A G T G
	5320	5330	5340
00-1 1-9000	C A G T G A G C A T	G G T C C A G T T T	T C A T T A C T A T
99-1 1-9000	C A G T A A A C A T	G G T C C C A A A T	T C A T T A C C A T
	5350	5360	5370
00-1 1-9000	A G A G G T T G A T	G A C A T G A T A T	G G A C T C A C A A
99-1 1-9000	A G A G G C A G A T	G A T A T G A T A T	G G A C T C A C A A
	5380	5390	5400
00-1 1-9000	G G A C T T A A A A	G A A G C T T T A T	C T G A T G G G A T
99-1 1-9000	A G A A T T A A A A	G A A A C A C T G T	C T G A T G G G A T
	5410	5420	5430
00-1 1-9000	A G T G A A G T C T	C A T A C T A A C A	T T T A C A A T T G
99-1 1-9000	A G T A A A A T C A	C A C A C C A A T A	T T T A T A G T T G
	5440	5450	5460
00-1 1-9000	T T A T T T A G A A	A A C A T A G A A A	T T A T A T A T G T
99-1 1-9000	T T A C T T A G A A	A A T A T A G A A A	T A A T A T A T G T

Figure 53 cont'd

00-1 1-9000	5470 C A A G G C T T A C	5480 T T A A G T T A G T	5490 A A A A A C - - A C
99-1 1-9000	T A A A A C T T A C	T T A A G T T A G T	A A A A A A T A A A
00-1 1-9000	5500 A T C A G A G T G G	5510 G A T A A A T G A C	5520 A A T G A T A A C A
99-1 1-9000	A A T A G A A T G G	G A T A A A T G A C	A A T G A A A A C A
00-1 1-9000	5530 T T A G A T G T C A	5540 T T A A A A G T G A	5550 T G G G T C T T C A
99-1 1-9000	T T A G A T G T C A	T A A A A A G T G A	T G G A T C C T C A
00-1 1-9000	5560 A A A A C A T G T A	5570 C T C A C C T C A A	5580 A A A A A T A A T T
99-1 1-9000	G A A A C G T G T A	A T C A A C T C A A	A A A A A T A A T A
00-1 1-9000	5590 A A A G A C C A C T	5600 C T G G T A A A G T	5610 G C T T A T T G T A
99-1 1-9000	A A A A A A C A C T	C A G G T A A A G T	G C T T A T T G C A
00-1 1-9000	5620 C T T A A G T T A A	5630 T A T T A G C T T T	5640 A C T A A C A T T T
99-1 1-9000	C T A A A A C T G A	T A T T G G C C T T	A C T G A C A T T T
00-1 1-9000	5650 C T C A C A G T A A	5660 C A A T C A C C A T	5670 C A A T T A T A T A
99-1 1-9000	T T C A C A G C A A	C A A T C A C T G T	C A A C T A T A T A
00-1 1-9000	5680 A A A G T G G A A A	5690 A C A A T C T G C A	5700 A A T A T G C C A G
99-1 1-9000	A A A G T A G A A A	A C A A T T T G C A	G G C A T G T C A A
00-1 1-9000	5710 T C A A A A A C T G	5720 A A T C A G A C A A	5730 A A A G G A C T C A
99-1 1-9000	C C A A A A A A T G	A A T C A G A C A A	A A A G G T C A C A
00-1 1-9000	5740 T C A T C A A A T A	5750 C C A C A T C A G T	5760 C A C A A C C A A G
99-1 1-9000	A A G C C A A A T A	C C A C A T C A A C	A A C A A T C A G A
00-1 1-9000	5770 A C T A C T C T A A	5780 A T C A T G A T A T	5790 C A C A C A G T A T
99-1 1-9000	C C C A C A C C C G	A T C C A A C T G T	A G T A C A T C A T
00-1 1-9000	5800 T T T A A A A G T T	5810 T G A T T C A A A G	5820 G T A T A C A A A C
99-1 1-9000	T T G A A A A G G C	T G A T T C A G A G	A C A C A C C A A C
00-1 1-9000	5830 T C T G - - C A A	5840 T A A A C A G T G A	5850 C A C A T G C T G G
99-1 1-9000	T C T G T C A C A A	A A G A C A G C G A	T A C T T G T T G G

Figure 53 cont'd

	5860	5870	5880
00-1 1-9000	A A A A T A A A C A	G A A A T C A A T G	C A C A A A T A T A
99-1 1-9000	A G A A T A C A C A	A G A A T C A A C G	T A C A A A T A T A
	5890	5900	5910
00-1 1-9000	A C A A C A T A C A	A A T T T T T A T G	T T T T A A A T C T
99-1 1-9000	A A A A T A T A C A	A G T T C T T A T G	C T C T G G G T T C
	5920	5930	5940
00-1 1-9000	G A A G A C A C A A	A A A C C A A C A A	T T G T G A T A A A
99-1 1-9000	A C A A A T T C A A	A A G G T A C A G A	T T G T G A G G A A
	5950	5960	5970
00-1 1-9000	C T G A C A G A T T	T A T G C A G A A A	C A A A C C A A A A
99-1 1-9000	C C A A C A G C C C	T A T G C G A C A A	A A A G T T A A A A
	5980	5990	6000
00-1 1-9000	C C A G C A G T T G	G A G T G T A T C A	C A T A G T A G A A
99-1 1-9000	A C C A T A G T A G	A A A A A C A T A G	A A A A G C A G A A
	6010	6020	6030
00-1 1-9000	T G C C A T T G T A	T A T A C A C A G T	T A A A T G G A A G
99-1 1-9000	T G T C A C T G T C	T A C A T A C A A C	C G A G T G G G G G
	6040	6050	6060
00-1 1-9000	T G C T A T C A T T	A C C C A A C C G A	T G A A A C C C A A
99-1 1-9000	T G C C T T C A T C	C C T A A A A T - -	- - - A A C A C G G
	6070	6080	6090
00-1 1-9000	T C C T A A A T G T	T A A C A C C A G A	T T A G G A T C C A
99-1 1-9000	C T T T C A A C A T	T A A A A T C A G A	A C A A C C T C C A
	6100	6110	6120
00-1 1-9000	T C C A A G T C T G	T T A G T T C A A C	A A T T T A G T T A
99-1 1-9000	C C C A G G T C T A	T C A A T A C A G T	G G T T T A G C C A
	6130	6140	6150
00-1 1-9000	T T T A A A A A T A	T T T T G A A A A C	A A G T A A G T T T
99-1 1-9000	T T T A A A A A - -	- - C C G A A T A T	T A T C T A G G C T
	6160	6170	6180
00-1 1-9000	C T A T G A T A C T	T C A T A A T A A T	A A G T A A T A A T
99-1 1-9000	G C A C G A C A C T	T T G C A A T A A T	A T G C A A T A G T
	6190	6200	6210
00-1 1-9000	T A A T T G C T T A	A T C A T C A T C A	C A A C A T T A T T
99-1 1-9000	C A A T A G T T A A	A C C A C T G C T G	C A A A C T C A T C
	6220	6230	6240
00-1 1-9000	C G A A A C C A T A	A C T A T T C A A T	T T A A A A A G T A
99-1 1-9000	C A T A A T - A T A	A T C A C T G A G T	- - - - - A A T A C

Figure 53 cont'd

00-1 1-9000	6250 A A A A C A A T A	6280 A C A T G G G A C A	6310 A G T A G T T A T G
99-1 1-9000	A A A A T C A A G A	A A A T G G G A C A	A G T G G C T A T G
00-1 1-9000	6280 G A G G T G A A A G	6290 T G G A G A A C A T	6300 T C G A A C A A T A
99-1 1-9000	G A A G T A A G A G	T G G A G A A C A T	T C G A G C G A T A
00-1 1-9000	6310 G A T A T G C T C A	6320 A A G C A A G A G T	6330 A A A A A A T C G T
99-1 1-9000	G A C A T G T T C A	A A G C A A A G A T	A A A A A A C C G T
00-1 1-9000	6340 G T G G C A C G C A	6350 G C A A A T G C T T	6360 T A A A A A T G C C
99-1 1-9000	A T A A G A A G C A	G C A G G T G C T A	T A G A A A T G C T
00-1 1-9000	6370 T C T T T G G T C C	6380 T C A T A G G A A T	6390 A A C T A C A T T G
99-1 1-9000	A C A C T G A T C C	T T A T T G G A C T	A A C A G C G T T A
00-1 1-9000	6400 A G T A T T G C C C	6410 T C A A T A T C T A	6420 T C T G A T C A T A
99-1 1-9000	A G C A T G G C A C	T T A A T A T T T T	C C T G A T C A T C
00-1 1-9000	6430 A A C T A T A A A A	6440 T G C A A A A A A A	6450 C A C A T C T G A A
99-1 1-9000	G A T C A T G C A A	C A T T A A G A A A	C A T G A T C A A A
00-1 1-9000	6460 T C A G A A C A T C	6470 A C A C C A G C T C	6480 A T C A C C C A T G
99-1 1-9000	A C A G A A A A C T	G T G C T A A C A T	G C C G T C G G C A
00-1 1-9000	6490 G A A T C C A G C A	6500 G A G A A A C T C C	6510 A A C G G T C C C C
99-1 1-9000	G A A C C A A G C A	A A A A G A C C C C	A A T G A C C T C C
00-1 1-9000	6520 A C A G A C A A C T	6530 C A G A C A C C A A	6540 C T C A A G C C C A
99-1 1-9000	A C A G C A G G C C	C A A A C A C C A A	A C C C A A T C C A
00-1 1-9000	6550 C A G C A T C C A A	6560 C T C A A C A G T C	6570 C A C A G A A G G C
99-1 1-9000	C A G C A A G C A A	C A C A G T G G A C	C A C A G A G A A C
00-1 1-9000	6580 T C C A C A C T C T	6590 A C T T T G C A G C	6600 C T C A G C A A G C
99-1 1-9000	T C A A C A T C C C	C A G T A G C A A C	C C C A G A G G G C
00-1 1-9000	6610 T C A C C A G A G A	6620 C A G A A C C A A C	6630 A T C A A C A C C A
99-1 1-9000	C A T C C A T A C A	C A G G G A C A A C	T C A A A C A T C A

Figure 53 cont'd

00-1 1-9000	6640 G A T A C A A C A A	6650 A C C G C C C G C C	6660 C T T C G T C G A C
99-1 1-9000	G A C A C A A C A G	C T C C C C A G C A	A A C C A C A G A C
00-1 1-9000	6670 A C A C A C A C A A	6680 C A C C A C C A A G	6690 C G C A A G C A G A
99-1 1-9000	A A A C A C A C A G	C A C C G C T A A A	A T C A A C C A A T
00-1 1-9000	6700 A C A A A G A C A A	6710 G T C C G G C A G T	6720 C - C A C A C A A A
99-1 1-9000	G A A C A G A T C A	C C C A G A C A A C	C A C A G A G A A A
00-1 1-9000	6730 A A - A C A A C C C	6740 A A G G A C A A G C	6750 T C T A G A A C A C
99-1 1-9000	A A G A C A A T C A	G A G C A A C A A C	C C A A A A A A G G
00-1 1-9000	6760 - - - - - A T	6770 T C T C C A C C A C	6780 G G G C - - A A C G
99-1 1-9000	G A A A A A G G A A	A A G A A A A C A C	A A A C C A A A C C
00-1 1-9000	6790 A C A A G G A C G G	6800 C - - - A C G C A	6810 G A - A C C A C C
99-1 1-9000	A C A A G C A C A G	C T G C A A C C C A	A A C A A C C A A C
00-1 1-9000	6820 A C T C T C C G C A	6830 C A A G C A G C A C	6840 A A G A A A G A G A
99-1 1-9000	A C C A C C A A C C	A A A T C A G A A A	T G C A A G T G A G
00-1 1-9000	6850 C C G T C C A C A G	6860 C A T C A G T C C A	6870 A C C T G A C A T C
99-1 1-9000	A C A A T C A C A A	C A T C C G A C A G	A C C C A G A A C T
00-1 1-9000	6880 A G C G C A A C A A	6890 C C C A C A A A A A	6900 C G A A G A A G C A
99-1 1-9000	G A C A C C A C A A	C C C A A A G C A G	C G A A C A G A C A
00-1 1-9000	6910 A G T C C A G C G A	6920 G C C C A C A A A C	6930 A T C T G C A A G C
99-1 1-9000	A - C C C G G G C A	A C A G A C C C A A	G C T C C C C A C C
00-1 1-9000	6940 A C A A C A A G A A	6950 T A C A A A G G A A	6960 A A G C G T G G A G
99-1 1-9000	A C A C C A T G C A	T A G A G A G G T G	C A A A A C T C A A
00-1 1-9000	6970 G C C A A C A C A T	6980 C A - A C A A - C A	6990 T A C A A C C A A A
99-1 1-9000	A T G A G C A C A A	C A C A C A A A C A	T C C C A T C C A A
00-1 1-9000	7000 C T A G T T A A C A	7010 A A A A A T - A C A	7020 A A A T A A C T C T
99-1 1-9000	G T A G T T A A C A	A A A A A C C A C A	A A A T A A C C T T

Figure 53 cont'd

00-1 1-9000	7030 A A G A T A A A C C	7040 A T G C A G A C A C	7050 C A A C A A T G G A
99-1 1-9000	G A - - - A A A C C	A - - - - - A -	- - - - - A - -
00-1 1-9000	7060 G A A G C C A A A A	7070 G A C A A T T C A C	7080 A A T C T C C C C A
99-1 1-9000	- A A A C C A A A A	C A T A A A C C C A	G A - - - - C C C A
00-1 1-9000	7090 A A A A G G C A A C	7100 A A C A C C A T A T	7110 T A - - - G C T C T
99-1 1-9000	G A A A A A C A T A	G A C A C C A T A T	G G A A G G T T C T
00-1 1-9000	7120 G C C C A A A T C T	7130 C C C T G G A A A A	7140 A A C A C T C G C C
99-1 1-9000	A G C A T A T G C A	C C A A T G A G A T	G G C A T C T G T T
00-1 1-9000	7150 C A T A T A C C A A	7160 A A A T A C C A C A	7170 A C C A C C C C A A
99-1 1-9000	C A T G T A T C A A	T A G C A C C A C C	A T C A T T C A A G
00-1 1-9000	7180 G A A A A A A A C T	7190 G G G C A A A A C A	7200 A C A C C C A A G A
99-1 1-9000	G A A T A A G A A G	A G G C G A A A - -	- - A T T T A A G G
00-1 1-9000	7210 G A C A A A T A A C	7220 A A T G G A T C C T	7230 C T C A A T G A A T
99-1 1-9000	G A T A A A T G A C	A A T G G A T C C C	T T T T G T G A A T
00-1 1-9000	7240 C C A C T G T T A A	7250 T G T C T A T C T T	7260 C C T G A C T C A T
99-1 1-9000	C T A C T G T T A A	T G T T T A T C T C	C C T G A T T C A T
00-1 1-9000	7270 A T C T T A A A G G	7280 A G T G A T T T C C	7290 T T T A G T G A G A
99-1 1-9000	A T C T C A A A G G	A G T A A T A T C T	T T T A G T G A A A
00-1 1-9000	7300 C T A A T G C A A T	7310 T G G T T C A T G T	7320 C T C T T A A A A A
99-1 1-9000	C C A A T G C A A T	T G G A T C A T G T	C T T T T G A A A A
00-1 1-9000	7330 G A C C T T A C C T	7340 A A A A A A T G A C	7350 A A C A C T G C A A
99-1 1-9000	G A C C C T A T C T	A A A A A A T G A C	A A C A C T G C C A
00-1 1-9000	7360 A A G T T G C C A T	7370 A G A G A A T C C T	7380 G T T A T C G A G C
99-1 1-9000	A A G T T G C T G T	A G A A A A C C C T	G T T G T T G A A C
00-1 1-9000	7390 A T G T T A G A C T	7400 C A A A A A T G C A	7410 G T C A A T T C T A
99-1 1-9000	A T G T G A G G C T	T A G A A A T G C A	G T C A T G A C C A

Figure 53 cont'd

	7420	7430	7440
00-1 1-9000	A G A T G A A A A T	A T C A G A T T A C	A A G A T A G T A G
99-1 1-9000	A A A T G A A G A T	A T C A G A T T A T	A A A G T G G T T G
	7450	7460	7470
00-1 1-9000	A G C C A G T A A A	C A T G C A A C A T	G A A A T T A T G A
99-1 1-9000	A A C C A G T T A A	T A T G C A G C A T	G A A A T A A T G A
	7480	7490	7500
00-1 1-9000	A G A A T G T A C A	C A G T T G T G A G	C T C A C A T T A T
99-1 1-9000	A A A A T A T A C A	T A G T T G T G A G	C T T A C A T T A T
	7510	7520	7530
00-1 1-9000	T A A A A C A G T T	T T T A A C A A G G	A G T A A A A A T A
99-1 1-9000	T A A A A C A A T T	C T T A A C G A G A	A G C A A A A A C A
	7540	7550	7560
00-1 1-9000	T T A G C A C T C T	C A A A T T A A A T	A T G A T A T G T G
99-1 1-9000	T T A G C T C T C T	A A A A T T A A A T	A T G A T A T G T G
	7570	7580	7590
00-1 1-9000	A T T G G C T G C A	G T T A A A G T C T	A C A T C A G A T G
99-1 1-9000	A T T G G T T A C A	G T T A A A A T C C	A C T T C A G A T A
	7600	7610	7620
00-1 1-9000	A T A C C T C A A T	C C T A A G T T T T	A T A G A T G T A G
99-1 1-9000	A C A C A T C A A T	T C T C A A T T T T	A T A G A T G T G G
	7630	7640	7650
00-1 1-9000	A A T T T A T A C C	T A G C T G G G T A	A G C A A T T G G T
99-1 1-9000	A G T T C A T A C C	C G T T T G G G T A	A G C A A T T G G T
	7660	7670	7680
00-1 1-9000	T T A G T A A T T G	G T A C A A T C T C	A A C A A G T T G A
99-1 1-9000	T C A G T A A C T G	G T A T A A T C T C	A A T A A A T T A A
	7690	7700	7710
00-1 1-9000	T T C T G G A A T T	C A G G A A A G A A	G A A G T A A T A A
99-1 1-9000	T C T T A G A G T T	T A G A A G A G A A	G A A G T A A T A A
	7720	7730	7740
00-1 1-9000	G A A C T G G T T C	A A T C T T G T G T	A G G T C A T T G G
99-1 1-9000	G A A C T G G T T C	A A T T T T A T G T	A G A T C A C T A G
	7750	7760	7770
00-1 1-9000	G T A A A T T A G T	T T T T G T T G T A	T C A T C A T A T G
99-1 1-9000	G C A A G T T A G T	T T T T A T T G T A	T C A T C T T A T G
	7780	7790	7800
00-1 1-9000	G A T G T A T A G T	C A A G A G C A A C	A A A A G C A A A A
99-1 1-9000	G A T G T G T A G T	A A A A A G C A A C	A A A A G T A A A A

Figure 53 cont'd

00-1 1-9000	7810 G A G T G A G C T T	7820 C T T C A C A T A C	7830 A A T C A A C T G T
99-1 1-9000	G A G T G A G C T T	T T T C A C C T A T	A A C C A A C T G T
00-1 1-9000	7840 T A A C A T G G A A	7850 A G A T G T G A T G	7860 T T A A G T A G A T
99-1 1-9000	T A A C A T G G A A	A G A T G T G A T G	T T A A G T A G A T
00-1 1-9000	7870 T C A A T G C A A A	7880 T T T T T G T A T A	7890 T G G G T A A G C A
99-1 1-9000	T C A A T G C A A A	C T T T T G T A T A	T G G G T A A G T A
00-1 1-9000	7900 A C A G T C T G A A	7910 T G A A A A T C A A	7920 G A A G G G C T A G
99-1 1-9000	A C A A C C T G A A	C A A A A A T C A A	G A A G G A C T A G
00-1 1-9000	7930 G G T T G A G A A G	7940 T A A T C T G C A A	7950 G G C A T A T T A A
99-1 1-9000	G A C T T A G A A G	C A A T C T G C A A	G G T A T G T T A A
00-1 1-9000	7960 C T A A T A A G C T	7970 A T A T G A A A C T	7980 G T A G A T T A T A
99-1 1-9000	C C A A T A A A T T	A T A T G A A A C T	G T T G A T T A C A
00-1 1-9000	7990 T G C T T A G T T T	8000 A T G T T G C A A T	8010 G A A G G T T T C T
99-1 1-9000	T G C T A A G C C T	A T G C T G C A A T	G A A G G A T T C T
00-1 1-9000	8020 C A C T T G T G A A	8030 A G A G T T C G A A	8040 G G C T T T A T T A
99-1 1-9000	C T C T G G T G A A	A G A G T T T G A A	G G A T T T A T T A
00-1 1-9000	8050 T G A G T G A A A T	8060 T C T T A G G A T T	8070 A C T G A A C A T G
99-1 1-9000	T G A G T G A A A T	T C T A A A A A T T	A C T G A G C A T G
00-1 1-9000	8080 C T C A A T T C A G	8090 T A C T A G A T T T	8100 A G A A A T A C T T
99-1 1-9000	C T C A G T T C A G	T A C T A G G T T T	A G G A A T A C T T
00-1 1-9000	8110 T A T T A A A T G G	8120 A T T A A C T G A T	8130 C A A T T A A C A A
99-1 1-9000	T A T T G A A T G G	G T T A A C T G A A	C A A T T A T C A G
00-1 1-9000	8140 A A T T A A A A A A	8150 T A A A A A C A G A	8160 C T C A G A G T T C
99-1 1-9000	T G T T G A A A G C	T A A G A A C A G A	T C T A G A G T T C
00-1 1-9000	8170 A T G G T A C C G T	8180 G T T A G A A A A T	8190 A A T G A T T A T C
99-1 1-9000	T T G G A A C T A T	A T T A G A A A A C	A A C A A T T A C C

Figure 53 cont'd

WO 03/072719

PCT/US03/05271

	8200	.111/132.	8210	8220
00-1 1-9000	CAATGTACGA	AGTTGTACTT	AAGTTATTAG	
99-1 1-9000	CTATGTACGA	AGTAGTACTT	AAATTATTAG	
	8230	8240	8250	
00-1 1-9000	GAGATACTTT	GAGATGTATT	AAATTATTAA	
99-1 1-9000	GGGACACCTT	GAAAAGCATA	AAGTTATTAA	
	8260	8270	8280	
00-1 1-9000	TCAATAAAAA	CTTAGAGAAAT	GCTGCTGAAT	
99-1 1-9000	TTAACAAGAA	TTTAGAAAAAT	GCTGCAGAAAT	
	8290	8300	8310	
00-1 1-9000	TATACTATAT	ATTTAGAAATA	TTGGGTCAACC	
99-1 1-9000	TATAATTATAT	ATTCAGAAAT	TTTGGACACC	
	8320	8330	8340	
00-1 1-9000	CAATGGTAGA	TGAAAGAGAT	GCAATGGATG	
99-1 1-9000	CTATGGTAGA	TGAGAGGGA	GCAATGGATG	
	8350	8360	8370	
00-1 1-9000	CTGTCAAATT	AAACAATGAA	ATCACAAAAA	
99-1 1-9000	CTGTTAAATT	AAACAATGAG	ATTACAAAAA	
	8380	8390	8400	
00-1 1-9000	TCCTTAGGTG	GGAGAGCTTG	ACAGAACTAA	
99-1 1-9000	TTCTTAAATT	AGAGAGTTTA	ACAGAACTAA	
	8410	8420	8430	
00-1 1-9000	GAGGGGCATT	CATATTAAAGG	ATTATCAAAG	
99-1 1-9000	GAGGAGCATT	TATACTAAGA	ATTATAAAAG	
	8440	8450	8460	
00-1 1-9000	GATTTGTAGA	CAACAACAAA	AGATGGCCCA	
99-1 1-9000	GGTTTGTAGA	CAATAATAAA	AGATGGCCTA	
	8470	8480	8490	
00-1 1-9000	AAATTAAAAA	CTTAAAAAGTG	CTTAGTAAGA	
99-1 1-9000	AAATTAAAGAA	TTTAAAAAGTG	CTCAGCAAAA	
	8500	8510	8520	
00-1 1-9000	GATGGACTAT	GTA CTTCAAA	GCAAAAAGTT	
99-1 1-9000	GATGGGCTAT	GTA TTTCAA	GCTAAAAGTT	
	8530	8540	8550	
00-1 1-9000	ACCCCAAGTCA	ACTTGAATTAA	AGCGAACAAG	
99-1 1-9000	ACCCTAGCCA	ACTTGAGCTA	AGTGTAACAAG	
	8560	8570	8580	
00-1 1-9000	ATTTT TTAGA	GCTTGCTGCA	ATACAGTTTG	
99-1 1-9000	ATTTT TTAGA	ACTTGCTGCA	GTACAATTTG	

Figure 53 cont'd

WO 03/072719

PCT/US03/05271

	8590	112/132	8600	8610
00-1 1-9000	A A C A A G A G T T	T T C T G T C C C T	G A A A A A A C C A	
99-1 1-9000	A G C A G G A A T T	C T C T G T A C C T	G A A A A A A C C A	
	8620	8630	8640	
00-1 1-9000	A C C T T G A G A T	G G T A T T A A A T	G A T A A A G C T A	
99-1 1-9000	A C C T T G A G A T	G G T A T T A A A T	G A T A A A G C A A	
	8650	8660	8670	
00-1 1-9000	T A T C A C C T C C	T A A A A G A T T A	A T A T G G T C T G	
99-1 1-9000	T A T C A C C T C C	A A A A A A G C T A	A T A T G G T C T G	
	8680	8690	8700	
00-1 1-9000	T G T A T C C A A A	A A A T T A C T T A	C C T G A G A A A A	
99-1 1-9000	T A T A T C C A A A	A A A C T A C C T G	C C T G A A A C T A	
	8710	8720	8730	
00-1 1-9000	T A A A A A A T C G	A T A T C T A G A A	G A G A C T T T C A	
99-1 1-9000	T A A A A A A T C A	A T A T T T A G A A	G A G G C T T T C A	
	8740	8750	8760	
00-1 1-9000	A T G C A A G T G A	T A G T C T C A A A	A C A A G A A G A G	
99-1 1-9000	A T G C A A G T G A	C A G C C A A A G A	A C A A G G A G A G	
	8770	8780	8790	
00-1 1-9000	T A C T A G A G T A	C T A T T T G A A A	G A T A A T A A A T	
99-1 1-9000	T C T T A G A A T T	T T A C T T A A A A	G A T T G T A A A T	
	8800	8810	8820	
00-1 1-9000	T C G A C C A A A A	A G A A C T T A A A	A G T T A T G T T G	
99-1 1-9000	T T G A T C A A A A	A G A A C T T A A A	C G T T A T G T A A	
	8830	8840	8850	
00-1 1-9000	T T A A A C A A G A	A T A T T T A A A T	G A T A A G G A T C	
99-1 1-9000	T T A A A C A A G A	G T A T C T G A A T	G A C A A A G A C C	
	8860	8870	8880	
00-1 1-9000	A T A T T G T C T C	G C T A A C T G G A	A A A G A A A G A G	
99-1 1-9000	A C A T T G T C T C	G T T A A C T G G G	A A G G A A A G A G	
	8890	8900	8910	
00-1 1-9000	A A T T A A G T G T	A G G T A G A A T G	T T T G C T A T G C	
99-1 1-9000	A A T T A A G T G T	A G G T A G G A T G	T T T G C A A T G C	
	8920	8930	8940	
00-1 1-9000	A A C C A G G A A A	A C A G C G A C A A	A T A C A A A T A T	
99-1 1-9000	A A C C A G G A A A	A C A A A G A C A G	A T A C A G A T A T	
	8950	8960	8970	
00-1 1-9000	T G G C T G A A A A	A T T G T T A G C T	G A T A A T A T T G	
99-1 1-9000	T A G C T G A G A A	A C T T C T A G C T	G A T A A T A T T G	

Figure 53 cont'd

WO 03/072719

PCT/US03/05271

	8980	113/132	8990	9000
00-1 1-9000	T A C C T T T T T T	C C C A G A A A C C	T T A A C A A A G T	
99-1 1-9000	T A C C T T T T T T	C C C A G A A A C T	T T A A C A A A G T	
	9010	9020	9030	
00-1 1-9000	A T G G T G A T C T	A G A T C T T C A G	A G A A T A A T G G	
99-1 1-9000	A T G G T G A C T T	A G A T C T C C A A	A G A A T T A T G G	
	9040	9050	9060	
00-1 1-9000	A A A T C A A A T C	G G A A C		
99-1 1-9000	A A A T A A A A T C	A G A A C T T T C T	T C C A T T A A A A	
	9070	9080	9090	
00-1 1-9000				
99-1 1-9000	C T A G A A A G A A	T G A T A G C T A C	A A C A A T T	

Figure 53 cont'd

WO 03/072719

PCT/US03/05271

114/132

00-1 7001-13350	1 10 A C A A T G G A G A	20 A G C C A A A A G A	30 C A A T T C A C A A
99-1 7001-13294	- - - - -	- - - - -	- - - - -
00-1 7001-13350	40 T C T C C C C A A A	50 A A G G C A A C A A	60 C A C C A T A T T A
99-1 7001-13294	- - - - -	- A A A C A T A G A	C A C C A T A T G G
00-1 7001-13350	70 - - - G C T C T G C	80 C C A A A T C T C C	90 C T G G A A A A A A
99-1 7001-13294	A A G G T T C T A G	C A T A T G C A C C	A A T G A G A T G G
00-1 7001-13350	100 C A C T C G C C C A	110 T A T A C C A A A A	120 A T A C C A C A A C
99-1 7001-13294	C A T C T G T T C A	T G T A T C A A T A	G C A C C A C C A T
00-1 7001-13350	130 C A C C C C A A G A	140 A A A A A A C T G G	150 G C A A A A C A A C
99-1 7001-13294	C A T T C A A G G A	A T A A G A A G A G	G C G A A A - - -
00-1 7001-13350	160 A C C C A A G A G A	170 C A A A T A A C A A	180 T G G A T C C T C T
99-1 7001-13294	A T T T A A G G G A	T A A A T G A C A A	T G G A T C C C T T
00-1 7001-13350	190 C A A T G A A T C C	200 A C T G T T A A T G	210 T C T A T C T T C C
99-1 7001-13294	T T G T G A A T C T	A C T G T T A A T G	T T T A T C T C C C
00-1 7001-13350	220 T G A C T C A T A T	230 C T T A A A G G A G	240 T G A T T T C C T T
99-1 7001-13294	T G A T T C A T A T	C T C A A A G G A G	T A A T A T C T T T
00-1 7001-13350	250 T A G T G A G A C T	260 A A T G C A A T T G	270 G T T C A T G T C T
99-1 7001-13294	T A G T G A A A C C	A A T G C A A T T G	G A T C A T G T C T
00-1 7001-13350	280 C T T A A A A A G A	290 C C T T A C C T A A	300 A A A A T G A C A A
99-1 7001-13294	T T T G A A A A G A	C C C T A T C T A A	A A A A T G A C A A
00-1 7001-13350	310 C A C T G C A A A A	320 G T T G C C A T A G	330 A G A A T C C T G T
99-1 7001-13294	C A C T G C C A A A	G T T G C T G T A G	A A A A C C C T G T
00-1 7001-13350	340 T A T C G A G C A T	350 G T T A G A C T C A	360 A A A A T G C A G T
99-1 7001-13294	T G T T G A A C A T	G T G A G G C T T A	G A A A T G C A G T
00-1 7001-13350	370 C A A T T C T A A G	380 A T G A A A A T A T	390 C A G A T T A C A A
99-1 7001-13294	C A T G A C C A A A	A T G A A G A T A T	C A G A T T A T A A

Figure 53 cont'd

115/132

00-1 7001-13350	400 G A T A G T A G A G	410 C C A G T A A A C A	420 T G C A A C A T G A
99-1 7001-13294	A G T G G T T G A A	C C A G T T A A T A	T G C A G C A T G A
00-1 7001-13350	430 A A T T A T G A A G	440 A A T G T A C A C A	450 G T T G T G A G C T
99-1 7001-13294	A A T A A T G A A A	A A T A T A C A T A	G T T G T G A G C T
00-1 7001-13350	460 C A C A T T A T T A	470 A A A C A G T T T T	480 T A A C A A G G A G
99-1 7001-13294	T A C A T T A T T A	A A A C A A T T C T	T A A C G A G A A G
00-1 7001-13350	490 T A A A A A T A T T	500 A G C A C T C T C A	510 A A T T A A A T A T
99-1 7001-13294	C A A A A A C A T T	A G C T C T C T A A	A A T T A A A T A T
00-1 7001-13350	520 G A T A T G T G A T	530 T G G C T G C A G T	540 T A A A G T C T A C
99-1 7001-13294	G A T A T G T G A T	T G G T T A C A G T	T A A A A T C C A C
00-1 7001-13350	550 A T C A G A T G A T	560 A C C T C A A T C C	570 T A A G T T T T A T
99-1 7001-13294	T T C A G A T A A C	A C A T C A A T T C	T C A A T T T T A T
00-1 7001-13350	580 A G A T G T A G A A	590 T T T A T A C C T A	600 G C T G G G T A A G
99-1 7001-13294	A G A T G T G G A G	T T C A T A C C C G	T T T G G G T A A G
00-1 7001-13350	610 C A A T T G G T T T	620 A G T A A T T G G T	630 A C A A T C T C A A
99-1 7001-13294	C A A T T G G T T C	A G T A A C T G G T	A T A A T C T C A A
00-1 7001-13350	640 C A A G T T G A T T	650 C T G G A A T T C A	660 G G A A A G A A G A
99-1 7001-13294	T A A A T T A A T C	T T A G A G T T T A	G A A G A G A A G A
00-1 7001-13350	670 A G T A A T A A G A	680 A C T G G T T C A A	690 T C T T G T G T A G
99-1 7001-13294	A G T A A T A A G A	A C T G G T T C A A	T T T T A T G T A G
00-1 7001-13350	700 G T C A T T G G G T	710 A A A T T A G T T T	720 T T G T T G T A T C
99-1 7001-13294	A T C A C T A G G C	A A G T T A G T T T	T T A T T G T A T C
00-1 7001-13350	730 A T C A T A T G G A	740 T G T A T A G T C A	750 A G A G C A A C A A
99-1 7001-13294	A T C T T A T G G A	T G T G T A G T A A	A A A G C A A C A A
00-1 7001-13350	760 A A G C A A A A G A	770 G T G A G C T T C T	780 T C A C A T A C A A
99-1 7001-13294	A A G T A A A A G A	G T G A G C T T T T	T C A C C T A T A A

Figure 53 cont'd

116/132

00-1 7001-13350	790 T C A A C T G T T A	800 A C A T G G A A A G	810 A T G T G A T G T T
99-1 7001-13294	C C A A C T G T T A	A C A T G G A A A G	A T G T G A T G T T
00-1 7001-13350	820 A A G T A G A T T C	830 A A T G C A A A T T	840 T T T G T A T A T G
99-1 7001-13294	A A G T A G A T T C	A A T G C A A A C T	T T T G T A T A T G
00-1 7001-13350	850 G G T A A G C A A C	860 A G T C T G A A T G	870 A A A A T C A A G A
99-1 7001-13294	G G T A A G T A A C	A A C C T G A A C A	A A A A T C A A G A
00-1 7001-13350	880 A G G G C T A G G G	890 T T G A G A A G T A	900 A T C T G C A A G G
99-1 7001-13294	A G G A C T A G G A	C T T A G A A G C A	A T C T G C A A G G
00-1 7001-13350	910 C A T A T T A A C T	920 A A T A A G C T A T	930 A T G A A A C T G T
99-1 7001-13294	T A T G T T A A C C	A A T A A A T T A T	A T G A A A C T G T
00-1 7001-13350	940 A G A T T A T A T G	950 C T T A G T T T A T	960 G T T G C A A T G A
99-1 7001-13294	T G A T T A C A T G	C T A A G C C T A T	G C T G C A A T G A
00-1 7001-13350	970 A G G T T T C T C A	980 C T T G T G A A A G	990 A G T T C G A A G G
99-1 7001-13294	A G G A T T C T C T	C T G G T G A A A G	A G T T T G A A G G
00-1 7001-13350	1000 C T T T A T T A T G	1010 A G T G A A A T T C	1020 T T A G G A T T A C
99-1 7001-13294	A T T T A T T A T G	A G T G A A A T T C	T A A A A A T T A C
00-1 7001-13350	1030 T G A A C A T G C T	1040 C A A T T C A G T A	1050 C T A G A T T T A G
99-1 7001-13294	T G A G C A T G C T	C A G T T C A G T A	C T A G G T T T A G
00-1 7001-13350	1060 A A A T A C T T T A	1070 T T A A A T G G A T	1080 T A A C T G A T C A
99-1 7001-13294	G A A T A C T T T A	T T G A A T G G G T	T A A C T G A A C A
00-1 7001-13350	1090 A T T A A C A A A A	1100 T T A A A A A A T A	1110 A A A A C A G A C T
99-1 7001-13294	A T T A T C A G T G	T T G A A A G C T A	A G A A C A G A T C
00-1 7001-13350	1120 C A G A G T T C A T	1130 G G T A C C G T G T	1140 T A G A A A A T A A
99-1 7001-13294	T A G A G T T C T T	G G A A C T A T A T	T A G A A A A C A A
00-1 7001-13350	1150 T G A T T A T C C A	1160 A T G T A C G A A G	1170 T T G T A C T T A A
99-1 7001-13294	C A A T T A C C C T	A T G T A C G A A G	T A G T A C T T A A

Figure 53 cont'd

117/132

	1180	1190	1200
00-1 7001-13350	G T T A T T A G G A	G A T A C T T T G A	G A T G T A T T A A
99-1 7001-13294	A T T A T T A G G G	G A C A C C T T G A	A A A G C A T A A A
	1210	1220	1230
00-1 7001-13350	A T T A T T A A T C	A A T A A A A A C T	T A G A G A A T G C
99-1 7001-13294	G T T A T T A A T T	A A C A A G A A T T	T A G A A A A T G C
	1240	1250	1260
00-1 7001-13350	T G C T G A A T T A	T A C T A T A T A T	T T A G A A T A T T
99-1 7001-13294	T G C A G A A T T A	T A T T A T A T A T	T C A G A A T T T T
	1270	1280	1290
00-1 7001-13350	C G G T C A C C C A	A T G G T A G A T G	A A A G A G A T G C
99-1 7001-13294	T G G A C A C C C T	A T G G T A G A T G	A G A G G G A A G C
	1300	1310	1320
00-1 7001-13350	A A T G G A T G C T	G T C A A A T T A A	A C A A T G A A A T
99-1 7001-13294	A A T G G A T G C T	G T T A A A T T A A	A C A A T G A G A T
	1330	1340	1350
00-1 7001-13350	C A C A A A A A T C	C T T A G G T G G G	A G A G C T T G A C
99-1 7001-13294	T A C A A A A A T T	C T T A A A T T A G	A G A G T T T A A C
	1360	1370	1380
00-1 7001-13350	A G A A C T A A G A	G G G G C A T T C A	T A T T A A G G A T
99-1 7001-13294	A G A A C T A A G A	G G A G C A T T T A	T A C T A A G A A T
	1390	1400	1410
00-1 7001-13350	T A T C A A A G G A	T T T G T A G A C A	A C A A C A A A A G
99-1 7001-13294	T A T A A A A G G G	T T T G T A G A C A	A T A A T A A A A G
	1420	1430	1440
00-1 7001-13350	A T G G C C C A A A	A T T A A A A A C T	T A A A A G T G C T
99-1 7001-13294	A T G G C C T A A A	A T T A A G A A T T	T A A A A G T G C T
	1450	1460	1470
00-1 7001-13350	T A G T A A G A G A	T G G A C T A T G T	A C T T C A A A G C
99-1 7001-13294	C A G C A A A A G A	T G G G C T A T G T	A T T T C A A A G C
	1480	1490	1500
00-1 7001-13350	A A A A A G T T A C	C C C A G T C A A C	T T G A A T T A A G
99-1 7001-13294	T A A A A G T T A C	C C T A G C C A A C	T T G A G C T A A G
	1510	1520	1530
00-1 7001-13350	C G A A C A A G A T	T T T T T A G A G C	T T G C T G C A A T
99-1 7001-13294	T G T A C A A G A T	T T T T T A G A A C	T T G C T G C A G T
	1540	1550	1560
00-1 7001-13350	A C A G T T T G A A	C A A G A G T T T T	C T G T C C C T G A
99-1 7001-13294	A C A A T T T G A G	C A G G A A T T C T	C T G T A C C T G A

Figure 53 cont'd

118/132

	1570	1580	1590
00-1 7001-13350	A A A A A C C A A C	C T T G A G A T G G	T A T T A A A T G A
99-1 7001-13294	A A A A A C C A A C	C T T G A G A T G G	T A T T A A A T G A
	1600	1610	1620
00-1 7001-13350	T A A A G C T A T A	T C A C C T C C T A	A A A G A T T A A T
99-1 7001-13294	T A A A G C A A T A	T C A C C T C C A A	A A A A G C T A A T
	1630	1640	1650
00-1 7001-13350	A T G G T C T G T G	T A T C C A A A A A	A T T A C T T A C C
99-1 7001-13294	A T G G T C T G T A	T A T C C A A A A A	A C T A C C T G C C
	1660	1670	1680
00-1 7001-13350	T G A G A A A A T A	A A A A A T C G A T	A T C T A G A A G A
99-1 7001-13294	T G A A A C T A T A	A A A A A T C A A T	A T T T A G A A G A
	1690	1700	1710
00-1 7001-13350	G A C T T T C A A T	G C A A G T G A T A	G T C T C A A A A C
99-1 7001-13294	G G C T T T C A A T	G C A A G T G A C A	G C C A A A G A A C
	1720	1730	1740
00-1 7001-13350	A A G A A G A G T A	C T A G A G T A C T	A T T T G A A A G A
99-1 7001-13294	A A G G A G A G T C	T T A G A A T T T T	A C T T A A A A G A
	1750	1760	1770
00-1 7001-13350	T A A T A A A T T C	G A C C A A A A A G	A A C T T A A A A G
99-1 7001-13294	T T G T A A A T T T	G A T C A A A A A G	A A C T T A A A C G
	1780	1790	1800
00-1 7001-13350	T T A T G T T G T T	A A A C A A G A A T	A T T T A A A T G A
99-1 7001-13294	T T A T G T A A T T	A A A C A A G A G T	A T C T G A A T G A
	1810	1820	1830
00-1 7001-13350	T A A G G A T C A T	A T T G T C T C G C	T A A C T G G A A A
99-1 7001-13294	C A A A G A C C A C	A T T G T C T C G T	T A A C T G G G A A
	1840	1850	1860
00-1 7001-13350	A G A A A G A G A A	T T A A G T G T A G	G T A G A A T G T T
99-1 7001-13294	G G A A A G A G A A	T T A A G T G T A G	G T A G G A T G T T
	1870	1880	1890
00-1 7001-13350	T G C T A T G C A A	C C A G G A A A A C	A G C G A C A A A T
99-1 7001-13294	T G C A A T G C A A	C C A G G A A A A C	A A A G A C A G A T
	1900	1910	1920
00-1 7001-13350	A C A A A T A T T G	G C T G A A A A A T	T G T T A G C T G A
99-1 7001-13294	A C A G A T A T T A	G C T G A G A A A C	T T C T A G C T G A
	1930	1940	1950
00-1 7001-13350	T A A T A T T G T A	C C T T T T T T C C	C A G A A A C C T T
99-1 7001-13294	T A A T A T T G T A	C C T T T T T T C C	C A G A A A C T T T

Figure 53 cont'd

119/132

	1960	1970	1980
00-1 7001-13350	A A C A A A G T A T	G G T G A T C T A G	A T C T T C A G A G
99-1 7001-13294	A A C A A A G T A T	G G T G A C T T A G	A T C T C C A A A G
	1990	2000	2010
00-1 7001-13350	A A T A A T G G A A	A T C A A A T C G G	A A C T T T C T T C
99-1 7001-13294	A A T T A T G G A A	A T A A A A T C A G	A A C T T T C T T C
	2020	2030	2040
00-1 7001-13350	T A T T A A A A C T	A G A A G A A A T G	A T A G T T A T A A
99-1 7001-13294	C A T T A A A A C T	A G A A A G A A T G	A T A G C T A C A A
	2050	2060	2070
00-1 7001-13350	T A A T T A C A T T	G C A A G A G C A T	C C A T A G T A A C
99-1 7001-13294	C A A T T A T A T T	G C A A G G G C C T	C T A T A G T A A C
	2080	2090	2100
00-1 7001-13350	A G A T T T A A G T	A A G T T C A A C C	A A G C C T T T A G
99-1 7001-13294	A G A C T T A A G T	A A G T T C A A T C	A G G C C T T T A G
	2110	2120	2130
00-1 7001-13350	G T A T G A A A C T	A C A G C G A T C T	G T G C G G A T G T
99-1 7001-13294	A T A T G A A A C C	A C A G C T A T A T	G T G C A G A T G T
	2140	2150	2160
00-1 7001-13350	A G C A G A T G A A	C T A C A T G G A A	C A C A A A G C C T
99-1 7001-13294	A G C T G A T G A G	T T A C A T G G G A	C A C A A A G C T T
	2170	2180	2190
00-1 7001-13350	A T T C T G T T G G	T T A C A T C T T A	T C G T C C C T A T
99-1 7001-13294	A T T C T G T T G G	T T A C A T C T T A	T T G T T C C C A T
	2200	2210	2220
00-1 7001-13350	G A C A A C A A T G	A T A T G T G C C T	A T A G A C A T G C
99-1 7001-13294	G A C T A C A A T G	A T A T G T G C A T	A C A G A C A T G C
	2230	2240	2250
00-1 7001-13350	A C C A C C A G A A	A C A A A A G G T G	A A T A T G A T A T
99-1 7001-13294	A C C A C C A G A A	A C A A A A G G G G	A A T A T G A T A T
	2260	2270	2280
00-1 7001-13350	A G A T A A G A T A	G A A G A G C A A A	G T G G T T T A T A
99-1 7001-13294	A G A C A A A A T A	C A A G A G C A A A	G C G G A T T A T A
	2290	2300	2310
00-1 7001-13350	T A G A T A T C A T	A T G G G T G G T A	T T G A A G G A T G
99-1 7001-13294	C A G A T A T C A T	A T G G G A G G G A	T T G A A G G G T G
	2320	2330	2340
00-1 7001-13350	G T G T C A A A A A	C T C T G G A C A A	T G G A A G C T A T
99-1 7001-13294	G T G C C A G A A G	T T A T G G A C A A	T G G A A G C A A T

Figure 53 cont'd

	2350	2360	2370
10-1 7001-13350	A T C T C T A T T A	G A T G T T G T A T	C T G T A A A A A C
99-1 7001-13294	A T C C T T G T T A	G A T G T A G T A T	C T G T G A A G A C
	2380	2390	2400
10-1 7001-13350	A C G A T G T C A A	A T G A C A T C T T	T A T T A A A C G G
99-1 7001-13294	T C G C T G T C A G	A T G A C C T C T C	T A T T A A A C G G
	2410	2420	2430
10-1 7001-13350	T G A C A A C C A A	T C A A T A G A T G	T A A G T A A A C C
99-1 7001-13294	A G A C A A T C A G	T C A A T A G A T G	T T A G T A A A C C
	2440	2450	2460
10-1 7001-13350	A G T T A A G T T A	T C T G A G G G T T	T A G A T G A A G T
99-1 7001-13294	A G T A A A A T T G	T C T G A A G G T A	T A G A T G A A G T
	2470	2480	2490
00-1 7001-13350	G A A A G C A G A T	T A T A G C T T G G	C T G T A A A A A T
99-1 7001-13294	A A A A G C A G A C	T A T A G C T T A G	C A A T T A G A A T
	2500	2510	2520
00-1 7001-13350	G T T A A A A G A A	A T A A G A G A T G	C A T A C A G A A A
99-1 7001-13294	G C T T A A A G A A	A T A A G A G A T G	C T T A T A A A A A
	2530	2540	2550
00-1 7001-13350	T A T A G G C C A T	A A A C T T A A A G	A A G G G G A A A C
99-1 7001-13294	C A T T G G T C A T	A A A C T C A A A G	A A G G T G A A A C
	2560	2570	2580
00-1 7001-13350	A T A T A T A T C A	A G A G A T C T T C	A G T T T A T A A G
99-1 7001-13294	A T A T A T A T C A	A G G G A T C T C C	A A T T T A T A A G
	2590	2600	2610
00-1 7001-13350	T A A G G T G A T T	C A A T C T G A A G	G A G T A A T G C A
99-1 7001-13294	T A A G G T G A T T	C A A T C T G A A G	G A G T C A T G C A
	2620	2630	2640
00-1 7001-13350	T C C T A C C C C T	A T A A A A A A G A	T C T T A A G A G T
99-1 7001-13294	T C C T A C C C C T	A T A A A A A A G A	T A T T A A G A G T
	2650	2660	2670
00-1 7001-13350	G G G A C C A T G G	A T A A A C A C A A	T A T T A G A T G A
99-1 7001-13294	A G G T C C T T G G	A T A A A T A C A A	T A C T A G A T G A
	2680	2690	2700
00-1 7001-13350	C A T T A A A A C C	A G T G C A G A G T	C A A T A G G G A G
99-1 7001-13294	T A T T A A A A C C	A G T G C A G A A T	C A A T A G G A A G
	2710	2720	2730
00-1 7001-13350	T C T A T G T C A G	G A A T T A G A A T	T T A G G G G G G A
99-1 7001-13294	T C T A T G T C A A	G A A C T A G A A T	T C A G A G G G G A

Figure 53 cont'd

121/132

00-1 7001-13350	2740 A A G C A T A A T A	2750 G T T A G T C T G A	2760 T A T T A A G G A A
99-1 7001-13294	G A G T A T A C T A	G T T A G C T T G A	T A T T A A G G A A
00-1 7001-13350	2770 T T T T T G G C T G	2780 T A T A A T T T A T	2790 A C A T G C A T G A
99-1 7001-13294	T T T C T G G C T G	T A T A A C T T G T	A C A T G T A T G A
00-1 7001-13350	2800 A T C A A A G C A A	2810 C A C C C C C T A G	2820 C A G G G A A G C A
99-1 7001-13294	G T C A A A A C A G	C A C C C A T T A G	C T G G G A A G C A
00-1 7001-13350	2830 G T T A T T C A A A	2840 C A A C T A A A T A	2850 A A A C A T T A A C
99-1 7001-13294	A C T G T T C A A G	C A A T T G A A C A	A A A C A T T A A C
00-1 7001-13350	2860 A T C A G T G C A G	2870 A G A T T T T T T G	2880 A A A T A A A A A A
99-1 7001-13294	A T C T G T G C A G	A G A T T T T T T G	A A C T G A A G A A
00-1 7001-13350	2890 G G A A A A T G A A	2900 G T A G T A G A T C	2910 T A T G G A T G A A
99-1 7001-13294	A G A A A A T G A T	G T G G T T G A C C	T A T G G A T G A A
00-1 7001-13350	2920 C A T A C C A A T G	2930 C A G T T T G G A G	2940 G A G G A G A T C C
99-1 7001-13294	T A T A C C A A T G	C A G T T T G G A G	G G G G A G A T C C
00-1 7001-13350	2950 A G T A G T C T T C	2960 T A T A G A T C T T	2970 T C T A T A G A A G
99-1 7001-13294	A G T A G T T T T T	T A C A G A T C T T	T T T A C A G A A G
00-1 7001-13350	2980 G A C C C C T G A T	2990 T T T T T A A C T G	3000 A A G C A A T C A G
99-1 7001-13294	G A C T C C C G A T	T T C C T A A C T G	A A G C A A T C A G
00-1 7001-13350	3010 T C A T G T G G A T	3020 A T T C T G T T A A	3030 G A A T A T C A G C
99-1 7001-13294	C C A T G T G G A T	T T A C T G T T A A	A A G T G T C A A A
00-1 7001-13350	3040 C A A C A T A A G A	3050 A A T G A A G C G A	3060 A A A T A A G T T T
99-1 7001-13294	C A A T A T C A A A	G A T G A G A C T A	A G A T A C G A T T
00-1 7001-13350	3070 C T T C A A A G C C	3080 T T A C T G T C A A	3090 T A G A A A A A A A
99-1 7001-13294	T T T C A A A G C C	T T A T T A T C T A	T A G A A A A G A A
00-1 7001-13350	3100 T G A A C G T G C T	3110 A C A C T G A C A A	3120 C A C T A A T G A G
99-1 7001-13294	T G A A C G T G C T	A C A T T A A C A A	C A C T A A T G A G

Figure 53 cont'd

122/132

	3130	3140	3150
00-1 7001-13350	A G A T C C T C A A	G C T G T T G G C T	C A G A G C G A C A
99-1 7001-13294	A G A C C C T C A G	G C A G T A G G A T	C A G A A C G A C A
	3160	3170	3180
00-1 7001-13350	A G C A A A A G T A	A C A A G T G A T A	T C A A T A G A A C
99-1 7001-13294	A G C T A A G G T A	A C A A G T G A T A	T A A A T A G A A C
	3190	3200	3210
00-1 7001-13350	A G C A G T T A C C	A G C A T C T T A A	G T C T T T C T C C
99-1 7001-13294	A G C A G T T A C C	A G C A T A C T G A	G T C T A T C T C C
	3220	3230	3240
00-1 7001-13350	A A A T C A A C T T	T T C A G C G A T A	G T G C T A T A C A
99-1 7001-13294	G A A T C A G C T C	T T C T G T G A T A	G T G C T A T A C A
	3250	3260	3270
00-1 7001-13350	C T A C A G T A G A	A A T G A A G A A G	A G G T C G G A A T
99-1 7001-13294	T T A T A G T A G A	A A T G A G G A A G	A A G T T G G G A T
	3280	3290	3300
00-1 7001-13350	C A T T G C T G A C	A A C A T A A C A C	C T G T T T A T C C
99-1 7001-13294	C A T T G C A G A C	A A C A T A A C A C	C T G T C T A T C C
	3310	3320	3330
00-1 7001-13350	T C A T G G A C T G	A G A G T T T T G T	A T G A A T C A T T
99-1 7001-13294	T C A T G G G C T G	A G A G T G C T C T	A T G A A T C A C T
	3340	3350	3360
00-1 7001-13350	A C C T T T T C A T	A A A G C T G A A A	A A G T T G T G A A
99-1 7001-13294	A C C T T T T C A T	A A G G C T G A A A	A G G T T G T C A A
	3370	3380	3390
00-1 7001-13350	T A T G A T A T C A	G G A A C G A A A T	C C A T A A C C A A
99-1 7001-13294	T A T G A T A T C A	G G C A C A A A G T	C T A T A A C T A A
	3400	3410	3420
00-1 7001-13350	C T T A T T A C A G	A G A A C A T C T G	C T A T T A A T G G
99-1 7001-13294	T C T A T T A C A G	A G A A C A T C T G	C T A T C A A T G G
	3430	3440	3450
00-1 7001-13350	T G A A G A T A T T	G A C A G A G C T G	T A T C C A T G A T
99-1 7001-13294	T G A A G A T A T T	G A T A G A G C A G	T G T C T A T G A T
	3460	3470	3480
00-1 7001-13350	G C T G G A G A A C	C T A G G A T T A T	T A T C T A G A A T
99-1 7001-13294	G T T A G A G A A C	T T A G G G T T G T	T A T C T A G A A T
	3490	3500	3510
00-1 7001-13350	A T T G T C A G T A	G T T G T T G A T A	G T A T A G A A A T
99-1 7001-13294	A T T G T C A G T A	A T A A T T A A T A	G T A T A G A A A T

Figure 53 cont'd

123/132

00-1 7001-13350	3520 T C C A A C C A A A	3530 T C T A A T G G T A	3540 G G C T G A T A T G
99-1 7001-13294	A C C A A T C A A G	T C C A A T G G C A	G A T T G A T A T G
00-1 7001-13350	3550 T T G T C A G A T A	3560 T C T A G A A C C C	3570 T A A G G G A G A C
99-1 7001-13294	C T G T C A A A T T	T C C A A G A C C T	T G A G A G A A A A
00-1 7001-13350	3580 A T C A T G G A A T	3590 A A T A T G G A A A	3600 T A G T T G G A G T
99-1 7001-13294	A T C A T G G A A C	A A T A T G G A A A	T A G T A G G A G T
00-1 7001-13350	3610 A A C A T C C C C T	3620 A G C A T C A C T A	3630 C A T G C A T G G A
99-1 7001-13294	G A C A T C T C C T	A G T A T T G T G A	C A T G T A T G G A
00-1 7001-13350	3640 T G T C A T A T A T	3650 G C A A C T A G C T	3660 C T C A T T T G A A
99-1 7001-13294	T G T T G T G T A T	G C A A C T A G T T	C T C A T T T A A A
00-1 7001-13350	3670 A G G G A T A A T C	3680 A T T G A A A A G T	3690 T C A G C A C T G A
99-1 7001-13294	A G G A A T A A T T	A T T G A A A A A T	T C A G T A C T G A
00-1 7001-13350	3700 C A G A A C T A C A	3710 A G A G G T C A A A	3720 G A G G T C C A A A
99-1 7001-13294	C A A G A C C A C A	A G A G G T C A G A	G G G G A C C A A A
00-1 7001-13350	3730 G A G C C C T T G G	3740 G T A G G G T C G A	3750 G C A C T C A A G A
99-1 7001-13294	A A G C C C C T G G	G T A G G A T C A A	G C A C T C A A G A
00-1 7001-13350	3760 G A A A A A A T T A	3770 G T T C C T G T T T	3780 A T A A C A G A C A
99-1 7001-13294	G A A A A A A T T G	G T T C C T G T T T	A T A A T A G A C A
00-1 7001-13350	3790 A A T T C T T T C A	3800 A A A C A A C A A A	3810 G A G A A C A G C T
99-1 7001-13294	A A T T C T T T C A	A A A C A A C A A A	A A G A G C A A C T
00-1 7001-13350	3820 A G A A G C A A T T	3830 G G A A A A A T G A	3840 G A T G G G T A T A
99-1 7001-13294	G G A A G C A A T A	G G G A A A A T G A	G G T G G G T G T A
00-1 7001-13350	3850 T A A A G G G A C A	3860 C C A G G T T T A A	3870 G A C G A T T A C T
99-1 7001-13294	C A A A G G A A C T	C C A G G G C T A A	G A A G A T T G C T
00-1 7001-13350	3880 C A A T A A G A T T	3890 T G T C T T G G A A	3900 G T T T A G G C A T
99-1 7001-13294	C A A C A A G A T T	T G C A T A G G A A	G C T T A G G T A T

Figure 53 cont'd

124/132

3910	3920	3930
00-1 7001-13350 T A G T T A C A A A	T G T G T A A A A C	C T T T A T T A C C
99-1 7001-13294 T A G C T A T A A A	T G T G T G A A A C	C T T T A T T A C C
3940	3950	3960
00-1 7001-13350 T A G G T T T A T G	A G T G T A A A T T	T C C T A C A C A G
99-1 7001-13294 A A G A T T C A T G	A G T G T A A A C T	T C T T A C A T A G
3970	3980	3990
00-1 7001-13350 G T T A T C T G T C	A G T A G T A G A C	C T A T G G A A T T
99-1 7001-13294 G T T A T C T G T T	A G T A G T A G A C	C C A T G G A A T T
4000	4010	4020
00-1 7001-13350 C C C A G C A T C A	G T T C C A G C T T	A T A G A A C A A C
99-1 7001-13294 C C C A G C T T C T	G T T C C A G C T T	A C A G G A C A A C
4030	4040	4050
00-1 7001-13350 A A A T T A C C A T	T T T G A C A C T A	G T C C T A T T A A
99-1 7001-13294 A A A T T A C C A T	T T T G A C A C T A	G T C C A A T C A A
4060	4070	4080
00-1 7001-13350 T C A A G C A C T A	A G T G A G A G A T	T T G G G A A T G A
99-1 7001-13294 C C A A G C A T T A	A G T G A G A G G T	T C G G G A A C G A
4090	4100	4110
00-1 7001-13350 A G A T A T T A A T	T T G G T C T T C C	A A A A T G C A A T
99-1 7001-13294 A G A C A T T A A T	T T A G T G T T C C	A A A A T G C A A T
4120	4130	4140
00-1 7001-13350 C A G C T G T G G A	A T T A G C A T A A	T G A G T G T A G T
99-1 7001-13294 C A G C T G C G G A	A T T A G T A T A A	T G A G T G T T G T
4150	4160	4170
00-1 7001-13350 A G A A C A A T T A	A C T G G T A G G A	G T C C A A A A C A
99-1 7001-13294 A G A A C A G T T A	A C T G G T A G A A	G C C C A A A A C A
4180	4190	4200
00-1 7001-13350 G T T A G T T T T A	A T A C C T C A A T	T A G A A G A A A T
99-1 7001-13294 A T T A G T C C T A	A T C C C T C A A T	T A G A A G A G A T
4210	4220	4230
00-1 7001-13350 A G A C A T T A T G	C C A C C A C C A G	T G T T T C A A G G
99-1 7001-13294 A G A T A T T A T G	C C T C C T C C T G	T A T T T C A A G G
4240	4250	4260
00-1 7001-13350 G A A A T T C A A T	T A T A A G C T A G	T A G A T A A G A T
99-1 7001-13294 A A A A T T C A A T	T A T A A A C T A G	T T G A T A A G A T
4270	4280	4290
00-1 7001-13350 A A C T T C T G A T	C A A C A T A T C T	T C A G T C C A G A
99-1 7001-13294 A A C C T C C G A T	C A A C A C A T C T	T C A G T C C T G A

Figure 53 cont'd

125/132

	4300	4310	4320
00-1 7001-13350	C A A A A T A G A T	A T G T T A A C A C	T G G G G A A A A T
99-1 7001-13294	C A A A A T A G A C	A T A T T A A C A C	T A G G G A A G A T
	4330	4340	4350
00-1 7001-13350	G C T C A T G C C C	A C T A T A A A A G	G T C A G A A A A C
99-1 7001-13294	G C T T A T G C C T	A C C A T A A A A G	G T C A A A A A A C
	4360	4370	4380
00-1 7001-13350	A G A T C A G T T C	C T G A A C A A G A	G A G A G A A T T A
99-1 7001-13294	T G A T C A G T T C	T T A A A T A A G A	G A G A A A A C T A
	4390	4400	4410
00-1 7001-13350	T T T C C A T G G G	A A T A A T C T T A	T T G A G T C T T T
99-1 7001-13294	T T T T C A T G G A	A A T A A T T T A A	T T G A A T C T T T
	4420	4430	4440
00-1 7001-13350	G T C A G C A G C G	T T A G C A T G T C	A T T G G T G T G G
99-1 7001-13294	A T C T G C A G C A	C T T G C A T G C C	A C T G G T G T G G
	4450	4460	4470
00-1 7001-13350	G A T A T T A A C A	G A G C A A T G T A	T A G A A A A T A A
99-1 7001-13294	G A T A T T A A C A	G A A C A G T G C A	T A G A A A A C A A
	4480	4490	4500
00-1 7001-13350	T A T T T T C A A G	A A A G A C T G G G	G T G A C G G G T T
99-1 7001-13294	T A T C T T T A G G	A A A G A T T G G G	G T G A T G G G T T
	4510	4520	4530
00-1 7001-13350	C A T A T C G G A T	C A T G C T T T T A	T G G A C T T C A A
99-1 7001-13294	C A T C T C A G A T	C A T G C C T T C A	T G G A T T T C A A
	4540	4550	4560
00-1 7001-13350	A A T A T T C C T A	T G T G T C T T T A	A A A C T A A A C T
99-1 7001-13294	G G T A T T T C T A	T G T G T A T T T A	A A A C C A A A C T
	4570	4580	4590
00-1 7001-13350	T T T A T G T A G T	T G G G G G T C C C	A A G G G A A A A A
99-1 7001-13294	T T T A T G T A G T	T G G G G A T C T C	A A G G A A A G A A
	4600	4610	4620
00-1 7001-13350	C A T T A A A G A T	G A A G A T A T A G	T A G A T G A A T C
99-1 7001-13294	T G T A A A A G A T	G A A G A T A T A A	T A G A T G A A T C
	4630	4640	4650
00-1 7001-13350	A A T A G A T A A A	C T G T T A A G G A	T T G A T A A T A C
99-1 7001-13294	C A T T G A C A A A	T T A T T A A G A A	T T G A C A A C A C
	4660	4670	4680
00-1 7001-13350	T T T T T G G A G A	A T G T T C A G C A	A G G T T A T G T T
99-1 7001-13294	C T T T T G G A G A	A T G T T C A G C A	A A G T C A T G T T

Figure 53 cont'd

	4690	4700	4710
00-1 7001-13350	T G A A T C A A A G	G T T A A G A A A A	G G A T A A T G T T
99-1 7001-13294	T G A A T C A A A A	G T C A A A A A A A	G A A T A A T G T T
	4720	4730	4740
00-1 7001-13350	A T A T G A T G T A	A A A T T T C T A T	C A T T A G T A G G
99-1 7001-13294	A T A T G A T G T G	A A A T T C C T A T	C A T T A G T A G G
	4750	4760	4770
00-1 7001-13350	T T A T A T A G G G	T T T A A G A A T T	G G T T T A T A G A
99-1 7001-13294	T T A T A T A G G A	T T T A A A A A C T	G G T T T A T A G A
	4780	4790	4800
00-1 7001-13350	A C A G T T G A G A	T C A G C T G A G T	T G C A T G A G G T
99-1 7001-13294	A C A G T T A A G A	G T G G T A G A A T	T G C A T G A G G T
	4810	4820	4830
00-1 7001-13350	A C C T T G G A T T	G T C A A T G C C G	A A G G T G A T C T
99-1 7001-13294	A C C T T G G A T T	G T C A A T G C T G	A A G G A G A G T T
	4840	4850	4860
00-1 7001-13350	G G T T G A G A T C	A A G T C A A T T A	A A A T C T A T T T
99-1 7001-13294	A G T T G A A A T T	A A A T C A A T C A	A A A T T T A T C T
	4870	4880	4890
00-1 7001-13350	G C A A C T G A T A	G A G C A A A G T T	T A T T T T T A A G
99-1 7001-13294	G C A G T T A A T A	G A A C A A A G T C	T A T C T T T G A G
	4900	4910	4920
00-1 7001-13350	A A T A A C T G T T	T T G A A C T A T A	C A G A T A T G G C
99-1 7001-13294	A A T A A C T G T A	T T G A A T T A T A	C A G A C A T G G C
	4930	4940	4950
00-1 7001-13350	A C A T G C T C T C	A C A A G A T T A A	T C A G A A A G A A
99-1 7001-13294	A C A T G C T C T T	A C A C G A T T A A	T T A G G A A A A A
	4960	4970	4980
00-1 7001-13350	G T T G A T G T G T	G A T A A T G C A C	T A T T A A C T C C
99-1 7001-13294	A T T G A T G T G T	G A T A A T G C A C	T C T T T A A T C C
	4990	5000	5010
00-1 7001-13350	G A T T C C A T C C	C C A A T G G T T A	A T T T A A C T C A
99-1 7001-13294	A A G T T C A T C A	C C A A T G T T T A	A T C T A A C T C A
	5020	5030	5040
00-1 7001-13350	A G T T A T T G A T	C C T A C A G A A C	A A T T A G C T T A
99-1 7001-13294	G G T T A T T G A T	C C C A C A A C A C	A A C T A G A C T A
	5050	5060	5070
00-1 7001-13350	T T T C C C T A A G	A T A A C A T T T G	A A A G G C T A A A
99-1 7001-13294	T T T T C C T A G G	A T A A T A T T T G	A G A G G T T A A A

Figure 53 cont'd

127/132

00-1 7001-13350	5080 A A A T T A T G A C	5090 A C T A G T T C A A	5100 A T T A T G C T A A
99-1 7001-13294	A A G T T A T G A T	A C C A G T T C A G	A C T A C A A C A A
00-1 7001-13350	5110 A G G A A A G C T A	5120 A C A A G G A A T T	5130 A C A T G A T A C T
99-1 7001-13294	A G G G A A G T T A	A C A A G G A A T T	A C A T G A C A T T
00-1 7001-13350	5140 G T T G C C A T G G	5150 C A A C A T G T T A	5160 A T A G A T A T A A
99-1 7001-13294	A T T A C C A T G G	C A A C A C G T A A	A C A G G T A C A A
00-1 7001-13350	5170 C T T T G T C T T T	5180 A G T T C T A C T G	5190 G A T G T A A A G T
99-1 7001-13294	T T T T G T C T T T	A G T T C T A C A G	G T T G T A A A G T
00-1 7001-13350	5200 T A G T C T A A A A	5210 A C A T G C A T T G	5220 G A A A A C T T A T
99-1 7001-13294	C A G T T T G A A G	A C A T G C A T C G	G G A A A T T G A T
00-1 7001-13350	5230 G A A A G A T C T A	5240 A A C C C T A A A G	5250 T T C T G T A C T T
99-1 7001-13294	A A A G G A T T T A	A A T C C T A A A G	T T C T T T A C T T
00-1 7001-13350	5260 T A T T G G A G A A	5270 G G G G C A G G A A	5280 A T T G G A T G G C
99-1 7001-13294	T A T T G G A G A A	G G A G C A G G T A	A C T G G A T G G C
00-1 7001-13350	5290 C A G A A C A G C A	5300 T G T G A A T A T C	5310 C T G A C A T C A A
99-1 7001-13294	A A G A A C A G C A	T G T G A A T A T C	C T G A T A T A A A
00-1 7001-13350	5320 A T T T G T A T A C	5330 A G A A G T T T A A	5340 A A G A T G A C C T
99-1 7001-13294	A T T T G T A T A T	A G G A G T T T A A	A G G A T G A C C T
00-1 7001-13350	5350 T G A T C A T C A T	5360 T A T C C T T T G G	5370 A A T A C C A G A G
99-1 7001-13294	T G A T C A C C A T	T A C C C A T T A G	A A T A T C A A A G
00-1 7001-13350	5380 A G T T A T A G G A	5390 G A A T T A A G C A	5400 G G A T A A T A G A
99-1 7001-13294	G G T A A T A G G T	G A T C T A A A T A	G G G T G A T A G A
00-1 7001-13350	5410 T A G C G G T G A A	5420 G G G C T T T C A A	5430 T G G A A A C A A C
99-1 7001-13294	T A G T G G T G A A	G G A T T A T C A A	T G G A A A C C A C
00-1 7001-13350	5440 A G A T G C A A C T	5450 C A A A A A A C T C	5460 A T T G G G A T T T
99-1 7001-13294	A G A T G C A A C T	C A A A A A A C T C	A T T G G G A C T T

Figure 53 cont'd

7682-063

(Sheet 128 of 132)

00-1 7001-13350	5470 G A T A C A C A G A	5480 G T A A G C A A A G	5490 A T G C T T T A T T
99-1 7001-13294	G A T A C A C A G A	A T A A G T A A A G	A T G C T T T A T T
00-1 7001-13350	5500 A A T A A C T T T A	5510 T G T G A T G C A G	5520 A A T T T A A G G A
99-1 7001-13294	G A T A A C A T T G	T G T G A T G C A G	A A T T C A A A A A
00-1 7001-13350	5530 C A G A G A T G A T	5540 T T T T T T A A G A	5550 T G G T A A T T C T
99-1 7001-13294	C A G A G A T G A T	T T C T T T A A G A	T G G T A A T C C T
00-1 7001-13350	5560 A T G G A G G A A A	5570 C A T G T A T T A T	5580 C A T G C A G A A T
99-1 7001-13294	T T G G A G A A A A	C A T G T A T T A T	C T T G T A G A A T
00-1 7001-13350	5590 T T G C A C T A C T	5600 T A T G G G A C A G	5610 A C C T C T A T T T
99-1 7001-13294	C T G T A C A G C T	T A T G G A A C A G	A T C T T T A C T T
00-1 7001-13350	5620 A T T C G C A A A G	5630 T A T C A T G C T A	5640 A A G A C T G C A A
99-1 7001-13294	A T T T G C A A A G	T A T C A T G C G G	T G G A C T G C A A
00-1 7001-13350	5650 T G T A A A A T T A	5660 C C T T T T T T T G	5670 T G A G A T C A G T
99-1 7001-13294	T A T A A A A T T A	C C A T T T T T T G	T A A G A T C T G T
00-1 7001-13350	5680 A G C C A C C T T T	5690 A T T A T G C A A G	5700 G T A G T A A A C T
99-1 7001-13294	A G C T A C T T T T	A T T A T G C A A G	G A A G C A A A T T
00-1 7001-13350	5710 G T C A G G G T C A	5720 G A A T G C T A C A	5730 T A C T C T T A A C
99-1 7001-13294	A T C A G G G T C A	G A A T G T T A C A	T A C T T T T A A C
00-1 7001-13350	5740 A C T A G G C C A C	5750 C A C A A C A A T T	5760 T A C C C T G C C A
99-1 7001-13294	A T T A G G T C A T	C A C A A T A A T C	T A C C C T G T C A
00-1 7001-13350	5770 T G G A G A A A T A	5780 C A A A A T T C T A	5790 A G A T G A A A A T
99-1 7001-13294	T G G A G A A A T A	C A A A A T T C C A	A A A T G A G A A T
00-1 7001-13350	5800 A G C A G T G T G T	5810 A A T G A T T T T T	5820 A T G C T G C A A A
99-1 7001-13294	A G C A G T G T G T	A A T G A T T T C T	A T G C C T C A A A
00-1 7001-13350	5830 A A A A C T T G A C	5840 A A T A A A T C T A	5850 T T G A A G C C A A
99-1 7001-13294	G A A A C T G G A C	A A C A A A T C A A	T T G A A G C A A A

Figure 53 cont'd

129/132




00-1 7001-13350	CTGTAAATCA	CTTTTATCAG	GGCTAAGAAAT
99-1 7001-13294	CTGCAAAATCT	CTTCTATCAG	GATTGAGAAAT
00-1 7001-13350	ACCGATAAAT	AAGAAAGAAAT	TAAATAGACA
99-1 7001-13294	ACCTATAAAG	AAAAAGGAGT	TAAATAGACA
00-1 7001-13350	GAGAAAGGTTA	TTAACA CTAC	AAAGCAACCA
99-1 7001-13294	AAAGAAATTG	TTAACA CTAC	AAAGTAACCA
00-1 7001-13350	TTCTTCTGTA	GCAACAGTTG	GAGGTAGCAA
99-1 7001-13294	TTCTTCTATA	GCAACAGTTG	GCGGCAGTAA
00-1 7001-13350	GGTCATAGAG	TCTAAATGGT	TAAACAACA
99-1 7001-13294	GATTATAGAA	TCCAATGGT	TAAAGAAATA
00-1 7001-13350	GGCAAAACACA	ATAATTGATT	GGTTAGAAC
99-1 7001-13294	AGCAAGTACA	ATAATTGATT	GGTTAGAGCA
00-1 7001-13350	TATTTTAAAT	TCTCCA AAG	GTGAATTAAA
99-1 7001-13294	TATTTTGAAT	TCTCCA AAG	GTGAATTAAA
00-1 7001-13350	TTATGATTTT	TTTGAAGCAT	TAGAAAATAC
99-1 7001-13294	CTATGATTTT	TTTGAAGCAT	TAGAGAACAC
00-1 7001-13350	TTACCCTAAT	ATGATTAAAC	TAAATAGATA
99-1 7001-13294	ATACCCTCAAT	ATGATCAAGC	TTATAGATA
00-1 7001-13350	TCTAGGGAAT	GCAGAGATAA	AAAAACTGAT
99-1 7001-13294	TTTGGGAAT	GCAGAAATAA	AGAAACTAAT
00-1 7001-13350	CAAGTA ACT	GGATATATGC	TTGTAAGTAA
99-1 7001-13294	CAAGGTCACT	GGGTATATGC	TTGTGAGTAA
00-1 7001-13350	AAAATGA AAA	ATGATA AAAA	TGATA AAAATA
99-1 7001-13294	G AAGT - AATA	ATAATGATAA	TGATTAAACCA
00-1 7001-13350	GGTGACA ACT	TCATACTATT	CC - AAAGTAA
99-1 7001-13294	- - - - TAATC	TCACACA ACT	GAGAAAATAA

Figure 53 cont'd

	 6250	 6260	 6270
0-1 7001-13350	T C A T T T G A T T	A T G C A A T T A T	G T A A T A G T T A
9-1 7001-13294	T C G T C T A A C A	G T T T A G T T G A	T C A T T A G T T A
	 6280	 6290	 6300
0-1 7001-13350	A T T A A A A A C T	A A A A A T C A A A	A G T T A G A A A C
9-1 7001-13294	T T T A A A A T T A	T A A A A T A G T A	A C T A A C T G A T
	 6310	 6320	 6330
0-1 7001-13350	T A A C A A C T G T	C A T T A A G T T T	A T T A A A A A T A
9-1 7001-13294	A A A A A A T C A G	A A A T T G A A A T	T G A A T G T A T A
	 6340	 6350	 6360
0-1 7001-13350	A G A A A T T A T A	A T T G G A T G T A	T A C G
9-1 7001-13294	C G G T T T T T T T	G C C G T	


Figure 53 cont'd

FIGURE 54

APPROACHES**A. Self Ligation****B. 3' RACE****C. 5' RACE**

Consensus Sequence Analysis
or Clonal Sequence Analysis

FIGURE 55
5' cDNA Terminal Sequences of hMPV



Clonal Analysis of 96 PCR colonies

	<u># Colony</u>	<u>Ratio</u>
5'-ACGCGAAAAAACGCG	15	31%
CGCGAAAAAACGCG	6	12%
GCGAAAAAACGCG	5	10%
CGAAAAAACGCG	23	47%

Total 49 near full-length clones

M							
	00-1	hRSV	bRSV	PMV	APV-A	APV-C	APV-B
00-1	1,00	0,37	0,37	0,37	0,77	0,87	0,75
hRSV	---	1,00	0,91	0,41	0,37	0,37	0,37
bRSV	---	---	1,00	0,42	0,35	0,36	0,35
PMV	---	---	---	1,00	0,37	0,38	0,38
APV-A	---	---	---	---	1,00	0,78	0,89
APV-C	---	---	---	---	---	1,00	0,77
APV-B	---	---	---	---	---	---	1,00

N							
	00-1	hRSV	bRSV	PVM	APV-A	APV-C	APV-B
00-1	1,00	0,20	0,22	0,21	0,40	0,52	0,40
hRSV	---	1,00	0,59	0,30	0,18	0,21	0,18
bRSV	---	---	1,00	0,31	0,21	0,23	0,21
PVM	---	---	---	1,00	0,21	0,23	0,21
APVA	---	---	---	---	1,00	0,42	1,00
APVC	---	---	---	---	---	1,00	0,42
APVB	---	---	---	---	---	---	1,00

F							
	00-1	hRSV	bRSV	PVM	APV-A	APV-C	APV-B
00-1	1,00	0,32	0,33	0,37	0,67	0,80	0,66
hRSV	---	1,00	0,82	0,40	0,35	0,35	0,35
bRSV	---	---	1,00	0,41	0,34	0,36	0,34
PVM	---	---	---	1,00	0,38	0,38	0,39
APV-A	---	---	---	---	1,00	0,72	0,84
APV-C	---	---	---	---	---	1,00	0,72
APV-B	---	---	---	---	---	---	1,00

P						
	00-1	hRSV	bRSV	PMV	APV-A	APV-C
00-1	1,00	0,25	0,26	0,27	0,55	0,67
hRSV	---	1,00	0,81	0,30	0,28	0,26
bRSV	---	---	1,00	0,29	0,28	0,26
PMV	---	---	---	1,00	0,23	0,27
APV-A	---	---	---	---	1,00	0,52
APV-C	---	---	---	---	---	1,00

L8				
	00-1	hRSV	bRSV	APV-A
00-1	1,00	0,36	0,35	0,56
hRSV	---	1,00	0,79	0,36
bRSV	---	---	1,00	0,35
APV-A	---	---	---	1,00

L9/10				
	00-1	hRSV	bRSV	APV-A
00-1	1,00	0,30	0,30	0,53
hRSV	---	1,00	0,83	0,34
bRSV	---	---	1,00	0,32
APV-A	---	---	---	1,00